February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e72WRITING COMMITTEE MEMBERS*
Catherine M. Otto, MD, FACC, FAHA, Co-Chair
Rick A. Nishimura, MD, MACC, FAHA, Co-Chair
Robert O. Bonow, MD, MS, MACC, FAHA
Blase A. Carabello, MD, FACC, FAHA
John P . Erwin III, MD, FACC, FAHA
Federico Gentile, MD, FACC
Hani Jneid, MD, FACC, FAHA
Eric V. Krieger, MD, FACC
Michael Mack, MD, MACC
Christopher McLeod, MBCHB, PhD, FAHA
Patrick T. O’Gara, MD, MACC, FAHA†
Vera H. Rigolin, MD, FACC, FAHA
Thoralf M. Sundt III, MD, FACC, FAHA
Annemarie Thompson, MD
Christopher Toly
© 2020 by the American College 
of Cardiology Foundation and the 
American Heart Association, Inc.ACC/AHA CLINICAL PRACTICE GUIDELINE
2020 ACC/AHA Guideline for the Management 
of Patients With Valvular Heart Disease
A Report of the American College of Cardiology/American Heart 
Association Joint Committee on Clinical Practice GuidelinesCirculation
https://www.ahajournals.org/journal/circDeveloped in collaboration with and 
endorsed by the American Association 
for Thoracic Surgery, American 
Society of Echocardiography, Society 
for Cardiovascular Angiography and 
Interventions, Society of Cardiovascular 
Anesthesiologists, and Society of 
Thoracic Surgeons
ACC/AHA Joint Committee on Clinical 
Practice Guidelines Members, see page 
e184
*Writing committee members are required to recuse themselves from voting on sections to which their specific 
relationships with industry may apply; see Appendix 1 for detailed information. 
†ACC/AHA Joint Committee on Clinical Practice Guidelines Liaison.
The American Heart Association requests that this document be cited as follows: Otto CM, Nishimura RA, Bonow 
RO, Carabello BA, Erwin JP 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O’Gara PT, Rigolin VH, Sundt TM 
3rd, Thompson A, Toly C. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: 
a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice 
Guidelines. Circulation. 2021;143:e72-e227. doi: 10.1161/CIR.0000000000000923Key Words: AHA Scientific Statements 
◼ anticoagulation therapy ◼ aortic 
regurgitation ◼ aortic stenosis  
◼ bicuspid aortic valve ◼ cardiac surgery  
◼ guidelines ◼ infective endocarditis  
◼ mitral regurgitation ◼ mitral stenosis 
◼ mitral transcatheter edge-to-edge 
repair ◼ prosthetic valve  
◼ pulmonic regurgitation ◼ pulmonic 
stenosis ◼ transcatheter aortic valve 
replacement or implantation ◼ tricuspid 
regurgitation ◼ tricuspid stenosis  
◼ valvular heart disease
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e73
CLINICAL STATEMENTS  
AND GUIDELINESTABLE OF CONTENTS
Top 10 Take-Home Messages  . . . . . . . . . . . . . . . . . . . . . . . e74
Preamble  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e75 
1. Introduction  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e76
1.1. Methodology and Evidence Review  . . . . . . . . . . . e76
1.2. Organization of the Writing Committee  . . . . . . . . e76
1.3. Document Review and Approval  . . . . . . . . . . . . . . e76
1.4. Scope of the Guideline  . . . . . . . . . . . . . . . . . . . . . . e76
1.5. Class of Recommendation and Level of Evidence  . e77
1.6. Abbreviations  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e77
2. General Principles  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e78
2.1. Evaluation of the Patient With Known or  
Suspected Native VHD  . . . . . . . . . . . . . . . . . . . . . . e78
2.2. Definitions of Severity of Valve Disease  . . . . . . . . e78
2.3. Diagnosis and Follow-Up   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . e78
2.3.1. Diagnostic Testing: Initial Diagnosis 30  . . .e78
2.3.2. Diagnostic Testing: Changing Signs or 
Symptoms  . . . . . . . . . . . . . . . . . . . . . . . . . . e80
2.3.3. Diagnostic Testing: Routine Follow-Up  . . . e80
2.3.4. Diagnostic Testing: Cardiac Catheterization  . .e81
2.3.5. Diagnostic Testing: Exercise Testing  . . . . . . e81
2.4. Basic Principles of Medical Therapy  . . . . . . . . . . . . e81
2.4.1. Secondary Prevention of Rheumatic Fever e82
2.4.2. IE Prophylaxis  . . . . . . . . . . . . . . . . . . . . . . . . e82
2.4.3. Anticoagulation for AF in Patients With VHD e83
2.5. Evaluation of Surgical and Interventional Risk  . . .e85
2.6. The Multidisciplinary Heart Valve Team and  
Heart Valve Centers  . . . . . . . . . . . . . . . . . . . . . . . . e86 
2.7. Management of Patients With VHD After Valve 
Intervention  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e88 
2.7.1. Procedural Complications  . . . . . . . . . . . . . . e89
2.7.2. Primary and Secondary Risk Factor  
Evaluation and Treatment  . . . . . . . . . . . . . . e89
2.7.3. Persistent Symptoms After Valve Intervention  . .e89
2.7.4. Periodic Imaging After Valve Intervention  .e89
3. Aortic Stenosis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e90
3.1. Stages of Valvular AS  . . . . . . . . . . . . . . . . . . . . . . . e90
3.2. Aortic Stenosis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e90
3.2.1. Diagnosis and Follow-Up  . . . . . . . . . . . . . . e90
3.2.2. Medical Therapy  . . . . . . . . . . . . . . . . . . . . . e93
3.2.3. Timing of Intervention  . . . . . . . . . . . . . . . . e94
3.2.4. Choice of Intervention  . . . . . . . . . . . . . . . . e97
4. Aortic Regurgitation  . . . . . . . . . . . . . . . . . . . . . . . . . . . e104
4.1. Acute Aortic Regurgitation  . . . . . . . . . . . . . . . . . e104
4.1.1. Diagnosis of AR  . . . . . . . . . . . . . . . . . . . . . e104
4.1.2. Intervention  . . . . . . . . . . . . . . . . . . . . . . . . e104
4.2. Stages of Chronic AR  . . . . . . . . . . . . . . . . . . . . . . e104
4.3. Chronic AR  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e106
4.3.1. Diagnosis of Chronic AR  . . . . . . . . . . . . . . e106
4.3.2. Medical Therapy  . . . . . . . . . . . . . . . . . . . . e106
4.3.3. Timing of Intervention  . . . . . . . . . . . . . . . e107
5. Bicuspid Aortic Valve  . . . . . . . . . . . . . . . . . . . . . . . . . . . e109
5.1. BAV and Associated Aortopathy  . . . . . . . . . . . . . e109
5.1.1. Diagnosis and Follow-Up of BAV  . . . . . . . e109
5.1.2. Interventions for Patients With BAV  . . . . e109
6. Mitral Stenosis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e112 
6.1. Stages of MS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e113 
6.2. Rheumatic MS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . e113
6.2.1. Diagnosis and Follow-Up of Rheumatic MS e113
6.2.2. Medical Therapy  . . . . . . . . . . . . . . . . . . . . e1156.2.3. Intervention  . . . . . . . . . . . . . . . . . . . . . . . e116
6.3. Nonrheumatic Calcific MS  . . . . . . . . . . . . . . . . . e118
7. Mitral Regurgitation  . . . . . . . . . . . . . . . . . . . . . . . . . . e119
7.1. Acute MR  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e119
7.1.1. Diagnosis of Acute MR  . . . . . . . . . . . . . . e119
7.1.2. Medical Therapy  . . . . . . . . . . . . . . . . . . . e119
7.1.3. Intervention  . . . . . . . . . . . . . . . . . . . . . . . e119
7.2. Chronic Primary MR  . . . . . . . . . . . . . . . . . . . . . . e119
7.2.1. Stages of Chronic Primary MR  . . . . . . . . e119
7.2.2. Diagnosis and Follow-Up of Chronic  
Primary MR  . . . . . . . . . . . . . . . . . . . . . . . e120
7.2.3. Medical Therapy  . . . . . . . . . . . . . . . . . . . e123
7.2.4. Intervention  . . . . . . . . . . . . . . . . . . . . . . . e124
7.3. Chronic Secondary MR  . . . . . . . . . . . . . . . . . . . e126
7.3.1. Stages of Chronic Secondary MR  . . . . . e126
7.3.2. Diagnosis of Chronic Secondary MR  . . .e127
7.3.3. Medical Therapy  . . . . . . . . . . . . . . . . . . . e128
7.3.4. Intervention  . . . . . . . . . . . . . . . . . . . . . . . e129
8. Tricuspid Valve Disease  . . . . . . . . . . . . . . . . . . . . . . . . e131
8.1. Classification and Stages of TR  . . . . . . . . . . . . . e131
8.2. Tricuspid Regurgitation  . . . . . . . . . . . . . . . . . . . e131
8.2.1. Diagnosis of TR  . . . . . . . . . . . . . . . . . . . . e131
8.2.2. Medical Therapy  . . . . . . . . . . . . . . . . . . . e132
8.2.3. Timing of Intervention  . . . . . . . . . . . . . . e133
9. Pulmonic Valve Disease ..................... e135
10. Mixed Valve Disease  . . . . . . . . . . . . . . . . . . . . . . . . . . e135
10.1. Diagnosis of Mixed VHD  . . . . . . . . . . . . . . . . . . e135
10.2. Timing of Intervention for Mixed VHD  . . . . . . e136
10.2.1. Intervention for Mixed AS and AR   .  .  . e136
10.2.2. Intervention for Mixed AS and MR  . . .e136 
10.2.3. Intervention for Mixed MS and MR  . . e137
10.2.4. Intervention for Mixed MS and AR  . . .e137
10.2.5. Intervention for Mixed MS and AS  . . .e137
11. Prosthetic Valves  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e137
11.1. Evaluation and Selection of Prosthetic Valves  .e137
11.1.1. Diagnosis and Follow-Up of Prosthetic 
Valves  . . . . . . . . . . . . . . . . . . . . . . . . . . e137
11.1.2.  Selection of Prosthetic Valve Type: 
Bioprosthetic Versus Mechanical Valve e139
11.2. Antithrombotic Therapy  . . . . . . . . . . . . . . . . . . e142
11.3. Bridging Therapy   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . e146
11.4. Excessive Anticoagulation and Serious  
Bleeding With Prosthetic Valves  . . . . . . . . . . . e148
11.5. Thromboembolic Events With Prosthetic Valves  .e148
11.6. Acute Mechanical Valve Thrombosis  . . . . . . . . e149
11.6.1. Diagnosis of Acute Mechanical Valve 
Thrombosis  . . . . . . . . . . . . . . . . . . . . . . e149
11.6.2. Intervention  . . . . . . . . . . . . . . . . . . . . . e150
11.7. Bioprosthetic Valve Thrombosis  . . . . . . . . . . . . e150
11.7.1. Diagnosis of Bioprosthetic Valve 
Thrombosis  . . . . . . . . . . . . . . . . . . . . . . e150
11.7.2. Medical Therapy  . . . . . . . . . . . . . . . . . . e150
11.8. Prosthetic Valve Stenosis  . . . . . . . . . . . . . . . . . . e151
11.8.1. Diagnosis of Prosthetic Valve Stenosis  . . . e151
11.8.2. Intervention for Prosthetic Valve Stenosis  .e152
11.9. Prosthetic Valve Regurgitation  . . . . . . . . . . . . . e152
11.9.1. Diagnosis of Prosthetic Valve 
Regurgitation ................. e153
11.9.2. Medical Therapy  . . . . . . . . . . . . . . . . . . e154
11.9.3. Intervention  . . . . . . . . . . . . . . . . . . . . . e154
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e74
CLINICAL STATEMENTS  
AND GUIDELINES12. Infective Endocarditis  . . . . . . . . . . . . . . . . . . . . . . . . . e155
12.1. Classification of Endocarditis  . . . . . . . . . . . . . . e155
12.2. Diagnosis of IE  . . . . . . . . . . . . . . . . . . . . . . . . . e156
12.3. Medical Therapy  . . . . . . . . . . . . . . . . . . . . . . . . e160
12.4. Intervention  . . . . . . . . . . . . . . . . . . . . . . . . . . . . e162
13. Pregnancy and VHD  . . . . . . . . . . . . . . . . . . . . . . . . . . e165
13.1. Initial Management of Women With VHD  
Before and During Pregnancy  . . . . . . . . . . . . . e165
13.1.1. Medical Therapy for Women With  
VHD Before and During Pregnancy  . e166
13.1.2. Intervention for Women With Native  
VHD Before and During Pregnancy  . e166
13.2. Prosthetic Valves in Pregnant Women  . . . . . . e169
13.2.1. Initial Management  . . . . . . . . . . . . . . e169
13.2.2. Anticoagulation for Pregnant Women 
With Mechanical Prosthetic Heart  
Valves  . . . . . . . . . . . . . . . . . . . . . . . . . . e170
14. Surgical Considerations  . . . . . . . . . . . . . . . . . . . . . . . e174
14.1. Evaluation and Management of CAD in  
Patients With VHD  . . . . . . . . . . . . . . . . . . . . . . e174
14.1.1. Management of CAD in Patients 
Undergoing TAVI  . . . . . . . . . . . . . . . . e174
14.1.2. Management of CAD in Patients 
Undergoing Valve Surgery  . . . . . . . . . e176
14.2. Intervention for AF in Patients With VHD  . . . e177
15. Noncardiac Surgery in Patients With VHD  . . . . . . . . e178
15.1. Diagnosis of Patients With VHD Undergoing 
Noncardiac Surgery  . . . . . . . . . . . . . . . . . . . . . e178
15.2. Management of the Symptomatic Patient  . . .e179
15.3. Management of the Asymptomatic Patient  . .e180
16. Evidence Gaps and Future Directions  . . . . . . . . . . . . e181
16.1. Prevention of Valve Disease: Stage A  . . . . . . . e181
16.2. Medical Therapy to Treat or Prevent Disease 
Progression: Stage B  . . . . . . . . . . . . . . . . . . . . . e182
16.3. Optimal Timing of Intervention: Stage C  . . . .e182
16.4. Better Options for Intervention: Stage D   .  .  .  . e182
References  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e184
Appendix 1. Author Relationships With Industry and  
Other Entities (Relevant)  . . . . . . . . . . . . . . . . . . . . . . . . e222
Appendix 2. Reviewer Relationships With Industry and  
Other Entities (Comprehensive)  . . . . . . . . . . . . . . . . . . e224
TOP 10 TAKE-HOME MESSAGES
1. Disease stages in patients with valvular heart dis-
ease should be classified (Stages A, B, C, and D) 
on the basis of symptoms, valve anatomy, the 
severity of valve dysfunction, and the response of 
the ventricle and pulmonary circulation.
2. In the evaluation of a patient with valvular heart 
disease, history and physical examination find-
ings should be correlated with the results of 
noninvasive testing (ie, ECG, chest x-ray, trans-
thoracic echocardiogram). If there is discordance 
between the physical examination and initial 
noninvasive testing, consider further noninva-
sive (computed tomography, cardiac magnetic 
resonance imaging, stress testing) or invasive 
(transesophageal echocardiography, cardiac catheterization) testing to determine optimal 
treatment strategy.
3. For patients with valvular heart disease and atrial 
fibrillation (except for patients with rheumatic 
mitral stenosis or a mechanical prosthesis), the 
decision to use oral anticoagulation to prevent 
thromboembolic events, with either a vitamin K 
antagonist or a non–vitamin K antagonist anti-
coagulant, should be made in a shared decision-
making process based on the CHA2DS2-VASc 
score. Patients with rheumatic mitral stenosis 
or a mechanical prosthesis and atrial fibrillation 
should receive oral anticoagulation with a vitamin 
K antagonist.
4. All patients with severe valvular heart disease 
being considered for valve intervention should 
be evaluated by a multidisciplinary team, with 
either referral to or consultation with a Primary or 
Comprehensive Valve Center.
5. Treatment of severe aortic stenosis with either a 
transcatheter or surgical valve prosthesis should 
be based primarily on symptoms or reduced ven-
tricular systolic function. Earlier intervention may 
be considered if indicated by results of exercise 
testing, biomarkers, rapid progression, or the 
presence of very severe stenosis.
6. Indications for transcatheter aortic valve implan-
tation are expanding as a result of multiple 
randomized trials of transcatheter aortic valve 
implantation versus surgical aortic valve replace-
ment. The choice of type of intervention for a 
patient with severe aortic stenosis should be a 
shared decision-making process that considers the 
lifetime risks and benefits associated with type of 
valve (mechanical versus bioprosthetic) and type 
of approach (transcatheter versus surgical).
7. Indications for intervention for valvular regurgi-
tation are relief of symptoms and prevention of 
the irreversible long-term consequences of left 
ventricular volume overload. Thresholds for inter -
vention now are lower than they were previously 
because of more durable treatment options and 
lower procedural risks.
8. A mitral transcatheter edge-to-edge repair is of 
benefit to patients with severely symptomatic 
primary mitral regurgitation who are at high or 
prohibitive risk for surgery, as well as to a select 
subset of patients with secondary mitral regurgi-
tation who remain severely symptomatic despite 
guideline-directed management and therapy for 
heart failure.
9. Patients presenting with severe symptomatic iso-
lated tricuspid regurgitation, commonly associ-
ated with device leads and atrial fibrillation, may 
benefit from surgical intervention to reduce symp-
toms and recurrent hospitalizations if done before 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e75
CLINICAL STATEMENTS  
AND GUIDELINESthe onset of severe right ventricular dysfunction or 
end-organ damage to the liver and kidney.
10. Bioprosthetic valve dysfunction may occur 
because of either degeneration of the valve 
leaflets or valve thrombosis. Catheter-based 
treatment for prosthetic valve dysfunction is 
reasonable in selected patients for bioprosthetic 
leaflet degeneration or paravalvular leak in the 
absence of active infection.
PREAMBLE
Since 1980, the American College of Cardiology (ACC) 
and American Heart Association (AHA) have translated sci-
entific evidence into clinical practice guidelines with recom-
mendations to improve cardiovascular health. These guide-
lines, which are based on systematic methods to evaluate 
and classify evidence, provide a foundation for the delivery 
of quality cardiovascular care. The ACC and AHA sponsor 
the development and publication of clinical practice guide-
lines without commercial support, and members volunteer 
their time to the writing and review efforts. Guidelines are 
official policy of the ACC and AHA. For some guidelines, 
the ACC and AHA partner with other organizations.
Intended Use
Clinical practice guidelines provide recommendations 
applicable to patients with or at risk of developing car -
diovascular disease. The focus is on medical practice in 
the United States, but these guidelines are relevant to 
patients throughout the world. Although guidelines may 
be used to inform regulatory or payer decisions, the in-
tent is to improve quality of care and align with patients’ 
interests. Guidelines are intended to define practices 
meeting the needs of patients in most, but not all, cir -
cumstances, and should not replace clinical judgment.
Clinical Implementation
Management, in accordance with guideline recom-
mendations, is effective only when followed by both 
practitioners and patients. Adherence to recommen-
dations can be enhanced by shared decision-making 
between clinicians and patients, with patient engage-
ment in selecting interventions on the basis of individ-
ual values, preferences, and associated conditions and 
comorbidities.
Methodology and Modernization
The ACC/AHA Joint Committee on Clinical Practice 
Guidelines (Joint Committee) continuously reviews, up-
dates, and modifies guideline methodology on the ba-
sis of published standards from organizations, including 
the Institute of Medicine,1,2 and on the basis of internal reevaluation. Similarly, presentation and delivery of 
guidelines are reevaluated and modified in response to 
evolving technologies and other factors to optimally fa-
cilitate dissemination of information to healthcare pro-
fessionals at the point of care.
Numerous modifications to the guidelines have been 
implemented to make them shorter and enhance “user-
friendliness.” Guidelines are written and presented in 
a modular “knowledge chunk” format, in which each 
chunk includes a table of recommendations, a brief 
synopsis, recommendation-specific supportive text and, 
when appropriate, flow diagrams or additional tables. 
Hyperlinked references are provided for each modular 
knowledge chunk to facilitate quick access and review. 
Word limit targets and a web supplement for useful but 
noncritical tables and figures are 2 recent modifications.
In recognition of the importance of cost–value con-
siderations, in certain guidelines, when appropriate and 
feasible, an analysis of value for a drug, device, or in-
tervention may be performed in accordance with the 
ACC/AHA methodology.3
To ensure that guideline recommendations remain 
current, new data will be reviewed on an ongoing ba-
sis by the writing committee and staff. Going forward, 
targeted sections or knowledge chunks will be revised 
dynamically after publication and timely peer review 
of potentially practice-changing science. The previous 
designations of “full revision” and “focused update” 
will be phased out. For additional information and poli-
cies on guideline development, readers may consult the 
ACC/AHA guideline methodology manual4 and other 
methodology articles.5–7
Selection of Writing Committee Members
The Joint Committee strives to ensure that the guide-
line writing committee members have requisite content 
expertise and are representative of the broader cardio-
vascular community. Experts are selected across a spec-
trum of backgrounds, representing different geographic 
regions, sexes, races, ethnicities, intellectual perspectives 
or biases, and clinical practice settings. Organizations and 
professional societies with related interests and expertise 
are invited to participate as partners or collaborators.
Relationships With Industry and Other 
Entities
The ACC and AHA have rigorous policies and meth-
ods to ensure that documents are developed without 
bias or improper influence. The complete policy on re-
lationships with industry and other entities (RWI) can 
be found at https://www.acc.org/guidelines/about-
guidelines-and-clinical-documents/relationships-with-
industry-policy .  Appendix 1 of the guideline lists writing 
committee members’ relevant RWI; for the purposes of 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e76
CLINICAL STATEMENTS  
AND GUIDELINESfull transparency, their comprehensive disclosure infor -
mation is available online (https://www.ahajournals.org/
doi/suppl/10.1161/CIR.0000000000000923). Compre-
hensive disclosure information for the Joint Commit-
tee is also available at https://www.acc.org/guidelines/
about-guidelines-and-clinical-documents/guidelines-
and-documents-task-forces.
Evidence Review and Evidence Review 
Committees
In developing recommendations, the writing com-
mittee uses evidence-based methodologies that are 
based on all available data.4–5 Literature searches fo-
cus on randomized controlled trials (RCTs) but also 
include registries, nonrandomized comparative and 
descriptive studies, case series, cohort studies, sys-
tematic reviews, and expert opinion. Only key refer -
ences are cited.
An independent evidence review committee is 
commissioned when there are one or more questions 
deemed of utmost clinical importance that merit for -
mal systematic review to determine which patients 
are most likely to benefit from a drug, device, or 
treatment strategy, and to what degree. Criteria for 
commissioning an evidence review committee and 
formal systematic review include absence of a current 
authoritative systematic review, feasibility of defining 
the benefit and risk in a time frame consistent with 
the writing of a guideline, relevance to a substantial 
number of patients, and likelihood that the findings 
can be translated into actionable recommendations. 
Evidence review committee members may include 
methodologists, epidemiologists, clinicians, and bio-
statisticians. Recommendations developed by the 
writing committee on the basis of the systematic re-
view are marked “SR.”
Guideline-Directed Management and 
Therapy
The term guideline-directed management and therapy 
(GDMT) encompasses clinical evaluation, diagnos-
tic testing, and both pharmacological and procedural 
treatments. For these and all recommended drug treat-
ment regimens, the reader should confirm dosage with 
product insert material and evaluate for contraindica-
tions and interactions. Recommendations are limited to 
drugs, devices, and treatments approved for clinical use 
in the United States.
Patrick T. O’Gara, MD, MACC, FAHA
Chair, ACC/AHA Joint Committee on Clinical Practice 
Guidelines1. INTRODUCTION
1.1. Methodology and Evidence Review
The recommendations listed in this document are, 
whenever possible, evidence based. An extensive review 
was conducted on literature published through March 
1, 2020. Searches were extended to studies, reviews, 
and other evidence involving human subjects that were 
published in English and indexed in PubMed, EMBASE, 
Cochrane, Agency for Healthcare Research and Quality 
Reports, and other selected databases relevant to this 
guideline. Key search words included but were not limit-
ed to the following: valvular heart disease, aortic steno-
sis, aortic regurgitation, bicuspid aortic valve, mitral ste-
nosis, mitral regurgitation, tricuspid stenosis, tricuspid 
regurgitation, pulmonic stenosis, pulmonic regurgita-
tion, prosthetic valves, anticoagulation therapy, infective 
endocarditis, cardiac surgery, transcatheter aortic valve 
replacement or implantation, and percutaneous mitra-
clip. Additionally, the committee reviewed documents 
related to the subject matter previously published by the 
ACC and AHA. The references selected and published in 
this document are representative and not all-inclusive.
1.2. Organization of the Writing 
Committee
The writing committee was composed of clinicians, 
which included cardiologists, interventionalists, sur -
geons, anesthesiologists, and a patient representative. 
Members were required to disclose all RWI relevant to 
the data under consideration.
1.3. Document Review and Approval
This document was reviewed by 2 official reviewers each 
nominated by the ACC and the AHA, as well as content 
reviewers nominated by the ACC and AHA. Reviewers’ 
RWI information was distributed to the writing commit-
tee and is published in this document (Appendix 2).
1.4. Scope of the Guideline
The focus of this guideline is the diagnosis and man-
agement of adult patients with valvular heart disease 
(VHD). A full revision of the original 1998 VHD guide-
line was made in 2006, and an update was made in 
2008.1 Another full revision was made in 2014,2 with an 
update in 2017.3 There was an additional statement of 
clarification specifically for surgery for aortic dilation in 
patients with bicuspid aortic valves (BAV) in 2016.4 The 
present guideline will replace the 2014 guideline and 
2017 focused update. Some recommendations from 
the earlier VHD guidelines have been updated as war -
ranted by new evidence or a better understanding of 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e77
CLINICAL STATEMENTS  
AND GUIDELINESearlier evidence, whereas others that were inaccurate, 
irrelevant, or overlapping were deleted or modified. 
Throughout, our goal was to provide the clinician with 
concise, evidence-based, contemporary recommenda-
tions and the supporting documentation to encourage 
their use. Where applicable, sections were divided into 
subsections of 1) diagnosis and follow-up, 2) medical 
therapy, and 3) intervention. The purpose of these sub-
sections is to categorize the Class of Recommendation 
according to the clinical decision-making pathways that 
caregivers use in the management of patients with VHD.
The document recommends a combination of life-
style modifications and medications that constitute 
components of GDMT. For both GDMT and other rec-
ommended drug treatment regimens, the reader is 
advised to confirm dosages with product insert mate-
rial and to carefully evaluate for contraindications and 
drug–drug interactions. Table  1 is a list of associated 
guidelines that may be of interest to the reader.
1.5. Class of Recommendation and Level 
of Evidence
The Class of Recommendation (COR) indicates the 
strength of recommendation, encompassing the esti-
mated magnitude and certainty of benefit in proportion 
to risk. The Level of Evidence (LOE) rates the quality of 
scientific evidence supporting the intervention on the 
basis of the type, quantity, and consistency of data from 
clinical trials and other sources (Table 2).11.6. AbbreviationsTable 1. Associated Guidelines and Related References
Title OrganizationPublication Year 
(Reference)
Recommendations for Evaluation of the Severity of Native Valvular Regurgitation With Two-Dimensional and 
Doppler EchocardiographyASE 20175
European Association of Echocardiography Recommendations for the Assessment of Valvular Regurgitation, 
Part 2: Mitral and Tricuspid Regurgitation (Native Valve Disease)EAE 20106
Guidelines for the Management of Patients With Atrial Fibrillation ACC/AHA/ESC 2006, 2008, 20197–9
Guidelines for the Management of Adults With Congenital Heart Disease ACC/AHA 201810
Echocardiographic Assessment of Valve Stenosis: EAE/ASE Recommendations for Clinical Practice EAE/ASE 200911
Recommendations on the Echocardiographic Assessment of Aortic Valve Stenosis: A Focused Update from the 
European Association of Cardiovascular Imaging and the American Society of EchocardiographyEACI/ASE 201712
Guidelines for the Evaluation of Valvular Regurgitation After Percutaneous Valve Repair or Replacement:  
A Report from the American Society of Echocardiography ASE 201913
Recommendations for Evaluation of Prosthetic Valves With Echocardiography and Doppler Ultrasound ASE 200914
Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy ACCF/AHA 201115
202016
Guidelines on the Management of Cardiovascular Diseases During Pregnancy ESC 2011, 201817, 18
Antithrombotic and Thrombolytic Therapy for Valvular Disease: Antithrombotic Therapy and Prevention of Thrombosis ACCP 201219
Guidelines on the Management of Valvular Heart Disease ESC/EACTS 201220
201721
Guideline for the Management of Heart Failure ACCF/AHA 201722
ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; ACCP , American College of Chest Physicians; AHA, 
American Heart Association; ASE, American Society of Echocardiography; EACI, European Association of Cardiovascular Imaging; EACTS, European Association of 
Cardio Thoracic Surgery; EAE, European Association of Echocardiography; and ESC, European Society of Cardiology.
Abbreviation Meaning/Phrase
2D 2-dimensional
3D 3-dimensional
ACE angiotensin-converting enzyme
AF atrial fibrillation
ARB angiotensin receptor blocker
aPTT activated partial thromboplastin time
AR aortic regurgitation
AS aortic stenosis
AVR aortic valve replacement
BAV bicuspid aortic valve
BNP B-type natriuretic peptide
CABG coronary artery bypass graft surgery
CAD coronary artery disease
CMR cardiac magnetic resonance
COR Class of Recommendation
CT computed tomography
ECG electrocardiogram
GDMT guideline-directed management and therapy
HF heart failure
IE infective endocarditis
INR international normalized ratio
LA left atrium (left atrial)
LMWH low-molecular-weight heparin
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e78
CLINICAL STATEMENTS  
AND GUIDELINES2. GENERAL PRINCIPLES
2.1. Evaluation of the Patient With 
Known or Suspected Native VHD
Patients with VHD may present with a heart murmur, 
symptoms, or incidental findings of valvular abnormali-
ties on noninvasive testing. Irrespective of the presenta-
tion, all patients with known or suspected VHD should 
undergo an initial meticulous history and physical ex-
amination. A detailed physical examination should be 
performed to diagnose and assess the severity of valve 
lesions. An electrocardiogram (ECG) to confirm heart 
rhythm and a chest x-ray to assess the presence or ab-
sence of pulmonary congestion or other lung pathology 
may be helpful in the initial assessment of patients with 
known or suspected VHD. A comprehensive transtho-
racic echocardiogram (TTE) with 2-dimensional (2D) im-
aging and Doppler interrogation should be performed 
for diagnosis and evaluation of known or suspected 
VHD. The TTE also provides additional information, 
such as the effect of the valve lesion on the cardiac 
chambers and great vessels, as well as an assessment 
of other valve lesions. To determine the optimal treat-
ment for a patient with VHD, ancillary testing may be 
required, such as transesophageal echocardiography (TEE), computed tomography (CT), cardiac magnetic 
resonance (CMR) imaging, stress testing, Holter moni-
toring, diagnostic hemodynamic cardiac catheteriza-
tion, or positron emission tomography (PET) combined 
with CT imaging. If intervention is contemplated, surgi-
cal or procedural risk should be estimated and other 
factors also considered, including comorbidities, frailty, 
and patient preferences and values (Table 3).
2.2. Definitions of Severity of Valve 
Disease
Classification of valve disease severity is based on multiple 
criteria, including symptoms, valve anatomy, valve hemo-
dynamics and the effects of valve dysfunction on ven-
tricular and vascular function (eg, end-organ damage). 
Surgical and transcatheter interventions are performed 
primarily on patients with severe VHD, but diagnosis, pa-
tient education, periodic monitoring, and medical thera-
py are essential elements in the management of patients 
at risk of VHD and with mild to moderate valve dysfunc-
tion. This document provides a classification of the pro-
gression of VHD, with 4 stages (A to D). Indications for 
intervention and periodic monitoring are dependent on 
1) the presence or absence of symptoms, 2) the severity 
of VHD, 3) the response of the LV and/or RV to volume 
or pressure overload caused by VHD, and 4) the effects 
on the pulmonary or systemic circulation (Table 4). The 
purpose of valvular intervention is to improve symptoms, 
prolong survival, and minimize the risk of VHD-related 
complications, such as irreversible ventricular dysfunction, 
pulmonary hypertension, stroke, and atrial fibrillation 
(AF). Thus, the criteria for “severe” VHD are based on 
predictors of clinical outcome from observational studies, 
registry data, and randomized clinical trials (RCTs) of pa-
tients with VHD. Of course, severity is a continuous vari-
able; categorizing disease into stages, from A to D, simply 
provides a framework, or starting point, for diagnosis and 
management, and it is recognized that not all patients 
will fit perfectly into a specific stage. Some patients will 
have symptoms or end-organ damage with valve hemo-
dynamics that do not quite meet specific disease severity 
criteria, and numerical measures may not match exactly 
across all categories. Conversely, other patients may re-
main asymptomatic without obvious evidence of end-
organ damage despite apparently severe VHD. Criteria 
for the stages of each individual valve lesion are listed in 
Section 3.1 (Table 13), Section 4.2 (Table 15), Section 6.1 
(Table 16), Section 7.2 (Table 17), Section 7.3 (Table 18), 
and Section 8.1 (Table 20).
2.3. Diagnosis and Follow-Up
2.3.1. Diagnostic Testing: Initial Diagnosis
TTE is the standard diagnostic test in the initial evalu-
ation of patients with known or suspected VHD.1–4 LOE Level of Evidence
LV left ventricle (left ventricular)
LVEDD left ventricular end-diastolic dimension
LVEF left ventricular ejection fraction
LVESD left ventricular end-systolic dimension
MDT multidisciplinary team
MR mitral regurgitation
MS mitral stenosis
NOAC non–vitamin K oral anticoagulant
NYHA New York Heart Association
PCI percutaneous coronary intervention
PET positron emission tomography
PMBC percutaneous mitral balloon commissurotomy
RCT randomized controlled trial
RV right ventricle (right ventricular)
SAVR surgical aortic valve replacement
TAVI transcatheter aortic valve implantation
TEE transesophageal echocardiography (echocardiogram)
TEER transcatheter edge-to-edge repair
TR tricuspid regurgitation
TTE transthoracic echocardiography (echocardiogram)
UFH unfractionated heparin
VHD valvular heart disease
ViV valve-in-valve
VKA vitamin K antagonist
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e79
CLINICAL STATEMENTS  
AND GUIDELINESTTE allows accurate assessment of valve anatomy and 
etiology, concurrent valve disease, and associated ab-
normalities, such as aortic dilation. Left ventricular (LV) 
anatomy and function are characterized by linear di-
mensions, as well as by 2D and 3D volumes and ejec-
tion fraction (LVEF), and it is recognized that decisions 
are most robust when based on sequential studies, giv-
en the inherent measurement variability for these pa-
rameters.5 Doppler echocardiography provides accurate 
noninvasive determination of valve hemodynamics.1,2,6 
For stenotic lesions, key measurements are maximum 
velocity, mean gradient, and valve area. For regurgi-
tant lesions, calculation of regurgitant orifice area, vol-
ume, and fraction is performed, when possible in the 
context of a multiparameter severity grade based on color Doppler imaging, continuous- and pulsed-wave 
Doppler recordings, and the presence or absence of 
distal flow reversals. Pulmonary systolic pressure also 
is estimated, along with qualitative evaluation of right 
ventricular (RV) size and function.7 In selected patients, 
additional testing, such as stress testing, TEE, cardiac 
catheterization, and CT or CMR imaging, might be 
indicated. However, both the performance and inter -
pretation of these diagnostic tests require meticulous 
attention to detail, as well as expertise in cardiac imag-
ing and evaluation of hemodynamics. Because echocar -
diography remains the mainstay of the initial evaluation 
of all patients with VHD, it is recommended that the 
laboratory be an Intersocietal Accreditation Commis-
sion (IAC)–accredited program.8Table 2. Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient 
Care (Updated May 2019)*
 
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e80
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
2.3.2. Diagnostic Testing: Changing Signs or 
Symptoms
Patients with VHD should be instructed to promptly re-
port any change in symptom status. The onset of symp-
toms or a change in the physical examination should 
raise concern about the cardiac response to the valve 
lesion, necessitating a repeat TTE. A repeat comprehen-
sive TTE study can determine whether symptoms are 
caused by progressive valve dysfunction, deterioration 
of the ventricular response to the volume or pressure 
overload, or another etiology. New signs on physical 
examination also warrant a repeat TTE.1–7 This requires 
that patients with known VHD have access to a primary 
care provider and a cardiovascular specialist.
2.3.3. Diagnostic Testing: Routine Follow-Up
After initial evaluation of an asymptomatic patient with 
VHD, the clinician should continue regular follow-up with 
periodic examinations and TTE. The purpose of follow-
up is to prevent the irreversible consequences of severe VHD, primarily affecting the status of the ventricles and 
pulmonary circulation, which may occur in the absence 
of symptoms. At a minimum, a yearly history and physical 
examination are necessary. The frequency of repeat 2D 
and Doppler echocardiography is based on the type and 
severity of the valve lesion, the known rate of progression 
of the specific valve lesion, and the effect of the valve le-
sion on the affected ventricle (Table 5).1–14 Patients with 
Stages C2 and D disease are not included in this table 
because they would be considered candidates for inter -
vention. The follow-up interval may be extended in pa-
tients with mild regurgitation who show no change over 
a 10- to 15-year period. In addition to routine periodic 
imaging, the onset of symptoms or a change in the physi-
cal examination should raise concern about the cardiac 
response to the valve lesion, necessitating a repeat TTE.
2.3.4. Diagnostic Testing: Cardiac Catheterization
Although TTE is now able to provide the required 
anatomic and hemodynamic information in most Table 3. Evaluation of Patients With Known or Suspected VHD
Reason Test Indication
Initial evaluation: All patients with known or 
suspected valve diseaseTTE* Establishes chamber size and function, valve morphology and severity, and 
effect on pulmonary and systemic circulation
History and physical Establishes symptom severity, comorbidities, valve disease presence and 
severity, and presence of HF 
ECG Establishes rhythm, LV function, and presence or absence of hypertrophy
Further diagnostic testing: Information required for 
equivocal symptom status, discrepancy between 
examination and echocardiogram, further definition 
of valve disease, or assessing response of the 
ventricles and pulmonary circulation to load and to 
exerciseChest x-ray Important for the symptomatic patient; establishes heart size and presence 
or absence of pulmonary vascular congestion, intrinsic lung disease, and 
calcification of aorta and pericardium
TEE Provides high-quality assessment of mitral and prosthetic valve, including 
definition of intracardiac masses and possible associated abnormalities 
(eg, intracardiac abscess, LA thrombus)
CMR Provides assessment of LV volumes and function, valve severity, and aortic 
disease
PET CT Aids in determination of active infection or inflammation
Stress testing Gives an objective measure of exercise capacity
Catheterization Provides measurement of intracardiac and pulmonary pressures, valve 
severity, and hemodynamic response to exercise and drugs
Further risk stratification: Information on future 
risk of the valve disease, which is important for 
determination of timing of interventionBiomarkers Provide indirect assessment of filling pressures and myocardial damage
TTE strain Helps assess intrinsic myocardial performance
CMR Assesses fibrosis by gadolinium enhancement
Stress testing Provides prognostic markers
Procedural risk Quantified by STS (Predicted Risk of Mortality) and TAVI scores
Frailty score Provides assessment of risk of procedure and chance of recovery of quality of life
Preprocedural testing: Testing required before valve 
interventionDental examination Rules out potential infection sources
CT coronary angiogram 
or invasive coronary 
angiogramGives an assessment of coronary anatomy
CT: Peripheral Assesses femoral access for TAVI and other transcatheter procedures
CT: Cardiac Assesses suitability for TAVI and other transcatheter procedures
*TTE is the standard initial diagnostic test in the initial evaluation of patients with known or suspected VHD.
CMR indicates cardiac magnetic resonance; CT, computed tomography; ECG, electrocardiogram; HF, heart failure; LV, left ventricular; PET, positron emission 
tomography; STS, Society of Thoracic Surgeons; TAVI, transcatheter aortic valve implantation; TEE, transesophageal echocardiography; TTE, transthoracic 
echocardiography; and VHD, valvular heart disease.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e81
CLINICAL STATEMENTS  
AND GUIDELINESpatients with VHD, there is still a subset of patients 
in whom hemodynamic catheterization is necessary 
to ensure that the proper decision about treatment 
is made. If noninvasive testing yields inconclusive 
data, particularly in the symptomatic patient, or if 
there is a discrepancy between the noninvasive tests 
and clinical findings, a hemodynamic cardiac cath-
eterization with direct intracardiac measurements of 
transvalvular pressure gradients and cardiac output 
measurements provides valuable clinical information. 
Severity of stenosis may be underestimated when im-
aging is difficult or when the Doppler beam is not 
aligned parallel to the direction of the high-velocity 
jet. Severity of valve regurgitation may be overesti-
mated or underestimated if the image or Doppler 
data quality is suboptimal. Contrast angiography is 
sometimes useful for a semiquantitative assessment 
of the severity of regurgitation in those instances in 
which the noninvasive results are discordant with the 
physical examination.1 A major advantage of cardiac 
catheterization is the measurement of intracardiac 
pressures and pulmonary vascular resistance, which 
may further aid in decision-making about valve intervention. Diagnostic interventions that can be 
performed in the catheterization laboratory include 
the use of dobutamine in low-flow states, pulmonary 
vasodilators in pulmonary hypertension, and exercise 
hemodynamics in patients with discrepant symp-
toms.1,2 A hemodynamic catheterization needs to be 
done with meticulous attention to detail by persons 
with knowledge and expertise in assessing patients 
with VHD.
2.3.5. Diagnostic Testing: Exercise Testing
In a subset of patients, exercise stress testing will be 
of additional value in determining optimal therapy. 
Because of the slow, insidious rate of progression 
of many valve lesions, patients may deny symptoms 
as they gradually limit their activity level over several 
years to match the gradual limitations imposed by 
the valve lesion. In patients with an equivocal history 
of symptoms, exercise testing helps identify those 
who are truly symptomatic.1,2 Exercise stress testing 
(ie, examining the exercise capacity and blood pres-
sure response) is of prognostic value in patients with 
asymptomatic valve disease and provides further in-
formation about the timing of a potential interven-
tion.3–11 It is important that exercise testing in patients 
with severe VHD always be performed by trained op-
erators, with continuous monitoring of the ECG and 
blood pressure.
2.4. Basic Principles of Medical Therapy
In patients being evaluated for VHD, standard GDMT 
for cardiac risk factors, including hypertension, diabetes 
mellitus, and hyperlipidemia, should not be neglected. 
Heart-healthy lifestyle factors (exercising, consuming a 
healthy diet, not smoking, and maintaining a normal 
body size) are no different for patients with VHD than 
for the general population. Many patients with asymp-
tomatic VHD feel better with regular aerobic exercise to 
improve cardiovascular fitness.1–3 Although heavy iso-
metric repetitive training might increase LV afterload, 
resistive training with small free weights or repetitive Table 4. Stages of VHD
Stage Definition Description
A At risk Patients with risk factors for 
development of VHD
B Progressive Patients with progressive VHD (mild to 
moderate severity and asymptomatic)
C
 
 Asymptomatic 
severe
 
 Asymptomatic patients who have the 
criteria for severe VHD:
  C1: Asymptomatic patients with 
severe VHD in whom the LV or RV 
remains compensated
  C2: Asymptomatic patients with 
severe VHD with decompensation of 
the LV or RV
D Symptomatic severe Patients who have developed symptoms 
as a result of VHD
LV indicates left ventricle; RV, right ventricle; and VHD, valvular heart 
disease.
Table 5. Frequency of Echocardiograms in Asymptomatic Patients With VHD and Normal LV Function
StageType of Valve Lesion
Aortic Stenosis* Aortic Regurgitation Mitral Stenosis Mitral Regurgitation
Progressive (Stage B) Every 3–5 y (mild severity; 
Vmax 2.0–2.9 m/s)Every 3–5 y (mild severity) Every 3–5 y (MV area >1.5 
cm2)Every 3–5 y (mild severity)
Every 1–2 y moderate 
severity; Vmax 3.0–3.9 m/s)Every 1–2 y (moderate 
severity)Every 1–2 y (moderate 
severity)
Severe asymptomatic
(Stage C1)Every 6–12 mo (Vmax ≥4 m/s) Every 6–12 mo Every 1–2 y (MV area 1.0–
1.5 cm2)Every 6–12 mo
Dilating LV: More frequently Every year (MV area <1.0 cm2)Dilating LV: More frequently
Patients with mixed valve disease may require serial evaluations at intervals earlier than recommended for single-valve lesions. These intervals apply to most 
patients with each valve lesion and do not take into consideration the etiology of the valve disease.
*With normal stroke volume.
LV indicates left ventricle; MV, mitral valve; VHD, valvular heart disease; and Vmax, maximum velocity.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al  2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021
 
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e82
CLINICAL STATEMENTS  
AND GUIDELINESisolated muscle training may be used to strengthen in-
dividual muscle groups. Most patients with LV systolic dysfunction and severe VHD will undergo intervention 
for the valve itself. However, if intervention is declined 
or not feasible, standard GDMT drug therapy for LV sys-tolic dysfunction should be continued, including diuret-ics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta blockers, 
aldosterone antagonists, and/or sacubitril/valsartan and biventricular pacing, as indicated in the guidelines for heart failure (HF).
1 In patients with stenotic valve lesions, 
abrupt lowering of blood pressure should be avoided.1 
Rheumatic fever prophylaxis and infective endocardi-
tis (IE) prophylaxis should be provided to appropriate 
groups of patients, as outlined in Sections 2.4.1 and 
2.4.2. The maintenance of optimal oral health remains the most important component of an overall healthcare program in preventing IE. Influenza and pneumococcal vaccinations should follow standard recommendations 
in patients with VHD. For subsets of patients with AF and VHD, anticoagulation is discussed in Section 2.4.3.
2.4.1. Secondary Prevention of Rheumatic Fever
Recommendation for Secondary Prevention of Rheumatic Fever
COR LOE Recommendation
1 C-EO1. 
 
In patients with rheumatic heart 
disease, secondary prevention of 
rheumatic fever is indicated (Tables 6 and 7).
1 
Synopsis
Rheumatic fever is an important cause of VHD world-
wide, although it is less common in high-income coun-tries. Rapid detection and treatment of streptococcal 
pharyngitis constitute primary prevention of rheumatic 
fever. For patients with previous episodes of rheumatic fever or in those with evidence of rheumatic heart dis-ease, long-term antistreptococcal prophylaxis is indicat-ed for secondary prevention.
1Recommendation-Specific Supportive Text
1. Recurrent rheumatic fever is associated with a 
worsening of rheumatic heart disease. However, infection with group A streptococcus does not 
have to be symptomatic to trigger a recurrence, 
and rheumatic fever can recur even when the symptomatic infection is treated. Prevention of recurrent rheumatic fever requires long-term anti-microbial prophylaxis rather than recognition and 
treatment of acute episodes of group A strepto-coccus pharyngitis. The recommended treatment regimens and duration of secondary prophylaxis are shown in Tables 6 and 7.
2.4.2. IE Prophylaxis
Recommendations for IE Prophylaxis
Referenced studies that support the recommendations are 
summarized in
 
Online Data Supplement 1.
COR LOE Recommendations
2a C-LD1.
  
Antibiotic prophylaxis is reasonable before 
dental procedures that involve manipulation of gingival tissue, manipulation of the periapical region of teeth, or perforation of the oral mucosa in patients with VHD who have any of the following
1–9:
a.
  
Prosthetic cardiac valves, including 
transcatheter-implanted prostheses and homografts.
b.
  
Prosthetic material used for cardiac valve 
repair, such as annuloplasty rings, chords, or clips.
c.
  
Previous IE.
d.
  
Unrepaired cyanotic congenital heart disease or repaired congenital heart disease, with residual shunts or valvular regurgitation at the site of or adjacent to the site of a prosthetic patch or prosthetic device.
e.
  
Cardiac transplant with valve regurgitation 
attributable to a structurally abnormal valve.
3: No 
BenefitB-NR2.
  
In patients with VHD who are at high risk of IE, antibiotic prophylaxis is not recommended for nondental procedures (eg, TEE, esophagogastroduodenoscopy, colonoscopy, or cystoscopy) in the absence of active infection.
10,11Table 6.  Secondary Prevention of Rheumatic Fever
Antibiotics for Prevention Dosage*
Penicillin G benzathine 1.2 million U intramuscularly every 4 wk†
Penicillin V potassium 250 mg orally twice daily
Sulfadiazine 1 g orally once daily
Macrolide or azalide antibiotic 
(for patients allergic to penicillin and sulfadiazine)‡Varies
*In patients with documented valvular heart disease, the duration of 
rheumatic fever prophylaxis should be ≥10 y or until the patient is 40 y of age 
(whichever is longer). Lifelong prophylaxis may be recommended if the patient is at high risk of group A streptococcus exposure. Secondary rheumatic heart disease prophylaxis is required even after valve replacement.
†Administration every 3 wk is recommended in certain high-risk situations.‡Macrolide antibiotics should not be used in persons taking other 
medications that inhibit cytochrome P450 3A, such as azole antifungal agents, HIV protease inhibitors, and some selective serotonin reuptake inhibitors.
Adapted from Gerber et al.
1Table 7.  Duration of Secondary Prophylaxis for Rheumatic Fever
Type Duration After Last Attack*
Rheumatic fever with carditis and 
residual heart disease (persistent VHD†)10 y or until patient is 40 y of age (whichever is longer)
Rheumatic fever with carditis but no residual heart disease (no valvular disease†)10 y or until patient is 21 y of age (whichever is longer)
Rheumatic fever without carditis 5 y or until patient is 21 y of age (whichever is longer)
*Lifelong prophylaxis may be recommended if the patient is at high risk 
of group A streptococcus exposure. Secondary rheumatic heart disease 
prophylaxis is required even after valve replacement.
†Clinical or echocardiographic evidence.VHD indicates valvular heart disease.Adapted from Gerber et al.
1
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e83
CLINICAL STATEMENTS  
AND GUIDELINESSynopsis
With the absence of RCTs addressing the efficacy of anti-
biotic prophylaxis for prevention of IE1,12–14 and given un-
certainty about which patient populations are at highest 
risk, these recommendations are based on pathophysio-
logical considerations, limited data, and clinical expertise. 
A prospective study demonstrated that prophylactic anti-
biotics given to patients for what is typically considered a 
high-risk dental procedure reduced but did not eliminate 
the incidence of bacteremia.2 A 2013 Cochrane Data-
base systematic review of antibiotic prophylaxis for the 
prevention of IE in dentistry concluded that there is no 
evidence to determine whether antibiotic prophylaxis is 
effective or ineffective, highlighting the need for further 
study of this long-standing clinical dilemma.1 Epidemio-
logical data conflict with regard to changes in the in-
cidence of IE after adoption of more limited antibiotic 
prophylaxis guidelines.15–22 The consensus of the writing 
committee is that antibiotic prophylaxis is reasonable for 
the subset of patients at highest risk of developing IE and 
at high risk of experiencing adverse outcomes from IE. 
There is no evidence for IE prophylaxis in gastrointestinal 
procedures or genitourinary procedures, in the absence 
of known active infection.
Recommendation-Specific Supportive Text
1. The risk of developing IE is highest in patients with 
a prosthetic valve, prior IE, or congenital heart dis-
ease with residual flow disturbances.3 IE has been 
reported to occur after transcatheter aortic valve 
implantation (TAVI) at rates equal to or exceeding 
those associated with surgical aortic valve replace-
ment (SAVR) and is associated with a high 1-year 
mortality rate of 75%.23,24 IE may also occur after 
valve repair with prosthetic material, which results 
in high in-hospital and 1-year mortality rates, 
even with surgical intervention.25,26 IE appears to 
be more common in heart transplant recipients 
than in the general population, according to lim-
ited data.3 The risk of IE is highest in the first 6 
months after transplantation because of endothe-
lial disruption, high-intensity immunosuppressive 
therapy, frequent central venous catheter access, 
and frequent endomyocardial biopsies.3 Persons 
at risk of IE can reduce potential sources of bac-
terial seeding by maintaining optimal oral health 
through regular professional dental care and the 
use of appropriate dental products, such as man-
ual, powered, and ultrasonic toothbrushes; dental 
floss; and other plaque-removal devices.
2. Transient bacteremia is commonly seen in rou-
tine activities such as brushing teeth and floss-
ing (20% to 68%), using toothpicks (20% to 
40%), and simply chewing food (7% to 51%). The incidence of IE after most procedures is low, 
with no controlled data supporting the benefit of 
antibiotic prophylaxis. Indiscriminate use of anti-
biotics can be associated with the development 
of resistant organisms, Clostridium difficile colitis, 
unnecessary expense, and drug toxicity. The rate 
of transient bacteremia during or immediately 
after endoscopy is 2% to 5%, and the organisms 
typically identified are unlikely to cause IE.11,27,28 
The rate of bacteremia does not increase with 
biopsy, polypectomy, or sphincterotomy. Some 
gastrointestinal procedures are associated with 
rates of bacteremia higher than that for simple 
endoscopy; these procedures include esophageal 
dilation (as high as 45%), sclerotherapy (31%), 
and endoscopic retrograde cholangiopancreatog-
raphy (6% to 18%).29 However, no studies have 
shown reduced rates of IE with antibiotic prophy-
laxis. Surgery, instrumentation, or diagnostic pro-
cedures that involve the genitourinary tract may 
cause bacteremia. In the absence of infection, the 
rate of bacteremia after urinary tract procedures 
is low. In patients with bacteriuria, antimicrobial 
therapy before elective procedures, including lith-
otripsy, typically is provided.30
2.4.3. Anticoagulation for AF in Patients With 
VHD
Recommendations for Anticoagulation for AF in Patients With VHD
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 2.
COR LOE Recommendations
1 A1.  For patients with AF and native valve heart 
disease (except rheumatic mitral stenosis 
[MS]) or who received a bioprosthetic valve >3 
months ago, a non–vitamin K oral anticoagulant 
(NOAC) is an effective alternative to VKA 
anticoagulation and should be administered on 
the basis of the patient’s CHA2DS2-VASc score.1,2
1 C-EO2.  For patients with AF and rheumatic MS, 
long-term VKA oral anticoagulation is 
recommended. 
2a B-NR3.  For patients with new-onset AF ≤3 months 
after surgical or transcatheter bioprosthetic 
valve replacement, anticoagulation with a VKA 
is reasonable.3–6
3: Harm B-R4.  In patients with mechanical heart valves 
with or without AF who require long-term 
anticoagulation with VKA to prevent valve 
thrombosis, NOACs are not recommended.7 
Synopsis
Patients with VHD and AF should be evaluated for risk 
of thromboembolic events and to treat them with oral 
anticoagulation if they are at high risk. VKAs are the 
anticoagulation drugs of choice for patients with rheu-
matic MS and mechanical heart valves. NOACs are an 
alternative to VKAs in patients with AF and 1) with 
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e84
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
bioprosthetic valves >3 months after implantation or, 
2) with native VHD excluding rheumatic MS (Figure 1).
Recommendation-Specific Supportive Text
1. The 4 large RCTs8–14 comparing NOACs with war -
farin included small numbers of patients with 
VHD, prior valve repair, and bioprosthetic valves 
(excluding moderate to severe rheumatic MS 
and mechanical heart valves). In addition to the 
subsequent meta-analyses,1,15–17 examinations of 
insurance claims data and large registries18 have 
consistently confirmed no signal for a differen-
tial effect between NOAC and VKA therapy.19,20 
More consistently observed is a net clinical ben-
efit, with fewer events in patients using NOACs 
than in patients on VKA therapy. Validation of the 
CHA2DS2-VASc risk schema in patients with VHD 
(excluding moderate to severe rheumatic MS and 
mechanical heart valves) has been performed in 
large registries,2 confirming the applicability of 
this score. Bioprosthetic valves do not appear to 
be independent predictors of thromboembolic 
events in patients with AF.19
2. The coexistence of AF and rheumatic MS is com-
mon and confers a substantial risk of throm-
boembolic events. These patients have been 
specifically excluded from NOAC trials, yet a single registry study and a US claims database 
analysis do suggest that NOACs may be poten-
tially preferable.21,22 These findings need further 
validation, and currently the use of NOACs can-
not be supported over VKA (target international 
normalized ratio [INR] of 2.5).
3. Postoperative AF after VHD intervention is 
associated with increased stroke and mortality 
rates3,4 irrespective of the CHA2DS2-VASc score. 
Anticoagulation in this setting may reduce these 
endpoints. There are conflicting data about the 
safety and efficacy of NOAC therapy in patients 
early after implantation of a bioprosthesis.5,6,23 
Until more data are available, the writing com-
mittee favors using VKA for patients with AF in 
the first 3 months after surgical or transcath-
eter bioprosthetic valve implantation to prevent 
thromboembolic events. The optimal duration 
of anticoagulation is not well defined. Repeat 
evaluation is encouraged in all patients to detect 
arrhythmia recurrence in the context of their 
CHA2DS2-VASc scores.
4. The phase II study comparing dabigatran to warfarin 
(RE-ALIGN [Randomized, Phase II Study to Evaluate 
the Safety and Pharmacokinetics of Oral Dabigatran 
Etexilate in Patients after Heart Valve Replacement]) 
was halted prematurely because of excess stroke and 
Figure 1. Anticoagulation for AF in Patients With VHD.
Colors correspond to Table 2. AF indicates atrial fibrillation; MS, mitral stenosis; NOAC, non–vitamin K oral anticoagulant; VHD, valvular heart disease; and VKA, 
vitamin K antagonist.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al  2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 
February 2, 2021 e85
CLINICAL STATEMENTS  
AND GUIDELINESbleeding in the dabigatran group. Until there is an 
explanation of why these adverse events occurred, there is insufficient evidence to support the use of NOACs for patients with mechanical heart valves.
7
2.5. Evaluation of Surgical and 
Interventional Risk
Recommendation for Evaluation of Surgical and Interventional Risk
COR LOE Recommendation
1 C-EO1.
  
For patients with VHD for whom 
intervention is contemplated, individual 
risks should be calculated for specific surgical and/or transcatheter procedures, using online tools when available, and discussed before the procedure as a part of a shared decision-making process. 
Synopsis
Risk assessment has become a foundational element 
of the preprocedural evaluation of patients with VHD for whom intervention to correct the valve lesion may be contemplated. Although there are limitations to the scoring systems used to estimate the risk of adverse 
outcomes, these estimates provide a useful point of reference against which procedural benefits can be weighed. Numerical estimates of risk are just one com-ponent of the multidisciplinary team (MDT) assessment process, and factors not routinely included in risk algo-rithms (eg, liver disease, porcelain aorta) add important dimensions. The availability of TAVI for treatment of symptomatic severe aortic stenosis (AS) across the sur -
gical risk spectrum emphasizes the need to have discus-sions about younger age at implantation, valve durabil-ity, and the potential need for permanent pacemaker implantation. For young patients (eg, <65 years of age) who opt for a surgical bioprosthesis, strategies for se-quential procedures over a longer follow-up period (ie, valve-in-valve [ViV] TAVI versus reoperation) must be addressed.
Recommendation-Specific Supportive Text
1. The decision to intervene, as well as the type of 
procedure recommended, is based on an assess-ment of patient-, procedure-, and institution- or operator-specific short-term risks and long-term benefits (Table 8). Surgical mortality rate and major 
morbidity risks can be calculated with a web-based tool derived from the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery database for 6 specific procedures (
http://riskcalc.sts.org/
stswebriskcalc/calculate
). TAVI-specific risk predic-
tion tools are also available (
http://tools.acc.org/
TAVRRisk/#!/content/evaluate/
).1–6 Frailty assess-
ment for at-risk patients is routine.7–11 Patients 
toward the higher end of the risk spectrum, for 
whom intervention would be futile or associated with a high likelihood of a poor outcome, should Table 8.  Risk Assessment for Surgical Valve Procedures
CriteriaLow-Risk SAVR (Must 
Meet ALL Criteria in This 
Column)Low-Risk Surgical Mitral 
Valve Repair for Primary 
MR (Must Meet ALL 
Criteria in This Column)High Surgical Risk 
(Any 1 Criterion in This 
Column)Prohibitive Surgical Risk (Any 1 
Criterion in This Column)
STS-predicted risk of 
death*<3%
AND<1%
AND>8%
ORPredicted risk of death or major morbidity 
(all-cause) >50% at 30 d
OR
Frailty† None
ANDNone
AND≤1 Indice (moderate to 
severe)
OR≥2 Indices (moderate to severe)
OR
Cardiac or other major 
organ system compromise not to be improved postoperatively‡None
ANDNone
AND1 to 2 Organ systems
OR≥3 Organ systems
OR
Procedure-specific impediment§None None Possible procedure-specific 
impedimentSevere procedure-specific impediment
*Use of the STS Predicted Risk of Mortality (
http://riskcalc.sts.org/stswebriskcalc/#/
) to predict risk in a given institution with reasonable reliability is appropriate 
only if institutional outcomes are within 1 standard deviation of the STS average observed/expected mortality ratio for the procedure in question. The EUROSCORE 
II risk calculator may also be considered for use and is available at 
http://www.euroscore.org/calc.html
.
†Seven frailty indices: Katz Activities of Daily Living (independence in feeding, bathing, dressing, transferring, toileting, and urinary continence) plus 
independence in ambulation (no walking aid or assistance required, or completion of a 5-m walk in <6 s). Other scoring systems can be applied to calculate no, mild, or moderate to severe frailty.
‡Examples of major organ system compromise include cardiac dysfunction (severe LV systolic or diastolic dysfunction or RV dysfunction, fixed pulmonary 
hypertension); kidney dysfunction (chronic kidney disease, stage 3 or worse); pulmonary dysfunction (FEV
1 <50% or DLCO2 <50% of predicted); central nervous 
system dysfunction (dementia, Alzheimer’s disease, Parkinson’s disease, cerebrovascular accident with persistent physical limitation); gastrointestinal dysfunction 
(Crohn’s disease, ulcerative colitis, nutritional impairment, or serum albumin <3.0); cancer (active malignancy); and liver dysfunction (any history of cirrhosis, variceal bleeding, or elevated INR in the absence of VKA therapy).
§Examples of procedure-specific impediments include presence of tracheostomy, heavily calcified (porcelain) ascending aorta, chest malformation, arterial 
coronary graft adherent to posterior chest wall, and radiation damage.
D
LCO2 indicates diffusion capacity for carbon dioxide; FEV1, forced expiratory volume in 1 s; INR, international normalized ratio; LV, left ventricular; MR, mitral 
regurgitation; RV, right ventricular; SAVR, surgical aortic valve replacement; STS, Society of Thoracic Surgeons; and VKA, vitamin K antagonist.
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e86
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
be identified.12–18 Risk prediction tools for trans-
catheter mitral valve repair are comparatively less 
robust.17–19 The relationship between operator/
institutional case volume and outcomes has been 
explored for surgical20 and transcatheter21–23 aor-
tic valve replacement (AVR), surgical mitral valve 
repair and replacement,24–32 and transcatheter 
mitral valve repair.33 Table  9 includes examples 
of several factors that impact outcomes but are 
not routinely captured in currently available risk 
scores. Perioperative mortality rates for 6 specific 
surgical procedures are shown in Table  10. The 
potential to return to activities of daily living after 
an intervention must be considered.2.6. The Multidisciplinary Heart Valve 
Team and Heart Valve Centers
Recommendations for the Multidisciplinary Heart Valve Team and 
Heart Valve Centers 
COR LOE Recommendations
1 C-EO1.  Patients with severe VHD should be evaluated 
by a Multidisciplinary Heart Valve Team (MDT) 
when intervention is considered. 
2a C-LD2.  Consultation with or referral to a Primary 
or Comprehensive Heart Valve Center is 
reasonable when treatment options are being 
discussed for 1) asymptomatic patients with 
severe VHD, 2) patients who may benefit from 
valve repair versus valve replacement, or 3) 
patients with multiple comorbidities for whom 
valve intervention is considered.1–19
Synopsis
The value of the MDT has become increasingly appar -
ent as options in the treatment of VHD have broad-
ened. Heart Valve Centers, in the context of an inte-
grated multi-institutional model of care for patients 
with VHD, allow optimization of patient outcomes 
through improved decision-making and matching of 
patients to providers with appropriate expertise, expe-
rience, and resources.12 Primary and Comprehensive 
Heart Valve Centers are defined by their offerings and 
expertise in the management of patients with VHD12 
(Table 11).Table 9. Examples of Procedure-Specific Risk Factors for Interventions Not Incorporated Into Existing Risk Scores
SAVR TAVISurgical Mitral Valve Repair or 
Replacement TEER
Technical or anatomic
  Prior mediastinal radiation Aorto-iliac occlusive disease precluding 
transfemoral approachPrior sternotomy Multivalve disease
  Ascending aortic calcification 
(porcelain aorta may be 
prohibitive)Aortic arch atherosclerosis (protuberant 
lesions)
Severe MR or TR
Low-lying coronary arteries
Basal septal hypertrophy
Valve morphology (eg, bicuspid or 
unicuspid valve)
Extensive LV outflow tract calcificationPrior mediastinal radiation
Ascending aortic calcification 
(porcelain aorta may be prohibitive)Valve morphology (eg, 
thickening, perforations, clefts, 
calcification, and stenosis)
Prior mitral valve surgery
Comorbidities
  Severe COPD or home oxygen 
therapy
  Pulmonary hypertension
  Severe RV dysfunction
  Hepatic dysfunction
  Frailty*Severe COPD or home oxygen therapy
Pulmonary hypertension
Severe RV dysfunction
Hepatic dysfunction
Frailty*Severe COPD or home oxygen 
therapy
Pulmonary hypertension
Hepatic dysfunction
Frailty*Severe COPD or home oxygen 
therapy
Pulmonary hypertension
Hepatic dysfunction
Frailty*
Futility
  STS score >15
  Life expectancy <1 y
  Poor candidate for rehabilitationSTS score >15
Life expectancy <1 y
Poor candidate for rehabilitationSTS score >15
Life expectancy <1 y
Poor candidate for rehabilitationSTS score >15
Life expectancy <1 y
Poor candidate for rehabilitation
*Validated frailty scores include the Katz Activities of Daily Living Score.10,34,35
COPD indicates chronic obstructive pulmonary disease; MR, mitral regurgitation; RV, right ventricular; SAVR, surgical aortic valve replacement; STS, Society of 
Thoracic Surgeons; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; and TR, tricuspid regurgitation.
Table 10. Median Operative Mortality Rates for Specific Surgical 
Procedures (STS Adult Cardiac Surgery Database, 2019)
Procedure Mortality Rate (%)
AVR 2.2
AVR and CABG 4
AVR and mitral valve replacement 9
Mitral valve replacement 5
Mitral valve replacement and CABG 9
Mitral valve repair 1
Mitral valve repair and CABG 5
AVR indicates aortic valve replacement; CABG, coronary artery bypass graft 
surgery; and STS, Society of Thoracic Surgeons.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e87
CLINICAL STATEMENTS  
AND GUIDELINESTable 11. Structure of Primary and Comprehensive Valve Centers
Comprehensive (Level I) Valve Center Primary (Level II) Valve Center
Interventional procedures*
  TAVI–transfemoral TAVI–transfemoral
  Percutaneous aortic valve balloon dilation Percutaneous aortic valve balloon dilation
  TAVI–alternative access, including transthoracic (transaortic, transapical) 
and extrathoracic (eg, subclavian, carotid, caval) approaches 
  Valve-in-valve procedures  
 TEER  
  Prosthetic valve paravalvular leak closure  
  Percutaneous mitral balloon commissurotomy  
Surgical procedures*
  SAVR SAVR
  Valve-sparing aortic root procedures  
  Aortic root procedures for aneurysmal disease  
  Concomitant septal myectomy with AVR  
  Root enlargement with AVR  
  Mitral repair for primary MR Mitral repair for posterior leaflet primary MR†
  Mitral valve replacement‡ Mitral valve replacement‡
  Multivalve operations  
  Reoperative valve surgery  
  Isolated or concomitant tricuspid valve repair or replacement Concomitant tricuspid valve repair or replacement with mitral surgery
Imaging personnel
  Echocardiographer with expertise in valve disease and transcatheter and 
surgical interventionsEchocardiographer with expertise in valve disease and transcatheter and 
surgical interventions
  Expertise in CT with application to valve assessment and procedural 
planningExpertise in CT with application to valve assessment and procedural planning
  Interventional echocardiographer to provide imaging guidance for 
transcatheter and intraoperative procedures 
  Expertise in cardiac MRI with application to assessment of VHD  
Criteria for imaging personnel
  A formalized role/position for a “valve echocardiographer” who performs 
both the pre- and postprocedural assessment of valve diseaseA formalized role/position for a “valve echocardiographer” who performs 
both the pre- and postprocedural assessment of valve disease
  A formalized role/position for the expert in CT who oversees the 
preprocedural assessment of patients with valve diseaseA formalized role/position for the expert in CT who oversees the 
preprocedural assessment of patients with valve disease
  A formalized role/position for an interventional echocardiographer  
Institutional facilities and infrastructure
  MDT MDT
  A formalized role/position for a dedicated valve coordinator who organizes 
care across the continuum and system of careA formalized role/position for a dedicated valve coordinator who organizes 
care across the continuum and system of care
  Cardiac anesthesia support Cardiac anesthesia support
  Palliative care team Palliative care team
  Vascular surgery support Vascular surgery support
  Neurology stroke team Neurology stroke team
  Consultative services with other cardiovascular subspecialties  
  Consultative services with other medical and surgical subspecialties  
  Echocardiography–3D TEE; comprehensive TTE for assessment of valve 
diseaseEchocardiography–comprehensive TTE for assessment of valve disease
  Cardiac CT Cardiac CT
  ICU ICU
(Continued )
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e88
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Recommendation-Specific Supportive Text
1. The MDT is an established feature of heart valve 
programs20 and has been formally endorsed by the 
ACC, the American Society of Echocardiography, 
the Society for Cardiovascular Angiography 
and Interventions, the American Association for 
Thoracic Surgery, and the STS.12 Key members of 
the MDT include cardiologists with subspecialty 
expertise in the clinical evaluation of patients with 
VHD, as well as specialists in advanced cardiovas-
cular imaging. For the evaluation of the patient 
with secondary mitral regurgitation (MR) and tri-
cuspid regurgitation (TR), a specialist in HF also is 
included. Interventional cardiologists with training 
and expertise in VHD and surgeons experienced in 
the treatment of VHD anchor the MDT. Other team 
members include cardiovascular nurses, cardiovas-
cular anesthesiologists, and intensivists involved 
in periprocedural care. Finally, the engagement of 
the primary clinical cardiologist and patient is of 
critical importance. The MDT facilitates presenta-
tion of all appropriate options for medical, inter -
ventional, and surgical treatment to the patient in 
a balanced manner, using tools and techniques for 
shared decision-making in which patient prefer -
ences are considered.
2. Decision-making is particularly challenging for 
the asymptomatic VHD patient, for whom the 
risks of operative mortality and perioperative 
morbidity must be very low and the chances of 
a successful and durable surgical outcome very 
high. There is a substantial body of literature to support a relationship between institutional vol-
ume and mortality rate for many cardiovascular 
procedures, including SAVR,1–5 TAVI,6 and surgi-
cal mitral valve repair.7–11 Consideration should be 
given to consultation with or referral to a Primary 
or Comprehensive Heart Valve Center for asymp-
tomatic patients with severe VHD. Although 
excellent outcomes certainly can be achieved at 
lower-volume centers, assurance of outcomes 
equivalent to those of a higher-volume center 
is statistically more challenging.12 Similarly, for 
patients with multiple comorbidities for whom 
multispecialty collaboration is anticipated, care at 
a Comprehensive or Primary Valve Center ensures 
optimal outcomes. Although findings are mixed,13 
there are data to support relationships between 
center volume and complication rates in cardiac 
surgical care,14 between center volume and fail-
ure to rescue after procedural complications,15–17 
and between center volume and elements of 
infrastructure support.18,19
2.7. Management of Patients With VHD 
After Valve Intervention
Interventions in patients with VHD include both trans-
catheter and surgical approaches. A valve interven-
tion leaves the patient with either a prosthetic valve 
or a valve repair, often with an implanted device or 
other prosthetic material. Valve intervention does not 
eliminate valve disease; it replaces native valve disease 
with palliated valve disease. Patients with VHD con-
tinue to require periodic evaluation after intervention   Temporary mechanical support (including percutaneous support devices 
such as intra-aortic balloon counterpulsation, temporary percutaneous 
ventricular assist device or ECMO)Temporary mechanical support (including percutaneous support devices such 
as intra-aortic balloon counterpulsation, temporary percutaneous ventricular 
assist device or ECMO)
  Left/right ventricular assist device capabilities (on-site or at an affiliated 
institution) 
  Cardiac catheterization laboratory, hybrid catheterization laboratory, or 
hybrid OR laboratory§Cardiac catheterization laboratory
  PPM and ICD implantation PPM and ICD implantation
 Criteria for institutional facilities and infrastructure
  IAC echocardiography laboratory accreditation IAC echocardiography laboratory accreditation
  24/7 intensivist coverage for ICU  
*A primary (Level II) Center may provide additional procedures traditionally offered at a Comprehensive (Level I) Center as long as the criteria for competence 
and outcomes are met.
†If intraoperative imaging and surgical expertise exist.
‡If mitral valve anatomy is not suitable for valve repair.
§Equipped with a fixed radiographic imaging system and flat-panel fluoroscopy, offering catheterization laboratory-quality imaging and hemodynamic capability.
AVR indicates aortic valve replacement; CT, computed tomography; ECMO, extracorporeal membrane oxygenation; ICD, implantable cardioverter defibrillator; 
IAC, Intersocietal Accreditation Commission; ICU, intensive care unit; MDT, multidisciplinary team; MR, mitral regurgitation; MRI, magnetic resonance imaging; 
OR operating room; PPM, permanent pacemaker; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation; TEE, transesophageal 
echocardiography; TEER, transcatheter edge-to-edge repair; TTE, transthoracic echocardiography; VHD, valvular heart disease; and ViV, valve-in-valve.
Used with permission from Nishimura et al.12Table 11. Continued
Comprehensive (Level I) Valve Center Primary (Level II) Valve Center
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e89
CLINICAL STATEMENTS  
AND GUIDELINESfor early postprocedural issues, long-term medical 
therapy, monitoring of the prosthetic valve or repair, 
management of concurrent cardiac conditions, and 
persistent symptoms or functional limitation. Endo-
carditis prophylaxis is discussed in Section 2.4.2; an-
tithrombotic therapy for prosthetic valves in Sections 
11.2 to 11.5; and prosthetic valve complications, in-
cluding valve thrombosis, stenosis, or regurgitation, in 
Sections 11.6 to 11.8.
2.7.1. Procedural Complications
The most common complication early after surgical 
valve replacement is postoperative AF, which occurs 
in up to one-third of patients within 3 months of sur -
gery (see Sections 2.4.3 and 14.1). Other complications 
include stroke, vascular and bleeding complications, 
pericarditis, heart block requiring temporary or perma-
nent pacing (especially after AVR), HF, renal dysfunc-
tion, and infection. Complications after transcatheter 
interventions depend on the specific procedure but can 
include the need for permanent pacing, paravalvular 
leak, stroke, vascular complications, and residual valve 
dysfunction.
2.7.2. Primary and Secondary Risk Factor 
Evaluation and Treatment
Concurrent coronary artery disease (CAD) is common 
in adults with VHD. Management of CAD at the time 
of valve intervention is discussed in Section 14.2. Af-
ter valve intervention, evaluate and treat patients with 
CAD risk factors according to current guidelines for 
primary and secondary prevention. Although there is 
no convincing evidence that treating CAD risk factors 
will reduce the likelihood of progressive valve dysfunc-
tion after intervention, cardiovascular outcomes are im-
proved overall because of a reduced rate of coronary 
events.2.7.3. Persistent Symptoms After Valve 
Intervention
Persistent symptoms occur in many patients after 
valve intervention. The first step in evaluation is to as-
sess valve function to ensure symptoms are not caused 
by persistent or recurrent stenosis, regurgitation, or a 
valve complication. The next step is to evaluate and 
treat any concurrent cardiac disease and noncardiac 
conditions that may be the cause of symptoms. Symp-
toms also may be attributable to irreversible conse-
quences of valve disease, including LV systolic and 
diastolic dysfunction, pulmonary hypertension, and 
RV dysfunction. Treatment of symptoms for these pa-
tients is based on GDMT for HF and/or pulmonary hy-
pertension.
2.7.4. Periodic Imaging After Valve Intervention
Recommendation for Periodic Imaging After Valve Intervention
COR LOE Recommendation
1 C-EO1.  In asymptomatic patients with any type of valve 
intervention, a baseline postprocedural TTE 
followed by periodic monitoring with TTE is 
recommended, depending on type of intervention, 
length of time after intervention, ventricular 
function, and concurrent cardiac conditions.
Synopsis
A TTE is useful after either catheter-based or surgi-
cal intervention to provide a baseline measurement of 
valve function and the status of the ventricle. Repeat 
TTE is recommended with either new symptoms or a 
change in the physical examination. The timing of pe-
riodic follow-up imaging is based on the type of valve 
intervention.
Table 12. Timing of Periodic Imaging After Valve Intervention
Valve InterventionImaging Follow-Up*
Minimal Imaging Frequency† Location
Mechanical valve (surgical) Baseline Primary Valve Center
Bioprosthetic valve (surgical) Baseline, 5 and 10 y after surgery,‡ and then 
annuallyPrimary Valve Center
Bioprosthetic valve (transcatheter) Baseline and then annually Primary Valve Center
Mitral valve repair (surgical) Baseline, 1 y, and then every 2 to 3 y Primary Valve Center
Mitral valve repair (transcatheter) Baseline and then annually Comprehensive Valve Center
Bicuspid aortic valve disease Continued post-AVR monitoring of aortic size 
if aortic diameter is ≥4.0 cm at time of AVR, as 
detailed in Section 5.1Primary Valve Center
*Initial postprocedural TTE is recommended for all patients, ideally 1 to 3 months after the procedure. Annual clinical follow-up is recommended annually for all 
patients after valve intervention at a Primary or Comprehensive Valve Center.
†Repeat imaging is appropriate at shorter follow-up intervals for changing signs or symptoms, during pregnancy, and to monitor residual or concurrent cardiac dysfunction.
‡Imaging may be done more frequently in patients with bioprosthetic surgical valves if there are risk factors for early valve degeneration (eg, younger age, renal 
failure, diabetes).
AVR indicates aortic valve replacement; and TTE, transthoracic echocardiography.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e90
CLINICAL STATEMENTS  
AND GUIDELINESRecommendation-Specific Supportive Text
1. In patients who have had a valve intervention, 
most cardiologists continue to see patients for 
a clinical history and physical examination at 
annual intervals, or more frequently if needed for 
symptoms or concurrent conditions. A baseline 
TTE study is recommended after all valve inter -
ventions, including replacement with a prosthetic 
valve (see Section 11.1). This baseline postproce-
dural study ideally is performed 1 to 3 months 
after intervention to ensure loading conditions 
have returned to normal, but in some cases it 
may need to be done during the index hospital-
ization for the patient’s convenience. The tim-
ing of subsequent periodic imaging after valve 
intervention is based on the type of valve pros-
thesis or repair, length of time after valve inter -
vention, residual valve dysfunction, ventricular 
size and systolic function, and any concurrent 
cardiac conditions (Table 12). TTE is the standard 
approach for periodic imaging, supplemented by 
TEE when prosthetic mitral valve dysfunction is a 
concern (see Section 11.1). Additional imaging 
with CT, fluoroscopy CMR, or PET is reserved for 
patients for whom there is concern about valve 
dysfunction (see Section 11.1) or endocarditis 
(see Section 12.1).1,2
3. AORTIC STENOSIS
3.1. Stages of Valvular AS
Medical and interventional approaches to the manage-
ment of patients with valvular AS depend on accurate 
diagnosis of the cause and stage of the disease process. 
Table 13 shows the stages of AS, ranging from patients 
at risk of AS (Stage A) or with progressive hemody-
namic obstruction (Stage B) to severe asymptomatic 
(Stage C) and symptomatic AS (Stage D). Each stage 
is defined by patient symptoms, valve anatomy, valve 
hemodynamics, and changes in the LV and vascula-
ture. Hemodynamic severity is best characterized by the 
transaortic maximum velocity (or mean pressure gradi-
ent) when the transaortic volume flow rate is normal. 
Some patients with AS have a low transaortic volume 
flow rate that is either because of LV systolic dysfunc-
tion with a low LVEF or because of a small, hypertro-
phied LV with a low stroke volume. Severe AS with low 
flow is designated D2 (with a low LVEF) or D3 (with a 
normal LVEF). Meticulous attention to detail is required 
during assessment of aortic valve hemodynamics, either 
with Doppler echocardiography or cardiac catheteriza-
tion, and the inherent variability of the measurements 
and calculations should always be considered in clinical 
decision-making.3.2. Aortic Stenosis
3.2.1. Diagnosis and Follow-Up
3.2.1.1. Diagnostic Testing: Initial Diagnosis
Recommendations for Diagnostic Testing: Initial Diagnosis of AS
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 3.
COR LOE Recommendations
1 A1.   In patients with signs or symptoms of AS or a 
BAV, TTE is indicated for accurate diagnosis of 
the cause of AS, assessment of hemodynamic 
severity, measurement of LV size and systolic 
function, and determination of prognosis and 
timing of valve intervention.1,2 
1 B-NR2.  In patients with suspected low-flow, low-
gradient severe AS with normal LVEF (Stage 
D3), optimization of blood pressure control 
is recommended before measurement of AS 
severity by TTE, TEE, cardiac catheterization, 
or CMR.3–7
2a B-NR3.  In patients with suspected low-flow, low-
gradient severe AS with reduced LVEF 
(Stage D2), low-dose dobutamine stress 
testing with echocardiographic or invasive 
hemodynamic measurements is reasonable 
to further define severity and assess 
contractile reserve.8–10
2a B-NR4.  In patients with suspected low-flow, low-
gradient severe AS with normal or reduced 
LVEF (Stages D2 and D3), calculation of the 
ratio of the outflow tract to aortic velocity is 
reasonable to further define severity.1,11–13
2a B-NR5.  In patients with suspected low-flow, low-
gradient severe AS with normal or reduced 
LVEF (Stages D2 and D3), measurement of 
aortic valve calcium score by CT imaging is 
reasonable to further define severity.14–18
Synopsis
The overall approach to the initial diagnosis of VHD 
is discussed in Section 2.3, and additional consid-
erations specific to patients with AS are addressed 
here.
Recommendation-Specific Supportive Text
1. In adult patients, physical examination may not 
be accurate for diagnosis of and assessment 
of severity of AS. Echocardiographic imaging 
allows reliable evaluation of valve anatomy and 
motion and the degree of valve obstruction. 
In addition, TTE is useful for measuring LV size 
and systolic function, identifying concurrent 
AR or MR, and estimating pulmonary systolic 
pressure.1,2,11,12,19–27
2. Measurements of AS severity made when the 
patient is hypertensive may underestimate or, less 
often, overestimate stenosis severity. Systemic 
hypertension imposes a second pressure load on 
the LV, in addition to valve obstruction, which 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e91
CLINICAL STATEMENTS  
AND GUIDELINESresults in a lower forward stroke volume and 
lower transaortic pressure gradient than when 
the patient is normotensive. Thus, Doppler veloc-
ity data and invasive pressure measurements 
ideally are recorded when the patient is normo-
tensive. If results indicate only moderate stenosis 
but were recorded when the patient was hyper -
tensive, repeat measurements when the blood pressure is better controlled ensure that a diag-
nosis of severe AS is not missed.
3. Patients with severe AS and LVEF <50% present 
with an aortic valve area <1.0 cm2 but a low 
transvalvular velocity and pressure gradient (ie, 
velocity <4 m/s or mean gradient <40 mm Hg) 
at rest. In these patients, severe AS with LV 
systolic dysfunction attributable to afterload Table 13. Stages of AS
Stage Definition Valve Anatomy Valve HemodynamicsHemodynamic 
Consequences Symptoms
A At risk of AS BAV (or other congenital 
valve anomaly)
Aortic valve sclerosisAortic Vmax <2 m/s with 
normal leaflet motionNone None
B Progressive AS Mild to moderate leaflet 
calcification/fibrosis of a 
bicuspid or trileaflet valve 
with some reduction in 
systolic motion or
Rheumatic valve changes 
with commissural fusionMild AS: aortic Vmax 2.0–2.9 
m/s or mean ∆P <20 mm Hg
Moderate AS: aortic Vmax 
3.0–3.9 m/s or mean ∆P 
20–39 mm HgEarly LV diastolic 
dysfunction may be 
present
Normal LVEFNone
C: Asymptomatic severe AS
C1 Asymptomatic severe 
ASSevere leaflet calcification/
fibrosis or congenital 
stenosis with severely 
reduced leaflet openingAortic Vmax ≥4 m/s or mean 
∆P ≥40 mm Hg
AVA typically is ≤1.0 cm2 (or 
AVAi 0.6 cm2/m2) but not 
required to define severe AS
Very severe AS is an aortic 
Vmax ≥5 m/s or mean P ≥60 
mm HgLV diastolic dysfunction
Mild LV hypertrophy
Normal LVEFNone
Exercise testing is 
reasonable to confirm 
symptom status
C2 Asymptomatic severe 
AS with LV systolic 
dysfunctionSevere leaflet calcification/
fibrosis or congenital 
stenosis with severely 
reduced leaflet openingAortic Vmax ≥4 m/s or mean 
∆P ≥40 mm Hg
AVA typically ≤1.0 cm2 (or 
AVAi 0.6 cm2/m2) but not 
required to define severe ASLVEF <50% None
D: Symptomatic severe AS
D1 Symptomatic severe 
high-gradient ASSevere leaflet calcification/
fibrosis or congenital 
stenosis with severely 
reduced leaflet openingAortic Vmax ≥4 m/s or mean 
∆P ≥40 mm Hg
AVA typically ≤1.0 cm2 (or 
AVAi ≤0.6 cm2/m2) but may 
be larger with mixed AS/ARLV diastolic dysfunction
LV hypertrophy
Pulmonary 
hypertension may be 
presentExertional dyspnea, 
decreased exercise 
tolerance, or HF
Exertional angina
Exertional syncope or 
presyncope
D2 Symptomatic severe 
low-flow, low-gradient 
AS with reduced LVEFSevere leaflet calcification/
fibrosis with severely 
reduced leaflet motionAVA ≤1.0 cm2 with resting 
aortic Vmax <4 m/s or mean 
∆P <40 mm Hg
Dobutamine stress 
echocardiography shows 
AVA <1.0 cm2 with Vmax ≥4 
m/s at any flow rateLV diastolic dysfunction
LV hypertrophy
LVEF <50%HF
Angina
Syncope or presyncope
D3 Symptomatic severe 
low-gradient AS 
with normal LVEF or 
paradoxical low-flow 
severe ASSevere leaflet calcification/
fibrosis with severely 
reduced leaflet motionAVA ≤1.0 cm2 (indexed AVA 
≤0.6 cm2/m2) with an aortic 
Vmax <4 m/s or mean ∆P <40 
mm Hg
AND
Stroke volume index <35 
mL/m2
Measured when patient is 
normotensive (systolic blood 
pressure <140 mm Hg)Increased LV relative 
wall thickness
Small LV chamber with 
low stroke volume
Restrictive diastolic 
filling
LVEF ≥50%HF
Angina
Syncope or presyncope
AR indicates aortic regurgitation; AS, aortic stenosis; AVA, aortic valve area circulation; AVAi, AVA indexed to body surface area; BAV, bicuspid aortic valve; ΔP , 
pressure gradient between the LV and aorta HF, heart failure; LV, left ventricular; LVEF, left ventricular ejection fraction; and Vmax, maximum velocity.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e92
CLINICAL STATEMENTS  
AND GUIDELINESmismatch must be distinguished from primary 
myocardial dysfunction with only moderate 
AS. Dobutamine stress echocardiography may 
be useful with measurement of aortic velocity 
(or mean pressure gradient) and valve area at 
baseline and at higher flow rates (maximum 
dose dobutamine 20 mcg/kg per minute) under 
appropriate clinical and hemodynamic moni-
toring. Severe AS is characterized by a fixed 
valve area, resulting in an increase in trans-
aortic velocity to ≥ 4 m/s (mean gradient ≥ 40 
mm Hg) at any flow rate, but with valve area 
remaining ≤1.0 cm2. In contrast, in patients 
with moderate AS and primary LV dysfunction, 
there is an increase in valve area as volume 
flow rate increases, resulting in only a mod-
est increase in transaortic velocity or gradient. 
Some patients fail to show an increase in stroke 
volume ≥20% with dobutamine, referred to as 
“lack of contractile reserve” or “lack of flow  
reserve.”8,9,19,28–32
4. The key measurements for clinical decision-mak-
ing in patients with AS are the maximum aortic 
velocity, mean pressure gradient (calculated with 
the Bernoulli equation), and valve area (calculated 
with the continuity equation). An additional mea-
surement that may be useful when there are dis-
crepancies in these measures or in other clinical 
or imaging data is the ratio of the velocity in the 
LV outflow tract proximal to the aortic valve and 
the velocity in the narrowed aortic orifice. The 
outflow tract–to–aortic velocity ratio is indepen-
dent of body size and eliminates potential errors 
in calculated valve area related to measurement 
of LV outflow tract diameter or area. A normal 
ratio is close to 1.0, whereas a ratio of ≤0.25 
corresponds to a valve area 25% of normal for 
that patient, which is consistent with severe AS 
and is a predictor of symptom onset and adverse 
outcomes.12,13,21,22,23
5. The degree of aortic valve calcification is a 
strong predictor of clinical outcome, even when 
evaluated qualitatively by echocardiography.33 
Quantitation of aortic valve calcium by CT imag-
ing is especially useful in patients with low-flow, 
low-gradient AS of unclear severity with either 
a normal or reduced LVEF. Sex-specific Agaston 
unit thresholds for diagnosis of severe AS are 
1300 in women and 2000 in men. These differ -
ent thresholds reflect the contribution of leaflet 
fibrosis, in addition to calcification, to increased 
leaflet stiffness in women. CT imaging also is 
used for procedural planning in patients under -
going TAVI, for measurement of annulus area, leaflet length, and the annular–to–coronary 
ostial distance.14–18
3.2.1.2. Diagnostic Testing: Changing Signs or 
Symptoms
In patients with known valvular AS, repeat TTE is pru-
dent when physical examination shows an increase in 
the loudness of the murmur, the murmur peaks later in 
systole, the A2 component of the second heart sound 
is diminished or absent, or symptoms occur that might 
be attributable to AS. Repeat TTE is also appropriate in 
patients with AS who are exposed to increased hemo-
dynamic demands, either electively, such as with non-
cardiac surgery or pregnancy, or acutely, such as with a 
systemic infection, anemia, or gastrointestinal bleeding. 
In these clinical settings, knowledge of the severity of 
valve obstruction and LV function is critical for optimiz-
ing loading conditions and maintaining a normal car -
diac output.
3.2.1.3. Diagnostic Testing: Routine Follow-Up
Timing of periodic clinical evaluation of asymptomatic 
patients with severe AS depends on comorbidities and 
patient-specific factors, as well as AS severity (Table 4). 
When severe AS is present (aortic velocity ≥4.0 m/s), 
the rate of progression to symptoms is high, with 
an event-free survival rate of only 30% to 50% at 2 
years. In patients with asymptomatic severe AS, peri-
odic monitoring is needed because symptom onset is 
insidious and may not be recognized by the patient. 
With moderate AS (aortic velocity 3.0–3.9 m/s), the 
average annual rate of progression is an increase in ve-
locity of 0.3 m/s, increase in mean pressure gradient 
of 7 mm Hg, and decrease in valve area of 0.1 cm2. 
There is marked individual variability, with more rapid 
progression in older patients and in patients with more 
severe leaflet calcification. In patients with aortic scle-
rosis, defined as focal areas of valve calcification and 
leaflet thickening with an aortic velocity <2.0 m/s, pro-
gression to severe AS occurs in about 10% of patients 
within 5 years. Patients with BAV disease are also at 
risk of progressive valve stenosis, with AS being the 
most common reason for intervention in patients with 
a BAV (Section 5.1.1).1–13
3.2.1.4. Diagnostic Testing: Cardiac Catheterization
Diagnostic TTE and Doppler data can be obtained in 
nearly all patients, but severity of AS may be underes-
timated if image quality is poor or if a parallel intercept 
angle is not obtained between the ultrasound beam and 
aortic jet. When data from noninvasive testing are non-
diagnostic or if there is a discrepancy between clinical 
and echocardiographic evaluation, cardiac catheteriza-
tion for determination of severity of AS can be helpful. 
Transaortic pressure gradient recordings allow measure-
ment of the mean transaortic gradient via simultaneous 
LV and aortic pressure measurements. Aortic valve area 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e93
CLINICAL STATEMENTS  
AND GUIDELINESis calculated with the Gorlin formula by using a Fick or 
thermodilution cardiac output measurement. See Sec-
tion 14.1 for recommendations on coronary angiogra-
phy in patients with AS.1,2
3.2.1.5. Diagnostic Testing: Exercise Testing
Recommendations for Diagnostic Testing: Exercise Testing in 
Patients With AS
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 4.
COR LOE Recommendations
2a B-NR1.  In asymptomatic patients with severe AS 
(Stage C1), exercise testing is reasonable 
to assess physiological changes with 
exercise and to confirm the absence of 
symptoms.1–4
3: Harm B-NR2.  In symptomatic patients with severe 
AS (Stage D1, aortic velocity ≥4.0 
m/s or mean pressure gradient ≥40 
mm Hg), exercise testing should not be 
performed because of the risk of severe 
hemodynamic compromise.5
Synopsis 
In a subset of asymptomatic patients with severe AS, 
exercise testing can provide additional diagnostic and 
prognostic information, but it should not be performed 
in symptomatic patients with severe AS.
Recommendation-Specific Supportive Text
1. When performed under the direct supervision of 
an experienced clinician, with close monitoring of 
blood pressure and ECG, exercise testing in asymp-
tomatic patients is relatively safe and may provide 
information that is not evident during the initial 
clinical evaluation, particularly when the patient’s 
functional capacity is unclear. Patients with symp-
toms provoked by exercise testing should be con-
sidered symptomatic, even if the clinical history is 
equivocal. Although it can be challenging to sep-
arate normal exercise limitations from abnormal 
symptoms that are attributable to AS, particularly 
in elderly sedentary patients, exercise-induced 
angina, excessive dyspnea early in exercise, dizzi-
ness, and syncope are consistent with symptoms 
of AS. Exercise testing can also identify a limited 
exercise capacity or an abnormal blood pressure 
response. Recording aortic valve hemodynam-
ics with exercise is of limited value and does not 
show additive value for predicting clinical out-
come when baseline measures of hemodynamic 
severity and functional status are considered. In 
addition, recording hemodynamics with exercise 
is challenging, and simpler parameters are ade-
quate in most patients.2–4,6–112. As reported in several prospective and retrospec-
tive studies, the risk of exercise testing is low in 
asymptomatic patients with AS. However, exer -
cise testing is avoided in symptomatic patients 
with AS because of a high risk of complications, 
including syncope, ventricular tachycardia, and 
death. In a prospective survey of 20 medical cen-
ters in Sweden that included 50 000 exercise tests 
done over an 18-month period, the complication 
rate was 18.4 per 10 000 tests; morbidity rate, 
5.2 per 10 000 tests; and mortality rate, 0.4 per 
10 000 tests. Although the number of patients 
with AS was not reported, 12 of the 92 complica-
tions occurred in patients with AS: 8 had a decline 
in blood pressure during exercise, 1 had asystole, 
and 3 had ventricular tachycardia.2,4,5,7–10,12
3.2.2. Medical Therapy
Recommendations for Medical Therapy of AS
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 5.
COR LOE Recommendations
1 B-NR1.  In patients at risk of developing AS (Stage 
A) and in patients with asymptomatic AS 
(Stages B and C), hypertension should 
be treated according to standard GDMT, 
started at a low dose, and gradually titrated 
upward as needed, with appropriate clinical 
monitoring.1–3
1 A2.  In all patients with calcific AS, statin therapy 
is indicated for primary and secondary 
prevention of atherosclerosis on the basis of 
standard risk scores.4–6
2b B-NR3.  In patients who have undergone TAVI, 
renin–angiotensin system blocker therapy (ACE 
inhibitor or ARB) may be considered to reduce 
the long-term risk of all-cause mortality.7,8
3: No 
BenefitA4.  In patients with calcific AS (Stages B and C), 
statin therapy is not indicated for prevention of 
hemodynamic progression of AS.4–6
Synopsis
Medical treatment of hypertension and hyperlipidemia 
according to GDMT is appropriate for patients with AS. 
ACE inhibitor or ARB treatment may reduce the mortal-
ity rate in patients with AS who underwent TAVI.
Recommendation-Specific Supportive Text
1. Hypertension is common in patients with AS, may 
be a risk factor for AS, and adds to the total pres-
sure overload on the LV in combination with valve 
obstruction. Concern that antihypertensive medi-
cations might result in a decrease in cardiac output 
has not been corroborated in studies of medical 
therapy, including 2 small RCTs, likely because 
AS does not result in “fixed” valve obstruction 
until late in the disease process. In 1616 patients 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e94
CLINICAL STATEMENTS  
AND GUIDELINESwith asymptomatic AS in the SEAS (Simvastatin 
Ezetimibe in Aortic Stenosis) study, hypertension 
(n=1340) was associated with a 56% higher rate 
of ischemic cardiovascular events and a 2-fold 
higher mortality rate (both P<0.01) than those 
seen in normotensive patients with AS, although 
no impact on progression of valve stenosis lead-
ing to symptoms requiring AVR was seen. Medical 
therapy for hypertension follows standard guide-
lines, starting at a low dose and gradually titrating 
upward as needed to achieve blood pressure con-
trol. There are no studies addressing specific anti-
hypertensive medications in patients with AS, but 
diuretics may reduce stroke volume, particularly if 
the LV chamber is small at baseline. In theory, ACE 
inhibitors may be advantageous because of the 
potential beneficial effects on LV fibrosis, in addi-
tion to control of hypertension. Consideration 
should be given to a higher target blood pressure 
for patients with AS than is recommended for the 
general population, but this is an underexplored 
area, and further data are needed before a differ -
ent target blood pressure can be recommended 
for patients with AS.1–3,9–13
2. Concurrent CAD is common in patients with AS, 
and all patients should be screened and treated 
for hypercholesterolemia, with GDMT used for 
primary and secondary prevention of CAD. In 
RCTs of statin therapy for mild to moderate 
AS, although aortic valve event rates were not 
reduced, the rate of ischemic events was reduced 
by about 20% in the statin therapy group even 
though these patients did not meet standard cri-
teria for statin therapy.4–6,14,15
3. In patients undergoing TAVI, observational and 
registry data show that those who were treated 
with renin–angiotensin system blocker therapy 
after the procedure had a lower 1-year mortality 
rate than those not treated with renin–angio-
tensin system blocker therapy, with a rela-
tive risk reduction of about 20% to 50% and 
an absolute risk reduction between 2.4% and 
5.0%. When stratified by LVEF, having a pre-
scription for a renin–angiotensin system inhibi-
tor, versus no prescription, was associated with 
a lower 1-year mortality rate among patients 
with preserved LVEF but not among those with 
reduced LVEF.7,8,16,17
4. Despite experimental models and retrospective 
clinical studies suggesting that lipid-lowering 
therapy with a statin might prevent disease pro-
gression of calcific AS, 3 large well-designed RCTs 
failed to show a benefit, either in terms of changes 
in hemodynamic severity or in clinical outcomes, 
in patients with mild to moderate valve obstruc-
tion. Thus, at the time of publication, there are no data to support the use of statins for prevention 
of progression of AS.7,8,16,17
3.2.3. Timing of Intervention
Recommendations for Timing of Intervention of AS
Referenced studies that support the recommendations are 
summarized in Online Data Supplements 4 and 6 to 10.
COR LOE Recommendations
1 A  1.  In adults with severe high-gradient AS (Stage 
D1) and symptoms of exertional dyspnea, HF, 
angina, syncope, or presyncope by history or 
on exercise testing, AVR is indicated.1–7 
1 B-NR  2.  In asymptomatic patients with severe AS 
and an LVEF <50% (Stage C2), AVR is 
indicated.8–11 
1 B-NR  3.  In asymptomatic patients with severe AS 
(Stage C1) who are undergoing cardiac 
surgery for other indications, AVR is 
indicated.12–16 
1 B-NR  4.  In symptomatic patients with low-flow, low-
gradient severe AS with reduced LVEF (Stage 
D2), AVR is recommended.17–24 
1 B-NR  5.  In symptomatic patients with low-flow, low-
gradient severe AS with normal LVEF (Stage 
D3), AVR is recommended if AS is the most 
likely cause of symptoms.25–27 
2a B-NR  6.  In apparently asymptomatic patients with 
severe AS (Stage C1) and low surgical risk, 
AVR is reasonable when an exercise test 
demonstrates decreased exercise tolerance 
(normalized for age and sex) or a fall in 
systolic blood pressure of ≥10 mm Hg from 
baseline to peak exercise.13,28–30 
2a B-R  7.  In asymptomatic patients with very severe AS 
(defined as an aortic velocity of ≥5 m/s) and 
low surgical risk, AVR is reasonable.15,31–35 
2a B-NR  8.  In apparently asymptomatic patients with severe 
AS (Stage C1) and low surgical risk, AVR is 
reasonable when the serum B-type natriuretic 
peptide (BNP) level is >3 times normal.32,36–38 
2a B-NR  9.  In asymptomatic patients with high-gradient 
severe AS (Stage C1) and low surgical risk, AVR 
is reasonable when serial testing shows an 
increase in aortic velocity ≥ 0.3 m/s per year.39,40
2b B-NR10.  In asymptomatic patients with severe high-
gradient AS (Stage C1) and a progressive 
decrease in LVEF on at least 3 serial 
imaging studies to <60%, AVR may be 
considered.8–11,33
2b C-EO11.  In patients with moderate AS (Stage B) who 
are undergoing cardiac surgery for other 
indications, AVR may be considered. 
Synopsis
See the table of recommendations for a summary of 
recommendations from this section and Figure  2 for 
indications for AVR in patients with AS. These recom-
mendations for timing of intervention for AS apply to 
both SAVR and TAVI. The integrative approach to as-
sessing risk of SAVR or TAVI is discussed in Section 2.5. 
The specific type of intervention for AS is discussed in 
Section 3.2.4.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e95
CLINICAL STATEMENTS  
AND GUIDELINESRecommendation-Specific Supportive Text
1. In symptomatic patients with severe high-gradi-
ent AS (Stage D1), ample evidence demonstrates 
the beneficial effects of AVR on survival, symp-
toms, and LV systolic function.35,41–46 The most 
common initial symptom of AS is exertional dys-
pnea or decreased exercise tolerance. Clinical 
vigilance is needed to recognize these early 
symptoms and proceed promptly to AVR. More 
severe “classical” symptoms of AS, including HF, 
syncope, or angina, can be avoided by appropri-
ate treatment at the onset of even mild symp-
toms. Outcomes after surgical or transcatheter 
AVR are excellent in patients who do not have a 
high procedural risk.41,43–45 Surgical series demon-
strate improved symptoms after AVR, and most 
patients have an improvement in exercise toler -
ance, as documented in studies with pre- and 
post-AVR exercise stress testing.41,43–46 Historical observation studies on outcomes in symptomatic 
patients with severe AS have been confirmed 
in RCTs comparing TAVI with palliative care in 
patients with a prohibitive surgical risk. The 
choice of surgical versus transcatheter AVR for 
patients with an indication for AVR is discussed 
in Section 3.2.4.1–3,5,6,12–16,35,42,47–55
2. In asymptomatic patients with severe AS and 
normal LV systolic function, the survival rate dur -
ing the asymptomatic phase is similar to that of 
age-matched controls, with a low risk of sud-
den death (<1% per year) when patients are fol-
lowed prospectively and when patients promptly 
report symptom onset. However, in patients 
with a low LVEF and severe AS, survival is better 
in those who undergo AVR than in those treated 
medically. The depressed LVEF in many patients 
is caused by excessive afterload (afterload mis-
match), and LV function improves after AVR in 
such patients. If LV dysfunction is not caused 
Figure 2. Timing of intervention for AS.
Colors correspond to Table 2. Arrows show the decision pathways that result in a recommendation for AVR. Periodic monitoring is indicated for all patients in 
whom AVR is not yet indicated, including those with asymptomatic (Stage C) and symptomatic (Stage D) AS and those with low-gradient AS (Stage D2 or D3) 
who do not meet the criteria for intervention. See Section 3.2.4 for choice of valve type (mechanical versus bioprosthetic [TAVI or SAVR]) when AVR is indicated. 
AS indicates aortic stenosis; AVA, aortic valve area; AVAi, aortic valve area index; AVR, aortic valve replacement; BNP , B-type natriuretic peptide; BP , blood pressure; 
DSE, dobutamine stress echocardiography ETT, exercise treadmill test; LVEF, left ventricular ejection fraction; ∆Pmean, mean systolic pressure gradient between LV 
and aorta; SAVR, surgical aortic valve replacement; SVI, stroke volume index; TAVI, transcatheter aortic valve implantation; TAVR, transcatheter aortic valve replace-
ment; and Vmax, maximum velocity.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e96
CLINICAL STATEMENTS  
AND GUIDELINESby afterload mismatch, survival is still improved, 
likely because of the reduced afterload with 
AVR, but improvement in LV function and reso-
lution of symptoms might not be complete after 
AVR.17,23,24,56–62
3. Prospective clinical studies demonstrate that dis-
ease progression occurs in nearly all patients with 
severe asymptomatic AS. Symptom onset within 
2 to 5 years is likely when aortic velocity is ≥4.0 
m/s or mean pressure gradient is ≥40 mm Hg. The 
additive risk of AVR at the time of other cardiac 
surgery is less than the risk of reoperation within 
5 years.12–16,63–65
4. Mean pressure gradient is a strong predic-
tor of outcome after AVR, with better out-
comes seen in patients with higher gradients. 
Outcomes are poor with severe low-gradient 
AS but are still better with AVR than with medi-
cal therapy in those with a low LVEF, particu-
larly when contractile reserve is present. The 
document “Echocardiographic Assessment of 
Valve Stenosis: EAE/ASE Recommendations for 
Clinical Practice” defines severe AS on dobuta-
mine stress testing as a maximum velocity >4.0 
m/s with a valve area ≤1.0 cm2 at any point dur -
ing the test protocol, with a maximum dobu-
tamine dose of 20 mcg/kg per minute.66 The 
recommendation for AVR in these patients is 
based on outcome data in several prospective 
nonrandomized studies. LVEF typically increases 
by 10 LVEF units and may return to normal if 
afterload mismatch was the cause of LV systolic 
dysfunction. If dobutamine stress testing indi-
cates moderate, not severe AS, GDMT for HF 
can be continued without AVR. Patients without 
contractile reserve may also benefit from AVR, 
but decisions in these high-risk patients must 
be individualized because outcomes are poor 
with either surgical or medical therapy. The 
role of TAVI in these patients is currently under 
investigation.17,22–24,59,60,67
5. A subset of patients with severe AS presents with 
symptoms and with a low velocity, low gradient, 
and low stroke volume index, despite a normal 
LVEF. Low-flow, low-gradient severe AS with 
preserved LVEF should be considered in patients 
with a severely calcified aortic valve, an aortic 
velocity <4.0 m/s (mean pressure gradient <40 
mm Hg), and a valve area ≤ 1.0 cm2 when stroke 
volume index is <35 mL/m2. Typically, the LV is 
small, with thick walls, diastolic dysfunction, and 
a normal LVEF (≥ 50%). The first diagnostic step 
is to ensure that data were recorded and mea-
sured correctly. If hypertension is present, blood 
pressure is controlled before reevaluation of AS 
severity. Next, valve area is indexed to body size because an apparent small valve area may be 
only moderate AS in a small patient; an aortic 
valve area index ≤ 0.6 cm2/m2 suggests severe 
AS. Transaortic stroke volume is calculated by 
Doppler or 2D imaging. Measurement of a CT 
calcium score often is helpful. Evaluation for 
other potential causes of symptoms ensures that 
symptoms are most likely attributable to valve 
obstruction. Although the survival rate after TAVI 
is lower in patients with low-flow severe AS than 
in patients with normal-flow severe AS, AVR 
appears beneficial, with an increase in stroke 
volume and improved survival as compared with 
medical therapy.18,25–27,54,68–76
6. Exercise testing may be helpful in clarifying 
symptom status in patients with severe AS. 
When symptoms are provoked by exercise test-
ing, the patient is considered symptomatic and 
meets a COR 1 recommendation for AVR; symp-
toms are symptoms, whether reported sponta-
neously by the patient or provoked on exercise 
testing. The rate of symptom onset within 1 to 
2 years is high (about 60% to 80%) in patients 
without overt symptoms who demonstrate 1) 
a fall of ≥10 mm Hg in systolic blood pressure 
from baseline to peak exercise or 2) a significant 
decrease in exercise tolerance as compared with 
age and sex normal standards. Management 
of patients with a lack of appropriate rise in 
BP with exercise is less clear. Decisions about 
elective AVR in these patients include consid-
eration of surgical risk, patient preferences, 
and clinical factors, such as age and comorbid 
conditions.13,28,77–82
7. In patients with very severe AS and an aortic 
velocity ≥5.0 m/s or mean pressure gradient ≥60 
mm Hg, the rate of symptom onset is approxi-
mately 50% at 2 years. On multivariable analy-
sis of a large cohort of adults with asymptomatic 
AS (>500 patients), an aortic velocity ≥5 m/s was 
associated with a >6-fold increased risk of cardio-
vascular mortality (hazard ratio [HR]: 6.31; 95% 
CI: 2.61–15.9).33 A randomized trial of SAVR ver -
sus continued surveillance showed a significant 
survival benefit to early surgery in patients with 
aortic velocity ≥4.5 m/s.31 In patients very severe 
asymptomatic AS and low surgical risk, a decision 
to proceed with AVR or continue watchful wait-
ing takes into account patient age, avoidance of 
patient–prosthesis mismatch, anticoagulation 
issues, and patient preferences.31–33,39
8. An elevated serum BNP level is a marker of sub-
clinical HF and LV decompensation. In a cohort 
of 387 asymptomatic adults with severe AS, 
elevated BNP levels were associated with an 
increased 5-year risk of AS-related events, with a 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e97
CLINICAL STATEMENTS  
AND GUIDELINEShazard ratio for a BNP level >300 pg/mL (3 times 
normal) of 7.38 (CI: 3.21 to 16.9).32 Serum BNP 
levels also are predictive of symptom onset during 
follow-up and persistent symptoms after AVR.36
9. Hemodynamic progression eventually leading to 
symptom onset occurs in nearly all asymptomatic 
patients with AS once the aortic velocity reaches 
≥2 m/s. Although the average rate of hemody-
namic progression for calcific stenosis of a trileaf-
let valve is an increase in aortic velocity of about 
0.3 m/s per year, an increase in mean gradient of 
7 to 8 mm Hg per year, and a decrease in valve 
area of 0.15 cm2 per year, there is marked vari-
ability between patients in disease progression. 
Predictors of rapid disease progression include 
older age, more severe valve calcification, and a 
faster rate of hemodynamic progression on serial 
studies. In patients with an aortic velocity >4 m/s 
in addition to predictors of rapid disease progres-
sion, symptom onset is likely in the near future, so 
there is less benefit to waiting for symptom onset. 
Thus, elective AVR may be considered if the sur -
gical risk is low and after consideration of other 
clinical factors and patient preferences.
10.   In adults with initially asymptomatic severe AS, 
the rate of sudden death is low (<1% per year). 
However, an aortic velocity ≥5 m/s or an LVEF 
<60% each is associated with higher all-cause 
and cardiovascular mortality rates in the absence 
of AVR.31 A multivariate analysis of predictors of 
death in a large cohort (>500 patients) showed 
a >4-fold higher risk of cardiovascular death for 
those with an LVEF <60% than for those with a 
higher LVEF (HR: 4.47; 95% CI: 2.06 to 9.70).33 
A progressive decrease in LVEF is most likely in 
those with an LVEF <60% before AS becomes 
severe.8,9,11 Evaluation for other causes of a 
decline in LVEF is appropriate, particularly when 
AS is not yet severe, but a progressive decline 
in LV systolic function is of concern and should 
prompt more frequent evaluation; and consider -
ation of AVR when repeat studies show a progres-
sive decline in LVEF without other cause with a 
lack of response to medical therapy. The presence 
of at least 3 serial imaging studies showing a con-
sistent decline in LVEF ensures that the changes 
seen are not simply attributable to recording, 
measurement, or physiological variability.8–11
11.   Hemodynamic progression eventually leading to 
symptom onset occurs in nearly all asymptom-
atic patients with AS. The survival rate during the 
asymptomatic phase is similar to age-matched 
controls, with a low risk of sudden death (<1% 
per year) when patients are followed prospec-
tively and when patients promptly report symp-
tom onset. The rate of symptom onset is strongly dependent on the severity of AS, with an event-
free survival rate of about 75% to 80% at 2 years 
in those with a jet velocity <3.0 m/s, compared 
with only 30% to 50% in those with a jet veloc-
ity ≥4.0 m/s. Patients with asymptomatic AS 
require periodic monitoring for development of 
symptoms and progressive disease (Section 3.1). 
In patients with moderate calcific AS undergoing 
cardiac surgery for other indications, the risk of 
progressive VHD is balanced against the risk of 
repeat surgery or TAVI (Sections 4.3.3 and 10). 
This decision must be individualized on the basis 
of the specific operative risk in each patient, clini-
cal factors such as age and comorbid conditions, 
valve durability, and patient preferences.13,49,62–64
3.2.4. Choice of Intervention
3.2.4.1. Choice of Mechanical Versus Bioprosthetic 
AVR
Recommendations for Choice of Mechanical Versus Bioprosthetic AVR
Referenced studies that support the recommendations are 
summarized in Online Data Supplements 11 and 12.
COR LOE Recommendations
1 C-EO1.  In patients with an indication for AVR, 
the choice of prosthetic valve should be 
based on a shared decision-making process 
that accounts for the patient’s values and 
preferences and includes discussion of the 
indications for and risks of anticoagulant 
therapy and the potential need for and risks 
associated with valve reintervention. 
1 C-EO2.  For patients of any age requiring AVR 
for whom VKA anticoagulant therapy 
is contraindicated, cannot be managed 
appropriately, or is not desired, a bioprosthetic 
AVR is recommended. 
2a B-R3.  For patients <50 years of age who do not 
have a contraindication to anticoagulation 
and require AVR, it is reasonable to choose 
a mechanical aortic prosthesis over a 
bioprosthetic valve.1
2a B-NR4.  For patients 50 to 65 years of age who require 
AVR and who do not have a contraindication 
to anticoagulation, it is reasonable to 
individualize the choice of either a mechanical 
or bioprosthetic AVR with consideration of 
individual patient factors and after informed 
shared decision-making.1–10
2a B-R5.  In patients >65 years of age who require AVR, 
it is reasonable to choose a bioprosthesis over 
a mechanical valve.1
2b B-NR6.  In patients <50 years of age who prefer a 
bioprosthetic AVR and have appropriate 
anatomy, replacement of the aortic valve by 
a pulmonic autograft (the Ross procedure) 
may be considered at a Comprehensive Valve 
Center.11–13
Synopsis 
Shared decision-making about the choice of pros-
thetic valve type is influenced by several factors, 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e98
CLINICAL STATEMENTS  
AND GUIDELINESincluding patient age, values, and preferences; ex-
pected bioprosthetic valve durability, avoidance of pa-
tient–prosthesis mismatch, and the potential need for 
and timing of reintervention; and the risks associated 
with long-term VKA anticoagulation with a mechani-
cal valve replacement. Despite the significantly higher 
rate of bioprosthetic structural valve deterioration ob-
served in younger versus older patients,7–11,14,15 many 
patients choose to avoid a mechanical prosthesis be-
cause they are unwilling to consider long-term VKA 
therapy because of the inconvenience of monitoring, 
dietary restrictions, medication interactions, and the 
need to restrict participation in some types of athletic 
activity. A mechanical valve might be a prudent choice 
for patients for whom a second surgical procedure 
would involve very high risk (eg, those with prior ra-
diation exposure). The availability of TAVI has changed 
the dynamics of the discussion of the trade-offs be-
tween mechanical and bioprosthetic valves in younger 
patients16–19 (Table 22).
Recommendation-Specific Supportive Text
1. The choice of valve prosthesis in each patient is 
based on consideration of several factors, includ-
ing valve durability, expected hemodynamics for 
valve type and size, surgical or interventional risk, 
the potential need for long-term anticoagulation, 
and patient values and preferences. The trade-off 
between the risk of reintervention for biopros-
thetic valve deterioration and the risk of long-
term anticoagulation should be discussed. Some 
patients prefer to avoid repeat surgery and are 
willing to accept the risks and inconvenience of 
lifelong anticoagulant therapy. Other patients are 
unwilling to consider long-term anticoagulation 
because of the inconvenience of monitoring, the 
attendant dietary and medication interactions, and 
the need to restrict participation in some types of 
physical activity. The incidence of structural dete-
rioration of a bioprosthesis is greater in younger 
patients, but the risk of bleeding from anticoagu-
lation is higher in older patients. In patients with 
shortened longevity and/or multiple comorbidi-
ties, a bioprosthesis might be more appropriate. 
In women who desire subsequent pregnancy, the 
issue of anticoagulation during pregnancy is an 
additional consideration (see pregnancy-related 
issues in Section 13.5).20,21
2. Anticoagulant therapy with VKA is necessary in all 
patients with a mechanical valve to prevent valve 
thrombosis and thromboembolic events. If anti-
coagulation is contraindicated or if the patient 
refuses VKA therapy, an alternative valve choice 
is appropriate. Newer anticoagulant agents have not been shown to be safe or effective in patients 
with mechanical heart valves.
3. Patients <50 years of age at the time of AVR incur 
a higher and earlier risk of bioprosthetic valve 
deterioration.4,10,14,22–24 Overall, the predicted 
15-year risk of needing reoperation because of 
structural deterioration is 22% for patients 50 
years of age, 30% for patients 40 years of age, 
and 50% for patients 20 years of age, although 
it is recognized that all bioprostheses are not alike 
in terms of durability.14 Anticoagulation with a 
VKA can be accomplished with acceptable risk 
in most patients <50 years of age, particularly in 
compliant patients with appropriate monitoring 
of INR levels. Thus, the balance between valve 
durability and risk of bleeding and thromboem-
bolic events favors the choice of a mechanical 
valve in patients <50 years of age, unless antico-
agulation is not desired, cannot be monitored, or 
is contraindicated.
4. Uncertainty and debate continue about which 
type of AVR is appropriate for patients 50 to 
65 years of age. Newer surgical bioprosthetic 
valves may show greater freedom from struc-
tural deterioration, specifically in the older indi-
vidual, although a high late mortality rate in 
these studies may preclude recognition of valve 
dysfunction.14–19 The risks of bleeding and throm-
boembolism with mechanical prostheses are low, 
especially in compliant patients with appropriate 
INR monitoring. Several studies have shown a 
survival advantage with a mechanical prosthesis 
in this age group. Alternatively, large retrospec-
tive observational studies have shown similar 
long-term survival rates in patients 50 to 69 years 
of age undergoing mechanical versus biopros-
thetic valve replacement.22–24 In general, patients 
with mechanical valves experience a higher risk 
of bleeding caused by anticoagulation, whereas 
individuals who receive bioprosthetic valves expe-
rience a higher rate of reoperation because of 
structural deterioration of the prosthesis, as well 
as perhaps a decrease in survival rate.6,25–27 There 
are several other factors to consider in the choice 
of type of valve prosthesis (see Section 11.1). 
Ultimately, the choice of mechanical versus bio-
prosthetic valve replacement for all patients, but 
especially for those between 50 and 65 years of 
age, is a shared decision-making process that 
must account for the trade-offs between dura-
bility (and the need for reintervention), bleeding, 
and thromboembolism.1
5. In patients >65 years of age at the time of bio-
prosthetic AVR, the likelihood of primary struc-
tural deterioration at 15 to 20 years is only about 
10%.28–31 In addition, older patients are at higher 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e99
CLINICAL STATEMENTS  
AND GUIDELINESrisk of bleeding complications related to VKA 
therapy and more often require interruption of 
VKA therapy for noncardiac surgical and inter -
ventional procedures. It is reasonable to use a 
bioprosthetic valve in patients >65 years of age 
to avoid the risks of anticoagulation because the 
durability of the valve exceeds the expected years 
of life.
6. Replacement of the aortic valve with a pulmo-
nary autograft (the Ross procedure) is a complex 
operation involving replacement of the aortic 
valve by the patient’s own pulmonic valve, along 
with placement of a pulmonic valve homograft. 
The Ross procedure allows the patient to avoid 
a prosthetic heart valve and the risks of antico-
agulation and it provides excellent valve hemody-
namics. However, both the pulmonic homograft 
in the pulmonic position and the pulmonary 
autograft (the neoaortic valve) are at risk of valve 
degeneration. The failure of the Ross procedure 
is most often attributable to regurgitation of the 
neoaortic valve in the second decade after the 
operation. In addition, at least half of pulmonic 
homograft valves require reintervention within 10 
to 20 years. Calcification of the homograft and 
adhesions between the homograft and neoaorta 
may increase the difficulty of reoperation. The 
Ross procedure typically is reserved for younger 
patients with appropriate anatomy and tissue 
characteristics for whom anticoagulation is either 
contraindicated or undesirable, and it is performed 
only at Comprehensive Valve Centers by surgeons 
experienced in this procedure.11–13,32
3.2.4.2. Choice of SAVR Versus TAVI for Patients for 
Whom a Bioprosthetic AVR Is Appropriate
Recommendations for Choice of SAVR Versus TAVI for Patients for 
Whom a Bioprosthetic AVR Is Appropriate
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 11 to 13.
COR LOE Recommendations
1 A1.  For symptomatic and asymptomatic patients 
with severe AS and any indication for AVR who 
are <65 years of age or have a life expectancy 
>20 years, SAVR is recommended.1–3
1 A2.  For symptomatic patients with severe AS 
who are 65 to 80 years of age and have no 
anatomic contraindication to transfemoral 
TAVI, either SAVR or transfemoral TAVI is 
recommended after shared decision-making 
about the balance between expected patient 
longevity and valve durability.1,4–8
1 A3.  For symptomatic patients with severe AS who 
are >80 years of age or for younger patients 
with a life expectancy <10 years and no 
anatomic contraindication to transfemoral 
TAVI, transfemoral TAVI is recommended in 
preference to SAVR.1,4–101 B-NR4.  In asymptomatic patients with severe AS 
and an LVEF <50% who are ≤80 years of 
age and have no anatomic contraindication 
to transfemoral TAVI, the decision between 
TAVI and SAVR should follow the same 
recommendations as for symptomatic patients 
in Recommendations 1, 2, and 3 above.1,2,4–10 
1 B-NR5.  For asymptomatic patients with severe AS 
and an abnormal exercise test, very severe AS, 
rapid progression, or an elevated BNP (COR 2a 
indications for AVR), SAVR is recommended in 
preference to TAVI.1–3,11
1 A6.  For patients with an indication for AVR for 
whom a bioprosthetic valve is preferred but 
valve or vascular anatomy or other factors are 
not suitable for transfemoral TAVI, SAVR is 
recommended. 1–3,11
1 A7.  For symptomatic patients of any age with 
severe AS and a high or prohibitive surgical 
risk, TAVI is recommended if predicted post-
TAVI survival is >12 months with an acceptable 
quality of life.12,13,14,15
1 C-EO8.  For symptomatic patients with severe AS 
for whom predicted post-TAVI or post-SAVR 
survival is <12 months or for whom minimal 
improvement in quality of life is expected, 
palliative care is recommended after shared 
decision-making, including discussion of 
patient preferences and values.
2b C-EO9.  In critically ill patients with severe AS, 
percutaneous aortic balloon dilation may be 
considered as a bridge to SAVR or TAVI. 
Synopsis
In patients considering a bioprosthetic AVR, the next 
step is the choice between SAVR and TAVI. In patients 
with a high or prohibitive risk for SAVR (see Section 
2.5), decision-making focuses on TAVI versus pallia-
tive care. When surgical risk is not high or prohibitive, 
procedure-specific impediments are assessed (Fig-
ure 3). When both SAVR and TAVI are options, a prime 
consideration is the limited data about TAVI durabil-
ity. SAVR has been used for more than 50 years, with 
ample durability data available for specific valve types 
across different age groups. Currently, robust durabil-
ity data for TAVI extend to only about 5 years. SAVR 
valve deterioration typically occurs after >10 years, so 
longer-term TAVI durability data are needed. A key 
factor in decision-making is the ratio of patient life 
expectancy to known valve durability, with patient age 
often used as a surrogate for life expectancy. For a 
woman in the United States, the average additional 
expected years of life are 25 at age 60 years, 17 at age 
70 years, and 10 at age 80 years. For a man, expected 
additional years of life are 22 at age 60 years, 14 at 
age 70 years, and 8 at age 80 years. The age break-
points shown in these recommendations reflect these Recommendations for Choice of SAVR Versus TAVI for Patients for 
Whom a Bioprosthetic AVR Is Appropriate (Continued)
COR LOE Recommendations
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e100
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Figure 3. Choice of SAVR versus TAVI when AVR is indicated for valvular AS.
Colors correspond to Table 2. *Approximate ages, based on US Actuarial Life Expectancy tables, are provided for guidance. The balance between expected patient 
longevity and valve durability varies continuously across the age range, with more durable valves preferred for patients with a longer life expectancy. Bioprosthetic 
valve durability is finite (with shorter durability for younger patients), whereas mechanical valves are very durable but require lifelong anticoagulation. Long-term 
(20-y) data on outcomes with surgical bioprosthetic valves are available; robust data on transcatheter bioprosthetic valves extend to only 5 years, leading to 
uncertainty about longer-term outcomes. The decision about valve type should be individualized on the basis of patient-specific factors that might affect expected 
longevity. †Placement of a transcatheter valve requires vascular anatomy that allows transfemoral delivery and the absence of aortic root dilation that would re-
quire surgical replacement. Valvular anatomy must be suitable for placement of the specific prosthetic valve, including annulus size and shape, leaflet number and 
calcification, and coronary ostial height. See ACC Expert Consensus Statement.20 AS indicates aortic stenosis; AVR, aortic valve replacement; LVEF, left ventricular 
ejection fraction; QOL, quality of life; SAVR, surgical aortic valve replacement; STS, Society of Thoracic Surgeons; TAVI, transcatheter aortic valve implantation; TF, 
transfemoral; and VKA, vitamin K antagonist.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e101
CLINICAL STATEMENTS  
AND GUIDELINESstatistical averages and serve as the starting point 
for shared decision-making, not as absolute values 
for chronological age. Some younger patients with 
comorbid conditions have a limited life expectancy, 
whereas some older patients have a longer-than-av-
erage life expectancy. Decision-making should be indi-
vidualized on the basis of patient-specific factors that 
affect longevity or quality of life, such as comorbid 
cardiac and noncardiac conditions, frailty, dementia, 
and other factors. In addition, the choice of implanta-
tion approach is based on a shared decision-making 
process that accounts for the patient’s values and pref-
erences and includes discussion of the indications for 
and against each approach and the potential need for 
and risks associated with valve reintervention.16–19
Recommendation-Specific Supportive Text
1. SAVR has demonstrated excellent durability and 
outcomes for both mechanical and bioprosthetic 
valves. Earlier RCTs comparing SAVR and TAVI in 
patients with a higher surgical risk included only 
older patients, with a mean age in the mid-80s. 
More recent RCTs that included patients at low 
to intermediate surgical risk had a mean age in 
the mid-70s, but there were very few patients 
<65 years of age, so the evidence base cannot 
be extrapolated to these patients. In addition, 
valve durability is of higher priority in younger 
patients, who typically have a longer life expec-
tancy and lower surgical risk. As longer-term data 
on TAVI valve durability become available, the age 
range for recommending TAVI may shift, but at 
this time the most prudent course, based on the 
published evidence, is to recommend SAVR for 
adults <65 years of age unless life expectancy is 
limited by comorbid cardiac or noncardiac condi-
tions. The final choice of implantation approach is 
based on a shared decision-making process that 
accounts for the patient’s values and preferences 
and includes discussion of the indications for and 
against each approach and the potential need 
for and risks associated with valve reintervention. 
There are no data for the use of TAVI in patients 
<65 years of age.21
2. Both SAVR and TAVI are effective approaches 
to AVR in adults 65 to 80 years of age. Patients 
enrolled in RCTs of TAVI versus SAVR had high-
velocity severe AS (Stage D1). However, less 
robust data from observational studies and regis-
try data are encouraging with regard to TAVI for 
symptomatic patients with low-flow, low-gradi-
ent severe AS (Stages D2 and D3). Thus, these 
guidelines make the same recommendations for 
symptomatic patients with confirmed severe AS regardless of flow rate. TAVI has a slightly lower 
mortality risk and is associated with a shorter hos-
pital length of stay, more rapid return to normal 
activities, lower risk of transient or permanent AF, 
less bleeding, and less pain than SAVR. On the 
other hand, SAVR is associated with a lower risk 
of paravalvular leak, less need for valve reinterven-
tion, and less need for a permanent pacemaker. 
When the choice of SAVR or TAVI is being made 
in an individual patient between 65 and 80 years 
of age, other factors, such as vascular access, 
comorbid cardiac and noncardiac conditions that 
affect risk of either approach, expected functional 
status and survival after AVR, and patient values 
and preferences, must be considered. The choice 
of mechanical or bioprosthetic SAVR (Section 11) 
versus a TAVI is an important consideration and is 
influenced by durability considerations, because 
durability of transcatheter valves beyond 5 to 6 
years is not yet known.2
3. TAVI is a safe and effective procedure for treat-
ment of severe symptomatic AS in all adults 
regardless of estimated surgical risk. The mortality 
rate for transfemoral TAVI is lower than that for  
SAVR, with a HR of 0.88 and a 95% CI of 0.78 to 
0.99 in a meta-analysis of RCTs. TAVI also is asso-
ciated with a lower risk of stroke (HR: 0.81; 95% 
CI: 0.68–0.98; P=0.028), major bleeding, and AF, 
as well as a shorter hospital length of stay, less 
pain, and more rapid return to normal activities.3 
Compared with SAVR, TAVI results in higher rates 
of vascular complications, paravalvular regurgita-
tion, permanent pacemaker implantation, and 
valve intervention, but most patients will consider 
that the advantages of TAVI outweigh these dis-
advantages. TAVI valves are durable to at least 5 
years, and the limited data on TAVI durability are 
of less concern to most patients >80 years of age 
because the valve durability is likely to be longer 
than the patient’s life expectancy.22 If significant 
valve deterioration does occur, a second TAVI 
within the first prosthesis, (called a valve-in-valve 
TAVI), is likely to be possible. When a transfemo-
ral approach is not possible, other factors, such 
as alternative vascular access, comorbid cardiac 
and noncardiac conditions, expected functional 
status and survival after AVR, and patient values 
and preferences, must be considered. The spe-
cific choice of a balloon-expandable valve or self-
expanding valve depends on patient anatomy and 
other considerations.23–28
4. An LVEF <50% in a patient with severe AS is a 
COR 1 indication for AVR, so the choice of TAVI 
versus SAVR in these patients is based on the 
same considerations as in patients with symptoms 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e102
CLINICAL STATEMENTS  
AND GUIDELINESattributable to severe AS. From a pathophysiolog-
ical point of view, the reasons for thinking that 
TAVI might be especially beneficial with severe AS 
and a low LVEF are the avoidance of myocardial 
ischemia with an open surgical procedure and 
the greater reduction in afterload with a larger 
effective valve area. However, outcome data from 
RCTs show that a low LVEF also is a risk factor 
for adverse outcomes even with TAVI.29 The final 
choice of implantation approach is based on a 
shared decision-making process that accounts for 
the patient’s values and preferences and includes 
discussion of the indications for and against each 
approach and the potential need for and risks 
associated with valve reintervention. Studies on 
the potential benefit of TAVI in patients with 
moderate AS and LV systolic dysfunction are in 
progress.
5. Published RCTs comparing TAVI and SAVR 
included only patients with symptoms attrib-
utable to severe AS. Asymptomatic patients 
with COR 2a indications for AVR should either 
undergo SAVR or wait until a COR 1 indication 
is present before intervention. The recommen-
dation for SAVR in preference to TAVI includes 
asymptomatic patients for whom AVR is being 
considered because of an abnormal exercise 
blood pressure response, an elevated serum BNP 
level, rapid hemodynamic progression, or very 
severe AS with a velocity of ≥ 5 m/s. The final 
choice of implantation approach is based on a 
shared decision-making process that accounts for 
the patient’s values and preferences and includes 
discussion of the indications for and against each 
approach and the potential need for and risks 
associated with valve reintervention.30–32
6. Published RCTs have focused primarily on TAVI 
via the transfemoral vascular access route. 
The mortality rate has been higher with TAVI 
by nonfemoral access routes than with SAVR, 
possibly because of the access approach itself, 
but more likely because of the higher comor -
bidity burden and risk in patients with vascular 
disease severe enough to preclude transfemo-
ral access. When transfemoral TAVI is not fea-
sible, SAVR or palliative care options should be 
included in the shared decision-making discus-
sion. The final choice of implantation approach 
is based on a shared decision-making process 
that accounts for the patient’s values and pref-
erences and includes discussion of the indica-
tions for and against each approach and the 
potential need for and risks associated with 
valve reintervention.1,337. TAVI was compared with standard medical 
therapy in a prospective RCT of patients with 
severe symptomatic AS who were deemed inop-
erable.12,14,34 The rate of all-cause death at 2 
years was lower with TAVI (43.3%) (HR: 0.58; 
95% CI: 0.36–0.92; P =0.02) than with standard 
medical therapy (68%).12,14,34 Standard therapy 
included percutaneous aortic balloon dilation in 
84%. There was a reduction in repeat hospital-
ization with TAVI (55% versus 72.5%; P <0.001). 
In addition, only 25.2% of survivors were in New 
York Heart Association (NYHA) class III or IV 1 
year after TAVI, compared with 58% of patients 
receiving standard therapy (P <0.001). However, 
the rate of major stroke was higher with TAVI 
than with standard therapy at 30 days (5.05% 
versus 1.0%; P =0.06) and remained higher at 
2 years (13.8% versus 5.5%; P=0.01). Major 
vascular complications occurred in 16.2% 
with TAVI versus 1.1% with standard therapy 
(P<0.001).12,14,34 Similarly, in a nonrandomized 
study of 489 patients with severe symptom-
atic AS and extreme surgical risk treated with a 
self-expanding TAVI valve, the rate of all-cause 
death at 12 months was 26% with TAVI, com-
pared with an expected mortality rate of 43% if 
patients had been treated medically.13 The final 
choice of TAVI versus palliative care is based on 
a shared decision-making process that accounts 
for the patient’s values and preferences and 
includes discussion of the indication, risks, and 
benefits for and against each approach.
8. The survival and symptom reduction benefit 
of TAVI is seen only in appropriately selected 
patients. Baseline clinical factors associated with 
a poor outcome after TAVI include advanced age, 
frailty, smoking or chronic obstructive pulmonary 
disease, pulmonary hypertension, liver disease, 
prior stroke, anemia, and other systemic condi-
tions. The STS estimated surgical risk score pro-
vides a useful measure of the extent of patient 
comorbidities and may help identify which 
patients will benefit from TAVI. Patients with a 
mechanical impediment to SAVR, such as a por -
celain aorta or prior chest radiation damage, may 
have better outcomes after TAVI than do frail 
patients or those with moderate to severe disease 
in more than one other organ system.12,14,34 The 
likely benefits and risks of TAVI are considered in 
weighing the risk–benefit ratio of intervention in 
an individual patient. TAVI is not recommended 
in patients with 1) a life expectancy of <1 year 
even with a successful procedure or 2) those with 
a chance of “survival with benefit” of <25% at 2 
years.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e103
CLINICAL STATEMENTS  
AND GUIDELINES9. Percutaneous aortic balloon dilation has a role in 
treating children, adolescents, and young adults 
with AS, but its role in treating older patients 
is very limited. The mechanism by which bal-
loon dilation modestly reduces the severity of stenosis in older patients is fracture of calcific 
deposits within the valve leaflets and, to a minor 
degree, stretching of the annulus and separa-
tion of the calcified or fused commissures. 
Immediate hemodynamic results include a Table 14. A Simplified Framework With Examples of Factors Favoring SAVR, TAVI, or Palliation Instead of Aortic Valve Intervention
Favors SAVR Favors TAVI Favors Palliation
Age/life expectancy* Younger age/longer life expectancy Older age/fewer expected remaining 
years of lifeLimited life expectancy
Valve anatomy BAV
Subaortic (LV outflow tract) calcification
Rheumatic valve disease
Small or large aortic annulus†Calcific AS of a trileaflet valve  
Prosthetic valve preference Mechanical or surgical bioprosthetic 
valve preferred
Concern for patient–prosthesis 
mismatch (annular enlargement might 
be considered)Bioprosthetic valve preferred
Favorable ratio of life expectancy to 
valve durability
TAVI provides larger valve area than 
same size SAVR 
Concurrent cardiac conditions Aortic dilation‡
Severe primary MR
Severe CAD requiring bypass grafting
Septal hypertrophy requiring myectomy
AFSevere calcification of the ascending 
aorta (“porcelain” aorta)Irreversible severe LV systolic 
dysfunction
Severe MR attributable to annular 
calcification
Noncardiac conditions  Severe lung, liver, or renal disease
Mobility issues (high procedural risk 
with sternotomy)Symptoms likely attributable to 
noncardiac conditions
Severe dementia
Moderate to severe involvement of 
≥2 other organ systems
Frailty Not frail or few frailty measures Frailty likely to improve after TAVI Severe frailty unlikely to improve 
after TAVI
Estimated procedural or surgical 
risk of SAVR or TAVISAVR risk low
TAVI risk highTAVI risk low to medium
SAVR risk high to prohibitiveProhibitive SAVR risk (>15%) or post-
TAVI life expectancy <1 y
Procedure-specific impediments Valve anatomy, annular size, or low 
coronary ostial height precludes TAVI
Vascular access does not allow 
transfemoral TAVIPrevious cardiac surgery with at-risk 
coronary grafts
Previous chest irradiationValve anatomy, annular size, or 
coronary ostial height precludes TAVI
Vascular access does not allow 
transfemoral TAVI
Goals of Care and patient 
preferences and valuesLess uncertainty about valve durability
Avoid repeat intervention
Lower risk of permanent pacer
Life prolongation
Symptom relief
Improved long-term exercise capacity 
and QOL
Avoid vascular complications
Accepts longer hospital stay, pain in 
recovery periodAccepts uncertainty about valve 
durability and possible repeat 
intervention
Higher risk of permanent pacer
Life prolongation
Symptom relief
Improved exercise capacity and QOL
Prefers shorter hospital stay, less 
postprocedural painLife prolongation not an important 
goal
Avoid futile or unnecessary 
diagnostic or therapeutic procedures
Avoid procedural stroke risk
Avoid possibility of cardiac pacer
*Expected remaining years of life can be estimated from US Actuarial Life Expectancy tables. The balance between expected patient longevity and 
valve durability varies continuously across the age range, with more durable valves preferred for patients with a longer life expectancy. Bioprosthetic valve 
durability is finite (with shorter durability for younger patients), whereas mechanical valves are very durable but require lifelong anticoagulation. Long-term 
(20-y) data on outcomes with surgical bioprosthetic valves are available; robust data on transcatheter bioprosthetic valves extend only to 5 y, leading to 
uncertainty about longer-term outcomes. The decision about valve type should be individualized on the basis of patient-specific factors that might affect 
expected longevity.
†A large aortic annulus may not be suitable for currently available transcatheter valve sizes. With a small aortic annulus or aorta, a surgical annulus-enlarging 
procedure may be needed to allow placement of a larger prosthesis and avoid patient–prosthesis mismatch.
‡Dilation of the aortic sinuses or ascending aorta may require concurrent surgical replacement, particularly in younger patients with a BAV.
AF indicates atrial fibrillation; AS, aortic stenosis; BAV, bicuspid aortic valve; CAD, coronary artery disease; LV, left ventricular; MR, mitral regurgitation; QOL, 
quality of life; SAVR, surgical aortic valve replacement; and TAVI, transcatheter aortic valve implantation.
Modified from Burke et al.16
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e104
CLINICAL STATEMENTS  
AND GUIDELINESmoderate reduction in the transvalvular pressure 
gradient, but the postdilation valve area rarely 
exceeds 1.0 cm2. Despite the modest change in 
valve area, an early symptomatic improvement 
usually occurs. However, serious acute compli-
cations, including acute severe AR, restenosis, 
and clinical deterioration, occur within 6 to 12 
months in most patients. Therefore, in patients 
with AS, percutaneous aortic balloon dilation 
is not a substitute for AVR. Some clinicians 
contend that, despite the procedural morbid-
ity and mortality rates and limited long-term 
results, percutaneous aortic balloon dilation 
can have a temporary role in the management 
of some symptomatic patients, such as those 
patients with severe AS and refractory pulmo-
nary edema or cardiogenic shock, who might 
benefit from percutaneous aortic balloon dila-
tion as a “bridge” to TAVI or SAVR. However, 
this approach is used less frequently given the 
availability and success of immediate TAVI even 
in very high-risk patients (Table 14).35–38
4. AORTIC REGURGITATION
4.1. Acute Aortic Regurgitation
Acute aortic regurgitation (AR) may result from abnor -
malities of the valve, most often endocarditis, or abnor -
malities of the aorta, primarily aortic dissection. Acute 
AR may also occur as an iatrogenic complication of a 
transcatheter procedure or after blunt chest trauma. 
The acute volume overload on the LV usually results in 
severe pulmonary congestion, as well as a low forward 
cardiac output. Urgent diagnosis and rapid intervention 
are lifesaving.
4.1.1. Diagnosis of Acute AR
TTE or TEE is indispensable in confirming the pres-
ence, severity, and etiology of acute AR; determining 
whether there is rapid equilibration of the aortic and 
LV diastolic pressures; visualizing the aortic root; and 
evaluating LV size and systolic function.1,2 A short 
deceleration time on the aortic flow velocity curve 
and early closure of the mitral valve are indicators of 
markedly elevated LV end-diastolic pressure. A pres-
sure half-time of <300 ms on the AR velocity curve 
indicates rapid equilibration of the aortic and LV 
diastolic pressures. The degree of holodiastolic flow 
reversal in the aortic arch, in comparison with the 
forward systolic flow, provides a quick semiquantita-
tive estimate of regurgitant fraction. Acute severe AR 
caused by aortic dissection is a surgical emergency. 
CT imaging is the primary approach for diagnosis of acute aortic dissection because it is highly accurate 
and continuously available at most medical centers. 
MRI is rarely used in the acute setting because of pa-
tient instability. TEE may be used when CT imaging 
is unavailable and is helpful in intraoperative assess-
ment of aortic valve function before and after the 
surgical intervention. The sensitivity and specificity of 
TTE for diagnosis of Type A3 aortic dissection are only 
60% to 80%, whereas TEE has a sensitivity of 98% 
to 100% and a specificity of 95% to 100%. Angiog-
raphy should be considered only when the diagno-
sis cannot be determined by noninvasive imaging or 
when the differential diagnosis is an acute coronary 
syndrome.
4.1.2. Intervention for Acute AR
In patients with acute severe AR resulting from IE 
or aortic dissection, medical therapy to reduce LV 
afterload may allow temporary stabilization, but 
surgery should not be delayed, especially if there 
is hypotension, pulmonary edema, or evidence of 
low flow.1–4 Intra-aortic balloon counterpulsation is 
contraindicated in patients with acute severe AR.5 
Beta blockers are often used in treating aortic dis-
section. However, these agents should be used very 
cautiously, if at all, for other causes of acute AR be-
cause they will block the compensatory tachycardia 
and could precipitate a marked reduction in blood 
pressure.
4.2. Stages of Chronic AR
The most common causes of chronic severe AR in 
the United States and other high-income countries 
are BAV disease and primary diseases of the ascend-
ing aorta or the sinuses of Valsalva. Rheumatic heart 
disease is the leading cause of AR in many low- to 
middle-income countries. With calcific valve disease, 
regurgitation often accompanies AS, but the degree 
of regurgitation usually is mild to moderate, not se-
vere. In most patients with AR, the disease course 
is chronic and slowly progressive, with increasing LV 
volume overload and LV adaptation via chamber dila-
tion and hypertrophy. Management of patients with 
AR depends on an accurate diagnosis of the cause 
and stage of the disease process. Table  15 shows 
the stages of AR, ranging from patients at risk of 
AR (Stage A) or with progressive mild to moderate 
AR (Stage B) to severe asymptomatic (Stage C) and 
symptomatic (Stage D) AR. Each of these stages is 
defined by valve anatomy, valve hemodynamics, se-
verity of LV dilation, and LV systolic function, as well 
as by patient symptoms.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e105
CLINICAL STATEMENTS  
AND GUIDELINESTable 15. Stages of Chronic AR
Stage Definition Valve Anatomy Valve HemodynamicsHemodynamic 
Consequences Symptoms
A At risk of AR BAV (or other congenital valve 
anomaly)
Aortic valve sclerosis
Diseases of the aortic sinuses or 
ascending aorta
History of rheumatic fever or 
known rheumatic heart disease
IEAR severity: none or trace None None
B Progressive AR Mild to moderate calcification of 
a trileaflet valve BAV (or other 
congenital valve anomaly)
Dilated aortic sinuses
Rheumatic valve changes
Previous IEMild AR:
 Jet width <25% of LVOT
 Vena contracta <0.3 cm
  Regurgitant volume <30 mL/
beat
 Regurgitant fraction <30%
 ERO <0.10 cm2
  Angiography grade 1
Moderate AR:
 Jet width 25%–64% of LVOT
 Vena contracta 0.3–0.6 cm
  Regurgitant volume 30–59 mL/
beat
  Regurgitant fraction 30% to 
49%
 ERO 0.10–0.29 cm2
 Angiography grade 2Normal LV systolic function
Normal LV volume or mild 
LV dilationNone
C Asymptomatic 
severe ARCalcific aortic valve disease
Bicuspid valve (or other 
congenital abnormality)
Dilated aortic sinuses or 
ascending aorta
Rheumatic valve changes
IE with abnormal leaflet closure 
or perforationSevere AR:
 Jet width ≥65% of LVOT
 Vena contracta >0.6 cm
  Holodiastolic flow reversal in 
the proximal abdominal aorta
  Regurgitant volume ≥60 mL/
beat
 Regurgitant fraction ≥50%
 ERO ≥0.3 cm2
 Angiography grade 3 to 4
  In addition, diagnosis of chronic 
severe AR requires evidence of 
LV dilationC1: Normal LVEF (>55%) 
and mild to moderate LV 
dilation (LVESD <50 mm)
C2: Abnormal LV systolic 
function with depressed 
LVEF (≤55%) or severe LV 
dilation (LVESD >50 mm or 
indexed LVESD >25 mm/m2)None; exercise 
testing is 
reasonable to 
confirm symptom 
status
D Symptomatic 
severe ARCalcific valve disease
Bicuspid valve (or other 
congenital abnormality)
Dilated aortic sinuses or 
ascending aorta
Rheumatic valve changes
Previous IE with abnormal leaflet 
closure or perforationSevere AR:
  Doppler jet width ≥65% of 
LVOT
 Vena contracta >0.6 cm
  Holodiastolic flow reversal in 
the proximal abdominal aorta
  Regurgitant volume ≥60 mL/
beat
 Regurgitant fraction ≥50%
 ERO ≥0.3 cm2
 Angiography grade 3 to 4
  In addition, diagnosis of chronic 
severe AR requires evidence of 
LV dilationSymptomatic severe AR may 
occur with normal systolic 
function (LVEF >55%), mild 
to moderate LV dysfunction 
(LVEF 40% to 55%), or 
severe LV dysfunction (LVEF 
<40%)
Moderate to severe LV 
dilation is presentExertional 
dyspnea or 
angina or 
more severe HF 
symptoms
AR indicates aortic regurgitation; BAV, bicuspid aortic valve; ERO, effective regurgitant orifice; HF, heart failure; IE, infective endocarditis; LV, left ventricular; LVEF, 
left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; and LVOT, left ventricular outflow tract.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e106
CLINICAL STATEMENTS  
AND GUIDELINES4.3. Chronic AR
4.3.1. Diagnosis of Chronic AR
Recommendations for Diagnostic Testing of Chronic AR
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 14.
COR LOE Recommendations
1 B-NR1.  In patients with signs or symptoms of AR, TTE 
is indicated for assessment of the cause and 
severity of regurgitation, LV size and systolic 
function, prognosis, and timing of valve 
intervention.1–19
1 B-NR2.  In patients with a BAV or with known dilation 
of the aortic sinuses or ascending aorta, TTE is 
indicated to evaluate the presence and severity 
of AR.1
1 B-NR3.  In patients with moderate or severe AR and 
suboptimal TTE images or a discrepancy 
between clinical and TTE findings, TEE, CMR, 
or cardiac catheterization is indicated for the 
assessment of LV systolic function, systolic and 
diastolic volumes, aortic size, and AR severity.20–25
Synopsis
TTE provides diagnostic information about the etiology 
and mechanism of AR (including valve reparability), se-
verity of regurgitation, morphology of the ascending 
aorta, and LV response to the increases in preload and 
afterload. Imaging with TEE, CMR, or aortic angiogra-
phy provides additional information when needed.
Recommendation-Specific Supportive Text
1. Although qualitative measures of AR severity are 
adequate in many situations, when AR is signifi-
cant (Stages B and C), quantitative measures of 
regurgitant volume and effective regurgitant 
orifice (ERO) area1 are better predictors of clini-
cal outcome.2,3 Measures of LV systolic function 
(LVEF or fractional shortening) and LV end-systolic 
dimension (LVESD) or LV end-systolic volume are 
predictive of the development of HF symptoms or 
death in initially asymptomatic patients (Stages 
B and C1) and are significant determinants of 
survival and functional results after surgery in 
asymptomatic and symptomatic patients (Stages 
C2 and D).2–18,26 Symptomatic patients (Stage D) 
with normal LVEF have a significantly better long-
term postoperative survival rate than those with 
depressed systolic function.
2. Auscultation has high specificity for detecting AR 
but low sensitivity and diagnostic accuracy.27 TTE 
can identify AR in patients who have been deemed 
to be at risk on the basis of the presence of known 
aortic dilation or a condition associated with 
abnormal aortic valve function, such as a BAV.3. TTE and CMR are useful for evaluating patients 
in whom there is discordance between clinical 
assessment and severity of AR by TTE or when 
TTE images are suboptimal. CMR imaging pro-
vides accurate and reproducible measures of 
regurgitant volume and regurgitant fraction in 
patients with AR, as well as assessment of aortic 
morphology, LV volume, and LV systolic func-
tion. Cardiac catheterization with LV and aortic 
angiography, as well as quantitation of regurgi-
tation severity, is another option.20–25,28–30
4.3.2. Medical Therapy
Recommendations for Medical Therapy of Chronic AR
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 14.
COR LOE Recommendations
1 B-NR1.  In asymptomatic patients with chronic AR 
(Stages B and C), treatment of hypertension 
(systolic blood pressure >140 mm Hg) is 
recommended.1–3
1 B-NR2.  In patients with severe AR who have 
symptoms and/or LV systolic dysfunction 
(Stages C2 and D) but a prohibitive surgical 
risk, GDMT for reduced LVEF with ACE 
inhibitors, ARBs, and/or sacubitril/valsartan is 
recommended.4
Synopsis
There is no evidence that vasodilating drugs reduce se-
verity of AR or alter the disease course in patients with 
significant AR in the absence of systemic hypertension. 
Recommendations for GDMT for hypertension and HF 
apply to patients with chronic asymptomatic AR, as for 
the general population.
Recommendation-Specific Supportive Text
1. Severe AR is associated with a wide pulse pres-
sure, such that systolic blood pressure is higher 
than in patients without AR even when systemic 
vascular resistance is normal. Transaortic stroke 
volume increases further with medications that 
lower heart rate, such as beta blockers, which 
may result in a paradoxical apparent increase in 
blood pressure. Vasodilating drugs, such as ACE 
inhibitors or ARBs, do not affect heart rate and 
thus may reduce systolic blood pressure without 
a substantial reduction in diastolic blood pres-
sure in patients with chronic AR.1,2,5–8
2. In symptomatic patients who are candidates 
for surgery, medical therapy is not a substitute 
for AVR. However, medical therapy is help-
ful for alleviating symptoms in patients who 
are considered to be at very high surgical risk 
because of concomitant comorbid medical 
conditions.5,9
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e107
CLINICAL STATEMENTS  
AND GUIDELINES4.3.3. Timing of Intervention
Recommendations for Timing of Intervention for Chronic AR
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 15 to 17.
COR LOE Recommendations
1 B-NR1.  In symptomatic patients with severe AR (Stage 
D), aortic valve surgery is indicated regardless 
of LV systolic function.1–7
1 B-NR2.  In asymptomatic patients with chronic severe 
AR and LV systolic dysfunction (LVEF ≤55%) 
(Stage C2), aortic valve surgery is indicated 
if no other cause for systolic dysfunction is 
identified.3,5,8–12
1 C-EO3.  In patients with severe AR (Stage C or D) 
who are undergoing cardiac surgery for other 
indications, aortic valve surgery is indicated.
2a B-NR4.  In asymptomatic patients with severe AR and 
normal LV systolic function (LVEF >55%), aortic 
valve surgery is reasonable when the LV is 
severely enlarged (LVESD >50 mm or indexed 
LVESD >25 mm/m2) (Stage C2).10,11,13–24
2a C-EO5.  In patients with moderate AR (Stage B) who 
are undergoing cardiac or aortic surgery 
for other indications, aortic valve surgery is 
reasonable.
2b B-NR6.  In asymptomatic patients with severe AR 
and normal LV systolic function at rest (LVEF 
>55%; Stage C1) and low surgical risk, aortic 
valve surgery may be considered when there 
is a progressive decline in LVEF on at least 3 
serial studies to the low–normal range (LVEF 
55% to 60%) or a progressive increase in 
LV dilation into the severe range (LV end-
diastolic dimension [LVEDD]  
>65 mm).12,16,17,20,25–28
3: Harm B-NR7.  In patients with isolated severe AR who have 
indications for SAVR and are candidates for 
surgery, TAVI should not be performed.29–32
Synopsis
Most patients with indications for surgery for chronic 
severe AR require valve replacement with a mechani-
cal or bioprosthetic valve (Figure  4). Preservation of 
the native aortic valve (“valve sparing”) may be pos-
sible in selected patients with favorable valve anatomy 
who are undergoing surgical replacement of the aortic 
sinuses and/or ascending aorta.33–39 Although advanc-
es are occurring in primary aortic valve repair,37,40–42 
this approach is not yet generalizable, and durabil-
ity is not known. Current recommendations for AVR 
related to severity of LV dilation are based on mea-
surement of LV short-axis diameters. There are limited 
data demonstrating prognostic value of LV volume 
measurements in chronic AR using left ventriculogra-
phy,43 2D echocardiography,18,44 and CMR.45,46 Normal 
limits for LV volumes have been determined, as have 
criteria for severe LV dilation, but these values differ 
between 2D echocardiography, 3D echocardiography, 
and CMR,47,48 and there are insufficient data on the 
relationship between LV volumes and outcomes of patients with AR. This is an area in need of further 
investigation. Other markers of LV dysfunction and re-
modeling, such as global longitudinal strain and circu-
lation biomarkers,44,46,49–51 likewise require additional 
clinical outcome studies.
Recommendation-Specific Supportive Text
1. Symptoms are an important indication for AVR 
in patients with chronic severe AR, and the most 
important aspect of the clinical evaluation is tak-
ing a careful, detailed history to elicit symptoms 
or diminution of exercise capacity. Patients with 
chronic severe AR who develop symptoms have 
a high risk of death if AVR is not performed,52 
and survival and functional status after AVR are 
related to the severity of preoperative symptoms, 
assessed either subjectively or objectively with 
exercise testing.1–4 Even among symptomatic 
patients with a severe reduction in LVEF (<35%), 
AVR results in improved survival rate.5–7
2. LV systolic function is an important determi-
nant of survival and functional status after 
AVR.3–5,8,9,12,53–61 Outcomes are optimal when 
surgery is performed before LVEF decreases 
below 55%.16,25,26 In asymptomatic patients 
with LV systolic dysfunction, postoperative out-
comes are better if AVR is performed before 
onset of symptoms.53
3. Patients with chronic severe AR may be referred 
for other types of cardiac surgery, such as CABG, 
mitral valve surgery, or surgery for correction of 
dilation of the aortic root or ascending aorta. In 
these patients, AVR will prevent both the hemo-
dynamic consequences of persistent AR during 
the perioperative period and the possible need 
for a second cardiac operation in the near future. 
Patients undergoing surgical repair or replacement 
of the aortic root or ascending aorta may be can-
didates for aortic valve–sparing procedures.33–39
4. LVESD in patients with chronic AR reflects both 
the severity of the LV volume overload and the 
degree of LV systolic shortening.54,62 An elevated 
LVESD often reflects LV systolic dysfunction with 
a depressed LVEF. If LVEF is normal, an increased 
LVESD indicates a significant degree of LV remod-
eling and is associated with subsequent develop-
ment of symptoms and/or LV systolic dysfunction 
and an increased mortality rate after AVR.17,20,21 
Most studies have used unadjusted LVESD, but 
indexing for body size is important, particularly in 
women or small patients.13,19,52 Recent data indi-
cate that the LVESD index threshold for optimal 
postoperative survival may be even smaller than 
25 mm/m2,14–16 but more outcome data, and ide-
ally an RCT, of earlier intervention are needed. 
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e108
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
LV volumes may be a more sensitive predictor of 
cardiac events than LVESD index in asymptomatic 
patients,18 but more data are needed to deter -
mine the threshold values of LV systolic volume 
that best predict postoperative outcomes.
5. In patients with moderate AR who are undergo-
ing other forms of cardiac surgery, such as CABG, 
mitral valve surgery, or replacement of the ascend-
ing aorta, the decision to intervene on the aortic 
valve concurrently includes consideration of several 
factors, including aortic valve anatomy, aortic root 
size and shape, regurgitant severity, other comor -
bidities, and patients’ preferences and values. 
Patients undergoing surgical repair or replacement 
of the aortic root or ascending aorta may be candi-
dates for a valve-sparing procedure.33–39
6. LVEDD, a marker of the severity of LV volume 
overload in patients with chronic AR, is signifi-
cantly associated with clinical outcomes in asymp-
tomatic patients, and progressive increases in 
LVEDD are associated with subsequent need for 
surgery.16,17,20,25–28 In asymptomatic patients, it is important to ensure that apparent changes in LV 
size or LVEF are not due simply to measurement or 
physiological variability. In addition, confirmation 
of severe regurgitation by quantitative measures of 
AR severity with TTE, TEE, or, when needed, CMR 
provides confidence that AR is the cause of LV dila-
tion or decrease in LVEF. When there is an apparent 
significant fall in EF or increase in LV size, repeat 
imaging typically is performed at 3- to 6-month 
intervals unless there is clinical deterioration.
7. TAVI for isolated chronic AR is challenging because 
of dilation of the aortic annulus and aortic root 
and, in many patients, lack of sufficient leaflet 
calcification. Risks of TAVI for treatment of AR 
include transcatheter valve migration and signifi-
cant paravalvular leak.29–32 TAVI is rarely feasible, 
and then only in carefully selected patients with 
severe AR and HF who have a prohibitive surgi-
cal risk and in whom valvular calcification and 
annular size are appropriate for a transcatheter 
approach.
Figure 4. Timing of intervention for AR.
Colors correspond to Table 2. AR indicates aortic 
regurgitation; AVR, aortic valve replacement; EDD, 
end-diastolic dimension; ERO, effective regurgi-
tant orifice; LVEF, left ventricular ejection fraction; 
LVESD, left ventricular end-systolic dimension; RF, 
regurgitant fraction; RVol, regurgitant volume; and 
VC, vena contracta
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e109
CLINICAL STATEMENTS  
AND GUIDELINES5. BICUSPID AORTIC VALVE
5.1. BAV and Associated Aortopathy
5.1.1. Diagnosis and Follow-Up of BAV
5.1.1.1. Diagnostic Testing: Initial Diagnosis
Recommendations for Diagnostic Testing: Initial Diagnosis of BAV
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 18.
COR LOE Recommendations
1 B-NR1.  In patients with a known BAV, TTE is 
indicated to evaluate valve morphology, 
measure severity of AS and AR, assess the 
shape and diameter of the aortic sinuses 
and ascending aorta, and evaluate for the 
presence of aortic coarctation for prediction 
of clinical outcome and to determine timing 
of intervention.1–4
1 C-LD2.  In patients with BAV, CMR angiography or CT 
angiography is indicated when morphology 
of the aortic sinuses, sinotubular junction, or 
ascending aorta cannot be assessed accurately 
or fully by echocardiography.4,5
2b B-NR3.  In first-degree relatives of patients with 
a known BAV, a screening TTE might be 
considered to look for the presence of a BAV 
or asymptomatic dilation of the aortic sinuses 
and ascending aorta.6
Synopsis 
BAV is a common congenital anomaly that affects 0.5% 
to 2.0% of adults with a 3:1 male-to-female predomi-
nance.1 Patients with BAV may develop isolated aortic 
valve disease, including isolated AR, AS, or a combina-
tion of the two. Aortic aneurysms have been reported 
in 20% to 40% of patients with BAV.1 This aortopathy 
can occur independent of valve function and consists 
of dilation of the aortic sinuses, the ascending aorta, 
or the arch. Therefore, patients with BAV require care-
ful evaluation of both the aortic valve and the aorta 
throughout their lifetimes (Figure 5).
Recommendation-Specific Supportive Text
1. Many patients with BAV will develop AS or AR over 
their lifetimes. In a recent meta-analysis of natural 
history studies of patients with BAV, 13% to 30% 
of patients developed moderate or greater AR 
and 12% to 37% developed moderate or greater 
AS during follow-up.1 TTE usually is adequate for 
evaluation of aortic valve anatomy and hemody-
namics. TEE provides improved 2D and 3D images 
if needed. Aortic enlargement at the level of the 
sinuses or proximal ascending aorta has been 
reported in 20% to 40% of patients with BAV,1 
and some develop severe aneurysmal dilation 
and are at increased risk of aortic dissection.2,3,7–10 
Aortic measurements are reported at the aortic 
annulus, sinuses of Valsalva, sinotubular junction, 
and mid-ascending aorta. Doppler interrogation of the proximal descending aorta and abdominal 
aorta should also be performed to evaluate for 
the presence of aortic coarctation, which is asso-
ciated with BAV in a subset of patients, although 
a coarctation also can be detected by comparing 
arm and leg blood pressures.
2. CT angiography or CMR provides better images 
of the aortic sinuses, sinotubular junction, or 
ascending aorta when TTE does not adequately 
visualize the sinus and proximal 5 to 6 cm of 
the ascending aorta. The choice of CMR versus 
CT angiography depends on patient preference, 
insurance coverage, institutional expertise, and 
consideration of radiation exposure.
3. In about 20% to 30% of patients with a BAV, 
other family members also have a BAV and/or an 
associated aortopathy. A specific genetic cause 
has not been identified, and the patterns of 
inheritance are variable. Imaging can identify the 
presence of a BAV and aortic dilation, but there is 
a paucity of data on the cost-effectiveness of this 
approach and whether earlier diagnosis would 
improve long-term clinical outcomes.6,11
5.1.1.2. Diagnostic Testing: Routine Follow-Up
Recommendations for Diagnostic Testing: Routine Follow-Up of 
Patients With a BAV
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 18.
COR LOE Recommendations
2a C-LD1.  In patients with BAV and a diameter of the 
aortic sinuses or ascending aorta of ≥4.0 
cm, lifelong serial evaluation of the size 
and morphology of the aortic sinuses and 
ascending aorta by echocardiography, CMR, 
or CT angiography is reasonable, with the 
examination interval determined by the degree 
and rate of progression of aortic dilation and 
by family history.1–5
2a B-NR2.  In patients with a BAV who have undergone 
AVR, continued lifelong serial interval imaging 
of the aorta is reasonable if the diameter of 
the aortic sinuses or ascending aorta is ≥4.0 
cm.6,7
Synopsis 
Patients with BAV with and without associated aortic 
aortopathy require lifelong surveillance. Because pro-
gression of valve disease and growth of the aorta can 
occur in the absence of symptoms, diagnostic imaging 
plays an integral role in the surveillance process.
Recommendation-Specific Supportive Text
1. Aortopathy is present in approximately 20% to 
40% of patients with a BAV and is associated with 
dilation of the aortic sinuses, the ascending aorta, 
and/or the arch.1 In a retrospective case series of 
918 patients with BAV followed for 2 to 12 years 
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e110
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
with serial imaging, 47% required valve surgery 
but only 3.8% required aortic grafting without 
valve replacement, and <0.1% had aortic dissec-
tion.5 In a systematic review of 13 studies with 
>11 000 patients with a BAV, aortic dilation was 
present in 20% to 40%, but only 0.4% suffered 
aortic dissection.1 Aortic imaging at least annually 
is prudent in patients with BAV and significant aor -
tic dilation (>4.5 cm) to determine the appropriate 
timing of surgical intervention. Patients with risk 
factors that increase the risk of aortic dissection, 
such as a rapid rate of change in aortic diameter 
or a family history of aortic dissection, may also 
require more frequent monitoring. In patients 
with milder dilation that shows no change on 
sequential studies and with a negative family his-
tory, a longer interval between imaging studies is 
appropriate.1–4,8,9
2. In a retrospective review of 1286 patients with 
a BAV who underwent isolated AVR with a 
median of 12 years of follow-up, subsequent 
aortic dissection occurred in 1%, ascending aor -
tic replacement surgery was needed in 0.9%, 
and progressive aortic enlargement was noted in 
9.9%.6 In a smaller cohort of 153 patients with a BAV with prior AVR, 3% required proximal aor -
tic surgery after 15 years of follow-up. No cases 
of aortic dissection were noted.7,10 These stud-
ies demonstrate that the aorta may continue to 
dilate in patients with a BAV who undergo valve 
replacement surgery.11
5.1.2. Interventions for Patients With BAV
5.1.2.1. Intervention: Replacement of the Aorta
Recommendations for Intervention: Replacement of the Aorta in 
Patients With a BAV
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 18.
COR LOE Recommendations
1 B-NR1.  In asymptomatic or symptomatic patients 
with a BAV and a diameter of the aortic 
sinuses or ascending aorta >5.5 cm, operative 
intervention to replace the aortic sinuses and/
or the ascending aorta is recommended.1–3
2a B-NR2.  In asymptomatic patients with a BAV, a 
diameter of the aortic sinuses or ascending 
aorta of 5.0 to 5.5 cm, and an additional risk 
factor for dissection (eg, family history of aortic 
dissection, aortic growth rate >0.5 cm per 
year, aortic coarctation), operative intervention 
to replace the aortic sinuses and/or the 
ascending aorta is reasonable if the surgery is 
performed at a Comprehensive Valve Center.3,4
Figure 5. Intervals for imaging the aorta in 
patients with a BAV.
Colors correspond to Table 2. BAV indicates 
bicuspid aortic valve; CTA, computed tomographic 
angiography; CMR, cardiac magnetic resonance; 
TTE, transthoracic echocardiography.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e111
CLINICAL STATEMENTS  
AND GUIDELINES2a B-NR3.  In patients with a BAV with indications for 
SAVR and a diameter of the aortic sinuses 
or ascending aorta ≥4.5 cm, replacement of 
the aortic sinuses and/or ascending aorta is 
reasonable if the surgery is performed at a 
Comprehensive Valve Center.4–7
2b C-LD4.  In patients with a BAV who meet criteria for 
replacement of the aortic sinuses, valve-sparing 
surgery may be considered if the surgery is 
performed at a Comprehensive Valve Center.8,9
2b B-NR5.  In asymptomatic patients with a BAV who are 
at low surgical risk, have a diameter of the 
aortic sinuses or ascending aorta of 5.0 to 5.5 
cm, and have no additional risk factors for 
dissection, operative intervention to replace 
the aortic sinuses and/or the ascending aorta 
may be considered if the surgery is performed 
at a Comprehensive Valve Center.4–7,10–14
Synopsis 
The timing and type of surgery for replacement of the 
aorta are dependent on the anatomy of the aorta (as 
demonstrated on imaging), patient characteristics, and 
institutional expertise (Figure 6).
Recommendation-Specific Supportive Text
1. Retrospective studies of patients with a BAV have 
shown that the incidence of aortic dissection is very 
low and is estimated to be approximately 0.4% with 
routine surveillance of the aorta.1 However, data are 
limited with regard to the degree of aortic dilation at 
which the risk of dissection is high enough to war -
rant operative intervention in patients who do not 
fulfill criteria for AVR on the basis of severe AS or AR. 
Thus, an individualized approach to the timing of 
surgical intervention for a dilated aorta is suggested. 
Surgery is recommended in patients with a BAV with 
or without symptoms and with a diameter of the 
aortic sinuses or the ascending aorta of ≥ 5.5 cm.2
2. Specific risk factors, including family history of 
aortic dissection, aortic growth rate >0.5 cm per 
year, and aortic coarctation, are associated with 
a greater risk of aortic dissection. In patients 
with these risk factors, operative intervention to 
replace the aortic sinuses and/or the ascending 
aorta is reasonable when the aortic dimension is 
5.0 to 5.5 cm, if the surgery is performed at a 
Comprehensive Valve Center.4,10–12,15
3. In patients with a BAV, data are limited with regard 
to the degree of aortic dilation at which the risk of 
dissection is high enough to warrant replacement 
of the ascending aorta at the time of AVR. The risk 
of progressive aortic dilation and dissection after 
AVR in patients with BAV has been the subject of 
several studies, but definitive data are lacking. In patients undergoing AVR because of severe AS or 
AR, replacement of the ascending aorta is reason-
able when the aortic diameter is >4.5 cm.4–7,10–14
4. There are a limited number of patients with BAV 
who meet criteria for operative intervention on 
the aortic sinuses and/or ascending aorta but have 
a well-functioning aortic valve. Because of the 
growing experience with valve-sparing surgery on 
highly selected patients,8,9 surgical replacement of 
the aorta with aortic valve repair or reimplantation 
may be considered. However, given the complexity 
of this procedure, surgery should be performed at 
a Comprehensive Valve Center.
5. Data are limited with regard to the degree of 
aortic dilation at which the risk of dissection is 
high enough to warrant operative intervention in 
patients who do not fulfill criteria for AVR on the 
basis of severe AS or AR. In asymptomatic patients 
with a BAV and a diameter of the aortic sinuses 
and/or ascending aorta of 5.0 to 5.5 cm who are at 
low surgical risk and have no additional risk factors 
for aortic dissection, surgery to replace the aortic 
sinuses and/or ascending aorta may be considered 
as long as surgery is performed at a Comprehensive 
Valve Center. Additionally, shared decision-making 
between the patient and the healthcare team is 
needed to clearly outline the risks of surgery and 
weigh them against the potential reduction in 
future risk of aortic dissection.4–7,10–14
5.1.2.2. Intervention: Repair or Replacement of the 
Aortic Valve
Recommendations for Intervention: Repair or Replacement of the 
Aortic Valve
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 18.
COR LOE Recommendations
2b C-LD1.  In patients with BAV and severe AR who meet 
criteria for AVR, aortic valve repair may be 
considered in selected patients if the surgery is 
performed at a Comprehensive Valve Center.1–3
2b B-NR2.  In patients with BAV and symptomatic, severe 
AS, TAVI may be considered as an alternative 
to SAVR after consideration of patient-
specific procedural risks, values, trade-offs, 
and preferences, and when the surgery is 
performed at a Comprehensive Valve Center.4–6
Synopsis
The indications for the timing of aortic valve interven-
tion in patients with a BAV and AS or AR is similar to 
those for trileaflet aortic valves. See the respective sec-
tions on AS (Section 3.2) and AR (Section 4). The choice 
of prosthetic valve type in patients with a BAV is similar 
to that for patients with trileaflet valves. See the sec-
tion on prosthetic valve choices (Section 3.2.4.1) for full 
details. Given the unique nature of BAV, however, there 
are additional specific considerations.Recommendations for Intervention: Replacement of the Aorta in 
Patients With a BAV (Continued)
COR LOE Recommendations
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e112
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Recommendation-Specific Supportive Text
1. Surgical repair of the aortic valve may be feasible 
in selected patients, depending on valve and aortic 
root anatomy and tissue characteristics. Published 
data suggest that valve repair can be performed 
safely and effectively by surgeons with training 
and experience in these techniques.1–3,7 However, 
given the complexities of patient selection and 
surgical techniques, such surgeries should be per -
formed at a Comprehensive Valve Center.
2. Recent trials have demonstrated the benefits of 
TAVI in patients with severe, symptomatic AS. 
However, the early pivotal TAVI trials excluded 
patients with BAV. Initial studies using early-gener -
ation valves suggested a higher rate of paravalvular 
leak in the BAV population.4,5 Data from the STS/
ACC Transcatheter Valve Therapies Registry, which 
includes all consecutive TAVI procedures performed 
in the United States, suggest that with the use 
of newer-generation prosthetic valves the rate of 
paravalvular leak is no different in patients with a BAV than in patients with a trileaflet aortic valve. 
This registry also showed no difference in mortality 
rate at 30 days and 1 year between the BAV and 
tricuspid valve groups. However, the stroke rate at 
30 days was higher in the BAV group.6 Other con-
siderations are the younger age of patients with a 
BAV, for whom the risk–benefit ratio of TAVI versus 
SAVR needs careful consideration. RCTs are needed 
to obtain full clarity on the optimal use of TAVI in 
this population, as well as long-term outcomes.
6. MITRAL STENOSIS
The incidence of rheumatic MS is low in high-income 
countries and has been slowly declining in low- and mid-
dle-income countries, but MS remains a major cause of 
valve disease worldwide. Rheumatic MS is much more 
common in women (about 80% of cases) than in men. 
The clinical presentation of rheumatic MS varies, with 
patients from regions with a high disease prevalence 
presenting at a young age (teen years to age 30 years) 
Figure 6. Intervention for replacement of the 
aorta in patients with a BAV.
Colors correspond to Table 2. *Family history of 
aortic dissection, aortic growth rate ≥0.5 cm/y, 
and/or presence of aortic coarctation. BAV 
indicates bicuspid aortic valve; AVR, aortic valve re-
placement; and CVC, Comprehensive Valve Center.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e113
CLINICAL STATEMENTS  
AND GUIDELINESwith commissural fusion but pliable noncalcified valve 
leaflets. In contrast, the presentation in regions with a 
low disease prevalence occurs more often in older pa-
tients (age 50 to 70 years) who present decades after the 
initial rheumatic fever episode with calcified fibrotic leaf-
lets in addition to commissural fusion and subvalvular 
involvement. Older patients with MS often have multiple 
other cardiac and noncardiac comorbidities, such as ath-
erosclerotic disease, hypertension, and diastolic dysfunc-
tion, all of which need to be taken into consideration in 
patient evaluation and management.1,2
Although most of MS in the world results from rheumat-
ic heart disease, nonrheumatic calcific MS is found with in-
creasing frequency in the elderly population in high-income 
countries Calcific MS is the result of calcification of the mi-
tral annulus that extends into the leaflet bases, resulting in 
both narrowing of the annulus and rigidity of the leaflets.3–5
6.1. Stages of MS
The stages of MS are defined by patient symptoms, valve 
anatomy, valve hemodynamics, and the consequences 
of valve obstruction on the left atrium (LA) and pulmo-
nary circulation (Table  16). Rheumatic valve disease is 
the primary cause of MS, with anatomic features reflect-
ing this disease process. Hemodynamic severity is best 
characterized by valve area, either directly planimetered 
by 2D or 3D imaging or calculated from the diastolic 
pressure half-time.1 The definition of “severe” MS is 
based on the severity of symptoms, as well as the sever -
ity at which intervention will improve symptoms. Thus, 
a mitral valve area ≤ 1.5 cm2 is considered severe, which 
typically corresponds to a transmitral mean gradient of >5 mm Hg to 10 mm Hg at a normal heart rate. How-
ever, mean pressure gradient is highly dependent on 
transvalvular flow rate, the diastolic filling period, and 
heart rate. Mitral pressure half-time also has limitations, 
and is dependent upon LV and LA compliance as well 
as stenosis severity. Other approaches to calculation of 
the mitral valve area, such as the continuity equation or 
Gorlin formula, may be used if discrepancies exist. These 
pertain primarily to patients with rheumatic MS.
6.2. Rheumatic MS
6.2.1. Diagnosis and Follow-Up of Rheumatic MS
6.2.1.1. Diagnostic Testing: Initial Diagnosis
Recommendations for Diagnostic Testing: Initial Diagnosis of 
Rheumatic MS
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 19.
COR LOE Recommendations
1 B-NR1.  In patients with signs or symptoms of 
rheumatic MS, TTE is indicated to establish 
the diagnosis, quantify hemodynamic severity, 
assess concomitant valvular lesions, and 
demonstrate valve morphology (to determine 
suitability for mitral commissurotomy).1–3
1 C-LD2.  In patients considered for percutaneous 
mitral balloon commissurotomy (PMBC), TEE 
should be performed to assess the presence or 
absence of LA thrombus and to evaluate the 
severity of MR.4–6
Synopsis
For patients with rheumatic MS, TTE is the initial di-
agnostic test to determine the severity of the stenosis Table 16. Stages of MS
Stage Definition Valve Anatomy Valve HemodynamicsHemodynamic 
Consequences Symptoms
A At risk of MS Mild valve doming during diastole Normal transmitral flow velocity None None
B Progressive MS Rheumatic valve changes with 
commissural fusion and diastolic 
doming of the mitral valve leaflets
Planimetered mitral valve area 
>1.5 cm2Increased transmitral flow 
velocities
Mitral valve area >1.5 cm2
Diastolic pressure half-time 
<150 msMild to moderate LA 
enlargement
Normal pulmonary 
pressure at restNone
C Asymptomatic severe 
MSRheumatic valve changes with 
commissural fusion and diastolic 
doming of the mitral valve 
leaflets
Planimetered mitral valve area 
≤1.5 cm2Mitral valve area ≤1.5 cm2
Diastolic pressure half-time 
≥150 msSevere LA enlargement
Elevated PASP >50 
mm HgNone
D Symptomatic severe MS Rheumatic valve changes with 
commissural fusion and diastolic 
doming of the mitral valve leaflets
Planimetered mitral valve area 
≤1.5 cm2Mitral valve area ≤1.5 cm2
Diastolic pressure half-time 
≥150 msSevere LA enlargement
Elevated PASP >50 
mm HgDecreased 
exercise 
tolerance
Exertional 
dyspnea
The transmitral mean pressure gradient should be obtained to further determine the hemodynamic effect of the MS and is usually >5 mm Hg to 10 mm Hg in 
severe MS; however, because of the variability of the mean pressure gradient with heart rate and forward flow, it has not been included in the criteria for severity.
LA indicates left atrial; MS, mitral stenosis; and PASP , pulmonary artery systolic pressure.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e114
CLINICAL STATEMENTS  
AND GUIDELINESand suitability for PMBC. If PMBC is being considered, 
a TEE can further evaluate the presence and severity of 
concomitant MR and rule out LA thrombus.
Recommendation-Specific Supportive Text
1. TTE is the imaging modality of choice to eluci-
date the anatomy and functional significance 
of rheumatic MS.1 The parasternal long-axis 
window can identify the characteristic diastolic 
doming of the mitral valve, whereas short-axis 
scanning will demonstrate commissural fusion 
and allow planimetry of the mitral orifice. Use 
of 3D echocardiography (either TTE or TEE) pro-
vides greater accuracy of measurement of the 
mitral valve area.7,8 Doppler echocardiography 
mean transvalvular gradients always should be 
reported with heart rate because a high heart rate 
will result in overestimation of stenosis severity.9 
Estimated RV systolic pressure is obtained from 
the TR velocity. Concomitant MR should be quan-
tified, along with any other valve lesions (Section 
7.3.1.1). Several scores are available for evalua-
tion of mitral valve morphology and prediction of 
outcomes with PMBC, and these scores consider 
valve thickening, mobility, and calcification with 
subvalvular chordal fusion.10,11 Characterization 
of commissural morphology and calcification fur -
ther predicts suitability for commissurotomy.2,3,12,13 
Additional assessment of rheumatic MS includes 
the mitral pressure half-time, with acknowledg-
ment that this parameter is also affected by LA 
and LV compliance. If the mean gradient does not 
match the valve area, other methods, such as the 
continuity equation, should be considered.14
2. TEE offers excellent visualization of the mitral 
valve and LA and is an alternative approach to 
assessment of rheumatic MS in patients whose 
TTE images are technically limited. In patients 
being considered for PMBC, a TEE can rule out LA 
cavity and appendage thrombi.4–6 TEE also is use-
ful for evaluation of MR severity in patients being 
considered for PMBC because shadowing of the 
LA on TTE may result in underestimation of MR 
severity. MR that is more than mild is a contrain-
dication to PMBC.
6.2.1.2. Diagnostic Testing: Changing Signs or 
Symptoms
Patients with an established diagnosis of rheumatic MS 
may experience a change in symptoms attributable to 
disease progression related to recurrent episodes of rheu-
matic fever leading to further valve damage; progressive 
narrowing of the mitral valve attributable to leaflet fibro-
sis and thickening; progressive pulmonary hypertension; or worsening of concomitant MR or other valve lesions. 
In addition, symptom status may change with no change 
in rheumatic MS severity because of an increased he-
modynamic load (for example, because of pregnancy), 
new-onset or rapid AF, fever, anemia, or hyperthyroid-
ism, or hemodynamic shifts in the perioperative period 
of patients undergoing noncardiac surgery. In such cases, 
a repeat TTE examination can quantify the mitral valve 
gradient and area, as well as other parameters that may 
contribute to a change in symptoms.
6.2.1.3. Diagnostic Testing: Routine Follow-Up
Rheumatic MS is a slowly progressive disease, char -
acterized by a prolonged latent phase between the 
initial rheumatic illness and the development of valve 
stenosis.1–3 The latent phase is an interval typically 
measured in decades in high-income countries but 
in considerably shorter periods in low- to middle-in-
come countries, likely because of recurrent carditis. 
Once mild stenosis has developed, further narrow-
ing is slow (decrease in valve area of 0.1 cm2 per 
year on average), although the rate of progression 
is highly variable.3 Importantly, progressive enlarge-
ment of the RV and a rise in RV systolic pressure can 
be observed, even in the absence of a decrease in 
mitral valve area. Accordingly, repeat TTE at intervals 
dictated by valve area is an important aspect of dis-
ease management, even in patients without symp-
toms (Table 4).
6.2.1.4. Diagnostic Testing: Cardiac Catheterization
In the contemporary era, assessment of MS and associ-
ated lesions can be obtained in most patients by TTE, 
occasionally supplemented by TEE. However, there will 
be a subset of patients with nondiagnostic studies or 
for whom there is discordance between the clinical and 
echocardiographic findings. In older patients, other fac-
tors contributing to symptoms may need to be further 
sorted out, such as concomitant diastolic dysfunction, 
LA noncompliance, or intrinsic pulmonary vascular dis-
ease. Cardiac catheterization is useful in these patients 
to further characterize rheumatic MS hemodynamics 
and etiology of symptoms, as it can measure absolute 
pressures in the LV, LA, and pulmonary circulation at 
rest and with exercise. Although the mean pulmonary 
artery wedge pressure is an acceptable substitute for 
mean LA pressure, the LV–to–pulmonary wedge gra-
dient will overestimate the true transmitral gradient 
because of phase delay and delayed transmission of 
pressure changes.1 Nonetheless, the absolute mean 
pulmonary artery wedge pressure and its relationship 
to the LV diastolic pressure and pulmonary artery pres-
sure can provide useful clinical information. The Gorlin 
equation can be used for an independent calculation of 
mitral valve area.2,3
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e115
CLINICAL STATEMENTS  
AND GUIDELINES6.2.1.5. Diagnostic Testing: Exercise Testing
Recommendation for Diagnostic Testing: Exercise Testing in Patients 
With Rheumatic MS
COR LOE Recommendation
1 C-LD1.  In patients with rheumatic MS and a 
discrepancy between resting echocardiographic 
findings and clinical symptoms, exercise 
testing with Doppler or invasive hemodynamic 
assessment is recommended to evaluate 
symptomatic response, exercise capacity, and 
the response of the mean mitral gradient and 
pulmonary artery pressure.1–5
Synopsis
Exercise testing with either Doppler echocardiography 
or cardiac catheterization is important when the resting 
hemodynamics do not match the clinical symptoms in 
patients with rheumatic MS.
Recommendation-Specific Supportive Text
1. Exercise testing with hemodynamics is helpful in 
the management of rheumatic MS when a patient’s 
symptoms seem significantly greater than or less 
than would be expected from TTE. Results have 
been published in which both exercise and dobu-
tamine were used with Doppler echocardiography, 
although exercise is preferred in general as the more 
physiological test.1–6 Most experience is with tread-
mill exercise, with images and Doppler obtained 
immediately after stress, but bicycle exercise allows 
data acquisition at various stages of exercise. Bicycle 
exercise testing during cardiac catheterization can 
also be performed for direct measurements of pul-
monary artery wedge pressure and pulmonary pres-
sures at rest and with exercise. Simple functional 
capacity helps to quantify the patient’s symptoms. 
Changes in valve gradient should be measured, 
as well as the estimated pulmonary artery systolic 
pressure. If the patient cannot exercise, increasing 
the heart rate with maneuvers such as leg lifts or 
sit-ups may be useful.
6.2.2. Medical Therapy
Recommendations for Medical Therapy in Patients With Rheumatic MS
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 20.
COR LOE Recommendations
1 C-LD1.  In patients with rheumatic MS and 1) AF, 2) 
a prior embolic event, or 3) an LA thrombus, 
anticoagulation with a VKA is indicated.1–7 
2a C-LD2.  In patients with rheumatic MS and AF with a 
rapid ventricular response, heart rate control 
can be beneficial.8
2a A3.  In patients with rheumatic MS in normal sinus 
rhythm with symptomatic resting or exertional 
sinus tachycardia, heart rate control can be 
beneficial to manage symptoms.9–15Synopsis
In patients with rheumatic MS and AF, anticoagulation 
decreases the incidence of thromboembolic events. An-
ticoagulation can also decrease the incidence of throm-
boembolic events in patients with rheumatic MS if 
there has been a prior embolic event or if an LA throm-
bus was visualized. In symptomatic patients with MS 
who are in normal sinus rhythm and have tachycardia, 
heart rate control with beta blockers, calcium channel 
blockers, or ivabradine will lengthen the diastolic fill-
ing period and lower LA pressure. However, routine use 
of heart rate control for patients with rheumatic MS in 
normal sinus rhythm in the absence of tachycardia may 
result in chronotropic incompetence, preventing an ad-
equate cardiac output response to exercise.
Recommendation-Specific Supportive Text
1. Patients with rheumatic MS with AF and prior 
embolic events are at high risk of arterial embo-
lization when AF or an LA thrombus is present. 
Treatment with VKA anticoagulation will decrease 
the incidence of these events.3–7,16 It is controver -
sial whether long-term anticoagulation should be 
given to patients with rheumatic MS in normal 
sinus rhythm on the basis of LA enlargement or 
spontaneous contrast on TEE.17,18 Patients with 
very large left atria have more spontaneous echo-
cardiographic contrast and lower LA appendage 
Doppler velocities,19 which have been associated 
with a higher rate of embolic events, but no data 
directly link large left atria to embolic events. 
Non–vitamin K oral anticoagulation has not been 
studied in patients with rheumatic MS, and these 
patients were excluded from the randomized AF 
trials. In addition to the much higher risk of embo-
lization with rheumatic valve disease as compared 
with other causes of valve disease, there is con-
cern that rheumatic disease also affects the atrial 
muscle, resulting in an increased risk of blood flow 
stasis and thrombosis in the body of the LA, as 
well as the LA appendage.1 Further studies are 
required to confirm these findings.2
2. Patients with rheumatic MS are prone to develop-
ing atrial arrhythmias—specifically AF. Significant 
detrimental hemodynamic consequences may be 
associated with the acute development of AF, pri-
marily from the rapid ventricular response, which 
shortens the diastolic filling period and increases 
LA pressure.16 The treatment of acute AF consists 
of anticoagulation and control of the heart rate 
response with negative dromotropic agents. If the 
rate cannot be adequately controlled with medica-
tions, cardioversion may be necessary to improve 
hemodynamics. In the stable patient, the decision 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e116
CLINICAL STATEMENTS  
AND GUIDELINESfor rate control versus rhythm control is dependent 
on multiple factors, including the duration of AF, 
hemodynamic response to AF, LA size, prior epi-
sodes of AF, and history of embolic events. It is more 
difficult to achieve rhythm control in patients with 
rheumatic MS because the rheumatic process itself 
may lead to progressive fibrosis and enlargement 
of the atria, fibrosis of the internodal and interatrial 
tracts, and damage to the sinoatrial node.
3. The use of negative dromotropic agents for the 
treatment of symptoms in patients with rheumatic 
MS in normal sinus rhythm has been controversial. 
Although a reduction in heart rate and prolonga-
tion of the diastolic filling period will decrease the 
transmitral mean gradient, studies have shown 
that treatment with beta blockade may not 
improve or may even decrease exercise tolerance, 
most likely because of the limitation of the cardiac 
output attributable to a limited stroke volume and 
chronotropic incompetence.9–11 Nonetheless, there 
are now several randomized trials that have exam-
ined beta blockers and ivabradine in patients with 
rheumatic MS and have shown that either drug 
can increase exercise duration and improve symp-
toms,2–15 To explain these differences, the earlier 
trials that found no benefit of beta blockers were 
performed in older patients with underlying chro-
notropic incompetence, whereas the randomized 
trials showing benefit were performed primarily in 
younger patients with higher resting and exercise-
induced heart rates. Thus, the use of beta blockers 
or ivabradine to improve symptoms may be effec-
tive only in patients who do not have underlying 
chronotropic incompetence. When medical ther -
apy is considered for relief of symptoms in patients 
with rheumatic MS, it must be remembered that 
intervention with PMBC relieves symptoms in those 
patients with an appropriate valve morphology.
6.2.3. Intervention
Recommendations for Intervention for Rheumatic MS
Referenced studies that support the recommendations are 
summarized in Online Data Supplements 21 to 24.
COR LOE Recommendations
1 A1.  In symptomatic patients (NYHA class II, III, or 
IV) with severe rheumatic MS (mitral valve 
area ≤1.5 cm2, Stage D) and favorable valve 
morphology with less than moderate (2+) 
MR* in the absence of LA thrombus, PMBC 
is recommended if it can be performed at a 
Comprehensive Valve Center.1–12
1 B-NR2.  In severely symptomatic patients (NYHA class 
III or IV) with severe rheumatic MS (mitral 
valve area ≤1.5 cm2, Stage D) who 1) are not 
candidates for PMBC, 2) have failed a previous 
PMBC, 3) require other cardiac procedures, or 
4) do not have access to PMBC, mitral valve 
surgery (repair, commissurotomy, or valve 
replacement) is indicated.6,7,13 2a B-NR3.  In asymptomatic patients with severe 
rheumatic MS (mitral valve area ≤1.5 cm2, 
Stage C) and favorable valve morphology 
with less than 2+ MR in the absence of LA 
thrombus who have elevated pulmonary 
pressures (pulmonary artery systolic pressure 
>50 mm Hg), PMBC is reasonable if it can be 
performed at a Comprehensive Valve Center.14
2b C-LD4.  In asymptomatic patients with severe 
rheumatic MS (mitral valve area ≤1.5 cm2, 
Stage C) and favorable valve morphology 
with less than 2+/ MR* in the absence of LA 
thrombus who have new onset of AF, PMBC 
may be considered if it can be performed at a 
Comprehensive Valve Center.15
2b C-LD5.  In symptomatic patients (NYHA class II, III, 
or IV) with rheumatic MS and an mitral 
valve area >1.5 cm2, if there is evidence of 
hemodynamically significant rheumatic MS 
on the basis of a pulmonary artery wedge 
pressure >25 mm Hg or a mean mitral valve 
gradient >15 mm Hg during exercise, PMBC 
may be considered if it can be performed at a 
Comprehensive Valve Center.16
2b B-NR6.  In severely symptomatic patients (NYHA class 
III or IV) with severe rheumatic MS (mitral valve 
area ≤1.5 cm2, Stage D) who have a suboptimal 
valve anatomy and who are not candidates for 
surgery or are at high risk for surgery, PMBC 
may be considered if it can be performed at a 
Comprehensive Valve Center.17–19
*2+ on a 0 to 4+ scale according to Sellar’s criteria or less than moderate 
by Doppler echocardiography.20
Synopsis
The optimal treatment of patients with rheumatic MS is 
either PMBC or surgery (open or closed commissuroto-
my). Although these procedures can result in excellent 
outcomes by splitting open fused commissures to re-
lieve stenosis, both the catheter-based and the surgical 
procedures require a high level of expertise and should 
be performed at experienced centers. In the United 
States, there has been a 7.5% decrease in the use of 
PMBC, accompanied by a 15.9% increase in complica-
tion rate.21 Excellent short- and long-term outcomes can 
be achieved with surgical commissurotomy, but surgical 
commissurotomy is not routinely or widely performed 
by most surgeons in the United States. Thus, in the clini-
cal decision-making process for a patient with rheumat-
ic MS, it is essential to know the results of the available 
interventional procedures. Mitral valve replacement is an 
option for treatment only if there is no other option and 
the patient has severe limiting symptoms (Figure 7).
Recommendation-Specific Supportive Text
1. Randomized trials have established the safety 
and efficacy of PMBC as compared with surgical 
closed or open commissurotomy in patients with a Recommendations for Intervention for Rheumatic MS
(Continued)
COR LOE Recommendations
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e117
CLINICAL STATEMENTS  
AND GUIDELINESfavorable valve morphology with less than 2+ MR 
in the absence of LA thrombus.6,8–12 PMBC is per -
formed by advancing one or more balloon cath-
eters across the mitral valve and inflating them, 
thereby splitting the commissures. Favorable valve 
morphology consists of mobile and relatively thin 
valve leaflets, which are free of calcium, in the 
absence of significant subvalvular fusion.18,19,22,23 
An anatomic mitral morphology score can be 
used to determine suitability for PMBC and to 
evaluate the appearance of the commissures and 
degree of calcification.1,24,25 Clinical factors, such 
as age, NYHA class, and presence or absence of 
AF, are also predictive of outcome. Older patients 
with lower gradients (<10 mm Hg) will not have 
as good an outcome as patients with higher gra-
dients, probably because of other concomitant 
problems that cause symptoms, such as LV dia-
stolic dysfunction and LA noncompliance, mea-
sured by net atrial–ventricular compliance.26–30 
PMBC should be performed only by experienced 
operators, with immediate availability of surgical 
backup for potential complications. Long-term 
follow-up has shown 70% to 80% of patients 
with an initial good result after PMBC to be free of 
recurrent symptoms at 10 years, and 30% to 40% 
are free of recurrent symptoms at 20 years.1–7
2. Mitral valve surgery is an established therapy for 
rheumatic MS, with the preferred approach being 
commissurotomy (either closed, where the valve is opened blindly through the LA or LV, or open, which 
allows more extensive surgery under direct visual-
ization) when anatomy is favorable.31–36 However, 
in the presence of severe valvular thickening and 
subvalvular fibrosis with leaflet tethering, mitral 
valve replacement may be the best option. In addi-
tion to those who have suboptimal valve anatomy 
(or failed PMBC), patients with moderate or severe 
TR may also have a better outcome with a surgi-
cal approach that includes tricuspid valve repair.37 
Patients undergoing surgical commissurotomy at 
centers with a high level of expertise may have 
better long-term outcomes than those undergoing 
PMBC.6,7 Because the natural history of rheumatic 
MS is one of slow progression over decades, sur -
gery should be delayed until the patient has severe 
limiting symptoms (NYHA class III or IV), particu-
larly if mitral valve repair is contemplated.
3. Although most patients with rheumatic MS who are 
asymptomatic will do well for years without inter -
vention, an elevation of pulmonary artery pressure 
is an indication that there is progressive elevation 
of LA pressure affecting the pulmonary circulation. 
An elevated pulmonary pressure can be assessed 
by Doppler echocardiography. Although there may 
be a decrease in pulmonary pressure after relief 
of the rheumatic MS,38 some patients will have 
developed intrinsic pulmonary vascular disease, as 
evidenced by a poorer long-term survival rate in 
patients who have pulmonary hypertension before 
Figure 7. Intervention for MS.
Colors correspond to Table 2. *Repair, commis-
surotomy, or valve replacement. AF indicates atrial 
fibrillation; CVC, Comprehensive Valve Center; MR, 
mitral regurgitation; MS, mitral stenosis; MV, mitral 
valve; MVA, mitral valve area; NYHA, New York 
Heart Association; PASP , pulmonary artery systolic 
pressure; and PMBC, percutaneous mitral balloon 
commissurotomy.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e118
CLINICAL STATEMENTS  
AND GUIDELINESintervention.14,39 An elevated pulmonary arterial 
resistance before intervention is associated with RV 
dysfunction and TR after the procedure.40–42 Thus, 
PMBC may prevent the adverse consequences of 
irreversible pulmonary hypertension if it can be 
performed with a high success rate and low risk 
in patients who are developing pulmonary hyper -
tension. Correction of the MR before irreversible 
changes occur can be curative. Thus, in chronic 
primary MR, MR is the disease.
4. The new onset of AF may be an indication for pro-
ceeding with PMBC in the asymptomatic patient 
with a favorable valve morphology for several rea-
sons. First, AF may be the equivalent of symptom 
onset, signifying that rheumatic MS is resulting in 
progressive LA damage. Second, AF increases the 
risk of thromboembolic events in patients with 
rheumatic MS. In addition, a shortened diastolic 
filling interval with AF and a rapid ventricular 
response further increase LV pressure. Finally, the 
presence of AF is associated with worse outcomes 
in patients with rheumatic MS and with subop-
timal results after PMBC.43 In theory, lowering a 
high LA pressure after PMBC might be beneficial 
in restoring normal sinus rhythm. Although there 
is no randomized trial to prove the effectiveness of 
intervening early, there is a documented improve-
ment in P-wave dispersion after PMBC, which may 
affect the ability to restore normal sinus rhythm.15
5. Some patients have symptoms from rheumatic 
MS even with a mitral valve area >1.5 cm2 and 
a resting mean transmitral gradient <10 mm Hg. 
This may be related to the variability and reliability 
of measuring a mitral valve area by either planim-
etering a short-axis image of the mitral valve or 
using a diastolic half-time for indirect calculation 
of the mitral valve area. There are also patients 
who have a relatively low gradient at rest who 
generate a much higher gradient with exercise, 
with symptoms developing from the higher LA 
pressure. Thus, in these patients in whom there is 
a discrepancy between the clinical symptoms and 
the resting hemodynamics, exercise testing with 
measurement of the mean transmitral gradient 
or the direct pulmonary artery wedge, or both, is 
useful.44–48 Patients who increase their gradients 
to >15 mm Hg with exercise have been shown to 
improve symptomatically after PMBC.16
6. Both anatomic valve morphology and the pres-
ence of commissural calcification predict suc-
cessful PMBC. However, in all such series, this 
predictive ability is not absolute, with 42% of 
patients with an anatomic valve Wilkins morphol-
ogy score >822,23,31,32 having an optimal outcome 
(25% increase in mitral valve area to >1.5 cm2) and 
38% of patients with commissural calcium having event-free survival at 1.8 years.18,19,22,23 Accordingly, 
severely symptomatic patients who are poor surgi-
cal candidates may benefit from PMBC even with 
suboptimal valve anatomy.17 Patients who refuse 
surgery may also be offered PMBC after discussion 
about the potential complications associated with 
this procedure when it is performed in patients 
with suboptimal valve anatomy.
6.3. Nonrheumatic Calcific MS
Recommendation for Nonrheumatic Calcific MS
COR LOE Recommendation
2b C-LD1.  In severely symptomatic patients (NYHA class 
III or IV) with severe MS (mitral valve area ≤1.5 
cm2, Stage D) attributable to extensive mitral 
annular calcification, valve intervention may 
be considered only after discussion of the high 
procedural risk and the individual patient’s 
preferences and values.1–3
Synopsis
Although most MS in the world results from rheumatic 
heart disease, calcific MS is found with increasing fre-
quency in the elderly population in high-income coun-
tries.2–10 Calcific MS is the result of calcification of the 
mitral annulus that extends into the leaflet bases, result-
ing both in narrowing of the annulus and rigidity of the 
leaflets. In contrast to rheumatic MS, there is no commis-
sural fusion, and the leaflet tips are usually unaffected. 
The progression of calcific MS is variable, ranging from 
an increase of <1.0 to up to 9 mm Hg per year.9,11 The 
prognosis of this group of patients is poor, with a 5-year 
survival rate <50%, most likely because of advanced age 
and other comorbidities.4 Determination of the severity 
of stenosis is difficult because of extensive calcification, 
which prevents measurement of an accurate planime-
tered area, and the significant abnormalities of LA and LV 
compliance, which cause a high gradient in the absence 
of severe obstruction.12–16 These patients are at high risk 
with any intervention because of the extensive calcifica-
tion, as well as advanced age and multiple comorbidi-
ties. Thus, in patients with calcific MS, the indications for 
any intervention differ from those for rheumatic MS, and 
intervention for calcific MS should be performed only in 
the highly symptomatic patient. Nonrheumatic MS can 
also be present after radiation therapy and after a mitral 
valve repair with a small annuloplasty ring.
Recommendation-Specific Supportive Text
1. Indications for intervention in patients with cal-
cific MS are different from those for rheumatic 
MS for the following reasons. First, because calci-
fication involves the annulus and base of the leaf-
lets without commissural fusion, there is no role 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e119
CLINICAL STATEMENTS  
AND GUIDELINESfor PMBC or surgical commissurotomy. Second, 
the presence of severe mitral annular calcification 
can be quite challenging for the surgeon because 
of technically difficult in securely attaching the 
prosthetic valve and placement of the prosthetic 
valve may result in narrowing of the orifice.17–22 
Finally, patients with calcification are often elderly 
and debilitated, have multiple comorbidities, and 
are at high surgical risk.1–3 For these reasons, 
intervention should be delayed until symptoms 
are severely limiting and cannot be managed with 
diuresis and heart rate control. Catheter-based 
therapies for these high–surgical risk patients are 
being developed and evaluated.23
7. MITRAL REGURGITATION
7.1. Acute MR
Acute MR may be caused by disruption of different parts 
of the mitral valve apparatus. IE may cause leaflet perfo-
ration or chordal rupture. Spontaneous chordal rupture 
may occur in patients with myxomatous mitral valve dis-
ease. Rupture of the papillary muscle occurs in patients 
who have an acute ST-segment–elevation myocardial 
infarction, usually associated with an inferior infarction. 
The acute volume overload on the LV and LA results in 
pulmonary congestion and low forward cardiac out-
put.1–4 Diagnosis of the presence and etiology of acute 
MR, along with urgent intervention, may be lifesaving.
7.1.1. Diagnosis of Acute MR
In patients with acute MR, TTE is the initial imaging mo-
dality of choice to evaluate LV function, RV function, 
pulmonary artery pressure, and mechanism of MR. The 
patient with severe acute MR, which might occur from 
chordal rupture, usually experiences acute hemody-
namic decompensation. The sudden volume overload 
increases LA and pulmonary venous pressures, leading 
to pulmonary congestion and hypoxia, whereas de-
creased blood delivery to the tissues with a concomitant 
decrease in LV systolic pressure limits the pressure gradi-
ent, driving MR to early systole. Thus, the murmur may 
be short and unimpressive, as may be the color jet of 
MR by TTE. In the presence of sudden acute and he-
modynamic instability after myocardial infarction, with 
hyperdynamic LV function by TTE and no other cause 
for the deterioration, TEE can be especially helpful in 
detecting papillary muscle or chordal rupture or valvular 
vegetations and annular abscesses that may further ac-
centuate the need for a more urgent surgical approach.1
7.1.2. Medical Therapy
Vasodilator therapy improves hemodynamic compen-
sation in acute MR. The premise for use of vasodila-
tors in acute MR is a reduction in impedance of aortic 
flow, thereby preferentially guiding flow away from the LV-to-LA pathway, decreasing MR while simultaneously 
increasing forward output to the LV-to-aortic path-
way.1,2 This is usually accomplished by infusion of an 
easily titratable agent, such as sodium nitroprusside or 
nicardipine. Use of vasodilators is often limited by sys-
temic hypotension that is exacerbated when peripheral 
resistance is decreased. Intra-aortic balloon counterpul-
sation can be helpful to treat acute severe MR. By low-
ering systolic aortic pressure, intra-aortic balloon coun-
terpulsation decreases LV afterload, increasing forward 
output while decreasing regurgitant volume. Simulta-
neously, intra-aortic balloon counterpulsation increases 
diastolic and mean aortic pressures, thereby supporting 
the systemic circulation. The use of a percutaneous cir -
culatory assist device may stabilize a patient with acute 
hemodynamic compromise before the procedure.
7.1.3. Intervention
Prompt mitral valve surgery, preferably mitral repair if 
possible, is lifesaving in the symptomatic patient with 
acute severe primary MR. The severity of acute primary 
MR is variable, and some patients with more moderate 
amounts of MR may develop compensation as LV dila-
tion allows for lower filling pressure and increased for -
ward cardiac output. However, most patients with acute 
severe MR require surgical correction for reestablishment 
of normal hemodynamics and for relief of symptoms.1–5 
This is especially true for a complete papillary muscle rup-
ture that causes very severe MR, which is poorly tolerated.
7.2. Chronic Primary MR
7.2.1. Stages of Chronic Primary MR
In assessing the patient with chronic MR, it is important 
to distinguish between chronic primary (degenerative) 
MR and chronic secondary (functional) MR, as these 2 
conditions have more differences than similarities. Pri-
mary MR is a disease of the mitral valve apparatus, and 
secondary MR is a disease of the ventricle or atria. In 
chronic primary MR, the pathology of ≥1 of the com-
ponents of the valve (leaflets, chordae tendineae, papil-
lary muscles, annulus) causes valve incompetence, with 
systolic regurgitation of blood from the LV to the LA 
(Table 17). The most common cause of chronic primary 
MR in high-income countries is mitral valve prolapse, 
which has a wide spectrum of etiology and presenta-
tion. Younger populations present with severe myxo-
matous degeneration with gross redundancy of both 
anterior and posterior leaflets and the chordal appa-
ratus (Barlow’s valve). A subset of these patients will 
present with ventricular arrhythmias, mitral annular 
disjunction, and LV dilation. Alternatively, older popu-
lations present with fibroelastic deficiency disease, in 
which lack of connective tissue leads to chordal rup-
ture. The differentiation between these 2 etiologies 
may have implications for operative intervention. Other 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e120
CLINICAL STATEMENTS  
AND GUIDELINESless common causes of chronic primary MR include IE, 
connective tissue disorders, rheumatic heart disease, 
cleft mitral valve, and radiation heart disease. If vol-
ume overload of chronic primary MR is prolonged and 
severe, it causes myocardial damage, HF, and eventual 
death. Correction of the MR before irreversible changes 
occur can be curative.
7.2.2. Diagnosis and Follow-Up of Chronic 
Primary MR
7.2.2.1. Diagnostic Testing: Initial Diagnosis
Recommendations for Diagnostic Testing: Initial Diagnosis of 
Chronic MR
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 25.
COR LOE Recommendations
1 B-NR1.  In patients with known or suspected primary 
MR, TTE is indicated for baseline evaluation 
of LV size and function, RV function, LA size, 
pulmonary artery pressure, and the mechanism 
and severity of primary MR (Stages A to D).1–5
1 C-EO2.  In patients with primary MR, when TTE 
provides insufficient or discordant information, 
TEE is indicated for evaluation of the severity 
of MR, mechanism of MR, and status of LV 
function (Stages B to D).
1 B-NR3.  In patients with primary MR, CMR is indicated 
to assess LV and RV volumes and function and 
may help with assessing MR severity when 
there is a discrepancy between the findings on 
clinical assessment and echocardiography.6–9 
1 B-NR4.  In patients with severe primary MR undergoing 
mitral intervention, intraoperative TEE is 
indicated to establish the anatomic basis for 
primary MR (Stages C and D) and to guide 
repair.10,11
Synopsis
TTE is the initial imaging modality for patients with 
primary MR to look at valve morphology, severity of 
the MR, and the status of the LV, with TEE, CMR, or 
cardiac catheterization performed when insufficient or 
discordant information is obtained from the TTE. A TEE 
should be used to guide mitral valve interventions.
Recommendation-Specific Supportive Text
1. TTE images provide the diagnostic data needed 
for clinical decision-making in chronic primary 
MR.1–5,12 The outcome of the patient with chronic 
primary MR is determined by lesion severity,5 
symptomatic status.13–15 the presence of LV dys-
function, and whether valve pathology is cor -
rectable by valve repair, which is superior to valve 
replacement when repair is possible. Usually only 
severe (not mild or moderate) MR leads to nega-
tive sequelae.5,6 Favorable loading conditions in 
MR increase LVEF but do not affect the extent 
of shortening. Thus, a “normal” LVEF in MR is approximately 70%. The onset of LV dysfunction 
is inferred when LVEF declines toward 60% or 
when the LV is unable to contract to a diameter 
<40 mm at end systole.16–18 Although chamber 
volumes may give more information about car -
diac remodeling,19 2D volume accuracy is variable 
in clinical practice. Determination of MR severity 
is made by integrating all available data. These 
data include measurements of the effective ori-
fice area, regurgitant volume, regurgitant frac-
tion (obtained by using the proximal isovelocity 
surface area or quantitative Doppler flow mea-
surements),1–3,5,20 color jet area, vena contracta, 
continuous-wave Doppler intensity, and the trans-
mitral jet velocity curve. In mitral valve prolapse, 
MR may be non-holosystolic (mid-late systole). 
Thus, careful attention in assessing its severity is 
needed as conventional color Doppler parameter 
may overestimate its severity on a single image 
frame. Volumetric measurements provide a better 
assessment in this situation.9
2. TEE provides excellent imaging of the mitral valve 
and should be performed when TTE images are 
inadequate to fulfill the goals of TTE noted pre-
viously. TEE is especially useful in cases of MR 
attributable to IE because TEE can provide infor -
mation about other potentially infected struc-
tures. TEE may allow more precise quantitation 
of regurgitant severity and provide a better esti-
mate of the likelihood of a successful surgical 
valve repair than does TTE. Three-dimensional 
TEE may be helpful in further visualizing the 
abnormal mitral valve anatomy, offering a “sur -
gical” view of the valve. Mitral valve repair is 
preferable to valve replacement because of a 
lower operative mortality rate and avoidance of 
the complications inherent to prosthetic valves. 
Although the final decision about repair versus 
replacement is made in the operating room, TEE 
can help predict surgical strategy beforehand. 
Thus, if repair is likely, it might be performed ear -
lier in the course of the disease than if replace-
ment is necessary.
3. In most cases, TTE provides the data needed for 
adequate cardiac evaluation of the patient with 
MR. However, in cases where TTE image quality is 
poor, CMR may be of value in MR evaluation. CMR 
produces highly accurate data on LV volumes, RV 
volumes, and LVEF, as well as an assessment of 
regurgitant fraction for estimating MR severity.6–9 
However, outcome data on large numbers of 
patients have been derived from echocardiogra-
phy, and it is uncertain whether CMR data can 
be used interchangeably with echocardiographic 
data in predicting outcomes. CMR is less helpful 
in establishing mitral pathoanatomy.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e121
CLINICAL STATEMENTS  
AND GUIDELINES4. Intraoperative TEE is the standard for imaging dur -
ing MR surgery. Before the operative incision, TEE 
may give the surgeon a better understanding of 
the valve anatomy and type of repair that will likely 
be performed, although this decision is ultimately 
made when the valve is inspected visually.10,11 
Three-dimensional TEE (“surgical view”) may be 
helpful in further visualizing the abnormal mitral 
valve anatomy. Because anesthesia lessens after -
load, preload, and mitral valve closing force, deci-
sions about severity of MR should be evaluated at 
the same loading conditions as occurred during the 
awake state. Intraoperative TEE is especially help-
ful in gauging the adequacy of repair.11 Because 
even mild residual MR after repair increases the 
likelihood of later repair failure that would necessi-
tate reoperation,21 surgeons strive for near-perfect 
operative repair. Adequacy of repair is judged by 
TEE after physiological filling pressure and blood 
pressure have been established. If more than trivial 
MR is detected in the operating room after repair, 
repair revision usually ensues. TEE also helps to diagnose underfilling of the LV, which can lead 
to systolic anterior leaflet motion with outflow 
obstruction and unneeded repair. In those patients 
with primary severe MR who are at high surgical 
risk, TEE is helpful in determining the feasibility of 
transcatheter edge-to-edge repair.22,23
7.2.2.2. Diagnostic Testing: Changing Signs or 
Symptoms
Recommendation for Diagnostic Testing: Changing Signs or 
Symptoms in Patients With Primary MR
Referenced studies that support the recommendation are 
summarized in Online Data Supplement 26.
COR LOE Recommendation
1 B-NR1.  In patients with primary MR (Stages B to 
D) and new-onset or changing symptoms, 
TTE is indicated to evaluate the mitral valve 
apparatus and LV function.1,2
Synopsis
A repeat TTE provides clinically relevant information 
about patients who are being followed for primary MR 
who develop new-onset symptoms.Table 17. Stages of Chronic Primary MR
Stage Definition Valve Anatomy Valve Hemodynamics*Hemodynamic 
Consequences Symptoms
A At risk of MR Mild mitral valve prolapse with 
normal coaptation
Mild valve thickening and leaflet 
restrictionNo MR jet or small central jet 
area <20% LA on Doppler
Small vena contracta <0.3 cmNone None
B Progressive MR Moderate to severe mitral valve 
prolapse with normal coaptation
Rheumatic valve changes with 
leaflet restriction and loss of 
central coaptation
Prior IECentral jet MR 20%–40% LA 
or late systolic eccentric jet MR
Vena contracta <0.7 cm
Regurgitant volume <60 mL
Regurgitant fraction <50%
ERO <0.40 cm2
Angiographic grade 1+ to 2+Mild LA enlargement
No LV enlargement
Normal pulmonary 
pressureNone
C Asymptomatic severe 
MRSevere mitral valve prolapse with 
loss of coaptation or flail leaflet
Rheumatic valve changes with 
leaflet restriction and loss of 
central coaptation
Prior IE
Thickening of leaflets with 
radiation heart diseaseCentral jet MR >40% LA or 
holosystolic eccentric jet MR
Vena contracta ≥0.7 cm
Regurgitant volume ≥60 mL
Regurgitant fraction ≥50%
ERO ≥0.40 cm2
Angiographic grade 3+ to 4+Moderate or severe LA 
enlargement
LV enlargement
Pulmonary hypertension 
may be present at rest or 
with exercise
C1: LVEF >60% and 
LVESD <40 mm
C2: LVEF ≤60% and/or 
LVESD ≥40 mmNone
D Symptomatic severe MR Severe mitral valve prolapse with 
loss of coaptation or flail leaflet
Rheumatic valve changes with 
leaflet restriction and loss of 
central coaptation
Prior IE
Thickening of leaflets with 
radiation heart diseaseCentral jet MR >40% LA or 
holosystolic eccentric jet MR
Vena contracta ≥0.7 cm
Regurgitant volume ≥60 mL
Regurgitant fraction ≥50%
ERO ≥0.40 cm2
Angiographic grade 3+ to 4+Moderate or severe LA 
enlargement
LV enlargement
Pulmonary hypertension 
presentDecreased 
exercise 
tolerance
Exertional 
dyspnea
*Several valve hemodynamic criteria are provided for assessment of MR severity, but not all criteria for each category will be present in each patient. 
Categorization of MR severity as mild, moderate, or severe depends on data quality and integration of these parameters in conjunction with other clinical evidence.
ERO indicates effective regurgitant orifice; IE, infective endocarditis; LA, left atrium/atrial; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD; left 
ventricular end-systolic dimension; and MR, mitral regurgitation.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e122
CLINICAL STATEMENTS  
AND GUIDELINESRecommendation-Specific Supportive Text
1. The onset of symptoms in severe MR (dyspnea on 
exertion, orthopnea, or declining exercise tolerance) 
is an indication for mitral intervention even if LV 
function is preserved.2 Symptoms are the culmina-
tion of the pathophysiology of MR and may indicate 
changes in LV or LA compliance; increase in pulmo-
nary artery pressure; decrease in RV function; or the 
coexistence of TR. Therefore, symptoms add patho-
physiological data not readily available from imag-
ing, if other confounding factors can be excluded. 
Furthermore, there is no evidence that treatment 
with diuretics or other therapies that might relieve 
symptoms changes the prognostic effect of symp-
tom onset. Once symptoms have occurred and are 
caused by MR, mitral valve surgery will improve the 
natural history even if medication has led to improve-
ment. Repeat TTE at the time of symptom onset is 
indicated to confirm that symptoms are likely attrib-
utable to MR or its effect on the LV, which in turn 
supports surgical correction.1 The new onset of AF is 
also an indication for repeat TTE to look for changes 
in severity of MR and the status of the LV.
7.2.2.3. Diagnostic Testing: Routine Follow-Up
Recommendations for Diagnostic Testing: Routine Follow-Up for 
Chronic Primary MR
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 27.
COR LOE Recommendations
1 B-NR1.  For asymptomatic patients with severe primary 
MR (Stages B and C1), TTE is indicated every 
6 to 12 months for surveillance of LV function 
(estimated by LVEF, LVEDD, and LVESD) and 
assessment of pulmonary artery pressure.1–11 
2b B-NR2.  In asymptomatic patients with severe 
primary MR (Stages B and C1), use of serum 
biomarkers and novel measurements of LV 
function, such as global longitudinal strain, 
may be considered as an adjunct to guide 
timing of intervention.12–21 
Synopsis
Asymptomatic patients with severe primary MR require 
periodic TTE to determine optimal timing of interven-
tion. Biomarkers and other measures of LV function, 
such as global longitudinal strain, may also be helpful 
to guide intervention.
Recommendation-Specific Supportive Text
1. TTE provides valuable information for surveillance 
of LV function (estimated by LVEF and LVESD) 
and pulmonary artery pressure in asymptomatic 
patients with severe primary MR (Stage C1) if 
performed every 6 to 12 months.1,2,4,5,7–11 Chronic 
severe MR is tolerated poorly, reaching a trigger for surgery at an average rate of about 8% per 
year.5,10 This progression varies from patient to 
patient, and because prognosis worsens if cor -
rection of MR is delayed beyond the onset of 
these triggers, referral to a Comprehensive Valve 
Center for early repair or careful surveillance is 
of value. Because echocardiographic measure-
ments are variable, management decisions that 
rest on these measurements should be con-
firmed by repeat sequential TTE. In patients with 
milder chronic primary MR (Stages A and B), TTE 
is indicated periodically to evaluate for changes 
in MR severity, depending on valve anatomy 
and other considerations, because regurgitation 
may worsen over time. Because this process may 
develop slowly, MR can become severe and even 
lead to LV dysfunction in the absence of symp-
toms or clinical signs (Table 4).3,6
2. Symptom onset is a crucial demarcation point in 
the natural history of MR and also a trigger for 
intervention. Because symptoms develop gradu-
ally, patients may fail to recognize or ignore symp-
toms. Natriuretic peptide levels provide objective 
evidence in patients with chronic severe MR, with 
elevated levels indicating increased reliance on 
preload to maintain an adequate forward cardiac 
output.12–18,20 Thus, serum natriuretic peptide 
levels may be helpful in making management 
decisions about intervention when other data 
are conflicting. LVEF is used as a key determi-
nant of LV function in timing MR intervention. 
Unfortunately, LVEF is load dependent and often 
overestimates LV function in MR. Global longi-
tudinal strain, although also load dependent, 
appears more sensitive to LV dysfunction in 
patients with chronic MR and, as such, might give 
warning that LV function is declining before LVEF 
becomes abnormal.15,16,19,21 Thus, novel markers 
of LV systolic function, such as global longitudi-
nal strain, may be useful adjuncts in assessing LV 
function in patients with chronic MR.
7.2.2.4. Diagnostic Testing: Cardiac Catheterization
Left ventriculography and hemodynamic measurements 
are useful when clinical assessment and noninvasive 
tests are inconclusive or discordant with regard to 1) se-
verity of MR, 2) LV function, or 3) the need for surgery.1 
Noninvasive imaging is adequate for evaluation of MR 
in most cases. However, invasive hemodynamic evalu-
ation may be necessary in some cases, especially when 
there is a clinical discrepancy between symptomatic sta-
tus and noninvasive testing. Elevated filling pressures 
support a cardiac cause of dyspnea and may indicate 
severely abnormal pathophysiology even when the pa-
tient claims to be asymptomatic. Conversely, a normal 
invasive hemodynamic examination in a symptomatic 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e123
CLINICAL STATEMENTS  
AND GUIDELINESpatient with what appears to be less than severe MR 
suggests a noncardiac cause for the symptoms. Hemo-
dynamic evaluation can be especially helpful in patients 
with concomitant lung disease. Normal LA (or pulmo-
nary artery wedge) pressure and a large transpulmonary 
gradient suggest pulmonary hypertension that is attrib-
utable to lung disease rather than mitral valve disease. 
Left ventriculography may also be of diagnostic benefit. 
Whereas echocardiographic-Doppler interrogation of 
the mitral valve measures flow velocity, ventriculography 
uses the density of contrast to determine the amount of 
blood flow from the LV to the LA. Although only semi-
quantitative, a carefully performed ventriculogram can 
help in quantifying MR severity. Additional hemodynam-
ic interventions, such as exercise or leg raising, may be 
helpful when the resting information is equivocal.
7.2.2.5. Diagnostic Testing: Exercise Testing
Recommendation for Diagnostic Testing: Exercise Testing for 
Chronic Primary MR
Referenced studies that support the recommendation are 
summarized in Online Data Supplement 28.
COR LOE Recommendation
2a B-NR1.  In patients with primary MR (Stages B and 
C) and symptoms that might be attributable 
to MR, hemodynamic exercise testing 
using Doppler echocardiography or cardiac 
catheterization or cardiopulmonary exercise 
testing is reasonable.1–4 
Synopsis
In a subset of apparently asymptomatic patients with se-
vere primary MR, exercise testing with hemodynamics can 
provide additional diagnostic and prognostic information.
Recommendation-Specific Supportive Text
1. The onset of symptoms represents a key develop-
ment in severe MR. However, some patients may 
not recognize their symptoms, may deny them, or 
may alter their lifestyle to remain asymptomatic. 
A formal treadmill exercise test can establish true 
exercise tolerance and can also form the base-
line for future symptom assessment. Additional 
information about a cardiac or noncardiac limita-
tion can be obtained from oxygen consumption 
measurements during exercise. When patients do 
complain of symptoms, they usually complain of 
dyspnea with exertion, yet noninvasive evaluation 
is usually made at rest. Exercise echocardiography 
or exercise invasive hemodynamics may add addi-
tional prognostic value beyond conventional exer -
cise treadmill testing in patients with asymptomatic 
moderate or severe chronic primary MR.1–4 MR may 
worsen during exercise, or filling pressures may 
become markedly abnormal, helping to demon-
strate MR as the cause of the patient’s dyspnea.1–47.2.3. Medical Therapy
Recommendations for Medical Therapy for Chronic Primary MR
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 29.
COR LOE Recommendations
2a B-NR1.  In symptomatic or asymptomatic patients with 
severe primary MR and LV systolic dysfunction 
(Stages C2 and D) in whom surgery is not 
possible or must be delayed, GDMT for systolic 
dysfunction is reasonable.1–3 
3: No 
BenefitB-NR2.  In asymptomatic patients with primary MR 
and normal LV systolic function (Stages B and 
C1), vasodilator therapy is not indicated if the 
patient is normotensive.4–8
Synopsis
In patients with primary MR, there is no convincing 
evidence that vasodilator therapy reduces MR severity. 
However, GDMT for LV systolic dysfunction or systemic 
hypertension should be implemented as in any patient 
with these conditions.
Recommendation-Specific Supportive Text
1. Patients with MR and LV dysfunction experience 
myocardial damage and HF. With onset of LV 
systolic dysfunction, surgery is usually indicated. 
However, in those patients in whom surgery (or 
transcatheter repair) is not performed or will be 
delayed, medical therapy for systolic dysfunction 
may be helpful to treat the LV dysfunction alone. 
Although data specific to patients with MR with LV 
dysfunction are sparse, treatment of such patients 
would consist of the standard regimen for HF, 
including beta-adrenergic blockade, ACE inhibitors 
or ARBs, and possibly aldosterone antagonists.1–3 
Perhaps the best data exist for the use of beta 
blockers,1 which reverse LV dysfunction in experi-
mental MR.2 Patients who are receiving beta block-
ers may have better surgical outcomes and delayed 
onset of LV dysfunction as compared with those 
not taking these medications.3 ACE inhibition has 
not been effective in experimental MR with LV 
dysfunction. Because aldosterone antagonism is 
thought to work in part by inhibiting fibrosis, its 
role in MR, where little fibrosis occurs, is unclear.
2. Because vasodilator therapy appears to be effec-
tive in acute severe symptomatic MR, it seems rea-
sonable to attempt afterload reduction in chronic 
asymptomatic MR with normal LV function in an 
effort to forestall the need for surgery. However, 
the results from the limited number of trials 
addressing this therapy have been disappointing, 
demonstrating little or no clinically important ben-
efit.4–8 Conversely, because vasodilators decrease 
LV size and mitral closing force, they may increase 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e124
CLINICAL STATEMENTS  
AND GUIDELINESmitral valve prolapse, worsening rather than 
decreasing severity of MR.6 The foregoing does not 
apply to patients with concomitant hypertension. 
Hypertension must be treated because of the well-
known morbidity and mortality associated with 
that condition and because increased LV systolic 
pressure by itself increases the systolic transmitral 
gradient and worsens severity of MR.
7.2.4. Intervention
Recommendations for Intervention for Chronic Primary MR
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 30.
COR LOE Recommendations
1 B-NR1.  In symptomatic patients with severe primary 
MR (Stage D), mitral valve intervention is 
recommended irrespective of LV systolic 
function.1,2
1 B-NR2.  In asymptomatic patients with severe primary 
MR and LV systolic dysfunction (LVEF ≤60%, 
LVESD ≥40 mm) (Stage C2), mitral valve 
surgery is recommended.3–10 
1 B-NR3.  In patients with severe primary MR for whom 
surgery is indicated, mitral valve repair is 
recommended in preference to mitral valve 
replacement when the anatomic cause of MR 
is degenerative disease, if a successful and 
durable repair is possible.11–15
2a B-NR4.  In asymptomatic patients with severe 
primary MR and normal LV systolic function 
(LVEF ≥60% and LVESD ≤40 mm) (Stage 
C1), mitral valve repair is reasonable when 
the likelihood of a successful and durable 
repair without residual MR is >95% with an 
expected mortality rate of <1%, when it can 
be performed at a Primary or Comprehensive 
Valve Center.4,13,16 
2b C-LD5.  In asymptomatic patients with severe primary 
MR and normal LV systolic function (LVEF 
>60% and LVESD <40 mm) (Stage C1) but 
with a progressive increase in LV size or 
decrease in EF on ≥3 serial imaging studies, 
mitral valve surgery may be considered 
irrespective of the probability of a successful 
and durable repair.16
2a B-NR6.  In severely symptomatic patients (NYHA class 
III or IV) with primary severe MR and high or 
prohibitive surgical risk, transcatheter edge-to-
edge repair (TEER) is reasonable if mitral valve 
anatomy is favorable for the repair procedure 
and patient life expectancy is at least 1 year.17,18
2b B-NR7.  In symptomatic patients with severe primary 
MR attributable to rheumatic valve disease, 
mitral valve repair may be considered at a 
Comprehensive Valve Center by an experienced 
team when surgical treatment is indicated, if a 
durable and successful repair is likely.19
3: Harm B-NR8.  In patients with severe primary MR where 
leaflet pathology is limited to less than 
one half the posterior leaflet, mitral valve 
replacement should not be performed unless 
mitral valve repair has been attempted at a 
Primary or Comprehensive Valve Center and 
was unsuccessful.11–14,20–22 Synopsis
Anterior and/or bileaflet primary mitral valve disease re-
quires a complex and extensive repair,20,23–26 and durabil-
ity of the repair is less certain than for simple posterior 
leaflet intervention. Freedom from reoperation is approxi-
mately 80%, and freedom from recurrent moderate or 
severe MR is 60% at 15 to 20 years in complex cases. 
These results are superior to the results of mitral valve re-
placement if the repair is performed at high-volume valve 
surgery centers,27–29 even in elderly patients.30,31 Repair 
should also be attempted, if possible, with other causes 
of severe MR, such as papillary muscle rupture, IE, and 
cleft mitral valve. However, the results of very complex 
repair in younger patients may be matched by the re-
sults of durable mechanical mitral valve replacement with 
careful management of anticoagulation. The Heart Valve 
Team should assign complex repairs to experienced mitral 
valve surgeons with established excellent operative and 
long-term outcomes. The probability of mitral valve repair 
rather than mitral valve replacement and overall outcome 
correlate with surgeon-specific mitral volumes.21,27 The 
hospital mortality rate is 50% lower, on average, in the 
highest-volume hospitals that perform 50 repairs per year. 
However, some low-volume hospitals outperform the 
median high-volume hospitals. This overlap suggests that 
hospital- or surgeon-specific volumes should not be used 
as a surrogate for actual surgeon-specific repair rates and 
outcomes (Figure 8). The management of patients with 
combined severe primary MR and AS is discussed in the 
Mixed Valve Disease section (Section 10.2.2).
Recommendation-Specific Supportive Text
1. Primary MR is a mechanical problem of the leaflet 
coaptation that has only a mechanical solution—
that of mitral valve mechanical intervention. The 
onset of symptoms that results from severe MR 
worsens prognosis even when LV function appears 
to be normal,1,2 and the negative prognosis extends 
even to mild symptoms.2 Thus, the onset of symp-
toms is an indication for prompt mitral valve surgery.
2. The goal of therapy in MR is to correct it before 
the onset of LV systolic dysfunction and its sub-
sequent adverse effect on patient outcomes. The 
ideal time for mitral valve surgery is when the 
patient’s LV approaches but has not yet reached 
the parameters that indicate systolic dysfunction 
(LVEF ≤60% or LVESD ≥40 mm).3–7,16 Because 
symptoms do not always coincide with LV dys-
function, imaging surveillance is used to plan 
surgery before severe dysfunction has occurred. If 
moderate LV dysfunction is already present, prog-
nosis is worse after mitral valve operation.5–7,9,10,16 
Thus, further delay (although symptoms are 
absent) will lead to greater LV dysfunction and a 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e125
CLINICAL STATEMENTS  
AND GUIDELINESstill worse prognosis. Because the loading condi-
tions in MR allow continued late ejection into a 
lower-impedance LA, a higher cutoff for “nor -
mal” LVEF is used in MR than in other types of 
heart disease. Although it is clearly inadvisable to 
allow patients’ LV function to deteriorate beyond 
the benchmarks of an LVEF ≤60% or LVESD ≥40 
mm, some recovery of LV function can still occur 
even if these thresholds have been crossed.5,32
3. Repair success increases with surgical volume and 
expertise, which is a principle guiding surgical 
referral.21,27 However, mitral valve replacement is 
preferable to a poor repair. The results of a mini-
mally invasive approach may be similar to those 
of a full median sternotomy if the minimally inva-
sive operation is performed by highly experienced 
surgeons.33–38 When leaflet dysfunction is limited 
so that only annuloplasty and repair of the pos-
terior leaflet are necessary, an operative mortality 
rate of <1%, long-term survival rate equivalent 
to that of the age-matched general population, approximately 95% freedom from reoperation, 
and >80% freedom from recurrent moderate or 
severe MR at 15 to 20 years after operation are exp
ected.23,24,39,40
4. The onset of symptoms, LV dysfunction, or pul-
monary hypertension worsens the prognosis for 
MR. Careful surveillance may result in timing of 
valve surgery before these negative sequelae 
occur. However, an attractive alternative strat-
egy for treating severe chronic primary MR is 
to perform early mitral repair before these trig-
gers are reached. Early mitral repair avoids the 
need for intensive surveillance and also obvi-
ates the possibility that patients might become 
lost to follow-up or delay seeing their clini-
cian until advanced LV dysfunction has already 
ensued.4,13,16,22 For the early mitral repair strat-
egy to be effective, a durable repair must be 
provided. An unwanted valve replacement and 
its attendant risks, or a failed repair necessitat-
ing reoperation, could be a complication of this 
Figure 8. Primary MR.
Colors correspond to Table 2. *See Prosthetic Valve section (11.1.2) for choice of mitral valve replacement if mitral valve repair is not possible. CVC indicates Com-
prehensive Valve Center; ERO, effective regurgitant orifice; ESD, end-systolic dimension; LVEF, ejection fraction; MR, mitral regurgitation; MV, mitral valve; MVR, 
mitral valve replacement; RF, regurgitant fraction; RVol, regurgitant volume; and VC, vena contracta.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e126
CLINICAL STATEMENTS  
AND GUIDELINESapproach. Thus, there must be a high degree of 
certainty that a durable repair can be performed. 
This certainty comes from the track record of the 
surgical team in operating on the specific type of 
lesion under consideration. Thus, asymptomatic 
patients should be treated in a Comprehensive 
Valve Center.21,24,27–29 In excellent hands, patients 
with severe MR from flail leaflets who undergo 
early operation as opposed to watchful waiting 
have a lower risk of developing HF and lower 
mortality rates.4,13,15
5. MR may lead to progressively more severe MR as 
the initial level of MR causes LV dilation, which 
increases stress on the mitral apparatus, caus-
ing further damage to the valve apparatus, more 
severe MR, and further LV dilation—thus initiating 
a perpetual cycle of ever-increasing LV volumes 
and MR. Longstanding volume overload leads to 
irreversible LV dysfunction and a poorer progno-
sis. Patients with severe MR who develop an LVEF 
<60% or LVESD ≥40 mm have already developed 
LV systolic dysfunction.5,6 One study has sug-
gested that for LV function and size to return to 
normal after mitral valve repair, the LVEF should 
be >64% and LVESD <37 mm.16 Thus, when lon-
gitudinal follow-up demonstrates a progressive 
decrease of LVEF toward 60% or a progressive 
increase in LVESD approaching 40 mm, it is rea-
sonable to consider intervention.41 In severe MR, 
TTE is recommended at 3- to 6-month intervals or 
more frequently as the ventricle enlarges.
6. Mitral transcatheter edge-to-edge repair (TEER) 
with the anterior and posterior leaflets clipped 
together at ≥1 locations is safe and effective in 
treating severely symptomatic patients with pri-
mary MR who are at high or prohibitive surgi-
cal risk.17,18,42 Studies of TEER with a mitral valve 
clip have demonstrated improved symptoms and 
a reduction in MR by 2 to 3 grades, leading to 
reverse remodeling of the LV. Superior outcomes 
were shown with surgery versus TEER, and thus it 
is only the patients who are at high or prohibitive 
risk for surgery for whom TEER is performed.
7. Rheumatic mitral valve disease is less suitable for 
mitral repair compared with complex degenera-
tive disease. Durability of the repair is limited by 
thickened or calcified leaflets, extensive subval-
vular disease with chordal fusion and shortening, 
and progression of rheumatic disease. Freedom 
from reoperation at 20 years, even in experienced 
hands, is in the 50% to 60% range. In a large 
series from Korea, repair was accomplished in 
22% of patients operated on for rheumatic dis-
ease.19 One-third of these patients who underwent 
repair had significant stenosis or regurgitation at 10 years. Repair of rheumatic mitral valve disease 
should be limited to patients with less advanced 
disease in whom a durable repair can be accom-
plished or to patients in whom a mechanical pros-
thesis cannot be used because of anticoagulation 
management concerns.43
8. Mitral valve repair is the procedure of choice for 
isolated severe primary MR limited to less than 
one-half of the posterior leaflet, and mitral valve 
replacement is inappropriate unless mitral valve 
repair has been attempted and was unsuccess-
ful.11–14,21,22 Surgical repair of primary MR has 
been remarkably successful. Repair of isolated 
degenerative mitral disease, when leaflet dys-
function is sufficiently limited that only annu-
loplasty and repair of the posterior leaflet are 
necessary, has led to outcomes distinctly supe-
rior to those with biological or mechanical mitral 
valve replacement.11–14 Repair is associated with 
an operative mortality rate of <1%, long-term 
survival rate equivalent to that of age-matched 
general population, approximately 95% free-
dom from reoperation, and >80% freedom 
from recurrent moderate or severe (≥ 3) MR at 
15 to 20 years after surgery.15,39 As much as 
one-half of the posterior leaflet may be excised, 
plicated, or resuspended. Posterior leaflet repair 
has become sufficiently standardized in this 
situation so that repair, rather than mitral valve 
replacement, is the standard of care. Execution 
of this procedure with a success rate ≥ 95% 
should be the expectation of every cardiac sur -
geon who performs mitral valve procedures.
7.3. Chronic Secondary MR
7.3.1. Stages of Chronic Secondary MR
In chronic secondary MR, the mitral valve leaflets and 
chords usually are normal or minimally thickened. In-
stead, MR is associated with severe LV dysfunction 
caused by CAD (ischemic chronic secondary MR) or id-
iopathic myocardial disease (nonischemic chronic sec-
ondary MR). The abnormal and dilated LV causes papil-
lary muscle displacement, which in turn results in leaflet 
tethering with associated annular dilation that prevents 
adequate leaflet coaptation. Secondary MR may also 
develop because of LA dilation and enlargement of the 
mitral annulus, which often occurs with AF and other 
cardiomyopathies. There are instances in which both 
primary and secondary MR are present. The best ther -
apy for chronic secondary MR is not clear because MR 
is only one component of the disease, and restoration 
of mitral valve competence is not curative. The optimal 
criteria for defining severe secondary MR have been 
controversial. Compared with primary MR, adverse out-
comes in secondary MR are associated with a smaller 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e127
CLINICAL STATEMENTS  
AND GUIDELINEScalculated ERO; the severity of secondary MR may in-
crease over time because of adverse remodeling of the 
LV or mitral annulus; and Doppler methods for calcula-
tions of ERO area by the flow convergence method may 
underestimate severity because of the crescentic shape 
of the regurgitant orifice.1,2 Even so, on the basis of the 
criteria used for determination of “severe” MR in RCTs 
of surgical intervention for secondary MR,3–6 the recom-
mended definition of severe secondary MR is now the 
same as for primary MR (ERO ≥0.4 cm2 and regurgitant 
volume ≥60 mL) (Table 18).
7.3.2. Diagnosis of Chronic Secondary MR
Recommendations for Diagnosis of Secondary MR
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 31.
COR LOE Recommendations
1 B-NR1.  In patients with chronic secondary MR (Stages 
B to D), TTE is useful to establish the etiology 
and to assess the extent of regional and 
global LV remodeling and systolic dysfunction, 
severity of MR, and magnitude of pulmonary 
hypertension.1,2
1 C-EO2.  In patients with chronic secondary MR (Stages 
B to D), noninvasive imaging (stress nuclear/
PET, CMR, or stress echocardiography), 
coronary CT angiography, or coronary 
arteriography is useful to establish etiology of 
MR and to assess myocardial viability.
1 B-NR3.  In patients with chronic secondary MR 
with severe symptoms (Stage D) that are 
unresponsive to GDMT who are being 
considered for transcatheter mitral valve 
interventions, TEE is indicated to determine 
suitability for the procedure.3–8
1 C-EO4.  In patients with chronic secondary MR 
undergoing transcatheter mitral valve 
intervention, intraprocedural guidance with 
TEE is recommended.4,7,9–13
Synopsis
In symptomatic patients with chronic secondary MR, TTE 
is the initial diagnostic modality. Assessment of the coro-
nary anatomy and myocardial viability may be helpful in 
management if ischemic MR is suspected. If transcatheter 
mitral valve intervention is contemplated, TEE determines 
suitability for the procedure and guides the procedure.1
Recommendation-Specific Supportive Text
1. TTE is essential in patients with MR to identify 
patients with primary MR and those with sec-
ondary forms of MR. In general, in patients with 
LV systolic dysfunction and symptoms of HF, the 
presence of chronic secondary MR of any sever -
ity is associated with a worse prognosis than that 
seen in the absence of MR. Most patients with secondary MR have global LV dysfunction, but in 
some patients, a limited but strategically placed 
wall motion abnormality may also cause chronic 
secondary MR. An initial TTE helps establish the 
cause of chronic secondary MR and also serves 
as a baseline for future comparisons. In patients 
with secondary MR, severe MR is defined as an 
ERO ≥40 mm2, but outcome studies have shown 
poor prognosis in those with moderate MR (ERO 
≥20 mm2).1,2
2. Prognosis is poor for both ischemic and non-
ischemic MR, but ischemic MR lends itself to 
the possibility of revascularization and potential 
improvement in LV function if CAD has led to 
large areas of hibernating viable myocardium. 
Long-term results of the STICH (Surgical Treatment 
for Ischemic Heart Failure) trial demonstrated an 
improved 10-year survival rate in patients with 
ischemic cardiomyopathy and LVEF <35% who 
underwent CABG plus GDMT as compared with 
those randomized to GDMT alone. CT angiog-
raphy is usually adequate to rule out significant 
CAD and thus rule out ischemic MR. If CAD is 
detected and noninvasive testing demonstrates 
areas of viability, coronary arteriography is pur -
sued to better define the anatomy for potential 
revascularization.14,15 Although the presence of 
myocardial viability did not determine the effect 
of revascularization on survival in the STICH trial, 
there is a subset of patients with viable myocar -
dium in whom the ischemic MR will respond to 
revascularization.16–18
3. Clinical trials have identified anatomic consid-
erations, detectable by TEE, that can identify 
patients with secondary MR who have a valve 
morphology amenable to TEER. In the COAPT 
(Cardiovascular Outcomes Assessment of the 
MitraClip Percutaneous Therapy for Heart Failure 
Patients with Functional Mitral Regurgitation) trial 
of patients with secondary MR and HF, exclusion 
criteria included vertical coaptation length <2 mm 
in valves with leaflet tethering, evidence of calci-
fication in the grasping area of the A2 or P2 scal-
lops, presence of a significant cleft of A2 or P2 
scallops, and lack of both primary and secondary 
chordal support. These are similar criteria to the 
earlier EVEREST trial. TEE is standard preproce-
dural imaging to determine suitability for TEER.3–8
4. During mitral TEER, TEE assists in guiding posi-
tioning of the clip(s), assessing success of the 
procedure, determining whether more than a 
single clip is necessary to reduce MR, and assur -
ing that the clip(s) has not created MS.4,7,9–13
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e128
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
7.3.3. Medical Therapy
Recommendations for Medical Therapy for Secondary MR
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 31.
COR LOE Recommendations
1 A1.  Patients with chronic severe secondary MR 
(Stages C and D) and HF with reduced LVEF 
should receive standard GDMT for HF, including 
ACE inhibitors, ARBs, beta blockers, aldosterone 
antagonists, and/or sacubitril/valsartan, and 
biventricular pacing as indicated.1–11
1 C-EO2.  In patients with chronic severe secondary 
MR and HF with reduced LVEF, a cardiologist 
expert in the management of patients 
with HF and LV systolic dysfunction should 
be the primary MDT member responsible 
for implementing and monitoring optimal 
GDMT.9,12 
Synopsis
GDMT for HF with reduced LVEF in patients with se-
vere secondary MR should be provided, in conjunc-
tion with a cardiology expert, in the management 
of HF.Recommendation-Specific Supportive Text
1. Chronic secondary MR usually develops as a result 
of LV systolic dysfunction. Thus, standard GDMT 
for HF forms the mainstay of therapy. Diuretics, 
beta blockers, ACE inhibitors or ARBs, and aldo-
sterone antagonists help improve symptoms and/
or prolong life in patients with HF in general and 
probably do so even when HF is complicated 
by chronic secondary MR. GDMT can reduce LV 
volumes (reverse remodeling) in many patients, 
which reduces severity of secondary MR.1–11
2. Secondary MR is often responsive to GDMT 
(including coronary revascularization or car -
diac resynchronization therapy in appropriate 
patients). Optimization of GDMT should be under 
the supervision of a cardiologist expert in the 
treatment of patients with HF to achieve optimal 
results and to determine with the MDT when 
symptoms are truly refractory to GDMT before 
decisions are made for surgical or transcatheter 
treatment.9,12Table 18. Stages of Secondary MR
Stage Definition Valve AnatomyValve 
Hemodynamics*Associated Cardiac 
Findings Symptoms
A At risk of MR Normal valve leaflets, chords, 
and annulus in a patient with 
CAD or cardiomyopathyNo MR jet or small 
central jet area <20% 
LA on Doppler
Small vena contracta 
<0.30 cmNormal or mildly dilated LV 
size with fixed (infarction) or 
inducible (ischemia) regional 
wall motion abnormalities
Primary myocardial disease 
with LV dilation and systolic 
dysfunctionSymptoms attributable 
to coronary ischemia or 
HF may be present that 
respond to revascularization 
and appropriate medical 
therapy
B Progressive MR Regional wall motion 
abnormalities with mild 
tethering of mitral leaflet
Annular dilation with mild loss 
of central coaptation of the 
mitral leafletsERO <0.40 cm2†
Regurgitant volume 
<60 mL
Regurgitant fraction 
<50%Regional wall motion 
abnormalities with reduced 
LV systolic function
LV dilation and systolic 
dysfunction attributable to 
primary myocardial diseaseSymptoms attributable 
to coronary ischemia or 
HF may be present that 
respond to revascularization 
and appropriate medical 
therapy
C Asymptomatic 
severe MRRegional wall motion 
abnormalities and/or LV dilation 
with severe tethering of mitral 
leaflet
Annular dilation with severe 
loss of central coaptation of the 
mitral leafletsERO ≥0.40 cm2†
Regurgitant volume 
≥60 mL‡
Regurgitant fraction 
≥50%Regional wall motion 
abnormalities with reduced 
LV systolic function
LV dilation and systolic 
dysfunction attributable to 
primary myocardial diseaseSymptoms attributable 
to coronary ischemia or 
HF may be present that 
respond to revascularization 
and appropriate medical 
therapy
D Symptomatic 
severe MRRegional wall motion 
abnormalities and/or LV dilation 
with severe tethering of mitral 
leaflet
Annular dilation with severe 
loss of central coaptation of the 
mitral leafletsERO ≥0.40 cm2†
Regurgitant volume 
≥60 mL‡
Regurgitant fraction 
≥50%Regional wall motion 
abnormalities with reduced 
LV systolic function
LV dilation and systolic 
dysfunction attributable to 
primary myocardial diseaseHF symptoms attributable 
to MR persist even after 
revascularization and 
optimization of medical 
therapy
Decreased exercise 
tolerance
Exertional dyspnea
*Several valve hemodynamic criteria are provided for assessment of MR severity, but not all criteria for each category will be present in each patient. 
Categorization of MR severity as mild, moderate, or severe depends on data quality and integration of these parameters in conjunction with other clinical evidence.
†The measurement of the proximal isovelocity surface area by 2D TTE in patients with secondary MR underestimates the true ERO because of the crescentic 
shape of the proximal convergence.
‡May be lower in low-flow states.
2D indicates 2-dimensional; CAD, coronary artery disease; ERO, effective regurgitant orifice; HF, heart failure; LA, left atrium; LV, left ventricular; MR, mitral 
regurgitation; and TTE, transthoracic echocardiogram.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e129
CLINICAL STATEMENTS  
AND GUIDELINES7.3.4. Intervention
Recommendations for Intervention for Secondary MR
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 31.
COR LOE Recommendations
2a B-R1.  In patients with chronic severe secondary MR 
related to LV systolic dysfunction (LVEF <50%) 
who have persistent symptoms (NYHA class 
II, III, or IV) while on optimal GDMT for HF 
(Stage D), TEER is reasonable in patients with 
appropriate anatomy as defined on TEE and 
with LVEF between 20% and 50%, LVESD ≤70 
mm, and pulmonary artery systolic pressure 
≤70 mm Hg.1–8
2a B-NR2.  In patients with severe secondary MR (Stages 
C and D), mitral valve surgery is reasonable 
when CABG is undertaken for the treatment 
of myocardial ischemia.9–15
2b B-NR3.  In patients with chronic severe secondary MR 
from atrial annular dilation with preserved 
LV systolic function (LVEF ≥50%) who have 
severe persistent symptoms (NYHA class III 
or IV) despite therapy for HF and therapy for 
associated AF or other comorbidities (Stage D), 
mitral valve surgery may be considered.16–20
2b B-NR4.  In patients with chronic severe secondary 
MR related to LV systolic dysfunction (LVEF 
<50%) who have persistent severe symptoms 
(NYHA class III or IV) while on optimal GDMT 
for HF (Stage D), mitral valve surgery may be 
considered.9,12,21–43
2b B-R5.  In patients with CAD and chronic severe 
secondary MR related to LV systolic 
dysfunction (LVEF <50%) (Stage D) who are 
undergoing mitral valve surgery because of 
severe symptoms (NYHA class III or IV) that 
persist despite GDMT for HF, chordal-sparing 
mitral valve replacement may be reasonable 
to choose over downsized annuloplasty 
repair.9,12,21–32,44–47
Synopsis
Mitral TEER is indicated to improve symptoms and pro-
long life in a select subset of patients with chronic se-
vere secondary MR, LV systolic dysfunction, and persis-
tent severe symptoms while on optimal GDMT. Surgery 
may improve symptoms in these patients, with mitral 
valve replacement preferred over repair. A subset of pa-
tients with severe MR attributable to AF may benefit 
from mitral valve surgery and concomitant atrial maze 
procedure (Figure 9).
Recommendation-Specific Supportive Text
1. The COAPT trial of transcatheter treatment of 
secondary MR demonstrated improvement in sur -
vival, hospitalization, symptoms, and quality of 
life in patients with persistent symptoms despite 
optimization of GDMT who were randomized to 
TEER, as compared with those randomized to con-
tinued GDMT. In contrast, MITRA-FR (Multicentre 
Randomized Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe 
Secondary Mitral Regurgitation) enrolled patients 
with greater degrees of LV enlargement and less 
severe MR (mean ERO area 0.31 cm2 versus 0.41 
cm2) and reported no benefit of TEER in reducing 
the composite endpoint of death or hospitalization 
as compared with medical therapy. In addition, 
the inclusion criterion in MITRA-FR of an LVESD up 
to 70 mm represents extreme dilation; in contrast, 
in the COAPT trial, the mean LVESD was smaller 
(52±9 mm), and even the LVEDD rarely exceeded 
70 mm (mean 62±7 mm). Thus, the enrollment 
criteria in COAPT trial (LVEF between 20% and 
50%, LVESD ≤70 mm, pulmonary artery systolic 
pressure ≤70 mm Hg, and persistent symptoms 
[NYHA class II, III, or IV] while on optimal GDMT) 
are the current standard selection criteria for TEER 
for secondary MR. Observational studies have 
suggested that a greater reduction in MR sever -
ity with TEER is associated with greater  LV and 
LA reverse remodeling.1–8,48,49 The exact anatomy 
and mechanism of MR also needs to be taken into 
consideration when determining candidacy for 
transcatheter repair.
2. There is no proof that surgical correction of 
chronic secondary MR is effective in prolonging 
life, but observational studies and a substudy 
of the randomized STICH trial suggest that it is 
wise to address the mitral valve during CABG 
for severe CAD when secondary MR is severe. 
Although it may be hoped that the revascular -
ization will recruit hibernating myocardium and 
reduce chronic secondary MR, this has not been 
demonstrated, and failing to correct chronic 
severe secondary MR may leave the patient 
with severe residual MR. The risks and benefits 
of additional surgical interventions should be 
weighed in patients with LV systolic dysfunc-
tion.9–13 For patients with secondary MR under -
going operation for other valve disease, see 
Section 10.2 (Timing of Intervention for Mixed 
Valve Disease).
3. MR may develop in patients with preserved LV 
systolic function who have progressive LA dila-
tion, leading to enlargement of the mitral annu-
lus and malcoaptation of the leaflets.51,52 This 
may arise in conditions such as HF with preserved 
LVEF, restrictive cardiomyopathy, and nonobstruc-
tive hypertrophic cardiomyopathy. These patients 
often have associated AF, which may contribute 
to the progression of LA and annular dilation, 
thus increasing the severity of MR,18,53 and suc-
cessful ablation of AF may reduce or eliminate 
MR.53 Isolated annular dilation accounts for <20% 
of patients referred for surgery of severe MR in 
the STS database, but it is also the etiology with 
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e130
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
the highest mitral valve repair rates (85%).16,17 
The limited data addressing mitral valve repair in 
patients with annular dilation related to AF indi-
cate low operative risk.18–20
4. There is limited evidence that mitral valve sur -
gery improves survival in symptomatic patients 
with secondary MR. In addition, surgery may 
improve symptoms and quality of life in these 
patients whose symptoms persist despite GDMT. 
Small RCTs demonstrate that mitral valve surgery 
reduces chamber size and improves peak oxygen 
consumption in chronic severe secondary MR. 
Ischemic or dilated cardiomyopathy presents dif-
ferent challenges for mitral repair. Regurgitation 
is caused by annular dilation, as well as by apical 
and lateral displacement of the papillary muscles. 
New techniques have facilitated mitral repair 
in this situation, but durability of the repair is dependent primarily on regression or progression 
of ventricular dilation. If the heart continues to 
dilate, long-term durability of the repair is moot; 
the survival of the patient is limited.9,12,21–43
5. In an RCT of mitral valve repair versus mitral 
valve replacement in patients with severe isch-
emic MR, there was no difference between 
repair and mitral valve replacement in survival 
rate or LV remodeling at 2 years. However, the 
rate of recurrence of moderate or severe MR 
over 2 years was higher in the repair group than 
in the replacement group, leading to a higher 
incidence of HF and repeat hospitalization. The 
lack of apparent benefit of valve repair over 
valve replacement in secondary MR versus pri-
mary MR, with less durable repairs in secondary 
MR, highlights that primary and secondary MR 
are 2 different diseases.9,12,21–32,44–47
Figure 9. Secondary MR.
Colors correspond to Table 2. *Chordal-sparing 
MV replacement may be reasonable to choose 
over downsized annuloplasty repair. AF indicates 
atrial fibrillation; CABG, coronary artery bypass 
graft; ERO, effective regurgitant orifice; GDMT, 
guideline-directed management and therapy; 
HF, heart failure; LVEF, left ventricular ejection 
fraction; LVESD, left ventricular end-systolic 
dimension; MR, mitral regurgitation; MV, mitral 
valve; PASP , pulmonary artery systolic pressure; 
RF, regurgitant fraction; RVol, regurgitant volume; 
and Rx, medication.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e131
CLINICAL STATEMENTS  
AND GUIDELINES8. TRICUSPID VALVE DISEASE
8.1. Classification and Stages of TR
Trace to mild degrees of TR of no physiological con-
sequence are commonly detected on TTE in subjects 
with anatomically normal valves. However, significant 
or worsening TR is associated with poor long-term 
outcomes.1–7 Primary disorders of the tricuspid appa-
ratus that can lead to more significant degrees of TR 
include rheumatic disease, IE, congenital disease (Eb-
stein’s), myxomatous changes, and other problems af-
fecting the tricuspid valve leaflets (blunt chest trauma, 
carcinoid, drugs, and radiation) (Table 19). A growing 
number of patients develop significant TR from iatro-
genic etiologies (device leads and endomyocardial biop-
sies).8–10 Most cases of significant TR are secondary and 
related to tricuspid annular dilation and leaflet tether -
ing in the setting of RV remodeling because of pressure 
or volume overload, as seen in patients with pulmo-
nary hypertension (primary or secondary to left-sided 
heart disease) or dilated cardiomyopathies.11–13 In addi-
tion, there appears to be a subgroup of patients with 
significant isolated TR attributable primarily to annular 
dilation, usually associated with AF in the absence of 
pulmonary hypertension or LV systolic dysfunction.2,14–18 
Table 20 shows the stages of TR as defined for other 
valve lesions. Asymptomatic patients with severe TR 
(Stage C) present with an elevated central venous pres-
sure and imaging evidence of significant TR.
Symptomatic patients with severe TR (Stage D) have 
symptoms of fatigue, abdominal bloating, and periph-
eral edema. End-organ damage, such as hepatic failure 
and renal failure, is an adverse consequence of Stage D 
TR that markedly affects survival.19–23 The severity of TR 
can be dynamic and dependent on changes in preload 
and pulmonary pressure.
8.2. Tricuspid Regurgitation
8.2.1. Diagnosis of TR
Recommendations for Diagnosis of TR
COR LOE Recommendations
1 C-LD1.  In patients with TR, TTE is indicated to evaluate 
the presence and severity of TR, determine 
the etiology, measure the sizes of the right-
sided chambers and inferior vena cava, assess 
RV systolic function, estimate pulmonary 
artery systolic pressure, and characterize any 
associated left-sided heart disease.1,2 
2a C-LD2.  In patients with TR, invasive measurement 
of the cardiac index, right-sided diastolic 
pressures, pulmonary artery pressures, and 
pulmonary vascular resistance, as well as 
right ventriculography, can be useful when 
clinical and noninvasive data are discordant or 
inadequate.3–5 Synopsis
TTE can determine the etiology of TR and its effect on 
the RV. Cardiac catheterization is of clinical value if the 
information from TTE is inadequate or discordant with 
the clinical presentation.6–10
Recommendation-Specific Supportive Text
1. TTE can distinguish primary TR (abnormal valve 
leaflets) from secondary TR (normal valve leaf-
lets), define any associated left-sided valvular 
or myocardial disease, and provide an estimate 
of pulmonary artery systolic pressure.11–15 
Characterization of the severity of TR relies on 
an integrative assessment of multiple param-
eters, as recommended by the American Society 
of Echocardiography and European Association 
of Echocardiography,1,2 but many limitations 
remain. In patients with TR undergoing left-
sided valve surgery, an annular diastolic diameter 
>40 mm (or >21 mm/m2) indicates an increased 
risk of persistent or progressive TR after isolated 
mitral valve surgery.13 Pulmonary artery systolic 
pressure is estimated from maximal TR velocity. 
Assessment of RV systolic function is challenged 
by geometric and image acquisition constraints, 
as well as by variability in RV loading condi-
tion.16,17 Normal RV systolic function is defined 
by several parameters, including tricuspid annu-
lar plane systolic excursion >16 mm, tricuspid 
valve systolic annular velocity >10.0 cm/s, and 
RV end-systolic area <20.0 cm2 or fractional area 
change >35%. Other imaging modalities, such 
as 3D TEE, magnetic resonance imaging, and CT 
scan, may provide more accurate information on 
the status of the RV.
2. When physical examination and TTE data on 
estimated pulmonary artery systolic pressure are 
either discordant or inadequate, invasive mea-
surement of pulmonary artery pressures and pul-
monary vascular resistance can be helpful to guide Table 19. Classification of TR
Primary Secondary
Rheumatic
Infective endocarditis
Iatrogenic (device leads, 
endomyocardial biopsy)
Congenital (eg, Ebstein’s, levo-
transposition of the great arteries)
Other (eg, trauma, carcinoid, drugs, 
irradiation)Pulmonary hypertension with RV 
remodeling (primary or secondary 
to left-sided heart disease)
Dilated cardiomyopathy
Annular dilation (associated with 
AF)*
RV volume overload (shunts/high 
output)
*Isolated TR is associated with AF and has LVEF >60%, pulmonary artery 
systolic pressure <50 mm Hg, and no left-sided valve disease, with normal-
appearing tricuspid valve leaflets.
AF indicates atrial fibrillation; LVEF, left ventricular ejection fraction; RV, 
right ventricular; and TR, tricuspid regurgitation.
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e132
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
clinical decision-making in individual patients.3–5 A 
weak TR signal or the presence of severe TR may 
result in underestimation of pulmonary systolic 
pressure; direct invasive measurement can resolve 
this uncertainty. Data from invasive measurement 
are essential for patients in whom the cause of 
pulmonary hypertension is uncertain or when 
assessment of pulmonary vascular reactivity after 
vasodilator challenge is needed. Direct measure-
ments of right atrial pressure may also be useful 
for clinical decision-making. Right ventriculogra-
phy may further aid in the evaluation of the sever -
ity of TR and the status of the RV. Thermodilution 
cardiac output measurements may be inaccurate 
with severe TR, and thus a Fick cardiac output 
should be measured to apply to the calculation of 
pulmonary resistance.
8.2.2. Medical Therapy
Recommendations for Medical Therapy for TR
COR LOE Recommendations
2a C-EO1.  In patients with signs and symptoms 
of right-sided HF attributable to severe 
TR (Stages C and D), diuretics can be 
useful. 
2a C-EO2.  In patients with signs and symptoms 
of right-sided HF attributable to 
severe secondary TR (Stages C and D), 
therapies to treat the primary cause 
of HF (eg, pulmonary vasodilators 
to reduce elevated pulmonary artery 
pressures, GDMT for HF with reduced 
LVEF, or rhythm control of AF) can be 
useful1,2 Synopsis
Diuretic therapy treats the systemic congestion in pa-
tients with severe symptomatic TR. In patients with sec-
ondary TR, treatment of the underlying primary cause 
may decrease the severity of the TR.
Recommendation-Specific Supportive Text
1. Patients with severe TR usually present with signs 
or symptoms of right-sided HF, including periph-
eral edema and ascites. Low-salt diet and support 
stockings may be helpful. Diuretics can be used to 
decrease volume overload in these patients. Loop 
diuretics are typically provided and may relieve 
systemic congestion, but their use can be limited 
by worsening low-flow syndrome. Aldosterone 
antagonists may be of additive benefit, especially 
in the setting of hepatic congestion, which may 
promote secondary hyperaldosteronism.
2. Medical therapies for management of severe TR 
(Stages C and D) are limited. Attention should 
be focused on the underlying etiologies in 
patients with secondary TR. Reduction of pul-
monary artery pressures and pulmonary vascular 
resistance with specific pulmonary vasomodula-
tors may be helpful to reduce RV afterload and 
secondary TR in selected patients with pulmo-
nary hypertension.1,2 GDMT is effective for sec-
ondary TR attributable to HF with reduced LVEF. 
Restoration of normal sinus rhythm may be 
effective for secondary TR attributable to annu-
lar dilation associated with AF.3,4Table 20. Stages of TR
Stage Definition Valve Hemodynamics Hemodynamic ConsequencesClinical Symptoms and 
Presentation
B Progressive TR Central jet <50% RA
Vena contracta width <0.7 cm
ERO <0.40 cm2
Regurgitant volume <45 mLNone None
C Asymptomatic severe TR Central jet ≥50% RA
Vena contracta width ≥0.7 cm
ERO ≥0.40 cm2
Regurgitant volume ≥45 mL
Dense continuous wave signal with 
triangular shape
Hepatic vein systolic flow reversalDilated RV and RA
Elevated RA with “c-V” waveElevated venous pressure
No symptoms
D Symptomatic severe TR Central jet ≥50% RA
Vena contracta width ≥0.7 cm
ERO ≥0.40 cm2
Regurgitant volume ≥45 mL
Dense continuous wave signal with 
triangular shape
Hepatic vein systolic flow reversalDilated RV and RA
Elevated RA with “c-V” waveElevated venous pressure
Dyspnea on exertion, fatigue, 
ascites, edema
c-V wave indicates systolic positive wave; ERO, effective regurgitant orifice; RA, right atrial; RV, right ventricular; and TR, tricuspid regurgitation.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e133
CLINICAL STATEMENTS  
AND GUIDELINES8.2.3. Timing of Intervention
Recommendations for Timing of Intervention
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 32.
COR LOE Recommendations
1 B-NR1.  In patients with severe TR (Stages C and D) 
undergoing left-sided valve surgery, tricuspid 
valve surgery is recommended.1–8 
2a B-NR2.  In patients with progressive TR (Stage B) 
undergoing left-sided valve surgery, tricuspid 
valve surgery can be beneficial in the context 
of either 1) tricuspid annular dilation (tricuspid 
annulus end diastolic diameter >4.0 cm) or 2) 
prior signs and symptoms of right-sided HF.3–10 
2a B-NR3.  In patients with signs and symptoms of 
right-sided HF and severe primary TR (Stage 
D), isolated tricuspid valve surgery can be 
beneficial to reduce symptoms and recurrent 
hospitalizations.11–14 
2a B-NR4.  In patients with signs and symptoms of right-
sided HF and severe isolated secondary TR 
attributable to annular dilation (in the absence 
of pulmonary hypertension or left-sided 
disease) who are poorly responsive to medical 
therapy (Stage D), isolated tricuspid valve 
surgery can be beneficial to reduce symptoms 
and recurrent hospitalizations.11,12,15–19
2b C-LD5.  In asymptomatic patients with severe primary 
TR (Stage C) and progressive RV dilation or 
systolic dysfunction, isolated tricuspid valve 
surgery may be considered.12,20 
2b B-NR6.  In patients with signs and symptoms of right-
sided HF and severe TR (Stage D) who have 
undergone previous left-sided valve surgery, 
reoperation with isolated tricuspid valve 
surgery may be considered in the absence of 
severe pulmonary hypertension or severe RV 
systolic dysfunction.1,2,11,18 
Synopsis
Treatment of secondary TR is targeted at pulmonary 
hypertension or myocardial disease. Surgical treatment 
is performed for selected patients with TR at the time 
of surgery for left-sided valve lesions to treat severe 
TR (Stages C and D) and to prevent later development 
of severe TR in patients with progressive TR (Stage B). 
Surgical intervention should be considered for selected 
patients with isolated TR (either primary TR or second-
ary TR attributable to annular dilation in the absence 
of pulmonary hypertension or dilated cardiomyopathy). 
Intervention for severe isolated TR had a high reported 
operative mortality rate (up to 8% to 20%), but most 
of these interventions were performed after end-organ 
damage.21 However, outcomes of patients with severe 
primary TR are poor with medical management. There is 
renewed interest in earlier surgery for patients with se-
vere isolated TR before the onset of severe RV dysfunc-
tion or end-organ damage.2,11,12,18,19,22 This interest is 
attributable to 1) an increasing number of patients pre-
senting with right-sided HF from isolated TR,23–25 2) more 
advanced surgical techniques, and 3) better selection processes, resulting in a lower operative risk with docu-
mented improvement in symptoms (Figure 10).11,12,15–19
There is growing interest in the development of cath-
eter-based therapies for these patients with severe iso-
lated TR.26,27
Recommendation-Specific Supportive Text
1. Severe TR of either a primary or secondary etiol-
ogy may not improve predictably after treatment 
of the left-sided valve lesion and reduction of RV 
afterload; as such, severe TR should be addressed 
as part of the index procedure.1,2,28–31 Reoperation 
for severe, isolated TR after left-sided valve surgery 
is associated with a perioperative mortality rate of 
10% to 25%.1,29 Tricuspid valve repair does not 
add appreciably to the risks of surgery.1,2,28–31 There 
has been a significant increase in the number of 
tricuspid valve repairs performed for this indica-
tion over the past decade. Tricuspid valve repair is 
preferable to replacement, but replacement may 
be necessary if there is marked dilation of the 
annulus or intrinsic disease of the tricuspid leaf-
lets.28,31 Observational data have shown a lower 
operative risk with tricuspid valve repair than with 
replacement, but this may be related to patient 
selection, given that the latter would be inserted 
in patients with a severely dilated annulus and 
abnormal leaflets to prevent recurrent or residual 
regurgitation. The risks and benefits of tricuspid 
valve operation should be carefully considered in 
the presence of severe RV systolic dysfunction or 
irreversible pulmonary hypertension because of 
the possibility of RV failure after operation.
2. Left uncorrected at the time of left-sided valve 
surgery, mild or moderate degrees of second-
ary TR may progress over time in approximately 
25% of patients and result in reduced long-term 
functional outcome and survival.32 Risk factors for 
persistence or progression of TR include tricuspid 
annulus dilation (>40 mm diameter or 21 mm/m2  
diameter indexed to body surface area on pre-
operative TTE measured at end diastole; >70 
mm diameter on direct intraoperative measure-
ment of the intercomissural distance), degree 
of RV dysfunction or remodeling, leaflet tether -
ing height, pulmonary artery hypertension, AF, 
and intra-annular RV pacemaker or implantable 
cardioverter-defibrillator leads.3–10,33–36 Several 
observational studies and one prospective RCT 
have demonstrated the benefit of tricuspid repair 
at the time of mitral valve surgery for progres-
sive TR (Stage B) with tricuspid annulus dilation 
on echocardiographic and functional parameters, 
although data on outcomes such as survival and 
major adverse events are lacking.3–10,33–35 Because 
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e134
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
the severity of TR may be dynamic, dependent on 
the preload and pulmonary pressures, a past his-
tory of signs or symptoms of right-sided HF indi-
cates the propensity to develop more severe TR 
and should be considered an indication for con-
comitant tricuspid valve repair.
3. In patients with symptomatic severe primary TR, 
reduction or elimination of the regurgitant vol-
ume load by tricuspid valve surgery can allevi-
ate systemic venous and hepatic congestion and 
decrease reliance on diuretics.11,12,20 Patients with 
severe congestive hepatopathy may also benefit 
from surgery to prevent irreversible cirrhosis of the 
liver. Quality and duration of long-term survival are 
related to residual RV function. In patients with 
severe symptomatic primary TR from either device 
leads or endomyocardial biopsy, TR develops rap-
idly, and surgery can be done before the onset of 
RV dysfunction.11,37 Correction of symptomatic 
severe primary TR (Stage D) in patients without 
left-sided valve disease would preferentially be per -
formed before the onset of significant RV dysfunc-
tion or end-organ damage. Randomized studies 
of early intervention are lacking, and the benefit 
might be limited by the risk of intervention, subop-
timal reduction in TR severity, or suboptimal dura-
bility of currently available approaches to tricuspid 
valve repair and replacement.
4. There is now recognition that TR can develop in 
association with AF and annular dilation (a form of 
secondary TR).23–25 Notably, AF-related TR appears to 
represent a fundamentally different pathophysiol-
ogy from other forms of secondary TR, with greater basal dilation and annular enlargement, as com-
pared with the RV elongation with leaflet tethering 
seen in patients who have secondary TR caused by 
pulmonary hypertension or myocardial disease.24 
These patients with AF-related TR have rapid pro-
gression of TR severity and right-sided chamber dila-
tion. In appropriately selected symptomatic patients 
with AF-related severe TR, quality of life and symp-
toms can be improved by surgical intervention for 
TR. In patients undergoing intervention, overall 
outcomes are better in those without severe RV 
dysfunction or end-organ damage. Newer surgical 
techniques and a better selection process resulted 
in an acceptable operative mortality rate (<4% to 
5%) for isolated TR in selected patients.2,11,12,15–19,22,38
5. The optimal timing of tricuspid valve surgery 
for asymptomatic or minimally symptomatic 
patients with severe primary TR has not been 
established. Extrapolation from limited experi-
ences reported for patients with stable carcinoid 
heart disease and patients with a flail tricuspid 
leaflet, as well as application of the manage-
ment principles adopted for patients with severe 
MR, suggest that serial assessments of RV size 
and function might trigger consideration of cor -
rective surgery in selected patients with severe 
primary TR when a pattern of continued deterio-
ration can be established and the surgical risk is 
considered acceptable.13,14 In otherwise healthy 
patients without other comorbidities, such as 
patients with severe TR attributable to trauma, 
the surgical risk associated with tricuspid valve 
operation is low (<1% to 2% operative mortality 
Figure 10. Tricuspid regurgitation.
Colors correspond to Table 2. GDMT indicates 
guideline-directed management and therapy; HF, 
heart failure; PAP , pulmonary artery pressure; PH, 
pulmonary hypertension; RV, right ventricular; TR, 
tricuspid regurgitation; and TV, tricuspid valve.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e135
CLINICAL STATEMENTS  
AND GUIDELINESrate) in the absence of RV dysfunction or pulmo-
nary hypertension.
6. Isolated tricuspid valve surgery for severe TR his-
torically has been performed relatively late in the 
natural history of the disease, when patients have 
become symptomatic with signs of right-sided HF. 
Unadjusted mortality rates for isolated tricuspid valve 
surgery have therefore exceeded those reported for 
isolated aortic or mitral valve surgery, and this trend 
has been even more pronounced for reoperative tri-
cuspid surgery late after left-sided valve surgery.1,2,39 
This high reoperative mortality rate is likely related 
to the advanced nature of RV failure encountered at 
the time of the second procedure, residual pulmo-
nary hypertension, LV dysfunction, and other valve 
abnormalities. The hazards imposed by reoperation 
have influenced decision-making for initial repair of 
functional TR at the time of left-sided valve surgery 
in an attempt to prevent the development of severe 
TR later after the left-sided valve surgery. However, 
if there is no significant pulmonary hypertension or 
severe RV systolic dysfunction, operation for severe 
symptomatic isolated TR years after surgery for left-
sided disease may improve symptoms of right-sided 
HF, if done before the onset of severe RV dysfunc-
tion or end-organ damage with either hepatic or 
renal dysfunction.11,18
9. PULMONIC VALVE DISEASE
See guidelines for the management of adults with con-
genital heart disease.1
10. MIXED VALVE DISEASE
10.1. Diagnosis of Mixed VHD
Recommendations for Diagnosis and Follow-Up of Patients With 
Mixed Valve Disease
COR LOE Recommendations
1 C-EO1.  For patients with mixed valve disease, TTE is 
recommended to assess the etiology, severity, 
and pathophysiological impact. 
2a C-EO2.  In patients with ambiguous symptoms that 
are suspected to be attributable to mixed 
mitral valve disease, further assessment of 
filling pressure by using biomarkers or invasive 
hemodynamic measurements at rest or with 
exercise is reasonable.
Synopsis
Mixed valve disease is either 1) stenosis and regurgita-
tion of a single valve or 2) stenosis or regurgitation of 2 
separate valves. Mixed valve disease presents a special 
diagnostic challenge to the clinician in assessing the im-
pact of the lesions on cardiac remodeling, ventricular function, and timing of intervention.1–5 For many pa-
tients with mixed valve disease, there is a predominant 
valve lesion (ie, stenosis versus regurgitation; mitral 
versus aortic), and symptoms and pathophysiology re-
semble those of a pure dominant lesion. When pres-
sure overload predominates, there is usually concentric 
hypertrophy, whereas volume overloads cause chamber 
dilation and eccentric hypertrophy; management should 
follow the guidelines for the predominant lesion. How-
ever, in other cases, patients present with a more bal-
anced picture, with the mixed pathophysiology making 
patient management difficult. It may be that neither 
lesion by itself reaches Stage C as described in previ-
ous sections for pure lesions, yet the lesions may be, in 
combination, severe enough to impact outcome. Mixed 
valve disease was primarily attributable to rheumatic 
disease in the past, but it is now more frequently seen 
with degenerative disease or after prior chest radiation.5 
Decision-making for patients with mixed valve disease is 
frequently complex and may require referral to or con-
sultation with a Comprehensive Valve Center.
Recommendation-Specific Supportive Text
1. The complex nature of mixed valve disease 
requires a comprehensive imaging approach that 
involves assessing each lesion separately and then 
collectively judging how the lesions affect the 
patient’s overall presentation. TTE is the standard 
modality for measuring jet velocities, valve areas, 
regurgitant flow, and regurgitant orifice areas. 
TTE establishes the baseline for pathoanatomy 
and pathophysiology from which comparison is 
made as the lesions progress over time. Doppler 
hemodynamics have been validated for patients 
with single-valve disease but have not necessarily 
been studied in patients with multivalve disease. 
Limitations exist for assessment of calculations, 
such as those for valve areas, because of differen-
tial flows with multivalve disease.2–5
2. The complex nature of mixed valve disease 
makes it necessary to consider all available 
data to reach a final management decision. 
Although natural history data for many types of 
mixed valve disease are lacking, it is reasonable 
to assume that the onset of symptoms is a neg-
ative prognostic occurrence, as it is for all other 
valve lesions. The difficulty may lie in attribut-
ing such symptoms to the mixed valve disease 
at hand, especially if TTE demonstrates moder -
ate but not severe mixed disease. Elevated BNP 
and elevated filling pressures at catheterization, 
either at rest or with exercise, support that car -
diac disease is the cause of the patient’s symp-
toms and may help to further quantify lesion 
severity.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e136
CLINICAL STATEMENTS  
AND GUIDELINES10.2. Timing of Intervention for Mixed 
VHD
10.2.1. Intervention for Mixed AS and AR
Recommendations for Timing of Intervention for Mixed AS and AR
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 33.
COR LOE Recommendations
1 B-NR1.  In symptomatic patients with combined AS 
and AR and a peak transvalvular jet velocity 
of at least 4.0 m/s or a mean transvalvular 
gradient of at least 40 mm Hg, AVR is 
recommended.1,2 
1 C-EO2.  In asymptomatic patients with combined AS 
and AR who have a jet velocity of ≥4.0 m/s 
with an LVEF <50%, SAVR is recommended.1,2
Synopsis
The indications for AVR in patients with combined AS 
and AR and a peak transvalvular jet velocity of ≥4.0 m/s 
are the same as for patients with severe isolated AS.
Recommendation-Specific Supportive Text
1. Currently, isolated moderate AS or moderate AR 
is placed in Stage B, progressive disease for which 
no therapeutic action is indicated. However, some 
patients with moderate mixed disease develop 
symptoms that stem from their valve disease. 
Formerly, the argument was raised that if there 
were no AR, the aortic jet velocity and gradient 
would be correspondingly lower and would not 
meet the definitions for severe AS, and obvi-
ously there would be only moderate AR by defi-
nition. Therefore, no action was recommended. 
However, recent data suggest that the natural his-
tory of moderate mixed disease behaves similarly 
to that of pure severe AS1,2 and that moderate 
mixed disease has a mortality risk similar to that 
of pure severe AS. Thus, valve replacement is war -
ranted for the symptomatic patient if the patient’s 
data fulfill any of the criteria for severe AS. The 
decision about whether to proceed with TAVI ver -
sus SAVR is discussed in Section 3.2.4.2.
2. For patients with mixed moderate AS/AR who 
have developed LV dysfunction, as evidenced by 
an LVEF of <50%, and who have no other reason 
for LV dysfunction, valve disease is presumed to be 
the cause. In such patients, SAVR is indicated.1,2
10.2.2. Intervention for Mixed AS and MR
Patients with combined AS and MR present a dif-
ficult and complex decision-making process. There 
are many potential different scenarios and nuances 
involved to arrive at the optimal approach for an in-
dividual patient, which needs to be made by an MDT 
with shared decision-making with the patient. Over -
all, patients with severe AS and severe primary MR are best treated with SAVR and mitral valve surgery 
unless the surgical risk is high or prohibitive. If there is 
a high or prohibitive surgical risk, a staged procedure, 
with TAVI followed by mitral TEER, can be effective. 
If there is severe AS and severe secondary MR, either 
SAVR and mitral valve surgery or a staged approach 
with TAVI followed by mitral TEER are options. Be-
cause there are limited data to support COR, the writ-
ing committee has created a table that provides the 
reader with a perspective on possible interventions 
in these complex patients (Table 21). Evaluating the 
short- and long-term outcomes of these approaches 
will be important.
These proposed procedures are based on the following:
• Many patients with AS also have significant MR that 
is attributable to either organic (primary) causes or 
LV remodeling (secondary MR). AVR for AS reduces 
LV pressure, thereby reducing the pressure gradi-
ent that propels volume across the incompetent 
mitral valve. Although it is reasonable to expect 
that AVR would reduce MR by reducing LV systolic 
pressure, this fails to occur in many cases. Not sur -
prisingly, primary MR is more likely to persist after 
AVR than is secondary MR because AVR does not 
correct intrinsic mitral valve disease.1–5 Therefore, in 
patients with both AS and MR who are at a low 
or intermediate surgical risk, it is reasonable to 
address both valves with surgery. This is particularly 
true if the mitral valve can be repaired.1
• For patients with both AS and severe primary MR in 
whom the mitral valve cannot be repaired, a deci-
sion about treatment of the MR will need to be 
made by the MDT, taking into consideration mul-
tiple factors, including the additive risk of a mitral 
valve replacement. Mitral TEER at a later date may 
be an option but is likely to have a suboptimal 
result if the valve cannot be surgically repaired. 
Thus, double valve replacement with both AVR 
and mitral valve replacement would be an option 
if they can be performed at an acceptable level of 
risk, given that the outcome of the MR after AVR 
is uncertain.
• Patients with severe AS who are at high to prohibi-
tive surgical risk are best served by TAVI. As noted 
previously, primary MR may not improve after 
AVR.2–5 If symptoms persist after TAVI and if there 
is suitable anatomy, percutaneous mitral repair can 
be performed, which can reduce MR and improve 
symptoms.6
• For patients with AS who have secondary MR, the 
fate of MR after SAVR or TAVI is uncertain.2–5,7–10 
Although secondary MR is more likely to improve 
after AVR than is MR attributable to primary mitral 
valve disease, secondary MR does not improve or 
may even worsen after AVR in many cases.7–10 The 
mechanism by which reduction in LV pressure after 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e137
CLINICAL STATEMENTS  
AND GUIDELINESAVR does not reduce secondary MR is unknown. 
With SAVR, the mitral valve can be inspected and 
addressed, unlike with TAVI, where the mitral 
valve is left untreated. An alternative approach to 
patients with AS and secondary MR is to perform 
TAVI first, and if symptoms remain with persistent 
severe MR, mitral TEER can be performed if there 
is suitable anatomy.6 The transcatheter approach 
would be preferred if the patient is at high to pro-
hibitive surgical risk.
10.2.3. Intervention for Mixed MS and MR
Mixed MS and MR often occurs in patients with rheu-
matic valve disease. Occasionally, mixed MS/MR can oc-
cur in patients with severe mitral annular calcification. 
Asymptomatic mixed disease may be benign because 
MS protects the LV from the severe volume overload of 
pure MR. However, if symptoms attributable to mixed 
mitral disease occur, they are likely because of increased 
LA pressure from combined increased LA inflow from 
MR and obstruction to outflow from the LA. An en-
larged LA, a high transmitral gradient, or direct mea-
surement of a high LA or pulmonary artery wedge pres-
sure suggest a valvular basis for the patient’s symptoms. 
In such cases, mitral valve replacement may be neces-
sary if therapy with diuretics do not relieve symptoms, 
but it should be performed only in patients who have 
severe limiting symptoms
10.2.4. Intervention for Mixed MS and AR
Combined MS and AR usually result from rheumatic 
heart disease. When they occur concomitantly, MS is 
usually the more severe lesion. However, because MS limits LV filling, it may reduce the stroke volume pre-
sented to the aortic valve, in turn reducing the apparent 
severity of AR.1,2 Furthermore, MS reduces the LV cav-
ity size for any degree of AR, causing further potential 
underestimation of AR severity. In this regard, contrast 
aortography visualizes AR flow, instead of the echo-
cardiographic visualization of AR velocity of flow, and 
may be helpful, as is precise assessment of AR regur -
gitant fraction. In patients who have continued severe 
symptoms not responsive to diuretics, intervention with 
valve surgery should be pursued. If mitral anatomy is 
favorable, options are PMBC to treat the MS, followed 
by AVR or SAVR and open mitral commissurotomy. In 
this way, the increased mortality risk of double valve 
replacement is avoided.3
10.2.5. Intervention for Mixed MS and AS
Almost always the product of rheumatic heart disease, 
the combination of MS and AS can be very confusing 
to the clinician. When either lesion is severe, it may limit 
cardiac output, resulting in reduced flow to the other 
valve, which reduces transvalvular gradient, leading to 
underestimation of lesion severity. Echocardiography 
and invasive hemodynamics are usually necessary to 
fully assess the severity of each lesion and to decide on 
appropriate intervention.
11. PROSTHETIC VALVES
11.1. Evaluation and Selection of 
Prosthetic Valves
11.1.1. Diagnosis and Follow-Up of Prosthetic 
Valves
Recommendations for Diagnosis and Follow-Up of Prosthetic Valves
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 34.
COR LOE Recommendations
1 B-NR1.  In patients with a surgical or transcatheter 
prosthetic valve and in patients who have 
had valve repair, an initial postprocedural TTE 
study is recommended for evaluation of valve 
hemodynamics and ventricular function.1–4 
1 C-EO2.  In patients with a prosthetic valve or prior valve 
repair and a change in clinical symptoms or 
signs suggesting valve dysfunction, repeat TTE 
is recommended. 
1 C-LD3.  In patients with a prosthetic valve replacement 
or prior valve repair and clinical symptoms or 
signs that suggest prosthetic valve dysfunction, 
additional imaging with TEE, gated cardiac CT, 
or fluoroscopy is recommended, even if TTE 
does not show valve dysfunction.
2a C-LD4.  In patients with a bioprosthetic surgical valve, 
TTE at 5 and 10 years and then annually 
after implantation is reasonable, even in the 
absence of a change in clinical status. 
2a C-LD5.  In patients with a bioprosthetic TAVI, TTE 
annually is reasonable.Table 21. AS/MR Mixed Valve Disease
Severe AS Severe MR Surgical Risk Procedure
SAVR candidate Primary MR
Repairable valveLow 
intermediateSAVR
Surgical mitral 
valve repair
SAVR candidate Primary MR
Valve not 
repairableLow 
intermediateSAVR
Surgical mitral 
valve replacement
TAVI candidate Primary
Repairable valveHigh 
prohibitiveTAVI
Mitral TEER*
SAVR candidate
TAVI candidateSecondary MR Low 
intermediateSAVR
Surgical mitral 
valve repair/mitral 
valve replacement
or
TAVI
Mitral TEER*
TAVI candidate Secondary MR High 
prohibitiveTAVI
Mitral TEER*
*Consider TEER as a later staged procedure if symptoms and severe MR 
persist after treatment of the AS.
AS indicates aortic stenosis; MR, mitral regurgitation; SAVR, surgical aortic 
valve replacement; TAVI, transcatheter aortic valve implantation; and TEER, 
transcatheter edge-to-edge repair.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e138
CLINICAL STATEMENTS  
AND GUIDELINESSynopsis
The clinical course of patients with prosthetic heart 
valves or repaired native valves is influenced by several 
factors, including ventricular function, AF, pulmonary 
hypertension, and CAD, as well as by the development 
of valve-related complications. The interval between 
routine follow-up visits depends on the patient’s valve 
type, the presence of residual heart disease, and other 
clinical factors. Attention to optimal dental care and en-
docarditis prophylaxis and any needed anticoagulation 
is a requisite component of care.
TTE is the primary imaging modality for postopera-
tive assessment of prosthetic valve or repaired native 
valve function. In the absence of early complications, 
the index study is performed during hospitalization or 
within the first several weeks thereafter, depending on 
individual patient circumstances and the type of valve 
procedure. Additional imaging, such as TEE, cardiac CT, 
or fluoroscopy, may be required when valve dysfunc-
tion is suspected and in the context of the clinical pre-
sentation. A schedule for surveillance TTE studies has 
become an established feature of long-term follow-up, 
although the frequency of routine studies that are per -
formed in the absence of clinical change will vary as a 
function of valve type.
Recommendation-Specific Supportive Text
1. TTE after valve implantation or repair provides an 
assessment of the procedural results and serves 
as a baseline against which comparison can be 
made for any change. TTE provides accurate mea-
surements of transvalvular velocities and pressure 
gradients, as well as detection and quantitation 
of transvalvular and paravalvular leak.1–4 Normal 
transvalvular velocities and gradients vary across 
different types and sizes of prosthetic valves 
but are also affected by patient-specific factors, 
including body size and cardiac output. The 
postoperative study, recorded when the patient 
is asymptomatic and in a stable hemodynamic 
state, provides Doppler flow data for a specific 
valve in an individual patient. In addition, TTE pro-
vides assessment of other valve disease(s), pulmo-
nary artery pressure, atrial size, LV and RV size and 
function, and pericardial disease.
2. Bioprosthetic or repaired native valve dysfunc-
tion typically presents with the insidious onset 
of HF symptoms or a change in the ausculta-
tory findings. More abrupt and severe symptoms 
may occur with infective endocarditis or rupture 
of a valve cusp. Patients with mechanical valve 
dysfunction may present with HF, shock, throm-
boembolic events, hemolysis, or a change in 
auscultatory findings. Presentation may often be acute or subacute because of thrombus forma-
tion and more abrupt impairment of leaflet open-
ing or closure. Attention should be directed to the 
trend in recent INR determinations. Prosthesis–
patient mismatch and functional stenosis of a 
repaired native valve are also to be considered 
in the evaluation of patients with HF symptoms. 
Repeat noninvasive assessment begins with trans-
thoracic echocardiography, comparison with the 
index postoperative study when available, and 
the use of other modalities as dictated by the 
clinical context and preliminary findings.
3. TTE is the preferred approach for initial assessment 
of suspected prosthetic valve dysfunction because 
it allows for measurement of transvalvular velocity, 
gradient, and valve area. TTE also allows quantita-
tion of LV volumes and LVEF, an estimate of pulmo-
nary artery systolic pressure, and evaluation of right 
heart function. However, the LA side of a prosthetic 
mitral valve is obscured by acoustic shadowing 
from the TTE approach, resulting in reduced sensi-
tivity for detection of prosthetic MR and prosthetic 
mitral valve thrombus, pannus, or vegetation. TEE 
provides superior imaging of the LA side of the 
mitral prosthesis and is accurate for diagnosis of 
prosthetic mitral valve dysfunction.5,6 Both TTE and 
TEE are also needed for patients with prosthetic 
aortic valves in whom the posterior aspect of the 
valve is shadowed on the TTE approach and the 
anterior aspect of the valve is shadowed on the 
TEE approach.7,8 TEE has superior sensitivity for the 
detection of vegetations and abscess formation in 
patients with suspected prosthetic valve (or annu-
loplasty ring) endocarditis. With mechanical valve 
obstruction, fluoroscopy or CT imaging can also be 
helpful for detection of reduced motion caused by 
pannus ingrowth or thrombus.
4. Studies based on TTE follow-up estimate that 
approximately 30% of patients with a surgical 
aortic valve bioprosthesis develop evidence of 
valve dysfunction over the 10 years after implan-
tation (defined as an increase in mean gradient 
of ≥10 mm Hg or a worsening of transprosthetic 
regurgitation from mild to moderate or from 
moderate to severe).9 The incidence of clinically 
important structural valve deterioration increases 
markedly more than 10 years after surgery, such 
that routine annual TTE studies thereafter are rea-
sonable.10,11 Risk factors associated with acceler -
ated (<5 years) valve deterioration include young 
age (<60 years) at implantation, smoking, diabe-
tes mellitus, chronic kidney disease, initial mean 
gradient ≥15 mm Hg, and valve type.9,12 The selec-
tive adoption of an earlier, annual TTE screening 
program may be considered for at-risk patients 
on an individual basis, as up to 13% of patients 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e139
CLINICAL STATEMENTS  
AND GUIDELINESwith a surgical aortic valve develop hemodynamic 
valve dysfunction at a median of 6.7 to 9.9 years 
after implantation.12 Patients typically remain 
asymptomatic until valve dysfunction is severe 
enough to result in adverse hemodynamic conse-
quences or AF. Depending on the valve type and 
mechanism of regurgitation, some patients with 
asymptomatic, significant prosthetic valve regur -
gitation may require reintervention. For example, 
if prosthetic regurgitation is attributable to a bio-
prosthetic leaflet tear, more severe acute regur -
gitation may occur suddenly and cause clinical 
decompensation. With prosthetic valve stenosis, 
TTE diagnosis while the patient is asymptomatic 
alerts the clinician to the need for more frequent 
follow-up. A standardized definition and grading 
system for structural valve deterioration for sur -
gical and transcatheter aortic valves have been 
proposed.13 In patients with mechanical valve 
prostheses, routine annual TTE evaluation is not 
needed if the postoperative baseline study is nor -
mal and no clinical change is apparent. Many of 
these patients require TTE studies for other indi-
cations, however, such as for the assessment of 
LV function, pulmonary artery pressure, or other 
cardiac or valve disease.
5. Durability data for bioprosthetic TAVI valves are 
less robust than the data for surgically implanted 
bioprosthetic valves. To date, the intermediate-
term durability of TAVI valves has compared 
favorably with that of SAVR valves, as reported 
in randomized trials and registries.14–21 For the 
most part, these data reflect observations made 
in older patients and may not be applicable to 
younger populations (eg, <70 years). TAVI-based 
protocols typically include routine TTE before dis-
charge and at 30 days and 1 year, in part because 
of reporting requirements. In the absence of clini-
cal change, routine annual TTE studies are reason-
able as experience continues to accumulate.
11.1.2. Selection of Prosthetic Valve Type: 
Bioprosthetic Versus Mechanical Valve
Recommendations for Prosthetic Valve Type: Bioprosthetic Versus 
Mechanical Valve
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 35.
COR LOE Recommendations
1 C-LD1.  For patients who require heart valve 
replacement, the choice of prosthetic valve 
should be based on a shared decision-making 
process that accounts for the patient’s values 
and preferences and includes discussion of 
the indications for and risks of anticoagulant 
therapy and the potential need for and risks 
associated with valve reintervention. 1 C-EO2.  For patients of any age requiring valve 
replacement for whom anticoagulant therapy 
is contraindicated, cannot be managed 
appropriately, or is not desired, a bioprosthetic 
valve is recommended. 
2a B-NR3.  For patients <50 years of age who do not 
have a contraindication to anticoagulation 
and require AVR, it is reasonable to choose 
a mechanical aortic prosthesis over a 
bioprosthetic valve.1
2a B-NR4.  For patients 50 to 65 years of age who require 
AVR and who do not have a contraindication 
to anticoagulation, it is reasonable to 
individualize the choice of either a mechanical 
or bioprosthetic AVR, with consideration of 
individual patient factors and after informed 
shared decision-making.1–10
2a B-NR5.  In patients >65 years of age who require AVR, 
it is reasonable to choose a bioprosthesis over 
a mechanical valve.1
2a B-NR6.  For patients <65 years of age who have an 
indication for mitral valve replacement, do not 
have a contraindication to anticoagulation, 
and are unable to undergo mitral valve repair, 
it is reasonable to choose a mechanical mitral 
prosthesis over a bioprosthetic valve.1,7,10,11
2a B-NR7.  For patients ≥65 years of age who require 
mitral valve replacement and are unable to 
undergo mitral valve repair, it is reasonable 
to choose a bioprosthesis over a mechanical 
valve.1,7,11
2b B-NR8.  In patients <50 years of age who prefer a 
bioprosthetic AVR and have appropriate 
anatomy, replacement of the aortic valve by 
a pulmonic autograft (the Ross procedure) 
may be considered at a Comprehensive Valve 
Center.12–14
Synopsis
Shared decision-making about the choice of prosthetic 
valve type is influenced by several factors, including pa-
tient age, values, and preferences; expected bioprosthetic 
valve durability, avoidance of patient–prosthesis mis-
match, and the potential need for and timing of reinter -
vention; and the risks associated with long-term VKA an-
ticoagulation after a mechanical valve replacement. (See 
also Section 3.2.4 regarding valve choice in patients with 
AS.) Despite the significantly higher rate of bioprosthetic 
structural valve deterioration observed in younger versus 
older patients,7–12,15 many younger patients choose to 
avoid a mechanical prosthesis because they are unwilling 
to consider long-term VKA therapy because of the incon-
venience of monitoring, dietary restrictions, medication 
interactions, and the need to restrict participation in some 
types of athletic activity. A mechanical valve might be a 
prudent choice for patients for whom a second surgical 
procedure would be very high risk (eg, those with prior 
radiation exposure). The availability of TAVI has changed Recommendations for Prosthetic Valve Type: Bioprosthetic Versus 
Mechanical Valve (Continued)
COR LOE Recommendations
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e140
CLINICAL STATEMENTS  
AND GUIDELINESthe dynamics of the discussion of the trade-offs between 
mechanical and bioprosthetic valves in younger patients 
(Table 22) (Figure 11).16–19
Recommendation-Specific Supportive Text
1. The choice of valve prosthesis in each patient is 
based on consideration of several factors, includ-
ing valve durability, expected hemodynamics for 
valve type and size, surgical or interventional risk, 
the potential need for long-term anticoagulation, 
and patient values and preferences. The trade-off 
between the risk of reintervention for biopros-
thetic valve deterioration and the risk of long-
term anticoagulation should be discussed. Some 
patients prefer to avoid repeat surgery and are 
willing to accept the risks and inconvenience of 
lifelong anticoagulant therapy. Other patients are 
unwilling to consider long-term anticoagulation 
because of the inconvenience of monitoring, the 
attendant dietary and medication interactions, 
and the need to restrict participation in some 
types of physical activity. The incidence of struc-
tural deterioration of a bioprosthesis is greater 
in younger patients, but the risk of bleeding 
from anticoagulation is higher in older patients. 
In patients with shortened longevity or multiple 
comorbidities, a bioprosthesis might be more 
appropriate. In women who desire subsequent 
pregnancy, the issue of anticoagulation during 
pregnancy is an additional consideration (see 
pregnancy-related issues in Section 13.5).20,21
2. Anticoagulant therapy with VKA is necessary in all 
patients with a mechanical valve to prevent valve 
thrombosis and thromboembolic events. If anti-
coagulation is contraindicated or if the patient 
refuses VKA therapy, an alternative valve choice 
is appropriate. Newer anticoagulant agents have 
not been shown to be safe or effective in patients 
with mechanical heart valves.
3. Patients <50 years of age at the time of AVR 
incur a higher and earlier risk of bioprosthetic 
valve deterioration.4,10,11,22–24 Overall, the predicted 
15-year risk of needing reoperation because of 
structural deterioration is 22% for patients 50 
years of age, 30% for patients 40 years of age, 
and 50% for patients 20 years of age, although it 
is recognized that all bioprostheses are not alike in 
terms of durability.11 Anticoagulation with a VKA 
can be accomplished with acceptable risk in most 
patients <50 years of age, particularly in compliant 
patients with appropriate monitoring of INR levels. 
Thus, the balance between valve durability and 
risk of bleeding and thromboembolic events favors 
the choice of a mechanical valve in patients <50 years of age, unless anticoagulation is not desired, 
cannot be monitored, or is contraindicated.
4. Uncertainty and debate continue about which 
type of AVR is appropriate for patients 50 to 
65 years of age. Newer surgical bioprosthetic 
valves may show greater freedom from struc-
tural deterioration, specifically in the older indi-
vidual, although a high late mortality rate in these 
studies may preclude recognition of valve dys-
function.11,15–19 The risks of bleeding and throm-
boembolism with mechanical prostheses are low, 
especially in compliant patients with appropriate 
INR monitoring. Several studies have shown a sur -
vival advantage with a mechanical prosthesis in 
this age group. Alternatively, large retrospective 
observational studies have shown similar long-
term survival rates in patients 50 to 69 years of 
age undergoing mechanical versus bioprosthetic 
valve replacement.22–24 In general, patients with 
mechanical valves experience a higher risk of 
bleeding because of anticoagulation, whereas 
individuals who receive bioprosthetic valves expe-
rience a higher rate of reoperation attributable 
to structural deterioration of the prosthesis, as 
well as perhaps a decrease in survival rate.6,25–27 
Several other factors should be considered in the 
choice of type of valve prosthesis (see Section 
11.1). Ultimately, the choice of mechanical versus Table 22. Selected Factors That May Impact Shared Decision-Making 
for the Choice of Prosthetic Valve
Favor Mechanical Prosthesis Favor Bioprosthesis
Age <50 y
  Increased incidence of structural 
deterioration with bioprosthesis 
(15-y risk: 30% for age 40 y, 
50% for age 20 y)
  Lower risk of anticoagulation 
complicationsAge >65 y
  Low incidence of structural 
deterioration (15-y risk: <10% 
for age >70 y)
  Higher risk of anticoagulation 
complications
Patient preference (avoid risk of 
reintervention)Patient preference (avoid risk and 
inconvenience of anticoagulation)
Low risk of long-term 
anticoagulationHigh risk of long-term 
anticoagulation
Compliant patient with either 
home monitoring or close access to 
INR monitoringLimited access to medical care or 
inability to regulate VKA
Other indication for long-term 
anticoagulation (eg, AF)Access to surgical centers with low 
reoperation mortality rate
High-risk reintervention (eg, 
porcelain aorta, prior radiation 
therapy)Access to transcatheter ViV 
replacement
Small aortic root size for AVR (may 
preclude ViV procedure in future)TAVI valves have larger effective 
orifice areas for smaller valve sizes 
(avoid patient–prosthesis mismatch)
AF indicates atrial fibrillation; AVR, aortic valve replacement; INR, 
international normalized ratio; TAVI, transcatheter aortic valve implantation; 
ViV, valve-in-valve; and VKA, vitamin K antagonist.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e141
CLINICAL STATEMENTS  
AND GUIDELINESbioprosthetic valve replacement for all patients, 
but especially for those between 50 and 65 years 
of age, should be made in a shared decision-mak-
ing process that must account for the trade-offs 
between durability (and the need for reinterven-
tion), bleeding, and thromboembolism.1
5. In patients >65 years of age at the time of bio-
prosthetic AVR, the likelihood of primary struc-
tural deterioration at 15 to 20 years is only about 
10%.28–31 In addition, older patients are at higher 
risk of bleeding complications related to VKA ther -
apy and more often require interruption of VKA 
therapy for noncardiac surgical and interventional 
procedures. It is reasonable to use a bioprosthetic 
valve in patients >65 years of age to avoid the 
risks of anticoagulation because the durability of 
the valve exceeds the expected years of life.
6. In general, patients with mechanical valve replace-
ment experience a higher risk of bleeding because 
of anticoagulation, whereas individuals who 
receive a bioprosthetic valve replacement incur a 
higher risk of repeat intervention attributable to 
structural valve deterioration. In patients <65 years 
of age, observational data suggest better long-term 
outcomes with a mechanical mitral valve replace-
ment, even when the risks and inconvenience of 
long-term VKA anticoagulation are considered. In a propensity-matched analysis from New York’s 
Statewide Planning and Research Cooperative 
System (SPARCS), although there was no survival 
difference for patients 50 to 69 years of age under -
going mechanical versus bioprosthetic mitral valve 
replacement,7 the rates of reoperation were lower 
(HR: 0.59) with a mechanical valve, though stroke 
risk (HR: 1.62) was higher. In the 2017 report from 
the California Office of Statewide Health Planning 
and Development,1 for patients who underwent 
mitral-valve replacement and were 40 to 69 years 
of age, receipt of a biological prosthesis was associ-
ated with a mortality rate significantly higher than 
that seen with receipt of a mechanical prosthesis.1 
The choice of a mechanical mitral valve in patients 
<65 years of age who are good candidates for 
anticoagulation should account for these observa-
tional, nonrandomized data and abide by the prin-
ciples of shared decision-making.1,7,10
7. Hazards associated with anticoagulation 
increase with age, and rates of structural valve 
deterioration decline significantly. In patients 
>65 years of age, the ratio of valve durability 
to life expectancy supports the use of a bio-
prosthetic mitral valve replacement, which 
allows avoidance of the risks of long-term VKA 
anticoagulation in these older patients. In 1 
Figure 11. Prosthetic valves: choice of biopros-
thetic versus mechanical valve type.
Colors correspond to Table 2. *Approximate ages, 
based on US Actuarial Life Expectancy tables, 
are provided for guidance. The balance between 
expected patient longevity and valve durability var -
ies continuously across the age range, with more 
durable valves preferred for patients with a longer 
life expectancy. Bioprosthetic valve durability is 
finite (with shorter durability for younger patients), 
whereas mechanical valves are very durable but 
require lifelong anticoagulation. Long-term (20-y) 
data on outcomes with surgical bioprosthetic 
valves are available; robust data on transcatheter 
bioprosthetic valves extend to only 5 y, leading to 
uncertainty about longer-term outcomes. The deci-
sion about valve type should be individualized on 
the basis of patient-specific factors that might af-
fect expected longevity. †See Section 3.2.4.2 for a 
discussion of the choice of TAVI versus SAVR. AVR 
indicates aortic valve replacement; CVC, Compre-
hensive Valve Center; VKA, vitamin K antagonist; 
SAVR, surgical aortic valve replacement; and TAVI, 
transcatheter aortic valve implantation.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e142
CLINICAL STATEMENTS  
AND GUIDELINESobservational study, the expected durability of a 
bioprosthetic mitral valve replacement was 11.4 
years in patients <60 years of age, 16.6 years 
in those 60 to 70 years of age, and 19.4 years 
in those >70 years of age.11 In the 2017 report 
from the California Office of Statewide Health 
Planning and Development,1 overall survival 
rates were similar for patients 70 to 79 years of 
age who underwent mechanical versus biopros-
thetic mitral valve replacement, and bleeding 
risk was lower with a bioprosthetic valve.1
8. Replacement of the aortic valve with a pulmo-
nary autograft (the Ross procedure) is a complex 
operation involving replacement of the aortic 
valve by the patient’s own pulmonic valve, along 
with placement of a pulmonic valve homograft. 
The Ross procedure allows the patient to avoid 
a prosthetic heart valve and the risks of antico-
agulation, and it provides excellent valve hemody-
namics. However, both the pulmonic homograft 
in the pulmonic position and the pulmonary 
autograft (the neoaortic valve) are at risk of valve 
degeneration. The failure of the Ross procedure 
is most often attributable to regurgitation of the 
neoaortic valve in the second decade after the 
operation. In addition, at least half of pulmonic 
homograft valves require reintervention within 10 
to 20 years. Calcification of the homograft and 
adhesions between the homograft and neoaorta 
may increase the difficulty of reoperation. The 
Ross procedure typically is reserved for younger 
patients with appropriate anatomy and tissue 
characteristics in whom anticoagulation is either 
contraindicated or undesirable, and it is per -
formed only at Comprehensive Valve Centers by 
surgeons experienced in this procedure.12–14,32
11.2. Antithrombotic Therapy
Recommendations for Antithrombotic Therapy for Prosthetic Valves
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 36.
COR LOE Recommendations
1 A1.  In patients with a mechanical prosthetic 
valve, anticoagulation with a VKA is 
recommended.1–5
1 B-NR2.  For patients with a mechanical bileaflet or 
current-generation single-tilting disk AVR 
and no risk factors for thromboembolism, 
anticoagulation with a VKA to achieve an INR 
of 2.5 is recommended.6–8
1 B-NR3.  For patients with a mechanical AVR and 
additional risk factors for thromboembolism 
(eg, AF, previous thromboembolism, LV 
dysfunction, hypercoagulable state) or an 
older-generation prosthesis (eg, ball-in-cage), 
anticoagulation with a VKA is indicated to 
achieve an INR of 3.0.9,10 1 B-NR  4.  For patients with a mechanical mitral valve 
replacement, anticoagulation with a VKA is 
indicated to achieve an INR of 3.0.9,11 
2a B-R  5.  For patients with a bioprosthetic TAVI, 
aspirin 75 to 100 mg daily is reasonable in 
the absence of other indications for oral 
anticoagulants.12–14
2a B-NR  6.  For all patients with a bioprosthetic SAVR or 
mitral valve replacement, aspirin 75 to 100 
mg daily is reasonable in the absence of other 
indications for oral anticoagulants.9,15–18
2a B-NR  7.  For patients with a bioprosthetic SAVR or 
mitral valve replacement who are at low risk 
of bleeding, anticoagulation with a VKA to 
achieve an INR of 2.5 is reasonable for at 
least 3 months and for as long as 6 months 
after surgical replacement.15,19–25
2b B-R  8.  For patients with a mechanical SAVR or mitral 
valve replacement who are managed with a 
VKA and have an indication for antiplatelet 
therapy, addition of aspirin 75 to 100 mg 
daily may be considered when the risk of 
bleeding is low.26 
2b B-R  9.  For patients with a mechanical On-X AVR and 
no thromboembolic risk factors, use of a VKA 
targeted to a lower INR (1.5–2.0) may be 
reasonable starting ≥3 months after surgery, 
with continuation of aspirin 75 to 100 mg 
daily.27,28
2b B-NR10.  For patients with a bioprosthetic TAVI 
who are at low risk of bleeding, dual-
antiplatelet therapy with aspirin 75 to 
100 mg and clopidogrel 75 mg may be 
reasonable for 3 to 6 months after valve 
implantation.12,13,29
2b B-NR11.  For patients with a bioprosthetic TAVI who 
are at low risk of bleeding, anticoagulation 
with a VKA to achieve an INR of 2.5 may be 
reasonable for at least 3 months after valve 
implantation.23,31–33
3: Harm B-R12.  For patients with bioprosthetic TAVI, 
treatment with low-dose rivaroxaban 
(10 mg daily) plus aspirin (75–100 mg) is 
contraindicated in the absence of other 
indications for oral anticoagulants.30
3: Harm B-R13.  For patients with a mechanical valve 
prosthesis, anticoagulation with the 
direct thrombin inhibitor, dabigatran, is 
contraindicated.4,5
3: Harm C-EO14.  For patients with a mechanical valve 
prosthesis, the use of anti-Xa direct oral 
anticoagulants has not been assessed and is 
not recommended.34–37 
Synopsis
Antithrombotic therapy after prosthetic valve implanta-
tion is provided to prevent valve/leaflet thrombosis and 
reduce the incidence of thromboembolic complications. 
The use of any strategy must be balanced against the 
risk of bleeding. VKAs remain the cornerstone of therapy Recommendations for Antithrombotic Therapy for Prosthetic Valves
(Continued)
COR LOE Recommendations
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e143
CLINICAL STATEMENTS  
AND GUIDELINESfor patients with mechanical valve prostheses. Oral anti-
thrombin and anti-Xa agents are not approved for use in 
these patients. The addition of mono- or dual-antiplatelet 
therapy to VKA treatment for other indications (eg, acute 
coronary syndrome or percutaneous coronary interven-
tion [PCI]) must be done with caution. The evidence base 
for the optimal antithrombotic strategy across subgroups 
of patients who have received a bioprosthetic valve is not 
robust. Practice patterns around the use of antiplatelet 
and anticoagulant medications in these patients vary as 
a function of method of implantation (surgical versus 
transcatheter), the presence of any independent indica-
tion for anticoagulation (eg, AF, venous thromboembolic 
disease), and local/institutional care pathways (Figure 12).
Recommendation-Specific Supportive Text
1. All patients with mechanical valves require life-
long anticoagulant therapy with a VKA.1–5 In addi-
tion to the thrombogenicity of the intravascular 
prosthetic material, mechanical valves impose 
abnormal flow conditions, with zones of low 
flow within their components, as well as areas of 
high-shear stress, which can cause platelet activa-
tion that leads to valve thrombosis and embolic 
events. Therapy with an oral VKA at an INR goal 
appropriate for the comorbidity of the patient 
and the type and position of the mechanical valve 
prosthesis is required to decrease the incidence 
of thromboembolism and associated morbid-
ity. Data show that anticoagulation with a VKA 
is protective against valve thrombosis (OR: 0.11; 
95% CI: 0.07–0.2) and thromboembolic events 
(OR: 0.21; 95% CI: 0.16–0.27). It is preferable to 
specify a single INR target for each patient and 
to recognize that the acceptable range includes 
0.5 INR units on each side of this target. A spe-
cific target is preferable because it reduces the 
likelihood of patients having INR values consis-
tently near the upper or lower boundary of the 
range. Fluctuations in INR are associated with an 
increased incidence of complications in patients 
with prosthetic heart valves.19,38
2. The rate of thromboembolism in patients with a 
bileaflet mechanical AVR treated with a VKA is 
estimated to be 0.53% per patient-year over the 
INR range of 2.0 to 4.5. In a large retrospective 
study, adverse events increased if the INR was >4.0 
in patients with a mechanical AVR. In patients 
with a current-generation mechanical AVR with-
out other risk factors for thromboembolism, in 
the group treated to an INR of 2.0 to 3.0, the risk 
of thromboembolic events was similar to, but the 
risk of bleeding lower than, those of the group 
treated to an INR of 3.0 to 4.5 (P<0.01).7 In a ran-
domized trial comparing moderate-intensity (INR 2.0–3.0) with high-intensity (INR 3.0 to 4.5) oral 
anticoagulation in patients with a single mechani-
cal valve replacement, there was no difference in 
embolic events but a reduction in bleeding with 
the moderate-intensity group.8 In a study com-
paring an INR target of 1.5 to 2.5 with a target 
of 2.0 to 3.0 in patients with current-generation 
mechanical aortic prosthetic valves and no other 
thromboembolic risk factors, the lower INR target 
range was noninferior, but the quality of the evi-
dence was low.6 For current-generation mechani-
cal valve prostheses in the aortic position, an INR 
of 2.5 (range, 2.0–3.0) provides a reasonable bal-
ance between the risks of thromboembolism and 
bleeding.8,9
3. In patients with an aortic mechanical prosthesis 
who are at higher risk of thromboembolic com-
plications, the INR should be maintained at 3.0 
(range, 2.5–3.5). Risk factors include AF, previous 
thromboembolism, hypercoagulable state, and 
older-generation prosthesis (eg, ball-in-cage).10 
Severe LV dysfunction may also increase throm-
boembolic risk.9
4. The incidence of thromboembolism is higher 
with mitral than with aortic mechanical valves, 
and it is lower in mitral mechanical valve patients 
with a higher rather than a lower INR. In the 
GELIA (German Experience with Low Intensity 
Anticoagulation) study of patients with a 
mechanical mitral prosthesis, a lower INR range 
(2.0–3.5) was associated with a lower survival 
rate than that seen with a higher target INR 
range (2.5–4.5).11 Patient compliance may be 
challenging with higher INR goals. In one study, 
patients with a target INR between 2.0 and 3.5 
were within that range 74.5% of the time. In 
contrast, patients with a target INR of 3.0 to 4.5 
were within range only 44.5% of the time. An 
INR target of 3.0 (range, 2.5–3.5) provides a rea-
sonable balance between the risks of under- or 
over-anticoagulation in patients with a mechani-
cal mitral valve.9
5. Prior recommendations about the use of anti-
platelet therapy after TAVI were derived from the 
protocols used in the pivotal randomized stud-
ies showing the safety and effectiveness of this 
technology. These protocols were in turn adopted 
from studies of patients undergoing PCI. The small 
and underpowered ARTE trial (Aspirin Versus 
Aspirin plus Clopidogrel Following Transcatheter 
Aortic Valve Implantation) suggested that single-
agent therapy, compared with dual-agent ther -
apy, tended to reduce the risk of major adverse 
events (death, myocardial infarction, stroke, tran-
sient ischemic attack, and major or life-threaten-
ing bleeding) after TAVI. Whereas there were no 
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e144
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
differences between the groups with respect to 
death, stroke, or myocardial infarction, dual ther -
apy was associated with a significantly increased 
risk of major or life-threatening bleeding.12 A 
systematic review and meta-analysis comprising 
approximately 2500 patients suggested that sin-
gle-agent therapy is associated with fewer 30-day 
deaths and less major bleeding than is seen with 
dual-agent therapy.13 There are several ongoing 
trials on this subject.39
6. The risk of thromboembolism is approximately 
0.7% per year in patients with biological valves 
in sinus rhythm; Figure 13 is derived from several 
studies in which most patients were not undergo-
ing therapy with VKA. Among patients with bio-
prosthetic valves, those with a mitral prosthesis 
have higher rates of thromboembolism than do 
those with an aortic prosthesis (2.4% per patient-
year versus 1.9% per patient-year).15 In studies 
of patients with bioprosthetic aortic valves who 
were in sinus rhythm and had no other indi-
cations for anticoagulation, the incidence of thromboembolic events, bleeding, and death was 
similar in those who received aspirin or aspirin-
like antiplatelet agents only and in those who 
received VKA.16,17,19 There are no studies examin-
ing the long-term effects of antiplatelet agents in 
patients with bioprosthetic mitral valve repair or 
mitral valve repair; the beneficial effects seen with 
bioprosthetic aortic valves may apply to mitral 
valves, as well.9,18
7. Many patients who undergo surgical implantation 
of a bioprosthetic mitral or aortic valve will not 
require lifelong anticoagulation in the absence of 
an independent indication, such as AF. However, 
there is an increased risk of ischemic stroke early 
after operation, particularly in the first 90 to 180 
days after either bioprosthetic AVR or mitral valve 
replacement.5,24,31,34–37,40 Anticoagulation early 
after valve implantation is intended to decrease 
the risk of thromboembolism until the prosthetic 
valve is fully endothelialized. The potential ben-
efit of anticoagulation therapy must be weighed 
against the risk of bleeding. In a nonrandomized 
Figure 12. Antithrombotic therapy for prosthetic valves.
Colors correspond to Table 2. *Thromboembolic risk factors include an older-generation valve, AF, previous thromboembolism, hypercoagulable state, and LV sys-
tolic dysfunction. †For a mechanical On-X AVR and no thromboembolic risk factors, a goal INR of 1.5–2.0 plus aspirin 75–100 mg daily may be reasonable starting 
≥3 months after surgery. ASA indicates aspirin; AVR, aortic valve replacement; INR, international normalized ratio; MVR, mitral valve replacement; VKA, vitamin K 
antagonist; Rx, medication; and TAVI, transcatheter aortic valve implantation.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e145
CLINICAL STATEMENTS  
AND GUIDELINESstudy, patients with a bioprosthetic mitral valve 
replacement who received anticoagulation had 
a lower rate of thromboembolism than that of 
those who did not receive therapy with VKA.15 
Even with routine anticoagulation early after 
mitral valve surgery, the incidence of ischemic 
stroke within the first 30 postoperative days was 
higher after replacement with a biological pros-
thesis than after mitral valve repair (1.5%±0.4%) 
or replacement with a mechanical prosthesis.21 
Small studies have not established a convincing 
net benefit of anticoagulation after implantation 
of a bioprosthetic AVR24,25; however, a large obser -
vational Danish registry demonstrated a lower risk 
of stroke and death with VKA, which extended 
up to 6 months, without a significantly increased 
bleeding risk.20 Concern has been raised about 
the incidence of subclinical bioprosthetic valve 
leaflet thrombosis after surgical valve replace-
ment.19 In addition, the PARTNER 2 (Placement 
of Aortic Transcatheter Valves) investigators 
reported that the use of anticoagulation after 
bioprosthetic AVR in intermediate– or higher–sur -
gical risk patients was safe and associated with 
a significant reduction in 6-month stroke rates.23 
Ninety-five percent of the anticoagulated patients 
in this registry were discharged on warfarin in 
preference to a direct oral anticoagulant.
8. The prior recommendation to add low-dose aspi-
rin to therapeutic VKA therapy for a mechanical 
valve prosthesis was based on studies performed 
decades ago that included many patients with 
older-generation prostheses who also had addi-
tional thromboembolic and vascular risk factors. 
A 2013 Cochrane Systematic Review showed 
that compared with anticoagulation alone, the 
addition of an antiplatelet agent reduced the 
risk of thromboembolic events and the total 
mortality rate but at the cost of an increased and 
offsetting risk of major bleeding.26 The authors 
pointed out that the quality of the included tri-
als tended to be low, possibly reflecting the era 
when most trials were conducted. An individu-
alized approach that takes the risk of bleeding 
into account is required.
9. In patients without risk factors who receive a 
mechanical On-X aortic heart valve (On-X Life 
Technologies Inc., Austin, Texas), targeting the 
INR to a lower goal (1.5–2.0) in conjunction 
with aspirin 81 mg daily may be a strategy for 
long-term management. Warfarin dosing is tar -
geted to an INR of 2.5 (range, 2.0–3.0) for the 
first 3 months after surgery, during which low-
dose aspirin is also used.27 This recommenda-
tion is based on a single RCT27 of lower- versus 
standard-intensity VKA therapy (with low-dose aspirin) in patients undergoing On-X AVR. The 
lower-intensity INR group experienced signifi-
cantly less major and minor bleeding, whereas 
the rates of stroke, transient ischemic attack, 
total neurological events, and all-cause mortal-
ity were similar between the 2 groups. A sub-
sequent publication from these investigators 
showed harm with a strategy of dual-antiplate-
let therapy versus low-intensity anticoagulation 
plus low-dose aspirin.28
10.  The routine use of dual-antiplatelet therapy for 
6 months after TAVI, which has been the default 
strategy since the introduction of this technol-
ogy into clinical use, has been not been rigor -
ously assessed (see previous discussion). There 
are several ongoing trials evaluating antithrom-
botic strategies after TAVI. A small, single-center 
RCT of patients receiving a self-expanding TAVI 
device showed no difference in a composite 
endpoint of major adverse cardiac and cerebro-
vascular events or life-threatening bleeding with 
aspirin plus clopidogrel versus aspirin alone at 
30 days and 6 months.29 Compared with single-
agent therapy, dual-antiplatelet therapy may be 
associated with a higher risk of bleeding and 
no significant difference in rates of valve leaflet 
thrombosis, thromboembolism, or valve perfor -
mance.12,13 Other procedural and patient factors 
may impact the decision to use dual-antiplatelet 
therapy.
11.  The selective use of VKA therapy might be consid-
ered after TAVI in patients at low bleeding risk on 
an individual basis. The PARTNER 2 investigators 
reported that the use of an anticoagulant (95% 
warfarin) after TAVI in intermediate– or higher–
surgical risk patients was associated with a lower 
incidence of an increase in mean gradient >10 
mm Hg over the first year after implantation.23 
This Doppler finding may reflect the development 
of leaflet thrombosis, for which a change in the 
frequency of follow-up examinations or treatment 
could be considered. VKAs may be more effective 
than direct oral anticoagulants for reduction of 
death, myocardial infarction, and cerebrovascular 
events in patients undergoing TAVI with an indi-
cation for anticoagulation.33 The selective short-
term use of VKAs after ViV TAVI is predicated on 
the observation that valve thrombosis may be 
more frequent in this patient population.32
12.  The GALILEO (Global Study Comparing a 
Rivaroxaban-based Antithrombotic Strategy to an 
Antiplatelet-based Strategy after Transcatheter 
Aortic Valve Replacement to Optimize Clinical 
Outcomes) trial assessed a strategy of low-dose 
rivaroxaban (10 mg daily) plus low-dose aspirin 
(75–100 mg daily) versus an antiplatelet strategy 
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e146
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
of low-dose aspirin plus clopidogrel (75 mg daily). 
The study was terminated prematurely by the 
Data and Safety Monitoring Board because of 
safety concerns. The rivaroxaban strategy was 
associated with a higher risk of death or thrombo-
embolic complications and a higher risk of bleed-
ing than those seen with the antiplatelet-based 
strategy.30
13.  Dabigatran was compared with warfarin in 
the RE-ALIGN (Randomized, Phase II Study to 
Evaluate the Safety and Pharmacokinetics of Oral 
Dabigatran Etexilate in Patients after Heart Valve 
Replacement) trial. It was stopped prematurely for 
excessive thrombotic and bleeding complications 
in the dabigatran arm.4,5
14.  The safety and efficacy of conventional-dose oral 
anti-Xa agents in patients with a mechanical valve 
prosthesis have not been evaluated.33–3611.3. Bridging Therapy
Recommendations for Bridging Therapy During Interruption of Oral 
Anticoagulation in Patients With Prosthetic Heart Valves
COR LOE Recommendations
1 C-EO1.  For patients with mechanical heart valves 
who are undergoing minor procedures (eg, 
dental extractions or cataract removal) where 
bleeding is easily controlled, continuation of 
VKA anticoagulation with a therapeutic INR is 
recommended. 
1 C-LD2.  For patients with a bileaflet mechanical AVR 
and no other risk factors for thromboembolism 
who are undergoing invasive procedures, 
temporary interruption of VKA 
anticoagulation, without bridging agents while 
the INR is subtherapeutic, is recommended.
2a C-LD3.  For patients with a mechanical valve prosthesis 
receiving VKA therapy who require immediate/
emergency noncardiac surgery or an invasive 
procedure, administration of 4-factor 
prothrombin complex concentrate (or its 
activated form) is reasonable. 
Figure 13. Management of embolic events and valve thrombosis.
Colors correspond to Table 2. 3D indicates 3-dimensional; 4D, 4-dimensional; AVR, aortic valve replacement; CT, computed tomography; INR, international nor -
malized ratio; MVR, mitral valve replacement; Rx, medication; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography; and VKA, vitamin K 
antagonist.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e147
CLINICAL STATEMENTS  
AND GUIDELINES2a C-LD4.  For patients with bioprosthetic heart valves 
or annuloplasty rings who are receiving 
anticoagulation for AF, it is reasonable to 
consider the need for bridging anticoagulant 
therapy around the time of invasive procedures 
on the basis of the CHA2DS2-VASc score 
weighed against the risk of bleeding. 
2a C-LD5.  For patients who are undergoing invasive 
procedures and have 1) a mechanical AVR 
and any thromboembolic risk factor, 2) an 
older-generation mechanical AVR, or 3) a 
mechanical mitral valve replacement, bridging 
anticoagulation therapy during the preoperative 
time interval when the INR is subtherapeutic is 
reasonable on an individualized basis, with the 
risks of bleeding weighed against the benefits 
of thromboembolism prevention.
Synopsis
The management of patients with prosthetic heart 
valves or repaired native valves in whom interrup-
tion of anticoagulant therapy is needed for diagnostic 
or surgical procedures should take into account the 
type and location of the valve, the type of proce-
dure, thromboembolic risk factors, the length of time 
over which oral anticoagulation will be withheld, and 
bleeding risk. “Bridging” therapy with either intra-
venous unfractionated heparin (UFH) or low-molec-
ular-weight heparin (LMWH) has evolved empirically 
to reduce thromboembolic events during temporary 
interruption of oral anticoagulation in higher-risk pa-
tients, such as those with a mechanical mitral valve 
replacement or AVR and additional risk factors for 
thromboembolism.1
Recommendation-Specific Supportive Text
1. Antithrombotic therapy should not be stopped for 
procedures in which bleeding is unlikely or would 
be inconsequential if it occurred (eg, surgery on 
the skin, dental cleaning, or simple treatment for 
dental caries). Eye surgery, particularly for cata-
racts or glaucoma, is usually associated with very 
little bleeding and thus is frequently performed 
without alteration of anticoagulation with a VKA.
2. In patients with a bileaflet mechanical AVR and 
no other risk factors, the risk of thromboembo-
lism after stopping anticoagulation with a VKA is 
small if the drug is withheld for only a few days. 
In these low-risk patients, the inconvenience 
and expense of bridging anticoagulation can be 
avoided. When it is necessary to interrupt VKA 
therapy, the agent is stopped 2 to 4 days before 
the procedure and restarted as soon as bleeding 
risk allows, typically 24 hours after surgery.2,33. In patients with mechanical valves on long-term 
VKA therapy who require emergency surgery 
or invasive procedures, anticoagulation can be 
reversed by administration of intravenous pro-
thrombin complex concentrate. It replaces the 
coagulation factors that are decreased by VKAs and 
contains all coagulant factors, including II, VII, IX, 
and X, in inactivated form. Onset of effect is within 
5 to 15 minutes, and duration of effect persists for 
12 to 24 hours. With fresh frozen plasma, onset of 
effect is longer (1–4 hours), and duration of effect 
is shorter (<6 hours), depending on the dose given. 
The effect of prothrombin complex concentrate 
can be prolonged with vitamin K, if indicated.4
4. Although the large phase III trials comparing 
NOACs with warfarin excluded patients with 
moderate to severe rheumatic MS or mechani-
cal heart valves, some did include patients with 
other VHD and bioprosthetic valve replacement 
or repair.5 Many patients who develop an indica-
tion for anticoagulation late after bioprosthetic 
heart valve replacement or native valve repair are 
treated safely with direct oral anticoagulants, as 
predicated on their CHA2DS2-VASc score and the 
predicted risks of bleeding. Considerations about 
the need for bridging therapy in these individu-
als can follow the same strategy applied to other 
subsets of patients who have AF without mod-
erate to severe rheumatic MS or a mechanical 
prosthesis.
5. When interruption of oral VKA therapy is deemed 
necessary, the agent is usually stopped 3 to 4 days 
before the procedure and is restarted postopera-
tively as soon as bleeding risk allows. Bridging 
anticoagulation with intravenous UFH or subcuta-
neous LMWH is started when the INR falls below 
the therapeutic threshold (ie, 2.0 or 2.5, depend-
ing on the clinical context), usually 36 to 48 hours 
before surgery, and is stopped 4 to 6 hours (for 
intravenous UFH) or 12 hours (for subcutaneous 
LMWH) before the procedure. There are no ran-
domized comparative-effectiveness trials evaluat-
ing a strategy of bridging versus no bridging in 
adequate numbers of patients with prosthetic 
heart valves who need temporary interruption of 
oral anticoagulant therapy, although such studies 
are ongoing. The evidence cited to support bridg-
ing therapy derives from cohort studies with poor 
or no comparator groups.1,6–14 In patient groups 
other than those with mechanical heart valves, 
increasing concerns have surfaced that bridging 
therapy exposes patients to higher bleeding risks 
without reducing the risk of thromboembolism.15 
Accordingly, decisions about bridging should be 
individualized and should account for the trade-
offs between thrombosis and bleeding.Recommendations for Bridging Therapy During Interruption of Oral 
Anticoagulation in Patients With Prosthetic Heart Valves
(Continued)
COR LOE Recommendations
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e148
CLINICAL STATEMENTS  
AND GUIDELINES11.4. Excessive Anticoagulation and 
Serious Bleeding With Prosthetic Valves
Recommendations for Management of Excessive Anticoagulation 
and Serious Bleeding in Patients With Prosthetic Valves
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 37.
COR LOE Recommendations
2a C-LD1.  For patients with mechanical valves and 
uncontrollable bleeding who require 
immediate reversal of anticoagulation, 
administration of 4-factor prothrombin 
complex (or its activated form) is reasonable. 
2a C-LD2.  For patients with mechanical valves and 
uncontrollable bleeding who have received 
4-factor prothrombin concentrate complex, 
adjunctive use of intravenous vitamin K is 
reasonable if resumption of VKA therapy is 
not anticipated for 7 days. 
2a B-NR3.  For patients with bioprosthetic valves or 
annuloplasty rings who are receiving a 
direct oral anticoagulant and who require 
immediate reversal of anticoagulation because 
of uncontrollable bleeding, treatment with 
idarucizumab (for dabigatran) or andexanet 
alfa (for anti-Xa agents) is reasonable.1–5 
2b C-LD4.  For patients with a mechanical prosthetic valve 
and supratherapeutic INR (>5.0) who are not 
actively bleeding, the benefit of individualized 
treatment with oral vitamin K, in addition to 
temporary withdrawal of the VKA, is uncertain. 
Synopsis
Excessive VKA anticoagulation greatly increases the risk 
of hemorrhage. However, a rapid decrease in INR to a 
subtherapeutic level may increase the risk of thrombo-
embolism.6 Nevertheless, for patients who require im-
mediate reversal of VKA anticoagulation because of 
severe or life-threatening bleeding or the need for an 
emergency procedure, reversal is indicated.7 Preference 
is placed on the use of rapid-acting and reliable agents, 
such as prothrombin complex concentrate or its acti-
vated form. Addition of vitamin K can be considered on 
an individual basis.8–13 Specific antidotes are available to 
reverse the effects of dabigatran (idarucizumab) and the 
oral anti-Xa (andexanet alfa) anticoagulants.
Recommendation-Specific Supportive Text
1. Four-factor prothrombin complex concentrate 
includes factors II, VII, IX, and X. Onset of effect 
is within 5 to 15 minutes, and duration of effect 
is 12 to 24 hours. It is a more specific and reliable 
reversal agent than fresh frozen plasma.8
2. Vitamin K is a cofactor for hepatic production of 
factors II, VII, IX, and X. Onset of effect depends on 
the route of administration (intravenous versus oral), 
and the dose given should be predicated on the 
presence of active bleeding, the maintenance dose 
of the VKA, the magnitude of INR elevation, and 
the desired range into which to reduce the INR.7,9–11 A 10-mg intravenous dose is recommended for life-
threatening bleeding when there is no concern for 
restarting the VKA within the next week.
3. Idarucizumab (two, 2.5-mg bolus infusions no 
more than 15 minutes apart) is indicated to reverse 
the effect of dabigatran when clinically indicated.1,5 
Andexanet alfa (bolus and 2-hour infusion, with the 
dose dependent on the timing of exposure and the 
individual agent) is used to reverse the effect of the 
oral anti-Xa agents. Experience with these agents 
is accumulating.2–4 Prothrombin complex concen-
trate (or its activated form) has also been used with 
direct oral anticoagulant–related bleeding.
4. A systematic review of the effectiveness and safety 
of administering vitamin K to patients receiving 
VKA therapy with an INR between 4.5 and 10.0 
and without bleeding indicated a nonsignificant 
increased risk of mortality and thromboembolism 
with vitamin K administration, with only moderate 
certainty of the evidence. Patients receiving vitamin 
K had a nonsignificant increase in the likelihood of 
reaching goal INR, with very low certainty of the 
evidence. The findings suggested that patients on 
VKA therapy who have an INR between 4.5 and 
10.0 and are not bleeding are not likely to benefit 
from routine vitamin K administration in addition 
to temporary VKA cessation.13
11.5. Thromboembolic Events With 
Prosthetic Valves
Recommendations for Management of Thromboembolic Events 
With Prosthetic Valves
COR LOE Recommendations
2a C-EO1.  In patients with a mechanical AVR who 
experience a stroke or systemic embolic 
event while in therapeutic range on VKA 
anticoagulation, it is reasonable to increase the 
INR goal from 2.5 (range, 2.0–3.0) to 3.0 (range, 
2.5–3.5) or to add daily low-dose aspirin (75–
100 mg), with assessment of bleeding risk. 
2a C-EO2.  In patients with a mechanical mitral valve 
replacement who experience a stroke or 
systemic embolic event while in therapeutic 
range on VKA anticoagulation, it is reasonable 
to increase the INR goal from 3.0 (range, 
2.5–3.5) to 4.0 (range, 3.5–4.0) or to add 
daily low-dose aspirin (75–100 mg), with 
assessment of bleeding risk.
2b C-EO3.  In patients with a bioprosthetic surgical or 
transcatheter aortic valve or bioprosthetic 
mitral valve who experience a stroke or 
systemic embolic event while on antiplatelet 
therapy, VKA anticoagulation, instead of 
antiplatelet therapy may be considered after 
assessment of bleeding risk.1,2
Synopsis
For patients with a mechanical valve who suffer an 
embolic event, it is important to assess the adequacy 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e149
CLINICAL STATEMENTS  
AND GUIDELINESof VKA anticoagulation, document time spent in the 
therapeutic range, exclude IE, screen for new-onset AF, 
and consider whether an underlying hypercoagulable 
state might be a contributing factor. Thromboembolism 
in bioprosthetic heart valve recipients should similarly 
raise suspicion of IE or new-onset AF in the right clini-
cal setting. Leaflet thrombosis occurs more frequently 
with bioprosthetic transcatheter aortic valves than with 
bioprosthetic surgical aortic valves.1–4 Intensification of 
antithrombotic therapy should always account for indi-
vidual patient bleeding risk (Figure 13).
Recommendation-Specific Supportive Text
1. There are no comparative-effectiveness trials from 
which to assess the relative utility of higher-inten-
sity VKA therapy versus standard VKA therapy 
plus low-dose aspirin in mechanical valve recipi-
ents who have experienced stroke or systemic 
embolism while in target INR range. Excluding 
the common clinical occurrence of extended time 
in a subtherapeutic INR range is the first priority. 
Assessment of medication adherence, intercur -
rent illness, new or recently adjusted medications, 
dietary changes, and alcohol intake is critical. 
Whether to intensify VKA therapy or add low-
dose aspirin is a patient-specific, shared decision-
making proposition that must weigh several 
factors, including bleeding risk.
2. The approach to management of the patient 
with a systemic embolic event and a mechani-
cal mitral prosthesis includes review of INR levels 
to ensure the patient is in the target INR range 
most of the time. INR levels may have been sub-
therapeutic because of suboptimal medication 
adherence, intercurrent illness, new or recently 
adjusted medications, dietary changes, or alcohol 
intake. Whether to intensify VKA therapy or add 
low-dose aspirin is a patient-specific, shared deci-
sion-making proposition that must weigh several 
factors, including bleeding risk.
3. In those patients with a bioprosthetic valve who 
have a stroke or embolic event, further imaging 
with TEE or 3D CT scanning may show leaflet 
thrombosis, which should respond to anticoagu-
lation with either a VKA or a NOAC.1,2 The effec-
tiveness of anticoagulation in aortic and mitral 
bioprosthetic valve recipients in whom leaflet 
thrombosis cannot be established as the cause 
of thromboembolism is uncertain, and patients 
should undergo a full neurological evaluation to 
rule out other causes of the neurological event. 
Shared decision-making that accounts for bleed-
ing risk is a central feature of management.11.6. Acute Mechanical Valve Thrombosis
11.6.1. Diagnosis of Acute Mechanical Valve 
Thrombosis
Recommendation for Diagnosis of Acute Mechanical Valve 
Thrombosis
Referenced studies that support the recommendation are 
summarized in Online Data Supplement 38.
COR LOE Recommendation
1 B-NR1.  In patients with suspected mechanical 
prosthetic valve thrombosis, urgent 
evaluation with TTE, TEE, fluoroscopy, and/
or multidetector CT imaging is indicated to 
assess valve function, leaflet motion, and the 
presence and extent of thrombus.1–7
Synopsis
Mechanical valve thrombosis is typically a subacute to 
acute event resulting in rapid valve dysfunction because 
of abnormal or absent motion of the valve leaflets, which 
often is associated with inadequate VKA anticoagulation. 
However, recurrent valve thrombosis can be associated 
with pannus ingrowth in the chronic setting. Mechanical 
valve thrombosis can present with rapid onset of symp-
toms or acute pulmonary edema. Physical examination 
may demonstrate a stenotic murmur and muffled closing 
clicks, and further urgent diagnostic evaluation is required. 
The annual rate of prosthetic valve thrombosis with me-
chanical valves ranges from 0.1% to 5.7%. Higher rates 
of mechanical valve thrombosis are seen for some specific 
valve types, within the first 3 months after valve implanta-
tion and, for mechanical valves implanted in the mitral or 
tricuspid position compared with the aortic position.8
Recommendation-Specific Supportive Text
1. Mechanical prosthetic valve thrombosis is diag-
nosed by an abnormally elevated velocity or gra-
dient across the prosthesis, with either limited 
leaflet motion or attached mobile densities con-
sistent with thrombus, or both. Prosthetic valve 
obstruction is usually defined as a mean trans-
valvular gradient increase >50% (or an increase 
>10 mm Hg across an aortic prosthesis) compared 
with baseline, after exclusion of other causes, 
such as a high-output state. When mechani-
cal valve thrombosis is suspected, imaging and 
Doppler data from TTE provide information on 
valve function, estimated pulmonary pressures, 
and LV size and systolic function.9 Leaflet motion 
should be visualized with CT or TEE (particularly 
for a mitral prosthesis) or fluoroscopy (for an aor -
tic prosthesis).6,7,10–12 Prolonged periods of obser -
vation under fluoroscopy or TEE may be required 
to diagnose intermittent obstruction. The pres-
ence and quantification of thrombus and pannus 
should be evaluated by either TEE or CT.6,7,10–12
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e150
CLINICAL STATEMENTS  
AND GUIDELINES11.6.2. Intervention
Recommendation for Intervention for Mechanical Prosthetic Valve 
Thrombosis
Referenced studies that support the recommendation are 
summarized in Online Data Supplement 38.
COR LOE Recommendation
1 B-NR1.  For patients with a thrombosed left-sided 
mechanical prosthetic heart valve who present 
with symptoms of valve obstruction, urgent 
initial treatment with either slow-infusion, low-
dose fibrinolytic therapy or emergency surgery 
is recommended.1–12 
Synopsis
Patients presenting with a thrombosed mechanical 
valve require urgent therapy. The 2 options of low-
dose, continuous-infusion thrombolytic therapy or 
emergency surgery are both effective, with the decision 
to proceed with either one based on multiple clinical 
factors and local experience and expertise.
Recommendation-Specific Supportive Text
1. The decision between surgery and systemic 
fibrinolysis for symptomatic left-sided mechani-
cal valve thrombosis should be individualized 
(Table 23) after review by the heart valve team, 
while engaging the patient in a process of shared 
decision-making and accounting for local experi-
ence and expertise. The overall 30-day mortality 
rate with surgery is 10% to 15%, with a lower 
mortality rate of <5% in patients with NYHA 
class I or II symptoms.2,3,7 Recent studies using an 
echocardiogram-guided, slow-infusion, low-dose 
fibrinolytic protocol have shown hemodynamic 
success rates >90%, with embolic event rates 
<2% and major bleeding rates <2%.13 Systemic 
fibrinolysis is therefore an acceptable alternative 
to reoperation in patients at high or prohibitive 
surgical risk and in patients who have a small 
thrombus burden, mild HF symptoms (NYHA class 
I or II), and low bleeding risk. Absence of surgi-
cal expertise should be considered in the clinical 
decision-making process as a factor that favors 
thrombolytics, whereas recurrent valve thrombo-
sis favors a surgical approach (Table 23).
11.7. Bioprosthetic Valve Thrombosis
11.7.1. Diagnosis of Bioprosthetic Valve 
Thrombosis
Recommendation for Diagnosis of Bioprosthetic Valve Thrombosis
COR LOE Recommendation
2a C-LD1.  In patients with suspected bioprosthetic valve 
thrombosis, 3D TEE or 4D CT imaging can be 
useful to rule out leaflet thrombosis.1–5 Synopsis
Bioprosthetic valve thrombosis is most common in the 
first 3 months after implantation but also has been de-
scribed in patients years (typically 1 or 2) after valve im-
plantation, with the longest interval being 6.5 years.6 
Bioprosthetic valves are less thrombogenic than their 
mechanical counterparts. However, the diagnosis of 
subclinical bioprosthetic valve thrombosis has increased 
with use of CT imaging and as a function of the in-
creased numbers of implanted bioprosthetic valves, in-
cluding TAVI.1–5
Recommendation-Specific Supportive Text
1. Bioprosthetic valve thrombosis appears to be 
more common with transcatheter than with 
surgical bioprosthetic valves. Leaflet thrombosis 
often is suspected on the basis of an increased 
transvalvular velocity on routine echocardio-
graphic monitoring and can be confirmed by 
the finding of hypoattenuation of the valve 
leaflets on CMR imaging. When there is clinical 
evidence of stenosis, 3D TEE or 4D CT imaging 
may be useful to detect a layer of valve throm-
bus, which may respond to treatment with oral 
anticoagulation.
11.7.2. Medical Therapy
Recommendation for Medical Therapy
Referenced studies that support the recommendation are 
summarized in Online Data Supplement 39.
COR LOE Recommendation
2a B-NR1.  In patients with suspected or confirmed 
bioprosthetic valve thrombosis who are 
hemodynamically stable and have no 
contraindications to anticoagulation, initial 
treatment with a VKA is reasonable.1–6 
Synopsis
Patients with an obstructed bioprosthesis may have a 
thin layer of thrombus causing reduced leaflet motion. 
VKA treatment may result in resolution of the thrombus 
and improvement in valve function.
Recommendation-Specific Supportive Text
1. Multiple small nonrandomized studies support 
the use of VKAs to treat patients with clinical and 
subclinical bioprosthetic valve thrombosis after 
both SAVR and TAVI.1,3,4,6,7 VKA anticoagulation 
can result in a significant reduction of transvalvu-
lar gradient, improved leaflet motion, and clinical 
improvement.4,6,8
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e151
CLINICAL STATEMENTS  
AND GUIDELINES11.8. Prosthetic Valve Stenosis
11.8.1. Diagnosis of Prosthetic Valve Stenosis
Recommendations for Diagnosis of Prosthetic Valve Stenosis
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 40.
COR LOE Recommendations
1 B-NR1.  In patients with suspected mechanical or 
bioprosthetic valve stenosis, TTE and TEE are 
recommended to diagnosis the cause and 
severity of valve obstruction, assess ventricular 
function, and estimate pulmonary artery 
systolic pressure.1,2
1 C-EO2.  In patients with mechanical valve stenosis, 
fluoroscopy or cine-CT is recommended 
to assess motion of the mechanical valve 
leaflets. 
2a C-LD3.  In patients with bioprosthetic valve stenosis, 
3D TEE or 4D CT imaging can be useful to rule 
out leaflet thrombosis.3–7 
Synopsis
Prosthetic valve stenosis can occur with both mechani-
cal and bioprosthetic valves. Echocardiographic defi-
nitions of stenosis severity have been provided by the 
American Society of Echocardiography.1 Obstruction 
of a mechanical valve may be caused by thrombus for -
mation that leads to abnormal leaflet mobility, pannus 
ingrowth, or a combination of the two.8 Bioprosthetic 
valve stenosis may be caused by structural valve dete-
rioration, with leaflet degeneration by thickening, cal-
cification, or tear as the end stage of a slowly progres-
sive process resulting in abnormal leaflet motion, or it 
may be attributable to other structural causes, includ-
ing stent creep. Bioprosthetic valve stenosis may also be attributable to nonstructural causes, such as endocardi-
tis, leaflet thrombus, or pannus. The progressive stages 
are defined by the Valve Academic Research Consor -
tium criteria.9
Recommendation-Specific Supportive Text
1. TTE and TEE assessment can appropriately detect 
and quantify prosthetic valve stenosis.1 TTE 
within 3 months after valve implantation is useful 
to provide baseline data on valve hemodynamics 
and ventricular function. In some patients, the 
orifice area of the implanted prosthesis may be 
inadequate to meet the cardiac output demands 
of the patient, even when the prosthetic valve 
itself is functioning normally. This circumstance, 
termed patient–prosthesis mismatch, is associ-
ated with a high transvalvular gradient, per -
sistent LV hypertrophy, and an increased rate 
of cardiac events after valve replacement.10,11 
Diagnosis in the setting of bileaflet mechanical 
valves is complicated by nonlaminar patterns 
of blood flow, for which significant pressure 
recovery may be present; thus, a high velocity in 
the central narrow slit-like orifice may not cor -
relate with prosthetic valve stenosis or patient–
prosthesis mismatch. Prosthetic valve stenosis is 
distinguished from patient–prosthesis mismatch 
by comparison with the early postoperative base-
line study and by visualization of the appearance 
and motion of the valve leaflets. Prosthetic valve 
stenosis is characterized by a clinical course of 
progressive increase in transvalvular velocity and 
pressure gradient in conjunction with abnormal 
thickened/calcified leaflets (for bioprosthetic 
valves) or evidence of pannus formation (with 
mechanical valves).
2. The motion of the leaflets of a mechanical valve 
is best evaluated radiographically with fluoros-
copy or cine-CT imaging because strong reflec-
tions from the mechanical valve obscure motion 
on echocardiographic imaging in most patients, 
particularly as assessed on images from the trans-
thoracic approach. With fluoroscopic imaging, 
the angle of imaging must be adjusted to dem-
onstrate leaflet motion from a side view, permit-
ting measurement of the angles of opening and 
closure that can be compared with expected 
values for that valve type. Cine-CT images are 
obtained at a high frame rate focused on the 
prosthetic valve in a 3D acquisition. Compared 
with fluoroscopy, cine-CT 3D images are less 
operator dependent for measuring opening 
and closing angles. In addition, cine-CT allows 
detection of pannus or thrombus on or adjacent Table 23. Systemic Fibrinolysis Versus Surgery for Prosthetic Valve 
Thrombosis
Favor Surgery Favor Fibrinolysis
Readily available surgical expertise No surgical expertise available
Low surgical risk High surgical risk
Contraindication to fibrinolysis No contraindication to fibrinolysis
Recurrent valve thrombosis First-time episode of valve 
thrombosis
NYHA class IV NYHA class I, II, or III
Large clot (>0.8 cm2) Small clot (≤0.8 cm2)
LA thrombus No LA thrombus
Concomitant CAD in need of 
revascularizationNo or mild CAD
Other valve disease No other valve disease
Possible pannus Thrombus visualized
Patient choice Patient choice
CAD indicates coronary artery disease; and NYHA, New York Heart 
Association.
Adapted from several references.2,5,7,13,14
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e152
CLINICAL STATEMENTS  
AND GUIDELINESto the valve, which is not possible with fluoros-
copy. When excessive gradients are present with 
normal leaflet motion and no thrombus, either 
patient–prosthesis mismatch or pannus forma-
tion is present (or both).
3. Stenosis of a bioprosthesis may occur because of 
progressive structural valve degeneration or pan-
nus formation. However, stenosis can also occur 
because of a thin layer of thrombus on the valve 
cusps, which is reversible with oral anticoagula-
tion therapy. Bioprosthetic valves are less throm-
bogenic than their mechanical counterparts. 
However, the diagnosis of subclinical bioprosthetic 
valve thrombosis has increased with the use of CT 
imaging and as a function of the increased num-
bers of implanted bioprosthetic valves, including 
TAVI.3–7 When there is clinical evidence of biopros-
thetic valve stenosis, 3D TEE or 4D CT imaging 
may be useful to detect a layer of valve thrombus 
as the cause of the obstruction.
11.8.2. Intervention for Prosthetic Valve Stenosis
Recommendations for Intervention for Prosthetic Valve Stenosis
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 40.
COR LOE Recommendations
1 B-NR1.  In patients with symptomatic severe stenosis of 
a bioprosthetic or mechanical prosthetic valve, 
repeat surgical intervention is indicated unless 
surgical risk is high or prohibitive.1–3
2a B-NR2.  For severely symptomatic patients with 
bioprosthetic aortic valve stenosis and high or 
prohibitive surgical risk, a transcatheter ViV 
procedure is reasonable when performed at a 
Comprehensive Valve Center.4,5
2a B-NR3.  For patients with significant bioprosthetic 
valve stenosis attributable to suspected 
or documented valve thrombosis, oral 
anticoagulation with a VKA is reasonable.6–13 
Synopsis
Cumulative survival rates are higher with reoperative AVR 
than with transcatheter ViV treatment for prosthetic valve 
stenosis, and a surgical approach is associated with a re-
duced incidence of patient–prosthesis mismatch, reduced 
incidence of paravalvular leak, and lower aortic valve gra-
dients.14 The VIVID (Valve-In-Valve International Data) reg-
istry examined outcomes with ViV treatment of 459 pa-
tients, of whom 40% had isolated stenosis and 30% had 
mixed lesions.4 Within 1 month after the ViV procedure, 
7.6% of patients died and 1.7% had a major stroke. Of 
the survivors, 93% experienced good functional status 
(NYHA class I or II), with an overall 1-year survival rate of 
83.2%.4 Some systematic reviews comparing outcomes 
of transcatheter ViV with those of repeat SAVR suggest 
that hemodynamic outcomes are similar, but stroke and 
bleeding risks are lower with ViV.15 There is a subset of patients with bioprosthetic valve stenosis attributable to 
thrombus on the leaflets who may respond to oral anti-
coagulation with a VKA (Figure 14).6–13
Recommendation-Specific Supportive Text
1. Reoperative surgery for prosthetic valve stenosis is 
associated with acceptable mortality and morbid-
ity rates in the current era, but the risks are typi-
cally higher than those estimated at the time of 
initial surgery because of older patient age, clini-
cal status at the time of intervention, and reop-
erative status.2,16 The decision to proceed with 
surgical versus transcatheter intervention is based 
on available expertise, individual patient and valve 
characteristics, and shared decision-making.
2. Catheter-based therapy with transcatheter ViV has 
emerged as an acceptable alternative to reopera-
tive surgery for the treatment of high– and prohib-
itive–surgical risk patients with bioprosthetic AS.4,5 
Although coronary artery obstruction is more com-
mon with aortic ViV procedures than with TAVI for 
native AS, rates of paravalvular leak and permanent 
pacemaker implantation are lower with aortic ViV 
procedures than with TAVI for native AS. Annulus 
rupture has not been reported. Transcatheter ViV 
also has been successfully performed for failed surgi-
cal bioprostheses in the mitral, pulmonic, and tricus-
pid positions, although LV outflow obstruction may 
occur after mitral ViV implantation.
3. A subset of patients presents with stenosis of a 
bioprosthetic valve attributable to leaflet throm-
bosis that results in decreased mobility of the leaf-
lets. Leaflet thrombosis can occur from 1 month 
to years after implantation. If the patient is stable 
and has no contraindication to long-term anti-
coagulation, a trial of oral anticoagulation with 
VKA may result in resolution of the thrombus 
and improvement in hemodynamics.6–13 However, 
these patients are at increased risk of recurrent 
thrombosis (if the anticoagulation is stopped) 
and early structural deterioration, and thus they 
require close follow-up.17
11.9. Prosthetic Valve Regurgitation
Regurgitation in a mechanical prosthetic valve may be 
transvalvular, caused by impaired motion of the valve 
disk secondary to pannus, thrombus, or vegetation in-
terfering with complete closure of the valve occluders, 
or paravalvular, caused by suture line disruption related 
to technical error at implantation, suture failure, annu-
lar disruption, or endocarditis. Patients with severe mi-
tral annular calcification are particularly vulnerable to 
developing late paravalvular leak. Regurgitation in bio-
prosthetic valves may be paravalvular but more often is 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e153
CLINICAL STATEMENTS  
AND GUIDELINEStransvalvular, caused by leaflet immobility secondary to 
calcification or leaflet perforation or flail associated with 
areas of focal calcification.1 Echocardiographic defini-
tions of prosthetic valve regurgitation severity have been 
published by the American Society of Echocardiography.2
11.9.1. Diagnosis of Prosthetic Valve 
Regurgitation
Recommendations for Diagnosis of Prosthetic Valve Regurgitation
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 41.
COR LOE Recommendations
1 B-NR1.  In patients with suspected mechanical or 
bioprosthetic valve regurgitation, TTE and TEE 
are recommended to determine the cause and 
severity of the leak, assess ventricular function, 
and estimate pulmonary artery systolic pressure.1–4
1 C-EO2.  In patients undergoing a transcatheter 
procedure for paravalvular prosthetic 
regurgitation, 3D TEE is recommended for 
intraprocedural guidance.4–7Synopsis
The clinical presentation of prosthetic valve regur -
gitation varies depending on its severity, hemody-
namic effects, and etiology. In asymptomatic pa-
tients, prosthetic valve regurgitation may be found 
incidentally on routine clinical or imaging follow-up. 
A change in auscultatory findings (eg, change in 
prosthetic valve sounds or a new murmur) should 
prompt suspicion of prosthetic valve dysfunction. 
Symptomatic patients with prosthetic valve regurgi-
tation present with unexplained or new-onset HF or 
significant hemolysis with or without anemia. TTE is 
inadequate for evaluation of prosthetic mitral valves; 
TEE is needed when prosthetic MR is a concern. A 
critical step in evaluation of the patient with pros-
thetic valve regurgitation is to distinguish transval-
vular from paravalvular leak, which also requires TEE 
in addition to TTE.
Figure 14. Management of prosthetic valve stenosis and regurgitation.
Colors correspond to Table 2. 3D indicates 3-dimensional; 4D, 4-dimensional; CT, computed tomography; CVC, Comprehensive Valve Center; HF, heart failure; 
TEE, transesophageal echocardiography; TTE, transthoracic echocardiography/echocardiogram; and ViV, valve-in-valve.
*See Figure 13 if valve thrombosis is suspected.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e154
CLINICAL STATEMENTS  
AND GUIDELINESRecommendation-Specific Supportive Text
1. Echocardiography is the primary imaging modality to 
assess the location and quantify the severity of pros-
thetic valve regurgitation, often requiring both TTE 
and TEE approaches.1,3 Although TTE provides supe-
rior assessment of transvalvular gradients, chamber 
sizes, and function, TEE is better suited to identify the 
cause and location of regurgitation and is essential for 
prosthetic mitral valve because of acoustic shadow-
ing on TTE. Even with prosthetic aortic valves, acous-
tic shadowing may affect detection of a paravalvular 
leak by either TTE or TEE, with TTE being suboptimal 
to assess posterior paravalvular leak and TEE subop-
timal to assess anterior defects.3 The Valve Academic 
Research Consortium (VARC) has suggested an 
approach for assessment of paravalvular leak severity 
and constructed a 5-class grading scheme.7
2. 3D echocardiography plays a significant role in 
determining the precise location and size of the 
paravalvular leak in patients undergoing interven-
tion. For a successful transcatheter paravalvular 
leak closure, adequate paravalvular leak assess-
ment includes 1) precise location of the defect(s), 
2) precise dimensions, 3) orientation of the defect 
in relation to the sewing ring and prosthetic valve 
occluders or leaflets, and 4) location and orienta-
tion of the subvalvular structures. Real-time 3D TEE 
allows optimal visualization of the defects and direct 
guidance for catheter movement and positioning of 
the implanted device(s) during the transcatheter 
closure procedure.4,5 3D TEE also allows assessment 
of residual regurgitation after device placement. 
Limitations of 3D TEE include artifacts of ultrasound 
imaging (eg, dropout, acoustic shadowing, rever -
beration artifacts) and reduced temporal and spatial 
resolution.8 Transcatheter closure using intracardiac 
echocardiography guidance is possible and allevi-
ates the need for conscious sedation or anesthesia 
but allows only 2D and color Doppler imaging.9
11.9.2. Medical Therapy
Medical therapy for prosthetic valve regurgitation is ap-
propriate in asymptomatic patients or when the cause of 
regurgitation is valve thrombosis (see Sections 11.6 and 
11.8) or prosthetic valve endocarditis (see Section 12.3), 
although further intervention may ultimately be needed 
in many of these patients. Some patients tolerate asymp-
tomatic prosthetic valve regurgitation for many years, sim-
ilar to patients with native valve regurgitation. However, 
there may be patients who develop rapid progression of 
the severity of bioprosthetic valve regurgitation because 
of leaflet degeneration. In patients with hemolytic ane-
mia attributable to paravalvular regurgitation, medical 
management with folic acid and iron supplementation or 
periodic transfusion may be possible when the anemia is not severe, with intervention reserved for patients with 
symptomatic intractable anemia (see Section 11.8.3).
11.9.3. Intervention
Recommendations for Intervention
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 41.
COR LOE Recommendations
1 B-NR1.  In patients with intractable hemolysis or HF 
attributable to prosthetic transvalvular or 
paravalvular leak, surgery is recommended 
unless surgical risk is high or prohibitive.1–4
2a B-NR2.  In asymptomatic patients with severe 
prosthetic regurgitation and low operative risk, 
surgery is reasonable.1–4
2a B-NR3.  In patients with prosthetic paravalvular 
regurgitation with the following: 1) either 
intractable hemolysis or NYHA class III 
or IV symptoms and 2) who are at high 
or prohibitive surgical risk and 3) have 
anatomic features suitable for catheter-based 
therapy, percutaneous repair of paravalvular 
leak is reasonable when performed at a 
Comprehensive Valve Center.5–9
2a B-NR4.  For patients with severe HF symptoms caused 
by bioprosthetic valve regurgitation who are at 
high to prohibitive surgical risk, a transcatheter 
ViV procedure is reasonable when performed 
at a Comprehensive Valve Center.10–12
Synopsis
Prosthetic valve degeneration can result in regurgitation 
attributable to leaflet calcification and noncoaptation or 
leaflet degeneration with a tear or perforation. Acute 
or chronic severe regurgitation may result in HF symp-
toms and signs. Paravalvular leak may result in hemoly-
sis with symptoms attributable to anemia and HF. New 
paravalvular leak late after valve implantation raises the 
concern for IE, which should be excluded because the 
presence of infection would require antibiotic treat-
ment before surgical therapy and would be a contrain-
dication to transcatheter therapy. Symptomatic patients 
with paravalvular leak around a prosthetic valve are best 
managed by surgery, with percutaneous closure of the 
leak if the patient is at high or prohibitive surgical risk. 
Symptomatic patients with bioprosthetic valve regurgi-
tation are best managed by surgery, with a transcath-
eter ViV procedure if the patient is at high or prohibitive 
risk. Because of rapid progression of bioprosthetic re-
gurgitation, replacement of a leaking bioprosthesis may 
be considered even in the asymptomatic patient.
Recommendation-Specific Supportive Text
1. Surgery is a viable therapeutic option in many 
patients with symptomatic paravalvular leak and 
is associated with reasonable outcomes.1 The 
risks associated with surgical intervention depend 
on the procedure required, be it suture repair or 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e155
CLINICAL STATEMENTS  
AND GUIDELINESrepeat AVR. Although surgical reoperation is asso-
ciated with acceptable mortality and morbidity 
rates in the current era, it still carries a higher risk 
than the initial surgery. Kaneko and colleagues 
examined a cohort of 3380 patients from the STS 
database (2011–2013) who underwent elective 
isolated reoperative AVR, and they demonstrated 
a higher (but acceptable) operative mortality 
rate than that seen with initial AVR (4.6% versus 
2.2%; P<0.0001) and relatively low complication 
rates.13 This was true even among octogenarians 
who underwent reoperative AVR.3 In a cohort of 
136 consecutive patients who underwent surgical 
correction for a non–endocarditis-related aortic 
or mitral paravalvular leak (1986–2001), surgical 
correction of the paravalvular leak was associ-
ated with acceptable operative mortality (6.6%) 
and morbidity rates.1 More recently, Shah and 
colleagues reported an operative mortality rate 
of 3% among 495 patients undergoing surgery 
for paravalvular leak,14 with higher risk associated 
with mitral than with aortic valve procedures (odds 
ratio: 1.66; 95% CI: 1.25–2.20). These findings 
are consistent with the findings of Bouhout and 
colleagues,15 who reported operative mortality 
rates of 8% among mitral valve, 3% among aor -
tic valve, and 14% among double-valve patients 
in a total cohort of 190 patients undergoing sur -
gery indicated for paravalvular leak. Estimates of 
operative risk for individual patients can be calcu-
lated by using the STS risk calculator (http://risk-
calc.sts.org/stswebriskcalc/).16
2. Prosthetic valve deterioration can result in regurgi-
tation attributable to leaflet calcification and non-
coaptation or leaflet degeneration with a tear or 
perforation. Even in asymptomatic patients with 
severe prosthetic regurgitation, valve replacement 
is reasonable because of the risk of sudden clini-
cal deterioration if further leaflet tearing occurs. 
IE should be excluded or concurrently treated. If a 
“watchful waiting” approach is taken in asymp-
tomatic patients with severe prosthetic valve 
regurgitation, referral to a Comprehensive Heart 
Valve Center is prudent.
3. In some patients, operative risk is high, or surgery 
is not feasible. Nonrandomized studies have dem-
onstrated clinical success with percutaneous para-
valvular leak closure performed by expert operators 
under the supervision of an MDT at a Comprehensive 
Valve Center. Procedural success rates for percuta-
neous paravalvular leak closure, typically defined 
by no more than mild residual regurgitation and 
the absence of death and major complications, are 
highly variable. In a large single-center cohort, per -
cutaneous repair of 141 paravalvular defects was 
attempted in 115 patients, with an achieved overall success rate of 77% and a 30-day complication rate 
of 8.7%.6 In another study of 126 patients who 
underwent percutaneous paravalvular leak repair, 
Sorajja and colleagues reported a 3-year survival 
rate of 64.3%.5 The degree of residual regurgita-
tion affects symptom improvement and survival. In 
a cohort of 231 consecutive patients (2006–2017) 
who underwent percutaneous mitral paravalvu-
lar leak closure, the reduction of paravalvular leak 
to mild or less was achieved in 70% of patients.7,8 
Those patients with mild or less residual paravalvular 
leak had a survival rate at 3 years of 61%, compared 
with a rate of 47% in patients with greater degrees 
of residual paravalvular leak (P =0.002).7,8 Notably, 
treatment of HF symptoms with paravalvular leak 
closure is more successful than is treatment of 
hemolysis. IE should be excluded before attempted 
paravalvular leak repair.
4. The Valve-In-Valve International Data registry 
examined outcomes of transcatheter ViV proce-
dures in 459 patients, of whom about 30% had iso-
lated regurgitation and 30% had mixed lesions.10 
Within 1 month after the ViV procedure, 7.6% 
of patients died, 1.7% had a major stroke, and 
93% of survivors experienced good functional sta-
tus. The 1-year survival rate was 83.2%.10 Several 
systematic reviews have compared outcomes of 
transcatheter ViV with those of reoperative SAVR. 
In 1 report, ViV had similar hemodynamic out-
comes to repeat surgery and lower stroke risk and 
bleeding risk than repeat surgery.11 A meta-anal-
ysis of 498 patients demonstrated no significant 
differences in early and mid-term all-cause mor -
tality rates with ViV or reoperation.17 In another 
meta-analysis of 342 patients, reoperative AVR 
was compared with transcatheter ViV for failed 
degenerated aortic bioprosthesis and the group 
undergoing reoperative AVR had a lower all cause 
mortality with superior hemodynamic outcomes.18 
Thus, although transcatheter ViV appears to be 
a safe and feasible alternative to repeat SAVR in 
patients who are inoperable or at high surgical 
risk, repeat SAVR should remain the standard of 
care, particularly in low-risk patients.18
12. INFECTIVE ENDOCARDITIS
12.1. Classification of Endocarditis
Endocarditis is classified according to whether a native 
or prosthetic valve is affected and by timing of infec-
tion after valve intervention. Prevention of endocardi-
tis is important in all patients with valve disease, both 
before and after valve replacement or intervention (see 
Section 2.4.2). The risk factors involved with IE and the 
predominating causative organisms have evolved over 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e156
CLINICAL STATEMENTS  
AND GUIDELINESRecommendations for Diagnosis of IE (Continued)
COR LOE Recommendationstime, with a recent increased incidence of drug use–as-
sociated IE. IE is fatal unless treated appropriately, and 
there are no asymptomatic patients with endocarditis. 
The in-hospital mortality rate for IE is 15% to 20%, 
with a 1-year mortality rate approaching 40%. Nonin-
fective types of endocarditis are not addressed in these 
guidelines.
12.2. Diagnosis of IE
Recommendations for Diagnosis of IE
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 42.
COR LOE Recommendations
1 B-NR1.  In patients at risk of IE (eg, those with 
congenital or acquired VHD, previous IE, 
prosthetic heart valves, certain congenital 
or heritable heart malformations, 
immunodeficiency states, or injection drug 
use) who have unexplained fever blood, 
culture samples should be obtained.1 
1 B-NR2.  In patients with the recent onset of left-sided 
valve regurgitation, at least 2 sets of blood 
culture samples should be obtained.1–12
1 B-NR3.  In patients with suspected IE, the Modified 
Duke Criteria should be used for diagnosis 
(Tables 24 and 25).2–10 
1 B-NR4.  Patients with IE should be evaluated 
and managed with consultation with a 
multispecialty Heart Valve Team, which 
includes an infectious disease specialist, 
cardiologist, and cardiac surgeon; a cardiac 
anesthesiologist for surgically managed 
patients11; and a neurologist for patients with 
neurological events.11–13 
1 B-NR5.  In patients with suspected IE, TTE is 
recommended to identify vegetations, 
characterize the hemodynamic severity of 
valvular lesions, assess ventricular function 
and pulmonary pressures, and detect 
complications.14–23 
1 B-NR6.  In all patients with known or suspected 
IE and nondiagnostic TTE results, when 
complications have developed or are clinically 
suspected or when intracardiac device leads 
are present, TEE is recommended.21,23–40 
1 B-NR7.  In patients with IE who have a change in 
clinical signs or symptoms (eg, new murmur, 
embolism, persistent fever, HF, abscess, 
or atrioventricular heart block) and in 
patients at high risk of complications (eg, 
extensive infected tissue, large vegetation 
on initial echocardiogram, or staphylococcal, 
enterococcal, or fungal infections), 
TTE and/or TEE are recommended for 
reevaluation.24,31,41–46 
1 B-NR8.  In patients undergoing valve surgery for IE, 
intraoperative TEE is recommended.47–50 
1 B-NR9.  In patients being considered for an early 
change to oral antibiotic therapy for the 
treatment of stable IE, a baseline TEE before 
switching to oral therapy and a repeat TEE 
1 to 3 days before completion of the oral 
antibiotic regimen should be performed.51 2a B-NR10.  In patients with Staphylococcus aureus 
bacteremia without a known source, TEE is 
reasonable to diagnose possible IE.11,36,52–56 
2a B-NR11.  In patients with a prosthetic valve in the 
presence of persistent fever without 
bacteremia or a new murmur, a TEE is 
reasonable to aid in the diagnosis of IE.57–60 
2a B-NR12.  In patients in whom the anatomy cannot be 
clearly delineated by echocardiography in the 
setting of suspected paravalvular infections, 
CT imaging is reasonable.37,61–68
2a B-NR13.  In patients classified by Modified 
Duke Criteria as having “possible IE,” 
18F-fluorodeoxyglucose PET/CT is reasonable 
as adjunct diagnostic imaging.69–71 
2b B-NR14.  In patients with nosocomial S. aureus 
bacteremia with a known portal of entry 
from an extracardiac source, TEE might 
be considered to detect concomitant 
staphylococcal IE.22,53,54,72–74 
Synopsis
In patients with suspected endocarditis, the Modified 
Duke Criteria (Tables 24 and 25) are the current stan-
dard for diagnosis and incorporate clinical, imaging, 
and bacteriological criteria. These criteria have been 
well validated by comparison with surgical or autopsy 
findings and in the clinical outcomes of numerous 
studies involving a wide spectrum of patients, includ-
ing children, the elderly, prosthetic valve recipients, 
injection drug users, and non–drug users, as well as 
patients in both primary- and tertiary-care settings. 
For patients with VHD and known or suspected IE, ob-
tain blood culture results before initiation of antibiotic 
therapy. For diagnosis and management of patients 
with IE, additional members of the Heart Valve MDT 
include infectious disease experts, who can provide 
advanced approaches to microbiological diagnosis. 
Cardiac imaging with TTE, TEE, and now CT and CT/
PET imaging is critical for diagnosis of IE.4,6–10
Recommendation-Specific Supportive Text
1. Blood culture results are positive in 90% of patients 
with IE provided that ≥2 blood culture samples 
are obtained at different times, ideally >6 hours 
apart if clinical status allows, at peripheral sites 
before initiation of antimicrobial therapy. More 
important than the time interval of the collection 
of culture samples is observing strict aseptic tech-
nique, avoiding sampling from intravascular lines, 
and ensuring an adequate volume of blood for 
the culture sample. Routine incubation of blood 
culture samples for >7 days is no longer necessary 
in the era of continuous-monitoring blood culture 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e157
CLINICAL STATEMENTS  
AND GUIDELINESsystems and non–culture-based technology. In the 
10% of patients with culture-negative endocar -
ditis, serological testing or advanced laboratory 
diagnostics (eg, polymerase chain reaction) may 
be helpful to identify the etiologic agent.1,42,75–78
2. The recent onset of new or increased left-sided 
valve regurgitation, detected by the presence of 
a new or louder murmur followed by TTE confir -
mation, may be attributable to endocarditis, so 
it is prudent to obtain blood culture samples to 
exclude this diagnosis.
3. The Modified Duke Criteria (Tables 24 and 25) 
have been well validated by comparison with 
surgical or autopsy findings and in the clinical 
outcomes of numerous studies involving a wide 
spectrum of patients, including children, the 
elderly, prosthetic valve recipients, injection drug 
users, and non–drug users, as well as patients in 
both primary- and tertiary-care settings. About 
three-fourths of patients with IE are diagnosed 
within 30 days of the onset of infection, so clas-
sic clinical features of IE, such as embolic or 
vasculitic skin lesions, renal disease caused by 
immune complex deposition, and immunologic 
abnormalities, are often absent. In these cases, 
maintaining a high level of clinical suspicion with 
regard to the possibility of IE in patients who are 
susceptible is paramount.4,6–104. The diagnosis of IE can still be difficult and is fre-
quently delayed, which may cause progressive 
and potentially irreparable structural damage 
to the heart and other organ systems second-
ary to vascular–embolic and immunologically 
mediated events. Additionally, stroke (16.9%), 
embolization other than stroke (22.6%), HF 
(32.3%), intracardiac abscess (14.4%), and 
the need for surgical therapy (48.2%) remain 
common. Patients with suspected IE are most 
optimally managed in an environment that 
coordinates the management of specialists who 
are well attuned to the various organ systems, 
pathological processes, and potential treatment Table 24. Diagnosis of IE According to the Proposed Modified Duke 
Criteria
Definite IE
 Pathological criteria
   Microorganisms demonstrated by culture or histological examination 
of a vegetation, a vegetation that has embolized, or an intracardiac 
abscess specimen; or
   Pathological lesions: Vegetation or intracardiac abscess confirmed by 
histological examination showing active endocarditis
 Clinical criteria
  2 major criteria; or
  1 major criterion and 3 minor criteria; or
  5 minor criteria
Possible IE
 1 major criterion and 1 minor criterion; or
 3 minor criteria
Rejected
 Firm alternative diagnosis explaining evidence of IE; or
 Resolution of IE syndrome with antibiotic therapy for <4 d; or
  No pathological evidence of IE at surgery or autopsy, with antibiotic 
therapy for <4 d; or
 Does not meet criteria for possible IE as listed above
IE indicates infective endocarditis.
Adapted from Durack DT, et al,2 and Li JS, et al.4Table 25. Major and Minor Criteria in the Modified Duke Criteria for 
the Diagnosis of IE
Major criteria
 Blood culture positive for IE
   Typical microorganisms consistent with IE from 2 separate blood 
cultures:
    Viridans streptococci, Streptococcus bovis, HACEK group 
(Haemophilus spp, Actinobacillus actinomycetemcomitans, 
Cardiobacterium hominis, Eikenella spp, and Kingella kingae), S. 
aureus; or community-acquired enterococci, in the absence of a 
primary focus; or
   Microorganisms consistent with IE from persistently positive blood 
culture results, defined as follows:
    At least 2 positive culture results of blood samples drawn 12 h 
apart; or
    All of 3 or most of ≥4 separate culture samples of blood (with first 
and last samples drawn at least 1 h apart)
    Single positive blood culture result for Coxiella burnetii or antiphase 
I IgG antibody titer >1:800
 Evidence of endocardial involvement
  Echocardiogram positive for IE defined as follows:
   Oscillating intracardiac mass on valve or supporting structures, in the 
path of regurgitant jets, or on implanted material in the absence of an 
alternative anatomic explanation
  Abscess; or
  New partial dehiscence of prosthetic valve
   New valvular regurgitation (worsening or changing of preexisting 
murmur not sufficient)
Minor criteria
 Predisposition, predisposing heart condition, or injection drug use
 Fever, temperature >38°C (100.4°F)
  Vascular phenomena, major arterial emboli, septic pulmonary infarcts, 
mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, 
and Janeway lesions
  Immunological phenomena: glomerulonephritis, Osler’s nodes, Roth’s 
spots, and rheumatoid factor
  Microbiological evidence: positive blood culture but does not meet 
a major criterion as noted above* or serological evidence of active 
infection with organism consistent with IE
*Excludes single positive cultures for coagulase-negative staphylococci and 
organisms that do not cause IE.
IE indicates infective endocarditis; IgG, immunoglobulin G; and spp, 
species.
Adapted from Durack DT, et al,2 and Kupferwasser LI, et al.3
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e158
CLINICAL STATEMENTS  
AND GUIDELINESmodalities involved, ideally at centers with 
immediate access to cardiac surgery during the 
initial observation stages of the disease. With 
the emerging use of telemedicine, it may be rea-
sonable to manage patients with lower-acuity IE 
in a center without on-site multispecialty care by 
telecommunication with a Heart Valve MDT and 
infectious disease specialists, with rapid transfer 
of the patient to a Comprehensive Valve Center 
if needed.11–13
5. The presence of valvular vegetation is a major 
criterion in the diagnosis of IE. TTE has a sen-
sitivity between 50% and 90% and a specific-
ity >90% for detection of vegetations in native 
valve endocarditis. TTE has a sensitivity of only 
36% to 69% in prosthetic valve endocarditis, but 
TTE still has a role in these patients for detection 
and quantitation of valve dysfunction (even in 
the challenging situation of regurgitation in the 
mechanical prosthetic mitral valve, for which a 
proximal convergence zone may provide impor -
tant evidence for a paravalvular leak), evalua-
tion of ventricular size and systolic function, and 
estimation of pulmonary pressures. TTE exhibits 
superior imaging over TEE for the anterior aspect 
of a prosthetic aortic valve, which is commonly 
shadowed by the valve on TEE. TTE also allows 
measurement of aortic transvalvular velocity/
gradient, which is not always possible on TEE. 
Although TTE will not definitively exclude veg-
etations or abscesses in IE, it can identify very 
high-risk patients, establish the diagnosis, and 
guide early treatment decisions (Figure 8).14,19–23
6. The sensitivity of TEE in native valve endocarditis 
ranges from 90% to 100%, with sensitivity ranges 
slightly lower in prosthetic valve endocarditis. TEE 
is superior to TTE in the visualization of both veg-
etations and paravalvular complications, which can 
be anatomic (eg, valve perforation, abscesses, and 
pericardial effusion) or hemodynamic (eg, valve 
regurgitation, fistulae, and intracardiac thrombi) 
in nature. TTE and TEE are complementary for the 
comprehensive evaluation of hemodynamics and 
anatomy in patients with IE. TEE should be used as 
an adjunct in patients with echocardiographic fea-
tures of IE on TTE to rule out the presence of findings 
such as abscesses, which may alter the therapeutic 
approach to the management of the patient. TEE 
also serves a vital role in reassessment of patients 
with known IE with suspected clinical complica-
tions, as well as a guiding tool in the intraoperative 
assessment and management of the patient with 
IE. The timing of repeat examinations depends on 
the clinical presentation and course and on the vir -
ulence of the microorganism. Increasing vegetation size under therapy must be considered a risk fac-
tor for new embolic events, whereas unchanged 
or reduced vegetation size under therapy may be 
more difficult to interpret.23,29,32–40
7. HF, paravalvular extension, and embolic events 
represent the 3 most frequent and severe com-
plications of IE. They are also the 3 main indi-
cations for early surgery, which is performed 
in almost 50% of cases. If signs or symptoms 
consistent with any of these complications 
exist, there should be a very low threshold for 
repeat imaging in these patients. TEE may miss 
initial paravalvular abscesses, particularly when 
the study is performed early in the patient’s ill-
ness. In such cases, the incipient abscess may be 
seen only as nonspecific paravalvular thicken-
ing, which on repeat imaging across several days 
may become recognizable as it expands and cav-
itates. Similarly, paravalvular fistulae and pseu-
doaneurysms develop over time, and negative 
early TEE images do not exclude the potential for 
their development. A single negative TEE study 
cannot rule out underlying IE, and a repeat TEE 
study should be performed when a suspicion of 
persistence of infection remains or if complica-
tions ensue. Conversely, in the absence of clini-
cal deterioration or new signs and symptoms, 
routine follow-up echocardiography is probably 
of only limited clinical utility.24,41,42,44–46
8. Intraoperative TEE during cardiac surgery has an 
important role in the evaluation and quality con-
trol of a large variety of pathologies. Clinical and 
echocardiographic characteristics may change 
during an episode of IE because of the pro-
longed active phase and fluctuating course of 
this disease. Even if preoperative TEE has been 
performed, vegetation change/embolization or 
extension of the infectious process beyond the 
valve tissue may occur. In addition, other valves 
may become involved as the disease timeline 
progresses. Intraoperative TEE has been invalu-
able for baseline reassessment of anatomic or 
hemodynamic changes that may occur in the 
interval between the diagnostic echocardiogram 
and the time of surgery. TEE is also an important 
monitoring tool for evaluation of operative com-
plications, such as air emboli, and an important 
adjunct to ensure the quality of the intended 
surgical result.49,50
9. The recently published randomized POET (Partial 
Oral Treatment of Endocarditis) trial studied 400 
patients with “stable” left-sided IE caused by 
streptococcus, Enterococcus faecalis, S. aureus, 
or coagulase-negative staphylococci. Patients 
who had been on intravenous antibiotics for at 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e159
CLINICAL STATEMENTS  
AND GUIDELINESleast 10 days were randomized to continuation 
of the usual course of intravenous antibiotics 
or discharge to ambulatory treatment with oral 
antibiotics. As part of the study protocol, patients 
were reassessed by TEE within 1 to 3 days of 
completion of their assigned treatment to con-
firm that the patient had a sufficient response to 
therapy. The primary outcome was a composite 
of all-cause mortality, unplanned cardiac surgery, 
embolic events, or relapse of bacteremia with the 
primary pathogen. At 6 months after antibiotic 
treatment completion, the switch to early oral 
antibiotic therapy was noninferior to traditional 
long-term intravenous therapy.51
10. IE in patients with S. aureus bacteremia fre-
quently involves normal cardiac valves and is 
seldom accompanied by the physical stigmata 
of IE, rendering the diagnosis of the disease dif-
ficult. Reliance on physical examination findings 
and clinical stigmata is likely to result in under -
diagnosis of S. aureus IE in a large number of 
cases. TEE is cost-effective to guide duration of 
therapy in patients with intravascular catheter–
associated S. aureus bacteremia, patients with 
intracardiac electronic devices, or other patients 
at higher risk of IE (including those with previous 
prosthetic valve surgery) or associated complica-
tions. Despite early diagnosis and appropriate 
therapy, IE after S. aureus bacteremia is fre-
quently associated with disabling and life-threat-
ening sequelae. The overall mortality rate of S. 
aureus IE ranges from 19% to 65%. Other com-
plications include HF (20%–50%), paravalvular 
cardiac abscesses (30%–40%), neurological 
manifestations (30%), and systemic emboliza-
tion (40%).11,36,55,56
11. When compared with native valve endocarditis, 
prosthetic valve endocarditis is characterized by 
a lower incidence of vegetations (especially in 
mechanical prostheses) and a higher incidence of 
annular abscess and other paravalvular complica-
tions. Because cardiac auscultation may also be 
less revealing in prosthetic valve endocarditis and 
because ordinarily less virulent organisms may 
cause more anatomic destruction before culture 
or serological detection, early use of TEE in these 
high-risk patients is important. The sensitivity 
of TEE for detecting IE is lower with prosthetic 
valves than with native valves, so the importance 
of comparing serial echocardiographic studies is 
paramount to making the diagnosis.59,60
12. Electrocardiographic-synchronized, multidetector- 
row CT is emerging as an important tool for non-
invasive cardiac assessment and may be helpful 
in evaluating complications of IE. CT may also be indicated in right-sided IE to demonstrate the pres-
ence of septic pulmonary infarcts and abscesses. 
Although CT is less accurate than TTE and TEE for 
identifying valvular vegetation and valvular perfo-
rations, CT is useful for evaluating patients with 
equivocal findings on TEE and for evaluating com-
plications in patients with suspected paravalvular 
infection. CT imaging is particularly useful in pre-
operative evaluation of patients with aortic valve 
IE to evaluate coronary artery and aortic involve-
ment. In suspected prosthetic valve endocarditis, 
cardiac CT is less affected by the shadowing of 
mechanical valves or bioprosthetic valve sew-
ing rings than is ultrasonography. CT also allows 
evaluation of the motion of mechanical valve 
occluders and provides visualization of throm-
bus or infective material limiting valve occluder 
motion. Additional imaging modalities, such as 
cardiac valvular fluoroscopy, can be an adjunct to 
other clinical and imaging information to detect 
the presence of obstructive disease in mechanical 
prosthetic valves affected by IE.61,64–68
13. Diagnosis of IE can still be a vexing under -
taking. It has been shown that the use of 
18F-fluorodeoxyglucose PET/CT at the initial 
presentation of patients with suspected pros-
thetic valve endocarditis increases the diagnos-
tic capability of the Modified Duke Criteria. The 
inclusion of abnormal 18F-fluorodeoxyglucose 
cardiac uptake as a major criterion addition to 
the Modified Duke Criteria enabled a recatego-
rization of 76% of patients with prosthetic valve 
endocarditis initially classified as “possible” IE on 
admission to the hospital to “definite” IE. This 
tool must be used in centers with great experi-
ence with the technology, as this imaging tech-
nique may also be prone to false-positive results 
because of sterile inflammation in implanted 
prosthetic valves. 18F-fluorodeoxyglucose PET/
CT may also be considered a complementary 
diagnostic tool for some patients with suspected 
native valve endocarditis.69–71
14. Because the frequency of IE among patients with 
S. aureus bacteremia is reported to be approxi-
mately 30%, with many cases not being clinically 
suspected, TEE may be considered in the setting 
of S. aureus bacteremia to rule out IE. Even in 
S. aureus bacteremia from a known extracardiac 
source, such as an infected joint or joint prosthe-
sis, TEE might be considered, given known cases 
of seeding of valve tissue in this type of setting. 
Possible exceptions are patients who have no 
underlying cardiac predisposing conditions or 
clinical signs of IE whose fever and bacteremia 
resolve within 72 hours after removal of a likely 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e160
CLINICAL STATEMENTS  
AND GUIDELINESinfected focus (such as intravascular catheter 
removal). In the absence of 1) prolonged bac-
teremia lasting >4 days, 2) a permanent intra-
cardiac device, 3) hemodialysis dependency, or 
4) spinal infection or nonvertebral osteomyelitis, 
the risk of IE is relatively low, and routine TEE 
may not be necessary.22,53,54,74
12.3. Medical Therapy
Recommendations for Medical Therapy for IE
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 42.
COR LOE Recommendations
1 B-NR1.  In patients with IE, appropriate antibiotic 
therapy should be initiated and continued after 
blood cultures are obtained, with guidance 
from antibiotic sensitivity data and the 
infectious disease experts on the MDT.1–7 
1 B-R2.  Patients with suspected or confirmed IE associated 
with drug use should be referred to addiction 
treatment for opioid substitution therapy.8–10
2a B-NR3.  In patients with IE and with evidence of 
cerebral embolism or stroke, regardless of 
the other indications for anticoagulation, 
it is reasonable to temporarily discontinue 
anticoagulation.11–24 
2b B-R4.  In patients with left-sided IE caused by 
streptococcus, Enterococcus faecalis, S. aureus, 
or coagulase-negative staphylococci deemed 
stable by the MDT after initial intravenous 
antibiotics, a change to oral antibiotic therapy 
may be considered if TEE before the switch to 
oral therapy shows no paravalvular infection, 
if frequent and appropriate follow-up can be 
assured by the care team, and if a follow-up 
TEE can be performed 1 to 3 days before the 
completion of the antibiotic course.25 
2b B-NR5.  In patients receiving VKA anticoagulation 
at the time of IE diagnosis, temporary 
discontinuation of VKA anticoagulation may 
be considered.13,26–34 
3: Harm C-LD6.  Patients with known VHD should not receive 
antibiotics before blood cultures are obtained 
for unexplained fever.22,35,36 
Synopsis
Details of specific antimicrobial regimens have been 
published previously by the AHA, European Society of 
Cardiology, and British Society for Antimicrobial Che-
motherapy and are not repeated in this guideline. In 
patients on anticoagulant therapy for AF or a mechani-
cal heart valve, continued anticoagulation is associated 
with a higher risk of intracranial bleeding, particularly 
after an embolic event. In patients with suspected 
intravenous drug use, effective long-term therapy in-
cludes referral to an addiction treatment program. In 
a select subset of patients with a stable clinical course, 
it may be possible to convert from intravenous to oral antibiotics if TEE confirms the absence of paravalvu-
lar extension of the infection. In addition to antibiotic 
therapy, early surgical intervention often (approximate-
ly 50% of the time) is needed to manage infection and 
the sequelae of valve leaflet and paravalvular tissue de-
struction (Figure 15).1,2,37–42
Recommendation-Specific Supportive Text
1. Optimal treatment of IE is based on the appropri-
ately timed initiation of antimicrobial therapy that 
is effective against the specific infective organ-
ism involved. Empirical therapy may be neces-
sary in patients with septic shock or patients who 
show high-risk signs on presentation. Although 
no RCTs have been performed with regard to the 
use of antibiotic therapy in IE, the mortality rate 
before the antibiotic age neared 100%. Specific 
antimicrobial regimens, depending on the caus-
ative microorganism, have been published by the 
British Society for Antimicrobial Chemotherapy 
and the AHA. Because there are continuous 
changes in antimicrobial sensitivity over time, as 
well as regional and site-specific differences in 
antimicrobial susceptibility profiles, concomitant 
management with the assistance of a consul-
tant thoroughly familiar with these patterns is 
imperative.1–7
2. Drug use–associated endocarditis is associated 
with a significantly higher complexity of care, 
with increased rates of readmission, reinfection, 
and recurrent need for repeat interventions, 
and its incidence has risen 12-fold over the past 
decade. Addiction specialists are an important 
part of the Heart Valve Team for this patient pop-
ulation. Addiction studies have shown that treat-
ment outcomes for behavioral interventions alone 
for opioid use disorders are dismal, with >80% of 
patients returning to drug use. Some data show 
that patients who used pharmacotherapy, such 
as agonist therapy (opioid substitution therapy), 
in addition to behavioral treatments had a 50% 
reduction in relapse compared with those who 
used behavioral therapies alone.8–10
3. Stroke in patients with IE can have several 
mechanisms, including hemorrhagic transfor -
mation of an ischemic infarct, septic erosion of 
an atherosclerotic vessel without aneurysm for -
mation, and rupture of a mycotic aneurysm. Up 
to 35% of all patients with IE develop clinically 
evident systemic emboli. If more sensitive tests, 
such as magnetic resonance imaging, are used, 
a much higher proportion of patients with IE 
have evidence of emboli. In these patients, the 
most common cause of stroke is septic embolus 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e161
CLINICAL STATEMENTS  
AND GUIDELINESresulting in ischemia, often followed by hemor -
rhagic transformation. Anticoagulant therapy 
may increase the risk of an embolic infarct 
converting to a hemorrhagic infarct, and this 
risk must be weighed against the higher risk of 
recurrent embolization and valve dysfunction, 
particularly in patients on anticoagulation for a 
prosthetic valve. A specialist in the field of neu-
rology or neuroradiology should be added to 
the Heart Valve Team when stroke complicates 
IE.11,18–24
4. POET randomized stable patients who had left-
sided endocarditis caused by streptococcus, 
E. faecalis, S. aureus, or coagulase-negative 
staphylococci to treatment arms of contin-
ued intravenous treatment or a switch to oral 
antibiotic treatment after antibiotics had been 
administered intravenously for at least 10 days. 
Within 1 to 3 days before the completion of 
the assigned antibiotic treatment, TEE was per -
formed to confirm that the patient had a suf-
ficient response to treatment as part of this 
protocol.255. In patients with native valve endocarditis, rou-
tine use of VKA is not recommended. In patients 
on VKA for other indications who have IE, VKA 
discontinuation should be considered at the ini-
tial presentation for several reasons: 1) the risk 
of bleeding associated with any needed urgent 
invasive procedures, 2) the risk of hemorrhagic 
stroke, and 3) the possible need for early surgery, 
which is required in roughly 50% of patients 
with prosthetic valve endocarditis. There are no 
RCTs studying the use of bridging therapy with 
intravenous or subcutaneous anticoagulant ther -
apy in patients with IE, but observational studies 
suggest an increased risk of hemorrhagic stroke 
in patients on intravenous UFH during the acute 
phase of acute IE. Decisions about continued 
anticoagulation and antiplatelet therapy should 
ultimately be directed by the patient’s cardiologist 
and cardiothoracic surgeon, in consultation with 
a neurology specialist if neurological findings are 
clinically present or noted on imaging.11,27–34
6. Two sets of blood culture samples are the mini-
mum for a secure microbiological diagnosis of IE. 
Figure 15. Diagnosis of IE.
Colors correspond to Table 2. CT indicates computed tomography; IE, infective endocarditis; 18FDG, 18F-fluorodeoxyglucose; NVE, native valve  
endocarditis; PET, positron emission tomography; PVE, prosthetic valve endocarditis; TEE, transesophageal echocardiography; and TTE, transthoracic 
echocardiography.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e162
CLINICAL STATEMENTS  
AND GUIDELINESRecommendations for Intervention for IE (Continued)
COR LOE RecommendationsAntibiotic therapy is most effective if the identity 
and sensitivities of the responsible organism are 
known. S. aureus is the most common pathogen 
responsible for prosthetic valve endocarditis but 
still accounts for only 23% of cases. The leading 
cause of “culture-negative IE” is the use of antibi-
otics before blood cultures are obtained. Negative 
blood cultures in the setting of IE delay diagnosis 
and often require additional serological and poly-
merase chain reaction testing.22,35,36
12.4. Intervention
Recommendations for Intervention for IE
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 42.
COR LOE Recommendations
1 B-NR1.  Decisions about the timing of surgical 
intervention for IE should be made by a Heart 
Valve Team.1–6
1 B-NR2.  In patients with IE who present with valve 
dysfunction resulting in symptoms of HF, early 
surgery (during initial hospitalization and 
before completion of a full therapeutic course 
of antibiotics) is indicated.7–19
1 B-NR3.  In patients with left-sided IE caused by S. 
aureus, a fungal organism, or other highly 
resistant organisms, early surgery (during 
initial hospitalization and before completion 
of a full therapeutic course of antibiotics) is 
indicated.7,9,15,20–35
1 B-NR4.  In patients with IE complicated by heart 
block, annular or aortic abscess, or 
destructive penetrating lesions, early surgery 
(during initial hospitalization and before 
completion of a full therapeutic course of 
antibiotics) is indicated.7,9,36–44 
1 B-NR5.  In patients with IE and evidence of persistent 
infection as manifested by persistent 
bacteremia or fevers lasting >5 days after 
onset of appropriate antimicrobial therapy, 
early surgery (during initial hospitalization and 
before completion of a full therapeutic course 
of antibiotics) for IE is indicated.7,9,15,25,26,45–48 
1 B-NR6.  In all patients with definite endocarditis 
and an implanted cardiac electronic device, 
complete removal of the pacemaker or 
defibrillator systems, including all leads and 
the generator, is indicated.49–55 
1 C-LD7.  For patients with prosthetic valve endocarditis 
and relapsing infection (defined as recurrence 
of bacteremia after a complete course of 
appropriate antibiotics and subsequent 
negative blood culture results) without other 
identifiable source of infection, surgery is 
recommended.7 
1 C-LD8.  In patients with recurrent endocarditis and 
continued intravenous drug use, consultation 
with addiction medicine is recommended 
to discuss the long-term prognosis for the 
patient’s refraining from actions that risk 
reinfection before repeat surgical intervention 
is considered.56–602a B-NR9.  In patients with IE who present with recurrent 
emboli and persistent vegetations despite 
appropriate antibiotic therapy, early surgery 
(during initial hospitalization and before 
completion of a full therapeutic course of 
antibiotics) is reasonable.53,61–66 
2b B-NR10.  In patients with native left-sided 
valve endocarditis who exhibit mobile 
vegetations >10 mm in length (with 
or without clinical evidence of embolic 
phenomenon), early surgery (during initial 
hospitalization and before completion of a 
full therapeutic course of antibiotics) may be 
considered.20,61–63,67 
2b B-NR11.  In patients with IE and an indication for 
surgery who have suffered a stroke but have 
no evidence of intracranial hemorrhage or 
extensive neurological damage, operation 
without delay may be considered.68–70 
2b B-NR12.  For patients with IE and major ischemic 
stroke with extensive neurological damage 
or intracranial hemorrhage, if the patient 
is hemodynamically stable, delaying 
valve surgery for at least 4 weeks may be 
considered.68,71
Synopsis
Management of patients with IE requires a Heart Valve 
MDT supplemented by inclusion of infectious disease and 
neurology specialists. The indications for early surgery for 
patients with IE include HF, persistent infection, abscess, 
heart block, infection with highly resistant organisms, or 
recurrent emboli (with persistent vegetations). In patients 
with implanted electronic devices, infection of the entire 
system is likely, even if it appears confined to the leads on 
imaging, and this mandates removal of the entire system 
to eradicate the infection. In patients with an indication 
for early surgery, a cerebral embolic event is not a contra-
indication unless there is extensive neurological damage 
or intracranial hemorrhage (Figure 16).
Recommendation-Specific Supportive Text
1. IE is best managed in an environment with ready 
access to specialists in the fields of cardiology, car -
diothoracic surgery, and infectious disease, with 
the option for transfer of complicated cases to a 
Comprehensive Valve Center when needed. A risk-
scoring system using the STS database has been 
developed to predict surgical risk in patients with 
IE to help better counsel patients and more objec-
tively define the risks associated with surgery. One 
trial noted that even when surgery is indicated, 
women were less likely to undergo a surgical 
procedure than men (26% versus 47%) and that 
women had higher in-hospital and 1-year mortality 
rates than men despite similar comorbidities.1,2,4–6
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e163
CLINICAL STATEMENTS  
AND GUIDELINES2. Studies have reported a 21% in-hospital mor -
tality rate in patients with IE and HF who were 
treated with surgery versus a 45% mortality rate 
in those who were treated medically. In left-
heart native valve endocarditis, 4 baseline fea-
tures have been independently associated with 
6-month mortality: 1) abnormal mental status, 
2) moderate to severe HF, 3) bacterial etiology 
other than Viridans streptococci, and 4) medical 
therapy without valve surgery. Except in inject-
able drug users, the risk of reinfection after 
prosthetic valve surgery is low relative to the risk 
associated with not having surgery in patients 
with hemodynamic and microbial indications for 
surgery. Prosthetic valve endocarditis is clearly 
associated with both higher mortality rates 
(especially with HF, severe valvular dysfunction, 
or a staphylococcal or fungal infectious microbe) and higher post-treatment HF-related disability. 
Surgical series report surgical rates of 50% in 
patients with prosthetic valve endocarditis, and 
these patients show improved outcomes over 
medical therapy, even with controlling for sever -
ity of illness at time of diagnosis.8,9,15–19
3. Compared with patients with IE attributable 
to other organisms, patients with left-sided S. 
aureus IE were significantly more likely to die 
(20% versus 12%), experience an embolic event 
(60% versus 31%), have a central nervous sys-
tem event (20% versus 13%), and not undergo 
surgery (26% versus 39%). Staphylococcal pros-
thetic valve endocarditis has been associated 
with a mortality rate as high as 70%, which is 
driven by resistant staphylococcal species. When 
Staphylococcus is the bacteria, death occurs in 
<5% of patients with right-sided native valve 
Figure 16. Endocarditis treatment.
Colors correspond to Table 2. *IE caused by streptococcus, E. faecalis, S. aureus, or coagulase-negative staphylococci deemed stable by the Heart Valve Team. 
†Early surgery defined as during initial hospital course and before completion of a full course of appropriate antibiotics. ‡In patients with an indication for surgery 
and a stroke but no evidence of intracranial hemorrhage or extensive neurological damage, surgery without delay may be considered. DUA indicates drug use as-
sociated endocarditis; HF, heart failure; ICD, implantable cardioverter-defibrillator; ID, infectious disease; IE, infective endocarditis; IV, intravenous; NVE, native valve 
endocarditis; OST, opioid substitution treatment; pt, patient; PVE, prosthetic valve endocarditis; Rx, therapy; S. aureus, Staphylococcus aureus; TEE, transesopha-
geal echocardiography; TTE, transthoracic echocardiography; VHD, valvular heart disease; and VKA, vitamin K antagonist.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e164
CLINICAL STATEMENTS  
AND GUIDELINESendocarditis, which is an important distinction 
in injectable drug users. Certain pathogens, 
such as Pseudomonas aeruginosa, Brucella, 
fungi, enterococci, and gram-positive cocci are 
extremely difficult to cure with medical therapy 
alone and are also prone to abscess or fistula for -
mation and other cardiac tissue destruction. The 
mortality rate is also significantly lower in patients 
treated with antifungal agents combined with 
surgery than in those treated with antifungal 
agents alone (42% versus 59%).9,15,20,22,28–35
4. Abscess in native valve endocarditis is a life-
threatening complication that cannot be cured 
with antibiotic therapy alone. Extensive para-
valvular infections (including annular or aortic 
abscesses and destructive penetrating lesions or 
fistulae) are associated with a mortality rate of 
≥40% and heart block. The long-term results of 
surgery are very satisfactory, with an actuarial 
survival rate of 75%±6% at 5 years. Freedom 
from recurrent IE has been reported to be 76% 
at 8 years. Surgical series have shown that the 
surgical results are related more to a surgeon’s 
ability to remove all infected tissues and recon-
struct functional anatomy than to the type of 
valve used for a replacement. Patients with 
prosthetic valve endocarditis complicated by 
paravalvular invasion, as manifested by intracar -
diac abscesses, fistulae, or heart block, experi-
ence high mortality rates and are rarely cured 
by medical treatment alone. By contrast, surgi-
cal series have reported surgical survival rates of 
71% in this high-risk group.9,41–44
5. Blood culture samples will typically become nega-
tive after 48 hours of appropriate antimicrobial 
therapy, except for with methicillin-resistant S. 
aureus and other resistant organisms, for which 
it may take up to a week for cultures to become 
negative. Some caution is advised in patients who 
develop recurrent fever after an initially successful 
response to antibiotics because the fever could be 
explained by reasons other than the endocarditic 
valve. Ongoing infection despite antibiotic ther -
apy is common with aggressive microorganisms, 
resulting in abscess formation, valve destruction, 
fistulas, or large vegetations.7,9,15,46,48
6. Optimal therapy for cardiac device IE combines 
complete device extraction and a prolonged 
course of parenteral antibiotics with complete 
device and lead removal, even if evidence for 
infection appears to be limited to the generator 
pocket site. A prospective cohort study using data 
from the ICE-PCS (International Collaboration on 
Endocarditis–Prospective Cohort Study) showed 
that among patients with cardiac device IE, the 
rates of both concomitant valve infection and mortality are high, particularly if there is valve 
dysfunction. A proportional hazards regression 
analysis showed a survival benefit at 1 year for 
device removal during the initial hospitalization; 
28 of 141 patients (19.9%) who underwent 
device removal during the index hospitalization 
had died at 1 year, versus 13 of 34 (38.2%) who 
did not undergo device removal (HR: 0.42; 95% 
CI: 0.22–0.82).49,54,55,72
7. Relapsing infections may be caused by incom-
plete sterilization of valvular or paravalvular tis-
sue secondary to a deep tissue infection. Even in 
the absence of other indications for intervention, 
such as severe valve dysfunction or a resistant 
organism, if there is no other source for persis-
tent bacteremia, heart valve infection must be 
presumed to be the source. If the source of infec-
tion is uncertain, additional imaging with PET/CT 
may be helpful in decision-making.7
8. The incidence of drug use–associated IE continues 
to rise, with a known risk of IE that is 100-fold 
higher than that of the general population. In 
a National Institutes of Health–sponsored state-
wide health survey in the state of North Carolina, 
42% of all IE valve surgeries performed between 
2007 and 2017 were undertaken in patients with 
injection drug use–related IE. The care of these 
patients is associated with longer hospital stays, 
higher readmission rates, higher rates of recurrent 
IE, and higher costs of care. With evolving sci-
ence in addiction medicine, there is evidence that 
referral to addiction therapy can reduce mortality 
and morbidity rates in these patients. In patients 
admitted with drug use–associated endocarditis, 
addiction specialists are an integral part of the 
MDT.56–60
9. Embolic events are associated with increased 
morbidity and mortality in IE and occur in 20% 
to 40% of patients with IE. The risk of embo-
lism is highest during the first days after initia-
tion of antibiotic treatment and decreases after 
2 weeks. Embolic incidence decreases to 9% 
to 21% after initiation of antibiotic treatment. 
Factors associated with a new embolic event are 
vegetation size >10 mm and marked vegetation 
mobility (especially when associated with the 
anterior leaflet of the mitral valve). Early sur -
gery is associated with a reduction in the rate of 
embolic complications in patients who present 
with left-sided IE, severe VHD, and large vegeta-
tions (>10 mm).53,61,64–66
10.   With native valve endocarditis, large vegetation 
size is associated with a markedly higher rate 
of embolic phenomena. In an RCT of surgical 
intervention in patients with severe left-sided 
valve dysfunction and vegetations >10 mm in 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e165
CLINICAL STATEMENTS  
AND GUIDELINESlength (even in the absence of clinically appar -
ent embolic events or HF), there was no signifi-
cant difference in all-cause mortality rate at 6 
months in the early surgery versus the conven-
tional treatment groups (3% and 5%, respec-
tively; P=0.59); however, there was a marked 
reduction in the number of embolic events: 0% 
in the early surgery group compared with 21% 
in the conventional treatment group (P =0.005). 
Additionally, 77% of the conventional treat-
ment group required surgery during the initial 
hospitalization or during the follow-up phase 
secondary to HF, paravalvular extension, and 
heart block.20,61
11.   Stroke is an independent risk factor for 
postoperative death in patients with IE. 
Recommendations about the timing of opera-
tive intervention after a stroke in the setting of 
IE are hindered by the lack of RCTs and reliance 
on single-center experiences. In early observa-
tional data, there was a significantly decreased 
risk of in-hospital death when surgery was per -
formed >4 weeks after the stroke.73 These data 
were not risk adjusted. In an observational study 
that did adjust for factors such as age, para-
valvular abscess, and HF, the risk of in-hospital 
death was not significantly higher in the group 
who underwent surgery within a median time 
from admission to operation of 5 days, with 
only a 1% risk of perioperative hemorrhagic 
conversion.68–70,74
12.   Patients with hemorrhagic stroke and IE have a 
prohibitively high surgical risk for at least 4 weeks 
after the hemorrhagic event. One multicenter 
observational study71 showed wide variation in 
patient deaths when those who underwent sur -
gery within 4 weeks of a hemorrhagic stroke 
were compared with those whose surgery was 
delayed until after 4 weeks (75% versus 40%, 
respectively). The percentage of new postop-
erative bleeds was 50% in patients whose sur -
gery was performed in the first 2 weeks, 33% 
in patients whose surgery was performed in the 
third week, and 20% in patients whose surgery 
was performed at least 21 days after the neuro-
logical event.68
13. PREGNANCY AND VHD
The physiological hemodynamic changes associated 
with pregnancy are usually well tolerated in women 
with structurally normal hearts. However, for women 
with VHD, the hemodynamic burden may pose signifi-
cant challenges during pregnancy and delivery.13.1. Initial Management of Women With 
VHD Before and During Pregnancy
Recommendations for Initial Management of Women With VHD 
Before and During Pregnancy
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 43.
COR LOE Recommendations
1 B-NR1.  Women with suspected valve disease who 
are considering pregnancy should undergo a 
clinical evaluation and TTE before pregnancy.1–5 
1 B-NR2.  Women with severe valve disease (Stages 
C and D) who are considering pregnancy 
should undergo pre-pregnancy counseling 
by a cardiologist with expertise in managing 
women with VHD during pregnancy.1–5
1 B-NR3.  Pregnant women with severe valve disease 
(Stages C and D) should be monitored in a 
tertiary-care center with a dedicated Heart Valve 
Team of cardiologists, surgeons, anesthesiologists, 
and maternal-fetal medicine obstetricians with 
expertise in the management of high-risk cardiac 
conditions during pregnancy.1–12 
2a B-NR4.  In asymptomatic women with severe valve 
disease (Stage C1) who are considering 
pregnancy, exercise testing is reasonable 
before pregnancy for risk assessment.3–5,11,13–15
Synopsis
To assure the best possible outcome for a woman with 
VHD and her baby, a comprehensive evaluation is best 
performed before the time of conception. During preg-
nancy, the frequency and intensity of follow-up and 
treatment are heavily dependent on the type and sever -
ity of valve lesion, as well as patient symptoms.
Recommendation-Specific Supportive Text
1. The risks to the mother and fetus during preg-
nancy are highly dependent on the type and sever -
ity of valve disease. Clinical evaluation of women 
with VHD who are contemplating pregnancy 
includes a complete TTE with full anatomic and 
hemodynamic assessment of the valves.1–5  A con-
genital bicuspid or unicuspid aortic valve is often 
associated with dilation of the aortic sinuses, the 
ascending aorta, or both. Evaluation of women 
with a congenitally abnormal aortic valve includes 
assessment of the aorta before pregnancy 
because of the risk of further aortic enlargement 
and aortic dissection during pregnancy.1–5
2. Pre-pregnancy counseling with a cardiologist expe-
rienced with managing women with valve disease 
during pregnancy allows discussion of the risks of 
pregnancy for the mother and fetus. A complete 
assessment of functional capacity, severity of valve 
lesions, status of the LV and RV, and pulmonary 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e166
CLINICAL STATEMENTS  
AND GUIDELINESpressures is necessary to determine the risk of 
pregnancy and delivery. Medications are reviewed 
to avoid agents that may have potential harmful 
effects on the fetus. Pre-pregnancy evaluation 
also allows discussion of options for interventions 
before pregnancy, such as valve replacement, valve 
repair, or percutaneous aortic or mitral balloon 
dilation, particularly in those patients with severe 
rheumatic MS or AS.1–5
3. Women with severe valve disease who become 
pregnant are at an elevated risk of cardiac morbid-
ity and mortality. Babies born to such mothers are 
also at risk of serious complications. Identification 
and management of complications are improved 
by monitoring in a tertiary-care center with an 
experienced team of healthcare providers who 
have expertise in managing high-risk cardiac con-
ditions during pregnancy.1–12
4. Patients with severe valve disease may be asymp-
tomatic, which can pose a diagnostic and thera-
peutic dilemma in women with these disorders 
who are considering pregnancy. Exercise testing 
is reasonable to assist with risk assessment in 
patients in whom it is unclear whether pregnancy 
can be tolerated without an intervention to repair 
or replace the valve before pregnancy.3–5,11,13–15 
Symptoms provoked by exercise testing are syn-
onymous with spontaneous symptoms. Patients 
who develop symptoms on exercise testing 
should be treated as having symptomatic valve 
disease (Stage D), and should undergo pre-preg-
nancy counseling by a cardiologist with expertise 
in managing women with VHD during pregnancy
13.1.1. Medical Therapy for Women With VHD 
Before and During Pregnancy
Recommendations for Medical Therapy of Pregnant Women With 
VHD
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 43.
COR LOE Recommendations
2a C-LD1.  In pregnant women with VHD, beta-blocker 
medications are reasonable as required 
for heart rate control or treatment of 
arrhythmias.1–6 
2a C-LD2.  In pregnant women with VHD and HF 
symptoms (Stage D), diuretic medications are 
reasonable if needed for volume overload.7,8 
3: Harm B-NR3.  In pregnant women with VHD, ACE inhibitors 
and ARBs should not be given because of fetal 
risk.6,9–11 
Synopsis
Women with severe VHD are at risk of HF, arrhythmia, 
and other cardiac disorders during pregnancy. Although medical therapy may be necessary to preserve the moth-
er’s health, there may be negative consequences for the 
fetus. Therefore, the fetal effects of cardiac medications 
must be understood so that the appropriate risks and 
benefits can be weighed.1–6 Data from ROPAC (Registry 
On Pregnancy And Cardiac Disease), a large multicenter 
registry supported by the European Society of Cardiol-
ogy, showed an association between the use of cardiac 
medications during pregnancy and adverse fetal out-
come. This association was attributable, in part, to the 
associated maternal cardiac diseases that required the 
medications.6 Anticoagulation for pregnant women with 
AF should conform to the guidelines in nonpregnant 
patients.12,13 Recommendations for anticoagulation regi-
mens during pregnancy are discussed in section 13.2.2.
Recommendation-Specific Supportive Text
1. Beta-blocker medications are used to control heart 
rate or to treat arrhythmias. However, maternal 
use of beta blockers has been associated with a 
newborn birth weight approximately 100 g lower 
than that of newborns whose mothers did not 
take beta blockers.6 The use of beta blockers with 
beta-1 selectivity avoids the beta-2 effects on 
uterine relaxation. The incidence of fetal growth 
retardation is lower with metoprolol treatment 
than with atenolol treatment in pregnancy.1–6
2. Diuretic medications can alleviate the effects of vol-
ume overload in pregnant women with VHD and HF 
symptoms (Stage D). However, reduction of volume 
overload must be balanced against the reduction in 
placental blood flow associated with diuretic medi-
cations.7,8 Additionally, data from ROPAC suggested 
that maternal diuretic use was associated with rates 
of low birth weight and fetal mortality that were 
higher than for women not taking any medications. 
In part, this association was attributable to the 
severity of the underlying HF requiring treatment.7,8
3. ACE inhibitors and ARBs are strongly associated 
with fetal malformations when used by women 
during pregnancy.9–11
13.1.2. Intervention for Women With Native VHD 
Before and During Pregnancy
13.1.2.1. Pre-Pregnancy Intervention
Recommendations for Pre-Pregnancy Intervention in Women With 
VHD
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 43.
COR LOE Recommendations
1 B-NR1.  In symptomatic women with severe VHD who 
are considering pregnancy, intervention before 
pregnancy is recommended on the basis of 
standard indications.1–11 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e167
CLINICAL STATEMENTS  
AND GUIDELINES1 C-EO2.  In women who require a valve intervention 
before pregnancy, the choice of prosthetic 
valve should be based on a shared decision-
making process that accounts for the patient’s 
values and preferences, including discussion 
of the risks of mechanical valves during 
pregnancy and the reduced durability of 
bioprosthetic valves in young women.
2a C-LD3.  In asymptomatic women with severe 
rheumatic MS (mitral valve area ≤1.5 cm2, 
Stage C1) who are considering pregnancy, 
PMBC at a Comprehensive Valve Center is 
reasonable before pregnancy for those who 
have favorable valve morphology.1–5,12,13 
2a B-NR4.  In women of childbearing age who require 
valve replacement, bioprosthetic valves are 
preferred over mechanical valves because 
of the increased maternal and fetal risks of 
mechanical heart valves in pregnancy.14
2a C-EO5.  In asymptomatic women with severe AS (aortic 
velocity ≥4.0 m/s or mean pressure gradient ≥ 40 
mm Hg, Stage C) who are considering pregnancy, 
valve intervention before pregnancy is reasonable.
2b C-EO6.  In asymptomatic women with severe AS (aortic 
velocity ≥4.0 m/s or mean pressure gradient 
≥40 mm Hg, Stage C1) who are considering 
pregnancy, do not meet COR 1 criteria for 
intervention, and have a preconception 
evaluation confirming the absence of 
symptoms (including normal exercise stress 
testing and serum BNP measurements), 
medical management during pregnancy 
may be considered to avoid prosthetic valve 
replacement.
2b C-EO7.  In asymptomatic women with severe MR 
(Stage C1) and a valve suitable for repair who 
are considering pregnancy, valve repair before 
pregnancy at a Comprehensive Valve Center 
may be considered but only after detailed 
discussion with the patient about the risks and 
benefits of the surgery and its effect on future 
pregnancies.
Synopsis
In women with severe VHD who are considering preg-
nancy, the indications for considering intervention in-
clude the presence of symptoms, asymptomatic severe 
AS, asymptomatic severe MR with a repairable valve, and 
asymptomatic severe rheumatic MS with a valve morphol-
ogy suitable for PMBC. If a prosthetic valve is needed, the 
shared decision-making process about the choice of type 
of prosthetic valve should include discussion of the risks 
of valve thrombosis and adverse effects from anticoagula-
tion with mechanical valves versus the reduced durability 
of bioprosthetic valves in young women (Figure 17).
Recommendation-Specific Supportive Text
1. Standard indications for intervention in symptom-
atic patients with severe valve disease also apply 
to women who are considering pregnancy.1–112. Women of childbearing age who require valve 
intervention have important choices to make 
about the risks and benefits of the types of pros-
thetic valves. The risks to the mother and fetus 
of valve thrombosis and anticoagulation dur -
ing pregnancy with a mechanical valve must be 
weighed against the reduced durability of bio-
prosthetic valves in young women. For women 
considering a mechanical prosthesis, it has been 
proposed that they undergo a preoperative trial of 
anticoagulation with warfarin to assess the dose 
needed to achieve a target INR. In 1 small study, 
women who required <5 mg daily of warfarin 
and then underwent subsequent mechanical AVR 
did not experience maternal or fetal complica-
tions during pregnancy.15 Larger trials are needed, 
however, before this becomes standard practice. 
Shared decision-making with a cardiologist with 
expertise in the management of severe valve dis-
ease during pregnancy allows discussion of these 
issues in women of childbearing age before valve 
surgery, even when pregnancy is not planned in 
the near future.1,14,16
3. Severe rheumatic MS presents a significant risk of 
maternal adverse outcome during pregnancy. In 
asymptomatic women with severe rheumatic MS 
(mitral valve area ≤1.5 cm2, Stage C) and favor -
able valve morphology who are considering preg-
nancy, PMBC results in an increase in mitral valve 
area and reduction in transmitral gradient, which 
makes the patient more resilient to the hemody-
namic load of pregnancy.1–5,12,13
4. Pregnant women with a bioprosthetic valve, 
compared with women with a mechanical valve 
who are on anticoagulation, have a lower risk of 
valve thrombosis, excessive bleeding, and fetal 
and maternal death.14 The Ross procedure is an 
alternative if performed in women with favor -
able anatomy and at centers with expertise in the 
procedure.
5. Most patients with mild to moderate AS can tol-
erate the hemodynamic changes of pregnancy 
without cardiovascular events. Patients with 
severe AS are at an increased risk of complica-
tions, with HF developing in 10% to 44% of 
patients and arrhythmias in up to 25%, even 
if they were asymptomatic before pregnancy. 
Progressive as well as sudden deterioration may 
occur during pregnancy and delivery in patients 
with severe AS. Fetal complications are frequent 
also. Options for relief of valvular AS in young 
women include percutaneous aortic balloon 
dilation in patients with noncalcified congeni-
tal AS, the Ross procedure, or a surgical bio-
prosthetic or mechanical valve. TAVI has not 
been studied in young women, and few data Recommendations for Pre-Pregnancy Intervention in Women With 
VHD (Continued)
COR LOE Recommendations
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e168
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
exist on outcomes with this valve type during 
pregnancy.1,3,6–10
6. Some women with severe asymptomatic AS, 
normal LV systolic function, and normal bio-
markers may choose to undergo pregnancy 
without valve intervention. The risks of dete-
rioration during pregnancy must be balanced 
against the risk of mechanical valve complica-
tions during pregnancy or the long-term risks 
of a bioprosthetic valve in a young patient. In 
experienced centers, these women can often 
be treated with activity restriction, volume 
management, and optimization of loading 
conditions.1,3,6–10
7. The threshold for valve operation for valve 
regurgitation is higher in the asymptomatic 
patient who might ever become pregnant than in patients who will not become pregnant 
because there always is the possibility that valve 
repair will not be successful and a prosthetic 
valve will be needed. Most patients with asymp-
tomatic severe MR tolerate the hemodynamic 
changes of pregnancy, and there is no evidence 
for acceleration of LV dysfunction during preg-
nancy. High-risk features for development of HF 
during pregnancy in women with MR include 
depressed LV systolic function and pulmonary 
hypertension (pulmonary artery systolic pressure 
>50 mm Hg). In high-risk asymptomatic women 
with severe MR, referral to a Comprehensive 
Valve Center allows consideration of mitral 
valve morphology, the likelihood of a successful 
valve repair, and estimated surgical risk in the 
decision-making process.1,11,16
Figure 17. Preconception management of women with native valve disease.
Colors correspond to Table 2. TTE indicates transthoracic echocardiography; and VHD, valvular heart disease.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e169
CLINICAL STATEMENTS  
AND GUIDELINES13.1.2.2. During-Pregnancy Intervention
Recommendations for Intervention During Pregnancy in Women 
With VHD
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 43.
COR LOE Recommendations
2a B-NR1.  In pregnant women with severe AS (mean 
pressure gradient ≥40 mm Hg, Stage D), valve 
intervention during pregnancy is reasonable if 
there is hemodynamic deterioration or if there 
are NYHA class III or IV HF symptoms.1–7 
2a B-NR2.  In pregnant women with severe rheumatic MS 
(mitral valve area ≤1.5 cm2, Stage D) and with 
valve morphology favorable for PMBC who 
remain symptomatic with NYHA class III or IV 
HF symptoms despite medical therapy, PMBC is 
reasonable during pregnancy if it is performed 
at a Comprehensive Valve Center.8–12 
2a C-LD3.  In pregnant women with severe valve 
regurgitation and with NYHA class IV HF 
symptoms (Stage D) refractory to medical therapy, 
valve surgery is reasonable during pregnancy.13–16 
3: Harm C-LD4.  In pregnant women with VHD, valve surgeries 
should not be performed in the absence of 
severe HF symptoms refractory to medical 
therapy.13–16
Synopsis
In pregnant women with severe VHD who develop se-
vere, intractable symptoms despite maximal medical 
therapy, surgical or percutaneous intervention may be-
come necessary.
Recommendation-Specific Supportive Text
1. Patients with severe AS may develop progressive 
HF or sudden hemodynamic deterioration during 
the stress of pregnancy. Both open heart surgery 
and percutaneous balloon dilation of the aortic 
valve are high-risk procedures during pregnancy 
for both the mother and the fetus and should be 
performed only if there is hemodynamic deterio-
ration or if there are severe NYHA class III or IV 
HF symptoms. The type of intervention will be 
dependent on the valve morphology and on the 
expertise of the center. The intervention should 
always be performed in a center with a multidis-
ciplinary group of cardiologists, interventionalists, 
cardiac anesthesiologists, and obstetricians spe-
cializing in high-risk obstetrics.1–7,9–12
2. Patients with severe rheumatic MS may develop 
progressive HF or sudden hemodynamic deteriora-
tion during the hemodynamic stress of pregnancy. 
Percutaneous balloon dilation of the mitral valve is a 
high-risk procedure during pregnancy for both the 
mother and the fetus and should be performed only 
if there is hemodynamic deterioration or if there are 
severe NYHA class III or IV HF symptoms.17–19 The intervention will also be dependent on an accept-
able valve morphology. The intervention should 
always be performed in a center with a multidisci-
plinary group of cardiologists, interventionalists, car -
diac anesthesiologists, and obstetricians specializing 
in high-risk obstetrics.1–7,9–12,20
3. Regurgitant valve lesions are generally better toler -
ated during pregnancy than are stenotic ones. Valve 
surgery is reasonable only in the rare pregnant woman 
with severe valve regurgitation with NYHA class IV HF 
symptoms refractory to medical therapy.13–16
4. Valve surgery during pregnancy is high risk, with 
a 30% to 40% fetal mortality rate and up to 9% 
maternal mortality rate reported. It should be 
reserved only for patients with severe, intractable 
symptoms unresponsive to bed rest and maxi-
mally tolerated medical therapy.13–16
13.2. Prosthetic Valves in Pregnant 
Women
13.2.1. Initial Management
Recommendations for Initial Management of Prosthetic Heart 
Valves in Pregnant Women
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 44.
COR LOE Recommendations
1 C-EO1.  Women with a prosthetic valve should 
undergo pre-pregnancy assessment, including 
echocardiography, by a cardiologist with 
expertise in managing women with VHD 
during pregnancy. 
1 C-EO2.  Pregnant women with a mechanical prosthesis 
should be monitored in a tertiary-care center 
with a dedicated MDT of cardiologists, 
surgeons, anesthesiologists, and maternal-fetal 
medicine obstetricians with expertise in the 
management of high-risk cardiac conditions 
during pregnancy.1–3 
1 B-NR3.  Women with mechanical heart valves 
considering pregnancy should be counselled 
that pregnancy is high risk and that there is 
no anticoagulation strategy that is consistently 
safe for the mother and baby.3–6 
1 B-NR4.  Pregnant women with a mechanical prosthetic 
valve who have prosthetic valve obstruction or 
experience an embolic event should undergo 
a TEE.7–9
Synopsis
Pregnancy in women with mechanical heart valves is very 
high risk and has been classified by the World Health Or -
ganization as Risk Category III (significantly increased risk 
of maternal mortality or severe morbidity). Contemporary 
studies and prospective registries of pregnancy in women 
with mechanical heart valves confirm that maternal risk re-
mains high: Maternal mortality rate is approximately 1%, 
and the risk of valve thrombosis is approximately 5%.2,5,9 
Given the substantial risk of adverse maternal and fetal 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e170
CLINICAL STATEMENTS  
AND GUIDELINESevents, there is a need for specialized expertise in the coun-
seling and care of women with prosthetic heart valves who 
are considering pregnancy or who are pregnant.
Recommendation-Specific Supportive Text
1. A preconception TTE is used to assess valve func-
tion, ventricular function, and pulmonary artery 
systolic pressure. Preconception TTE can help 
identify women with valve dysfunction who may 
benefit from valve intervention before concep-
tion. Results can facilitate patient counseling 
about specific risks of pregnancy.
2. The management of prosthetic heart valves during 
pregnancy is substantially different from the man-
agement of prosthetic heart valves in a nonpregnant 
patient. There is a much higher risk of mechanical 
valve thrombosis during pregnancy because of 
the hypercoagulable state. Choosing the appro-
priate anticoagulation strategy to balance risks to 
the mother and fetus requires a team familiar with 
management of prosthetic heart valves in preg-
nancy to provide comprehensive counseling. The 
management of anticoagulation also requires spe-
cialized expertise, and frequent titration of VKA or 
heparin doses is needed.2,10 Transvalvular gradients 
increase during pregnancy because of increased 
heart rate, plasma volume, and stroke volume.1 In 
the event that valve intervention is required during 
pregnancy, the comprehensive Heart Valve Team 
and maternal-fetal medicine team is required to 
optimize maternal and fetal outcomes.
3. Each anticoagulation strategy has relative advan-
tages and disadvantages in terms of maternal and 
fetal safety, but there is no anticoagulation strat-
egy that is consistently safe for the mother and 
fetus. The maternal mortality rate is >1%, and seri-
ous maternal and fetal complications are common, 
even with modern mechanical heart valves and 
careful management.4–6 After counseling, some 
women with mechanical heart valves may choose 
not to become pregnant, whereas others may wish 
to proceed with pregnancy, so comprehensive and 
candid counseling about the risks of pregnancy 
with a mechanical heart valve is important.
4. Pregnancy is a time of increased risk of mechani-
cal valve thrombosis, so there should be high 
suspicion of valve thrombosis in women with an 
embolic event, clinical deterioration, symptoms of 
HF, or a pronounced increase in valve gradients or 
valve regurgitation during pregnancy. TEE is use-
ful to visualize leaflet motion and thrombus bur -
den. Fluoroscopy and gated cardiac CT are also 
useful in evaluating patients with suspected valve 
thrombosis.7,11,1213.2.2. Anticoagulation for Pregnant Women 
With Mechanical Prosthetic Heart Valves
Recommendations for Anticoagulation for Pregnant Women With 
Mechanical Prosthetic Heart Valves
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 44.
COR LOE Recommendations
1 B-NR1.  Pregnant women with mechanical prostheses 
should receive therapeutic anticoagulation 
with frequent monitoring during pregnancy.1–10 
1 B-NR2.  Women with mechanical heart valves who 
cannot maintain therapeutic anticoagulation 
with frequent monitoring should be 
counseled against pregnancy.7,8,10–15 
1 B-NR3.  Women with mechanical heart valves and 
their providers should use shared decision-
making to choose an anticoagulation strategy 
for pregnancy. Women should be informed 
that VKA during pregnancy is associated 
with the lowest likelihood of maternal 
complications but the highest likelihood 
of miscarriage, fetal death, and congenital 
abnormalities, particularly if taken during 
the first trimester and if the warfarin dose 
exceeds 5 mg/d.3–6,11,14,16 
1 C-LD4.  Pregnant women with mechanical valve 
prostheses who are on warfarin should 
switch to twice-daily LMWH (with a target 
anti-Xa level of 0.8 U/mL to 1.2 U/mL at 4 
to 6 hours after dose) or intravenous UFH 
(with an activated partial thromboplastin time 
[aPTT] 2 times control) at least 1 week before 
planned delivery.5,8,13,17–20 
1 C-LD5.  Pregnant women with mechanical valve 
prostheses who are on LMWH should switch 
to UFH (with an aPTT 2 times control) at least 
36 hours before planned delivery.19–21 
1 C-LD6.  Pregnant women with valve prostheses 
should stop UFH at least 6 hours before 
planned vaginal delivery.19–21 
1 C-LD7.  If labor begins or urgent delivery is required in 
a woman therapeutically anticoagulated with 
a VKA, cesarean section should be performed 
after reversal of anticoagulation.3,22,23 
2a B-NR8.  For pregnant women with mechanical 
prostheses who require a dose of warfarin 
≤5 mg/d to maintain a therapeutic INR, 
continuation of warfarin for all 3 trimesters 
is reasonable after full discussion with the 
patient about risks and benefits.3,6,16,18,22,24,25
2a B-NR9.  For pregnant women with mechanical 
prostheses who require >5 mg/d of warfarin 
to achieve a therapeutic INR, dose-adjusted 
LMWH (with a target anti-Xa level of 0.8 to 
1.2 U/mL at 4 to 6 hours after dose) at least 
2 times per day during the first trimester, 
followed by warfarin during the second and 
third trimesters, is reasonable.3,6,15,16,25
2a B-NR10.  For pregnant women with mechanical 
prostheses who require a dose of warfarin >5 
mg/d to achieve a therapeutic INR, and for 
whom dose-adjusted LMWH is unavailable, 
dose-adjusted continuous intravenous UFH 
during the first trimester (with aPTT 2 times 
control), followed by warfarin for the second 
and third trimesters, is reasonable.3,6,11,16 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e171
CLINICAL STATEMENTS  
AND GUIDELINES2a B-NR11.  For hemodynamically stable pregnant women 
with obstructive left-sided mechanical valve 
thrombosis, it is reasonable to manage with 
slow-infusion, low-dose fibrinolytic therapy.26 
2b B-NR12.  For pregnant women with mechanical 
prostheses who require a warfarin dose >5 
mg/d to achieve a therapeutic INR, dose-
adjusted LMWH (with a target anti-Xa level of 
0.8 to 1.2 U/mL at 4 to 6 hours after dose) at 
least 2 times per day for all 3 trimesters may 
be considered.3,6,14–16,27 
2b B-NR13.  For pregnant women with mechanical 
prostheses who require a dose of warfarin 
≤5 mg/d to maintain a therapeutic INR, 
dose-adjusted LMWH at least 2 times per 
day during the first trimester, followed by 
warfarin for the second and third trimesters, 
may be considered.1–3,6,12,16,22 
2b B-NR14.  For pregnant women with mechanical 
prostheses, aspirin 75 to 100 mg daily may 
be considered, in addition to anticoagulation, 
if needed for other indications.28 
3: Harm B-NR15.  For pregnant women with mechanical 
prostheses, LMWH should not be 
administered unless anti-Xa levels are 
monitored 4 to 6 hours after administration 
and dose is adjusted according to 
levels.8–10,15,27 
3: Harm B-R16.  For patients with mechanical valve 
prostheses, anticoagulation with the direct 
thrombin inhibitor, dabigatran, should not be 
administered.29 
3: Harm C-EO17.  The use of anti-Xa direct oral anticoagulants 
with mechanical heart valves in pregnancy 
has not been assessed and is not 
recommended.30–32 
Synopsis
Pregnant women with mechanical heart valves are at 
increased risk of serious maternal complications, in-
cluding valve thrombosis, thromboembolism, hemor -
rhage, and death. The risk of poor fetal outcomes is 
also high, with increased rates of spontaneous abor -
tion, fetal death, fetal hemorrhage, and teratogenic-
ity related to VKAs. For women with mechanical heart 
valves, the maternal mortality rate remains >1%. More 
than one-third of women with mechanical heart valves 
have a serious maternal or fetal complication during  
pregnancy.1–4,9,24,33,34
All women with mechanical heart valves require 
uninterrupted therapeutic anticoagulation throughout 
pregnancy. The choice of anticoagulation strategy is 
challenging because there are inherent trade-offs be-
tween maternal safety and fetal safety. Warfarin is the 
most effective anticoagulant at preventing thrombotic 
complications, but warfarin crosses the placenta and 
can cause miscarriage, spontaneous abortion, war -
farin embryopathy, or fetal intracranial hemorrhage. Although LMWH is not teratogenic, women with me-
chanical heart valves on LMWH are at increased risk 
of thrombotic events, particularly when LMWH is im-
properly dosed, monitored, or administered. There is 
no single optimal anticoagulation strategy that suits all 
women.
There are 3 potential strategies: 1) Continue warfa-
rin throughout pregnancy; 2) use heparin throughout 
pregnancy; and 3) use sequential therapy, with heparin 
during the first trimester and warfarin during the sec-
ond and third trimesters (Figure 18).
Recommendation-Specific Supportive Text
1. The risk of catastrophic valve failure or stroke is 
prohibitively high for women with mechanical 
heart valves who cannot take dose-adjusted and 
frequently monitored anticoagulation throughout 
pregnancy.1–10
2. Much of the maternal morbidity and mortality 
during pregnancy occurs in women who are not 
receiving appropriate doses of anticoagulation 
because of improper administration, improper 
monitoring, or medication nonadherence. 
Women who are not able to receive therapeutic 
anticoagulation or do not have access to frequent 
monitoring and dose adjustment are at prohibi-
tive risk for pregnancy.13–15
3. No anticoagulation strategy is optimally safe for 
both the mother and the fetus. Warfarin is saf-
est for the mother but crosses the placenta and 
can cause fetal intracranial hemorrhage; fetal 
loss; and teratogenicity, particularly at doses >5 
mg/d and when given during the first trimester, 
keeping in mind that the warfarin dose needed 
to maintain a therapeutic INR may change during 
pregnancy. Neither UFH nor LMWH crosses the 
placenta, but each is associated with higher rates 
of maternal complications than are seen with war -
farin.3,4,6,16,18,20,23,25,35,36 Depending on a woman’s 
values and priorities, she may choose an antico-
agulation strategy that minimizes maternal risk, 
minimizes fetal risk, or attempts to achieve a bal-
ance between maternal and fetal risk. Physicians 
should not assume a woman’s values or prefer -
ences, nor should physicians supplant their own 
preferences for those of the patient. Counseling 
and shared decision-making allows for a woman 
and her physician to choose the best anticoagula-
tion to achieve the woman’s goals.
4. Warfarin crosses the placental barrier and results 
in anticoagulation of the fetus, as well as the 
mother. There is a higher risk of fetal intracra-
nial hemorrhage if the mother is fully antico-
agulated with warfarin during vaginal delivery. 
Women taking warfarin can minimize the risk Recommendations for Anticoagulation for Pregnant Women With 
Mechanical Prosthetic Heart Valves (Continued)
COR LOE Recommendations
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e172
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Figure 18. Anticoagulation for prosthetic mechanical heart valves in women during pregnancy.
Colors correspond to Table 2.*Dose-adjusted LMWH should be given at least 2 times per day, with close monitoring of anti-Xa levels. Target to Xa level of 0.8 to 
1.2 U/mL, 4 to 6 hours after dose. Trough levels may aid in maintaining patient in therapeutic range. Continuous UFH should be adjusted to aPTT 2 times control. 
aPTT indicates activated partial thromboplastin time; IV, intravenous; LMWH, low-molecular-weight heparin; UFH, unfractionated heparin; and VKA, vitamin K 
antagonist.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e173
CLINICAL STATEMENTS  
AND GUIDELINESby switching to a heparin preparation before 
planned delivery.5,8,13,17–20
5. Although LMWH does not result in an antico-
agulated fetus, the risk of maternal hemorrhage 
is high if delivery occurs while the mother is on 
LMWH. Therefore, it is recommended that the 
mother be hospitalized before planned delivery, 
with discontinuation of long-acting anticoagu-
lation and initiation of intravenous continuous 
infusion of UFH to keep aPTT >2 times control 
levels.19,20
6. Intravenous heparin should be stopped long 
enough before delivery to reduce risk of mater -
nal bleeding and allow safe placement of epidural 
anesthesia (typically at least 6 hours). Exact tim-
ing should be coordinated with the obstetrics and 
anesthesia teams.19,20
7. Because warfarin results in an anticoagulated 
fetus, there is a high risk of fetal intracranial 
hemorrhage if vaginal delivery is attempted in 
a woman who is anticoagulated with warfarin. 
If a woman goes into labor while on warfarin, 
appropriate reversal of anticoagulation followed 
by cesarean section reduces the risk of fetal intra-
cranial hemorrhage.3,22,23
8. The teratogenic effects of warfarin are dose 
dependent. The rate of warfarin embryopathy 
is reduced (<3%) but not eliminated if the daily 
dose of warfarin is ≤5 mg/d.3,6.16,18,23,25,36,37 In most 
women, the effective dose of warfarin typically 
does not vary significantly during pregnancy.38 For 
women who require a dose ≤5 mg/d, continua-
tion of low-dose warfarin throughout pregnancy 
poses the lowest combined risk to mother and 
fetus.3,6,16 The number of reported pregnancies 
on low-dose warfarin is relatively small, and not 
all publications have found improved fetal out-
comes on low-dose warfarin,11 so caution should 
be exercised until more data are available.
9. If warfarin is taken in doses >5 mg/d during the 
first trimester of pregnancy, there is a >30% risk of 
fetal loss or embryopathy. For women who require 
>5 mg/d to maintain a therapeutic INR, replac-
ing warfarin with dose-adjusted LWMH during 
the first trimester reduces fetal loss.3,6,10,15,16,23,39,40 
While the patient is taking LMWH, anti-Xa levels 
should be monitored at least weekly and the dose 
adjusted accordingly. Fixed dosing is never appro-
priate, because it is associated with high maternal 
morbidity and mortality.41 After the first trimester, 
the fetal toxicity of warfarin is substantially lower, 
so switching back to warfarin for the second and 
third trimesters results in a reasonable balance 
between maternal safety and fetal safety.
10. In regions where LMWH is unavailable or cost-pro-
hibitive, or if anti-Xa levels cannot be monitored, continuous infusion of UFH can be used as an 
alternative to LMWH during the first trimester for 
women who require a warfarin dose of >5 mg/d.37 
If UFH is used during the first trimester, the dose 
should be adjusted to maintain an aPTT 2 times 
control. There are several disadvantages to UFH 
compared with LMWH: Women are at greater 
risk for line infections, osteoporosis, and hepa-
rin-induced thrombocytopenia, so UFH should 
be reserved for situations where dose-adjusted 
LMWH is not feasible.10 Intermittent subcutane-
ous injection of UFH is not an acceptable alterna-
tive because it is associated with prohibitive rates 
of valve thrombosis.42 UFH is associated with very 
high rates of valve thrombosis, stroke, and death 
in pregnant women with mechanical heart valves 
during the second and third trimesters.3,4,43
11. In carefully selected women with thrombosis of 
a mechanical heart valve during pregnancy, low-
dose, slow-infusion, tissue-type plasminogen acti-
vator (tPA) can be an alternative to surgical valve 
replacement. Women who are optimal candidates 
are hemodynamically stable and have obstructive 
prosthetic valve thrombosis, valve thrombosis with 
embolic complications, or nonobstructive valve 
thrombosis with a thrombus >10 mm.44 Given the 
high rates of fetal loss with cardiac surgery during 
pregnancy, thrombolysis is an attractive alterna-
tive for appropriately selected, hemodynamically 
stable women with mechanical valve thrombosis.
12. Although the teratogenicity of warfarin is high-
est during the first trimester, there is still a risk 
of pregnancy loss or fetal hemorrhage when 
warfarin is taken during the second and third 
trimesters. Therefore, after appropriate counsel-
ing, some women may choose to avoid warfarin 
entirely throughout pregnancy. For these women, 
dose-adjusted LMWH throughout pregnancy is 
the safest alterative. LMWH throughout preg-
nancy is associated with a higher rate of throm-
botic complications than warfarin. However, 
many of the thrombotic events occur when 
LMWH is administered improperly or monitored 
erratically or if patients are nonadherent.8,14,15,39 
When administered and monitored meticulously, 
LMWH can be safe.12 Effective dose monitoring 
includes weekly measurements of anti–factor 
Xa levels, with additional monitoring after dose 
adjustment.13 Measurement of trough levels to 
maintain a trough Xa level >0.6 IU/mL may help 
women maintain therapeutic anticoagulation 
while on LMWH.12,13
13. When warfarin is taken at a dose ≤5 mg/d, the 
risk of warfarin embryopathy is reduced but not 
entirely eliminated. Some women, after discussion 
with their physicians, may choose to substitute 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e174
CLINICAL STATEMENTS  
AND GUIDELINESLMWH for low-dose warfarin during the first tri-
mester to eliminate the risk of warfarin embry-
opathy. This choice improves fetal outcomes but 
at the cost of increased maternal thrombotic 
complications.1–3,12
14. Low-dose aspirin is regarded as safe during preg-
nancy and can be continued in women with 
mechanical heart valves if needed for other indi-
cations. There may be noncardiac indications for 
aspirin in pregnant women, such as prevention of 
preeclampsia.28
15. Studies using subcutaneous LMWH at a fixed 
dose without monitoring of anti-Xa levels in preg-
nant patients with mechanical prostheses found a 
high risk of valve thrombosis and maternal death. 
In pregnant women treated with dose-adjusted 
LMWH, the dose of LMWH required to maintain 
an adequate anti-Xa level 4 to 6 hours after admin-
istration increases throughout pregnancy.9,15,39,41
16. A randomized clinical trial of dabigatran in non-
pregnant patients with mechanical heart valves 
showed an increased rate of thromboembolic 
and bleeding complications with dabigatran com-
pared with warfarin.45 The safety and effective-
ness of anti-Xa direct oral anticoagulants has not 
been established in patients with mechanical heart 
valves. Additionally, the safety of anti-Xa direct 
oral anticoagulants in pregnancy is unknown.30–32
17. Anti-Xa direct oral anticoagulants have not been 
shown to be safe in patients with mechani-
cal heart valves, so they should not be used in 
pregnancy.
14. SURGICAL CONSIDERATIONS
Concomitant surgical procedures may be appropriate  
at the time of intervention for VHD in the interest of re-
ducing periprocedural risk (eg, treatment of significant 
CAD) or for optimizing long-term outcomes (eg, adding 
a maze procedure for AF treatment). Consideration may 
also be given to treating moderate disease in the inter -
est of obviating the need for subsequent reoperation—
for example, treating aortic dilation in the presence of 
a BAV. This is particularly true when one can anticipate 
particular difficulty in the conduct of a subsequent re-
operation, as may be the case for mitral valve interven-
tion after AVR or in a patient with prior mediastinal ir -
radiation for whom postoperative adhesions are often 
severe. The benefits of such concomitant procedures 
must be balanced against the potential impact on peri-
procedural risk due to added complexity. In particular, 
interventions that add significantly to aortic cross-clamp 
time may be discouraged in patients with poor LV func-
tion or significant pulmonary hypertension. Prolonga-
tion of cardiopulmonary bypass time may increase renal 
injury, particularly among those with preexisting renal dysfunction. More complex procedures may also pose a 
particular risk in patients with fragile tissue integrity or 
general frailty, and the additional dissection that may 
be required in a reoperative setting may tip the balance 
away from imposing additional risk by performing con-
comitant procedures.
14.1. Evaluation and Management of 
CAD in Patients With VHD
14.1.1. Management of CAD in Patients 
Undergoing TAVI
Recommendations for Management of CAD in Patients Undergoing 
TAVI
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 45.
COR LOE Recommendations
1 C-EO1.  In patients undergoing TAVI, 1) contrast-
enhanced coronary CT angiography (in 
patients with a low pretest probability for 
CAD) or 2) an invasive coronary angiogram is 
recommended to assess coronary anatomy and 
guide revascularization.
2a C-LD2.  In patients undergoing TAVI with significant 
left main or proximal CAD with or without 
angina, revascularization by PCI before TAVI is 
reasonable.1,2
2a C-LD3.  In patients with significant AS and significant 
CAD (luminal reduction >70% diameter, 
fractional flow reserve <0.8, instantaneous 
wave-free ratio <0.89) consisting of complex 
bifurcation left main and/or multivessel 
CAD with a SYNTAX (Synergy Between 
Percutaneous Coronary Intervention With 
Taxus and Cardiac Surgery) score >33, SAVR 
and CABG are reasonable and preferred over 
TAVI and PCI.3,4
Synopsis
CAD is common among patients presenting with AS, 
particularly the elderly. In the surgical experience, con-
comitant revascularization impacts long-term survival in 
a favorable way and is commonplace, as is preoperative 
coronary imaging. Similarly, there is an argument to be 
made for coronary revascularization among patients un-
dergoing TAVI, although the effects on late outcomes 
are less well defined and may not be the same as for 
SAVR, given the different demographics and comorbid-
ities of the TAVI versus SAVR populations. Nonetheless, 
at this point, diagnostic imaging and consideration of 
revascularization are appropriate (Figure 19).
Recommendation-Specific Supportive Text
1. The prevalence of CAD in patients with severe 
AS ranges between 15% and 80%.5 and varies 
depending on the definition of CAD used and the 
populations examined.6 The impact of CAD on 
outcomes is controversial,7,8 although one report 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e175
CLINICAL STATEMENTS  
AND GUIDELINESsingled out severe CAD (defined by a SYNTAX 
score >22) and incomplete revascularization as the 
only independent predictors of death after TAVI.9 
Assessment of the coronary anatomy is important 
in patients with severe AS to rule out obstructive 
CAD. Invasive coronary angiography is commonly 
performed. In patients with a low pretest prob-
ability of CAD, contrast-enhanced coronary CT 
angiography10 has an excellent negative predictive 
value.11,12 In patients with normal renal function, 
an option is to combine contrast-enhanced coro-
nary CT angiography with CT assessment of the 
peripheral circulation and heart structure as an ini-
tial imaging test, reserving coronary angiography 
for the event that the contrast-enhanced coronary 
CT angiography is nondiagnostic or significant 
CAD is found. Invasive functional assessment of 
coronary lesions in TAVI candidates by using frac-
tional flow reserve or instantaneous wave-free 
ratio is safe and feasible.13–15 Instantaneous wave-
free ratio may be particularly attractive because 
it does not require the administration of a vaso-
dilator and is less influenced by the effect of the stenotic aortic valve, although randomized clinical 
trials validating the utility of both are ongoing.
2. There are no RCTs to inform clinical practice on 
the benefits and timing of PCI in patients under -
going TAVI. The decision to perform PCI is there-
fore driven by myriad clinical factors (eg, presence 
of angina or ischemia, ability to take dual-anti-
platelet therapy before TAVI) and anatomic fac-
tors (eg, lesion location and complexity, technical 
feasibility) and should be individualized. Overall, 
nonrandomized studies suggest that PCI before 
TAVI is safe and feasible,1 even in patients with 
left main disease.2 Conceptually, pre-TAVI PCI 
also allows a safer procedure and circumvents 
future post-TAVI PCI, which can be occasionally 
challenging. Staged PCI before TAVI is a common 
strategy in clinical practice and is associated with 
lower contrast volume and renal failure than is the 
strategy of TAVI with concomitant PCI,1 although 
the timing of pre-TAVI PCI remains controversial.
3. Multiple RCTs have been conducted to define the 
optimal management of CAD in patients with-
out VHD based on the SYNTAX score to define 
Figure 19. Management of CAD in patients undergoing valve interventions.
Colors correspond to Table 2. *Including men age >40 years and postmenopausal women. AVR indicates aortic valve replacement; CAD, coronary artery disease; 
CABG, coronary artery bypass graft; CT, computed tomography; LV, left ventricular; MR, mitral regurgitation; PCI, percutaneous coronary intervention; SYNTAX, 
Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; and TAVI, transcatheter aortic valve implantation.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e176
CLINICAL STATEMENTS  
AND GUIDELINESthose least amenable to percutaneous treatment. 
Subsets of patients shown to have superior free-
dom from major adverse cardiac events include 
those with complex left main disease and those 
with a SYNTAX score >33.3 Accordingly, a surgical 
approach is reasonable in this subset of patients. 
Among SAVR patients, revascularization for those 
with significant CAD (>50% stenosis) has been 
shown to impact late risk of mortality favorably.4
14.1.2. Management of CAD in Patients 
Undergoing Valve Surgery
Recommendations for Management of CAD in Patients Undergoing 
Valve Surgery
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 45.
COR LOE Recommendations
1 C-LD1.  In patients with symptoms of angina, objective 
evidence of ischemia, decreased LV systolic 
function, history of CAD, or coronary risk 
factors (including men >40 years of age and 
postmenopausal women), invasive coronary 
angiography is indicated before valve 
intervention.1–8
1 C-LD2.  In patients with chronic severe secondary 
MR, invasive coronary angiography should be 
performed as part of the evaluation.9–11
2a B-NR3.  In selected patients with a low to intermediate 
pretest probability of CAD, contrast-enhanced 
coronary CT angiography is reasonable to 
exclude the presence of significant obstructive 
CAD.12–18
2a C-LD4.  In patients undergoing valve repair or 
replacement with significant proximal CAD 
(≥70% reduction in luminal diameter in major 
coronary arteries or ≥50% reduction in luminal 
diameter in the left main coronary artery 
and/or physiologically significance), CABG is 
reasonable for selective patients.19,20
Synopsis
Coronary imaging in the setting of VHD defines anat-
omy that may be at risk during surgery or interven-
tion. Given their similar demographic profiles, CAD 
and VHD frequently coexist, and in the case of sec-
ondary MR they have a pathophysiological link. Re-
vascularization, in turn, can impact periprocedural risk 
or long-term outcome. In the case of secondary MR, 
revascularization may positively impact the valve dis-
ease via reverse remodeling of the LV. In the surgical 
setting, where repeat intervention is at high cost to 
the patient, efforts are typically made to correct all 
surgically correctable disease present at the index op-
eration. Accordingly, an aggressive approach to revas-
cularization is appropriate. In the setting of percutane-
ous interventions, however, the option of sequential 
interventions with interval tests of improvement may 
be appropriate. In either case, less invasive imaging 
via contrast-enhanced coronary CT angiography is in-
creasingly adopted.Recommendation-Specific Supportive Text
1. CAD is frequently present among patients with 
VHD1–4 and may contribute to angina pecto-
ris among those with aortic valve disease.3,4 
Knowledge of coronary anatomy contributes to 
risk stratification, in addition to directing concom-
itant coronary revascularization. There is a very 
low prevalence of CAD among men <40 years of 
age and premenopausal women with no athero-
sclerotic risk factors2,5–7 or history of mediastinal 
radiation.8
2. Functional MR occurs in patients with structur -
ally normal valve leaflets and chordae because 
of LV dysfunction, including regional wall motion 
abnormalities or global dilation with displace-
ment of the papillary muscles, leaflet tethering, 
annular dilation, and decreased closing forces 
from reduced contractility.9–11 Because this LV dys-
function may be attributable to CAD and accom-
panying myocardial ischemia, the assessment of 
coronary anatomy status is necessary to complete 
the diagnosis and allow evaluation of revascular -
ization options.
3. Contrast-enhanced coronary CT angiography is 
an alternative to coronary angiography among 
selected patients who are at low to intermediate 
pretest probability of CAD before valve surgery.12 
This does not include patients who have active 
symptoms of angina, those with documented 
ischemia, or those with a prior history of CAD, 
all of whom should have selective coronary angi-
ography. Recent studies, most often in the set-
ting of a pre-TAVI evaluation, have demonstrated 
diagnostic sensitivity of >90%, specificity of 60% 
to 90%,13–15,21 and accuracy of >90%.21 Contrast-
enhanced coronary CT angiography may be safer 
than coronary angiography in selected patient 
populations, such as those with IE and vegeta-
tions on the aortic valve. However, a positive con-
trast-enhanced coronary CT angiogram, defined 
as the presence of epicardial CAD, requires con-
firmation with invasive coronary angiography 
to establish the need for and extent of CABG. 
The risk of radiation exposure and renal failure 
because of the contrast injection should be taken 
into consideration.
4. The presence of uncorrected CAD has been shown 
to negatively impact both perioperative22,23 and 
late outcomes of surgery for VHD.19. Accordingly, 
concomitant CABG has been favored. These stud-
ies of concomitant CABG at the time of valve 
surgery have demonstrated little or no adverse 
impact on the acute perioperative mortality rate, 
despite increased cross-clamp and cardiopulmo-
nary bypass times. Moreover, combined CABG 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e177
CLINICAL STATEMENTS  
AND GUIDELINESand valve surgery reduces the rate of perioperative 
myocardial infarction, and incomplete revascular -
ization is associated with greater postoperative 
LV systolic dysfunction and a reduced survival 
rate after surgery as compared with patients who 
receive complete revascularization. For more than 
a decade, improved myocardial preservation tech-
niques have been associated with reduced overall 
operative mortality rates, and it has become stan-
dard practice to bypass all significant coronary 
artery stenoses, when possible, in patients under -
going valve surgery. In patients with a significant 
stenosis of the left anterior descending artery, a 
left internal thoracic artery graft should be used 
if possible. Hybrid PCI followed by surgical valve 
repair or replacement has been reported favor -
ably but is restricted to patients at high risk with a 
combined surgical approach.20
14.2. Intervention for AF in Patients With 
VHD
Recommendations for Intervention for AF in Patients With VHD
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 46.
COR LOE Recommendations
1 C-LD1.  In patients with VHD and AF for whom 
surgical intervention is planned, the potential 
symptomatic benefits and additional 
procedural risks of adjunctive arrhythmia 
surgery at the time of cardiac valvular surgery 
should be discussed with the patient.1–11 
2a B-R2.  For symptomatic patients with paroxysmal or 
persistent AF who are undergoing valvular 
surgery, surgical pulmonary vein isolation 
or a maze procedure can be beneficial to 
reduce symptoms and prevent recurrent 
arrhythmias.1,2,12–15
2a B-NR3.  For patients with AF or atrial flutter who are 
undergoing valve surgery, LA appendage 
ligation/excision is reasonable to reduce the 
risk of thromboembolic events.16–19
2a B-NR4.  In patients undergoing LA surgical ablation 
of atrial arrhythmias and/or LA appendage 
ligation/excision, anticoagulation therapy is 
reasonable for at least 3 months after the 
procedure.20–22 
3: Harm B-NR5.  For patients without atrial arrhythmias who are 
undergoing valvular surgery, LA appendage 
occlusion/exclusion/amputation is potentially 
harmful.23 
Synopsis
For patients undergoing valve surgery with symptom-
atic AF or atrial flutter, concomitant maze procedure 
with or without atrial appendage occlusion/exclusion/
amputation is a proven treatment for the atrial arrhyth-
mia but requires postoperative anticoagulation for at 
least 3 months after the procedure (Figure 20).Recommendation-Specific Supportive Text
1. Surgical ablations, including pulmonary vein isola-
tion and atrial maze at the time of valvular surgery 
and other open cardiac operations, have been dem-
onstrated in multiple studies to reduce the recur -
rence of AF.5–11 Various approaches to pulmonary 
vein isolation and modified left atrial, right atrial, 
and bi-atrial maze procedures entail longer proce-
dure times, with higher risks of operative complica-
tions and permanent pacemaker implantation.1–4 
These adverse outcomes, coupled with the lack of 
large randomized trial data confirming mortality and 
stroke benefit, should be examined with the patient.
2. The atrial maze procedure properly refers to a 
specific bi-atrial lesion set performed by a “cut-
and-sew” technique or with tissue ablation tech-
nologies, including cryoenergy or radiofrequency. 
Of note, the term “maze” is often loosely applied 
to many variations of the original lesion set that 
may be less effective. When performed with com-
plete encirclement of the pulmonary veins, most 
commonly in combination with mitral valve repair 
or replacement but also with aortic or tricuspid 
valve procedures, the maze procedure affords 
freedom from AF with an efficacy similar to that 
of catheter-based approaches.1,2,12–15 Patients 
undergoing combined atrial maze procedure at 
the time of operation for MR have a greater free-
dom from recurrent AF than those who did not 
have a maze procedure.11 In patients with recur -
rent AF who are to undergo surgical correction 
of MR, catheter ablation is best deferred in favor 
of a concomitant surgical maze, thereby avoiding 
the potential complications of a catheter maze 
and a second procedure for the patient.
3. A reduction in thromboembolism has been demon-
strated by LA ligation/excision, although the ben-
efit is less evident in those patients who maintain 
anticoagulation.16–19 Discontinuation of oral antico-
agulation has also been associated with late stroke, 
highlighting that the LA appendage is not the 
exclusive source of all thrombi in patients with AF. 
Therefore, there are insufficient data to support rou-
tine discontinuation of anticoagulation in patients 
with AF who are undergoing LA ligation/excision.
4. Ablation with radiofrequency/cryoenergy or atrial 
suture lines provides an endocardial thrombo-
genic milieu, and in addition, surgical LA append-
age occlusion can be incomplete.20–22 In the 
context of atrial arrhythmias, manipulation of 
the LA, and post-cardioversion/defibrillation stun-
ning, atrial mechanical function can be slow to 
recover. The resultant stasis and thrombogenic 
endocardial lesions provide a nidus for thrombus 
development, placing this group of patients at 
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e178
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
risk of stroke. Nonrandomized registry data indi-
cate that stroke in the first 3 months after cath-
eter ablation is driven chiefly by discontinuation 
of oral anticoagulation.21 Both US and European 
guideline statements on catheter ablation rec-
ommend (on the basis of expert opinion alone) 
anticoagulation during this periprocedural phase 
while the endocardium heals from the ablation. 
By analogy, patients who have had surgical abla-
tion should be managed with at least 3 months 
of anticoagulation, regardless of their CHA2DS2-
VASc risk score. Subsequent anticoagulation 
should be based on evaluation of arrhythmia 
recurrence in the context of their CHA2DS2-VASc 
score. Anticoagulation should also be given for 
at least 3 months after LA ligation/excision. For 
patients receiving bioprostheses, a VKA would be 
the preferred method of anticoagulation for the 
first 3 months (see Section 2.4.3).
5. A higher incidence of early AF in all patients after 
LA appendage occlusion/exclusion has been dem-
onstrated.23 Together with the recognition that most patients do not develop AF after surgery, pre-
emptive LA appendage occlusion in patients with-
out preexisting AF cannot be recommended. No 
stroke benefit has been observed in this group of 
patients with no preemptive history of AF.
15. NONCARDIAC SURGERY IN 
PATIENTS WITH VHD
15.1. Diagnosis of Patients With VHD 
Undergoing Noncardiac Surgery
Recommendation for Diagnosis in Patients With VHD Undergoing 
Noncardiac Surgery
COR LOE Recommendation
1 C-EO1.  In patients with clinically suspected moderate or 
greater degrees of valvular stenosis or regurgitation 
who are undergoing noncardiac surgery, 
preoperative echocardiography is recommended.
Synopsis
The evaluation of patients with VHD who are undergo-
ing noncardiac surgery is dependent on the type and 
Figure 20. Intervention for AF in patients 
with VHD.
Colors correspond to Table 2. AF indicates atrial 
fibrillation; LA, left atrial, and VHD, valvular heart 
disease.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e179
CLINICAL STATEMENTS  
AND GUIDELINESseverity of VHD, including 1) the presence or absence of 
symptoms, 2) the severity of VHD, 3) the risk of noncar -
diac intervention, 4) the response of the LV and/or RV 
to the overload caused by VHD, and 5) the pulmonary 
artery systolic pressure. If the patient meets standard 
criteria for a cardiac intervention, it is prudent to de-
fer elective noncardiac procedures and proceed to valve 
intervention first.1–4 However, in emergency situations, 
noncardiac surgery may be necessary in the presence 
of uncorrected severe valve disease. All patients with 
severe VHD who are undergoing noncardiac surgery 
benefit from an evaluation by a Heart Team consisting 
of a cardiologist, cardiac anesthesiologist, and cardiac 
surgeons, in conjunction with the surgeon performing 
the procedure. In patients with severe VHD who are un-
dergoing low-risk surgical procedures or in patients with 
mild to moderate VHD, noninvasive monitoring in con-
sultation with a cardiovascular anesthesiologist may be 
all that is needed. In patients with severe VHD who are 
undergoing elevated-risk noncardiac surgery, decisions 
should be made as to whether to proceed with the non-
cardiac surgery and whether invasive hemodynamic or 
TEE imaging monitoring should be performed intraop-
eratively and postoperatively in an intensive care setting.
Recommendation-Specific Supportive Text
1. After a careful clinical evaluation and preopera-
tive resting 12-lead ECG, patients being evalu-
ated for noncardiac surgery who have known or 
suspected VHD of moderate or greater degree 
benefit from TTE.5 If there has been no change 
in clinical course, an echocardiogram within the 
past 12 months can be used. Most adverse events 
have occurred because the diagnosis of VHD was 
not known to the surgical team. The echocardio-
graphic evaluation should quantify the severity 
of valve stenosis or regurgitation, calculate sys-
tolic function, estimate diastolic function, evalu-
ate LV size and myocardial structure, estimate RV 
size and function, and estimate pulmonary artery 
systolic pressure.4 AS is present in 1% to 2% of 
all patients >65 years of age and 3% to 8% of 
all patients >75 years of age. Severe AS is asso-
ciated with an increased risk during noncardiac 
surgery, depending on the specific degree of valve 
narrowing, LV systolic function, concurrent CAD, 
type of surgery, and other risk factors associated 
with surgery. Rheumatic MS may also be poorly 
tolerated during the altered hemodynamics of 
anesthesia and noncardiac surgery. Left-sided 
regurgitant lesions are better tolerated but still 
convey increased risk, particularly if the anesthesi-
ologist and surgeon are unaware of the diagnosis 
or severity of valve disease.15.2.Management of the Symptomatic 
Patient
Recommendation for Management of the Symptomatic Patient 
With VHD Undergoing Noncardiac Surgery
COR LOE Recommendation
1 C-EO1.  In patients who meet standard indications 
for intervention for VHD (replacement and 
repair) on the basis of symptoms and disease 
severity, intervention should be performed 
before elective noncardiac surgery to reduce 
perioperative risk if possible, depending 
on the urgency and risk of the noncardiac 
procedure.1
Synopsis
Symptomatic patients with severe VHD benefit from 
valve intervention before noncardiac surgery, if possible.
Recommendation-Specific Supportive Text
1. Noncardiac surgery patients with symptom-
atic severe AS have the highest risk of cardiac 
complications; the estimated rate of cardiac 
complications in patients with undiagnosed 
severe AS undergoing noncardiac surgery is 
10% to 30%. AVR (SAVR, TAVI) performed 
before elective elevated-risk noncardiac sur -
gery in symptomatic patients with severe AS 
will prevent hemodynamic instability during, 
as well as after, noncardiac surgery.1–7 In AS 
patients who are undergoing noncardiac sur -
gery, there is lack of data on the efficacy or 
safety of TAVI,8 but TAVI is a reasonable option 
to avoid delay of semi-urgent noncardiac sur -
gery. In hemodynamically unstable patients at 
high to prohibitive surgical risk for AVR, bal-
loon aortic valvuloplasty as a bridging strategy 
may be an option.9–11 Symptomatic patients 
with rheumatic MS (the pathophysiology and 
implications of rheumatic MS and AS are simi-
lar) or patients with pulmonary artery systolic 
pressure >50 mm Hg benefit from valvular 
intervention before elective noncardiac surgery 
according to recommendations for rheumatic 
MS. Left-sided regurgitant lesions also convey 
increased cardiac risk during noncardiac sur -
gery.1,2 Although these lesions are generally 
better tolerated than stenotic valvular disease, 
in patients with MR and AR who are undergo-
ing elective elevated-risk (ie, intermediate- or 
high-risk) noncardiac surgery and who meet 
standard indications for intervention, mitral 
or aortic valve surgery (repair or replacement) 
optimally should be performed before noncar -
diac surgery.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e180
CLINICAL STATEMENTS  
AND GUIDELINES15.3. Management of the Asymptomatic 
Patient
Recommendations for Management of the Asymptomatic Patient 
With VHD Undergoing Noncardiac Surgery
Referenced studies that support the recommendations are 
summarized in Online Data Supplement 47.
COR LOE Recommendations
2a B-R1.  In asymptomatic patients with moderate or 
greater degrees of AS and normal LV systolic 
function, it is reasonable to perform elective 
noncardiac surgery.1–3
2a C-EO2.  In asymptomatic patients with moderate 
or greater degrees of rheumatic MS with 
less than severe pulmonary hypertension 
(pulmonary artery systolic pressure <50 
mm Hg), it is reasonable to perform elective 
noncardiac surgery. 
2a C-LD3.  In asymptomatic patients with moderate or 
greater degrees of MR and normal LV systolic 
function with less than severe pulmonary 
hypertension (pulmonary artery systolic 
pressure <50 mm Hg), it is reasonable to 
perform elective noncardiac surgery.4–7
2a C-LD4.  In asymptomatic patients with moderate or 
greater degrees of AR and normal LV systolic 
function, it is reasonable to perform elective 
noncardiac surgery.8
Synopsis
In asymptomatic patients with significant VHD who do 
not meet standard criteria for intervention, the risk as-
sociated with the noncardiac procedure can be mini-
mized by choosing an anesthetic approach that is ap-
propriate to the valve lesion and ensuring a higher level 
of intraoperative (and perioperative) monitoring, taking 
into account the underlying valvular abnormality, its ef-
fect on LV function, and comorbidities. In patients with 
VHD, the cardiovascular risk of noncardiac surgery is 
also impacted by other cardiovascular conditions, such 
as LV and RV dysfunction, CAD, pulmonary hyperten-
sion, and peripheral artery disease. In patients with 
moderate or greater degrees of AS, the hemodynamic 
effects of anesthesia and surgery are poorly tolerated; 
predictors of adverse outcomes include severity of AS, 
coexisting MR, pulmonary hypertension, and CAD. 
However, these comorbidities also increase the risk of 
AVR. Data are limited, but the risk–benefit ratio con-
tinues to favor managing asymptomatic patients with 
severe AS who are undergoing noncardiac surgery with 
hemodynamic monitoring and optimization of load-
ing conditions, rather than considering prophylactic 
AVR. The patient with rheumatic MS who is undergo-
ing noncardiac surgery is treated in a manner similar 
to the patient with AS. Regurgitant lesions also convey 
an increased risk of cardiac complications in patients 
undergoing noncardiac surgery and thus require careful 
evaluation and hemodynamic monitoring.Recommendation-Specific Supportive Text
1. Asymptomatic patients with severe AS and 
a normal LVEF can undergo noncardiac sur -
gery with acceptable risk, particularly in the 
absence of severe CAD.1–3 Thus, pre-operative 
evaluation to exclude severe CAD with CT or 
angiographic imaging may be useful. In these 
patients with severe asymptomatic AS, cardiac 
complications can be reduced by periprocedural 
continuous optimization of loading conditions, 
thereby avoiding hypotension and tachycardia. 
Sinus rhythm with normal heart rate should be 
maintained. Tachycardia and systemic hypoten-
sion may result in decreased coronary perfusion 
pressure, development of arrhythmias or isch-
emia, myocardial injury, cardiac failure, or death. 
Periprocedural hemodynamic monitoring with a 
right-heart catheter or intraoperative TEE may 
be particularly useful to allow continuous opti-
mization of loading conditions. Intraoperative 
and postoperative monitoring of blood pressure 
and intracardiac volume are implemented start-
ing in the preoperative period and continuing 
until hemodynamics are stable, up to 24 to 48 
hours after the procedure. General anesthetics 
are well tolerated, and the anesthetic agents 
should be chosen to maintain sinus rhythm and 
normotension. Phenylephrine or norepineph-
rine can be used to increase blood pressure in 
patients with no significant CAD.9,10 In case of 
systemic hypertension, arterial dilators, such as 
short-acting calcium channel blockers, are pre-
ferred. Epidural or spinal anesthetic interven-
tions should be modified to avoid rapid changes 
in systemic pressure, using only high-dilution 
neuraxial local anesthetic agents in combination 
with opioids.11–14
2. In asymptomatic patients with moderate or 
greater degrees of rheumatic MS with a pul-
monary artery systolic pressure <50 mm Hg, 
elevated-risk noncardiac surgery can be per -
formed with invasive hemodynamic monitoring 
to optimize loading conditions. Maintenance 
of LV preload and sinus rhythm should be the 
targets in the perioperative period. Preload 
should be maintained at a level high enough 
to allow an adequate forward cardiac output 
across the stenotic mitral valve but low enough 
to avoid pulmonary edema. Preload attain-
ment can be challenging and requires mea-
surement of cardiac output and pulmonary 
wedge pressure. Of particular concern is judi-
cious intravenous fluid administration, so as 
to avoid increases in the LA pressure and pul-
monary capillary pressure that may precipitate 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e181
CLINICAL STATEMENTS  
AND GUIDELINESacute pulmonary edema. Tachycardia should 
be avoided because of the shortened diastolic 
LV filling time across the stenotic mitral valve, 
resulting in an increase in LA pressure.15–17 In 
asymptomatic patients with significant rheu-
matic MS and with a pulmonary artery systolic 
pressure >50 mm Hg, the risk of elective inter -
mediate- to high-risk noncardiac surgery is 
considerably higher, so these patients should 
be evaluated and treated as outlined in the 
rheumatic MS section (Section 6.2).6,7,18
3. In asymptomatic patients with significant MR 
and normal LV systolic function with a pulmo-
nary artery systolic pressure <50 mm Hg who 
are undergoing elective noncardiac surgery, 
the overall hemodynamic goals are avoidance 
of both increased afterload and bradycardia by 
choosing the appropriate anesthetic scheme. 
Left-sided regurgitant lesions convey chronic 
LV volume overload and increased cardiac risk 
during noncardiac surgery but are better toler -
ated than is stenotic valvular disease.11 Patients 
with significant MR undergoing noncardiac 
surgery had higher rates of postoperative HF 
and myocardial infarction than did controls 
without MR.4 The combination of neuraxial 
local anesthetics and opioids produces a favor -
able systemic vasodilation for patients with 
regurgitant valve lesions. Patients with regur -
gitant lesions will also do well with general 
anesthesia, which also lowers systemic vas-
cular resistance. However, preload should be 
maintained.15,16 Invasive hemodynamic and/
or intraoperative TEE monitoring allows for 
continuous optimization of LV filling pressures 
and LV function during and after the opera-
tive procedure. Patients should be admitted to 
an intensive monitoring setting for up to 24 to 
72 hours after the procedure.15 In functional 
MR, especially in these patients for whom very 
careful attention to afterload control and fluid 
balance is crucial, anesthetic considerations 
should also include management of the under -
lying heart disease (ie, ischemic heart disease, 
hypertrophic cardiomyopathy).
4. Patients with severe AR are prone to hemody-
namic instability because of the detrimental 
effects of increased volume on myocardial wall 
stress. The perioperative stress associated with 
noncardiac surgery may lead to hypotension, 
arrhythmias, HF, or even death. Patients with sig-
nificant AR undergoing noncardiac surgery had a 
higher in-hospital mortality rate and higher mor -
bidity rate, including postoperative myocardial 
infarction, stroke, pulmonary edema, intubation >24 hours, and major arrhythmias, than those 
of case-matched controls without AR. Decreased 
LV systolic function, elevated serum creatinine 
>2 mg/dL, and intermediate- to high-risk non-
cardiac surgery were predictors of higher risk 
of cardiopulmonary complications and death.8 
Avoid bradycardia when AR is present because 
of the increase in total diastolic time. These 
patients are monitored with invasive systemic 
arterial and venous catheters and/or TEE and are 
admitted postoperatively to an intensive moni-
toring setting.
16. EVIDENCE GAPS AND FUTURE 
DIRECTIONS
Many recommendations for the evaluation and man-
agement of VHD continue to be based on clinical ex-
perience and observational studies, with prospective 
RCTs limited mostly to new devices. We recommend 
that research on valve disease span the spectrum from 
basic science to prospective randomized trials, includ-
ing medical therapy, and that studies focus on each 
stage of the disease process, from the patient at risk to 
the patient with end-stage disease. Newer approaches, 
such as artificial intelligence and machine learning, as 
well as imaging and engineering advances, may pro-
vide sophisticated tools for diagnosis and therapeutics. 
Research should be patient centered, with patients in-
cluded at every stage of the research process to ensure 
that questions and outcomes important to patients are 
included in the study design, implementation, and re-
porting.
16.1. Prevention of Valve Disease: Stage A
On a worldwide basis, rheumatic fever remains the pri-
mary cause of VHD; global health systems outcomes 
studies are needed to identify impediments to success-
ful primary and secondary prevention of rheumatic 
heart disease. Other approaches to prevention, such 
as vaccine development, and delaying disease progres-
sion once valve damage is present should also be ex-
plored. Disease prevention in patients at risk of other 
types of valve disease is needed, including the control 
of known cardiovascular risk factors. Some subgroups 
at risk of calcific AS can be identified, such as those 
with a congenital BAV or elevated lipoprotein(a) lev-
els. However, there are no known therapies to pre-
vent valve dysfunction in these patients. Basic science 
studies on the genetic and pathobiological causes of 
valve dysfunction will provide insight into mechanisms 
of disease that might allow identification of patients 
at risk and allow early intervention to prevent disease 
initiation.1–12
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e182
CLINICAL STATEMENTS  
AND GUIDELINES16.2. Medical Therapy to Treat or Prevent 
Disease Progression: Stage B
In patients with early VHD, including those with cal-
cific or myxomatous disease, there are currently no 
therapies to prevent disease progression in the valve 
leaflets. Instead, current recommendations are di-
rected toward patient monitoring, with the intent to 
intervene once severe disease is present that results in 
symptoms or abnormal cardiovascular function. Basic 
science studies are needed to identify potential tar -
gets for prevention of progressive VHD. Focused trans-
lational studies using sensitive, advanced imaging 
markers of disease progression may allow more rapid 
clinical implementation and better design of RCTs for 
promising new therapies. There also has been little 
consideration of the interaction of valvular, ventricu-
lar, and vascular involvement in the disease process. 
Additional studies are needed on therapies that might 
prevent the adverse consequences of VHD, such as LV 
dysfunction and pulmonary hypertension. Most im-
portantly, patient education and empowering patients 
to be active participants in managing their health con-
ditions and participating in shared decision-making 
are essential.1–5
16.3. Optimal Timing of Intervention: 
Stage C
Current approaches to identifying the optimal timing of 
intervention in patients with progressive valve disease 
are suboptimal. Symptom onset is a subjective measure 
and may occur too late in the disease course for optimal 
long-term outcomes. Despite the availability of sophisti-
cated approaches for measurement of LV volumes, sys-
tolic function, diastolic function, and other measures of 
myocardial performance, recommendations continue to 
rely on simple linear dimensions used in published se-
ries, with data that may not reflect contemporary clini-
cal outcomes. Studies are urgently needed that evalu-
ate the value of newer measures of LV size, function, 
and myocardial structure in predicting outcomes after 
valve intervention, especially in patients with chronic 
severe AR. However, LV enlargement and dysfunction 
are late consequences of valve dysfunction; as more 
durable approaches to restoring normal valve function 
are developed, the benefit–risk balance for intervention 
will shift to earlier in the disease. Studies examining the 
role of earlier markers of myocardial dysfunction, such 
as strain and strain-rate imaging, diastolic dysfunction, 
circulating blood markers, and other novel approaches 
to defining the optimal timing of intervention, also are 
needed.
Few studies have included adequate numbers of 
older adults to make specific recommendations for this 
group of patients, for whom particular concerns, such as cognitive function, frailty, and mobility challenges, 
may change the decision algorithms. In addition, wom-
en and minorities often are underrepresented in clinical 
trials. Directed efforts are needed to ensure all patient 
groups are included with numbers adequate to perform 
separate data analysis.
Given the relatively low risk associated with inter -
vention in otherwise healthy patients and the improved 
options for valve repair or replacement, RCTs of inter -
vention for severe asymptomatic VHD will be important 
and are in progress for some conditions, such as severe 
AS. Other specific conditions where clinical equipoise 
exists are asymptomatic severe AR with normal LV sys-
tolic function, severe primary MR with normal LV func-
tion and a high likelihood of valve repair, and the role of 
intervention for TR. Data from large, carefully designed 
registries are also needed for defining and improving 
quality of care. Long-term follow-up will be needed to 
ensure the lifetime risks of a prosthetic valve or valve 
repair are balanced against any benefits attributable to 
earlier intervention.1–4
16.4. Better Options for Intervention: 
Stage D
Better options are needed for valve repair and replace-
ment. The timing of intervention is based on the bal-
ance between outcomes with native valve disease and 
the risk and long-term durability of the valve after in-
tervention. As valve repair and replacement options 
improve, the balance will shift toward earlier interven-
tion. A valve substitute is needed that can be safely and 
reliably implanted, is nonthrombogenic, has hemody-
namics similar to a normal native valve, and is dura-
ble. Transcatheter valve procedures offer the promise 
of safe implantation and excellent hemodynamics, but 
long-term durability beyond 5 years is not yet known. 
In patients who require mechanical valve replacement, 
oral therapy is needed that provides effective anticoag-
ulation with a low risk of complications and no negative 
impact on quality of life.
Moderate to severe VHD is present in 2.5% of the 
US population and increases in prevalence with age. 
The disease affects between 4% and 9% of those 65 
to 75 years of age and 12% to 13% of those >75 years 
of age. Many of these patients require surgical or in-
terventional procedures. However, even with interven-
tion, overall survival is lower than expected, and the 
risk of adverse outcomes attributable to VHD is high, 
because of both limited options for restoring normal 
valve function and failure to intervene at the optimal 
time point in the disease course. Research is urgently 
needed on almost every aspect of VHD to ensure that 
patients who already have VHD receive optimal thera-
py and to prevent VHD in those at risk. Approaches to 
improving outcomes in patients with VHD include 1) 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e183
CLINICAL STATEMENTS  
AND GUIDELINESnational and international registries and RCTs, 2) con-
tinuous evaluation of outcomes data at each Compre-
hensive and Primary Heart Valve Center, and 3) focus 
on patient-centric care, with involvement of the patient in the decision-making process (Table 26). More acces-
sible quality and outcome data are also needed from 
Comprehensive Valve Centers to assist cardiologists 
and patients to make well-informed choices.1–3Table 26. Evidence Gaps and Future Directions for Patients With VHD
Evidence Gaps Future Directions
Identification of patients at risk and valve disease prevention (Stage A) 
  Disease mechanisms Basic science to identify specific targets for medical therapy
  Rheumatic heart disease Primary and secondary prevention 
  Calcific valve disease Identification of patients at risk
Risk factor intervention
Prevention of disease initiation
Medical therapy for progressive valve disease (Stage B) 
  Disease mechanisms Basic science to identify specific targets to slow or reverse disease progression 
  Medical intervention Targeted therapy using advanced imaging endpoints to study disease mechanisms 
  Ventricular and vascular interactions Dynamic interplay between valve disease severity and changes in ventricular anatomy and function
Modulation of ventricular and vascular dysfunction in patients with VHD
Optimal timing of intervention (Stage C) 
  Improved measures of disease severity Validation of newer measures of LV size (eg, volumes instead of dimension) and function (eg, 
strain) for timing of intervention decisions.
Evaluation of nonimaging parameters (serum markers and other novel approaches)
  Timing of intervention Timing of intervention in asymptomatic patients with valve regurgitation
Intervention for asymptomatic severe AS
Intervention for moderate AS with LV dysfunction
Identification of patients with secondary MR who benefit from intervention
  Patient-centered research Involvement of patients in identifying research questions, study design, and definition of outcomes 
  Inclusion of diverse patient groups Adequate representation of diverse patient populations in RCTs for VHD
  Decision aids Development and validation of improved decision aids for shared decision-making with patients
Implementation and validation of decision algorithms for physicians and Heart Valve Teams
Intervention options and long-term management (Stage D)
  Improved prosthetic valves Durability of TAVI valves
Nonthrombogenic durable surgical and transcatheter valves
  Optimal antithrombotic therapy Alternatives to VKA anticoagulation for mechanical valves
Management of anticoagulation during pregnancy
Optimal antithrombotic therapy after TAVI
  Medical therapy after AVR Medical therapy to address ventricular and vascular function
Optimal blood pressure targets after valve intervention
  Lower procedural risk Approaches to lower surgical morbidity and mortality rates
Prevention of postoperative AF
Noninvasive approaches for correction of valve dysfunction
  Prevention of complications Approaches to avoid need for permanent pacing after SAVR or TAVI
Better prevention, diagnosis and treatment of endocarditis.
Better prevention of thromboembolic events.
  Promoting equity Identify and address disparities in outcomes and survival across diverse patient populations
Develop novel, cost-effective approaches for long-term management in rural settings
Expand access to therapies for valvular dysfunction
AF indicates atrial fibrillation; AS, aortic stenosis; AVR, aortic valve replacement; LV, left ventricular; MR, mitral regurgitation; RCT, randomized controlled trial; 
SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation; VHD, valvular heart disease; and VKA, vitamin K antagonist.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e184
CLINICAL STATEMENTS  
AND GUIDELINESACC/AHA JOINT COMMITTEE 
MEMBERS
Patrick T. O’Gara, MD, MACC, FAHA, Chair; Joshua A. 
Beckman, MD, MS, FAHA, Chair-Elect; Glenn N. Levine, 
MD, FACC, FAHA, Immediate Past Chair*; Sana M. 
Al-Khatib, MD, MHS, FACC, FAHA*; Anastasia Arm-
bruster, PharmD, AACC; Kim K. Birtcher, PharmD, MS, 
AACC; Joaquin Ciggaroa, MD, FACC*; Anita Deswal, 
MD, MPH, FACC, FAHA; Dave L. Dixon, PharmD, FACC; 
Lee A. Fleisher, MD, FACC, FAHA*; Lisa de las Fuentes, 
MD, MS, FAHA, FASE; Federico Gentile, MD, FACC*; 
Zachary D. Goldberger, MD, MSc, FACC, FAHA; Bu-
lent Gorenek, MD, FACC, FESC; Norrisa Haynes, MD, 
MPH; Adrian F. Hernandez, MD, MHS; Mark A. Hlatky, 
MD, FACC, FAHA*; José A. Joglar, MD, FACC, FAHA; 
W. Schuyler Jones, MD, FACC; Joseph E. Marine, MD, 
FACC*; Daniel Mark, MD, MPH, FACC, FAHA; Latha 
Palaniappan, MD, MS, FAHA, FACC; Mariann R. Piano, 
RN, PhD, FAHA; Erica S. Spatz, MD, MHS, FACC; Jac-
queline Tamis-Holland, MD, FACC; Duminda N. Wijey-
sundera, MD, PhD*; Y. Joseph Woo, MD, FAHA, FACC
PRESIDENTS AND STAFF
American College of Cardiology
Athena Poppas, MD, FACC, President
Cathleen Gates, Chief Executive Officer
John S. Rumsfeld, MD, PhD, FACC, Chief Science and 
Quality Officer
MaryAnne Elma, MPH, Senior Director, Science,  
Education, Quality, and Publishing
Grace D. Ronan, Team Lead, Clinical Policy Publications
Timothy W. Schutt, MA, Clinical Policy Analyst
American College of Cardiology/
American Heart Association
Thomas S. D. Getchius, Director, Guideline Strategy and 
Operations
Abdul R. Abdullah, MD, Director, Guideline Science and 
Methodology
Laura Mitchell, Guideline Advisor
American Heart Association
Mitchell S.V. Elkind, MD, MS, FAAN, FAHA, President
Nancy Brown, Chief Executive Officer
Mariell Jessup, MD, FAHA, Chief Science and Medical 
Officer
Radhika Rajgopal Singh, PhD, Vice President, Office of 
Science, Medicine and HealthPaul St. Laurent, DNP , RN, Senior Science and Medicine 
Advisor, Office of Science, Medicine and Health
Jody Hundley, Production and Operations Manager,  
Scientific Publications, Office of Science Operations
 ARTICLE INFORMATION
This document was approved by the American College of Cardiology Clinical 
Policy Approval Committee in August 2020, the American Heart Association 
Science Advisory and Coordinating Committee in August 2020, and the Ameri-
can Heart Association Executive Committee in September 2020.
The Comprehensive RWI Data Supplement table is available with this article 
at https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000923
Supplemental materials are available with this article at https://www.
ahajournals.org/doi/suppl/10.1161/CIR.0000000000000923
This article has been copublished in Journal of the American College of 
Cardiology.
Copies: This document is available on the websites of the American 
College of Cardiology (www.acc.org) and the American Heart Association 
(https://professional.heart.org). A copy of the document is also available 
at https://professional.heart.org/statements by selecting the “Guidelines & 
Statements” button. To purchase additional reprints, call 215-356-2721 or 
email Meredith.Edelman@wolterskluwer.com.
The expert peer review of AHA-commissioned documents (eg, scientific 
statements, clinical practice guidelines, systematic reviews) is conducted by the 
AHA Office of Science Operations. For more on AHA statements and guidelines 
development, visit professional.heart.org/statements. Select the “Guidelines & 
Statements” drop-down menu near the top of the webpage, then click “Pub-
lication Development.”
Permissions: Multiple copies, modification, alteration, enhancement, and/
or distribution of this document are not permitted without the express permis-
sion of the American Heart Association. Instructions for obtaining permission 
are located at https://www.heart.org/permissions. A link to the “Copyright Per -
missions Request Form” appears in the second paragraph (https://www.heart.
org/en/about-us/statements-and-policies/copyright-request-form).
REFERENCES
Preamble
 1. Committee on Standards for Developing Trustworthy Clinical Practice 
Guidelines, Institute of Medicine (US). Clinical Practice Guidelines We Can 
Trust. Washington, DC: National Academies Press; 2011.
 2. Committee on Standards for Systematic Reviews of Comparative Ef-
fectiveness Research, Institute of Medicine (US). Finding What Works in 
Health Care: Standards for Systematic Reviews. Washington, DC: National 
Academies Press; 2011.
 3. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on 
cost/value methodology in clinical practice guidelines and performance 
measures: a report of the American College of Cardiology/American Heart 
Association Task Force on Performance Measures and Task Force on Prac-
tice Guidelines. Circulation. 2014;129:2329–45.
 4. ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and 
Policies From the ACCF/AHA Task Force on Practice Guidelines. American 
College of Cardiology and American Heart Association. 2010. Available 
at: https://professional.heart.org/-/media/phd-files/guidelines-and-state-
ments/methodology_manual_and_policies_ucm_319826.pdf. Accessed 
August 19, 2020.
 5. Halperin JL, Levine GN, Al-Khatib SM, et al. Further evolution of the ACC/
AHA clinical practice guideline recommendation classification system: a 
report of the American College of Cardiology/American Heart Association 
Task Force on Clinical Practice Guidelines. Circulation. 2016;133:1426–8.
 6. Arnett DK, Goodman RA, Halperin JL, et al. AHA/ACC/HHS strategies to 
enhance application of clinical practice guidelines in patients with cardio-
vascular disease and comorbid conditions: from the American Heart As-
sociation, American College of Cardiology, and U.S. Department of Health 
and Human Services. Circulation. 2014;130:1662–7.
 7. Levine GN, O’Gara PT, Beckman JA, et al. Recent innovations, modifica-
tions, and evolution of ACC/AHA clinical practice guidelines: an update 
for our constituencies: a report of the American College of Cardiology/*Former Joint Committee member; current member during the 
writing effort.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e185
CLINICAL STATEMENTS  
AND GUIDELINESAmerican Heart Association Task Force on Clinical Practice Guidelines. Cir -
culation. 2019;139:e879–86.
1.4. Scope of the Guideline
 1. Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for 
the management of patients with valvular heart disease: a report of the 
American College of Cardiology/American Heart Association Task Force 
on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines 
for the Management of Patients With Valvular Heart Disease). Developed 
in collaboration with the Society of Cardiovascular Anesthesiologists. Cir -
culation. 2006;114:e84–231.
 2. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for 
the management of patients with valvular heart disease: a report of the 
American College of Cardiology/American Heart Association Task Force 
on Practice Guidelines. Circulation. 2014;129:e521–643.
 3. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused up-
date of the 2014 AHA/ACC guideline for the management of patients 
with valvular heart disease: a report of the American College of Cardiol-
ogy/American Heart Association Task Force on Clinical Practice Guidelines. 
Circulation. 2017;135:e1159–95.
 4. Hiratzka LF, Creager MA, Isselbacher EM, et al. Surgery for aortic dilatation 
in patients with bicuspid aortic valves: a statement of clarification from 
the American College of Cardiology/American Heart Association Task 
Force on Clinical Practice Guidelines. Circulation. 2016;133:680–6.
 5. Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninva-
sive evaluation of native valvular regurgitation: a report from the Ameri-
can Society of Echocardiography. Developed in collaboration with the 
Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 
2017;30:303–71.
 6. Lancellotti P , Moura L, Pierard LA, et al. European Association of Echocar -
diography recommendations for the assessment of valvular regurgitation. 
Part 2: mitral and tricuspid regurgitation (native valve disease). Eur J Echo-
cardiogr. 2010;11:307–32.
 7. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines 
for the management of patients with atrial fibrillation: a report of the 
American College of Cardiology/American Heart Association Task Force 
on Practice Guidelines and the European Society of Cardiology Committee 
for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines 
for the Management of Patients With Atrial Fibrillation). Developed in col-
laboration with the European Heart Rhythm Association and the Heart 
Rhythm Society. Circulation. 2006;114:e257–354.
 8. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guide-
line for the management of patients with atrial fibrillation: a report of 
the American College of Cardiology/American Heart Association Task 
Force on practice guidelines and the Heart Rhythm Society. Circulation. 
2014;130:e199–267.
 9. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused up-
date of the 2014 AHA/ACC/HRS guideline for the management of pa-
tients with atrial fibrillation: a report of the American College of Cardiol-
ogy/American Heart Association Task Force on Clinical Practice Guidelines 
and the Heart Rhythm Society. Developed in collaboration with the Society 
of Thoracic Surgeons. Circulation. 2019;140:e125–51.
 10. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for 
the management of adults with congenital heart disease: a report of the 
American College of Cardiology/American Heart Association Task Force 
on Clinical Practice Guidelines. Circulation. 2019;139:e698–800.
 11. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment 
of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J 
Echocardiogr. 2009;10:1–25.
 12. Baumgartner H, Hung J, Bermejo J, et al. Recommendations on the echo-
cardiographic assessment of aortic valve stenosis: a focused update from 
the European Association of Cardiovascular Imaging and the American 
Society of Echocardiography. J Am Soc Echocardiogr. 2017;30:372–92.
 13. Zoghbi WA, Asch FM, Bruce C, et al. Guidelines for the evaluation of 
valvular regurgitation after percutaneous valve repair or replacement: a 
report from the American Society of Echocardiography. Developed in col-
laboration with the Society for Cardiovascular Angiography and Interven-
tions, Japanese Society of Echocardiography, and Society for Cardiovascu-
lar Magnetic Resonance. J Am Soc Echocardiogr. 2019;32:431–75.
 14. Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations for evalu-
ation of prosthetic valves with echocardiography and Doppler ultrasound: 
a report from the American Society of Echocardiography’s Guidelines and 
Standards Committee and the Task Force on Prosthetic Valves. Developed in conjunction with the American College of Cardiology Cardiovascular 
Imaging Committee, Cardiac Imaging Committee of the American Heart 
Association, the European Association of Echocardiography, a registered 
branch of the European Society of Cardiology, the Japanese Society of 
Echocardiography and the Canadian Society of Echocardiography. J Am 
Soc Echocardiogr. 2009;22:975–1014.
 15. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the 
diagnosis and treatment of hypertrophic cardiomyopathy: a report of the 
American College of Cardiology Foundation/American Heart Association 
Task Force on Practice Guidelines. Circulation. 2011;124:e783–831.
 16. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the 
diagnosis and treatment of patients with hypertrophic cardiomyopathy: 
a report of the American College of Cardiology/American Heart Associa-
tion Joint Committee on Clinical Practice Guidelines. Circulation. 2020: In 
press.
 17. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC guidelines 
on the management of cardiovascular diseases during pregnancy: the Task 
Force on the Management of Cardiovascular Diseases during Pregnancy 
of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:3147–
97.
 18. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC 
guidelines for the management of cardiovascular diseases during preg-
nancy. Eur Heart J. 2018;39:3165–241.
 19. Whitlock RP , Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic 
therapy for valvular disease: Antithrombotic Therapy and Prevention of 
Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based 
Clinical Practice Guidelines. Chest. 2012;141:e576S–600S.
 20. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of 
valvular heart disease (version 2012). Eur Heart J. 2012;33:2451–96.
 21. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the 
management of valvular heart disease. Eur Heart J. 2017;38:2739–91.
 22. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused 
update of the 2013 ACCF/AHA guideline for the management of heart 
failure: a report of the American College of Cardiology/American Heart 
Association Task Force on Clinical Practice Guidelines and the Heart Failure 
Society of America. Circulation. 2017;136:e137–61.
1.5. Class of Recommendation and Level 
of Evidence
 1. ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and 
Policies From the ACCF/AHA Task Force on Practice Guidelines. American 
College of Cardiology and American Heart Association. 2010. Available 
at: https://professional.heart.org/-/media/phd-files/guidelines-and-state-
ments/methodology_manual_and_policies_ucm_319826.pdf. Accessed 
August 19, 2020.
2. GENERAL PRINCIPLES
2.3. Diagnosis and Follow-Up
2.3.1. Diagnostic Testing: Initial Diagnosis
 1. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment 
of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J 
Echocardiogr. 2009;10:1–25.
 2. Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninva-
sive evaluation of native valvular regurgitation: a report from the Ameri-
can Society of Echocardiography. Developed in collaboration with the 
Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 
2017;30:303–71.
 3. Lancellotti P , Moura L, Pierard LA, et al. European Association of Echocar -
diography recommendations for the assessment of valvular regurgitation. 
Part 2: mitral and tricuspid regurgitation (native valve disease). Eur J Echo-
cardiogr. 2010;11:307–32.
 4. Baumgartner H, Hung J, Bermejo J, et al. Recommendations on the echo-
cardiographic assessment of aortic valve stenosis: a focused update from 
the European Association of Cardiovascular Imaging and the American 
Society of Echocardiography. J Am Soc Echocardiogr. 2017;30:372–92.
 5. Medvedofsky D, Maffessanti F, Weinert L, et al. 2D and 3D echocardiog-
raphy-derived indices of left ventricular function and shape: relationship 
with mortality. JACC Cardiovasc Imaging. 2018;11:1569–79.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e186
CLINICAL STATEMENTS  
AND GUIDELINES 6. Quinones MA, Otto CM, Stoddard M, et al. Recommendations for quantifica-
tion of Doppler echocardiography: a report from the Doppler Quantification 
Task Force of the Nomenclature and Standards Committee of the American 
Society of Echocardiography. J Am Soc Echocardiogr. 2002;15:167–84.
 7. Currie PJ, Seward JB, Reeder GS, et al. Continuous-wave Doppler echocar -
diographic assessment of severity of calcific aortic stenosis: a simultane-
ous Doppler-catheter correlative study in 100 adult patients. Circulation. 
1985;71:1162–9.
 8. Thaden JJ, Tsang MY, Ayoub C, et al. Association between echocardiogra-
phy laboratory accreditation and the quality of imaging and reporting for 
valvular heart disease. Circ Cardiovasc Imaging. 2017;10:e006140.
2.3.2. Diagnostic Testing: Changing Signs or 
Symptoms
 1. Carabello BA, Crawford FA Jr. Valvular heart disease. N Engl J Med. 
1997;337:32–41.
 2. Enriquez-Sarano M, Basmadjian AJ, Rossi A, et al. Progression of mitral 
regurgitation: a prospective Doppler echocardiographic study. J Am Coll 
Cardiol. 1999;34:1137–44.
 3. Gaasch WH, John RM, Aurigemma GP . Managing asymptomatic patients 
with chronic mitral regurgitation. Chest. 1995;108:842–7.
 4. Lancellotti P , Rosenhek R, Pibarot P , et al. ESC Working Group on Valvular 
Heart Disease position paper—heart valve clinics: organization, structure, 
and experiences. Eur Heart J. 2013;34:1597–606.
 5. Otto CM. Timing of aortic valve surgery. Heart. 2000;84:211–8.
 6. Otto CM, Pearlman AS, Gardner CL. Hemodynamic progression of aortic 
stenosis in adults assessed by Doppler echocardiography. J Am Coll Car -
diol. 1989;13:545–50.
 7. Rosenhek R, Rader F, Klaar U, et al. Outcome of watchful waiting in as-
ymptomatic severe mitral regurgitation. Circulation. 2006;113:2238–44.
2.3.3. Diagnostic Testing: Routine Follow-Up
 1. Bonow RO, Lakatos E, Maron BJ, et al. Serial long-term assessment of 
the natural history of asymptomatic patients with chronic aortic re-
gurgitation and normal left ventricular systolic function. Circulation. 
1991;84:1625–35.
 2. Carabello BA, Crawford FA Jr. Valvular heart disease. N Engl J Med. 
1997;337:32–41.
 3. Enriquez-Sarano M, Basmadjian AJ, Rossi A, et al. Progression of mitral 
regurgitation: a prospective Doppler echocardiographic study. J Am Coll 
Cardiol. 1999;34:1137–44.
 4. Gaasch WH, John RM, Aurigemma GP . Managing asymptomatic patients 
with chronic mitral regurgitation. Chest. 1995;108:842–7.
 5. Lancellotti P , Rosenhek R, Pibarot P , et al. ESC Working Group on Valvular 
Heart Disease position paper—heart valve clinics: organization, structure, 
and experiences. Eur Heart J. 2013;34:1597–606.
 6. Otto CM. Timing of aortic valve surgery. Heart. 2000;84:211–8.
 7. Rosenhek R, Rader F, Klaar U, et al. Outcome of watchful waiting in as-
ymptomatic severe mitral regurgitation. Circulation. 2006;113:2238–44.
 8. Enriquez-Sarano M, Tajik AJ, Schaff HV, et al. Echocardiographic predic-
tion of left ventricular function after correction of mitral regurgitation: 
results and clinical implications. J Am Coll Cardiol. 1994;24:1536–43.
 9. Otto CM, Salerno CT. Timing of surgery in asymptomatic mitral regurgita-
tion. N Engl J Med. 2005;352:928–9.
 10. Pellikka PA, Sarano ME, Nishimura RA, et al. Outcome of 622 adults with 
asymptomatic, hemodynamically significant aortic stenosis during pro-
longed follow-up. Circulation. 2005;111:3290–5.
 11. Rosenhek R, Iung B, Tornos P , et al. ESC Working Group on Valvular Heart 
Disease position paper: assessing the risk of interventions in patients with 
valvular heart disease. Eur Heart J. 2012;33:822–8, 8a, 8b.
 12. Taniguchi T, Morimoto T, Shiomi H, et al. Initial surgical versus conservative 
strategies in patients with asymptomatic severe aortic stenosis. J Am Coll 
Cardiol. 2015;66:2827–38.
 13. Kang D-H, Park S-J, Rim JH, et al. Early surgery versus conventional 
treatment in asymptomatic very severe aortic stenosis. Circulation. 
2010;121:1502–9.
 14. Genereux P , Stone GW, O’Gara PT, et al. Natural history, diagnostic ap-
proaches, and therapeutic strategies for patients with asymptomatic se-
vere aortic stenosis. J Am Coll Cardiol. 2016;67:2263–88.
2.3.4. Diagnostic Testing: Cardiac Catheterization
 1. Nishimura RA, Carabello BA. Hemodynamics in the cardiac catheterization 
laboratory of the 21st century. Circulation. 2012;125:2138–50. 2. Nishimura RA, Grantham JA, Connolly HM, et al. Low-output, low-gradi-
ent aortic stenosis in patients with depressed left ventricular systolic func-
tion: the clinical utility of the dobutamine challenge in the catheterization 
laboratory. Circulation. 2002;106:809–13.
2.3.5. Diagnostic Testing: Exercise Testing
 1. Aviles RJ, Nishimura RA, Pellikka PA, et al. Utility of stress Doppler echocar -
diography in patients undergoing percutaneous mitral balloon valvotomy. 
J Am Soc Echocardiogr. 2001;14:676–81.
 2. Messika-Zeitoun D, Johnson BD, Nkomo V, et al. Cardiopulmonary 
exercise testing determination of functional capacity in mitral regur -
gitation: physiologic and outcome implications. J Am Coll Cardiol. 
2006;47:2521–7.
 3. Lancellotti P , Lebois F, Simon M, et al. Prognostic importance of quantita-
tive exercise Doppler echocardiography in asymptomatic valvular aortic 
stenosis. Circulation. 2005;112:I377–82.
 4. Maréchaux S, Hachicha Z, Bellouin A, et al. Usefulness of exercise-stress 
echocardiography for risk stratification of true asymptomatic patients 
with aortic valve stenosis. Eur Heart J. 2010;31:1390–7.
 5. Otto CM, Pearlman AS, Kraft CD, et al. Physiologic changes with maxi-
mal exercise in asymptomatic valvular aortic stenosis assessed by Doppler 
echocardiography. J Am Coll Cardiol. 1992;20:1160–7.
 6. Pierard LA, Lancellotti P . Stress testing in valve disease. Heart. 
2007;93:766–72.
 7. Magne J, Mahjoub H, Dulgheru R, et al. Left ventricular contrac-
tile reserve in asymptomatic primary mitral regurgitation. Eur Heart J. 
2014;35:1608–16.
 8. Donal E, Mascle S, Brunet A, et al. Prediction of left ventricular ejection 
fraction 6 months after surgical correction of organic mitral regurgita-
tion: the value of exercise echocardiography and deformation imaging. 
Eur Heart J Cardiovasc Imaging. 2012;13:922–30.
 9. Wahi S, Haluska B, Pasquet A, et al. Exercise echocardiography predicts 
development of left ventricular dysfunction in medically and surgically 
treated patients with asymptomatic severe aortic regurgitation. Heart. 
2000;84:606–14.
 10. Gentry JL 3rd, Parikh PK, Alashi A, et al. Characteristics and outcomes in a 
contemporary group of patients with suspected significant mitral stenosis 
undergoing treadmill stress echocardiography. Circ Cardiovasc Imaging. 
2019;12:e009062.
 11. Lancellotti P , Dulgheru R, Go YY, et al. Stress echocardiography in patients 
with native valvular heart disease. Heart. 2018;104:807–13.
2.4. Basic Principles of Medical Therapy
 1. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused 
update of the 2013 ACCF/AHA guideline for the management of heart 
failure: a report of the American College of Cardiology/American Heart 
Association Task Force on Clinical Practice Guidelines and the Heart Failure 
Society of America. Circulation. 2017;136:e137–61.
 2. Gati S, Malhotra A, Sharma S. Exercise recommendations in patients with 
valvular heart disease. Heart. 2019;105:106–10.
 3. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on 
the primary prevention of cardiovascular disease: a report of the American 
College of Cardiology/American Heart Association Task Force on Clinical 
Practice Guidelines. Circulation. 2019;140:e596–646.
2.4.1. Secondary Prevention of Rheumatic Fever
 1. Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever 
and diagnosis and treatment of acute Streptococcal pharyngitis: a scien-
tific statement from the American Heart Association Rheumatic Fever, 
Endocarditis, and Kawasaki Disease Committee of the Council on Cardio-
vascular Disease in the Young, the Interdisciplinary Council on Functional 
Genomics and Translational Biology, and the Interdisciplinary Council on 
Quality of Care and Outcomes Research. Circulation. 2009;119:1541–51.
2.4.2. IE Prophylaxis
 1. Glenny A-M, Oliver R, Roberts GJ, et al. Antibiotics for the prophy-
laxis of bacterial endocarditis in dentistry. Cochrane Database Syst Rev. 
2013;CD003813.
 2. Mougeot FKB, Saunders SE, Brennan MT, et al. Associations between 
bacteremia from oral sources and distant-site infections: tooth brushing 
versus single tooth extraction. Oral Surg Oral Med Oral Pathol Oral Radiol. 
2015;119:430–5.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e187
CLINICAL STATEMENTS  
AND GUIDELINES 3. Sherman-Weber S, Axelrod P , Suh B, et al. Infective endocarditis following 
orthotopic heart transplantation: 10 cases and a review of the literature. 
Transpl Infect Dis. 2004;6:165–70.
 4. Lockhart PB, Brennan MT, Sasser HC, et al. Bacteremia associated with 
toothbrushing and dental extraction. Circulation. 2008;117:3118–25.
 5. Geist S-MRY, Fitzpatrick S, Geist JR. American Heart Association 2007 
guidelines on prevention of infective endocarditis. J Mich Dent Assoc. 
2007;89:50–6.
 6. Duval X, Alla F, Hoen B, et al. Estimated risk of endocarditis in adults 
with predisposing cardiac conditions undergoing dental procedures with 
or without antibiotic prophylaxis. Clin Infect Dis. 2006;42:e102–7.
 7. The 2015 ESC Guidelines for the management of infective endocarditis. 
Eur Heart J. 2015;36:3036–7.
 8. Horstkotte D, Rosin H, Friedrichs W, et al. Contribution for choosing the 
optimal prophylaxis of bacterial endocarditis. Eur Heart J. 1987;8:379–81.
 9. Strom BL, Abrutyn E, Berlin JA, et al. Dental and cardiac risk factors for 
infective endocarditis. A population-based, case-control study. Ann Intern 
Med. 1998;129:761–9.
 10. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocar -
ditis. Recommendations by the American Heart Association. Circulation. 
1997;96:358–66.
 11. Guarner-Argente C, Shah P , Buchner A, et al. Use of antimicrobials for 
EUS-guided FNA of pancreatic cysts: a retrospective, comparative analysis. 
Gastrointest Endosc. 2011;74:81–6.
 12. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocardi-
tis: guidelines from the American Heart Association: a guideline from the 
American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki 
Disease Committee, Council on Cardiovascular Disease in the Young, and 
the Council on Clinical Cardiology, Council on Cardiovascular Surgery and 
Anesthesia, and the Quality of Care and Outcomes Research Interdisciplin-
ary Working Group. Circulation. 2007;116:1736–54.
 13. Habib G, Lancellotti P , Antunes MJ, et al. 2015 ESC guidelines for the 
management of infective endocarditis: the Task Force for the Manage-
ment of Infective Endocarditis of the European Society of Cardiology 
(ESC). Eur Heart J. 2015;36:3036–7.
 14. Prophylaxis Against Infective Endocarditis: Antimicrobial Prophylaxis 
Against Infective Endocarditis in Adults and Children Undergoing Inter -
ventional Procedures. Available at: https://www.ncbi.nlm.nih.gov/books/
NBK554353/. Accessed October 12, 2020.
 15. Thornhill MH, Gibson TB, Cutler E, et al. Antibiotic prophylaxis and inci-
dence of endocarditis before and after the 2007 AHA recommendations. 
J Am Coll Cardiol. 2018;72:2443–54.
 16. Desimone DC, Tleyjeh IM, Correa de Sa DD, et al. Incidence of infective 
endocarditis caused by viridans group streptococci before and after pub-
lication of the 2007 American Heart Association’s endocarditis prevention 
guidelines. Circulation. 2012;126:60–4.
 17. Dayer MJ, Jones S, Prendergast B, et al. Incidence of infective endocardi-
tis in England, 2000–13: a secular trend, interrupted time-series analysis. 
Lancet. 2015;385:1219–28.
 18. Duval X, Delahaye F, Alla F, et al. Temporal trends in infective endocardi-
tis in the context of prophylaxis guideline modifications: three successive 
population-based surveys. J Am Coll Cardiol. 2012;59:1968–76.
 19. Pasquali SK, He X, Mohamad Z, et al. Trends in endocarditis hospitaliza-
tions at US children’s hospitals: impact of the 2007 American Heart As-
sociation antibiotic prophylaxis guidelines. Am Heart J. 2012;163:894–9.
 20. Pant S, Patel NJ, Deshmukh A, et al. Trends in infective endocarditis in-
cidence, microbiology, and valve replacement in the United States from 
2000 to 2011. J Am Coll Cardiol. 2015;65:2070–6.
 21. Thornhill MH, Dayer MJ, Forde JM, et al. Impact of the NICE guideline rec-
ommending cessation of antibiotic prophylaxis for prevention of infective 
endocarditis: before and after study. BMJ. 2011;342:d2392.
 22. Strom BL, Abrutyn E, Berlin JA, et al. Risk factors for infective endocarditis: 
oral hygiene and nondental exposures. Circulation. 2000;102:2842–8.
 23. Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H, et al. Infective endo-
carditis after transcatheter aortic valve implantation: results from a large 
multicenter registry. Circulation. 2015;131:1566–74.
 24. Mangner N, Woitek F, Haussig S, et al. Incidence, predictors, and outcome 
of patients developing infective endocarditis following transfemoral trans-
catheter aortic valve replacement. J Am Coll Cardiol. 2016;67:2907–8.
 25. Karavas AN, Filsoufi F, Mihaljevic T, et al. Risk factors and management of 
endocarditis after mitral valve repair. J Heart Valve Dis. 2002;11:660–4.
 26. Gillinov AM, Faber CN, Sabik JF, et al. Endocarditis after mitral valve repair. 
Ann Thorac Surg. 2002;73:1813–6.
 27. Botoman VA, Surawicz CM. Bacteremia with gastrointestinal endoscopic 
procedures. Gastrointest Endosc. 1986;32:342–6. 28. Low DE, Shoenut JP , Kennedy JK, et al. Risk of bacteremia with endoscopic 
sphincterotomy. Can J Surg. 1987;30:421–3.
 29. Low DE, Shoenut JP , Kennedy JK, et al. Prospective assessment of 
risk of bacteremia with colonoscopy and polypectomy. Dig Dis Sci. 
1987;32:1239–43.
 30. Wolf JS, Bennett CJ, Dmochowski RR, et al. Best practice policy statement 
on urologic surgery antimicrobial prophylaxis. J Urol. 2008;179:1379–90.
2.4.3. Anticoagulation for AF in Patients With 
VHD
 1. Pan K-L, Singer DE, Ovbiagele B, et al. Effects of non-vitamin K antagonist 
oral anticoagulants versus warfarin in patients with atrial fibrillation and 
valvular heart disease: a systematic review and meta-analysis. J Am Heart 
Assoc. 2017;6:e005835.
 2. Lip GYH, Jensen M, Melgaard L, et al. Stroke and bleeding risk scores 
in patients with atrial fibrillation and valvular heart disease: evaluating 
“valvular heart disease” in a nationwide cohort study. Europace. 2019;21: 
33–40.
 3. Vora AN, Dai D, Matsuoka R, et al. Incidence, management, and associ-
ated clinical outcomes of new-onset atrial fibrillation following transcath-
eter aortic valve replacement: an analysis from the STS/ACC TVT registry. 
JACC Cardiovasc Interv. 2018;11:1746–56.
 4. Seeger J, Gonska B, Rodewald C, et al. Apixaban in patients with atrial 
fibrillation after transfemoral aortic valve replacement. JACC Cardiovasc 
Interv. 2017;10:66–74.
 5. Jochheim D, Barbanti M, Capretti G, et al. Oral anticoagulant type and 
outcomes after transcatheter aortic valve replacement. JACC Cardiovasc 
Interv. 2019;12:1566–76.
 6. Mangner N, Crusius L, Haussig S, et al. Continued versus interrupted oral 
anticoagulation during transfemoral transcatheter aortic valve implanta-
tion and impact of postoperative anticoagulant management on outcome 
in patients with atrial fibrillation. Am J Cardiol. 2019;123:1134–41.
 7. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran ver -
sus warfarin in patients with mechanical heart valves. N Engl J Med. 
2013;369:1206–14.
 8. De Caterina R, Renda G, Carnicelli AP , et al. Valvular heart disease patients 
on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. J Am Coll Car -
diol. 2017;69:1372–82.
 9. Carnicelli AP , De Caterina R, Halperin JL, et al. Edoxaban for the preven-
tion of thromboembolism in patients with atrial fibrillation and biopros-
thetic valves. Circulation. 2017;135:1273–5.
 10. Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in comparison with war -
farin in patients with atrial fibrillation and valvular heart disease: find-
ings from the Apixaban for Reduction in Stroke and Other Thromboem-
bolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2015;132: 
624–32.
 11. Guimarães PO, Pokorney SD, Lopes RD, et al. Efficacy and safety of apixa-
ban vs warfarin in patients with atrial fibrillation and prior bioprosthetic 
valve replacement or valve repair: insights from the ARISTOTLE trial. Clin 
Cardiol. 2019;42:568–71.
 12. Vinereanu D, Wang A, Mulder H, et al. Outcomes in anticoagulated pa-
tients with atrial fibrillation and with mitral or aortic valve disease. Heart. 
2018;104:1292–9.
 13. Breithardt G, Baumgartner H, Berkowitz SD, et al. Native valve disease in 
patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. 
Heart. 2016;102:1036–43.
 14. Breithardt G, Baumgartner H, Berkowitz SD, et al. Clinical characteristics 
and outcomes with rivaroxaban vs. warfarin in patients with non-valvular 
atrial fibrillation but underlying native mitral and aortic valve disease par -
ticipating in the ROCKET AF trial. Eur Heart J. 2014;35:3377–85.
 15. Siontis KC, Yao X, Gersh BJ, et al. Direct oral anticoagulants in patients 
with atrial fibrillation and valvular heart disease other than significant 
mitral stenosis and mechanical valves: a meta-analysis. Circulation. 
2017;135:714–6.
 16. Andrade JG, Meseguer E, Didier R, et al. Non-vitamin K antagonist oral 
anticoagulants in atrial fibrillation patients with bioprosthetic valves. Ex-
pert Rev Cardiovasc Ther. 2018;1–6.
 17. Renda G, Ricci F, Giugliano RP , et al. Non-vitamin K antagonist oral antico-
agulants in patients with atrial fibrillation and valvular heart disease. J Am 
Coll Cardiol. 2017;69:1363–71.
 18. Briasoulis A, Inampudi C, Akintoye E, et al. Safety and efficacy of 
novel oral anticoagulants versus warfarin in Medicare beneficiaries 
with atrial fibrillation and valvular heart disease. J Am Heart Assoc. 
2018;7:e008773.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e188
CLINICAL STATEMENTS  
AND GUIDELINES 19. Philippart R, Brunet-Bernard A, Clementy N, et al. Oral anticoagulation, 
stroke and thromboembolism in patients with atrial fibrillation and valve 
bioprosthesis. The Loire Valley Atrial Fibrillation Project. Thromb Haemost. 
2016;115:1056–63.
 20. Duraes AR, de Souza Roriz P , de Almeida Nunes B, et al. Dabigatran 
Versus Warfarin After Bioprosthesis Valve Replacement for the Manage-
ment of Atrial Fibrillation Postoperatively: DAWA Pilot Study. Drugs R D. 
2016;16:149–54.
 21. Noseworthy PA, Yao X, Shah ND, et al. Comparative effectiveness and 
safety of non-vitamin K antagonist oral anticoagulants versus warfarin 
in patients with atrial fibrillation and valvular heart disease. Int J Cardiol. 
2016;209:181–3.
 22. Kim JY, Kim S-H, Myong J-P , et al. Outcomes of direct oral anticoagulants 
in patients with mitral stenosis. J Am Coll Cardiol. 2019;73:1123–31.
 23. Dangas GD, Tijssen JGP , Wohrle J, et al. A controlled trial of rivaroxaban af-
ter transcatheter aortic-valve replacement. N Engl J Med. 2020;382:120–9.
2.5. Evaluation of Surgical and 
Interventional Risk
 1. Edwards FH, Cohen DJ, O’Brien SM, et al. Development and validation of 
a risk prediction model for in-hospital mortality after transcatheter aortic 
valve replacement. JAMA Cardiol. 2016;1:46–52.
 2. Pilgrim T, Franzone A, Stortecky S, et al. Predicting mortality after trans-
catheter aortic valve replacement: external validation of the Transcatheter 
Valve Therapy registry model. Circ Cardiovasc Interv. 2017;10:e005481.
 3. Greason KL, Eleid MF, Nkomo VT, et al. Predictors of 1-year mortality after 
transcatheter aortic valve replacement. J Card Surg. 2018;33:243–9.
 4. Arsalan M, Weferling M, Hecker F, et al. TAVI risk scoring using established 
versus new scoring systems: role of the new STS/ACC model. EuroInter -
vention. 2018;13:1520–6.
 5. Kiani S, Kamioka N, Black GB, et al. Development of a risk score to predict 
new pacemaker implantation after transcatheter aortic valve replacement. 
JACC Cardiovasc Interv. 2019;12:2133–42.
 6. Thourani VH, O’Brien SM, Kelly JJ, et al. Development and application of a 
risk prediction model for in-hospital stroke after transcatheter aortic valve 
replacement: a report from the Society of Thoracic Surgeons/American 
College of Cardiology Transcatheter Valve Therapy Registry. Ann Thorac 
Surg. 2019;107:1097–103.
 7. Lytwyn J, Stammers AN, Kehler DS, et al. The impact of frailty on func-
tional survival in patients 1 year after cardiac surgery. J Thorac Cardiovasc 
Surg. 2017;154:1990–9.
 8. Afilalo J, Alexander KP , Mack MJ, et al. Frailty assessment in the cardiovas-
cular care of older adults. J Am Coll Cardiol. 2014;63:747–62.
 9. Schoenenberger AW, Moser A, Bertschi D, et al. Improvement of risk pre-
diction after transcatheter aortic valve replacement by combining frailty 
with conventional risk scores. JACC Cardiovasc Interv. 2018;11:395–403.
 10. Afilalo J, Lauck S, Kim DH, et al. Frailty in older adults undergoing 
aortic valve replacement: the FRAILTY-AVR study. J Am Coll Cardiol. 
2017;70:689–700.
 11. Arnold SV, O’Brien SM, Vemulapalli S, et al. Inclusion of functional status mea-
sures in the risk adjustment of 30-day mortality after transcatheter aortic 
valve replacement: a report from the Society of Thoracic Surgeons/American 
College of Cardiology TVT Registry. JACC Cardiovasc Interv. 2018;11:581–9.
 12. Arnold SV, Reynolds MR, Lei Y, et al. Predictors of poor outcomes after 
transcatheter aortic valve replacement: results from the PARTNER (Place-
ment of Aortic Transcatheter Valve) trial. Circulation. 2014;129:2682–90.
 13. Makkar RR, Fontana GP , Jilaihawi H, et al. Transcatheter aortic-valve 
replacement for inoperable severe aortic stenosis. N Engl J Med. 
2012;366:1696–704.
 14. Suri RM, Gulack BC, Brennan JM, et al. Outcomes of patients with severe 
chronic lung disease who are undergoing transcatheter aortic valve re-
placement. Ann Thorac Surg. 2015;100:2136–45.
 15. Thourani VH, Forcillo J, Beohar N, et al. Impact of preoperative chronic 
kidney disease in 2,531 high-risk and inoperable patients undergoing 
transcatheter aortic valve replacement in the PARTNER Trial. Ann Thorac 
Surg. 2016;102:1172–80.
 16. Puri R, Iung B, Cohen DJ, et al. TAVI or no TAVI: identifying patients un-
likely to benefit from transcatheter aortic valve implantation. Eur Heart J. 
2016;37:2217–25.
 17. Glower DD, Kar S, Trento A, et al. Percutaneous mitral valve repair for 
mitral regurgitation in high-risk patients: results of the EVEREST II study. J 
Am Coll Cardiol. 2014;64:172–81. 18. Lim DS, Reynolds MR, Feldman T, et al. Improved functional status and 
quality of life in prohibitive surgical risk patients with degenerative mi-
tral regurgitation after transcatheter mitral valve repair. J Am Coll Cardiol. 
2014;64:182–92.
 19. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve 
repair in patients with heart failure. N Engl J Med. 2018;379:2307–18.
 20. Birkmeyer JD, Siewers AE, Finlayson EVA, et al. Hospital volume and surgi-
cal mortality in the United States. N Engl J Med. 2002;346:1128–37.
 21. Vemulapalli S, Carroll JD, Mack MJ, et al. Procedural volume and out-
comes for transcatheter aortic-valve replacement. N Engl J Med. 
2019;380:2541–50.
 22. Carroll JD, Vemulapalli S, Dai D, et al. Procedural experience for transcath-
eter aortic valve replacement and relation to outcomes: the STS/ACC TVT 
registry. J Am Coll Cardiol. 2017;70:29–41.
 23. Russo MJ, McCabe JM, Thourani VH, et al. Case volume and outcomes af-
ter TAVR with balloon-expandable prostheses: insights from TVT registry. J 
Am Coll Cardiol. 2019;73:427–40.
 24. Bolling SF, Li S, O’Brien SM, et al. Predictors of mitral valve repair: clinical 
and surgeon factors. Ann Thorac Surg. 2010;90:1904–11.
 25. Badhwar V, Ofenloch JC, Rovin JD, et al. Noninferiority of closely moni-
tored mechanical valves to bioprostheses overshadowed by early mortality 
benefit in younger patients. Ann Thorac Surg. 2012;93:748–53.
 26. Hart SA, Krasuski RA, Wang A, et al. Pulmonary hypertension and elevat-
ed transpulmonary gradient in patients with mitral stenosis. J Heart Valve 
Dis. 2010;19:708–15.
 27. Weiner MM, Hofer I, Lin H-M, et al. Relationship among surgical vol-
ume, repair quality, and perioperative outcomes for repair of mitral in-
sufficiency in a mitral valve reference center. J Thorac Cardiovasc Surg. 
2014;148:2021–6.
 28. LaPar DJ, Ailawadi G, Isbell JM, et al. Mitral valve repair rates correlate 
with surgeon and institutional experience. J Thorac Cardiovasc Surg. 
2014;148:995–1003.
 29. Kilic A, Shah AS, Conte JV, et al. Operative outcomes in mitral valve sur -
gery: combined effect of surgeon and hospital volume in a population-
based analysis. J Thorac Cardiovasc Surg. 2013;146:638–46.
 30. Gammie JS, O’Brien SM, Griffith BP , et al. Influence of hospital procedural 
volume on care process and mortality for patients undergoing elective 
surgery for mitral regurgitation. Circulation. 2007;115:881–7.
 31. Vassileva CM, McNeely C, Spertus J, et al. Hospital volume, mitral repair 
rates, and mortality in mitral valve surgery in the elderly: an analysis of US 
hospitals treating Medicare fee-for-service patients. J Thorac Cardiovasc 
Surg. 2015;149:762–8, e1.
 32. Chikwe J, Toyoda N, Anyanwu AC, et al. Relation of mitral valve sur -
gery volume to repair rate, durability, and survival. J Am Coll Cardiol. 
2017;69:2397–406.
 33. Chhatriwalla AK, Vemulapalli S, Holmes DR Jr, et al. Institutional experi-
ence with transcatheter mitral valve repair and clinical outcomes: insights 
from the TVT registry. JACC Cardiovasc Interv. 2019;12:1342–52.
 34. Katz S, Downs TD, Cash HR, et al. Progress in development of the index of 
ADL. Gerontologist. 1970;10:20–30.
 35. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of 
fitness and frailty in elderly people. CMAJ. 2005;173:489–95.
2.6. The Multidisciplinary Heart Valve 
Team and Heart Valve Centers
 1. Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative 
mortality in the United States. N Engl J Med. 2003;349:2117–27.
 2. Patel HJ, Herbert MA, Drake DH, et al. Aortic valve replacement: using a 
statewide cardiac surgical database identifies a procedural volume hinge 
point. Ann Thorac Surg. 2013;96:1560–5.
 3. Dewey TM, Herbert MA, Ryan WH, et al. Influence of surgeon vol-
ume on outcomes with aortic valve replacement. Ann Thorac Surg. 
2012;93:1107–12.
 4. McNeely C, Markwell S, Filson K, et al. Effect of hospital volume on pros-
thesis use and mortality in aortic valve operations in the elderly. Ann Tho-
rac Surg. 2016;101:585–90.
 5. Khera R, Pandey A, Koshy T, et al. Role of hospital volumes in identifying 
low-performing and high-performing aortic and aitral valve surgical cen-
ters in the United States. JAMA Cardiol. 2017;2:1322–31.
 6. Carroll JD, Vemulapalli S, Dai D, et al. Procedural experience for transcath-
eter aortic valve replacement and relation to outcomes: the STS/ACC TVT 
registry. J Am Coll Cardiol. 2017;70:29–41.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e189
CLINICAL STATEMENTS  
AND GUIDELINES 7. Bolling SF, Li S, O’Brien SM, et al. Predictors of mitral valve repair: clinical 
and surgeon factors. Ann Thorac Surg. 2010;90:1904–11.
 8. Chikwe J, Toyoda N, Anyanwu AC, et al. Relation of mitral valve sur -
gery volume to repair rate, durability, and survival. J Am Coll Cardiol. 
2017;69:2397–406.
 9. Gammie JS, O’Brien SM, Griffith BP , et al. Influence of hospital procedural 
volume on care process and mortality for patients undergoing elective 
surgery for mitral regurgitation. Circulation. 2007;115:881–7.
 10. Kilic A, Shah AS, Conte JV, et al. Operative outcomes in mitral valve sur -
gery: combined effect of surgeon and hospital volume in a population-
based analysis. J Thorac Cardiovasc Surg. 2013;146:638–46.
 11. Vassileva CM, Boley T, Markwell S, et al. Impact of hospital annual mitral 
procedural volume on mitral valve repair rates and mortality. J Heart Valve 
Dis. 2012;21:41–7.
 12. Nishimura RA, O’Gara PT, Bavaria JE, et al. 2019 AATS/ACC/ASE/SCAI/STS ex-
pert consensus systems of care document: a proposal to optimize care for 
patients with valvular heart disease: a joint report of the American Association 
for Thoracic Surgery, American College of Cardiology, American Society of 
Echocardiography, Society for Cardiovascular Angiography and Interventions, 
and Society of Thoracic Surgeons. J Am Coll Cardiol. 2019;73:2609–35.
 13. Ando T, Adegbala O, Villablanca PA, et al. Failure to rescue, hospital vol-
ume, and in-hospital mortality after transcatheter aortic valve implanta-
tion. Am J Cardiol. 2018;122:828–32.
 14. Edwards FH, Ferraris VA, Kurlansky PA, et al. Failure to rescue rates af-
ter coronary artery bypass grafting: an analysis from the Society of 
Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg. 
2016;102:458–64.
 15. Scali ST, Giles KA, Kubilis P , et al. Impact of hospital volume on patient 
safety indicators and failure to rescue following open aortic aneurysm re-
pair. J Vasc Surg. 2020;71:1135–46.e4.
 16. Ghaferi AA, Birkmeyer JD, Dimick JB. Hospital volume and failure to res-
cue with high-risk surgery. Med Care. 2011;49:1076–81.
 17. Gonzalez AA, Dimick JB, Birkmeyer JD, et al. Understanding the volume-
outcome effect in cardiovascular surgery: the role of failure to rescue. 
JAMA Surg. 2014;149:119–23.
 18. Ward ST, Dimick JB, Zhang W, et al. Association between hospital staffing 
models and failure to rescue. Ann Surg. 2019;270:91–4.
 19. Wakeam E, Asafu-Adjei D, Ashley SW, et al. The association of intensiv-
ists with failure-to-rescue rates in outlier hospitals: results of a national 
survey of intensive care unit organizational characteristics. J Crit Care. 
2014;29:930–5.
 20. Holmes DR, Rich JB, Zoghbi WA, et al. The heart team of cardiovascular 
care. J Am Coll Cardiol. 2013;61:903–7.
2.7. Management of Patients With VHD 
After Valve Intervention
2.7.4. Periodic Imaging After Valve Intervention
 1. Salaun E, Mahjoub H, Girerd N, et al. Rate, timing, correlates, and out-
comes of hemodynamic valve deterioration after bioprosthetic surgical 
aortic valve replacement. Circulation. 2018;138:971–85.
 2. Salaun E, Mahjoub H, Dahou A, et al. Hemodynamic deterioration 
of surgically implanted bioprosthetic aortic valves. J Am Coll Cardiol. 
2018;72:241–51.
3. AORTIC STENOSIS
3.2.1. Diagnosis and Follow-Up
3.2.1.1. Diagnostic Testing: Initial Diagnosis
 1. Baumgartner H, Hung J, Bermejo J, et al. Recommendations on the 
echocardiographic assessment of aortic valve stenosis: a focused up-
date from the European Association of Cardiovascular Imaging and 
the American Society of Echocardiography. J Am Soc Echocardiogr. 
2017;30:372–92.
 2. Gardezi SKM, Myerson SG, Chambers J, et al. Cardiac auscultation poorly 
predicts the presence of valvular heart disease in asymptomatic primary 
care patients. Heart. 2018;104:1832–5.
 3. Eleid MF, Michelena HI, Nkomo VT, et al. Causes of death and predic-
tors of survival after aortic valve replacement in low flow vs. normal flow 
severe aortic stenosis with preserved ejection fraction. Eur Heart J Cardio-
vasc Imaging. 2015;16:1270–5. 4. Kadem L, Dumesnil JG, Rieu R, et al. Impact of systemic hypertension on 
the assessment of aortic stenosis. Heart. 2005;91:354–61.
 5. Laskey WK, Kussmaul WG 3rd. Hypertension, aortic valve stenosis, and 
the aorta: more lessons from TAVR. J Am Coll Cardiol. 2015;65:434–6.
 6. Yotti R, Bermejo J, Gutiérrez-Ibañes E, et al. Systemic vascular load in cal-
cific degenerative aortic valve stenosis: insight from percutaneous valve 
replacement. J Am Coll Cardiol. 2015;65:423–33.
 7. Lindman BR, Otto CM. Time to treat hypertension in patients with aortic 
stenosis. Circulation. 2013;128:1281–3.
 8. Lin SS, Roger VL, Pascoe R, et al. Dobutamine stress Doppler hemodynam-
ics in patients with aortic stenosis: feasibility, safety, and surgical correla-
tions. Am Heart J. 1998;136:1010–6.
 9. Monin JL, Monchi M, Gest V, et al. Aortic stenosis with severe left ven-
tricular dysfunction and low transvalvular pressure gradients: risk strati-
fication by low-dose dobutamine echocardiography. J Am Coll Cardiol. 
2001;37:2101–7.
 10. Clavel M-A, Fuchs C, Burwash IG, et al. Predictors of outcomes in low-
flow, low-gradient aortic stenosis: results of the multicenter TOPAS Study. 
Circulation. 2008;118:S234–42.
 11. Otto CM, Pearlman AS, Comess KA, et al. Determination of the stenotic 
aortic valve area in adults using Doppler echocardiography. J Am Coll Car -
diol. 1986;7:509–17.
 12. Oh JK, Taliercio CP , Holmes DR, et al. Prediction of the severity of aor -
tic stenosis by Doppler aortic valve area determination: prospective 
Doppler-catheterization correlation in 100 patients. J Am Coll Cardiol. 
1988;11:1227–34.
 13. Jander N, Hochholzer W, Kaufmann BA, et al. Velocity ratio predicts out-
comes in patients with low gradient severe aortic stenosis and preserved 
EF. Heart. 2014;100:1946–53.
 14. Pawade T, Clavel M-A, Tribouilloy C, et al. Computed tomography aortic 
valve calcium scoring in patients with aortic stenosis. Circ Cardiovasc Im-
aging. 2018;11:e007146.
 15. Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, 
asymptomatic aortic stenosis. N Engl J Med. 2000;343:611–7.
 16. Messika-Zeitoun D, Aubry M-C, Detaint D, et al. Evaluation and clinical 
implications of aortic valve calcification measured by electron-beam com-
puted tomography. Circulation. 2004;110:356–62.
 17. Cueff C, Serfaty J-M, Cimadevilla C, et al. Measurement of aortic valve 
calcification using multislice computed tomography: correlation with hae-
modynamic severity of aortic stenosis and clinical implication for patients 
with low ejection fraction. Heart. 2011;97:721–6.
 18. Clavel M-A, Pibarot P , Messika-Zeitoun D, et al. Impact of aortic valve 
calcification, as measured by MDCT, on survival in patients with aortic 
stenosis: results of an international registry study. J Am Coll Cardiol. 
2014;64:1202–13.
 19. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment 
of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J 
Echocardiogr. 2009;10:1–25.
 20. Currie PJ, Seward JB, Reeder GS, et al. Continuous-wave Doppler echocar -
diographic assessment of severity of calcific aortic stenosis: a simultane-
ous Doppler-catheter correlative study in 100 adult patients. Circulation. 
1985;71:1162–9.
 21. Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptom-
atic valvular aortic stenosis. Clinical, echocardiographic, and exercise pre-
dictors of outcome. Circulation. 1997;95:2262–70.
 22. Zoghbi WA, Farmer KL, Soto JG, et al. Accurate noninvasive quantifica-
tion of stenotic aortic valve area by Doppler echocardiography. Circula-
tion. 1986;73:452–9.
 23. Otto CM, Pearlman AS. Doppler echocardiography in adults with symp-
tomatic aortic stenosis. Diagnostic utility and cost-effectiveness. Arch In-
tern Med. 1988;148:2553–60.
 24. Rosenhek R, Klaar U, Schemper M, et al. Mild and moderate aortic steno-
sis. Natural history and risk stratification by echocardiography. Eur Heart J. 
2004;25:199–205.
 25. Otto CM. Valvular stenosis. In: Otto CM, ed. The Textbook of Clinical 
Echocardiography. 6th ed. Philadelphia, PA: Elsevier; 2018:288–323.
 26. Stewart RAH, Kerr AJ, Whalley GA, et al. Left ventricular systolic and dia-
stolic function assessed by tissue Doppler imaging and outcome in asymp-
tomatic aortic stenosis. Eur Heart J. 2010;31:2216–22.
 27. Jander N, Minners J. Aortic stenosis: disease severity, progression, and 
timing and type of intervention. In: Otto CM, ed. The Practice of Clinical 
Echocardiography. 6th ed. Philadelphia, PA: Elsevier; 2021. In press.
 28. Nishimura RA, Grantham JA, Connolly HM, et al. Low-output, low-gra-
dient aortic stenosis in patients with depressed left ventricular systolic 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e190
CLINICAL STATEMENTS  
AND GUIDELINESfunction: the clinical utility of the dobutamine challenge in the catheter -
ization laboratory. Circulation. 2002;106:809–13.
 29. Clavel MA, Webb JG, Rodés-Cabau J, et al. Comparison between trans-
catheter and surgical prosthetic valve implantation in patients with severe 
aortic stenosis and reduced left ventricular ejection fraction. Circulation. 
2010;122:1928–36.
 30. deFilippi CR, Willett DL, Brickner ME, et al. Usefulness of dobutamine 
echocardiography in distinguishing severe from nonsevere valvular aortic 
stenosis in patients with depressed left ventricular function and low trans-
valvular gradients. Am J Cardiol. 1995;75:191–4.
 31. Blais C, Burwash IG, Mundigler G, et al. Projected valve area at normal 
flow rate improves the assessment of stenosis severity in patients with 
low-flow, low-gradient aortic stenosis: the multicenter TOPAS (Truly or 
Pseudo-Severe Aortic Stenosis) study. Circulation. 2006;113:711–21.
 32. Pibarot P , Dumesnil JG. Low-flow, low-gradient aortic stenosis with nor -
mal and depressed left ventricular ejection fraction. J Am Coll Cardiol. 
2012;60:1845–53.
 33. Bradley SM, Foag K, Monteagudo K, et al. Use of routinely captured 
echocardiographic data in the diagnosis of severe aortic stenosis. Heart. 
2019;105:112–6.
3.2.1.3. Diagnostic Testing: Routine Follow-Up
 1. Otto CM, Pearlman AS, Gardner CL. Hemodynamic progression of aortic 
stenosis in adults assessed by Doppler echocardiography. J Am Coll Car -
diol. 1989;13:545–50.
 2. Brener SJ, Duffy CI, Thomas JD, et al. Progression of aortic stenosis in 394 
patients: relation to changes in myocardial and mitral valve dysfunction. J 
Am Coll Cardiol. 1995;25:305–10.
 3. Roger VL, Tajik AJ, Bailey KR, et al. Progression of aortic stenosis in 
adults: new appraisal using Doppler echocardiography. Am Heart J. 
1990;119:331–8.
 4. Bahler RC, Desser DR, Finkelhor RS, et al. Factors leading to progression of 
valvular aortic stenosis. Am J Cardiol. 1999;84:1044–8.
 5. Palta S, Pai AM, Gill KS, et al. New insights into the progression of 
aortic stenosis: implications for secondary prevention. Circulation. 
2000;101:2497–502.
 6. Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, 
asymptomatic aortic stenosis. N Engl J Med. 2000;343:611–7.
 7. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with sim-
vastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–
56.
 8. Cosmi JE, Kort S, Tunick PA, et al. The risk of the development of aortic 
stenosis in patients with “benign” aortic valve thickening. Arch Intern 
Med. 2002;162:2345–7.
 9. Novaro GM, Katz R, Aviles RJ, et al. Clinical factors, but not C-reactive pro-
tein, predict progression of calcific aortic-valve disease: the Cardiovascular 
Health Study. J Am Coll Cardiol. 2007;50:1992–8.
 10. Owens DS, Katz R, Takasu J, et al. Incidence and progression of aortic 
valve calcium in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J 
Cardiol. 2010;105:701–8.
 11. Tzemos N, Therrien J, Yip J, et al. Outcomes in adults with bicuspid aortic 
valves. JAMA. 2008;300:1317–25.
 12. Michelena HI, Desjardins VA, Avierinos J-F, et al. Natural history 
of asymptomatic patients with normally functioning or minimally 
dysfunctional bicuspid aortic valve in the community. Circulation. 
2008;117:2776–84.
 13. Lindman BR, Bonow RO, Otto CM. Current management of calcific aortic 
stenosis. Circ Res. 2013;113:223–37.
3.2.1.4. Diagnostic Testing: Cardiac Catheterization
 1. Shavelle DM. Evaluation of valvular heart disease by cardiac catheriza-
tion and angiocardiography. In: Otto CM, Bonow RO, eds. Valvular Heart 
Disease: A Companion to Braunwald’s Heart Disease. 4th ed. Philadelphia, 
PA: Elsevier/Saunders; 2014:91–106.
 2. Nishimura RA, Carabello BA. Hemodynamics in the cardiac catheterization 
laboratory of the 21st century. Circulation. 2012;125:2138–50.
3.2.1.5. Diagnostic Testing: Exercise Testing
 1. Saeed S, Rajani R, Seifert R, et al. Exercise testing in patients with asymp-
tomatic moderate or severe aortic stenosis. Heart. 2018;104:1836–42.
 2. Das P , Rimington H, Chambers J. Exercise testing to stratify risk in aortic 
stenosis. Eur Heart J. 2005;26:1309–13. 3. Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptom-
atic valvular aortic stenosis. Clinical, echocardiographic, and exercise pre-
dictors of outcome. Circulation. 1997;95:2262–70.
 4. Maréchaux S, Hachicha Z, Bellouin A, et al. Usefulness of exercise-stress 
echocardiography for risk stratification of true asymptomatic patients 
with aortic valve stenosis. Eur Heart J. 2010;31:1390–7.
 5. Atterhög JH, Jonsson B, Samuelsson R. Exercise testing: a prospective 
study of complication rates. Am Heart J. 1979;98:572–9.
 6. Otto CM, Pearlman AS, Gardner CL. Hemodynamic progression of aortic 
stenosis in adults assessed by Doppler echocardiography. J Am Coll Car -
diol. 1989;13:545–50.
 7. Lancellotti P , Lebois F, Simon M, et al. Prognostic importance of quantita-
tive exercise Doppler echocardiography in asymptomatic valvular aortic 
stenosis. Circulation. 2005;112:I377–82.
 8. Amato MC, Moffa PJ, Werner KE, et al. Treatment decision in asymptom-
atic aortic valve stenosis: role of exercise testing. Heart. 2001;86:381–6.
 9. Alborino D, Hoffmann JL, Fournet PC, et al. Value of exercise testing to 
evaluate the indication for surgery in asymptomatic patients with valvular 
aortic stenosis. J Heart Valve Dis. 2002;11:204–9.
 10. Takeda S, Rimington H, Chambers J. Prediction of symptom-onset in aortic 
stenosis: a comparison of pressure drop/flow slope and haemodynamic 
measures at rest. Int J Cardiol. 2001;81:131–7.
 11. Skalski J, Allison TG, Miller TD. The safety of cardiopulmonary exercise 
testing in a population with high-risk cardiovascular diseases. Circulation. 
2012;126:2465–72.
 12. Dhoble A, Sarano ME, Kopecky SL, et al. Safety of symptom-limited car -
diopulmonary exercise testing in patients with aortic stenosis. Am J Med. 
2012;125:704–8.
3.2.2. Medical Therapy
 1. Nazarzadeh M, Pinho-Gomes A-C, Smith Byrne K, et al. Systolic blood 
pressure and risk of valvular heart disease: a mendelian randomization 
study. JAMA Cardiol. 2019;4:788–95.
 2. Rahimi K, Mohseni H, Kiran A, et al. Elevated blood pressure and risk of 
aortic valve disease: a cohort analysis of 5.4 million UK adults. Eur Heart J. 
2018;39:3596–603.
 3. Nielsen OW, Sajadieh A, Sabbah M, et al. Assessing optimal blood pres-
sure in patients with asymptomatic aortic valve stenosis: the Simvastatin 
Ezetimibe in Aortic Stenosis study (SEAS). Circulation. 2016;134:455–68.
 4. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with sim-
vastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–
56.
 5. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of inten-
sive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 
2005;352:2389–97.
 6. Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with rosuvas-
tatin on progression of aortic stenosis: results of the Aortic Stenosis Pro-
gression Observation: Measuring Effects Of Rosuvastatin (ASTRONOMER) 
trial. Circulation. 2010;121:306–14.
 7. Ochiai T, Saito S, Yamanaka F, et al. Renin-angiotensin system block-
ade therapy after transcatheter aortic valve implantation. Heart. 
2018;104:644–51.
 8. Inohara T, Manandhar P , Kosinski AS, et al. Association of renin-angiotensin 
inhibitor treatment with mortality and heart failure readmission in patients 
with transcatheter aortic valve replacement. JAMA. 2018;320:2231–41.
 9. O’Brien KD, Zhao X-Q, Shavelle DM, et al. Hemodynamic effects of the 
angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to 
moderate aortic stenosis and preserved left ventricular function. J Investig 
Med. 2004;52:185–91.
 10. Chockalingam A, Venkatesan S, Subramaniam T, et al. Safety and efficacy 
of angiotensin-converting enzyme inhibitors in symptomatic severe aortic 
stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aor -
tic Stenosis (SCOPE-AS). Am Heart J. 2004;147:E19.
 11. Nadir MA, Wei L, Elder DHJ, et al. Impact of renin-angiotensin system 
blockade therapy on outcome in aortic stenosis. J Am Coll Cardiol. 
2011;58:570–6.
 12. Rieck ÅE, Cramariuc D, Boman K, et al. Hypertension in aortic stenosis: 
implications for left ventricular structure and cardiovascular events. Hyper -
tension. 2012;60:90–7.
 13. Briand M, Dumesnil JG, Kadem L, et al. Reduced systemic arterial compli-
ance impacts significantly on left ventricular afterload and function in aor -
tic stenosis: implications for diagnosis and treatment. J Am Coll Cardiol. 
2005;46:291–8.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e191
CLINICAL STATEMENTS  
AND GUIDELINES 14. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic 
valve endothelium to slow the progression of aortic stenosis. J Am Coll 
Cardiol. 2007;49:554–61.
 15. Rajamannan NM, Evans FJ, Aikawa E, et al. Calcific aortic valve disease: 
not simply a degenerative process: a review and agenda for research from 
the National Heart and Lung and Blood Institute Aortic Stenosis Working 
Group. Executive summary: calcific aortic valve disease—2011 update. 
Circulation. 2011;124:1783–91.
 16. Hansson NH, Sorensen J, Harms HJ, et al. Metoprolol reduces hemody-
namic and metabolic overload in asymptomatic aortic valve stenosis pa-
tients: a randomized trial. Circ Cardiovasc Imaging. 2017;10:e006557.
 17. Lindman BR, Zajarias A, Madrazo JA, et al. Effects of phosphodiesterase 
type 5 inhibition on systemic and pulmonary hemodynamics and ventricu-
lar function in patients with severe symptomatic aortic stenosis. Circula-
tion. 2012;125:2353–62.
3.2.3. Timing of Intervention
 1. Kapadia SR, Leon MB, Makkar RR, et al. 5-Year outcomes of transcatheter 
aortic valve replacement compared with standard treatment for patients 
with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. 
Lancet. 2015;385:2485–91.
 2. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implanta-
tion for aortic stenosis in patients who cannot undergo surgery. N Engl J 
Med. 2010;363:1597–607.
 3. Makkar RR, Fontana GP , Jilaihawi H, et al. Transcatheter aortic-valve 
replacement for inoperable severe aortic stenosis. N Engl J Med. 
2012;366:1696–704.
 4. Otto CM, Pearlman AS. Doppler echocardiography in adults with symp-
tomatic aortic stenosis. Diagnostic utility and cost-effectiveness. Arch In-
tern Med. 1988;148:2553–60.
 5. Turina J, Hess O, Sepulcri F, et al. Spontaneous course of aortic valve dis-
ease. Eur Heart J. 1987;8:471–83.
 6. Kelly TA, Rothbart RM, Cooper CM, et al. Comparison of outcome of 
asymptomatic to symptomatic patients older than 20 years of age with 
valvular aortic stenosis. Am J Cardiol. 1988;61:123–30.
 7. Pellikka PA, Nishimura RA, Bailey KR, et al. The natural history of adults 
with asymptomatic, hemodynamically significant aortic stenosis. J Am Coll 
Cardiol. 1990;15:1012–7.
 8. Dahl JS, Eleid MF, Michelena HI, et al. Effect of left ventricular ejection 
fraction on postoperative outcome in patients with severe aortic ste-
nosis undergoing aortic valve replacement. Circ Cardiovasc Imaging. 
2015;8:e002917.
 9. Taniguchi T, Morimoto T, Shiomi H, et al. Prognostic impact of left ven-
tricular ejection fraction in patients with severe aortic stenosis. JACC Car -
diovasc Interv. 2018;11:145–57.
 10. Ito S, Miranda WR, Nkomo VT, et al. Reduced left ventricular ejec-
tion fraction in patients with aortic stenosis. J Am Coll Cardiol. 
2018;71:1313–21.
 11. Bohbot Y, de Meester de Ravenstein C, Chadha G, et al. Relationship be-
tween left ventricular ejection fraction and mortality in asymptomatic and 
minimally symptomatic patients with severe aortic stenosis. JACC Cardio-
vasc Imaging. 2019;12:38–48.
 12. Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, 
asymptomatic aortic stenosis. N Engl J Med. 2000;343:611–7.
 13. Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptom-
atic valvular aortic stenosis. Clinical, echocardiographic, and exercise pre-
dictors of outcome. Circulation. 1997;95:2262–70.
 14. Pellikka PA, Sarano ME, Nishimura RA, et al. Outcome of 622 adults with 
asymptomatic, hemodynamically significant aortic stenosis during pro-
longed follow-up. Circulation. 2005;111:3290–5.
 15. Lancellotti P , Donal E, Magne J, et al. Risk stratification in asymptomatic 
moderate to severe aortic stenosis: the importance of the valvular, arterial 
and ventricular interplay. Heart. 2010;96:1364–71.
 16. Kang D-H, Park S-J, Rim JH, et al. Early surgery versus conventional 
treatment in asymptomatic very severe aortic stenosis. Circulation. 
2010;121:1502–9.
 17. Tribouilloy C, Lévy F, Rusinaru D, et al. Outcome after aortic valve re-
placement for low-flow/low-gradient aortic stenosis without contrac-
tile reserve on dobutamine stress echocardiography. J Am Coll Cardiol. 
2009;53:1865–73.
 18. Herrmann HC, Pibarot P , Hueter I, et al. Predictors of mortality and 
outcomes of therapy in low-flow severe aortic stenosis: a Placement 
of Aortic Transcatheter Valves (PARTNER) trial analysis. Circulation. 
2013;127:2316–26. 19. Anjan VY, Herrmann HC, Pibarot P , et al. Evaluation of flow after trans-
catheter aortic valve replacement in patients with low-flow aortic stenosis: 
a secondary analysis of the PARTNER randomized clinical trial. JAMA Car -
diol. 2016;1:584–92.
 20. Lopez-Marco A, Miller H, Youhana A, et al. Low-flow low-gradient aortic 
stenosis: surgical outcomes and mid-term results after isolated aortic valve 
replacement. Eur J Cardiothorac Surg. 2016;49:1685–90.
 21. O’Sullivan CJ, Englberger L, Hosek N, et al. Clinical outcomes and revascu-
larization strategies in patients with low-flow, low-gradient severe aortic 
valve stenosis according to the assigned treatment modality. JACC Cardio-
vasc Interv. 2015;8:704–17.
 22. Nishimura RA, Grantham JA, Connolly HM, et al. Low-output, low-gradi-
ent aortic stenosis in patients with depressed left ventricular systolic func-
tion: the clinical utility of the dobutamine challenge in the catheterization 
laboratory. Circulation. 2002;106:809–13.
 23. Monin J-L, Quéré J-P , Monchi M, et al. Low-gradient aortic stenosis: op-
erative risk stratification and predictors for long-term outcome: a mul-
ticenter study using dobutamine stress hemodynamics. Circulation. 
2003;108:319–24.
 24. Fougères E, Tribouilloy C, Monchi M, et al. Outcomes of pseudo-severe 
aortic stenosis under conservative treatment. Eur Heart J. 2012;33:2426–
33.
 25. Eleid MF, Padang R, Al-Hijji M, et al. Hemodynamic response in low-flow 
low-gradient aortic stenosis with preserved ejection fraction after TAVR. J 
Am Coll Cardiol. 2019;73:1731–2.
 26. Rusinaru D, Bohbot Y, Ringle A, et al. Impact of low stroke volume on 
mortality in patients with severe aortic stenosis and preserved left ven-
tricular ejection fraction. Eur Heart J. 2018;39:1992–9.
 27. Zheng Q, Djohan AH, Lim E, et al. Effects of aortic valve replacement on 
severe aortic stenosis and preserved systolic function: systematic review 
and network meta-analysis. Sci Rep. 2017;7:5092.
 28. Maréchaux S, Hachicha Z, Bellouin A, et al. Usefulness of exercise-stress 
echocardiography for risk stratification of true asymptomatic patients 
with aortic valve stenosis. Eur Heart J. 2010;31:1390–7.
 29. Saeed S, Mancia G, Rajani R, et al. Exercise treadmill testing in moderate 
or severe aortic stenosis: the left ventricular correlates of an exaggerated 
blood pressure rise. J Am Heart Assoc. 2018;7:e010735.
 30. Saeed S, Rajani R, Seifert R, et al. Exercise testing in patients with asymp-
tomatic moderate or severe aortic stenosis. Heart. 2018;104:1836–42.
 31. Kang D-H, Park S-J, Lee S-A, et al. Early surgery or conservative care for 
asymptomatic aortic stenosis. N Engl J Med. 2020;382:111–9.
 32. Nakatsuma K, Taniguchi T, Morimoto T, et al. B-type natriuretic peptide in 
patients with asymptomatic severe aortic stenosis. Heart. 2019;105:384–
90.
 33. Lancellotti P , Magne J, Dulgheru R, et al. Outcomes of patients with as-
ymptomatic aortic stenosis followed up in heart valve clinics. JAMA Car -
diol. 2018;3:1060–8.
 34. Taniguchi T, Morimoto T, Shiomi H, et al. Sudden death in patients with 
severe aortic stenosis: observations from the CURRENT AS registry. J Am 
Heart Assoc. 2018;7:e008397.
 35. Rosenhek R, Zilberszac R, Schemper M, et al. Natural history of very severe 
aortic stenosis. Circulation. 2010;121:151–6.
 36. Bergler-Klein J, Klaar U, Heger M, et al. Natriuretic peptides predict symp-
tom-free survival and postoperative outcome in severe aortic stenosis. 
Circulation. 2004;109:2302–8.
 37. Gerber IL, Stewart RAH, Legget ME, et al. Increased plasma natriuretic 
peptide levels reflect symptom onset in aortic stenosis. Circulation. 
2003;107:1884–90.
 38. Lim P , Monin JL, Monchi M, et al. Predictors of outcome in patients with 
severe aortic stenosis and normal left ventricular function: role of B-type 
natriuretic peptide. Eur Heart J. 2004;25:2048–53.
 39. Taniguchi T, Morimoto T, Shiomi H, et al. Initial surgical versus conservative 
strategies in patients with asymptomatic severe aortic stenosis. J Am Coll 
Cardiol. 2015;66:2827–38.
 40. Nishimura S, Izumi C, Nishiga M, et al. Predictors of rapid progression 
and clinical outcome of asymptomatic severe aortic stenosis. Circ J. 
2016;80:1863–9.
 41. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: patho-
genesis, disease progression, and treatment strategies. Circulation. 
2005;111:3316–26.
 42. Horstkotte D, Loogen F. The natural history of aortic valve stenosis. Eur 
Heart J. 1988;9(suppl E):57–64.
 43. Kvidal P , Bergström R, Hörte LG, et al. Observed and relative survival after 
aortic valve replacement. J Am Coll Cardiol. 2000;35:747–56.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e192
CLINICAL STATEMENTS  
AND GUIDELINES 44. Murphy ES, Lawson RM, Starr A, et al. Severe aortic stenosis in patients 60 
years of age or older: left ventricular function and 10-year survival after 
valve replacement. Circulation. 1981;64:II184–8.
 45. O’Brien SM, Shahian DM, Filardo G, et al. The Society of Thoracic Sur -
geons 2008 cardiac surgery risk models: part 2–isolated valve surgery. Ann 
Thorac Surg. 2009;88:S23–42.
 46. Schwarz F, Baumann P , Manthey J, et al. The effect of aortic valve replace-
ment on survival. Circulation. 1982;66:1105–10.
 47. Oh JK, Taliercio CP , Holmes DR, et al. Prediction of the severity of aor -
tic stenosis by Doppler aortic valve area determination: prospective 
Doppler-catheterization correlation in 100 patients. J Am Coll Cardiol. 
1988;11:1227–34.
 48. Galan A, Zoghbi WA, Quiñones MA. Determination of severity of valvular 
aortic stenosis by Doppler echocardiography and relation of findings to 
clinical outcome and agreement with hemodynamic measurements deter -
mined at cardiac catheterization. Am J Cardiol. 1991;67:1007–12.
 49. Rosenhek R, Klaar U, Schemper M, et al. Mild and moderate aortic steno-
sis. Natural history and risk stratification by echocardiography. Eur Heart J. 
2004;25:199–205.
 50. Stewart RAH, Kerr AJ, Whalley GA, et al. Left ventricular systolic and dia-
stolic function assessed by tissue Doppler imaging and outcome in asymp-
tomatic aortic stenosis. Eur Heart J. 2010;31:2216–22.
 51. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with sim-
vastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–
56.
 52. Kennedy KD, Nishimura RA, Holmes DR Jr, et al. Natural history of moder -
ate aortic stenosis. J Am Coll Cardiol. 1991;17:313–9.
 53. Jander N, Minners J, Holme I, et al. Outcome of patients with low-gradi-
ent “severe” aortic stenosis and preserved ejection fraction. Circulation. 
2011;123:887–95.
 54. Saito T, Muro T, Takeda H, et al. Prognostic value of aortic valve area in-
dex in asymptomatic patients with severe aortic stenosis. Am J Cardiol. 
2012;110:93–7.
 55. Pereira JJ, Lauer MS, Bashir M, et al. Survival after aortic valve replacement 
for severe aortic stenosis with low transvalvular gradients and severe left 
ventricular dysfunction. J Am Coll Cardiol. 2002;39:1356–63.
 56. Clavel MA, Webb JG, Rodés-Cabau J, et al. Comparison between trans-
catheter and surgical prosthetic valve implantation in patients with severe 
aortic stenosis and reduced left ventricular ejection fraction. Circulation. 
2010;122:1928–36.
 57. Connolly HM, Oh JK, Orszulak TA, et al. Aortic valve replacement for aor -
tic stenosis with severe left ventricular dysfunction. Prognostic indicators. 
Circulation. 1997;95:2395–400.
 58. Quéré J-P , Monin J-L, Levy F, et al. Influence of preoperative left ventricular 
contractile reserve on postoperative ejection fraction in low-gradient aor -
tic stenosis. Circulation. 2006;113:1738–44.
 59. Pai RG, Varadarajan P , Razzouk A. Survival benefit of aortic valve re-
placement in patients with severe aortic stenosis with low ejection frac-
tion and low gradient with normal ejection fraction. Ann Thorac Surg. 
2008;86:1781–9.
 60. Levy F, Laurent M, Monin JL, et al. Aortic valve replacement for low-flow/
low-gradient aortic stenosis operative risk stratification and long-term out-
come: a European multicenter study. J Am Coll Cardiol. 2008;51:1466–
72.
 61. Gotzmann M, Lindstaedt M, Bojara W, et al. Clinical outcome of trans-
catheter aortic valve implantation in patients with low-flow, low gradient 
aortic stenosis. Catheter Cardiovasc Interv. 2012;79:693–701.
 62. Pereira JJ, Balaban K, Lauer MS, et al. Aortic valve replacement in patients 
with mild or moderate aortic stenosis and coronary bypass surgery. Am J 
Med. 2005;118:735–42.
 63. Smith WT, Ferguson TB Jr, Ryan T, et al. Should coronary artery bypass 
graft surgery patients with mild or moderate aortic stenosis undergo con-
comitant aortic valve replacement? A decision analysis approach to the 
surgical dilemma. J Am Coll Cardiol. 2004;44:1241–7.
 64. Gillinov AM, Garcia MJ. When is concomitant aortic valve replacement 
indicated in patients with mild to moderate stenosis undergoing coronary 
revascularization? Curr Cardiol Rep. 2005;7:101–4.
 65. Bhattacharyya S, Hayward C, Pepper J, et al. Risk stratification in as-
ymptomatic severe aortic stenosis: a critical appraisal. Eur Heart J. 
2012;33:2377–87.
 66. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment 
of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J 
Echocardiogr. 2009;10:1–25.
 67. deFilippi CR, Willett DL, Brickner ME, et al. Usefulness of dobutamine 
echocardiography in distinguishing severe from nonsevere valvular aortic stenosis in patients with depressed left ventricular function and low trans-
valvular gradients. Am J Cardiol. 1995;75:191–4.
 68. Tarantini G, Covolo E, Razzolini R, et al. Valve replacement for severe aor -
tic stenosis with low transvalvular gradient and left ventricular ejection 
fraction exceeding 0.50. Ann Thorac Surg. 2011;91:1808–15.
 69. Clavel M-A, Dumesnil JG, Capoulade R, et al. Outcome of patients 
with aortic stenosis, small valve area, and low-flow, low-gradient de-
spite preserved left ventricular ejection fraction. J Am Coll Cardiol. 
2012;60:1259–67.
 70. Lancellotti P , Magne J, Donal E, et al. Clinical outcome in asymptomatic se-
vere aortic stenosis: insights from the new proposed aortic stenosis grad-
ing classification. J Am Coll Cardiol. 2012;59:235–43.
 71. Mehrotra P , Jansen K, Flynn AW, et al. Differential left ventricular remodel-
ling and longitudinal function distinguishes low flow from normal-flow 
preserved ejection fraction low-gradient severe aortic stenosis. Eur Heart 
J. 2013;34:1906–14.
 72. Lauten J, Rost C, Breithardt OA, et al. Invasive hemodynamic characteris-
tics of low gradient severe aortic stenosis despite preserved ejection frac-
tion. J Am Coll Cardiol. 2013;61:1799–808.
 73. Mangner N, Stachel G, Woitek F, et al. Predictors of mortality and symp-
tomatic outcome of patients with low-flow severe aortic stenosis under -
going transcatheter aortic valve replacement. J Am Heart Assoc. 2018;7: 
e010287.
 74. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for 
the management of valvular heart disease. Eur Heart J. 2017;38:  
2739–91.
 75. Ozkan A, Hachamovitch R, Kapadia SR, et al. Impact of aortic valve re-
placement on outcome of symptomatic patients with severe aortic ste-
nosis with low gradient and preserved left ventricular ejection fraction. 
Circulation. 2013;128:622–31.
 76. Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with rosuvas-
tatin on progression of aortic stenosis: results of the Aortic Stenosis Pro-
gression Observation: Measuring Effects Of Rosuvastatin (ASTRONOMER) 
trial. Circulation. 2010;121:306–14.
 77. Lancellotti P , Lebois F, Simon M, et al. Prognostic importance of quantita-
tive exercise Doppler echocardiography in asymptomatic valvular aortic 
stenosis. Circulation. 2005;112:I377–82.
 78. Das P , Rimington H, Chambers J. Exercise testing to stratify risk in aortic 
stenosis. Eur Heart J. 2005;26:1309–13.
 79. Alborino D, Hoffmann JL, Fournet PC, et al. Value of exercise testing to 
evaluate the indication for surgery in asymptomatic patients with valvular 
aortic stenosis. J Heart Valve Dis. 2002;11:204–9.
 80. Takeda S, Rimington H, Chambers J. Prediction of symptom-onset in aortic 
stenosis: a comparison of pressure drop/flow slope and haemodynamic 
measures at rest. Int J Cardiol. 2001;81:131–7.
 81. Skalski J, Allison TG, Miller TD. The safety of cardiopulmonary exercise 
testing in a population with high-risk cardiovascular diseases. Circulation. 
2012;126:2465–72.
 82. Dayan V, Vignolo G, Magne J, et al. Outcome and impact of aortic valve 
replacement in patients with preserved LVEF and low-gradient aortic ste-
nosis. J Am Coll Cardiol. 2015;66:2594–603.
3.2.4. Choice of Intervention
3.2.4.1. Choice of Mechanical Versus Bioprosthetic 
AVR
 1. Goldstone AB, Chiu P , Baiocchi M, et al. Mechanical or biologic pros-
theses for aortic-valve and mitral-valve replacement. N Engl J Med. 
2017;377:1847–57.
 2. Badhwar V, Ofenloch JC, Rovin JD, et al. Noninferiority of closely moni-
tored mechanical valves to bioprostheses overshadowed by early mortality 
benefit in younger patients. Ann Thorac Surg. 2012;93:748–53.
 3. Brown ML, Schaff HV, Lahr BD, et al. Aortic valve replacement in patients 
aged 50 to 70 years: improved outcome with mechanical versus biologic 
prostheses. J Thorac Cardiovasc Surg. 2008;135:878–84.
 4. van Geldorp MWA, Eric Jamieson WR, Kappetein AP , et al. Patient out-
come after aortic valve replacement with a mechanical or biological pros-
thesis: weighing lifetime anticoagulant-related event risk against reopera-
tion risk. J Thorac Cardiovasc Surg. 2009;137:881–6, 866.e1–5.
 5. Kulik A, Bédard P , Lam B-K, et al. Mechanical versus bioprosthetic 
valve replacement in middle-aged patients. Eur J Cardiothorac Surg. 
2006;30:485–91.
 6. Glaser N, Jackson V, Holzmann MJ, et al. Aortic valve replacement with 
mechanical vs. biological prostheses in patients aged 50–69 years. Eur 
Heart J. 2016;37:2658–67.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e193
CLINICAL STATEMENTS  
AND GUIDELINES 7. Chikwe J, Chiang YP , Egorova NN, et al. Survival and outcomes following 
bioprosthetic vs mechanical mitral valve replacement in patients aged 50 
to 69 years. JAMA. 2015;313:1435–42.
 8. McClure RS, McGurk S, Cevasco M, et al. Late outcomes comparison of 
nonelderly patients with stented bioprosthetic and mechanical valves in 
the aortic position: a propensity-matched analysis. J Thorac Cardiovasc 
Surg. 2014;148:1931–9.
 9. Chiang YP , Chikwe J, Moskowitz AJ, et al. Survival and long-term out-
comes following bioprosthetic vs mechanical aortic valve replacement in 
patients aged 50 to 69 years. JAMA. 2014;312:1323–9.
 10. Kaneko T, Aranki S, Javed Q, et al. Mechanical versus bioprosthetic mitral 
valve replacement in patients <65 years old. J Thorac Cardiovasc Surg. 
2014;147:117–26.
 11. Buratto E, Shi WY, Wynne R, et al. Improved survival after the Ross pro-
cedure compared with mechanical aortic valve replacement. J Am Coll 
Cardiol. 2018;71:1337–44.
 12. El-Hamamsy I, Eryigit Z, Stevens L-M, et al. Long-term outcomes after 
autograft versus homograft aortic root replacement in adults with aortic 
valve disease: a randomised controlled trial. Lancet. 2010;376:524–31.
 13. Martin E, Mohammadi S, Jacques F, et al. Clinical outcomes following the 
Ross procedure in adults: a 25-year longitudinal study. J Am Coll Cardiol. 
2017;70:1890–9.
 14. Bourguignon T, Bouquiaux-Stablo A-L, Loardi C, et al. Very late outcomes 
for mitral valve replacement with the Carpentier-Edwards pericardial bio-
prosthesis: 25-year follow-up of 450 implantations. J Thorac Cardiovasc 
Surg. 2014;148:2004–11.e1.
 15. Bourguignon T, El Khoury R, Candolfi P , et al. Very long-term outcomes 
of the Carpentier-Edwards PERIMOUNT aortic valve in patients aged 60 or 
younger. Ann Thorac Surg. 2015;100:853–9.
 16. Tuzcu EM, Kapadia SR, Vemulapalli S, et al. Transcatheter aortic valve re-
placement of failed surgically implanted bioprostheses: the STS/ACC reg-
istry. J Am Coll Cardiol. 2018;72:370–82.
 17. Ye J, Cheung A, Yamashita M, et al. Transcatheter aortic and mitral valve-
in-valve implantation for failed surgical bioprosthetic valves: an 8-year 
single-center experience. JACC Cardiovasc Interv. 2015;8:1735–44.
 18. Dvir D, Webb JG, Bleiziffer S, et al. Transcatheter aortic valve implantation 
in failed bioprosthetic surgical valves. JAMA. 2014;312:162–70.
 19. Dvir D, Webb J, Brecker S, et al. Transcatheter aortic valve replacement for 
degenerative bioprosthetic surgical valves: results from the global valve-in-
valve registry. Circulation. 2012;126:2335–44.
 20. Coylewright M, Forrest JK, McCabe JM, et al. TAVR in low-risk patients: 
FDA approval, the new NCD, and shared decision-making. J Am Coll Car -
diol. 2020;75:1208–11.
 21. Hess EP , Coylewright M, Frosch DL, et al. Implementation of shared deci-
sion making in cardiovascular care: past, present, and future. Circ Cardio-
vasc Qual Outcomes. 2014;7:797–803.
 22. Weber A, Noureddine H, Englberger L, et al. Ten-year comparison of peri-
cardial tissue valves versus mechanical prostheses for aortic valve replace-
ment in patients younger than 60 years of age. J Thorac Cardiovasc Surg. 
2012;144:1075–83.
 23. Hammermeister K, Sethi GK, Henderson WG, et al. Outcomes 15 years 
after valve replacement with a mechanical versus a bioprosthetic valve: 
final report of the Veterans Affairs randomized trial. J Am Coll Cardiol. 
2000;36:1152–8.
 24. Chan V, Jamieson WRE, Germann E, et al. Performance of bioprostheses 
and mechanical prostheses assessed by composites of valve-related com-
plications to 15 years after aortic valve replacement. J Thorac Cardiovasc 
Surg. 2006;131:1267–73.
 25. Dunning J, Gao H, Chambers J, et al. Aortic valve surgery: marked increas-
es in volume and significant decreases in mechanical valve use–an analysis 
of 41,227 patients over 5 years from the Society for Cardiothoracic Sur -
gery in Great Britain and Ireland National database. J Thorac Cardiovasc 
Surg. 2011;142:776–82.e3.
 26. Stassano P , L. DT, Monaco M, et al. Aortic valve replacement: a prospective 
randomized evaluation of mechanical versus biological valves in patients 
ages 55 to 70 years. J Am Coll Cardiol. 2009;54:1862–8.
 27. Brennan JM, Edwards FH, Zhao Y, et al. Long-term safety and effective-
ness of mechanical versus biologic aortic valve prostheses in older pa-
tients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery 
National Database. Circulation. 2013;127:1647–55.
 28. Banbury MK, Cosgrove DM 3rd, Thomas JD, et al. Hemodynamic stability 
during 17 years of the Carpentier-Edwards aortic pericardial bioprosthesis. 
Ann Thorac Surg. 2002;73:1460–5. 29. Dellgren G, David TE, Raanani E, et al. Late hemodynamic and clinical out-
comes of aortic valve replacement with the Carpentier-Edwards Perimount 
pericardial bioprosthesis. J Thorac Cardiovasc Surg. 2002;124:146–54.
 30. Borger MA, Ivanov J, Armstrong S, et al. Twenty-year results of the Han-
cock II bioprosthesis. J Heart Valve Dis. 2006;15:49–55.
 31. Mykén PSU, Bech-Hansen O. A 20-year experience of 1712 patients with 
the Biocor porcine bioprosthesis. J Thorac Cardiovasc Surg. 2009;137:76–
81.
 32. Mazine A, El-Hamamsy I, Verma S, et al. Ross procedure in adults for car -
diologists and cardiac Surgeons: JACC state-of-the-art review. J Am Coll 
Cardiol. 2018;72:2761–77.
3.2.4.2. Choice of SAVR Versus TAVI for Patients for 
Whom a Bioprosthetic AVR Is Appropriate
 1. Siemieniuk RA, Agoritsas T, Manja V, et al. Transcatheter versus surgi-
cal aortic valve replacement in patients with severe aortic stenosis at 
low and intermediate risk: systematic review and meta-analysis. BMJ. 
2016;354:i5130.
 2. Foroutan F, Guyatt GH, O’Brien K, et al. Prognosis after surgical replace-
ment with a bioprosthetic aortic valve in patients with severe symptom-
atic aortic stenosis: systematic review of observational studies. BMJ. 
2016;354:i5065.
 3. Siontis GCM, Overtchouk P , Cahill TJ, et al. Transcatheter aortic valve im-
plantation vs. surgical aortic valve replacement for treatment of symp-
tomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J. 
2019;40:3143–53.
 4. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replace-
ment with a self-expanding prosthesis. N Engl J Med. 2014;370:1790–8.
 5. Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aor -
tic valve replacement or surgical aortic valve replacement for high surgical 
risk patients with aortic stenosis (PARTNER 1): a randomised controlled 
trial. Lancet. 2015;385:2477–84.
 6. Deeb GM, Reardon MJ, Chetcuti S, et al. 3-Year outcomes in high-risk pa-
tients who underwent surgical or transcatheter aortic valve replacement. 
J Am Coll Cardiol. 2016;67:2565–74.
 7. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve 
replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609–
20.
 8. Thourani VH, Kodali S, Makkar RR, et al. Transcatheter aortic valve re-
placement versus surgical valve replacement in intermediate-risk patients: 
a propensity score analysis. Lancet. 2016;387:2218–25.
 9. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replace-
ment with a balloon-expandable valve in low-risk patients. N Engl J Med. 
2019;380:1695–705.
 10. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve re-
placement with a self-expanding valve in low-risk patients. N Engl J Med. 
2019;380:1706–15.
 11. Siontis KC, Killu AM. Silent and non-silent thromboembolic events after 
ventricular tachycardia ablation: modifiable risk with postprocedure anti-
coagulation? J Cardiovasc Electrophysiol. 2019;30:1197–9.
 12. Kapadia SR, Leon MB, Makkar RR, et al. 5-Year outcomes of transcatheter 
aortic valve replacement compared with standard treatment for patients 
with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. 
Lancet. 2015;385:2485–91.
 13. Popma JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve replace-
ment using a self-expanding bioprosthesis in patients with severe aortic 
stenosis at extreme risk for surgery. J Am Coll Cardiol. 2014;63:1972–81.
 14. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implanta-
tion for aortic stenosis in patients who cannot undergo surgery. N Engl J 
Med. 2010;363:1597–607.
 15. Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes af-
ter transcatheter or surgical aortic-valve replacement. N Engl J Med. 
2012;366:1686–95.
 16. Burke CR, Kirkpatrick JN, Otto CM. Goals of care in patients with severe 
aortic stenosis. Eur Heart J. 2020;41:929–32.
 17. Otto CM. Informed shared decisions for patients with aortic stenosis. N 
Engl J Med. 2019;380:1769–70.
 18. Social Security Administration (US). Actuarial Life Table. Available at: 
https://www.ssa.gov/oact/STATS/table4c6.html. Accessed February 29, 
2020.
 19. Salaun E, Clavel M-A, Rodés-Cabau J, et al. Bioprosthetic aortic valve 
durability in the era of transcatheter aortic valve implantation. Heart. 
2018;104:1323–32.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e194
CLINICAL STATEMENTS  
AND GUIDELINES 20. Nishimura RA, O’Gara PT, Bavaria JE, et al. 2019 AATS/ACC/ASE/SCAI/STS ex-
pert consensus systems of care document: a proposal to optimize care for 
patients with valvular heart disease: a joint report of the American Association 
for Thoracic Surgery, American College of Cardiology, American Society of 
Echocardiography, Society for Cardiovascular Angiography and Interventions, 
and Society of Thoracic Surgeons. J Am Coll Cardiol. 2019;73:2609–35.
 21. Kumar A, Sato K, Banerjee K, et al. Hemodynamic durability of transcath-
eter aortic valves using the updated Valve Academic Research Consor -
tium-2 criteria. Catheter Cardiovasc Interv. 2019;93:729–38.
 22. Foroutan F, Guyatt GH, Otto CM, et al. Structural valve deterioration after 
transcatheter aortic valve implantation. Heart. 2017;103:1899–905.
 23. Abdel-Wahab M, Neumann F-J, Mehilli J, et al. 1-Year outcomes after 
transcatheter aortic valve replacement with balloon-expandable versus 
self-expandable valves: results from the CHOICE randomized clinical trial. 
J Am Coll Cardiol. 2015;66:791–800.
 24. Lytvyn L, Guyatt GH, Manja V, et al. Patient values and preferences on 
transcatheter or surgical aortic valve replacement therapy for aortic steno-
sis: a systematic review. BMJ Open. 2016;6:e014327.
 25. Otto CM, Kumbhani DJ, Alexander KP , et al. 2017 ACC expert consensus 
decision pathway for transcatheter aortic valve replacement in the man-
agement of adults with aortic stenosis: a report of the American College 
of Cardiology Task Force on Clinical Expert Consensus Documents. J Am 
Coll Cardiol. 2017;69:1313–46.
 26. Abdel-Wahab M, Landt M, Neumann FJ, et al. 5-Year outcomes af-
ter TAVR with balloon-expandable versus self-expanding valves: results 
from the CHOICE Randomized Clinical Trial. JACC Cardiovasc Interv. 
2020;13:1071–82.
 27. Deharo P , Bisson A, Herbert J, et al. Impact of Sapien 3 balloon-expandable 
versus Evolut R self-expandable transcatheter aortic valve implantation in 
patients with aortic stenosis: data from a nationwide analysis. Circulation. 
2020;141:260–8.
 28. Van Belle E, Vincent F, Labreuche J, et al. Balloon-expandable versus self-
expanding transcatheter aortic valve replacement: a propensity-matched 
comparison from the FRANCE-TAVI Registry. Circulation. 2020;141:243–59.
 29. Furer A, Chen S, Redfors B, et al. Effect of baseline left ventricular ejection 
fraction on 2-year outcomes after transcatheter aortic valve replacement: 
analysis of the PARTNER 2 trials. Circ Heart Fail. 2019;12:e005809.
 30. Ribeiro HB, Lerakis S, Gilard M, et al. Transcatheter aortic valve replace-
ment in patients with low-flow, low-gradient aortic stenosis: the TOPAS-
TAVI registry. J Am Coll Cardiol. 2018;71:1297–308.
 31. Schewel J, Schlüter M, Schmidt T, et al. Early haemodynamic changes and 
long-term outcome of patients with severe low-gradient aortic stenosis after 
transcatheter aortic valve replacement. EuroIntervention. 2020;15:1181–9.
 32. Maes F, Lerakis S, Barbosa Ribeiro H, et al. Outcomes from transcatheter 
aortic valve replacement in patients with low-flow, low-gradient aortic 
stenosis and left ventricular ejection fraction less than 30%: a substudy 
from the TOPAS-TAVI registry. JAMA Cardiol. 2019;4:64–70.
 33. Elmariah S, Fearon WF, Inglessis I, et al. Transapical transcatheter aortic 
valve replacement is associated with increased cardiac mortality in pa-
tients with left ventricular dysfunction: insights from the PARTNER I trial. 
JACC Cardiovasc Interv. 2017;10:2414–22.
 34. Makkar RR, Fontana GP , Jilaihawi H, et al. Transcatheter aortic-valve 
replacement for inoperable severe aortic stenosis. N Engl J Med. 
2012;366:1696–704.
 35. Kolte D, Khera S, Vemulapalli S, et al. Outcomes following urgent/emer -
gent transcatheter aortic valve replacement: insights from the STS/ACC 
TVT registry. JACC Cardiovasc Interv. 2018;11:1175–85.
 36. Nagao K, Taniguchi T, Morimoto T, et al. Acute heart failure in patients 
with severe aortic stenosis—insights from the CURRENT AS registry. Circ J. 
2018;82:874–85.
 37. Szerlip M, Arsalan M, Mack MC, et al. Usefulness of balloon aortic valvu-
loplasty in the management of patients with aortic stenosis. Am J Cardiol. 
2017;120:1366–72.
 38. Bongiovanni D, Kühl C, Bleiziffer S, et al. Emergency treatment of decom-
pensated aortic stenosis. Heart. 2018;104:23–9.
4. AORTIC REGURGITATION
4.1. Acute Aortic Regurgitation
4.1.1. Diagnosis of AR
 1. Hamirani YS, Dietl CA, Voyles W, et al. Acute aortic regurgitation. Circula-
tion. 2012;126:1121–6. 2. Stout KK, Verrier ED. Acute valvular regurgitation. Circulation. 
2009;119:3232–41.
 3. Patel PA, Bavaria JE, Ghadimi K, et al. Aortic regurgitation in acute type-A 
aortic dissection: a clinical classification for the perioperative echocardiog-
rapher in the era of the functional aortic annulus. J Cardiothorac Vasc 
Anesth. 2018;32:586–97.
4.1.2. Intervention
 1. Hamirani YS, Dietl CA, Voyles W, et al. Acute aortic regurgitation. Circula-
tion. 2012;126:1121–6.
 2. Stout KK, Verrier ED. Acute valvular regurgitation. Circulation. 
2009;119:3232–41.
 3. Lalani T, Cabell CH, Benjamin DK, et al. Analysis of the impact of early sur -
gery on in-hospital mortality of native valve endocarditis: use of propensity 
score and instrumental variable methods to adjust for treatment-selection 
bias. Circulation. 2010;121:1005–13.
 4. Patel PA, Bavaria JE, Ghadimi K, et al. Aortic regurgitation in acute type-A 
aortic dissection: a clinical classification for the perioperative echocardiog-
rapher in the era of the functional aortic annulus. J Cardiothorac Vasc 
Anesth. 2018;32:586–97.
 5. Trost JC, Hillis LD. Intra-aortic balloon counterpulsation. Am J Cardiol. 
2006;97:1391–8.
4.3. Chronic AR
4.3.1. Diagnosis of Chronic AR
 1. Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninva-
sive evaluation of native valvular regurgitation: a report from the Ameri-
can Society of Echocardiography. Developed in collaboration with the 
Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 
2017;30:303–71.
 2. Detaint D, Messika-Zeitoun D, Maalouf J, et al. Quantitative echocar -
diographic determinants of clinical outcome in asymptomatic patients 
with aortic regurgitation: a prospective study. JACC Cardiovasc Imaging. 
2008;1:1–11.
 3. Pizarro R, Bazzino OO, Oberti PF, et al. Prospective validation of the prog-
nostic usefulness of B-type natriuretic peptide in asymptomatic patients 
with chronic severe aortic regurgitation. J Am Coll Cardiol. 2011;58:1705–
14.
 4. Bonow RO, Picone AL, McIntosh CL, et al. Survival and functional results 
after valve replacement for aortic regurgitation from 1976 to 1983: im-
pact of preoperative left ventricular function. Circulation. 1985;72:1244–
56.
 5. Cunha CL, Giuliani ER, Fuster V, et al. Preoperative M-mode echocardiog-
raphy as a predictor of surgical results in chronic aortic insufficiency. J 
Thorac Cardiovasc Surg. 1980;79:256–65.
 6. Bonow RO, Lakatos E, Maron BJ, et al. Serial long-term assessment of the 
natural history of asymptomatic patients with chronic aortic regurgitation 
and normal left ventricular systolic function. Circulation. 1991;84:1625–
35.
 7. Bonow RO, Rosing DR, McIntosh CL, et al. The natural history of asymp-
tomatic patients with aortic regurgitation and normal left ventricular func-
tion. Circulation. 1983;68:509–17.
 8. Borer JS, Hochreiter C, Herrold EM, et al. Prediction of indications for valve 
replacement among asymptomatic or minimally symptomatic patients 
with chronic aortic regurgitation and normal left ventricular performance. 
Circulation. 1998;97:525–34.
 9. Ishii K, Hirota Y, Suwa M, et al. Natural history and left ventricular re-
sponse in chronic aortic regurgitation. Am J Cardiol. 1996;78:357–61.
 10. Scognamiglio R, Fasoli G, Dalla Volta S. Progression of myocardial dysfunc-
tion in asymptomatic patients with severe aortic insufficiency. Clin Cardiol. 
1986;9:151–6.
 11. Scognamiglio R, Rahimtoola SH, Fasoli G, et al. Nifedipine in asymptom-
atic patients with severe aortic regurgitation and normal left ventricular 
function. N Engl J Med. 1994;331:689–94.
 12. Siemienczuk D, Greenberg B, Morris C, et al. Chronic aortic insufficiency: 
factors associated with progression to aortic valve replacement. Ann In-
tern Med. 1989;110:587–92.
 13. Tornos MP , Olona M, Permanyer-Miralda G, et al. Clinical outcome of se-
vere asymptomatic chronic aortic regurgitation: a long-term prospective 
follow-up study. Am Heart J. 1995;130:333–9.
 14. Tarasoutchi F, Grinberg M, Spina GS, et al. Ten-year clinical laboratory 
follow-up after application of a symptom-based therapeutic strategy to 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e195
CLINICAL STATEMENTS  
AND GUIDELINESpatients with severe chronic aortic regurgitation of predominant rheu-
matic etiology. J Am Coll Cardiol. 2003;41:1316–24.
 15. Saisho H, Arinaga K, Kikusaki S, et al. Long term results and predictors of 
left ventricular function recovery after aortic valve replacement for chronic 
aortic regurgitation. Ann Thorac Cardiovasc Surg. 2015;21:388–95.
 16. Mentias A, Feng K, Alashi A, et al. Long-term outcomes in patients with 
aortic regurgitation and preserved left ventricular ejection fraction. J Am 
Coll Cardiol. 2016;68:2144–53.
 17. Yang L-T, Michelena HI, Scott CG, et al. Outcomes in chronic hemodynam-
ically significant aortic regurgitation and limitations of current guidelines. J 
Am Coll Cardiol. 2019;73:1741–52.
 18. de Meester C, Gerber BL, Vancraeynest D, et al. Do guideline-based indi-
cations result in an outcome penalty for patients with severe aortic regur -
gitation? JACC Cardiovasc Imaging. 2019;12:2126–38.
 19. Yang LT, Enriquez-Sarano M, Michelena HI, et al. Predictors of progres-
sion in patients with stage B aortic regurgitation. J Am Coll Cardiol. 
2019;74:2480–92.
 20. Cawley PJ, Hamilton-Craig C, Owens DS, et al. Prospective comparison of 
valve regurgitation quantitation by cardiac magnetic resonance imaging 
and transthoracic echocardiography. Circ Cardiovasc Imaging. 2013;6:48–
57.
 21. Cranney GB, Lotan CS, Dean L, et al. Left ventricular volume measure-
ment using cardiac axis nuclear magnetic resonance imaging. Validation 
by calibrated ventricular angiography. Circulation. 1990;82:154–63.
 22. Dulce MC, Mostbeck GH, O’Sullivan M, et al. Severity of aortic regurgi-
tation: interstudy reproducibility of measurements with velocity-encoded 
cine MR imaging. Radiology. 1992;185:235–40.
 23. Gelfand EV, Hughes S, Hauser TH, et al. Severity of mitral and aortic re-
gurgitation as assessed by cardiovascular magnetic resonance: optimizing 
correlation with Doppler echocardiography. J Cardiovasc Magn Reson. 
2006;8:503–7.
 24. Myerson SG, d’Arcy J, Mohiaddin R, et al. Aortic regurgitation quantifi-
cation using cardiovascular magnetic resonance: association with clinical 
outcome. Circulation. 2012;126:1452–60.
 25. Kammerlander AA, Wiesinger M, Duca F, et al. Diagnostic and prognos-
tic utility of cardiac magnetic resonance imaging in aortic regurgitation. 
JACC Cardiovasc Imaging. 2019;12:1474–83.
 26. Teague SM, Heinsimer JA, Anderson JL, et al. Quantification of aortic re-
gurgitation utilizing continuous wave Doppler ultrasound. J Am Coll Car -
diol. 1986;8:592–9.
 27. Attenhofer Jost CH, Turina J, Mayer K, et al. Echocardiography in the eval-
uation of systolic murmurs of unknown cause. Am J Med. 2000;108:614–
20.
 28. Benjelloun H, Cranney GB, Kirk KA, et al. Interstudy reproducibility of bi-
plane cine nuclear magnetic resonance measurements of left ventricular 
function. Am J Cardiol. 1991;67:1413–20.
 29. Buser PT, Auffermann W, Holt WW, et al. Noninvasive evaluation of global 
left ventricular function with use of cine nuclear magnetic resonance. J 
Am Coll Cardiol. 1989;13:1294–300.
 30. Van Rossum AC, Visser FC, Sprenger M, et al. Evaluation of magnetic 
resonance imaging for determination of left ventricular ejection fraction 
and comparison with angiography. Am J Cardiol. 1988;62:628–33.
4.3.2. Medical Therapy
 1. Evangelista A, Tornos P , Sambola A, et al. Long-term vasodilator therapy in 
patients with severe aortic regurgitation. N Engl J Med. 2005;353:1342–9.
 2. Scognamiglio R, Rahimtoola SH, Fasoli G, et al. Nifedipine in asymptom-
atic patients with severe aortic regurgitation and normal left ventricular 
function. N Engl J Med. 1994;331:689–94.
 3. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on 
the primary prevention of cardiovascular disease: a report of the American 
College of Cardiology/American Heart Association Task Force on Clinical 
Practice Guidelines. Circulation. 2019;140:e596–646.
 4. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused 
update of the 2013 ACCF/AHA guideline for the management of heart 
failure: a report of the American College of Cardiology/American Heart 
Association Task Force on Clinical Practice Guidelines and the Heart Failure 
Society of America. Circulation. 2017;136:e137–61.
 5. Elder DHJ, Wei L, Szwejkowski BR, et al. The impact of renin-angiotensin-
aldosterone system blockade on heart failure outcomes and mortality in 
patients identified to have aortic regurgitation: a large population cohort 
study. J Am Coll Cardiol. 2011;58:2084–91.
 6. Fioretti P , Benussi B, Scardi S, et al. Afterload reduction with nifedipine in 
aortic insufficiency. Am J Cardiol. 1982;49:1728–32. 7. Lin M, Chiang HT, Lin SL, et al. Vasodilator therapy in chronic asymptom-
atic aortic regurgitation: enalapril versus hydralazine therapy. J Am Coll 
Cardiol. 1994;24:1046–53.
 8. Søndergaard L, Aldershvile J, Hildebrandt P , et al. Vasodilatation with 
felodipine in chronic asymptomatic aortic regurgitation. Am Heart J. 
2000;139:667–74.
 9. Sampat U, Varadarajan P , Turk R, et al. Effect of beta-blocker therapy on 
survival in patients with severe aortic regurgitation results from a cohort 
of 756 patients. J Am Coll Cardiol. 2009;54:452–7.
4.3.3. Timing of Intervention
 1. Bonow RO, Borer JS, Rosing DR, et al. Preoperative exercise capacity in 
symptomatic patients with aortic regurgitation as a predictor of post-
operative left ventricular function and long-term prognosis. Circulation. 
1980;62:1280–90.
 2. Klodas E, Enriquez-Sarano M, Tajik AJ, et al. Optimizing timing of surgical 
correction in patients with severe aortic regurgitation: role of symptoms. J 
Am Coll Cardiol. 1997;30:746–52.
 3. Chaliki HP , Mohty D, Avierinos J-F, et al. Outcomes after aortic valve re-
placement in patients with severe aortic regurgitation and markedly re-
duced left ventricular function. Circulation. 2002;106:2687–93.
 4. Tornos P , Sambola A, Permanyer-Miralda G, et al. Long-term outcome of 
surgically treated aortic regurgitation: influence of guideline adherence 
toward early surgery. J Am Coll Cardiol. 2006;47:1012–7.
 5. Bhudia SK, McCarthy PM, Kumpati GS, et al. Improved outcomes after 
aortic valve surgery for chronic aortic regurgitation with severe left ven-
tricular dysfunction. J Am Coll Cardiol. 2007;49:1465–71.
 6. Fiedler AG, Bhambhani V, Laikhter E, et al. Aortic valve replacement as-
sociated with survival in severe regurgitation and low ejection fraction. 
Heart. 2018;104:835–40.
 7. Kaneko T, Ejiofor JI, Neely RC, et al. Aortic regurgitation with markedly 
reduced left ventricular function is not a contraindication for aortic valve 
replacement. Ann Thorac Surg. 2016;102:41–7.
 8. Greves J, Rahimtoola SH, McAnulty JH, et al. Preoperative criteria predic-
tive of late survival following valve replacement for severe aortic regurgita-
tion. Am Heart J. 1981;101:300–8.
 9. Forman R, Firth BG, Barnard MS. Prognostic significance of preoperative 
left ventricular ejection fraction and valve lesion in patients with aortic 
valve replacement. Am J Cardiol. 1980;45:1120–5.
 10. Bonow RO, Picone AL, McIntosh CL, et al. Survival and functional results 
after valve replacement for aortic regurgitation from 1976 to 1983: im-
pact of preoperative left ventricular function. Circulation. 1985;72:1244–
56.
 11. Cormier B, Vahanian A, Luxereau P , et al. Should asymptomatic or mildly 
symptomatic aortic regurgitation be operated on? Z Kardiol. 1986;75(sup-
pl 2):141–5.
 12. Klodas E, Enriquez-Sarano M, Tajik AJ, et al. Aortic regurgitation compli-
cated by extreme left ventricular dilation: long-term outcome after surgi-
cal correction. J Am Coll Cardiol. 1996;27:670–7.
 13. Saisho H, Arinaga K, Kikusaki S, et al. Long term results and predictors of 
left ventricular function recovery after aortic valve replacement for chronic 
aortic regurgitation. Ann Thorac Cardiovasc Surg. 2015;21:388–95.
 14. Mentias A, Feng K, Alashi A, et al. Long-term outcomes in patients with 
aortic regurgitation and preserved left ventricular ejection fraction. J Am 
Coll Cardiol. 2016;68:2144–53.
 15. Yang L-T, Michelena HI, Scott CG, et al. Outcomes in chronic hemodynam-
ically significant aortic regurgitation and limitations of current guidelines. J 
Am Coll Cardiol. 2019;73:1741–52.
 16. de Meester C, Gerber BL, Vancraeynest D, et al. Do guideline-based indi-
cations result in an outcome penalty for patients with severe aortic regur -
gitation? JACC Cardiovasc Imaging. 2019;12:2126–38.
 17. Bonow RO, Lakatos E, Maron BJ, et al. Serial long-term assessment of the 
natural history of asymptomatic patients with chronic aortic regurgitation 
and normal left ventricular systolic function. Circulation. 1991;84:1625–35.
 18. Detaint D, Messika-Zeitoun D, Maalouf J, et al. Quantitative echocar -
diographic determinants of clinical outcome in asymptomatic patients 
with aortic regurgitation: a prospective study. JACC Cardiovasc Imaging. 
2008;1:1–11.
 19. Pizarro R, Bazzino OO, Oberti PF, et al. Prospective validation of the prognos-
tic usefulness of B-type natriuretic peptide in asymptomatic patients with 
chronic severe aortic regurgitation. J Am Coll Cardiol. 2011;58:1705–14.
 20. Tornos MP , Olona M, Permanyer-Miralda G, et al. Clinical outcome of se-
vere asymptomatic chronic aortic regurgitation: a long-term prospective 
follow-up study. Am Heart J. 1995;130:333–9.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e196
CLINICAL STATEMENTS  
AND GUIDELINES 21. Tarasoutchi F, Grinberg M, Spina GS, et al. Ten-year clinical laboratory 
follow-up after application of a symptom-based therapeutic strategy to 
patients with severe chronic aortic regurgitation of predominant rheu-
matic etiology. J Am Coll Cardiol. 2003;41:1316–24.
 22. Kumpuris AG, Quinones MA, Waggoner AD, et al. Importance of preoperative 
hypertrophy, wall stress and end-systolic dimension as echocardiographic 
predictors of normalization of left ventricular dilatation after valve replace-
ment in chronic aortic insufficiency. Am J Cardiol. 1982;49:1091–100.
 23. Fioretti P , Roelandt J, Bos RJ, et al. Echocardiography in chronic aortic in-
sufficiency. Is valve replacement too late when left ventricular end-systolic 
dimension reaches 55 mm? Circulation. 1983;67:216–21.
 24. Stone PH, Clark RD, Goldschlager N, et al. Determinants of prognosis of 
patients with aortic regurgitation who undergo aortic valve replacement. 
J Am Coll Cardiol. 1984;3:1118–26.
 25. Zhang Z, Yang J, Yu Y, et al. Preoperative ejection fraction determines 
early recovery of left ventricular end-diastolic dimension after aortic 
valve replacement for chronic severe aortic regurgitation. J Surg Res. 
2015;196:49–55.
 26. Murashita T, Schaff HV, Suri RM, et al. Impact of left ventricular systolic 
function on outcome of correction of chronic severe aortic valve regurgi-
tation: implications for timing of surgical intervention. Ann Thorac Surg. 
2017;103:1222–8.
 27. Wang Y, Jiang W, Liu J, et al. Early surgery versus conventional treatment 
for asymptomatic severe aortic regurgitation with normal ejection fraction 
and left ventricular dilatation. Eur J Cardiothorac Surg. 2017;52:118–24.
 28. Scognamiglio R, Rahimtoola SH, Fasoli G, et al. Nifedipine in asymptom-
atic patients with severe aortic regurgitation and normal left ventricular 
function. N Engl J Med. 1994;331:689–94.
 29. Sawaya FJ, Deutsch MA, Seiffert M, et al. Safety and efficacy of transcath-
eter aortic valve replacement in the treatment of pure aortic regurgitation 
in native valves and failing surgical bioprostheses: results from an Interna-
tional Registry Study. JACC Cardiovasc Interv. 2017;10:1048–56.
 30. Roy DA, Schaefer U, Guetta V, et al. Transcatheter aortic valve implanta-
tion for pure severe native aortic valve regurgitation. J Am Coll Cardiol. 
2013;61:1577–84.
 31. Seiffert M, Bader R, Kappert U, et al. Initial German experience with 
transapical implantation of a second-generation transcatheter heart 
valve for the treatment of aortic regurgitation. JACC Cardiovasc Interv. 
2014;7:1168–74.
 32. Jiang J, Liu X, He Y, et al. Transcatheter aortic valve replacement for 
pure native aortic valve regurgitation: a systematic review. Cardiology. 
2018;141:132–40.
 33. Aicher D, Kunihara T, Abou Issa O, et al. Valve configuration determines 
long-term results after repair of the bicuspid aortic valve. Circulation. 
2011;123:178–85.
 34. David TE, Armstrong S, Ivanov J, et al. Aortic valve sparing operations: an 
update. Ann Thorac Surg. 1999;67:1840–2.
 35. Kallenbach K, Hagl C, Walles T, et al. Results of valve-sparing aor -
tic root reconstruction in 158 consecutive patients. Ann Thorac Surg. 
2002;74:2026–32.
 36. Pettersson GB, Crucean AC, Savage R, et al. Toward predictable repair of 
regurgitant aortic valves: a systematic morphology-directed approach to 
bicommissural repair. J Am Coll Cardiol. 2008;52:40–9.
 37. de Kerchove L, Boodhwani M, Glineur D, et al. Valve sparing-root replace-
ment with the reimplantation technique to increase the durability of bi-
cuspid aortic valve repair. J Thorac Cardiovasc Surg. 2011;142:1430–8.
 38. Kari FA, Liang DH, Kvitting J-PE, et al. Tirone David valve-sparing aortic 
root replacement and cusp repair for bicuspid aortic valve disease. J Tho-
rac Cardiovasc Surg. 2013;145:S35–40.e1–2.
 39. Ouzounian M, Rao V, Manlhiot C, et al. Valve-sparing root replacement 
compared with composite valve graft procedures in patients with aortic 
root dilation. J Am Coll Cardiol. 2016;68:1838–47.
 40. Gleason TG. New graft formulation and modification of the David reim-
plantation technique. J Thorac Cardiovasc Surg. 2005;130:601–3.
 41. le Polain de Waroux JB, Pouleur AC, Robert A, et al. Mechanisms of recur -
rent aortic regurgitation after aortic valve repair: predictive value of intra-
operative transesophageal echocardiography. JACC Cardiovasc Imaging. 
2009;2:931–9.
 42. Boodhwani M, de Kerchove L, Glineur D, et al. Repair-oriented classifi-
cation of aortic insufficiency: impact on surgical techniques and clinical 
outcomes. J Thorac Cardiovasc Surg. 2009;137:286–94.
 43. Borow KM, Green LH, Mann T, et al. End-systolic volume as a predictor of 
postoperative left ventricular performance in volume overload from valvu-
lar regurgitation. Am J Med. 1980;68:655–63. 44. Pizarro R, Bazzino OO, Oberti PF, et al. Prospective validation of the prog-
nostic usefulness of B-type natriuretic peptide in asymptomatic patients 
with chronic severe aortic regurgitation. J Am Coll Cardiol. 2011;58:1705–
14.
 45. Myerson SG, d’Arcy J, Mohiaddin R, et al. Aortic regurgitation quantifi-
cation using cardiovascular magnetic resonance: association with clinical 
outcome. Circulation. 2012;126:1452–60.
 46. Kammerlander AA, Wiesinger M, Duca F, et al. Diagnostic and prognos-
tic utility of cardiac magnetic resonance imaging in aortic regurgitation. 
JACC Cardiovasc Imaging. 2019;12:1474–83.
 47. Lang RM, Badano LP , Mor-Avi V, et al. Recommendations for cardiac 
chamber quantification by echocardiography in adults: an update from 
the American Society of Echocardiography and the European Association 
of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39.e14.
 48. Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER, et al. Normal 
values for cardiovascular magnetic resonance in adults and children. J 
Cardiovasc Magn Reson. 2015;17:29.
 49. Lee JKT, Franzone A, Lanz J, et al. Early detection of subclinical myocardial 
damage in chronic aortic regurgitation and strategies for timely treatment 
of asymptomatic patients. Circulation. 2018;137:184–96.
 50. Alashi A, Mentias A, Abdallah A, et al. Incremental prognostic utility of 
left ventricular global longitudinal strain in asymptomatic patients with 
significant chronic aortic regurgitation and preserved left ventricular ejec-
tion fraction. JACC Cardiovasc Imaging. 2018;11:673–82.
 51. Olsen NT, Sogaard P , Larsson HB, et al. Speckle-tracking echocardiography 
for predicting outcome in chronic aortic regurgitation during conservative 
management and after surgery. JACC Cardiovasc Imaging. 2011;4:223–
30.
 52. Dujardin KS, Enriquez-Sarano M, Schaff HV, et al. Mortality and morbidity 
of aortic regurgitation in clinical practice. A long-term follow-up study. 
Circulation. 1999;99:1851–7.
 53. Bonow RO, Dodd JT, Maron BJ, et al. Long-term serial changes in left ven-
tricular function and reversal of ventricular dilatation after valve replace-
ment for chronic aortic regurgitation. Circulation. 1988;78:1108–20.
 54. Carabello BA, Williams H, Gash AK, et al. Hemodynamic predictors 
of outcome in patients undergoing valve replacement. Circulation. 
1986;74:1309–16.
 55. Cunha CL, Giuliani ER, Fuster V, et al. Preoperative M-mode echocardiog-
raphy as a predictor of surgical results in chronic aortic insufficiency. J 
Thorac Cardiovasc Surg. 1980;79:256–65.
 56. Daniel WG, Hood WP Jr, Siart A, et al. Chronic aortic regurgitation: reas-
sessment of the prognostic value of preoperative left ventricular end-sys-
tolic dimension and fractional shortening. Circulation. 1985;71:669–80.
 57. Henry WL, Bonow RO, Borer JS, et al. Observations on the optimum time 
for operative intervention for aortic regurgitation. I. Evaluation of the 
results of aortic valve replacement in symptomatic patients. Circulation. 
1980;61:471–83.
 58. Michel PL, Iung B, Abou Jaoude S, et al. The effect of left ventricular 
systolic function on long term survival in mitral and aortic regurgitation. J 
Heart Valve Dis. 1995;4(suppl 2):S160–8.
 59. Sheiban I, Trevi GP , Casarotto D, et al. Aortic valve replacement in patients 
with aortic incompetence. Preoperative parameters influencing long-term 
results. Z Kardiol. 1986;75(suppl 2):146–54.
 60. Taniguchi K, Nakano S, Hirose H, et al. Preoperative left ventricular func-
tion: minimal requirement for successful late results of valve replacement 
for aortic regurgitation. J Am Coll Cardiol. 1987;10:510–8.
 61. Turina J, Milincic J, Seifert B, et al. Valve replacement in chronic aortic 
regurgitation. True predictors of survival after extended follow-up. Circu-
lation. 1998;98:II100–6.
 62. Gaasch WH, Carroll JD, Levine HJ, et al. Chronic aortic regurgitation: 
prognostic value of left ventricular end-systolic dimension and end-dia-
stolic radius/thickness ratio. J Am Coll Cardiol. 1983;1:775–82.
5. BICUSPID AORTIC VALVE
5.1. BAV and Associated Aortopathy
5.1.1. Diagnosis and Follow-Up of BAV
5.1.1.1. Diagnostic Testing: Initial Diagnosis
 1. Masri A, Svensson LG, Griffin BP , et al. Contemporary natural his-
tory of bicuspid aortic valve disease: a systematic review. Heart. 
2017;103:1323–30.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e197
CLINICAL STATEMENTS  
AND GUIDELINES 2. Keane MG, Wiegers SE, Plappert T, et al. Bicuspid aortic valves are associ-
ated with aortic dilatation out of proportion to coexistent valvular lesions. 
Circulation. 2000;102:III35–9.
 3. Schaefer BM, Lewin MB, Stout KK, et al. The bicuspid aortic valve: an 
integrated phenotypic classification of leaflet morphology and aortic root 
shape. Heart. 2008;94:1634–8.
 4. Goldstein SA, Evangelista A, Abbara S, et al. Multimodality imaging of diseases 
of the thoracic aorta in adults: from the American Society of Echocardiogra-
phy and the European Association of Cardiovascular Imaging: endorsed by 
the Society of Cardiovascular Computed Tomography and Society for Car -
diovascular Magnetic Resonance. J Am Soc Echocardiogr. 2015;28:119–82.
 5. Kang J-W, Song HG, Yang DH, et al. Association between bicuspid aortic 
valve phenotype and patterns of valvular dysfunction and bicuspid aor -
topathy: comprehensive evaluation using MDCT and echocardiography. 
JACC Cardiovasc Imaging. 2013;6:150–61.
 6. Kerstjens-Frederikse WS, Du Marchie Sarvaas GJ, Ruiter JS, et al. Left ven-
tricular outflow tract obstruction: should cardiac screening be offered to 
first-degree relatives? Heart. 2011;97:1228–32.
 7. Pachulski RT, Weinberg AL, Chan KL. Aortic aneurysm in patients with 
functionally normal or minimally stenotic bicuspid aortic valve. Am J Car -
diol. 1991;67:781–2.
 8. Hahn RT, Roman MJ, Mogtader AH, et al. Association of aortic dilation 
with regurgitant, stenotic and functionally normal bicuspid aortic valves. J 
Am Coll Cardiol. 1992;19:283–8.
 9. Nistri S, Sorbo MD, Marin M, et al. Aortic root dilatation in young men 
with normally functioning bicuspid aortic valves. Heart. 1999;82:19–22.
 10. Novaro GM, Tiong IY, Pearce GL, et al. Features and predictors of ascend-
ing aortic dilatation in association with a congenital bicuspid aortic valve. 
Am J Cardiol. 2003;92:99–101.
 11. Michelena HI, Prakash SK, Della Corte A, et al. Bicuspid aortic valve: identifying 
knowledge gaps and rising to the challenge from the International Bicuspid 
Aortic Valve Consortium (BAVCon). Circulation. 2014;129:2691–704.
5.1.1.2. Diagnostic Testing: Routine Follow-Up
 1. Masri A, Svensson LG, Griffin BP , et al. Contemporary natural history of bi-
cuspid aortic valve disease: a systematic review. Heart. 2017;103:1323–30.
 2. Ferencik M, Pape LA. Changes in size of ascending aorta and aortic valve 
function with time in patients with congenitally bicuspid aortic valves. Am 
J Cardiol. 2003;92:43–6.
 3. Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complica-
tions in patients with bicuspid aortic valves. JAMA. 2011;306:1104–12.
 4. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates 
for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac 
Surg. 2002;73:17–27.
 5. Masri A, Kalahasti V, Alkharabsheh S, et al. Characteristics and long-term 
outcomes of contemporary patients with bicuspid aortic valves. J Thorac 
Cardiovasc Surg. 2016;151:1650–9.e1.
 6. McKellar SH, Michelena HI, Li Z, et al. Long-term risk of aortic events fol-
lowing aortic valve replacement in patients with bicuspid aortic valves. Am 
J Cardiol. 2010;106:1626–33.
 7. Girdauskas E, Disha K, Borger MA, et al. Long-term prognosis of ascend-
ing aortic aneurysm after aortic valve replacement for bicuspid versus tri-
cuspid aortic valve stenosis. J Thorac Cardiovasc Surg. 2014;147:276–82.
 8. Novaro GM, Griffin BP . Congenital bicuspid aortic valve and rate of as-
cending aortic dilatation. Am J Cardiol. 2004;93:525–6.
 9. Davies RR, Kaple RK, Mandapati D, et al. Natural history of ascending 
aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. Ann 
Thorac Surg. 2007;83:1338–44.
 10. Girdauskas E, Rouman M, Disha K, et al. The fate of mild-to-moderate 
proximal aortic dilatation after isolated aortic valve replacement for bicus-
pid aortic valve stenosis: a magnetic resonance imaging follow-up study†. 
Eur J Cardiothorac Surg. 2016;49:e80–6.
 11. Borger MA, Fedak PWM, Stephens EH, et al. The American Associa-
tion for Thoracic Surgery consensus guidelines on bicuspid aortic valve-
related aortopathy: Full online-only version. J Thorac Cardiovasc Surg. 
2018;156:e41–74.
5.1.2. Interventions for Patients With BAV
5.1.2.1. Intervention: Repair or Replacement of the Aorta
 1. Masri A, Svensson LG, Griffin BP , et al. Contemporary natural history of bi-
cuspid aortic valve disease: a systematic review. Heart. 2017;103:1323–30.
 2. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/
SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of 
patients with thoracic aortic disease. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice 
Guidelines, American Association for Thoracic Surgery, American College 
of Radiology, American Stroke Association, Society of Cardiovascular An-
esthesiologists, Society for Cardiovascular Angiography and Interventions, 
Society of Interventional Radiology, Society of Thoracic Surgeons,and Soci-
ety for Vascular Medicine. J Am Coll Cardiol. 2010;55:e27–129.
 3. Elefteriades JA. Natural history of thoracic aortic aneurysms: indica-
tions for surgery, and surgical versus nonsurgical risks. Ann Thorac Surg. 
2002;74:S1877–80.
 4. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates 
for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac 
Surg. 2002;73:17–27.
 5. Russo CF, Mazzetti S, Garatti A, et al. Aortic complications after bi-
cuspid aortic valve replacement: long-term results. Ann Thorac Surg. 
2002;74:S1773–6.
 6. Borger MA, Preston M, Ivanov J, et al. Should the ascending aorta be 
replaced more frequently in patients with bicuspid aortic valve disease? J 
Thorac Cardiovasc Surg. 2004;128:677–83.
 7. Svensson LG, Kim K-H, Blackstone EH, et al. Bicuspid aortic valve sur -
gery with proactive ascending aorta repair. J Thorac Cardiovasc Surg. 
2011;142:622–9, 9.9.e1–3.
 8. Beckerman Z, Kayatta MO, McPherson L, et al. Bicuspid aortic valve repair 
in the setting of severe aortic insufficiency. J Vis Surg. 2018;4:101.
 9. David TE, Feindel CM, David CM, et al. A quarter of a century of ex-
perience with aortic valve-sparing operations. J Thorac Cardiovasc Surg. 
2014;148:872–9.
 10. Davies RR, Kaple RK, Mandapati D, et al. Natural history of ascending 
aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. Ann 
Thorac Surg. 2007;83:1338–44.
 11. Ergin MA, Spielvogel D, Apaydin A, et al. Surgical treatment of the dilated 
ascending aorta: when and how? Ann Thorac Surg. 1999;67:1834–9.
 12. Svensson LG, Kim K-H, Lytle BW, et al. Relationship of aortic cross-sec-
tional area to height ratio and the risk of aortic dissection in patients with 
bicuspid aortic valves. J Thorac Cardiovasc Surg. 2003;126:892–3.
 13. Yasuda H, Nakatani S, Stugaard M, et al. Failure to prevent progressive 
dilation of ascending aorta by aortic valve replacement in patients with 
bicuspid aortic valve: comparison with tricuspid aortic valve. Circulation. 
2003;108(suppl 1):II291–4.
 14. Park CB, Greason KL, Suri RM, et al. Fate of nonreplaced sinuses of Valsalva in 
bicuspid aortic valve disease. J Thorac Cardiovasc Surg. 2011;142:278–84.
 15. Svensson LG, Adams DH, Bonow RO, et al. Aortic valve and ascending 
aorta guidelines for management and quality measures. Ann Thorac Surg. 
2013;95:S1–66.
5.1.2.2. Intervention: Repair or Replacement of the 
Aortic Valve
 1. David TE, Feindel CM, David CM, et al. A quarter of a century of ex-
perience with aortic valve-sparing operations. J Thorac Cardiovasc Surg. 
2014;148:872–9.
 2. Masri A, Kalahasti V, Alkharabsheh S, et al. Characteristics and long-term 
outcomes of contemporary patients with bicuspid aortic valves. J Thorac 
Cardiovasc Surg. 2016;151:1650–9.e1.
 3. Schneider U, Feldner SK, Hofmann C, et al. Two decades of experience 
with root remodeling and valve repair for bicuspid aortic valves. J Thorac 
Cardiovasc Surg. 2017;153:S65–71.
 4. Takagi H, Hari Y, Kawai N, et al. Meta-analysis of transcatheter aortic 
valve implantation for bicuspid versus tricuspid aortic valves. J Cardiol. 
2019;74:40–8.
 5. Kanjanahattakij N, Horn B, Vutthikraivit W, et al. Comparing outcomes 
after transcatheter aortic valve replacement in patients with stenotic bi-
cuspid and tricuspid aortic valve: a systematic review and meta-analysis. 
Clin Cardiol. 2018;41:896–902.
 6. Makkar RR, Yoon S-H, Leon MB, et al. Association between transcatheter 
aortic valve replacement for bicuspid vs tricuspid aortic stenosis and mor -
tality or stroke. JAMA. 2019;321:2193–202.
 7. Beckerman Z, Kayatta MO, McPherson L, et al. Bicuspid aortic valve repair 
in the setting of severe aortic insufficiency. J Vis Surg. 2018;4:101.
6. MITRAL STENOSIS
 1. Eleid MF, Nishimura RA, Lennon RJ, et al. Left ventricular diastolic dys-
function in patients with mitral stenosis undergoing percutaneous mitral 
balloon valvotomy. Mayo Clin Proc. 2013;88:337–44.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e198
CLINICAL STATEMENTS  
AND GUIDELINES 2. Nunes MCP , Tan TC, Elmariah S, et al. Net atrioventricular compliance is 
an independent predictor of cardiovascular death in mitral stenosis. Heart. 
2017;103:1891–8.
 3. Abramowitz Y, Jilaihawi H, Chakravarty T, et al. Mitral annulus calcifica-
tion. J Am Coll Cardiol. 2015;66:1934–41.
 4. Sud K, Agarwal S, Parashar A, et al. Degenerative mitral stenosis: unmet 
need for percutaneous interventions. Circulation. 2016;133:1594–604.
 5. Bertrand PB, Mihos CG, Yucel E. Mitral annular calcification and calcific 
mitral stenosis: therapeutic challenges and considerations. Curr Treat Op-
tions Cardiovasc Med. 2019;21:19.
6.1. Stages of MS
 1. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment 
of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J 
Echocardiogr. 2009;10:1–25.
6.2. Rheumatic MS
6.2.1. Diagnosis and Follow-Up of Rheumatic MS
6.2.1.1. Diagnostic Testing: Initial Diagnosis
 1. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment 
of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J 
Echocardiogr. 2009;10:1–25.
 2. Nunes MCP , Tan TC, Elmariah S, et al. The echo score revisited: impact of 
incorporating commissural morphology and leaflet displacement to the 
prediction of outcome for patients undergoing percutaneous mitral valvu-
loplasty. Circulation. 2014;129:886–95.
 3. Cannan CR, Nishimura RA, Reeder GS, et al. Echocardiographic assess-
ment of commissural calcium: a simple predictor of outcome after percu-
taneous mitral balloon valvotomy. J Am Coll Cardiol. 1997;29:175–80.
 4. Ellis K, Ziada KM, Vivekananthan D, et al. Transthoracic echocardiographic 
predictors of left atrial appendage thrombus. Am J Cardiol. 2006;97:421–5.
 5. Kronzon I, Tunick PA, Glassman E, et al. Transesophageal echocardiogra-
phy to detect atrial clots in candidates for percutaneous transseptal mitral 
balloon valvuloplasty. J Am Coll Cardiol. 1990;16:1320–2.
 6. Tessier P , Mercier LA, Burelle D, et al. Results of percutaneous mitral 
commissurotomy in patients with a left atrial appendage thrombus de-
tected by transesophageal echocardiography. J Am Soc Echocardiogr. 
1994;7:394–9.
 7. Gianstefani S, Monaghan MJ. Accurate assessment of the true mitral valve 
area in rheumatic mitral stenosis. Heart. 2013;99:219–21.
 8. Min S-Y, Song J-M, Kim Y-J, et al. Discrepancy between mitral valve areas 
measured by two-dimensional planimetry and three-dimensional tran-
soesophageal echocardiography in patients with mitral stenosis. Heart. 
2013;99:253–8.
 9. Nishimura RA, Rihal CS, Tajik AJ, et al. Accurate measurement of the 
transmitral gradient in patients with mitral stenosis: a simultaneous 
catheterization and Doppler echocardiographic study. J Am Coll Cardiol. 
1994;24:152–8.
 10. Abascal VM, Wilkins GT, O’Shea JP , et al. Prediction of successful outcome 
in 130 patients undergoing percutaneous balloon mitral valvotomy. Circu-
lation. 1990;82:448–56.
 11. Wilkins GT, Weyman AE, Abascal VM, et al. Percutaneous balloon dilata-
tion of the mitral valve: an analysis of echocardiographic variables related 
to outcome and the mechanism of dilatation. Br Heart J. 1988;60:299–
308.
 12. Sutaria N, Northridge DB, Shaw TR. Significance of commissural calcifica-
tion on outcome of mitral balloon valvotomy. Heart. 2000;84:398–402.
 13. Gajjala OR, Durgaprasad R, Velam V, et al. New integrated approach to 
percutaneous mitral valvuloplasty combining Wilkins score with com-
missural calcium score and commissural area ratio. Echocardiography. 
2017;34:1284–91.
 14. Thomas JD, Wilkins GT, Choong CY, et al. Inaccuracy of mitral pressure 
half-time immediately after percutaneous mitral valvotomy. Dependence 
on transmitral gradient and left atrial and ventricular compliance. Circula-
tion. 1988;78:980–93.
6.2.1.3. Diagnostic Testing: Routine Follow-Up
 1. Horstkotte D, Niehues R, Strauer BE. Pathomorphological aspects, aeti-
ology and natural history of acquired mitral valve stenosis. Eur Heart J. 
1991;12(suppl B):55–60. 2. Rinkevich D, Lessick J, Mutlak D, et al. Natural history of moderate mitral 
valve stenosis. Isr Med Assoc J. 2003;5:15–8.
 3. Sagie A, Freitas N, Padial LR, et al. Doppler echocardiographic assessment 
of long-term progression of mitral stenosis in 103 patients: valve area and 
right heart disease. J Am Coll Cardiol. 1996;28:472–9.
6.2.1.4. Diagnostic Testing: Cardiac Catheterization
 1. Nishimura RA, Rihal CS, Tajik AJ, et al. Accurate measurement of the 
transmitral gradient in patients with mitral stenosis: a simultaneous 
catheterization and Doppler echocardiographic study. J Am Coll Cardiol. 
1994;24:152–8.
 2. Gorlin R, Gorlin SG. Hydraulic formula for calculation of the area of the 
stenotic mitral valve, other cardiac valves, and central circulatory shunts. I. 
Am Heart J. 1951;41:1–29.
 3. Gorlin WB, Gorlin R. A generalized formulation of the Gorlin formula for 
calculating the area of the stenotic mitral valve and other stenotic cardiac 
valves. J Am Coll Cardiol. 1990;15:246–7.
6.2.1.5. Diagnostic Testing: Exercise Testing
 1. Cheitlin MD. Stress echocardiography in mitral stenosis: when is it useful? 
J Am Coll Cardiol. 2004;43:402–4.
 2. Cheriex EC, Pieters FA, Janssen JH, et al. Value of exercise Doppler-echocar -
diography in patients with mitral stenosis. Int J Cardiol. 1994;45:219–26.
 3. Grimaldi A, Olivotto I, Figini F, et al. Dynamic assessment of “valvular 
reserve capacity” in patients with rheumatic mitral stenosis. Eur Heart J 
Cardiovasc Imaging. 2012;13:476–82.
 4. Suh WM, Kern MJ. Addressing the hemodynamic dilemma of combined 
mitral and aortic stenosis. Catheter Cardiovasc Interv. 2008;71:944–9.
 5. Reis G, Motta MS, Barbosa MM, et al. Dobutamine stress echocardiog-
raphy for noninvasive assessment and risk stratification of patients with 
rheumatic mitral stenosis. J Am Coll Cardiol. 2004;43:393–401.
 6. Roshdy HS, Meshrif AM, El-Dosouky II. Value of the mitral valve resistance 
in evaluation of symptomatic patients with mild and moderate mitral ste-
nosis—a dobutamine stress echocardiographic study. Echocardiography. 
2014;31:347–52.
6.2.2. Medical Therapy
 1. Kim JY, Kim S-H, Myong J-P , et al. Outcomes of direct oral anticoagulants 
in patients with mitral stenosis. J Am Coll Cardiol. 2019;73:1123–31.
 2. Giugliano RP , O’Gara PT. DOACs in Patients with mitral stenosis and 
atrial fibrillation: time for a randomized clinical trial. J Am Coll Cardiol. 
2019;73:1132–4.
 3. Olesen KH. The natural history of 271 patients with mitral stenosis under 
medical treatment. Br Heart J. 1962;24:349–57.
 4. Rowe JC, Bland EF, Sprague HB, et al. The course of mitral stenosis 
without surgery: ten- and twenty-year perspectives. Ann Intern Med. 
1960;52:741–9.
 5. Szekely P . Systemic embolism and anticoagulant prophylaxis in rheumatic 
heart disease. Br Med J. 1964;1:1209–12.
 6. Wilson JK, Greenwood WF. The natural history of mitral stenosis. Can 
Med Assoc J. 1954;71:323–31.
 7. Omran H, Rang B, Schmidt H, et al. Incidence of left atrial thrombi in 
patients in sinus rhythm and with a recent neurologic deficit. Am Heart J. 
2000;140:658–62.
 8. Yusuf J, Goyal M, Mukhopadhyay S, et al. Effect of heart rate control 
on coagulation status in patients of rheumatic mitral stenosis with atrial 
fibrillation–a pilot study. Indian Heart J. 2015;67(suppl 2):S40–5.
 9. Rigolin VH, Higgenbotham MB, Robiolio PA, et al. Effect of inadequate 
cardiac output reserve on exercise tolerance in patients with moderate 
mitral stenosis. Am J Cardiol. 1997;80:236–40.
 10. Laufer-Perl M, Gura Y, Shimiaie J, et al. Mechanisms of effort intoler -
ance in patients with rheumatic mitral stenosis: combined echocardiog-
raphy and cardiopulmonary stress protocol. JACC Cardiovasc Imaging. 
2017;10:622–33.
 11. Kitzman DW, Upadhya B, Zhao D. New concepts in an old disease: exer -
cise intolerance in moderate mitral stenosis. JACC Cardiovasc Imaging. 
2017;10:634–6.
 12. Saggu DK, Narain VS, Dwivedi SK, et al. Effect of ivabradine on heart rate 
and duration of exercise in patients with mild-to-moderate mitral steno-
sis: a randomized comparison with metoprolol. J Cardiovasc Pharmacol. 
2015;65:552–4.
 13. Parakh N, Chaturvedi V, Kurian S, et al. Effect of ivabradine vs atenolol on 
heart rate and effort tolerance in patients with mild to moderate mitral 
stenosis and normal sinus rhythm. J Card Fail. 2012;18:282–8.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e199
CLINICAL STATEMENTS  
AND GUIDELINES 14. Agrawal V, Kumar N, Lohiya B, et al. Metoprolol vs ivabradine in patients 
with mitral stenosis in sinus rhythm. Int J Cardiol. 2016;221:562–6.
 15. Rajesh GN, Sajeer K, Sajeev CG, et al. A comparative study of ivabradine 
and atenolol in patients with moderate mitral stenosis in sinus rhythm. 
Indian Heart J. 2016;68:311–5.
 16. Iung B, Leenhardt A, Extramiana F. Management of atrial fibrillation in 
patients with rheumatic mitral stenosis. Heart. 2018;104:1062–8.
 17. Krishnamoorthy KM. Incidence and predictors of left atrial thrombus in 
patients with rheumatic mitral stenosis and sinus rhythm: a transesopha-
geal echocardiographic study. Echocardiography. 2012;29:876–7.
 18. Manjunath CN, Srinivasa KH, Panneerselvam A, et al. Incidence and pre-
dictors of left atrial thrombus in patients with rheumatic mitral stenosis 
and sinus rhythm: a transesophageal echocardiographic study. Echocar -
diography. 2011;28:457–60.
 19. Keenan NG, Cueff C, Cimadevilla C, et al. Usefulness of left atrial volume 
versus diameter to assess thromboembolic risk in mitral stenosis. Am J 
Cardiol. 2010;106:1152–6.
6.2.3. Intervention
 1. Nunes MCP , Tan TC, Elmariah S, et al. The echo score revisited: impact of 
incorporating commissural morphology and leaflet displacement to the 
prediction of outcome for patients undergoing percutaneous mitral valvu-
loplasty. Circulation. 2014;129:886–95.
 2. Bouleti C, Iung B, Laouénan C, et al. Late results of percutaneous mitral 
commissurotomy up to 20 years: development and validation of a risk 
score predicting late functional results from a series of 912 patients. Cir -
culation. 2012;125:2119–27.
 3. Meneguz-Moreno RA, Costa JR Jr, Gomes NL, et al. Very long term follow-
up after percutaneous balloon mitral valvuloplasty. JACC Cardiovasc In-
terv. 2018;11:1945–52.
 4. Rifaie O, Abdel-Dayem MK, Ramzy A, et al. Percutaneous mitral valvoto-
my versus closed surgical commissurotomy. Up to 15 years of follow-up of 
a prospective randomized study. J Cardiol. 2009;53:28–34.
 5. Cardoso LF, Grinberg M, Pomerantzeff PMA, et al. Comparison of open 
commissurotomy and balloon valvuloplasty in mitral stenosis. A five-year 
follow-up. Arq Bras Cardiol. 2004;83:248–52; 3–7.
 6. Cotrufo M, Renzulli A, Ismeno G, et al. Percutaneous mitral commissur -
otomy versus open mitral commissurotomy: a comparative study. Eur J 
Cardiothorac Surg. 1999;15:646–51.
 7. Song J-K, Kim M-J, Yun S-C, et al. Long-term outcomes of percutaneous 
mitral balloon valvuloplasty versus open cardiac surgery. J Thorac Cardio-
vasc Surg. 2010;139:103–10.
 8. Arora R, Nair M, Kalra GS, et al. Immediate and long-term results of bal-
loon and surgical closed mitral valvotomy: a randomized comparative 
study. Am Heart J. 1993;125:1091–4.
 9. Ben FM, Ayari M, Maatouk F, et al. Percutaneous balloon versus surgical 
closed and open mitral commissurotomy: seven-year follow-up results of 
a randomized trial. Circulation. 1998;97:245–50.
 10. Patel JJ, Shama D, Mitha AS, et al. Balloon valvuloplasty versus closed 
commissurotomy for pliable mitral stenosis: a prospective hemodynamic 
study. J Am Coll Cardiol. 1991;18:1318–22.
 11. Reyes VP , Raju BS, Wynne J, et al. Percutaneous balloon valvuloplasty com-
pared with open surgical commissurotomy for mitral stenosis. N Engl J 
Med. 1994;331:961–7.
 12. Turi ZG, Reyes VP , Raju BS, et al. Percutaneous balloon versus surgical 
closed commissurotomy for mitral stenosis. A prospective, randomized 
trial. Circulation. 1991;83:1179–85.
 13. Reichart DT, Sodian R, Zenker R, et al. Long-term (≤ 50 years) results of 
patients after mitral valve commissurotomy—a single-center experience. J 
Thorac Cardiovasc Surg. 2012;143:S96–8.
 14. Yang B, DeBenedictus C, Watt T, et al. The impact of concomitant pulmo-
nary hypertension on early and late outcomes following surgery for mitral 
stenosis. J Thorac Cardiovasc Surg. 2016;152:394–400.e1.
 15. Demirkan B, Guray Y, Guray U, et al. The acute effect of percutaneous 
mitral balloon valvuloplasty on atrial electromechanical delay and P-wave 
dispersion in patients with mitral stenosis. Herz. 2013;38:210–5.
 16. Aviles RJ, Nishimura RA, Pellikka PA, et al. Utility of stress Doppler echocar -
diography in patients undergoing percutaneous mitral balloon valvotomy. 
J Am Soc Echocardiogr. 2001;14:676–81.
 17. Bouleti C, Iung B, Himbert D, et al. Relationship between valve calcifica-
tion and long-term results of percutaneous mitral commissurotomy for 
rheumatic mitral stenosis. Circ Cardiovasc Interv. 2014;7:381–9.
 18. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment 
of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J 
Echocardiogr. 2009;10:1–25. 19. Cannan CR, Nishimura RA, Reeder GS, et al. Echocardiographic assess-
ment of commissural calcium: a simple predictor of outcome after percu-
taneous mitral balloon valvotomy. J Am Coll Cardiol. 1997;29:175–80.
 20. Apostolakis EE, Baikoussis NG. Methods of estimation of mitral valve re-
gurgitation for the cardiac surgeon. J Cardiothorac Surg. 2009;4:34.
 21. Badheka AO, Shah N, Ghatak A, et al. Balloon mitral valvuloplasty in the 
United States: a 13-year perspective. Am J Med. 2014;127:1126 e1–12.
 22. Abascal VM, Wilkins GT, O’Shea JP , et al. Prediction of successful outcome 
in 130 patients undergoing percutaneous balloon mitral valvotomy. Circu-
lation. 1990;82:448–56.
 23. Wilkins GT, Weyman AE, Abascal VM, et al. Percutaneous balloon dilata-
tion of the mitral valve: an analysis of echocardiographic variables related 
to outcome and the mechanism of dilatation. Br Heart J. 1988;60:299–
308.
 24. Sutaria N, Northridge DB, Shaw TR. Significance of commissural calcifica-
tion on outcome of mitral balloon valvotomy. Heart. 2000;84:398–402.
 25. Gajjala OR, Durgaprasad R, Velam V, et al. New integrated approach to 
percutaneous mitral valvuloplasty combining Wilkins score with com-
missural calcium score and commissural area ratio. Echocardiography. 
2017;34:1284–91.
 26. Cho I-J, Hong G-R, Lee SH, et al. Differences in characteristics, left atrial 
reverse remodeling, and functional outcomes after mitral valve replace-
ment in patients with low-gradient very severe mitral stenosis. J Am Soc 
Echocardiogr. 2016;29:759–67.
 27. El Sabbagh A, Reddy YNV, Barros-Gomes S, et al. Low-gradient severe mi-
tral stenosis: hemodynamic profiles, clinical characteristics, and outcomes. 
J Am Heart Assoc. 2019;8:e010736.
 28. Nunes MCP , Tan TC, Elmariah S, et al. Net atrioventricular compliance is 
an independent predictor of cardiovascular death in mitral stenosis. Heart. 
2017;103:1891–8.
 29. Eleid MF, Nishimura RA, Lennon RJ, et al. Left ventricular diastolic dys-
function in patients with mitral stenosis undergoing percutaneous mitral 
balloon valvotomy. Mayo Clin Proc. 2013;88:337–44.
 30. Cho I-J, Chang H-J, Lee SY, et al. Differential impact of net atrioventricular 
compliance on clinical outcomes in patients with mitral stenosis according 
to cardiac rhythm. J Am Soc Echocardiogr. 2017;30:552–60.
 31. Ellis LB, Singh JB, Morales DD, et al. Fifteen-to twenty-year study of one 
thousand patients undergoing closed mitral valvuloplasty. Circulation. 
1973;48:357–64.
 32. Finnegan JO, Gray DC, MacVaugh H 3rd, et al. The open approach to 
mitral commissurotomy. J Thorac Cardiovasc Surg. 1974;67:75–82.
 33. Gross RI, Cunningham JN Jr, Snively SL, et al. Long-term results of open 
radical mitral commissurotomy: ten year follow-up study of 202 patients. 
Am J Cardiol. 1981;47:821–5.
 34. Halseth WL, Elliott DP , Walker EL, et al. Open mitral commissurotomy. A 
modern re-evaluation. J Thorac Cardiovasc Surg. 1980;80:842–8.
 35. John S, Bashi VV, Jairaj PS, et al. Closed mitral valvotomy: early results 
and long-term follow-up of 3724 consecutive patients. Circulation. 
1983;68:891–6.
 36. Mullin MJ, Engelman RM, Isom OW, et al. Experience with open mitral 
commissurotomy in 100 consecutive patients. Surgery. 1974;76:974–82.
 37. Song H, Kang D-H, Kim JH, et al. Percutaneous mitral valvuloplasty versus 
surgical treatment in mitral stenosis with severe tricuspid regurgitation. 
Circulation. 2007;116:I246–50.
 38. Hart SA, Krasuski RA, Wang A, et al. Pulmonary hypertension and elevat-
ed transpulmonary gradient in patients with mitral stenosis. J Heart Valve 
Dis. 2010;19:708–15.
 39. Coutinho GF, Antunes MJ. Surgery for mitral stenosis in patients with 
pulmonary hypertension: how far can we go? J Thorac Cardiovasc Surg. 
2016;152:302–3.
 40. Mahfouz RA. Impact of pulmonary artery stiffness on right ventricular 
function and tricuspid regurgitation after successful percutaneous balloon 
mitral valvuloplasty: the importance of early intervention. Echocardiogra-
phy. 2012;29:1157–63.
 41. Arat N, Altay H, Korkmaz S, et al. The effect of baseline pulmonary artery 
pressure on right ventricular functions after mitral balloon valvuloplasty 
for rheumatic mitral stenosis: a tissue Doppler imaging study. Turk Kardi-
yol Dern Ars. 2008;36:223–30.
 42. Vincens JJ, Temizer D, Post JR, et al. Long-term outcome of cardiac surgery 
in patients with mitral stenosis and severe pulmonary hypertension. Circu-
lation. 1995;92:II137–42.
 43. Iung B, Leenhardt A, Extramiana F. Management of atrial fibrillation in 
patients with rheumatic mitral stenosis. Heart. 2018;104:1062–8.
 44. Cheitlin MD. Stress echocardiography in mitral stenosis: when is it useful? 
J Am Coll Cardiol. 2004;43:402–4.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e200
CLINICAL STATEMENTS  
AND GUIDELINES 45. Cheriex EC, Pieters FA, Janssen JH, et al. Value of exercise Doppler-echocar -
diography in patients with mitral stenosis. Int J Cardiol. 1994;45:219–26.
 46. Grimaldi A, Olivotto I, Figini F, et al. Dynamic assessment of “valvular 
reserve capacity” in patients with rheumatic mitral stenosis. Eur Heart J 
Cardiovasc Imaging. 2012;13:476–82.
 47. Suh WM, Kern MJ. Addressing the hemodynamic dilemma of combined 
mitral and aortic stenosis. Catheter Cardiovasc Interv. 2008;71:944–9.
 48. Reis G, Motta MS, Barbosa MM, et al. Dobutamine stress echocardiog-
raphy for noninvasive assessment and risk stratification of patients with 
rheumatic mitral stenosis. J Am Coll Cardiol. 2004;43:393–401.
6.3. Nonrheumatic Calcific MS
 1. Abramowitz Y, Jilaihawi H, Chakravarty T, et al. Mitral annulus calcifica-
tion. J Am Coll Cardiol. 2015;66:1934–41.
 2. Sud K, Agarwal S, Parashar A, et al. Degenerative mitral stenosis: unmet 
need for percutaneous interventions. Circulation. 2016;133:1594–604.
 3. Bertrand PB, Mihos CG, Yucel E. Mitral annular calcification and calcific 
mitral stenosis: therapeutic challenges and considerations. Curr Treat Op-
tions Cardiovasc Med. 2019;21:19.
 4. Pasca I, Dang P , Tyagi G, et al. Survival in patients with degenerative mitral 
stenosis: results from a large retrospective cohort study. J Am Soc Echocar -
diogr. 2016;29:461–9.
 5. Akram MR, Chan T, McAuliffe S, et al. Non-rheumatic annular mitral ste-
nosis: prevalence and characteristics. Eur J Echocardiogr. 2009;10:103–5.
 6. Asselbergs FW, Mozaffarian D, Katz R, et al. Association of renal function 
with cardiac calcifications in older adults: the cardiovascular health study. 
Nephrol Dial Transplant. 2009;24:834–40.
 7. Ix JH, Shlipak MG, Katz R, et al. Kidney function and aortic valve and 
mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis 
(MESA). Am J Kidney Dis. 2007;50:412–20.
 8. Jesri A, Braitman LE, Pressman GS. Severe mitral annular calcification pre-
dicts chronic kidney disease. Int J Cardiol. 2008;128:193–6.
 9. Pressman GS, Agarwal A, Braitman LE, et al. Mitral annular calcium caus-
ing mitral stenosis. Am J Cardiol. 2010;105:389–91.
 10. Rao AK, Djamali A, Korcarz CE, et al. Mitral annular calcification is associ-
ated with reduced left ventricular function and inflammation in patients 
with chronic kidney disease. J Am Soc Echocardiogr. 2008;21:747–50.
 11. Tsutsui RS, Banerjee K, Kapadia S, et al. Natural history of mitral stenosis 
in patients with mitral annular calcification. JACC Cardiovasc Imaging. 
2019;12:1105–7.
 12. Reddy YNV, Murgo JP , Nishimura RA. Complexity of defining severe “ste-
nosis” from mitral annular calcification. Circulation. 2019;140:523–5.
 13. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment 
of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J 
Echocardiogr. 2009;10:1–25.
 14. Chu JW, Levine RA, Chua S, et al. Assessing mitral valve area and orifice 
geometry in calcific mitral stenosis: a new solution by real-time three-
dimensional echocardiography. J Am Soc Echocardiogr. 2008;21:1006–9.
 15. Oktay AA, Gilliland YE, Lavie CJ, et al. Echocardiographic assessment of 
degenerative mitral stenosis: a diagnostic challenge of an emerging car -
diac disease. Curr Probl Cardiol. 2017;42:71–100.
 16. Movva R, Murthy K, Romero-Corral A, et al. Calcification of the mitral 
valve and annulus: systematic evaluation of effects on valve anatomy and 
function. J Am Soc Echocardiogr. 2013;26:1135–42.
 17. Hussain ST, Idrees J, Brozzi NA, et al. Use of annulus washer after debride-
ment: a new mitral valve replacement technique for patients with severe 
mitral annular calcification. J Thorac Cardiovasc Surg. 2013;145:1672–4.
 18. Kato Y, Hattori K, Bito Y, et al. Simple supra-annular prosthesis insertion 
for dialysis patients with extensive mitral annular calcification. J Heart 
Valve Dis. 2011;20:180–3.
 19. Lin PY, Kan CD, Luo CY, et al. Mitral valve replacement in the presence of 
massive posterior annular calcification. J Card Surg. 1999;14:266–9.
 20. McEnany MT. Mitral valve replacement in the presence of severe valvular 
and annular calcification. J Card Surg. 1993;8:117–24.
 21. Nataf P , Pavie A, Jault F, et al. Intraatrial insertion of a mitral prosthesis in 
a destroyed or calcified mitral annulus. Ann Thorac Surg. 1994;58:163–7.
 22. Shapira Y, Weisenberg DE, Vaturi M, et al. The impact of intraoperative 
transesophageal echocardiography in infective endocarditis. Isr Med As-
soc J. 2007;9:299–302.
 23. Guerrero M, Urena M, Himbert D, et al. 1-Year outcomes of transcatheter 
mitral valve replacement in patients with severe mitral annular calcifica-
tion. J Am Coll Cardiol. 2018;71:1841–53.7. MITRAL REGURGITATION
7.1. Acute MR
 1. Horstkotte D, Schulte HD, Niehues R, et al. Diagnostic and therapeutic 
considerations in acute, severe mitral regurgitation: experience in 42 con-
secutive patients entering the intensive care unit with pulmonary edema. 
J Heart Valve Dis. 1993;2:512–22.
 2. Yoran C, Yellin EL, Becker RM, et al. Mechanism of reduction of mitral 
regurgitation with vasodilator therapy. Am J Cardiol. 1979;43:773–7.
 3. Nanjappa MC, Ananthakrishna R, Hemanna Setty SK, et al. Acute severe 
mitral regurgitation following balloon mitral valvotomy: echocardiograph-
ic features, operative findings, and outcome in 50 surgical cases. Catheter 
Cardiovasc Interv. 2013;81:603–8.
 4. Watanabe N. Acute mitral regurgitation. Heart. 2019;105:671–7.
7.1.1. Diagnosis of Acute MR
 1. Watanabe N. Acute mitral regurgitation. Heart. 2019;105:671–7.
7.1.2. Medical Therapy
 1. Horstkotte D, Schulte HD, Niehues R, et al. Diagnostic and therapeutic 
considerations in acute, severe mitral regurgitation: experience in 42 con-
secutive patients entering the intensive care unit with pulmonary edema. 
J Heart Valve Dis. 1993;2:512–22.
 2. Yoran C, Yellin EL, Becker RM, et al. Mechanism of reduction of mitral 
regurgitation with vasodilator therapy. Am J Cardiol. 1979;43:773–7.
7.1.3. Intervention
 1. Nanjappa MC, Ananthakrishna R, Hemanna Setty SK, et al. Acute severe 
mitral regurgitation following balloon mitral valvotomy: echocardiograph-
ic features, operative findings, and outcome in 50 surgical cases. Catheter 
Cardiovasc Interv. 2013;81:603–8.
 2. Ternus BW, Mankad S, Edwards WD, et al. Clinical presentation and echo-
cardiographic diagnosis of postinfarction papillary muscle rupture: A re-
view of 22 cases. Echocardiography. 2017;34:973–7.
 3. Leitman M, Tyomkin V, Raanani E, et al. Assessment and Management of 
Acute Severe Mitral Regurgitation in the Intensive Care Unit. J Heart Valve 
Dis. 2017;26:161–8.
 4. Pasquier M, Sierro C, Yersin B, et al. Traumatic mitral valve injury after 
blunt chest trauma: a case report and review of the literature. J Trauma. 
2010;68:243–6.
 5. Pillai AA, Balasubramonian VR, Munuswamy H, et al. Acute severe mitral 
regurgitation with cardiogenic shock following balloon mitral valvuloplas-
ty: echocardiographic findings and outcomes following surgery. Cardio-
vasc Interv Ther. 2019;34:260–8.
7.2. Chronic Primary MR
7.2.2. Diagnosis and Follow-Up of Chronic 
Primary MR
7.2.2.1. Diagnostic Testing: Initial Diagnosis
 1. Bargiggia GS, Tronconi L, Sahn DJ, et al. A new method for quantitation 
of mitral regurgitation based on color flow Doppler imaging of flow con-
vergence proximal to regurgitant orifice. Circulation. 1991;84:1481–9.
 2. Recusani F, Bargiggia GS, Yoganathan AP , et al. A new method for quan-
tification of regurgitant flow rate using color Doppler flow imaging of the 
flow convergence region proximal to a discrete orifice. An in vitro study. 
Circulation. 1991;83:594–604.
 3. Tribouilloy C, Shen WF, Quere JP , et al. Assessment of severity of mitral 
regurgitation by measuring regurgitant jet width at its origin with trans-
esophageal Doppler color flow imaging. Circulation. 1992;85:1248–53.
 4. Tribouilloy C, Grigioni F, Avierinos JF, et al. Survival implication of left ventricular 
end-systolic diameter in mitral regurgitation due to flail leaflets a long-term 
follow-up multicenter study. J Am Coll Cardiol. 2009;54:1961–8.
 5. Enriquez-Sarano M, Avierinos J-F, Messika-Zeitoun D, et al. Quantitative 
determinants of the outcome of asymptomatic mitral regurgitation. N 
Engl J Med. 2005;352:875–83.
 6. Ozdogan O, Yuksel A, Gurgun C, et al. Evaluation of the severity of mitral 
regurgitation by the use of signal void in magnetic resonance imaging. 
Echocardiography. 2009;26:1127–35.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e201
CLINICAL STATEMENTS  
AND GUIDELINES 7. Pflugfelder PW, Sechtem UP , White RD, et al. Noninvasive evaluation of 
mitral regurgitation by analysis of left atrial signal loss in cine magnetic 
resonance. Am Heart J. 1989;117:1113–9.
 8. Myerson SG, d’Arcy J, Christiansen JP , et al. Determination of clinical 
outcome in mitral regurgitation with cardiovascular magnetic resonance 
quantification. Circulation. 2016;133:2287–96.
 9. Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive 
evaluation of native valvular regurgitation: a report from the American Society 
of Echocardiography. Developed in collaboration with the Society for Cardio-
vascular Magnetic Resonance. J Am Soc Echocardiogr. 2017;30:303–71.
 10. Dahm M, Iversen S, Schmid FX, et al. Intraoperative evaluation of recon-
struction of the atrioventricular valves by transesophageal echocardiogra-
phy. Thorac Cardiovasc Surg. 1987;35(Spec No. 2):140–2.
 11. Saiki Y, Kasegawa H, Kawase M, et al. Intraoperative TEE during mitral 
valve repair: does it predict early and late postoperative mitral valve dys-
function? Ann Thorac Surg. 1998;66:1277–81.
 12. Lancellotti P , Moura L, Pierard LA, et al. European Association of Echocar -
diography recommendations for the assessment of valvular regurgitation. 
Part 2: mitral and tricuspid regurgitation (native valve disease). Eur J Echo-
cardiogr. 2010;11:307–32.
 13. Carabello BA, Crawford FA Jr. Valvular heart disease. N Engl J Med. 
1997;337:32–41.
 14. Tribouilloy CM, Enriquez-Sarano M, Schaff HV, et al. Impact of preoperative 
symptoms on survival after surgical correction of organic mitral regurgitation: 
rationale for optimizing surgical indications. Circulation. 1999;99:400–5.
 15. Gillinov AM, Mihaljevic T, Blackstone EH, et al. Should patients with severe 
degenerative mitral regurgitation delay surgery until symptoms develop? 
Ann Thorac Surg. 2010;90:481–8.
 16. Enriquez-Sarano M, Tajik AJ, Schaff HV, et al. Echocardiographic predic-
tion of survival after surgical correction of organic mitral regurgitation. 
Circulation. 1994;90:830–7.
 17. Schuler G, Peterson KL, Johnson A, et al. Temporal response of left 
ventricular performance to mitral valve surgery. Circulation. 1979;59: 
1218–31.
 18. Galderisi M, Cosyns B, Edvardsen T, et al. Standardization of adult transthoracic 
echocardiography reporting in agreement with recent chamber quantification, 
diastolic function, and heart valve disease recommendations: an expert con-
sensus document of the European Association of Cardiovascular Imaging. Eur 
Heart J Cardiovasc Imaging. 2017;18:1301–10.
 19. Jenner J, Sörensson P , Pernow J, et al. Contrast enhancement and image 
quality influence two- and three-dimensional echocardiographic determi-
nation of left ventricular volumes: comparison with magnetic resonance 
imaging. Clin Med Insights Cardiol. 2019;13:1179546819831980.
 20. Tribouilloy C, Rusinaru D, Szymanski C, et al. Predicting left ventricular 
dysfunction after valve repair for mitral regurgitation due to leaflet pro-
lapse: additive value of left ventricular end-systolic dimension to ejection 
fraction. Eur J Echocardiogr. 2011;12:702–10.
 21. Suri RM, Clavel M-A, Schaff HV, et al. Effect of recurrent mitral regurgi-
tation following degenerative mitral valve repair: long-term analysis of 
competing outcomes. J Am Coll Cardiol. 2016;67:488–98.
 22. Bax JJ, Debonnaire P , Lancellotti P , et al. Transcatheter interventions for 
mitral regurgitation: multimodality imaging for patient selection and pro-
cedural guidance. JACC Cardiovasc Imaging. 2019;12:2029–48.
 23. Zoghbi WA, Asch FM, Bruce C, et al. Guidelines for the evaluation of val-
vular regurgitation after percutaneous valve repair or replacement: a report 
from the American Society of Echocardiography. Developed in collabora-
tion with the Society for Cardiovascular Angiography and Interventions, 
Japanese Society of Echocardiography, and Society for Cardiovascular 
Magnetic Resonance. J Am Soc Echocardiogr. 2019;32:431–75.
7.2.2.2. Diagnostic Testing: Changing Signs or 
Symptoms
 1. Antoine C, Benfari G, Michelena HI, et al. Clinical outcome of degenera-
tive mitral regurgitation: critical importance of echocardiographic quanti-
tative assessment in routine practice. Circulation. 2018;138:1317–26.
 2. Tribouilloy CM, Enriquez-Sarano M, Schaff HV, et al. Impact of preop-
erative symptoms on survival after surgical correction of organic mitral 
regurgitation: rationale for optimizing surgical indications. Circulation. 
1999;99:400–5.
7.2.2.3. Diagnostic Testing: Routine Follow-Up
 1. Zilberszac R, Heinze G, Binder T, et al. Long-term outcome of active sur -
veillance in severe but asymptomatic primary mitral regurgitation. JACC 
Cardiovasc Imaging. 2018;11:1213–21. 2. Ghoreishi M, Evans CF, DeFilippi CR, et al. Pulmonary hypertension ad-
versely affects short- and long-term survival after mitral valve operation 
for mitral regurgitation: implications for timing of surgery. J Thorac Car -
diovasc Surg. 2011;142:1439–52.
 3. Enriquez-Sarano M, Tajik AJ, Schaff HV, et al. Echocardiographic predic-
tion of survival after surgical correction of organic mitral regurgitation. 
Circulation. 1994;90:830–7.
 4. Kang D-H, Kim JH, Rim JH, et al. Comparison of early surgery versus con-
ventional treatment in asymptomatic severe mitral regurgitation. Circula-
tion. 2009;119:797–804.
 5. Bonow RO. Chronic mitral regurgitation and aortic regurgitation: have 
indications for surgery changed? J Am Coll Cardiol. 2013;61:693–701.
 6. Enriquez-Sarano M, Avierinos J-F, Messika-Zeitoun D, et al. Quantitative 
determinants of the outcome of asymptomatic mitral regurgitation. N 
Engl J Med. 2005;352:875–83.
 7. Rosenhek R, Rader F, Klaar U, et al. Outcome of watchful waiting in as-
ymptomatic severe mitral regurgitation. Circulation. 2006;113:2238–44.
 8. Grigioni F, Tribouilloy C, Avierinos JF, et al. Outcomes in mitral regurgita-
tion due to flail leaflets a multicenter European study. JACC Cardiovasc 
Imaging. 2008;1:133–41.
 9. Kang D-H, Park S-J, Sun BJ, et al. Early surgery versus conventional treat-
ment for asymptomatic severe mitral regurgitation: a propensity analysis. 
J Am Coll Cardiol. 2014;63:2398–407.
 10. Rosen SE, Borer JS, Hochreiter C, et al. Natural history of the asymp-
tomatic/minimally symptomatic patient with severe mitral regurgitation 
secondary to mitral valve prolapse and normal right and left ventricular 
performance. Am J Cardiol. 1994;74:374–80.
 11. Quiñones MA, Douglas PS, Foster E, et al. American College of Cardiology/
American Heart Association clinical competence statement on echocardiog-
raphy: a report of the American College of Cardiology/American Heart As-
sociation/American College of Physicians—American Society of Internal 
Medicine Task Force on Clinical Competence. Developed in collaboration 
with the American Society of Echocardiography, the Society of Cardiovascular 
Anesthesiologists, and the Society of Pediatric Echocardiography. Circulation. 
2003;107:1068–89.
 12. Detaint D, Messika-Zeitoun D, Avierinos J-F, et al. B-type natriuretic pep-
tide in organic mitral regurgitation: determinants and impact on outcome. 
Circulation. 2005;111:2391–7.
 13. Sutton TM, Stewart RAH, Gerber IL, et al. Plasma natriuretic peptide levels 
increase with symptoms and severity of mitral regurgitation. J Am Coll 
Cardiol. 2003;41:2280–7.
 14. Pizarro R, Bazzino OO, Oberti PF, et al. Prospective validation of the 
prognostic usefulness of brain natriuretic peptide in asymptomatic 
patients with chronic severe mitral regurgitation. J Am Coll Cardiol. 
2009;54:1099–106.
 15. Alashi A, Mentias A, Patel K, et al. Synergistic utility of brain natriuretic 
peptide and left ventricular global longitudinal strain in asymptomatic 
patients with significant primary mitral regurgitation and preserved sys-
tolic function undergoing mitral valve surgery. Circ Cardiovasc Imaging. 
2016;9:e004451.
 16. Klaar U, Gabriel H, Bergler-Klein J, et al. Prognostic value of serial B-type 
natriuretic peptide measurement in asymptomatic organic mitral regurgi-
tation. Eur J Heart Fail. 2011;13:163–9.
 17. Mentias A, Patel K, Patel H, et al. Prognostic utility of brain natri-
uretic peptide in asymptomatic patients with significant mitral regur -
gitation and preserved left ventricular ejection fraction. Am J Cardiol. 
2016;117:258–63.
 18. Magne J, Mahjoub H, Pierard LA, et al. Prognostic importance of brain na-
triuretic peptide and left ventricular longitudinal function in asymptomatic 
degenerative mitral regurgitation. Heart. 2012;98:584–91.
 19. Hiemstra YL, Tomsic A, van Wijngaarden SE, et al. Prognostic value of 
global longitudinal strain and etiology after surgery for primary mitral re-
gurgitation. JACC Cardiovasc Imaging. 2020;13:577–85.
 20. Clavel M-A, Tribouilloy C, Vanoverschelde J-L, et al. Association of B-type 
natriuretic peptide with survival in patients with degenerative mitral regur -
gitation. J Am Coll Cardiol. 2016;68:1297–307.
 21. Kim HM, Cho G-Y, Hwang I-C, et al. Myocardial strain in prediction of 
outcomes after surgery for severe mitral regurgitation. JACC Cardiovasc 
Imaging. 2018;11:1235–44.
7.2.2.4. Diagnostic Testing: Cardiac Catheterization
 1. Nishimura RA, Carabello BA. Hemodynamics in the cardiac catheterization 
laboratory of the 21st century. Circulation. 2012;125:2138–50.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e202
CLINICAL STATEMENTS  
AND GUIDELINES7.2.2.5. Diagnostic Testing: Exercise Testing
 1. Tischler MD, Battle RW, Ashikaga T, et al. Effects of exercise on left ven-
tricular performance determined by echocardiography in chronic, severe 
mitral regurgitation secondary to mitral valve prolapse. Am J Cardiol. 
1996;77:397–402.
 2. Tischler MD, Battle RW, Saha M, et al. Observations suggesting a high inci-
dence of exercise-induced severe mitral regurgitation in patients with mild 
rheumatic mitral valve disease at rest. J Am Coll Cardiol. 1995;25:128–33.
 3. Magne J, Lancellotti P , Piérard LA. Exercise-induced changes in degenera-
tive mitral regurgitation. J Am Coll Cardiol. 2010;56:300–9.
 4. Magne J, Lancellotti P , Piérard LA. Exercise pulmonary hypertension in as-
ymptomatic degenerative mitral regurgitation. Circulation. 2010;122:33–
41.
7.2.3. Medical Therapy
 1. Ahmed MI, Aban I, Lloyd SG, et al. A randomized controlled phase IIb trial 
of beta(1)-receptor blockade for chronic degenerative mitral regurgita-
tion. J Am Coll Cardiol. 2012;60:833–8.
 2. Nemoto S, Hamawaki M, De Freitas G, et al. Differential effects of the 
angiotensin-converting enzyme inhibitor lisinopril versus the beta-adren-
ergic receptor blocker atenolol on hemodynamics and left ventricular con-
tractile function in experimental mitral regurgitation. J Am Coll Cardiol. 
2002;40:149–54.
 3. Varadarajan P , Joshi N, Appel D, et al. Effect of beta-blocker therapy on 
survival in patients with severe mitral regurgitation and normal left ven-
tricular ejection fraction. Am J Cardiol. 2008;102:611–5.
 4. Dujardin KS, Enriquez-Sarano M, Bailey KR, et al. Effect of losartan on de-
gree of mitral regurgitation quantified by echocardiography. Am J Cardiol. 
2001;87:570–6.
 5. Harris KM, Aeppli DM, Carey CF. Effects of angiotensin-converting en-
zyme inhibition on mitral regurgitation severity, left ventricular size, and 
functional capacity. Am Heart J. 2005;150:1106.
 6. Kizilbash AM, Willett DL, Brickner ME, et al. Effects of afterload reduc-
tion on vena contracta width in mitral regurgitation. J Am Coll Cardiol. 
1998;32:427–31.
 7. Tischler MD, Rowan M, LeWinter MM. Effect of enalapril therapy on 
left ventricular mass and volumes in asymptomatic chronic, severe mi-
tral regurgitation secondary to mitral valve prolapse. Am J Cardiol. 
1998;82:242–5.
 8. Wisenbaugh T, Sinovich V, Dullabh A, et al. Six month pilot study of cap-
topril for mildly symptomatic, severe isolated mitral and isolated aortic 
regurgitation. J Heart Valve Dis. 1994;3:197–204.
7.2.4. Intervention
 1. Tribouilloy CM, Enriquez-Sarano M, Schaff HV, et al. Impact of preop-
erative symptoms on survival after surgical correction of organic mitral 
regurgitation: rationale for optimizing surgical indications. Circulation. 
1999;99:400–5.
 2. Gillinov AM, Mihaljevic T, Blackstone EH, et al. Should patients with severe 
degenerative mitral regurgitation delay surgery until symptoms develop? 
Ann Thorac Surg. 2010;90:481–8.
 3. Rosenhek R, Rader F, Klaar U, et al. Outcome of watchful waiting in as-
ymptomatic severe mitral regurgitation. Circulation. 2006;113:2238–44.
 4. Kang D-H, Kim JH, Rim JH, et al. Comparison of early surgery versus con-
ventional treatment in asymptomatic severe mitral regurgitation. Circula-
tion. 2009;119:797–804.
 5. Schuler G, Peterson KL, Johnson A, et al. Temporal response of left ven-
tricular performance to mitral valve surgery. Circulation. 1979;59:1218–
31.
 6. Enriquez-Sarano M, Tajik AJ, Schaff HV, et al. Echocardiographic predic-
tion of survival after surgical correction of organic mitral regurgitation. 
Circulation. 1994;90:830–7.
 7. Tribouilloy C, Grigioni F, Avierinos JF, et al. Survival implication of left ven-
tricular end-systolic diameter in mitral regurgitation due to flail leaflets a 
long-term follow-up multicenter study. J Am Coll Cardiol. 2009;54:1961–
8.
 8. Enriquez-Sarano M, Avierinos J-F, Messika-Zeitoun D, et al. Quantitative 
determinants of the outcome of asymptomatic mitral regurgitation. N 
Engl J Med. 2005;352:875–83.
 9. Crawford MH, Souchek J, Oprian CA, et al. Determinants of survival and 
left ventricular performance after mitral valve replacement. Department of 
Veterans Affairs Cooperative Study on Valvular Heart Disease. Circulation. 
1990;81:1173–81. 10. Borow KM, Green LH, Mann T, et al. End-systolic volume as a predictor of 
postoperative left ventricular performance in volume overload from valvu-
lar regurgitation. Am J Med. 1980;68:655–63.
 11. Suri RM, Clavel M-A, Schaff HV, et al. Effect of recurrent mitral regurgi-
tation following degenerative mitral valve repair: long-term analysis of 
competing outcomes. J Am Coll Cardiol. 2016;67:488–98.
 12. Vassileva CM, Mishkel G, McNeely C, et al. Long-term survival of patients 
undergoing mitral valve repair and replacement: a longitudinal analysis of 
Medicare fee-for-service beneficiaries. Circulation. 2013;127:1870–6.
 13. Suri RM, Vanoverschelde J-L, Grigioni F, et al. Association between early 
surgical intervention vs watchful waiting and outcomes for mitral regurgi-
tation due to flail mitral valve leaflets. JAMA. 2013;310:609–16.
 14. Grigioni F, Tribouilloy C, Avierinos JF, et al. Outcomes in mitral regurgita-
tion due to flail leaflets a multicenter European study. JACC Cardiovasc 
Imaging. 2008;1:133–41.
 15. Lazam S, Vanoverschelde J-L, Tribouilloy C, et al. Twenty-year outcome af-
ter mitral repair versus replacement for severe degenerative mitral regur -
gitation: analysis of a large, prospective, multicenter, international registry. 
Circulation. 2017;135:410–22.
 16. Tribouilloy C, Rusinaru D, Szymanski C, et al. Predicting left ventricular 
dysfunction after valve repair for mitral regurgitation due to leaflet pro-
lapse: additive value of left ventricular end-systolic dimension to ejection 
fraction. Eur J Echocardiogr. 2011;12:702–10.
 17. Feldman T, Kar S, Elmariah S, et al. Randomized comparison of percutane-
ous repair and surgery for mitral regurgitation: 5-year results of EVEREST 
II. J Am Coll Cardiol. 2015;66:2844–54.
 18. Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for 
mitral regurgitation. N Engl J Med. 2011;364:1395–406.
 19. Dillon J, Yakub MA, Kong PK, et al. Comparative long-term results of mi-
tral valve repair in adults with chronic rheumatic disease and degenerative 
disease: is repair for “burnt-out” rheumatic disease still inferior to repair 
for degenerative disease in the current era? J Thorac Cardiovasc Surg. 
2015;149:771–7.
 20. Gillinov AM, Blackstone EH, Alaulaqi A, et al. Outcomes after repair of 
the anterior mitral leaflet for degenerative disease. Ann Thorac Surg. 
2008;86:708–17.
 21. Weiner MM, Hofer I, Lin H-M, et al. Relationship among surgical vol-
ume, repair quality, and perioperative outcomes for repair of mitral in-
sufficiency in a mitral valve reference center. J Thorac Cardiovasc Surg. 
2014;148:2021–6.
 22. Enriquez-Sarano M, Suri RM, Clavel M-A, et al. Is there an outcome pen-
alty linked to guideline-based indications for valvular surgery? Early and 
long-term analysis of patients with organic mitral regurgitation. J Thorac 
Cardiovasc Surg. 2015;150:50–8.
 23. David TE, Ivanov J, Armstrong S, et al. A comparison of outcomes of mitral 
valve repair for degenerative disease with posterior, anterior, and bileaflet 
prolapse. J Thorac Cardiovasc Surg. 2005;130:1242–9.
 24. Suri RM, Schaff HV, Dearani JA, et al. Survival advantage and improved 
durability of mitral repair for leaflet prolapse subsets in the current era. 
Ann Thorac Surg. 2006;82:819–26.
 25. Castillo JG, Anyanwu AC, El-Eshmawi A, et al. All anterior and bileaflet 
mitral valve prolapses are repairable in the modern era of reconstructive 
surgery. Eur J Cardiothorac Surg. 2014;45:139–45.
 26. Chikwe J, Toyoda N, Anyanwu AC, et al. Relation of mitral valve sur -
gery volume to repair rate, durability, and survival. J Am Coll Cardiol. 
2017;69:2397–406.
 27. Castillo JG, Anyanwu AC, Fuster V, et al. A near 100% repair rate for 
mitral valve prolapse is achievable in a reference center: implications for 
future guidelines. J Thorac Cardiovasc Surg. 2012;144:308–12.
 28. El-Eshmawi A, Castillo JG, Tang GHL, et al. Developing a mitral valve cen-
ter of excellence. Curr Opin Cardiol. 2018;33:155–61.
 29. Bonow RO, Adams DH. The time has come to define centers of excellence 
in mitral valve repair. J Am Coll Cardiol. 2016;67:499–501.
 30. Badhwar V, Peterson ED, Jacobs JP , et al. Longitudinal outcome of isolated 
mitral repair in older patients: results from 14,604 procedures performed 
from 1991 to 2007. Ann Thorac Surg. 2012;94:1870–7.
 31. Chikwe J, Goldstone AB, Passage J, et al. A propensity score-adjusted ret-
rospective comparison of early and mid-term results of mitral valve repair 
versus replacement in octogenarians. Eur Heart J. 2011;32:618–26.
 32. Starling MR. Effects of valve surgery on left ventricular contractile 
function in patients with long-term mitral regurgitation. Circulation. 
1995;92:811–8.
 33. McClure RS, Athanasopoulos LV, McGurk S, et al. One thousand minimally 
invasive mitral valve operations: early outcomes, late outcomes, and echo-
cardiographic follow-up. J Thorac Cardiovasc Surg. 2013;145:1199–206.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e203
CLINICAL STATEMENTS  
AND GUIDELINES 34. Arcidi JM Jr, Rodriguez E, Elbeery JR, et al. Fifteen-year experience with 
minimally invasive approach for reoperations involving the mitral valve. J 
Thorac Cardiovasc Surg. 2012;143:1062–8.
 35. Holzhey DM, Seeburger J, Misfeld M, et al. Learning minimally invasive 
mitral valve surgery: a cumulative sum sequential probability analy-
sis of 3895 operations from a single high-volume center. Circulation. 
2013;128:483–91.
 36. Mihaljevic T, Jarrett CM, Gillinov AM, et al. Robotic repair of posterior 
mitral valve prolapse versus conventional approaches: potential realized. J 
Thorac Cardiovasc Surg. 2011;141:72–80.e1–4.
 37. Suri RM, Burkhart HM, Daly RC, et al. Robotic mitral valve repair for all 
prolapse subsets using techniques identical to open valvuloplasty: estab-
lishing the benchmark against which percutaneous interventions should 
be judged. J Thorac Cardiovasc Surg. 2011;142:970–9.
 38. Suri RM, Schaff HV, Meyer SR, et al. Thoracoscopic versus open mitral 
valve repair: a propensity score analysis of early outcomes. Ann Thorac 
Surg. 2009;88:1185–90.
 39. David TE, Armstrong S, McCrindle BW, et al. Late outcomes of mitral valve 
repair for mitral regurgitation due to degenerative disease. Circulation. 
2013;127:1485–92.
 40. David TE, David CM, Tsang W, et al. Long-term results of mitral valve 
repair for regurgitation due to leaflet prolapse. J Am Coll Cardiol. 
2019;74:1044–53.
 41. Quintana E, Suri RM, Thalji NM, et al. Left ventricular dysfunction after 
mitral valve repair–the fallacy of “normal” preoperative myocardial func-
tion. J Thorac Cardiovasc Surg. 2014;148:2752–60.
 42. Sorajja P , Vemulapalli S, Feldman T, et al. Outcomes with transcatheter 
mitral valve repair in the United States: an STS/ACC TVT registry report. J 
Am Coll Cardiol. 2017;70:2315–27.
 43. Yankah CA, Siniawski H, Detschades C, et al. Rheumatic mitral valve re-
pair: 22-year clinical results. J Heart Valve Dis. 2011;20:257–64.
7.3. Chronic Secondary MR
7.3.1. Stages of Chronic Secondary MR
 1. Uretsky S, Gillam L, Lang R, et al. Discordance between echocardiography 
and MRI in the assessment of mitral regurgitation severity: a prospective 
multicenter trial. J Am Coll Cardiol. 2015;65:1078–88.
 2. Grayburn PA, Carabello B, Hung J, et al. Defining “severe” secondary mi-
tral regurgitation: emphasizing an integrated approach. J Am Coll Cardiol. 
2014;64:2792–801.
 3. Acker MA, Parides MK, Perrault LP , et al. Mitral-valve repair versus re-
placement for severe ischemic mitral regurgitation. N Engl J Med. 
2014;370:23–32.
 4. Goldstein D, Moskowitz AJ, Gelijns AC, et al. Two-year outcomes of sur -
gical treatment of severe ischemic mitral regurgitation. N Engl J Med. 
2016;374:344–53.
 5. Michler RE, Smith PK, Parides MK, et al. Two-year outcomes of surgi-
cal treatment of moderate ischemic mitral regurgitation. N Engl J Med. 
2016;374:1932–41.
 6. Smith PK, Puskas JD, Ascheim DD, et al. Surgical treatment of moderate 
ischemic mitral regurgitation. N Engl J Med. 2014;371:2178–88.
7.3.2. Diagnosis of Chronic Secondary MR
 1. Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninva-
sive evaluation of native valvular regurgitation: a report from the Ameri-
can Society of Echocardiography. Developed in collaboration with the 
Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 
2017;30:303–71.
 2. Grigioni F, Enriquez-Sarano M, Zehr KJ, et al. Ischemic mitral regurgitation: 
long-term outcome and prognostic implications with quantitative Doppler 
assessment. Circulation. 2001;103:1759–64.
 3. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve 
repair in patients with heart failure. N Engl J Med. 2018;379:2307–18.
 4. Tommaso CL, Fullerton DA, Feldman T, et al. SCAI/AATS/ACC/STS 
operator and institutional requirements for transcatheter valve 
repair and replacement. Part II. mitral valve. J Am Coll Cardiol. 
2014;64:1515–26.
 5. Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interven-
tions in the real world: early and 1-year results from the ACCESS-EU, a 
prospective, multicenter, nonrandomized post-approval study of the Mi-
traClip therapy in Europe. J Am Coll Cardiol. 2013;62:1052–61. 6. Mauri L, Foster E, Glower DD, et al. 4-Year results of a randomized con-
trolled trial of percutaneous repair versus surgery for mitral regurgitation. 
J Am Coll Cardiol. 2013;62:317–28.
 7. Bax JJ, Debonnaire P , Lancellotti P , et al. Transcatheter interventions for 
mitral regurgitation: multimodality imaging for patient selection and pro-
cedural guidance. JACC Cardiovasc Imaging. 2019;12:2029–48.
 8. Zoghbi WA, Asch FM, Bruce C, et al. Guidelines for the evaluation of 
valvular regurgitation after percutaneous valve repair or replacement: a 
report from the American Society of Echocardiography. Developed in col-
laboration with the Society for Cardiovascular Angiography and Interven-
tions, Japanese Society of Echocardiography, and Society for Cardiovascu-
lar Magnetic Resonance. J Am Soc Echocardiogr. 2019;32:431–75.
 9. Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for 
mitral regurgitation. N Engl J Med. 2011;364:1395–406.
 10. Feldman T, Kar S, Elmariah S, et al. Randomized comparison of percutane-
ous repair and surgery for mitral regurgitation: 5-year results of EVEREST 
II. J Am Coll Cardiol. 2015;66:2844–54.
 11. Silvestry FE, Rodriguez LL, Herrmann HC, et al. Echocardiographic guid-
ance and assessment of percutaneous repair for mitral regurgitation with 
the Evalve MitraClip: lessons learned from EVEREST I. J Am Soc Echocar -
diogr. 2007;20:1131–40.
 12. Nickenig G, Estevez-Loureiro R, Franzen O, et al. Percutaneous mitral valve 
edge-to-edge repair: in-hospital results and 1-year follow-up of 628 pa-
tients of the 2011–2012 Pilot European Sentinel Registry. J Am Coll Car -
diol. 2014;64:875–84.
 13. Sorajja P , Vemulapalli S, Feldman T, et al. Outcomes with transcatheter 
mitral valve repair in the United States: an STS/ACC TVT registry report. J 
Am Coll Cardiol. 2017;70:2315–27.
 14. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery 
in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374: 
1511–20.
 15. Panza JA, Ellis AM, Al-Khalidi HR, et al. Myocardial viability and long-term 
outcomes in ischemic cardiomyopathy. N Engl J Med. 2019;381:739–48.
 16. Ji Q, Zhao Y, Shen J, et al. Predictors of ischemic mitral regurgitation im-
provement after surgical revascularization plus mitral valve repair for mod-
erate ischemic mitral regurgitation. J Card Surg. 2020;35:528–35.
 17. Kopjar T, Gasparovic H, Mestres CA, et al. Meta-analysis of concomitant 
mitral valve repair and coronary artery bypass surgery versus isolated coro-
nary artery bypass surgery in patients with moderate ischaemic mitral re-
gurgitation. Eur J Cardiothorac Surg. 2016;50:212–22.
 18. Virk SA, Tian DH, Sriravindrarajah A, et al. Mitral valve surgery and cor -
onary artery bypass grafting for moderate-to-severe ischemic mitral re-
gurgitation: meta-analysis of clinical and echocardiographic outcomes. J 
Thorac Cardiovasc Surg. 2017;154:127–36.
7.3.3. Medical Therapy
 1. SOLVD Investigators, Yusuf S, Pitt B, et al. Effect of enalapril on mortality 
and the development of heart failure in asymptomatic patients with re-
duced left ventricular ejection fractions. N Engl J Med. 1992;327:685–91.
 2. Eriksson SV, Eneroth P , Kjekshus J, et al. Neuroendocrine activation in rela-
tion to left ventricular function in chronic severe congestive heart failure: 
a subgroup analysis from the Cooperative North Scandinavian Enalapril 
Survival Study (CONSENSUS). Clin Cardiol. 1994;17:603–6.
 3. Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in pa-
tients with chronic heart failure and reduced left-ventricular systolic func-
tion intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-
Alternative trial. Lancet. 2003;362:772–6.
 4. Krum H, Roecker EB, Mohacsi P , et al. Effects of initiating carvedilol in 
patients with severe chronic heart failure: results from the COPERNICUS 
Study. JAMA. 2003;289:712–8.
 5. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbid-
ity and mortality in patients with severe heart failure. Randomized Aldac-
tone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17.
 6. St John Sutton MG, Plappert T, Abraham WT, et al. Effect of cardiac resyn-
chronization therapy on left ventricular size and function in chronic heart 
failure. Circulation. 2003;107:1985–90.
 7. van Bommel RJ, Marsan NA, Delgado V, et al. Cardiac resynchroniza-
tion therapy as a therapeutic option in patients with moderate-severe 
functional mitral regurgitation and high operative risk. Circulation. 
2011;124:912–9.
 8. Kang D-H, Park S-J, Shin S-H, et al. Angiotensin receptor neprilysin inhibi-
tor for functional mitral regurgitation. Circulation. 2019;139:1354–65.
 9. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for 
the management of heart failure: a report of the American College of 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e204
CLINICAL STATEMENTS  
AND GUIDELINESCardiology Foundation/American Heart Association Task Force on Practice 
Guidelines. Circulation. 2013;128:e240–327.
 10. Mullens W, Martens P . Sacubitril/valsartan to reduce secondary mitral re-
gurgitation. Circulation. 2019;139:1366–70.
 11. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in 
chronic heart failure. N Engl J Med. 2002;346:1845–53.
 12. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve 
repair in patients with heart failure. N Engl J Med. 2018;379:2307–18.
7.3.4. Intervention
 1. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve 
repair in patients with heart failure. N Engl J Med. 2018;379:2307–18.
 2. Obadia J-F, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair 
or medical treatment for secondary mitral regurgitation. N Engl J Med. 
2018;379:2297–306.
 3. Ailawadi G, Lim DS, Mack MJ, et al. One-year outcomes after MitraClip 
for functional mitral regurgitation. Circulation. 2019;139:37–47.
 4. Arnold SV, Chinnakondepalli KM, Spertus JA, et al. Health status after 
transcatheter mitral-valve repair in heart failure and secondary mitral re-
gurgitation: COAPT trial. J Am Coll Cardiol. 2019;73:2123–32.
 5. Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate 
functional mitral regurgitation: a new conceptual framework that recon-
ciles the results of the MITRA-FR and COAPT trials. JACC Cardiovasc Imag-
ing. 2019;12:353–62.
 6. Nishimura RA, Bonow RO. Percutaneous repair of secondary mitral regur -
gitation—a tale of two trials. N Engl J Med. 2018;379:2374–6.
 7. Swaans MJ, Bakker ALM, Alipour A, et al. Survival of transcatheter mitral 
valve repair compared with surgical and conservative treatment in high-
surgical-risk patients. JACC Cardiovasc Interv. 2014;7:875–81.
 8. Auricchio A, Schillinger W, Meyer S, et al. Correction of mitral regurgita-
tion in nonresponders to cardiac resynchronization therapy by MitraClip 
improves symptoms and promotes reverse remodeling. J Am Coll Cardiol. 
2011;58:2183–9.
 9. Deja MA, Grayburn PA, Sun B, et al. Influence of mitral regurgitation re-
pair on survival in the surgical treatment for ischemic heart failure trial. 
Circulation. 2012;125:2639–48.
 10. Di Mauro M, Di Giammarco G, Vitolla G, et al. Impact of no-to-moderate mitral 
regurgitation on late results after isolated coronary artery bypass grafting in 
patients with ischemic cardiomyopathy. Ann Thorac Surg. 2006;81:2128–34.
 11. Bax JJ, Braun J, Somer ST, et al. Restrictive annuloplasty and coronary 
revascularization in ischemic mitral regurgitation results in reverse left ven-
tricular remodeling. Circulation. 2004;110:II103–8.
 12. Fattouch K, Guccione F, Sampognaro R, et al. POINT: Efficacy of adding 
mitral valve restrictive annuloplasty to coronary artery bypass grafting in 
patients with moderate ischemic mitral valve regurgitation: a randomized 
trial. J Thorac Cardiovasc Surg. 2009;138:278–85.
 13. Samad Z, Shaw LK, Phelan M, et al. Management and outcomes in pa-
tients with moderate or severe functional mitral regurgitation and severe 
left ventricular dysfunction. Eur Heart J. 2015;36:2733–41.
 14. Nishimura RA, Vahanian A, Eleid MF, et al. Mitral valve disease–current 
management and future challenges. Lancet. 2016;387:1324–34.
 15. Deja MA, Grayburn PA, Sun B, et al. Influence of mitral regurgitation re-
pair on survival in the surgical treatment for ischemic heart failure trial. 
Circulation. 2012;125:2639–48.
 16. Rankin JS, Grau-Sepulveda M, Shahian DM, et al. The impact of mitral 
disease etiology on operative mortality after mitral valve operations. Ann 
Thorac Surg. 2018;106:1406–13.
 17. Gammie JS, Chikwe J, Badhwar V, et al. Isolated mitral valve surgery: the 
Society of Thoracic Surgeons Adult Cardiac Surgery Database analysis. 
Ann Thorac Surg. 2018;106:716–27.
 18. Kihara T, Gillinov AM, Takasaki K, et al. Mitral regurgitation associated 
with mitral annular dilation in patients with lone atrial fibrillation: an 
echocardiographic study. Echocardiography. 2009;26:885–9.
 19. Vohra HA, Whistance RN, Magan A, et al. Mitral valve repair for severe 
mitral regurgitation secondary to lone atrial fibrillation. Eur J Cardiothorac 
Surg. 2012;42:634–7.
 20. Takahashi Y, Abe Y, Sasaki Y, et al. Mitral valve repair for atrial functional 
mitral regurgitation in patients with chronic atrial fibrillation. Interact Car -
diovasc Thorac Surg. 2015;21:163–8.
 21. Goldstein D, Moskowitz AJ, Gelijns AC, et al. Two-year outcomes of sur -
gical treatment of severe ischemic mitral regurgitation. N Engl J Med. 
2016;374:344–53.
 22. Wu AH, Aaronson KD, Bolling SF, et al. Impact of mitral valve annuloplasty 
on mortality risk in patients with mitral regurgitation and left ventricular 
systolic dysfunction. J Am Coll Cardiol. 2005;45:381–7. 23. Grigioni F, Enriquez-Sarano M, Zehr KJ, et al. Ischemic mitral regurgitation: 
long-term outcome and prognostic implications with quantitative Doppler 
assessment. Circulation. 2001;103:1759–64.
 24. Lancellotti P , Gérard PL, Piérard LA. Long-term outcome of patients with 
heart failure and dynamic functional mitral regurgitation. Eur Heart J. 
2005;26:1528–32.
 25. Trichon BH, Felker GM, Shaw LK, et al. Relation of frequency and sever -
ity of mitral regurgitation to survival among patients with left ventricular 
systolic dysfunction and heart failure. Am J Cardiol. 2003;91:538–43.
 26. Rossi A, Dini FL, Faggiano P , et al. Independent prognostic value of func-
tional mitral regurgitation in patients with heart failure. A quantitative 
analysis of 1256 patients with ischaemic and non-ischaemic dilated car -
diomyopathy. Heart. 2011;97:1675–80.
 27. Mihaljevic T, Lam B-K, Rajeswaran J, et al. Impact of mitral valve annulo-
plasty combined with revascularization in patients with functional isch-
emic mitral regurgitation. J Am Coll Cardiol. 2007;49:2191–201.
 28. Harris KM, Sundt TM 3rd, Aeppli D, et al. Can late survival of patients with 
moderate ischemic mitral regurgitation be impacted by intervention on 
the valve? Ann Thorac Surg. 2002;74:1468–75.
 29. Benedetto U, Melina G, Roscitano A, et al. Does combined mitral valve 
surgery improve survival when compared to revascularization alone in 
patients with ischemic mitral regurgitation? A meta-analysis on 2479 pa-
tients. J Cardiovasc Med (Hagerstown). 2009;10:109–14.
 30. Cohn LH, Rizzo RJ, Adams DH, et al. The effect of pathophysiology on the 
surgical treatment of ischemic mitral regurgitation: operative and late risks 
of repair versus replacement. Eur J Cardiothorac Surg. 1995;9:568–74.
 31. Chan KMJ, Punjabi PP , Flather M, et al. Coronary artery bypass surgery 
with or without mitral valve annuloplasty in moderate functional ischemic 
mitral regurgitation: final results of the Randomized Ischemic Mitral Evalu-
ation (RIME) trial. Circulation. 2012;126:2502–10.
 32. Acker MA, Parides MK, Perrault LP , et al. Mitral-valve repair versus re-
placement for severe ischemic mitral regurgitation. N Engl J Med. 
2014;370:23–32.
 33. Sugimoto T, Okada M, Ozaki N, et al. Long-term evaluation of treatment 
for functional tricuspid regurgitation with regurgitant volume: character -
istic differences based on primary cardiac lesion. J Thorac Cardiovasc Surg. 
1999;117:463–71.
 34. Fukuda S, Gillinov AM, McCarthy PM, et al. Determinants of recurrent 
or residual functional tricuspid regurgitation after tricuspid annuloplasty. 
Circulation. 2006;114:I582–7.
 35. Ling LF, Obuchowski NA, Rodriguez L, et al. Accuracy and interobserver 
concordance of echocardiographic assessment of right ventricular size 
and systolic function: a quality control exercise. J Am Soc Echocardiogr. 
2012;25:709–13.
 36. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic 
assessment of the right heart in adults: a report from the American Society 
of Echocardiography. J Am Soc Echocardiogr. 2010;23:685–713.
 37. Beygui F, Furber A, Delépine S, et al. Routine breath-hold gradient echo 
MRI-derived right ventricular mass, volumes and function: accuracy, repro-
ducibility and coherence study. Int J Cardiovasc Imaging. 2004;20:509–
16.
 38. Caudron J, Fares J, Vivier P-H, et al. Diagnostic accuracy and variability 
of three semi-quantitative methods for assessing right ventricular systolic 
function from cardiac MRI in patients with acquired heart disease. Eur 
Radiol. 2011;21:2111–20.
 39. Maceira AM, Prasad SK, Khan M, et al. Reference right ventricular systolic 
and diastolic function normalized to age, gender and body surface area 
from steady-state free precession cardiovascular magnetic resonance. Eur 
Heart J. 2006;27:2879–88.
 40. Navia JL, Brozzi NA, Klein AL, et al. Moderate tricuspid regurgitation with 
left-sided degenerative heart valve disease: to repair or not to repair? Ann 
Thorac Surg. 2012;93:59–67.
 41. Nesser HJ, Tkalec W, Patel AR, et al. Quantitation of right ventricular 
volumes and ejection fraction by three-dimensional echocardiography in 
patients: comparison with magnetic resonance imaging and radionuclide 
ventriculography. Echocardiography. 2006;23:666–80.
 42. Pavlicek M, Wahl A, Rutz T, et al. Right ventricular systolic function assess-
ment: rank of echocardiographic methods vs. cardiac magnetic resonance 
imaging. Eur J Echocardiogr. 2011;12:871–80.
 43. Speiser U, Hirschberger M, Pilz G, et al. Tricuspid annular plane systolic 
excursion assessed using MRI for semi-quantification of right ventricular 
ejection fraction. Br J Radiol. 2012;85:e716–21.
 44. Magne J, Girerd N, Sénéchal M, et al. Mitral repair versus replacement for 
ischemic mitral regurgitation: comparison of short-term and long-term 
survival. Circulation. 2009;120:S104-11.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e205
CLINICAL STATEMENTS  
AND GUIDELINES 45. Lorusso R, Gelsomino S, Vizzardi E, et al. Mitral valve repair or replace-
ment for ischemic mitral regurgitation? The Italian Study on the Treat-
ment of Ischemic Mitral Regurgitation (ISTIMIR). J Thorac Cardiovasc Surg. 
2013;145:128–39.
 46. McGee EC, Gillinov AM, Blackstone EH, et al. Recurrent mitral regurgi-
tation after annuloplasty for functional ischemic mitral regurgitation. J 
Thorac Cardiovasc Surg. 2004;128:916–24.
 47. Miller DC. Ischemic mitral regurgitation redux–to repair or to replace? J 
Thorac Cardiovasc Surg. 2001;122:1059–62.
 48. Grayburn PA, Foster E, Sangli C, et al. Relationship between the mag-
nitude of reduction in mitral regurgitation severity and left ventricular 
and left atrial reverse remodeling after MitraClip therapy. Circulation. 
2013;128:1667–74.
 49. Pibarot P , Delgado V, Bax JJ. MITRA-FR vs. COAPT: lessons from two tri-
als with diametrically opposed results. Eur Heart J Cardiovasc Imaging. 
2019;20:620–4.
 50. Braun J, Bax JJ, Versteegh MI, et al. Preoperative left ventricular dimensions 
predict reverse remodeling following restrictive mitral annuloplasty in isch-
emic mitral regurgitation. Eur J Cardiothorac Surg. 2005;27:847–53.
 51. Kim D-H, Heo R, Handschumacher MD, et al. Mitral valve adaptation to 
isolated annular dilation: insights into the mechanism of atrial functional 
mitral regurgitation. JACC Cardiovasc Imaging. 2019;12:665–77.
 52. Deferm S, Bertrand PB, Verbrugge FH, et al. Atrial functional mitral regurgita-
tion: JACC review topic of the week. J Am Coll Cardiol. 2019;73:2465–76.
 53. Gertz ZM, Raina A, Saghy L, et al. Evidence of atrial functional mitral re-
gurgitation due to atrial fibrillation: reversal with arrhythmia control. J Am 
Coll Cardiol. 2011;58:1474–81.
8. TRICUSPID VALVE DISEASE
8.1. Classification and Stages of TR
 1. Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-
term survival. J Am Coll Cardiol. 2004;43:405–9.
 2. Topilsky Y, Nkomo VT, Vatury O, et al. Clinical outcome of isolated tricus-
pid regurgitation. JACC Cardiovasc Imaging. 2014;7:1185–94.
 3. Lee J-W, Song J-M, Park JP , et al. Long-term prognosis of isolated signifi-
cant tricuspid regurgitation. Circ J. 2010;74:375–80.
 4. Bar N, Schwartz LA, Biner S, et al. Clinical outcome of isolated tricuspid 
regurgitation in patients with preserved left ventricular ejection fraction 
and pulmonary hypertension. J Am Soc Echocardiogr. 2018;31:34–41.
 5. Benfari G, Antoine C, Miller WL, et al. Excess mortality associated with 
functional tricuspid regurgitation complicating heart failure with reduced 
ejection fraction. Circulation. 2019;140:196–206.
 6. Wang N, Fulcher J, Abeysuriya N, et al. Tricuspid regurgitation is associ-
ated with increased mortality independent of pulmonary pressures and 
right heart failure: a systematic review and meta-analysis. Eur Heart J. 
2019;40:476–84.
 7. Chorin E, Rozenbaum Z, Topilsky Y, et al. Tricuspid regurgitation and long-
term clinical outcomes. Eur Heart J Cardiovasc Imaging. 2020;21:157–65.
 8. Lin G, Nishimura RA, Connolly HM, et al. Severe symptomatic tricuspid 
valve regurgitation due to permanent pacemaker or implantable cardio-
verter-defibrillator leads. J Am Coll Cardiol. 2005;45:1672–5.
 9. Chang JD, Manning WJ, Ebrille E, et al. Tricuspid valve dysfunction fol-
lowing pacemaker or cardioverter-defibrillator implantation. J Am Coll 
Cardiol. 2017;69:2331–41.
 10. Paniagua D, Aldrich HR, Lieberman EH, et al. Increased prevalence of sig-
nificant tricuspid regurgitation in patients with transvenous pacemakers 
leads. Am J Cardiol. 1998;82:1130–2, A9.
 11. Park SJ, Gentry JL 3rd, Varma N, et al. Transvenous extraction of pace-
maker and defibrillator leads and the risk of tricuspid valve regurgitation. 
JACC Clin Electrophysiol. 2018;4:1421–8.
 12. Mediratta A, Addetia K, Yamat M, et al. 3D Echocardiographic location of 
implantable device leads and mechanism of associated tricuspid regurgi-
tation. JACC Cardiovasc Imaging. 2014;7:337–47.
 13. Addetia K, Harb SC, Hahn RT, et al. Cardiac implantable electronic de-
vice lead-induced tricuspid regurgitation. JACC Cardiovasc Imaging. 
2019;12:622–36.
 14. Topilsky Y, Khanna A, Le Tourneau T, et al. Clinical context and mechanism 
of functional tricuspid regurgitation in patients with and without pulmo-
nary hypertension. Circ Cardiovasc Imaging. 2012;5:314–23.
 15. Mutlak D, Lessick J, Reisner SA, et al. Echocardiography-based spectrum 
of severe tricuspid regurgitation: the frequency of apparently idiopathic 
tricuspid regurgitation. J Am Soc Echocardiogr. 2007;20:405–8. 16. Zhao SX, Soltanzad N, Swaminathan A, et al. Frequency and associat-
ed clinical features of functional tricuspid regurgitation in patients with 
chronic atrial fibrillation. Am J Cardiol. 2017;119:1371–7.
 17. Utsunomiya H, Itabashi Y, Mihara H, et al. Functional tricuspid regur -
gitation caused by chronic atrial fibrillation: a real-time 3-dimensional 
transesophageal echocardiography study. Circ Cardiovasc Imaging. 
2017;10:e004897.
 18. Yamasaki N, Kondo F, Kubo T, et al. Severe tricuspid regurgitation in the 
aged: atrial remodeling associated with long-standing atrial fibrillation. J 
Cardiol. 2006;48:315–23.
 19. Maeder MT, Holst DP , Kaye DM. Tricuspid regurgitation contributes to re-
nal dysfunction in patients with heart failure. J Card Fail. 2008;14:824–30.
 20. Lau GT, Tan HC, Kritharides L. Type of liver dysfunction in heart failure 
and its relation to the severity of tricuspid regurgitation. Am J Cardiol. 
2002;90:1405–9.
 21. Mangoni AA, DiSalvo TG, Vlahakes GJ, et al. Outcome following isolated 
tricuspid valve replacement. Eur J Cardiothorac Surg. 2001;19:68–73.
 22. Kim JB, Jung S-H, Choo SJ, et al. Surgical outcomes of severe tricuspid re-
gurgitation: predictors of adverse clinical outcomes. Heart. 2013;99:181–7.
 23. Ailawadi G, Lapar DJ, Swenson BR, et al. Model for end-stage liver dis-
ease predicts mortality for tricuspid valve surgery. Ann Thorac Surg. 
2009;87:1460–7.
8.2. Tricuspid Regurgitation
8.2.1. Diagnosis of TR
 1. Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninva-
sive evaluation of native valvular regurgitation: a report from the Ameri-
can Society of Echocardiography. Developed in collaboration with the 
Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 
2017;30:303–71.
 2. Lancellotti P , Moura L, Pierard LA, et al. European Association of Echocar -
diography recommendations for the assessment of valvular regurgitation. 
Part 2: mitral and tricuspid regurgitation (native valve disease). Eur J Echo-
cardiogr. 2010;11:307–32.
 3. Nishimura RA, Carabello BA. Hemodynamics in the cardiac catheterization 
laboratory of the 21st century. Circulation. 2012;125:2138–50.
 4. Hahn RT. Finding concordance in discord: the value of discordant invasive 
and echocardiographic pulmonary artery pressure measurements with se-
vere tricuspid regurgitation. Eur Heart J. 2020;41:2796–8.
 5. Lurz P , Orban M, Besler C, et al. Clinical characteristics, diagnosis, and 
risk stratification of pulmonary hypertension in severe tricuspid regurgita-
tion and implications for transcatheter tricuspid valve repair. Eur Heart J. 
2020;41:2785–95.
 6. Hahn RT, Thomas JD, Khalique OK, et al. Imaging assessment of tricuspid 
regurgitation severity. JACC Cardiovasc Imaging. 2019;12:469–90.
 7. Dahou A, Ong G, Hamid N, et al. Quantifying tricuspid regurgitation se-
verity: a comparison of proximal isovelocity surface area and novel quan-
titative Doppler methods. JACC Cardiovasc Imaging. 2019;12:560–2.
 8. Hahn RT, Zamorano JL. The need for a new tricuspid regurgitation grading 
scheme. Eur Heart J Cardiovasc Imaging. 2017;18:1342–3.
 9. Peri Y, Sadeh B, Sherez C, et al. Quantitative assessment of effective re-
gurgitant orifice: impact on risk stratification, and cut-off for severe and 
torrential tricuspid regurgitation grade. Eur Heart J Cardiovasc Imaging. 
2019;21:768–76.
 10. Utsunomiya H, Harada Y, Susawa H, et al. Comprehensive evaluation of 
tricuspid regurgitation location and severity using vena contracta analysis: 
a color Doppler three-dimensional transesophageal echocardiographic 
study. J Am Soc Echocardiogr. 2019;32:1526–37.e2.
 11. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for eval-
uation of the severity of native valvular regurgitation with two-dimensional 
and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16:777–802.
 12. Chopra HK, Nanda NC, Fan P , et al. Can two-dimensional echocardiogra-
phy and Doppler color flow mapping identify the need for tricuspid valve 
repair? J Am Coll Cardiol. 1989;14:1266–74.
 13. Dreyfus GD, Corbi PJ, Chan KMJ, et al. Secondary tricuspid regurgitation 
or dilatation: which should be the criteria for surgical repair? Ann Thorac 
Surg. 2005;79:127–32.
 14. Lancellotti P , Tribouilloy C, Hagendorff A, et al. European Association of 
Echocardiography recommendations for the assessment of valvular regur -
gitation. Part 1: aortic and pulmonary regurgitation (native valve disease). 
Eur J Echocardiogr. 2010;11:223–44.
 15. Sugimoto T, Okada M, Ozaki N, et al. Long-term evaluation of treat-
ment for functional tricuspid regurgitation with regurgitant volume: 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e206
CLINICAL STATEMENTS  
AND GUIDELINEScharacteristic differences based on primary cardiac lesion. J Thorac Car -
diovasc Surg. 1999;117:463–71.
 16. Ling LF, Obuchowski NA, Rodriguez L, et al. Accuracy and interobserver 
concordance of echocardiographic assessment of right ventricular size 
and systolic function: a quality control exercise. J Am Soc Echocardiogr. 
2012;25:709–13.
 17. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic 
assessment of the right heart in adults: a report from the American Society 
of Echocardiography. J Am Soc Echocardiogr. 2010;23:685–713.
8.2.2. Medical Therapy
 1. Antoniou T, Koletsis EN, Prokakis C, et al. Hemodynamic effects of com-
bination therapy with inhaled nitric oxide and iloprost in patients with 
pulmonary hypertension and right ventricular dysfunction after high-risk 
cardiac surgery. J Cardiothorac Vasc Anesth. 2013;27:459–66.
 2. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consen-
sus document on pulmonary hypertension a report of the American College 
of Cardiology Foundation Task Force on Expert Consensus Documents and 
the American Heart Association. Developed in collaboration with the Ameri-
can College of Chest Physicians; American Thoracic Society, Inc.; and the 
Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573–619.
 3. Wang J, Han J, Li Y, et al. Impact of surgical ablation of atrial fibrillation on 
the progression of tricuspid regurgitation and right-sided heart remodel-
ing after mitral-valve surgery: a propensity-score matching analysis. J Am 
Heart Assoc. 2016;5:e004213.
 4. Stulak JM, Schaff HV, Dearani JA, et al. Restoration of sinus rhythm by the 
Maze procedure halts progression of tricuspid regurgitation after mitral 
surgery. Ann Thorac Surg. 2008;86:40–4; discussion 44–5.
8.2.3. Timing of Intervention
 1. Staab ME, Nishimura RA, Dearani JA. Isolated tricuspid valve surgery for 
severe tricuspid regurgitation following prior left heart valve surgery: anal-
ysis of outcome in 34 patients. J Heart Valve Dis. 1999;8:567–74.
 2. Vassileva CM, Shabosky J, Boley T, et al. Tricuspid valve surgery: the past 
10 years from the Nationwide Inpatient Sample (NIS) database. J Thorac 
Cardiovasc Surg. 2012;143:1043–9.
 3. Dreyfus GD, Corbi PJ, Chan KMJ, et al. Secondary tricuspid regurgitation 
or dilatation: which should be the criteria for surgical repair? Ann Thorac 
Surg. 2005;79:127–32.
 4. Navia JL, Brozzi NA, Klein AL, et al. Moderate tricuspid regurgitation with 
left-sided degenerative heart valve disease: to repair or not to repair? Ann 
Thorac Surg. 2012;93:59–67.
 5. Benedetto U, Melina G, Angeloni E, et al. Prophylactic tricuspid annulo-
plasty in patients with dilated tricuspid annulus undergoing mitral valve 
surgery. J Thorac Cardiovasc Surg. 2012;143:632–8.
 6. Van de Veire NR, Braun J, Delgado V, et al. Tricuspid annuloplasty prevents 
right ventricular dilatation and progression of tricuspid regurgitation in 
patients with tricuspid annular dilatation undergoing mitral valve repair. J 
Thorac Cardiovasc Surg. 2011;141:1431–9.
 7. Calafiore AM, Gallina S, Iacò AL, et al. Mitral valve surgery for functional 
mitral regurgitation: should moderate-or-more tricuspid regurgitation be 
treated? A propensity score analysis. Ann Thorac Surg. 2009;87:698–703.
 8. Chan V, Burwash IG, Lam B-K, et al. Clinical and echocardiographic im-
pact of functional tricuspid regurgitation repair at the time of mitral valve 
replacement. Ann Thorac Surg. 2009;88:1209–15.
 9. Kim JB, Yoo DG, Kim GS, et al. Mild-to-moderate functional tricuspid re-
gurgitation in patients undergoing valve replacement for rheumatic mitral 
disease: the influence of tricuspid valve repair on clinical and echocardio-
graphic outcomes. Heart. 2012;98:24–30.
 10. Yilmaz O, Suri RM, Dearani JA, et al. Functional tricuspid regurgitation at 
the time of mitral valve repair for degenerative leaflet prolapse: the case 
for a selective approach. J Thorac Cardiovasc Surg. 2011;142:608–13.
 11. Hamandi M, Smith RL, Ryan WH, et al. Outcomes of isolated tricus-
pid valve surgery have improved in the modern era. Ann Thorac Surg. 
2019;108:11–5.
 12. Kim Y-J, Kwon D-A, Kim H-K, et al. Determinants of surgical outcome in pa-
tients with isolated tricuspid regurgitation. Circulation. 2009;120:1672–8.
 13. Messika-Zeitoun D, Thomson H, Bellamy M, et al. Medical and surgical 
outcome of tricuspid regurgitation caused by flail leaflets. J Thorac Car -
diovasc Surg. 2004;128:296–302.
 14. Møller JE, Pellikka PA, Bernheim AM, et al. Prognosis of carcinoid 
heart disease: analysis of 200 cases over two decades. Circulation. 
2005;112:3320–7. 15. Kadri AN, Menon V, Sammour YM, et al. Outcomes of patients with 
severe tricuspid regurgitation and congestive heart failure. Heart. 
2019;105:1813–7.
 16. Lee J-W, Song J-M, Park JP , et al. Long-term prognosis of isolated signifi-
cant tricuspid regurgitation. Circ J. 2010;74:375–80.
 17. Axtell AL, Bhambhani V, Moonsamy P , et al. Surgery does not improve 
survival in patients with isolated severe tricuspid regurgitation. J Am Coll 
Cardiol. 2019;74:715–25.
 18. Pfannmüller B, Misfeld M, Borger MA, et al. Isolated reoperative minimally 
invasive tricuspid valve operations. Ann Thorac Surg. 2012;94:2005–10.
 19. Kim JB, Jung S-H, Choo SJ, et al. Clinical and echocardiographic outcomes 
after surgery for severe isolated tricuspid regurgitation. J Thorac Cardio-
vasc Surg. 2013;146:278–84.
 20. Mangoni AA, DiSalvo TG, Vlahakes GJ, et al. Outcome following isolated 
tricuspid valve replacement. Eur J Cardiothorac Surg. 2001;19:68–73.
 21. Zack CJ, Fender EA, Chandrashekar P , et al. National trends and outcomes 
in isolated tricuspid valve surgery. J Am Coll Cardiol. 2017;70:2953–60.
 22. Topilsky Y, Khanna AD, Oh JK, et al. Preoperative factors associated 
with adverse outcome after tricuspid valve replacement. Circulation. 
2011;123:1929–39.
 23. Fender EA, Petrescu I, Ionescu F, et al. Prognostic importance and pre-
dictors of survival in isolated tricuspid regurgitation: a growing problem. 
Mayo Clin Proc. 2019;94:2032–9.
 24. Topilsky Y, Khanna A, Le Tourneau T, et al. Clinical context and mechanism 
of functional tricuspid regurgitation in patients with and without pulmo-
nary hypertension. Circ Cardiovasc Imaging. 2012;5:314–23.
 25. Mutlak D, Lessick J, Reisner SA, et al. Echocardiography-based spectrum 
of severe tricuspid regurgitation: the frequency of apparently idiopathic 
tricuspid regurgitation. J Am Soc Echocardiogr. 2007;20:405–8.
 26. Taramasso M, Hahn RT, Alessandrini H, et al. The international multicenter 
TriValve registry: which patients are undergoing transcatheter tricuspid re-
pair? JACC Cardiovasc Interv. 2017;10:1982–90.
 27. Asmarats L, Puri R, Latib A, et al. Transcatheter tricuspid valve interven-
tions: landscape, challenges, and future directions. J Am Coll Cardiol. 
2018;71:2935–56.
 28. Chikwe J, Anyanwu AC. Surgical strategies for functional tricuspid regur -
gitation. Semin Thorac Cardiovasc Surg. 2010;22:90–6.
 29. Kwon D-A, Park J-S, Chang H-J, et al. Prediction of outcome in patients 
undergoing surgery for severe tricuspid regurgitation following mitral 
valve surgery and role of tricuspid annular systolic velocity. Am J Cardiol. 
2006;98:659–61.
 30. Lee R, Li S, Rankin JS, et al. Fifteen-year outcome trends for valve surgery 
in North America. Ann Thorac Surg. 2011;91:677–84.
 31. Rogers JH, Bolling SF. The tricuspid valve: current perspective and evolving 
management of tricuspid regurgitation. Circulation. 2009;119:2718–25.
 32. Kwak J-J, Kim Y-J, Kim M-K, et al. Development of tricuspid regurgitation 
late after left-sided valve surgery: a single-center experience with long-
term echocardiographic examinations. Am Heart J. 2008;155:732–7.
 33. Chopra HK, Nanda NC, Fan P , et al. Can two-dimensional echocardiogra-
phy and Doppler color flow mapping identify the need for tricuspid valve 
repair? J Am Coll Cardiol. 1989;14:1266–74.
 34. Mahesh B, Wells F, Nashef S, et al. Role of concomitant tricuspid surgery 
in moderate functional tricuspid regurgitation in patients undergoing left 
heart valve surgery. Eur J Cardiothorac Surg. 2013;43:2–8.
 35. Shiran A, Sagie A. Tricuspid regurgitation in mitral valve disease incidence, 
prognostic implications, mechanism, and management. J Am Coll Cardiol. 
2009;53:401–8.
 36. Sagie A, Schwammenthal E, Padial LR, et al. Determinants of functional 
tricuspid regurgitation in incomplete tricuspid valve closure: Doppler color 
flow study of 109 patients. J Am Coll Cardiol. 1994;24:446–53.
 37. Lin G, Nishimura RA, Connolly HM, et al. Severe symptomatic tricuspid 
valve regurgitation due to permanent pacemaker or implantable cardio-
verter-defibrillator leads. J Am Coll Cardiol. 2005;45:1672–5.
 38. Alqahtani F, Berzingi CO, Aljohani S, et al. Contemporary trends in the use 
and outcomes of surgical treatment of tricuspid regurgitation. J Am Heart 
Assoc. 2017;6:e007597.
 39. Jeganathan R, Armstrong S, Al-Alao B, et al. The risk and outcomes of 
reoperative tricuspid valve surgery. Ann Thorac Surg. 2013;95:119–24.
9. PULMONIC VALVE DISEASE
 1. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for 
the management of adults with congenital heart disease: a report of the 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e207
CLINICAL STATEMENTS  
AND GUIDELINESAmerican College of Cardiology/American Heart Association Task Force 
on Clinical Practice Guidelines. Circulation. 2019;139:e698–800.
10. MIXED VALVE DISEASE
10.1. Diagnosis of Mixed VHD
 1. Unger P , Rosenhek R, Dedobbeleer C, et al. Management of multiple valve 
disease. Heart. 2011;97:272–7.
 2. Lee R, Li S, Rankin JS, et al. Fifteen-year outcome trends for valve surgery 
in North America. Ann Thorac Surg. 2011;91:677–84.
 3. Venneri L, Khattar RS, Senior R. Assessment of complex multi-valve dis-
ease and prosthetic valves. Heart Lung Circ. 2019;28:1436–46.
 4. Iung B, Delgado V, Rosenhek R, et al. Contemporary presentation and 
management of valvular heart disease: the EURObservational Research Pro-
gramme Valvular Heart Disease II Survey. Circulation. 2019;140:1156–69.
 5. Unger P , Clavel MA, Lindman BR, et al. Pathophysiology and management 
of multivalvular disease. Nat Rev Cardiol. 2016;13:429–40.
10.2. Timing of Intervention for Mixed 
VHD
10.2.1. Intervention for Mixed AS and AR
 1. Zilberszac R, Gabriel H, Schemper M, et al. Outcome of combined stenotic 
and regurgitant aortic valve disease. J Am Coll Cardiol. 2013;61:1489–95.
 2. Egbe AC, Luis SA, Padang R, et al. Outcomes in moderate mixed aor -
tic valve disease: is it time for a paradigm shift? J Am Coll Cardiol. 
2016;67:2321–9.
10.2.2. Intervention for Mixed AS and MR
 1. Gillinov AM, Blackstone EH, Cosgrove DM 3rd, et al. Mitral valve repair 
with aortic valve replacement is superior to double valve replacement. J 
Thorac Cardiovasc Surg. 2003;125:1372–87.
 2. Nombela-Franco L, Ribeiro HB, Urena M, et al. Significant mitral regurgita-
tion left untreated at the time of aortic valve replacement: a comprehen-
sive review of a frequent entity in the transcatheter aortic valve replace-
ment era. J Am Coll Cardiol. 2014;63:2643–58.
 3. Kiramijyan S, Koifman E, Asch FM, et al. Impact of functional versus or -
ganic baseline mitral regurgitation on short- and long-term outcomes af-
ter transcatheter aortic valve replacement. Am J Cardiol. 2016;117:839–
46.
 4. Chakravarty T, Van Belle E, Jilaihawi H, et al. Meta-analysis of the impact 
of mitral regurgitation on outcomes after transcatheter aortic valve im-
plantation. Am J Cardiol. 2015;115:942–9.
 5. Cortés C, Amat-Santos IJ, Nombela-Franco L, et al. Mitral regurgitation af-
ter transcatheter aortic valve replacement: prognosis, imaging predictors, 
and potential management. JACC Cardiovasc Interv. 2016;9:1603–14.
 6. Feldman T, Kar S, Elmariah S, et al. Randomized comparison of percutane-
ous repair and surgery for mitral regurgitation: 5-year results of EVEREST 
II. J Am Coll Cardiol. 2015;66:2844–54.
 7. Jeong DS, Park PW, Sung K, et al. Long-term clinical impact of functional 
mitral regurgitation after aortic valve replacement. Ann Thorac Surg. 
2011;92:1339–45.
 8. Ruel M, Kapila V, Price J, et al. Natural history and predictors of outcome 
in patients with concomitant functional mitral regurgitation at the time of 
aortic valve replacement. Circulation. 2006;114:I541–6.
 9. Barbanti M, Webb JG, Hahn RT, et al. Impact of preoperative moder -
ate/severe mitral regurgitation on 2-year outcome after transcath-
eter and surgical aortic valve replacement: insight from the Placement 
of Aortic Transcatheter Valve (PARTNER) Trial Cohort A. Circulation. 
2013;128:2776–84.
 10. Abdelghani M, Abdel-Wahab M, Hemetsberger R, et al. Fate and long-
term prognostic implications of mitral regurgitation in patients undergo-
ing transcatheter aortic valve replacement. Int J Cardiol. 2019;288:39–43.
10.2.4. Intervention for Mixed MS and AR
 1. Gash AK, Carabello BA, Kent RL, et al. Left ventricular performance in 
patients with coexistent mitral stenosis and aortic insufficiency. J Am Coll 
Cardiol. 1984;3:703–11.
 2. Unger P , Pibarot P , Tribouilloy C, et al. Multiple and mixed valvular heart 
diseases. Circ Cardiovasc Imaging. 2018;11:e007862. 3. Gillinov AM, Blackstone EH, Cosgrove DM 3rd, et al. Mitral valve repair 
with aortic valve replacement is superior to double valve replacement. J 
Thorac Cardiovasc Surg. 2003;125:1372–87.
11. PROSTHETIC VALVES
11.1. Evaluation and Selection of 
Prosthetic Valves
11.1.1. Diagnosis and Follow-Up of Prosthetic 
Valves
 1. Burstow DJ, Nishimura RA, Bailey KR, et al. Continuous wave Doppler 
echocardiographic measurement of prosthetic valve gradients. A simulta-
neous Doppler-catheter correlative study. Circulation. 1989;80:504–14.
 2. Baumgartner H, Khan S, DeRobertis M, et al. Effect of prosthetic aortic 
valve design on the Doppler-catheter gradient correlation: an in vitro study 
of normal St. Jude, Medtronic-Hall, Starr-Edwards and Hancock valves. J 
Am Coll Cardiol. 1992;19:324–32.
 3. Vandervoort PM, Greenberg NL, Powell KA, et al. Pressure recovery in 
bileaflet heart valve prostheses. Localized high velocities and gradients in 
central and side orifices with implications for Doppler-catheter gradient 
relation in aortic and mitral position. Circulation. 1995;92:3464–72.
 4. Dumesnil JG, Honos GN, Lemieux M, et al. Validation and applications of 
indexed aortic prosthetic valve areas calculated by Doppler echocardiog-
raphy. J Am Coll Cardiol. 1990;16:637–43.
 5. Van den Brink RBA. Evaluation of prosthetic heart valves by transesopha-
geal echocardiography: problems, pitfalls, and timing of echocardiogra-
phy. Semin Cardiothorac Vasc Anesth. 2006;10:89–100.
 6. Vitarelli A, Conde Y, Cimino E, et al. Assessment of severity of mechani-
cal prosthetic mitral regurgitation by transoesophageal echocardiography. 
Heart. 2004;90:539–44.
 7. Kronzon I, Sugeng L, Perk G, et al. Real-time 3-dimensional trans-
esophageal echocardiography in the evaluation of post-operative mitral 
annuloplasty ring and prosthetic valve dehiscence. J Am Coll Cardiol. 
2009;53:1543–7.
 8. Kim JY, Suh YJ, Han K, et al. Diagnostic value of advanced imaging mo-
dalities for the detection and differentiation of prosthetic valve obstruc-
tion: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 
2019;12:2182–92.
 9. Salaun E, Mahjoub H, Girerd N, et al. Rate, timing, correlates, and out-
comes of hemodynamic valve deterioration after bioprosthetic surgical 
aortic valve replacement. Circulation. 2018;138:971–85.
 10. Rahimtoola SH. Choice of prosthetic heart valve in adults an update. J Am 
Coll Cardiol. 2010;55:2413–26.
 11. van Geldorp MWA, Eric Jamieson WR, Kappetein AP , et al. Patient out-
come after aortic valve replacement with a mechanical or biological pros-
thesis: weighing lifetime anticoagulant-related event risk against reopera-
tion risk. J Thorac Cardiovasc Surg. 2009;137:881–6, 866.e1–5.
 12. Salaun E, Mahjoub H, Dahou A, et al. Hemodynamic deterioration 
of surgically implanted bioprosthetic aortic valves. J Am Coll Cardiol. 
2018;72:241–51.
 13. Dvir D, Bourguignon T, Otto CM, et al. Standardized definition of struc-
tural valve degeneration for surgical and transcatheter bioprosthetic aortic 
valves. Circulation. 2018;137:388–99.
 14. Douglas PS, Leon MB, Mack MJ, et al. Longitudinal hemodynamics of 
transcatheter and surgical aortic valves in the PARTNER trial. JAMA Car -
diol. 2017;2:1197–206.
 15. Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aor -
tic valve replacement or surgical aortic valve replacement for high surgical 
risk patients with aortic stenosis (PARTNER 1): a randomised controlled 
trial. Lancet. 2015;385:2477–84.
 16. Kapadia SR, Leon MB, Makkar RR, et al. 5-Year outcomes of transcatheter 
aortic valve replacement compared with standard treatment for patients 
with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. 
Lancet. 2015;385:2485–91.
 17. Fernandez-Santos S, Théron A, Pibarot P , et al. Valve hemodynamic per -
formance and myocardial strain after implantation of a third-generation, 
balloon-expandable, transcatheter aortic valve. Cardiol J. 2019 May 20. 
Online ahead of print. doi:10.5603/CJ.a2019.0049
 18. Manoharan G, Van Mieghem NM, Windecker S, et al. 1-Year outcomes 
with the Evolut R self-expanding transcatheter aortic valve: from the inter -
national FORWARD study. JACC Cardiovasc Interv. 2018;11:2326–34.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e208
CLINICAL STATEMENTS  
AND GUIDELINES 19. Gleason TG, Reardon MJ, Popma JJ, et al. 5-Year outcomes of self-ex-
panding transcatheter versus surgical aortic valve replacement in high-risk 
patients. J Am Coll Cardiol. 2018;72:2687–96.
 20. Blackman DJ, Saraf S, MacCarthy PA, et al. Long-term durability of trans-
catheter aortic valve prostheses. J Am Coll Cardiol. 2019;73:537–45.
 21. Søndergaard L, Ihlemann N, Capodanno D, et al. Durability of transcath-
eter and surgical bioprosthetic aortic valves in patients at lower surgical 
risk. J Am Coll Cardiol. 2019;73:546–53.
11.2.1. Selection of Prosthetic Valve Type: 
Bioprosthetic Versus Mechanical Valve
 1. Goldstone AB, Chiu P , Baiocchi M, et al. Mechanical or biologic pros-
theses for aortic-valve and mitral-valve replacement. N Engl J Med. 
2017;377:1847–57.
 2. Badhwar V, Ofenloch JC, Rovin JD, et al. Noninferiority of closely moni-
tored mechanical valves to bioprostheses overshadowed by early mortality 
benefit in younger patients. Ann Thorac Surg. 2012;93:748–53.
 3. Brown ML, Schaff HV, Lahr BD, et al. Aortic valve replacement in patients 
aged 50 to 70 years: improved outcome with mechanical versus biologic 
prostheses. J Thorac Cardiovasc Surg. 2008;135:878–84.
 4. van Geldorp MWA, Eric Jamieson WR, Kappetein AP , et al. Patient out-
come after aortic valve replacement with a mechanical or biological pros-
thesis: weighing lifetime anticoagulant-related event risk against reopera-
tion risk. J Thorac Cardiovasc Surg. 2009;137:881–6, 866.e1–5.
 5. Kulik A, Bédard P , Lam B-K, et al. Mechanical versus bioprosthetic 
valve replacement in middle-aged patients. Eur J Cardiothorac Surg. 
2006;30:485–91.
 6. Glaser N, Jackson V, Holzmann MJ, et al. Aortic valve replacement with 
mechanical vs. biological prostheses in patients aged 50–69 years. Eur 
Heart J. 2016;37:2658–67.
 7. Chikwe J, Chiang YP , Egorova NN, et al. Survival and outcomes following 
bioprosthetic vs mechanical mitral valve replacement in patients aged 50 
to 69 years. JAMA. 2015;313:1435–42.
 8. McClure RS, McGurk S, Cevasco M, et al. Late outcomes comparison of 
nonelderly patients with stented bioprosthetic and mechanical valves in 
the aortic position: a propensity-matched analysis. J Thorac Cardiovasc 
Surg. 2014;148:1931–9.
 9. Chiang YP , Chikwe J, Moskowitz AJ, et al. Survival and long-term out-
comes following bioprosthetic vs mechanical aortic valve replacement in 
patients aged 50 to 69 years. JAMA. 2014;312:1323–9.
 10. Kaneko T, Aranki S, Javed Q, et al. Mechanical versus bioprosthetic mitral 
valve replacement in patients <65 years old. J Thorac Cardiovasc Surg. 
2014;147:117–26.
 11. Bourguignon T, Bouquiaux-Stablo A-L, Loardi C, et al. Very late outcomes 
for mitral valve replacement with the Carpentier-Edwards pericardial bio-
prosthesis: 25-year follow-up of 450 implantations. J Thorac Cardiovasc 
Surg. 2014;148:2004–11.e1.
 12. Buratto E, Shi WY, Wynne R, et al. Improved survival after the Ross pro-
cedure compared with mechanical aortic valve replacement. J Am Coll 
Cardiol. 2018;71:1337–44.
 13. El-Hamamsy I, Eryigit Z, Stevens L-M, et al. Long-term outcomes after 
autograft versus homograft aortic root replacement in adults with aortic 
valve disease: a randomised controlled trial. Lancet. 2010;376:524–31.
 14. Martin E, Mohammadi S, Jacques F, et al. Clinical outcomes following the 
Ross procedure in adults: a 25-year longitudinal study. J Am Coll Cardiol. 
2017;70:1890–9.
 15. Bourguignon T, El Khoury R, Candolfi P , et al. Very long-term outcomes 
of the Carpentier-Edwards PERIMOUNT aortic valve in patients aged 60 or 
younger. Ann Thorac Surg. 2015;100:853–9.
 16. Tuzcu EM, Kapadia SR, Vemulapalli S, et al. Transcatheter aortic valve re-
placement of failed surgically implanted bioprostheses: the STS/ACC reg-
istry. J Am Coll Cardiol. 2018;72:370–82.
 17. Ye J, Cheung A, Yamashita M, et al. Transcatheter aortic and mitral valve-
in-valve implantation for failed surgical bioprosthetic valves: an 8-year 
single-center experience. JACC Cardiovasc Interv. 2015;8:1735–44.
 18. Dvir D, Webb JG, Bleiziffer S, et al. Transcatheter aortic valve implantation 
in failed bioprosthetic surgical valves. JAMA. 2014;312:162–70.
 19. Dvir D, Webb J, Brecker S, et al. Transcatheter aortic valve replacement for 
degenerative bioprosthetic surgical valves: results from the global valve-in-
valve registry. Circulation. 2012;126:2335–44.
 20. Coylewright M, Forrest JK, McCabe JM, et al. TAVR in low-risk patients: 
FDA approval, the new NCD, and shared decision-making. J Am Coll Car -
diol. 2020;75:1208–11. 21. Hess EP , Coylewright M, Frosch DL, et al. Implementation of shared deci-
sion making in cardiovascular care: past, present, and future. Circ Cardio-
vasc Qual Outcomes. 2014;7:797–803.
 22. Weber A, Noureddine H, Englberger L, et al. Ten-year comparison of peri-
cardial tissue valves versus mechanical prostheses for aortic valve replace-
ment in patients younger than 60 years of age. J Thorac Cardiovasc Surg. 
2012;144:1075–83.
 23. Hammermeister K, Sethi GK, Henderson WG, et al. Outcomes 15 years 
after valve replacement with a mechanical versus a bioprosthetic valve: 
final report of the Veterans Affairs randomized trial. J Am Coll Cardiol. 
2000;36:1152–8.
 24. Chan V, Jamieson WRE, Germann E, et al. Performance of bioprostheses 
and mechanical prostheses assessed by composites of valve-related com-
plications to 15 years after aortic valve replacement. J Thorac Cardiovasc 
Surg. 2006;131:1267–73.
 25. Dunning J, Gao H, Chambers J, et al. Aortic valve surgery: marked in-
creases in volume and significant decreases in mechanical valve use—an 
analysis of 41,227 patients over 5 years from the Society for Cardiotho-
racic Surgery in Great Britain and Ireland National database. J Thorac Car -
diovasc Surg. 2011;142:776–82.e3.
 26. Stassano P , L. DT, Monaco M, et al. Aortic valve replacement: a prospective 
randomized evaluation of mechanical versus biological valves in patients 
ages 55 to 70 years. J Am Coll Cardiol. 2009;54:1862–8.
 27. Brennan JM, Edwards FH, Zhao Y, et al. Long-term safety and effective-
ness of mechanical versus biologic aortic valve prostheses in older pa-
tients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery 
National Database. Circulation. 2013;127:1647–55.
 28. Banbury MK, Cosgrove DM 3rd, Thomas JD, et al. Hemodynamic stability 
during 17 years of the Carpentier-Edwards aortic pericardial bioprosthesis. 
Ann Thorac Surg. 2002;73:1460–5.
 29. Dellgren G, David TE, Raanani E, et al. Late hemodynamic and clinical out-
comes of aortic valve replacement with the Carpentier-Edwards Perimount 
pericardial bioprosthesis. J Thorac Cardiovasc Surg. 2002;124:146–54.
 30. Borger MA, Ivanov J, Armstrong S, et al. Twenty-year results of the Han-
cock II bioprosthesis. J Heart Valve Dis. 2006;15:49–55.
 31. Mykén PSU, Bech-Hansen O. A 20-year experience of 1712 patients with the 
Biocor porcine bioprosthesis. J Thorac Cardiovasc Surg. 2009;137:76–81.
 32. Mazine A, El-Hamamsy I, Verma S, et al. Ross procedure in adults for car -
diologists and cardiac surgeons: JACC state-of-the-art review. J Am Coll 
Cardiol. 2018;72:2761–77.
11.2. Antithrombotic Therapy
 1. Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding 
complications in patients with mechanical heart valve prostheses. Circula-
tion. 1994;89:635–41.
 2. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral antico-
agulant therapy in patients with mechanical heart valves. N Engl J Med. 
1995;333:11–7.
 3. Sun JCJ, Davidson MJ, Lamy A, et al. Antithrombotic management of pa-
tients with prosthetic heart valves: current evidence and future trends. 
Lancet. 2009;374:565–76.
 4. Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison of dabig-
atran etexilate with warfarin in patients with mechanical heart valves: the 
Randomized, phase II study to Evaluate the sAfety and pharmacokinetics 
of oraL dabIGatran etexilate in patients after heart valve replacemeNt (RE-
ALIGN). Am Heart J. 2012;163:931–7.e1.
 5. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran ver -
sus warfarin in patients with mechanical heart valves. N Engl J Med. 
2013;369:1206–14.
 6. Torella M, Torella D, Chiodini P , et al. LOWERing the INtensity of oral 
anticoaGulant Therapy in patients with bileaflet mechanical aortic 
valve replacement: results from the “LOWERING-IT” Trial. Am Heart J. 
2010;160:171–8.
 7. Hering D, Piper C, Bergemann R, et al. Thromboembolic and bleeding 
complications following St. Jude Medical valve replacement: results of 
the German Experience With Low-Intensity Anticoagulation Study. Chest. 
2005;127:53–9.
 8. Acar J, Iung B, Boissel JP , et al. AREVA: multicenter randomized compari-
son of low-dose versus standard-dose anticoagulation in patients with 
mechanical prosthetic heart valves. Circulation. 1996;94:2107–12.
 9. Whitlock RP , Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic 
therapy for valvular disease: Antithrombotic Therapy and Prevention of 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e209
CLINICAL STATEMENTS  
AND GUIDELINESThrombosis, 9th ed: American College of Chest Physicians Evidence-Based 
Clinical Practice Guidelines. Chest. 2012;141:e576S–600S.
 10. Horstkotte D, Scharf RE, Schultheiss HP . Intracardiac thrombosis: patient-
related and device-related factors. J Heart Valve Dis. 1995;4:114–20.
 11. Pruefer D, Dahm M, Dohmen G, et al. Intensity of oral anticoagulation af-
ter implantation of St. Jude Medical mitral or multiple valve replacement: 
lessons learned from GELIA (GELIA 5). Eur Heart J Suppl. 2001;3:Q39–43.
 12. Rodés-Cabau J, Masson J-B, Welsh RC, et al. Aspirin versus aspirin plus 
clopidogrel as antithrombotic treatment following transcatheter aortic 
valve replacement with a balloon-expandable valve: the ARTE (Aspirin Ver -
sus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implanta-
tion) randomized clinical trial. JACC Cardiovasc Interv. 2017;10:1357–65.
 13. Zuo W, Yang M, He Y, et al. Single or dual antiplatelet therapy after trans-
catheter aortic valve replacement: an updated systemic review and meta-
analysis. J Thorac Dis. 2019;11:959–68.
 14. Maes F, Stabile E, Ussia GP , et al. Meta-analysis comparing single versus 
dual antiplatelet therapy following transcatheter aortic valve implanta-
tion. Am J Cardiol. 2018;122:310–5.
 15. Heras M, Chesebro JH, Fuster V, et al. High risk of thromboemboli 
early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol. 
1995;25:1111–9.
 16. Colli A, Mestres CA, Castella M, et al. Comparing warfarin to aspirin 
(WoA) after aortic valve replacement with the St. Jude Medical Epic heart 
valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis. 
2007;16:667–71.
 17. Aramendi JI, Mestres C-A, Martinez-León J, et al. Triflusal versus oral an-
ticoagulation for primary prevention of thromboembolism after biopros-
thetic valve replacement (TRAC): prospective, randomized, co-operative 
trial. Eur J Cardiothorac Surg. 2005;27:854–60.
 18. Nuñez L, Gil Aguado M, Larrea JL, et al. Prevention of thromboembolism 
using aspirin after mitral valve replacement with porcine bioprosthesis. 
Ann Thorac Surg. 1984;37:84–7.
 19. Tiede DJ, Nishimura RA, Gastineau DA, et al. Modern management of 
prosthetic valve anticoagulation. Mayo Clin Proc. 1998;73:665–80.
 20. Mérie C, Køber L, Skov Olsen P , et al. Association of warfarin ther -
apy duration after bioprosthetic aortic valve replacement with risk 
of mortality, thromboembolic complications, and bleeding. JAMA. 
2012;308:2118–25.
 21. Russo A, Grigioni F, Avierinos J-F, et al. Thromboembolic complications 
after surgical correction of mitral regurgitation incidence, predictors, and 
clinical implications. J Am Coll Cardiol. 2008;51:1203–11.
 22. Egbe AC, Pislaru SV, Pellikka PA, et al. Bioprosthetic valve thrombosis ver -
sus structural failure: clinical and echocardiographic predictors. J Am Coll 
Cardiol. 2015;66:2285–94.
 23. Chakravarty T, Patel A, Kapadia S, et al. Anticoagulation after surgical or 
transcatheter bioprosthetic aortic valve replacement. J Am Coll Cardiol. 
2019;74:1190–200.
 24. Sundt TM, Zehr KJ, Dearani JA, et al. Is early anticoagulation with warfarin 
necessary after bioprosthetic aortic valve replacement? J Thorac Cardio-
vasc Surg. 2005;129:1024–31.
 25. El Bardissi AW, DiBardino DJ, Chen FY, et al. Is early antithrombotic ther -
apy necessary in patients with bioprosthetic aortic valves in normal sinus 
rhythm? J Thorac Cardiovasc Surg. 2010;139:1137–45.
 26. Massel DR, Little SH. Antiplatelet and anticoagulation for patients with 
prosthetic heart valves. Cochrane Database Syst Rev. 2013;CD003464.
 27. Puskas J, Gerdisch M, Nichols D, et al. Reduced anticoagulation after 
mechanical aortic valve replacement: interim results from the prospec-
tive randomized on-X valve anticoagulation clinical trial randomized Food 
and Drug Administration investigational device exemption trial. J Thorac 
Cardiovasc Surg. 2014;147:1202–10.
 28. Puskas JD, Gerdisch M, Nichols D, et al. Anticoagulation and antiplatelet 
strategies after On-X mechanical aortic valve replacement. J Am Coll Car -
diol. 2018;71:2717–26.
 29. Ussia GP , Scarabelli M, Mulè M, et al. Dual antiplatelet therapy versus as-
pirin alone in patients undergoing transcatheter aortic valve implantation. 
Am J Cardiol. 2011;108:1772–6.
 30. Dangas GD, Tijssen JGP , Wohrle J, et al. A controlled trial of rivaroxaban af-
ter transcatheter aortic-valve replacement. N Engl J Med. 2020;382:120–9.
 31. Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet throm-
bosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015–24.
 32. Jose J, Sulimov DS, El-Mawardy M, et al. Clinical bioprosthetic heart 
valve thrombosis after transcatheter aortic valve replacement: inci-
dence, characteristics, and treatment outcomes. JACC Cardiovasc Interv. 
2017;10:686–97. 33. Jochheim D, Barbanti M, Capretti G, et al. Oral anticoagulant type and 
outcomes after transcatheter aortic valve replacement. JACC Cardiovasc 
Interv. 2019;12:1566–76.
 34. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in 
patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
 35. Giugliano RP , Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in 
patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.
 36. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in non-
valvular atrial fibrillation. N Engl J Med. 2011;365:883–91.
 37. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin 
in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.
 38. Edmunds LH Jr. Thrombotic and bleeding complications of prosthetic 
heart valves. Ann Thorac Surg. 1987;44:430–45.
 39. Capodanno D, Angiolillo DJ. Antiplatelet therapy after implantation of 
bioresorbable vascular scaffolds: a review of the published data, practi-
cal recommendations, and future directions. JACC Cardiovasc Interv. 
2017;10:425–37.
 40. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagu-
lation in patients with atrial fibrillation. N Engl J Med. 2015;373:823–33.
11.3. Bridging Therapy
 1. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative manage-
ment of antithrombotic therapy: Antithrombotic Therapy and Prevention 
of Thrombosis, 9th ed: American College of Chest Physicians Evidence-
Based Clinical Practice Guidelines. Chest. 2012;141:e326S–50S.
 2. Kearon C, Hirsh J. Management of anticoagulation before and after elec-
tive surgery. N Engl J Med. 1997;336:1506–11.
 3. Tinker JH, Tarhan S. Discontinuing anticoagulant therapy in surgical pa-
tients with cardiac valve prostheses. Observations in 180 operations. 
JAMA. 1978;239:738–9.
 4. Lankiewicz MW, Hays J, Friedman KD, et al. Urgent reversal of warfarin with 
prothrombin complex concentrate. J Thromb Haemost. 2006;4:967–70.
 5. Renda G, Ricci F, Giugliano RP , et al. Non-vitamin K antagonist oral antico-
agulants in patients with atrial fibrillation and valvular heart disease. J Am 
Coll Cardiol. 2017;69:1363–71.
 6. Hammerstingl C, Tripp C, Schmidt H, et al. Periprocedural bridging ther -
apy with low-molecular-weight heparin in chronically anticoagulated pa-
tients with prosthetic mechanical heart valves: experience in 116 patients 
from the prospective BRAVE registry. J Heart Valve Dis. 2007;16:285–92.
 7. Spyropoulos AC, Turpie AG, Dunn AS, et al. Perioperative bridging therapy 
with unfractionated heparin or low-molecular-weight heparin in patients 
with mechanical prosthetic heart valves on long-term oral anticoagulants 
(from the REGIMEN Registry). Am J Cardiol. 2008;102:883–9.
 8. Pengo V, Cucchini U, Denas G, et al. Standardized low-molecular-weight 
heparin bridging regimen in outpatients on oral anticoagulants undergo-
ing invasive procedure or surgery: an inception cohort management study. 
Circulation. 2009;119:2920–7.
 9. Daniels PR, McBane RD, Litin SC, et al. Peri-procedural anticoagulation 
management of mechanical prosthetic heart valve patients. Thromb Res. 
2009;124:300–5.
 10. Bui HT, Krisnaswami A, Le CU, et al. Comparison of safety of subcutane-
ous enoxaparin as outpatient anticoagulation bridging therapy in patients 
with a mechanical heart valve versus patients with nonvalvular atrial fibril-
lation. Am J Cardiol. 2009;104:1429–33.
 11. Biteker M, Tekkesin AI, Can MM, et al. Outcome of noncardiac and non-
vascular surgery in patients with mechanical heart valves. Am J Cardiol. 
2012;110:562–7.
 12. Weiss A, Brose S, Ploetze K, et al. Half-dose enoxaparin vs. full-dose 
enoxaparin for postoperative bridging therapy in patients after cardiac 
surgery: which dose regimen should be preferred? Clin Hemorheol Micro-
circ. 2013;54:249–58.
 13. Pengo V, Palareti G, Cucchini U, et al. Low-intensity oral anticoagulant 
plus low-dose aspirin during the first six months versus standard-intensity 
oral anticoagulant therapy after mechanical heart valve replacement: a 
pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LI-
WACAP). Clin Appl Thromb Hemost. 2007;13:241–8.
 14. Hjellstrom L, Labaf A. Prophylactic doses of low-molecular weight hepa-
rin as periprocedural bridging therapy in mechanical heart valve patients. 
Thromb Res. 2018;163:180–4.
 15. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridg-
ing anticoagulation in patients with atrial fibrillation. N Engl J Med. 
2015;373:823–33.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e210
CLINICAL STATEMENTS  
AND GUIDELINES11.4. Excessive Anticoagulation and 
Serious Bleeding With Prosthetic Valves
 1. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran 
reversal. N Engl J Med. 2015;373:511–20.
 2. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal 
of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413–24.
 3. Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute 
major bleeding associated with factor Xa inhibitors. N Engl J Med. 
2016;375:1131–41.
 4. Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andex-
anet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 
2019;380:1326–35.
 5. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran rever -
sal - full cohort analysis. N Engl J Med. 2017;377:431–41.
 6. Genewein U, Haeberli A, Straub PW, et al. Rebound after cessation of 
oral anticoagulant therapy: the biochemical evidence. Br J Haematol. 
1996;92:479–85.
 7. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC expert consensus 
decision pathway on management of bleeding in patients on oral antico-
agulants: a report of the American College of Cardiology Task Force on Ex-
pert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70:3042–67.
 8. Tazarourte K, Riou B, Tremey B, et al. Guideline-concordant administra-
tion of prothrombin complex concentrate and vitamin K is associated with 
decreased mortality in patients with severe bleeding under vitamin K an-
tagonist treatment (EPAHK study). Crit Care. 2014;18:R81.
 9. Tsu LV, Dienes JE, Dager WE. Vitamin K dosing to reverse warfarin based 
on INR, route of administration, and home warfarin dose in the acute/
critical care setting. Ann Pharmacother. 2012;46:1617–26.
 10. Pernod G, Godiér A, Gozalo C, et al. French clinical practice guidelines 
on the management of patients on vitamin K antagonists in at-risk situ-
ations (overdose, risk of bleeding, and active bleeding). Thromb Res. 
2010;126:e167–74.
 11. Weibert RT, Le DT, Kayser SR, et al. Correction of excessive anticoagulation 
with low-dose oral vitamin K1. Ann Intern Med. 1997;126:959–62.
 12. Yiu K-H, Siu C-W, Jim M-H, et al. Comparison of the efficacy and safety 
profiles of intravenous vitamin K and fresh frozen plasma as treatment of 
warfarin-related over-anticoagulation in patients with mechanical heart 
valves. Am J Cardiol. 2006;97:409–11.
 13. Khatib R, Ludwikowska M, Witt DM, et al. Vitamin K for reversal of exces-
sive vitamin K antagonist anticoagulation: a systematic review and meta-
analysis. Blood Adv. 2019;3:789–96.
11.5. Thromboembolic Events With 
Prosthetic Valves
 1. Dangas GD, Weitz JI, Giustino G, et al. Prosthetic heart valve thrombosis. 
J Am Coll Cardiol. 2016;68:2670–89.
 2. Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet throm-
bosis in surgical and transcatheter bioprosthetic aortic valves: an observa-
tional study. Lancet. 2017;389:2383–92.
 3. Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet throm-
bosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015–24.
 4. Sondergaard L, De Backer O, Kofoed KF, et al. Natural history of subclini-
cal leaflet thrombosis affecting motion in bioprosthetic aortic valves. Eur 
Heart J. 2017;38:2201–7.
11.6. Acute Mechanical Valve Thrombosis
11.6.1. Diagnosis of Acute Mechanical Valve 
Thrombosis
 1. Montorsi P , De Bernardi F, Muratori M, et al. Role of cine-fluoroscopy, 
transthoracic, and transesophageal echocardiography in patients with sus-
pected prosthetic heart valve thrombosis. Am J Cardiol. 2000;85:58–64.
 2. Muratori M, Montorsi P , Teruzzi G, et al. Feasibility and diagnostic ac-
curacy of quantitative assessment of mechanical prostheses leaflet mo-
tion by transthoracic and transesophageal echocardiography in suspected 
prosthetic valve dysfunction. Am J Cardiol. 2006;97:94–100.
 3. Cianciulli TE, Lax JA, Beck MA, et al. Cinefluoroscopic assessment of me-
chanical disc prostheses: its value as a complementary method to echocar -
diography. J Heart Valve Dis. 2005;14:664–73. 4. Symersky P , Budde RPJ, de Mol BAJM, et al. Comparison of multidetector-
row computed tomography to echocardiography and fluoroscopy for 
evaluation of patients with mechanical prosthetic valve obstruction. Am J 
Cardiol. 2009;104:1128–34.
 5. Bapat V, Attia R, Redwood S, et al. Use of transcatheter heart valves for 
a valve-in-valve implantation in patients with degenerated aortic biopros-
thesis: technical considerations and results. J Thorac Cardiovasc Surg. 
2012;144:1372–9.
 6. Gündüz S, Özkan M, Kalçik M, et al. Sixty-four-section cardiac computed 
tomography in mechanical prosthetic heart valve dysfunction: thrombus 
or pannus. Circ Cardiovasc Imaging. 2015;8:e003246.
 7. Suh YJ, Lee S, Im DJ, et al. Added value of cardiac computed tomog-
raphy for evaluation of mechanical aortic valve: emphasis on evaluation 
of pannus with surgical findings as standard reference. Int J Cardiol. 
2016;214:454–60.
 8. Dangas GD, Weitz JI, Giustino G, et al. Prosthetic heart valve thrombosis. 
J Am Coll Cardiol. 2016;68:2670–89.
 9. Barbetseas J, Nagueh SF, Pitsavos C, et al. Differentiating thrombus from 
pannus formation in obstructed mechanical prosthetic valves: an evalu-
ation of clinical, transthoracic and transesophageal echocardiographic 
parameters. J Am Coll Cardiol. 1998;32:1410–7.
 10. Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations for evalu-
ation of prosthetic valves with echocardiography and Doppler ultrasound: 
a report from the American Society of Echocardiography’s Guidelines and 
Standards Committee and the Task Force on Prosthetic Valves. Developed 
in conjunction with the American College of Cardiology Cardiovascular 
Imaging Committee, Cardiac Imaging Committee of the American Heart 
Association, the European Association of Echocardiography, a registered 
branch of the European Society of Cardiology, the Japanese Society of 
Echocardiography and the Canadian Society of Echocardiography. J Am 
Soc Echocardiogr. 2009;22:975–1014.
 11. Özkan M, Gündüz S, Biteker M, et al. Comparison of different TEE-guided 
thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial. 
JACC Cardiovasc Imaging. 2013;6:206–16.
 12. Suchá D, Symersky P , Tanis W, et al. Multimodality imaging assessment of 
prosthetic heart valves. Circ Cardiovasc Imaging. 2015;8:e003703.
11.6.2. Intervention
 1. Cáceres-Lóriga FM, Pérez-López H, Morlans-Hernández K, et al. Throm-
bolysis as first choice therapy in prosthetic heart valve thrombosis. A study 
of 68 patients. J Thromb Thrombolysis. 2006;21:185–90.
 2. Karthikeyan G, Senguttuvan NB, Joseph J, et al. Urgent surgery compared 
with fibrinolytic therapy for the treatment of left-sided prosthetic heart 
valve thrombosis: a systematic review and meta-analysis of observational 
studies. Eur Heart J. 2013;34:1557–66.
 3. Keuleers S, Herijgers P , Herregods M-C, et al. Comparison of thrombolysis 
versus surgery as a first line therapy for prosthetic heart valve thrombosis. 
Am J Cardiol. 2011;107:275–9.
 4. Nagy A, Dénes M, Lengyel M. Predictors of the outcome of thrombolytic 
therapy in prosthetic mitral valve thrombosis: a study of 62 events. J Heart 
Valve Dis. 2009;18:268–75.
 5. Özkan M, Çakal B, Karakoyun S, et al. Thrombolytic therapy for the 
treatment of prosthetic heart valve thrombosis in pregnancy with low-
dose, slow infusion of tissue-type plasminogen activator. Circulation. 
2013;128:532–40.
 6. Özkan M, Gündüz S, Biteker M, et al. Comparison of different TEE-guided 
thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial. 
JACC Cardiovasc Imaging. 2013;6:206–16.
 7. Roudaut R, Lafitte S, Roudaut M-F, et al. Management of prosthetic heart 
valve obstruction: fibrinolysis versus surgery. Early results and long-term 
follow-up in a single-centre study of 263 cases. Arch Cardiovasc Dis. 
2009;102:269–77.
 8. Tong AT, Roudaut R, Ozkan M, et al. Transesophageal echocardiogra-
phy improves risk assessment of thrombolysis of prosthetic valve throm-
bosis: results of the international PRO-TEE registry. J Am Coll Cardiol. 
2004;43:77–84.
 9. Bade AS, Shaikh SSA, Khemani H, et al. Thrombolysis is an effective and 
safe therapy in stuck mitral valves with delayed presentation as well as 
hemodynamically unstable patients: a single centre study. Cardiol Res. 
2018;9:161–4.
 10. Pragt H, van Melle JP , Javadikasgari H, et al. Mechanical valves in the pul-
monary position: an international retrospective analysis. J Thorac Cardio-
vasc Surg. 2017;154:1371–8.e1.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e211
CLINICAL STATEMENTS  
AND GUIDELINES 11. Taherkhani M, Hashemi SR, Hekmat M, et al. Thrombolytic therapy for 
right-sided mechanical pulmonic and tricuspid valves: the largest survival 
analysis to date. Tex Heart Inst J. 2015;42:543–7.
 12. Kumar BM, Gnanaraj JP , Swaminathan N, et al. Assessment of hemody-
namic and clinical response in thrombolytic therapy for prosthetic valve 
thrombosis. Indian Heart J. 2017;69:S6.
 13. Özkan M, Gündüz S, Gürsoy OM, et al. Ultraslow thrombolytic therapy: a 
novel strategy in the management of PROsthetic MEchanical valve Throm-
bosis and the prEdictors of outcomE: the Ultra-slow PROMETEE trial. Am 
Heart J. 2015;170:409–18.
 14. Roudaut R, Lafitte S, Roudaut M-F, et al. Fibrinolysis of mechanical pros-
thetic valve thrombosis: a single-center study of 127 cases. J Am Coll 
Cardiol. 2003;41:653–8.
11.7. Bioprosthetic Valve Thrombosis
11.7.1. Diagnosis of Bioprosthetic Valve 
Thrombosis
 1. Puri R, Auffret V, Rodés-Cabau J. Bioprosthetic valve thrombosis. J Am Coll 
Cardiol. 2017;69:2193–211.
 2. Puvimanasinghe JP , Steyerberg EW, Takkenberg JJ, et al. Prognosis after 
aortic valve replacement with a bioprosthesis: predictions based on meta-
analysis and microsimulation. Circulation. 2001;103:1535–41.
 3. Dangas GD, Weitz JI, Giustino G, et al. Prosthetic heart valve thrombosis. 
J Am Coll Cardiol. 2016;68:2670–89.
 4. Jose J, Sulimov DS, El-Mawardy M, et al. Clinical bioprosthetic heart 
valve thrombosis after transcatheter aortic valve replacement: inci-
dence, characteristics, and treatment outcomes. JACC Cardiovasc Interv. 
2017;10:686–97.
 5. Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet throm-
bosis in surgical and transcatheter bioprosthetic aortic valves: an observa-
tional study. Lancet. 2017;389:2383–92.
 6. Pislaru SV, Hussain I, Pellikka PA, et al. Misconceptions, diagnostic chal-
lenges and treatment opportunities in bioprosthetic valve thrombosis: les-
sons from a case series. Eur J Cardiothorac Surg. 2015;47:725–32.
11.7.2. Medical Therapy
 1. Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet throm-
bosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015–24.
 2. Jander N, Kienzle R-P , Kayser G, et al. Usefulness of phenprocoumon for 
the treatment of obstructing thrombus in bioprostheses in the aortic valve 
position. Am J Cardiol. 2012;109:257–62.
 3. Butnaru A, Shaheen J, Tzivoni D, et al. Diagnosis and treatment of early 
bioprosthetic malfunction in the mitral valve position due to thrombus 
formation. Am J Cardiol. 2013;112:1439–44.
 4. Pislaru SV, Hussain I, Pellikka PA, et al. Misconceptions, diagnostic chal-
lenges and treatment opportunities in bioprosthetic valve thrombosis: les-
sons from a case series. Eur J Cardiothorac Surg. 2015;47:725–32.
 5. De Marchena E., Mesa J, Pomenti S, et al. Thrombus formation fol-
lowing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 
2015;8:728–39.
 6. Jose J, Sulimov DS, El-Mawardy M, et al. Clinical bioprosthetic heart 
valve thrombosis after transcatheter aortic valve replacement: inci-
dence, characteristics, and treatment outcomes. JACC Cardiovasc Interv. 
2017;10:686–97.
 7. Latib A, Naganuma T, Abdel-Wahab M, et al. Treatment and clinical out-
comes of transcatheter heart valve thrombosis. Circ Cardiovasc Interv. 
2015;8:e001779.
 8. Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet throm-
bosis in surgical and transcatheter bioprosthetic aortic valves: an observa-
tional study. Lancet. 2017;389:2383–92.
11.8. Prosthetic Valve Stenosis
11.8.1. Diagnosis of Prosthetic Valve Stenosis
 1. Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations for evalu-
ation of prosthetic valves with echocardiography and Doppler ultrasound: 
a report from the American Society of Echocardiography’s Guidelines and 
Standards Committee and the Task Force on Prosthetic Valves. Developed 
in conjunction with the American College of Cardiology Cardiovascular 
Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered 
branch of the European Society of Cardiology, the Japanese Society of 
Echocardiography and the Canadian Society of Echocardiography. J Am 
Soc Echocardiogr. 2009;22:975–1014.
 2. Lancellotti P , Pibarot P , Chambers J, et al. Recommendations for the im-
aging assessment of prosthetic heart valves: a report from the European 
Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 
2016;17:589–90.
 3. Puri R, Auffret V, Rodés-Cabau J. Bioprosthetic valve thrombosis. J Am Coll 
Cardiol. 2017;69:2193–211.
 4. Puvimanasinghe JP , Steyerberg EW, Takkenberg JJ, et al. Prognosis after 
aortic valve replacement with a bioprosthesis: predictions based on meta-
analysis and microsimulation. Circulation. 2001;103:1535–41.
 5. Dangas GD, Weitz JI, Giustino G, et al. Prosthetic heart valve thrombosis. 
J Am Coll Cardiol. 2016;68:2670–89.
 6. Jose J, Sulimov DS, El-Mawardy M, et al. Clinical bioprosthetic heart 
valve thrombosis after transcatheter aortic valve replacement: inci-
dence, characteristics, and treatment outcomes. JACC Cardiovasc Interv. 
2017;10:686–97.
 7. Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet throm-
bosis in surgical and transcatheter bioprosthetic aortic valves: an observa-
tional study. Lancet. 2017;389:2383–92.
 8. Barbetseas J, Nagueh SF, Pitsavos C, et al. Differentiating thrombus from 
pannus formation in obstructed mechanical prosthetic valves: an evalu-
ation of clinical, transthoracic and transesophageal echocardiographic 
parameters. J Am Coll Cardiol. 1998;32:1410–7.
 9. Dvir D, Bourguignon T, Otto CM, et al. Standardized definition of struc-
tural valve degeneration for surgical and transcatheter bioprosthetic aortic 
valves. Circulation. 2018;137:388–99.
 10. Pibarot P , Dumesnil JG. Prosthetic heart valves: selection of the optimal 
prosthesis and long-term management. Circulation. 2009;119:1034–48.
 11. Koene BM, Soliman Hamad MA, Bouma W, et al. Impact of prosthesis-
patient mismatch on early and late mortality after aortic valve replace-
ment. J Cardiothorac Surg. 2013;8:96.
11.8.2. Intervention for Prosthetic Valve Stenosis
 1. Leontyev S, Borger MA, Davierwala P , et al. Redo aortic valve surgery: early 
and late outcomes. Ann Thorac Surg. 2011;91:1120–6.
 2. Kaneko T, Vassileva CM, Englum B, et al. Contemporary outcomes of re-
peat aortic valve replacement: a benchmark for transcatheter valve-in-
valve procedures. Ann Thorac Surg. 2015;100:1298–304.
 3. Jaussaud N, Gariboldi V, Grisoli D, et al. Risk of reoperation for mitral 
bioprosthesis dysfunction. J Heart Valve Dis. 2012;21:56–60.
 4. Dvir D, Webb JG, Bleiziffer S, et al. Transcatheter aortic valve implantation 
in failed bioprosthetic surgical valves. JAMA. 2014;312:162–70.
 5. Ye J, Cheung A, Yamashita M, et al. Transcatheter aortic and mitral valve-
in-valve implantation for failed surgical bioprosthetic valves: an 8-year 
single-center experience. JACC Cardiovasc Interv. 2015;8:1735–44.
 6. Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet throm-
bosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015–24.
 7. Jander N, Kienzle R-P , Kayser G, et al. Usefulness of phenprocoumon for 
the treatment of obstructing thrombus in bioprostheses in the aortic valve 
position. Am J Cardiol. 2012;109:257–62.
 8. Butnaru A, Shaheen J, Tzivoni D, et al. Diagnosis and treatment of early 
bioprosthetic malfunction in the mitral valve position due to thrombus 
formation. Am J Cardiol. 2013;112:1439–44.
 9. Pislaru SV, Hussain I, Pellikka PA, et al. Misconceptions, diagnostic chal-
lenges and treatment opportunities in bioprosthetic valve thrombosis: les-
sons from a case series. Eur J Cardiothorac Surg. 2015;47:725–32.
 10. De Marchena E, Mesa J, Pomenti S, et al. Thrombus formation following trans-
catheter aortic valve replacement. JACC Cardiovasc Interv. 2015;8:728–39.
 11. Jose J, Sulimov DS, El-Mawardy M, et al. Clinical bioprosthetic heart 
valve thrombosis after transcatheter aortic valve replacement: inci-
dence, characteristics, and treatment outcomes. JACC Cardiovasc Interv. 
2017;10:686–97.
 12. Latib A, Naganuma T, Abdel-Wahab M, et al. Treatment and clinical out-
comes of transcatheter heart valve thrombosis. Circ Cardiovasc Interv. 
2015;8:e001779.
 13. Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet throm-
bosis in surgical and transcatheter bioprosthetic aortic valves: an observa-
tional study. Lancet. 2017;389:2383–92.
 14. Gozdek M, Raffa GM, Suwalski P , et al. Comparative performance of 
transcatheter aortic valve-in-valve implantation versus conventional surgi-
cal redo aortic valve replacement in patients with degenerated aortic valve 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e212
CLINICAL STATEMENTS  
AND GUIDELINESbioprostheses: systematic review and meta-analysis. Eur J Cardiothorac 
Surg. 2018;53:495–504.
 15. Takagi H, Hari Y, Kawai N, et al. Meta-analysis of transcatheter aortic 
valve implantation for bicuspid versus tricuspid aortic valves. J Cardiol. 
2019;74:40–8.
 16. Kaneko T, Aranki S, Javed Q, et al. Mechanical versus bioprosthetic mitral 
valve replacement in patients <65 years old. J Thorac Cardiovasc Surg. 
2014;147:117–26.
 17. Petrescu I, Egbe AC, Ionescu F, et al. Long-term outcomes of anticoagula-
tion for bioprosthetic valve thrombosis. J Am Coll Cardiol. 2020;75:857–66.
11.9. Prosthetic Valve Regurgitation
 1. Dvir D, Bourguignon T, Otto CM, et al. Standardized definition of struc-
tural valve degeneration for surgical and transcatheter bioprosthetic aortic 
valves. Circulation. 2018;137:388–99.
 2. Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations for evalu-
ation of prosthetic valves with echocardiography and Doppler ultrasound: 
a report from the American Society of Echocardiography’s Guidelines and 
Standards Committee and the Task Force on Prosthetic Valves. Developed 
in conjunction with the American College of Cardiology Cardiovascular 
Imaging Committee, Cardiac Imaging Committee of the American Heart 
Association, the European Association of Echocardiography, a registered 
branch of the European Society of Cardiology, the Japanese Society of 
Echocardiography and the Canadian Society of Echocardiography. J Am 
Soc Echocardiogr. 2009;22:975–1014.
11.9.1. Diagnosis of Prosthetic Valve 
Regurgitation
 1. Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations for evaluation 
of prosthetic valves with echocardiography and Doppler ultrasound: a report 
from the American Society of Echocardiography’s Guidelines and Standards 
Committee and the Task Force on Prosthetic Valves. Developed in conjunction 
with the American College of Cardiology Cardiovascular Imaging Committee, 
Cardiac Imaging Committee of the American Heart Association, the European 
Association of Echocardiography, a registered branch of the European Society 
of Cardiology, the Japanese Society of Echocardiography and the Canadian 
Society of Echocardiography. J Am Soc Echocardiogr. 2009;22:975–1014.
 2. Lancellotti P , Pibarot P , Chambers J, et al. Recommendations for the im-
aging assessment of prosthetic heart valves: a report from the European 
Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 
2016;17:589–90.
 3. Zoghbi WA, Asch FM, Bruce C, et al. Guidelines for the evaluation of 
valvular regurgitation after percutaneous valve repair or replacement: a 
report from the American Society of Echocardiography. Developed in col-
laboration with the Society for Cardiovascular Angiography and Interven-
tions, Japanese Society of Echocardiography, and Society for Cardiovascu-
lar Magnetic Resonance. J Am Soc Echocardiogr. 2019;32:431–75.
 4. Hascoet S, Smolka G, Bagate F, et al. Multimodality imaging guidance 
for percutaneous paravalvular leak closure: Insights from the multi-centre 
FFPP register. Arch Cardiovasc Dis. 2018;111:421–31.
 5. García-Fernández MA, Cortés M, García-Robles JA, et al. Utility of real-
time three-dimensional transesophageal echocardiography in evaluating 
the success of percutaneous transcatheter closure of mitral paravalvular 
leaks. J Am Soc Echocardiogr. 2010;23:26–32.
 6. Nombela-Franco L, Ribeiro HB, Urena M, et al. Significant mitral regurgita-
tion left untreated at the time of aortic valve replacement: a comprehen-
sive review of a frequent entity in the transcatheter aortic valve replace-
ment era. J Am Coll Cardiol. 2014;63:2643–58.
 7. Ruiz CE, Hahn RT, Berrebi A, et al. Clinical trial principles and endpoint 
definitions for paravalvular leaks in surgical prosthesis: an expert state-
ment. J Am Coll Cardiol. 2017;69:2067–87.
 8. Lang RM, Badano LP , Tsang W, et al. EAE/ASE recommendations for image 
acquisition and display using three-dimensional echocardiography. J Am 
Soc Echocardiogr. 2012;25:3–46.
 9. Ruparelia N, Cao J, Newton JD, et al. Paravalvular leak closure under 
intracardiac echocardiographic guidance. Catheter Cardiovasc Interv. 
2018;91:958–65.
11.9.3. Intervention
 1. Akins CW, Bitondo JM, Hilgenberg AD, et al. Early and late results of the 
surgical correction of cardiac prosthetic paravalvular leaks. J Heart Valve 
Dis. 2005;14:792–9. 2. Kaneko T, Vassileva CM, Englum B, et al. Contemporary outcomes of re-
peat aortic valve replacement: a benchmark for transcatheter valve-in-
valve procedures. Ann Thorac Surg. 2015;100:1298–304.
 3. Kaneko T, Aranki S, Javed Q, et al. Mechanical versus bioprosthetic mitral 
valve replacement in patients <65 years old. J Thorac Cardiovasc Surg. 
2014;147:117–26.
 4. Jaussaud N, Gariboldi V, Grisoli D, et al. Risk of reoperation for mitral 
bioprosthesis dysfunction. J Heart Valve Dis. 2012;21:56–60.
 5. Sorajja P , Cabalka AK, Hagler DJ, et al. Percutaneous repair of paravalvular 
prosthetic regurgitation: acute and 30-day outcomes in 115 patients. Circ 
Cardiovasc Interv. 2011;4:314–21.
 6. Sorajja P , Cabalka AK, Hagler DJ, et al. Long-term follow-up of percuta-
neous repair of paravalvular prosthetic regurgitation. J Am Coll Cardiol. 
2011;58:2218–24.
 7. Alkhouli M, Rihal CS, Zack CJ, et al. Transcatheter and surgical manage-
ment of mitral paravalvular leak: long-term outcomes. JACC Cardiovasc 
Interv. 2017;10:1946–56.
 8. Alkhouli M, Zack CJ, Sarraf M, et al. Successful percutaneous mitral para-
valvular leak closure is associated with improved midterm survival. Circ 
Cardiovasc Interv. 2017;10:e005730.
 9. Ruiz CE, Jelnin V, Kronzon I, et al. Clinical outcomes in patients undergo-
ing percutaneous closure of periprosthetic paravalvular leaks. J Am Coll 
Cardiol. 2011;58:2210–7.
 10. Dvir D, Webb JG, Bleiziffer S, et al. Transcatheter aortic valve implantation 
in failed bioprosthetic surgical valves. JAMA. 2014;312:162–70.
 11. Phan K, Zhao D-F, Wang N, et al. Transcatheter valve-in-valve implantation 
versus reoperative conventional aortic valve replacement: a systematic re-
view. J Thorac Dis. 2016;8:E83–93.
 12. Webb JG, Wood DA, Ye J, et al. Transcatheter valve-in-valve implantation 
for failed bioprosthetic heart valves. Circulation. 2010;121:1848–57.
 13. Kaneko T, Vassileva CM, Englum B, et al. Contemporary outcomes of re-
peat aortic valve replacement: a benchmark for transcatheter valve-in-
valve procedures. Ann Thorac Surg. 2015;100:1298–304.
 14. Shah S, Alashi A, Pettersson GB, et al. Characteristics and longer-term 
outcomes of paravalvular leak after aortic and mitral valve surgery. J Tho-
rac Cardiovasc Surg. 2019;157:1785–92.e1.
 15. Bouhout I, Mazine A, Ghoneim A, et al. Long-term results after surgical 
treatment of paravalvular leak in the aortic and mitral position. J Thorac 
Cardiovasc Surg. 2016;151:1260–6.e1.
 16. STS online risk calculator. Available at: http://riskcalc sts org/STSWebRisk-
Calc273/de aspx 2013. Accessed June 20, 2020.
 17. Takagi H, Hari Y, Kawai N, et al. Meta-analysis of transcatheter aortic 
valve implantation for bicuspid versus tricuspid aortic valves. J Cardiol. 
2019;74:40–8.
 18. Gozdek M, Raffa GM, Suwalski P , et al. Comparative performance of 
transcatheter aortic valve-in-valve implantation versus conventional surgi-
cal redo aortic valve replacement in patients with degenerated aortic valve 
bioprostheses: systematic review and meta-analysis. Eur J Cardiothorac 
Surg. 2018;53:495–504.
12. INFECTIVE ENDOCARDITIS
12.2. Diagnosis of IE
 1. Steckelberg JM, Wilson WR. Risk factors for infective endocarditis. Infect 
Dis Clin North Am. 1993;7:9–19.
 2. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective 
endocarditis: utilization of specific echocardiographic findings. Duke En-
docarditis Service. Am J Med. 1994;96:200–9.
 3. Kupferwasser LI, Darius H, Müller AM, et al. Diagnosis of culture-negative 
endocarditis: the role of the Duke criteria and the impact of transesopha-
geal echocardiography. Am Heart J. 2001;142:146–52.
 4. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria 
for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30:633–8.
 5. Pérez-Vázquez A, Fariñas MC, García-Palomo JD, et al. Evaluation of the 
Duke criteria in 93 episodes of prosthetic valve endocarditis: could sensi-
tivity be improved? Arch Intern Med. 2000;160:1185–91.
 6. Lukes AS, Bright DK, Durack DT. Diagnosis of infective endocarditis. Infect 
Dis Clin North Am. 1993;7:1–8.
 7. Dodds GA, Sexton DJ, Durack DT, et al. Negative predictive value of the 
Duke criteria for infective endocarditis. Am J Cardiol. 1996;77:403–7.
 8. Bayer AS. Diagnostic criteria for identifying cases of endocarditis—revisit-
ing the Duke criteria two years later. Clin Infect Dis. 1996;23:303–4.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e213
CLINICAL STATEMENTS  
AND GUIDELINES 9. Prendergast BD. Diagnostic criteria and problems in infective endocarditis. 
Heart. 2004;90:611–3.
 10. Tsutsumi T, Eron LJ. Clinical use of the Duke criteria in patients with sus-
pected infective endocarditis and negative transesophageal echocardio-
grams. Infect Dis Clin Pract. 2012;20:315–8.
 11. Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, etiology, and 
outcome of infective endocarditis in the 21st century: the International 
Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 
2009;169:463–73.
 12. Haldar SM, O’Gara PT. Infective endocarditis: diagnosis and management. 
Nat Clin Pract Cardiovasc Med. 2006;3:310–7.
 13. Bashore TM, Cabell C, Fowler V Jr. Update on infective endocarditis. Curr 
Probl Cardiol. 2006;31:274–352.
 14. Mügge A, Daniel WG, Frank G, et al. Echocardiography in infective endo-
carditis: reassessment of prognostic implications of vegetation size deter -
mined by the transthoracic and the transesophageal approach. J Am Coll 
Cardiol. 1989;14:631–8.
 15. Burger AJ, Peart B, Jabi H, et al. The role of two-dimensional echocar -
diology in the diagnosis of infective endocarditis [corrected]. Angiology. 
1991;42:552–60.
 16. Irani WN, Grayburn PA, Afridi I. A negative transthoracic echocardiogram 
obviates the need for transesophageal echocardiography in patients 
with suspected native valve active infective endocarditis. Am J Cardiol. 
1996;78:101–3.
 17. Liu Y-W, Tsai W-C, Hsu C-H, et al. Judicious use of transthoracic echocardiog-
raphy in infective endocarditis screening. Can J Cardiol. 2009;25:703–5.
 18. Kemp WE Jr, Citrin B, Byrd BF 3rd. Echocardiography in infective endocar -
ditis. South Med J. 1999;92:744–54.
 19. Rubenson DS, Tucker CR, Stinson EB, et al. The use of echocardiography 
in diagnosing culture-negative endocarditis. Circulation. 1981;64:641–6.
 20. Shapiro SM, Young E, De Guzman S, et al. Transesophageal echocardiog-
raphy in diagnosis of infective endocarditis. Chest. 1994;105:377–82.
 21. Erbel R, Rohmann S, Drexler M, et al. Improved diagnostic value of echo-
cardiography in patients with infective endocarditis by transoesophageal 
approach. A prospective study. Eur Heart J. 1988;9:43–53.
 22. Rasmussen RV, Høst U, Arpi M, et al. Prevalence of infective endocarditis 
in patients with Staphylococcus aureus bacteraemia: the value of screen-
ing with echocardiography. Eur J Echocardiogr. 2011;12:414–20.
 23. Reynolds HR, Jagen MA, Tunick PA, et al. Sensitivity of transthoracic versus 
transesophageal echocardiography for the detection of native valve veg-
etations in the modern era. J Am Soc Echocardiogr. 2003;16:67–70.
 24. Daniel WG, Mügge A, Martin RP , et al. Improvement in the diagnosis of 
abscesses associated with endocarditis by transesophageal echocardiog-
raphy. N Engl J Med. 1991;324:795–800.
 25. Sochowski RA, Chan KL. Implication of negative results on a monoplane 
transesophageal echocardiographic study in patients with suspected in-
fective endocarditis. J Am Coll Cardiol. 1993;21:216–21.
 26. Shively BK, Gurule FT, Roldan CA, et al. Diagnostic value of transesopha-
geal compared with transthoracic echocardiography in infective endocar -
ditis. J Am Coll Cardiol. 1991;18:391–7.
 27. Pedersen WR, Walker M, Olson JD, et al. Value of transesophageal echo-
cardiography as an adjunct to transthoracic echocardiography in evalua-
tion of native and prosthetic valve endocarditis. Chest. 1991;100:351–6.
 28. Ronderos RE, Portis M, Stoermann W, et al. Are all echocardiographic 
findings equally predictive for diagnosis in prosthetic endocarditis? J Am 
Soc Echocardiogr. 2004;17:664–9.
 29. Roe MT, Abramson MA, Li J, et al. Clinical information determines the 
impact of transesophageal echocardiography on the diagnosis of infective 
endocarditis by the duke criteria. Am Heart J. 2000;139:945–51.
 30. Karalis DG, Bansal RC, Hauck AJ, et al. Transesophageal echocardiograph-
ic recognition of subaortic complications in aortic valve endocarditis. Clini-
cal and surgical implications. Circulation. 1992;86:353–62.
 31. El-Ahdab F, Benjamin DK Jr, Wang A, et al. Risk of endocarditis among pa-
tients with prosthetic valves and Staphylococcus aureus bacteremia. Am J 
Med. 2005;118:225–9.
 32. Douglas PS, Garcia MJ, Haines DE, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/
SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiogra-
phy: a report of the American College of Cardiology Foundation Appropri-
ate Use Criteria Task Force, American Society of Echocardiography, Ameri-
can Heart Association, American Society of Nuclear Cardiology, Heart 
Failure Society of America, Heart Rhythm Society, Society for Cardiovas-
cular Angiography and Interventions, Society of Critical Care Medicine, 
Society of Cardiovascular Computed Tomography, and Society for Cardio-
vascular Magnetic Resonance. J Am Coll Cardiol. 2011;57:1126–66. 33. Cheitlin MD, Armstrong WF, Aurigemma GP , et al. ACC/AHA/ASE 2003 
guideline update for the clinical application of echocardiography: summa-
ry article: a report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee 
to Update the 1997 Guidelines for the Clinical Application of Echocar -
diography). Circulation. 2003;108:1146–62.
 34. Vilacosta I, Graupner C, San Román JA, et al. Risk of embolization after in-
stitution of antibiotic therapy for infective endocarditis. J Am Coll Cardiol. 
2002;39:1489–95.
 35. Hoen B, Alla F, Selton-Suty C, et al. Changing profile of infective endocar -
ditis: results of a 1-year survey in France. JAMA. 2002;288:75–81.
 36. Rosen AB, Fowler VG Jr, Corey GR, et al. Cost-effectiveness of trans-
esophageal echocardiography to determine the duration of therapy for 
intravascular catheter-associated Staphylococcus aureus bacteremia. Ann 
Intern Med. 1999;130:810–20.
 37. Fagman E, Perrotta S, Bech-Hanssen O, et al. ECG-gated computed to-
mography: a new role for patients with suspected aortic prosthetic valve 
endocarditis. Eur Radiol. 2012;22:2407–14.
 38. Rohmann S, Erbel R, Darius H, et al. Prediction of rapid versus prolonged 
healing of infective endocarditis by monitoring vegetation size. J Am Soc 
Echocardiogr. 1991;4:465–74.
 39. Massoure P-L, Reuter S, Lafitte S, et al. Pacemaker endocarditis: clinical 
features and management of 60 consecutive cases. Pacing Clin Electro-
physiol. 2007;30:12–9.
 40. Narducci ML, Pelargonio G, Russo E, et al. Usefulness of intracardiac echo-
cardiography for the diagnosis of cardiovascular implantable electronic 
device-related endocarditis. J Am Coll Cardiol. 2013;61:1398–405.
 41. Cabell CH, Jollis JG, Peterson GE, et al. Changing patient character -
istics and the effect on mortality in endocarditis. Arch Intern Med. 
2002;162:90–4.
 42. Habib G, Hoen B, Tornos P , et al. Guidelines on the prevention, diagnosis, 
and treatment of infective endocarditis (new version 2009): the Task Force 
on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of 
the European Society of Cardiology (ESC). Eur Heart J. 2009;30:2369–413.
 43. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J 
Med. 2001;345:1318–30.
 44. Lengyel M. The impact of transesophageal echocardiography on the man-
agement of prosthetic valve endocarditis: experience of 31 cases and re-
view of the literature. J Heart Valve Dis. 1997;6:204–11.
 45. Bayer AS. Infective endocarditis. Clin Infect Dis. 1993;17:313–20.
 46. Ghatak A, Pullatt R, Vyse S, et al. Appropriateness criteria are an imprecise 
measure for repeat echocardiograms. Echocardiography. 2011;28:131–5.
 47. Shapira Y, Weisenberg DE, Vaturi M, et al. The impact of intraoperative 
transesophageal echocardiography in infective endocarditis. Isr Med As-
soc J. 2007;9:299–302.
 48. Yao F, Han L, Xu Z, et al. Surgical treatment of multivalvular endocardi-
tis: twenty-one-year single center experience. J Thorac Cardiovasc Surg. 
2009;137:1475–80.
 49. Eltzschig HK, Rosenberger P , Löffler M, et al. Impact of intraoperative 
transesophageal echocardiography on surgical decisions in 12,566 pa-
tients undergoing cardiac surgery. Ann Thorac Surg. 2008;85:845–52.
 50. Silva F, Arruda R, Nobre A, et al. Impact of intraoperative transesophageal 
echocardiography in cardiac surgery: retrospective analysis of a series of 
850 examinations. Rev Port Cardiol. 2010;29:1363–82.
 51. Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibi-
otic treatment of endocarditis. N Engl J Med. 2019;380:415–24.
 52. Watanakunakorn C. Staphylococcus aureus endocarditis at a community 
teaching hospital, 1980 to 1991. An analysis of 106 cases. Arch Intern 
Med. 1994;154:2330–5.
 53. Abraham J, Mansour C, Veledar E, et al. Staphylococcus aureus bactere-
mia and endocarditis: the Grady Memorial Hospital experience with meth-
icillin-sensitive S aureus and methicillin-resistant S aureus bacteremia. Am 
Heart J. 2004;147:536–9.
 54. Kaasch AJ, Fowler VG Jr, Rieg S, et al. Use of a simple criteria set for guid-
ing echocardiography in nosocomial Staphylococcus aureus bacteremia. 
Clin Infect Dis. 2011;53:1–9.
 55. Petti CA, Fowler VG Jr. Staphylococcus aureus bacteremia and endocardi-
tis. Cardiol Clin. 2003;21:219–33, vii.
 56. Fowler VG Jr, Sanders LL, Kong LK, et al. Infective endocarditis due to 
Staphylococcus aureus: 59 prospectively identified cases with follow-up. 
Clin Infect Dis. 1999;28:106–14.
 57. San Martin J, Sarriá C, de las Cuevas C, et al. Relevance of clinical pre-
sentation and period of diagnosis in prosthetic valve endocarditis. J Heart 
Valve Dis. 2010;19:131–8.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e214
CLINICAL STATEMENTS  
AND GUIDELINES 58. Knudsen JB, Fuursted K, Petersen E, et al. Failure of clinical features of low 
probability endocarditis. The early echo remains essential. Scand Cardio-
vasc J. 2011;45:133–8.
 59. Lamas CC, Eykyn SJ. Suggested modifications to the Duke criteria for the 
clinical diagnosis of native valve and prosthetic valve endocarditis: analysis 
of 118 pathologically proven cases. Clin Infect Dis. 1997;25:713–9.
 60. Piper C, Körfer R, Horstkotte D. Prosthetic valve endocarditis. Heart. 
2001;85:590–3.
 61. Feuchtner GM, Stolzmann P , Dichtl W, et al. Multislice computed tomog-
raphy in infective endocarditis: comparison with transesophageal echocar -
diography and intraoperative findings. J Am Coll Cardiol. 2009;53:436–
44.
 62. Gahide G, Bommart S, Demaria R, et al. Preoperative evaluation in aortic 
endocarditis: findings on cardiac CT. AJR Am J Roentgenol. 2010;194:574–
8.
 63. Lentini S, Monaco F, Tancredi F, et al. Aortic valve infective endocardi-
tis: could multi-detector CT scan be proposed for routine screening of 
concomitant coronary artery disease before surgery? Ann Thorac Surg. 
2009;87:1585–7.
 64. Schoepf U, White R, Woodard P , et al. ACR Appropriateness Criteria®: 
Suspected Infective Endocarditis. Agency for Healthcare Research and 
Quality, 2011.
 65. Kung VWS, Jarral OA, Shipolini AR, et al. Is it safe to perform coronary 
angiography during acute endocarditis? Interact Cardiovasc Thorac Surg. 
2011;13:158–67.
 66. Cianciulli TE, Lax JA, Beck MA, et al. Cinefluoroscopic assessment of me-
chanical disc prostheses: its value as a complementary method to echocar -
diography. J Heart Valve Dis. 2005;14:664–73.
 67. Aoyagi S, Nishimi M, Kawano H, et al. Obstruction of St Jude Medical 
valves in the aortic position: significance of a combination of cineradiog-
raphy and echocardiography. J Thorac Cardiovasc Surg. 2000;120:142–7.
 68. Vogel W, Stoll HP , Bay W, et al. Cineradiography for determination of 
normal and abnormal function in mechanical heart valves. Am J Cardiol. 
1993;71:225–32.
 69. Mahmood M, Kendi AT, Ajmal S, et al. Meta-analysis of 18F-FDG PET/CT 
in the diagnosis of infective endocarditis. J Nucl Cardiol. 2019;26:922–35.
 70. de Camargo RA, Sommer Bitencourt M, Meneghetti JC, et al. The role 
of 18F-fluorodeoxyglucose positron emission tomography/computed to-
mography in the diagnosis of left-sided endocarditis: native vs prosthetic 
valves endocarditis. Clin Infect Dis. 2020;70:583–94.
 71. Scholtens AM, Swart LE, Verberne HJ, et al. Dual-time-point FDG PET/
CT imaging in prosthetic heart valve endocarditis. J Nucl Cardiol. 
2018;25:1960–7.
 72. Fowler VG Jr, Li J, Corey GR, et al. Role of echocardiography in evaluation 
of patients with Staphylococcus aureus bacteremia: experience in 103 pa-
tients. J Am Coll Cardiol. 1997;30:1072–8.
 73. Sullenberger AL, Avedissian LS, Kent SM. Importance of transesophageal 
echocardiography in the evaluation of Staphylococcus aureus bacteremia. 
J Heart Valve Dis. 2005;14:23–8.
 74. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infec-
tious Diseases Society of America for the treatment of methicillin-resistant 
Staphylococcus aureus infections in adults and children. Clin Infect Dis. 
2011;52:e18–55.
 75. Capp R, Chang Y, Brown DFM. Effective antibiotic treatment prescribed 
by emergency physicians in patients admitted to the intensive care unit 
with severe sepsis or septic shock: where is the gap? J Emerg Med. 
2011;41:573–80.
 76. Garza D, Becan-McBride K. Phlebotomy Handbook. Stamford, CT: Apple-
ton & Lange; 1998.
 77. Baron EJ, Scott JD, Tompkins LS. Prolonged incubation and extensive 
subculturing do not increase recovery of clinically significant micro-
organisms from standard automated blood cultures. Clin Infect Dis. 
2005;41:1677–80.
 78. Houpikian P , Raoult D. Blood culture-negative endocarditis in a refer -
ence center: etiologic diagnosis of 348 cases. Medicine (Baltimore). 
2005;84:162–73.
12.3. Medical Therapy
 1. Gould FK, Denning DW, Elliott TSJ, et al. Guidelines for the diagnosis and 
antibiotic treatment of endocarditis in adults: a report of the Working 
Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob 
Chemother. 2012;67:269–89. 2. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, 
antimicrobial therapy, and management of complications: a statement for 
healthcare professionals from the Committee on Rheumatic Fever, Endo-
carditis, and Kawasaki Disease, Council on Cardiovascular Disease in the 
Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovas-
cular Surgery and Anesthesia, American Heart Association. Circulation. 
2005;111:e394–e434.
 3. López J, Sevilla T, Vilacosta I, et al. Prognostic role of persistent positive 
blood cultures after initiation of antibiotic therapy in left-sided infective 
endocarditis. Eur Heart J. 2013;34:1749–54.
 4. Partridge DG, O’Brien E, Chapman ALN. Outpatient parenteral antibiotic 
therapy for infective endocarditis: a review of 4 years’ experience at a UK 
centre. Postgrad Med J. 2012;88:377–81.
 5. Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. 
Mayo Clin Proc. 2011;86:156–67.
 6. DiNubile MJ. Short-course antibiotic therapy for right-sided endocarditis 
caused by Staphylococcus aureus in injection drug users. Ann Intern Med. 
1994;121:873–6.
 7. Martí-Carvajal AJ, Dayer M, Conterno LO, et al. A comparison of different 
antibiotic regimens for the treatment of infective endocarditis. Cochrane 
Database Syst Rev. 2016;4:CD009880.
 8. Liebschutz JM, Crooks D, Herman D, et al. Buprenorphine treatment for 
hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA 
Intern Med. 2014;174:1369–76.
 9. Englander H, Weimer M, Solotaroff R, et al. Planning and designing the 
Improving Addiction Care Team (IMPACT) for hospitalized adults with sub-
stance use disorder. J Hosp Med. 2017;12:339–42.
 10. Schranz AJ, Fleischauer A, Chu VH, et al. Trends in drug use-associated 
infective endocarditis and heart valve surgery, 2007 to 2017: a study of 
statewide discharge data. Ann Intern Med. 2019;170:31–40.
 11. Whitlock RP , Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic 
therapy for valvular disease: Antithrombotic Therapy and Prevention of 
Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based 
Clinical Practice Guidelines. Chest. 2012;141:e576S–600S.
 12. Masuda J, Yutani C, Waki R, et al. Histopathological analysis of the mech-
anisms of intracranial hemorrhage complicating infective endocarditis. 
Stroke. 1992;23:843–50.
 13. Tornos P , Almirante B, Mirabet S, et al. Infective endocarditis due to Staph-
ylococcus aureus: deleterious effect of anticoagulant therapy. Arch Intern 
Med. 1999;159:473–5.
 14. Carpenter JL, McAllister CK. Anticoagulation in prosthetic valve endocar -
ditis. South Med J. 1983;76:1372–5.
 15. Lieberman A, Hass WK, Pinto R, et al. Intracranial hemorrhage and in-
farction in anticoagulated patients with prosthetic heart valves. Stroke. 
1978;9:18–24.
 16. Wilson WR, Geraci JE, Danielson GK, et al. Anticoagulant therapy and 
central nervous system complications in patients with prosthetic valve en-
docarditis. Circulation. 1978;57:1004–7.
 17. Ananthasubramaniam K, Beattie JN, Rosman HS, et al. How safely and for 
how long can warfarin therapy be withheld in prosthetic heart valve pa-
tients hospitalized with a major hemorrhage? Chest. 2001;119:478–84.
 18. Snygg-Martin U, Gustafsson L, Rosengren L, et al. Cerebrovascular com-
plications in patients with left-sided infective endocarditis are common: a 
prospective study using magnetic resonance imaging and neurochemical 
brain damage markers. Clin Infect Dis. 2008;47:23–30.
 19. Tunkel AR, Kaye D. Neurologic complications of infective endocarditis. 
Neurol Clin. 1993;11:419–40.
 20. Immediate anticoagulation of embolic stroke: brain hemorrhage and manage-
ment options. Cerebral Embolism Study Group. Stroke. 1984;15:779–89.
 21. Kamalakannan D, Beeai M, Gardin JM, et al. Anticoagulation in infective 
endocarditis: a survey of infectious disease specialists and cardiologists. 
Infect Dis Clin Pract. 2005;13:122–6.
 22. Nagpal A, Sohail MR, Steckelberg JM. Prosthetic valve endocarditis: state 
of the heart. Clin Invest. 2012;2:803–17.
 23. Thuny F, Avierinos J-F, Tribouilloy C, et al. Impact of cerebrovascular com-
plications on mortality and neurologic outcome during infective endocar -
ditis: a prospective multicentre study. Eur Heart J. 2007;28:1155–61.
 24. Duval X, Iung B, Klein I, et al. Effect of early cerebral magnetic resonance 
imaging on clinical decisions in infective endocarditis: a prospective study. 
Ann Intern Med. 2010;152:497–504, W175.
 25. Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibi-
otic treatment of endocarditis. N Engl J Med. 2019;380:415–24.
 26. Pruitt AA, Rubin RH, Karchmer AW, et al. Neurologic complications of 
bacterial endocarditis. Medicine (Baltimore). 1978;57:329–43.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e215
CLINICAL STATEMENTS  
AND GUIDELINES 27. Chan K-L, Tam J, Dumesnil JG, et al. Effect of long-term aspirin use on 
embolic events in infective endocarditis. Clin Infect Dis. 2008;46:37–41.
 28. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-
associated intracranial and extracranial hemorrhages. Am J Med. 
2007;120:700–5.
 29. Rasmussen RV, Snygg-Martin U, Olaison L, et al. Major cerebral events 
in Staphylococcus aureus infective endocarditis: is anticoagulant therapy 
safe? Cardiology. 2009;114:284–91.
 30. Sonneville R, Mirabel M, Hajage D, et al. Neurologic complications and 
outcomes of infective endocarditis in critically ill patients: the ENDO-
cardite en REAnimation prospective multicenter study. Crit Care Med. 
2011;39:1474–81.
 31. Chan K-L, Dumesnil JG, Cujec B, et al. A randomized trial of aspirin on 
the risk of embolic events in patients with infective endocarditis. J Am Coll 
Cardiol. 2003;42:775–80.
 32. Anavekar NS, Tleyjeh IM, Anavekar NS, et al. Impact of prior antiplate-
let therapy on risk of embolism in infective endocarditis. Clin Infect Dis. 
2007;44:1180–6.
 33. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system 
bleeding during antithrombotic therapy: recent data and ideas. Stroke. 
2005;36:1588–93.
 34. He J, Whelton PK, Vu B, et al. Aspirin and risk of hemorrhagic stroke: a 
meta-analysis of randomized controlled trials. JAMA. 1998;280:1930–5.
 35. Werner M, Andersson R, Olaison L, et al. A clinical study of culture-nega-
tive endocarditis. Medicine (Baltimore). 2003;82:263–73.
 36. Dellinger RP , Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: in-
ternational guidelines for management of severe sepsis and septic shock: 
2008. Crit Care Med. 2008;36:296–327.
 37. Habib G, Hoen B, Tornos P , et al. Guidelines on the prevention, diagnosis, 
and treatment of infective endocarditis (new version 2009): the Task Force 
on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of 
the European Society of Cardiology (ESC). Eur Heart J. 2009;30:2369–
413.
 38. Park CB, Greason KL, Suri RM, et al. Fate of nonreplaced sinuses of Valsalva 
in bicuspid aortic valve disease. J Thorac Cardiovasc Surg. 2011;142:278–
84.
 39. Cabell CH, Jollis JG, Peterson GE, et al. Changing patient character -
istics and the effect on mortality in endocarditis. Arch Intern Med. 
2002;162:90–4.
 40. Tleyjeh IM, Abdel-Latif A, Rahbi H, et al. A systematic review of popula-
tion-based studies of infective endocarditis. Chest. 2007;132:1025–35.
 41. Klug D, Lacroix D, Savoye C, et al. Systemic infection related to endocar -
ditis on pacemaker leads: clinical presentation and management. Circula-
tion. 1997;95:2098–107.
 42. Lalani T, Chu VH, Park LP , et al. In-hospital and 1-year mortality in patients 
undergoing early surgery for prosthetic valve endocarditis. JAMA Intern 
Med. 2013;173:1495–504.
12.4. Intervention
 1. Erba PA, Habib G, Glaudemans AWJM, et al. The round table approach 
in infective endocarditis & cardiovascular implantable electronic devices 
infections: make your e-Team come true. Eur J Nucl Med Mol Imaging. 
2017;44:1107–8.
 2. Chirillo F, Scotton P , Rocco F, et al. Impact of a multidisciplinary manage-
ment strategy on the outcome of patients with native valve infective en-
docarditis. Am J Cardiol. 2013;112:1171–6.
 3. Botelho-Nevers E, Thuny F, Casalta JP , et al. Dramatic reduction in infective 
endocarditis-related mortality with a management-based approach. Arch 
Intern Med. 2009;169:1290–8.
 4. Thuny F, Grisoli D, Collart F, et al. Management of infective endocarditis: 
challenges and perspectives. Lancet. 2012;379:965–75.
 5. Gaca JG, Sheng S, Daneshmand MA, et al. Outcomes for endocarditis 
surgery in North America: a simplified risk scoring system. J Thorac Car -
diovasc Surg. 2011;141:98–106.e1–2.
 6. Sambola A, Fernández-Hidalgo N, Almirante B, et al. Sex differences in 
native-valve infective endocarditis in a single tertiary-care hospital. Am J 
Cardiol. 2010;106:92–8.
 7. Wang A, Athan E, Pappas PA, et al. Contemporary clinical profile and 
outcome of prosthetic valve endocarditis. JAMA. 2007;297:1354–61.
 8. Lalani T, Chu VH, Park LP , et al. In-hospital and 1-year mortality in patients 
undergoing early surgery for prosthetic valve endocarditis. JAMA Intern 
Med. 2013;173:1495–504. 9. Nagpal A, Sohail MR, Steckelberg JM. Prosthetic valve endocarditis: state 
of the heart. Clin Invest. 2012;2:803–17.
 10. Jault F, Gandjbakhch I, Rama A, et al. Active native valve endocarditis: 
determinants of operative death and late mortality. Ann Thorac Surg. 
1997;63:1737–41.
 11. Hasbun R, Vikram HR, Barakat LA, et al. Complicated left-sided na-
tive valve endocarditis in adults: risk classification for mortality. JAMA. 
2003;289:1933–40.
 12. Kiefer T, Park L, Tribouilloy C, et al. Association between valvular surgery 
and mortality among patients with infective endocarditis complicated by 
heart failure. JAMA. 2011;306:2239–47.
 13. Tornos P , Sanz E, Permanyer-Miralda G, et al. Late prosthetic valve endo-
carditis. Immediate and long-term prognosis. Chest. 1992;101:37–41.
 14. Gordon SM, Serkey JM, Longworth DL, et al. Early onset prosthetic valve 
endocarditis: the Cleveland Clinic experience 1992–1997. Ann Thorac 
Surg. 2000;69:1388–92.
 15. Prendergast BD, Tornos P . Surgery for infective endocarditis: who and 
when? Circulation. 2010;121:1141–52.
 16. Funakoshi S, Kaji S, Yamamuro A, et al. Impact of early surgery in the 
active phase on long-term outcomes in left-sided native valve infective 
endocarditis. J Thorac Cardiovasc Surg. 2011;142:836–42.e1.
 17. Bauernschmitt R, Jakob HG, Vahl CF, et al. Operation for infective endo-
carditis: results after implantation of mechanical valves. Ann Thorac Surg. 
1998;65:359–64.
 18. Musci M, Siniawski H, Pasic M, et al. Surgical therapy in patients with 
active infective endocarditis: seven-year single centre experience in a sub-
group of 255 patients treated with the Shelhigh stentless bioprosthesis. 
Eur J Cardiothorac Surg. 2008;34:410–7.
 19. Yu VL, Fang GD, Keys TF, et al. Prosthetic valve endocarditis: superiority of 
surgical valve replacement versus medical therapy only. Ann Thorac Surg. 
1994;58:1073–7.
 20. Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, etiology, and 
outcome of infective endocarditis in the 21st century: the International 
Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 
2009;169:463–73.
 21. Remadi JP , Habib G, Nadji G, et al. Predictors of death and impact of 
surgery in Staphylococcus aureus infective endocarditis. Ann Thorac Surg. 
2007;83:1295–302.
 22. Hill EE, Herijgers P , Claus P , et al. Infective endocarditis: changing epidemi-
ology and predictors of 6-month mortality: a prospective cohort study. Eur 
Heart J. 2007;28:196–203.
 23. Aksoy O, Sexton DJ, Wang A, et al. Early surgery in patients with 
infective endocarditis: a propensity score analysis. Clin Infect Dis. 
2007;44:364–72.
 24. Ellis ME, Al-Abdely H, Sandridge A, et al. Fungal endocarditis: evidence in 
the world literature, 1965–1995. Clin Infect Dis. 2001;32:50–62.
 25. Wolff M, Witchitz S, Chastang C, et al. Prosthetic valve endocarditis in 
the ICU. Prognostic factors of overall survival in a series of 122 cases and 
consequences for treatment decision. Chest. 1995;108:688–94.
 26. Chirouze C, Cabell CH, Fowler VG Jr, et al. Prognostic factors in 61 cases 
of Staphylococcus aureus prosthetic valve infective endocarditis from the 
International Collaboration on Endocarditis merged database. Clin Infect 
Dis. 2004;38:1323–7.
 27. Melgar GR, Nasser RM, Gordon SM, et al. Fungal prosthetic valve endo-
carditis in 16 patients. An 11-year experience in a tertiary care hospital. 
Medicine (Baltimore). 1997;76:94–103.
 28. Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: 
a consequence of medical progress. JAMA. 2005;293:3012–21.
 29. Miro JM, Anguera I, Cabell CH, et al. Staphylococcus aureus native 
valve infective endocarditis: report of 566 episodes from the Interna-
tional Collaboration on Endocarditis Merged Database. Clin Infect Dis. 
2005;41:507–14.
 30. Hill EE, Peetermans WE, Vanderschueren S, et al. Methicillin-resistant ver -
sus methicillin-sensitive Staphylococcus aureus infective endocarditis. Eur 
J Clin Microbiol Infect Dis. 2008;27:445–50.
 31. Attaran S, Chukwuemeka A, Punjabi PP , et al. Do all patients with pros-
thetic valve endocarditis need surgery? Interact Cardiovasc Thorac Surg. 
2012;15:1057–61.
 32. Cowgill LD, Addonizio VP , Hopeman AR, et al. A practical approach to 
prosthetic valve endocarditis. Ann Thorac Surg. 1987;43:450–7.
 33. Ribera E, Gómez-Jimenez J, Cortes E, et al. Effectiveness of cloxacillin with 
and without gentamicin in short-term therapy for right-sided Staphylo-
coccus aureus endocarditis. A randomized, controlled trial. Ann Intern 
Med. 1996;125:969–74.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e216
CLINICAL STATEMENTS  
AND GUIDELINES 34. Rabkin DG, Mokadam NA, Miller DW, et al. Long-term outcome for the 
surgical treatment of infective endocarditis with a focus on intravenous 
drug users. Ann Thorac Surg. 2012;93:51–7.
 35. Hubbell G, Cheitlin MD, Rapaport E. Presentation, management, and 
follow-up evaluation of infective endocarditis in drug addicts. Am Heart J. 
1981;102:85–94.
 36. Wang K, Gobel F, Gleason DF, et al. Complete heart block complicating 
bacterial endocarditis. Circulation. 1972;46:939–47.
 37. Middlemost S, Wisenbaugh T, Meyerowitz C, et al. A case for early surgery 
in native left-sided endocarditis complicated by heart failure: results in 203 
patients. J Am Coll Cardiol. 1991;18:663–7.
 38. Chan K-L. Early clinical course and long-term outcome of patients 
with infective endocarditis complicated by perivalvular abscess. CMAJ. 
2002;167:19–24.
 39. Jault F, Gandjbakhch I, Chastre JC, et al. Prosthetic valve endocarditis with 
ring abscesses. Surgical management and long-term results. J Thorac Car -
diovasc Surg. 1993;105:1106–13.
 40. Anguera I, Miro JM, Vilacosta I, et al. Aorto-cavitary fistulous tract forma-
tion in infective endocarditis: clinical and echocardiographic features of 76 
cases and risk factors for mortality. Eur Heart J. 2005;26:288–97.
 41. Habib G, Avierinos J-F, Thuny F. Aortic valve endocarditis: is there an opti-
mal surgical timing? Curr Opin Cardiol. 2007;22:77–83.
 42. Spiliopoulos K, Haschemi A, Fink G, et al. Infective endocarditis complicat-
ed by paravalvular abscess: a surgical challenge. An 11-year single center 
experience. Heart Surg Forum. 2010;13:E67–73.
 43. d’Udekem Y, David TE, Feindel CM, et al. Long-term results of operation 
for paravalvular abscess. Ann Thorac Surg. 1996;62:48–53.
 44. Alonso-Valle H, Fariñas-Alvarez C, García-Palomo JD, et al. Clinical course 
and predictors of death in prosthetic valve endocarditis over a 20-year 
period. J Thorac Cardiovasc Surg. 2010;139:887–93.
 45. Klieverik LMA, Yacoub MH, Edwards S, et al. Surgical treatment of active 
native aortic valve endocarditis with allografts and mechanical prostheses. 
Ann Thorac Surg. 2009;88:1814–21.
 46. Hill EE, Herijgers P , Claus P , et al. Abscess in infective endocarditis: the 
value of transesophageal echocardiography and outcome: a 5-year study. 
Am Heart J. 2007;154:923–8.
 47. Manne MB, Shrestha NK, Lytle BW, et al. Outcomes after surgical treat-
ment of native and prosthetic valve infective endocarditis. Ann Thorac 
Surg. 2012;93:489–93.
 48. Head SJ, Mokhles MM, Osnabrugge RLJ, et al. Surgery in current therapy 
for infective endocarditis. Vasc Health Risk Manag. 2011;7:255–63.
 49. Narducci ML, Pelargonio G, Russo E, et al. Usefulness of intracardiac echo-
cardiography for the diagnosis of cardiovascular implantable electronic 
device-related endocarditis. J Am Coll Cardiol. 2013;61:1398–405.
 50. Sohail MR, Uslan DZ, Khan AH, et al. Infective endocarditis complicating 
permanent pacemaker and implantable cardioverter-defibrillator infec-
tion. Mayo Clin Proc. 2008;83:46–53.
 51. Athan E, Chu VH, Tattevin P , et al. Clinical characteristics and outcome 
of infective endocarditis involving implantable cardiac devices. JAMA. 
2012;307:1727–35.
 52. Rundström H, Kennergren C, Andersson R, et al. Pacemaker endocarditis 
during 18 years in Göteborg. Scand J Infect Dis. 2004;36:674–9.
 53. Ho H-H, Siu C-W, Yiu K-H, et al. Prosthetic valve endocarditis in a mul-
ticenter registry of Chinese patients. Asian Cardiovasc Thorac Ann. 
2010;18:430–4.
 54. Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular 
implantable electronic device infections and their management: a sci-
entific statement from the American Heart Association. Circulation. 
2010;121:458–77.
 55. Viganego F, O’Donoghue S, Eldadah Z, et al. Effect of early diagnosis and 
treatment with percutaneous lead extraction on survival in patients with 
cardiac device infections. Am J Cardiol. 2012;109:1466–71.
 56. Rudasill SE, Sanaiha Y, Mardock AL, et al. Clinical outcomes of in-
fective endocarditis in injection drug users. J Am Coll Cardiol. 
2019;73:559–70.
 57. Rodger L, Glockler-Lauf SD, Shojaei E, et al. Clinical characteristics and 
factors associated with mortality in first-episode infective endocarditis 
among persons who inject drugs. JAMA Netw Open. 2018;1:e185220.
 58. Schranz AJ, Fleischauer A, Chu VH, et al. Trends in drug use-associated 
infective endocarditis and heart valve surgery, 2007 to 2017: a study of 
statewide discharge data. Ann Intern Med. 2019;170:31–40.
 59. Rosenthal ES, Karchmer AW, Theisen-Toupal J, et al. Suboptimal addiction 
interventions for patients hospitalized with injection drug use-associated 
infective endocarditis. Am J Med. 2016;129:481–5. 60. Liebschutz JM, Crooks D, Herman D, et al. Buprenorphine treatment for 
hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA 
Intern Med. 2014;174:1369–76.
 61. Kang D-H, Kim Y-J, Kim S-H, et al. Early surgery versus conventional treat-
ment for infective endocarditis. N Engl J Med. 2012;366:2466–73.
 62. Thuny F, Di Salvo G, Belliard O, et al. Risk of embolism and death in in-
fective endocarditis: prognostic value of echocardiography: a prospective 
multicenter study. Circulation. 2005;112:69–75.
 63. Mügge A, Daniel WG, Frank G, et al. Echocardiography in infective endo-
carditis: reassessment of prognostic implications of vegetation size deter -
mined by the transthoracic and the transesophageal approach. J Am Coll 
Cardiol. 1989;14:631–8.
 64. Rohmann S, Erbel R, Darius H, et al. Prediction of rapid versus prolonged 
healing of infective endocarditis by monitoring vegetation size. J Am Soc 
Echocardiogr. 1991;4:465–74.
 65. Habib G. Embolic risk in subacute bacterial endocarditis: determinants 
and role of transesophageal echocardiography. Curr Infect Dis Rep. 
2005;7:264–71.
 66. Truninger K, Attenhofer Jost CH, Seifert B, et al. Long term follow up of 
prosthetic valve endocarditis: what characteristics identify patients who 
were treated successfully with antibiotics alone? Heart. 1999;82:714–20.
 67. Fosbol EL, Park LP , Chu VH, et al. The association between vegetation 
size and surgical treatment on 6-month mortality in left-sided infective 
endocarditis. Eur Heart J. 2019;40:2243–51.
 68. Suzuki M, Takanashi S, Ohshima Y, et al. Critical potential of early cardiac 
surgery for infective endocarditis with cardio-embolic strokes. Int J Car -
diol. 2017;227:222–4.
 69. García-Borbolla Fernández R, Sancho Jaldón M, Calle Pérez G, et al. Per -
cutaneous treatment of mitral valve periprosthetic leakage. An alternative 
to high-risk surgery? Rev Esp Cardiol. 2009;62:438–41.
 70. Nietlispach F, Johnson M, Moss RR, et al. Transcatheter closure of paraval-
vular defects using a purpose-specific occluder. JACC Cardiovasc Interv. 
2010;3:759–65.
 71. Klug D, Lacroix D, Savoye C, et al. Systemic infection related to endocar -
ditis on pacemaker leads: clinical presentation and management. Circula-
tion. 1997;95:2098–107.
 72. Baddour LM, Cha Y-M, Wilson WR. Clinical practice. Infections of cardio-
vascular implantable electronic devices. N Engl J Med. 2012;367:842–9.
 73. Cabell CH, Jollis JG, Peterson GE, et al. Changing patient character -
istics and the effect on mortality in endocarditis. Arch Intern Med. 
2002;162:90–4.
 74. Ghoreishi M, Foster N, Pasrija C, et al. Early operation in patients with 
mitral valve infective endocarditis and acute stroke is safe. Ann Thorac 
Surg. 2018;105:69–75.
13. PREGNANCY AND VHD
13.1. Initial Management of Women With 
VHD Before and During Pregnancy
 1. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC 
guidelines for the management of cardiovascular diseases during preg-
nancy. Eur Heart J. 2018;39:3165–241.
 2. Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study 
of pregnancy outcomes in women with heart disease. Circulation. 
2001;104:515–21.
 3. Elkayam U, Bitar F. Valvular heart disease and pregnancy part I: native 
valves. J Am Coll Cardiol. 2005;46:223–30.
 4. Leśniak-Sobelga A, Tracz W, KostKiewicz M, et al. Clinical and echocardio-
graphic assessment of pregnant women with valvular heart diseases–ma-
ternal and fetal outcome. Int J Cardiol. 2004;94:15–23.
 5. Ducas RA, Javier DA, D’Souza R, et al. Pregnancy outcomes in women 
with significant valve disease: a systematic review and meta-analysis. 
Heart. 2020;106:512–9.
 6. Orwat S, Diller G-P , van Hagen IM, et al. Risk of pregnancy in moderate 
and severe aortic stenosis: from the multinational ROPAC registry. J Am 
Coll Cardiol. 2016;68:1727–37.
 7. Roos-Hesselink J, Baris L, Johnson M, et al. Pregnancy outcomes in women 
with cardiovascular disease: evolving trends over 10 years in the ESC Registry 
Of Pregnancy And Cardiac disease (ROPAC). Eur Heart J. 2019;40:3848–55.
 8. Sliwa K, van Hagen IM, Budts W, et al. Pulmonary hypertension and 
pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e217
CLINICAL STATEMENTS  
AND GUIDELINESDisease (ROPAC) of the European Society of Cardiology. Eur J Heart Fail. 
2016;18:1119–28.
 9. Silversides CK, Grewal J, Mason J, et al. Pregnancy outcomes in 
women with heart disease: the CARPREG II study. J Am Coll Cardiol. 
2018;71:2419–30.
 10. Thomas E, Yang J, Xu J, et al. Pulmonary hypertension and pregnancy 
outcomes: insights from the national inpatient sample. J Am Heart Assoc. 
2017;6:e006144.
 11. Sugishita Y, Ito I, Kubo T. Pregnancy in cardiac patients: possible influence 
of volume overload by pregnancy on pulmonary circulation. Jpn Circ J. 
1986;50:376–83.
 12. van Hagen IM, Thorne SA, Taha N, et al. Pregnancy outcomes in women 
with rheumatic mitral valve disease: results from the Registry of Pregnancy 
and Cardiac Disease. Circulation. 2018;137:806–16.
 13. Lancellotti P , Lebois F, Simon M, et al. Prognostic importance of quantita-
tive exercise Doppler echocardiography in asymptomatic valvular aortic 
stenosis. Circulation. 2005;112:I377–82.
 14. Maréchaux S, Hachicha Z, Bellouin A, et al. Usefulness of exercise-stress 
echocardiography for risk stratification of true asymptomatic patients 
with aortic valve stenosis. Eur Heart J. 2010;31:1390–7.
 15. Das P , Rimington H, Chambers J. Exercise testing to stratify risk in aortic 
stenosis. Eur Heart J. 2005;26:1309–13.
13.1.1. Medical Therapy for Women With VHD 
Before and During Pregnancy
 1. Elkayam U, Bitar F. Valvular heart disease and pregnancy part I: native 
valves. J Am Coll Cardiol. 2005;46:223–30.
 2. al Kasab SM, Sabag T, al Zaibag M, et al. Beta-adrenergic receptor block-
ade in the management of pregnant women with mitral stenosis. Am J 
Obstet Gynecol. 1990;163:37–40.
 3. Nakhjavan FK, Katz MR, Maranhao V, et al. Analysis of influence of cat-
echolamine and tachycardia during supine exercise in patients with mitral 
stenosis and sinus rhythm. Br Heart J. 1969;31:753–61.
 4. Bhatia ML, Shrivastava S, Roy SB. Immediate haemodynamic effects of 
a beta adrenergic blocking agent-propranolol-in mitral stenosis at fixed 
heart rates. Br Heart J. 1972;34:638–44.
 5. Lydakis C, Lip GY, Beevers M, et al. Atenolol and fetal growth in pregnan-
cies complicated by hypertension. Am J Hypertens. 1999;12:541–7.
 6. Ruys TP , Maggioni A, Johnson MR, et al. Cardiac medication during preg-
nancy, data from the ROPAC. Int J Cardiol. 2014;177:124–8.
 7. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC 
guidelines for the management of cardiovascular diseases during preg-
nancy. Eur Heart J. 2018;39:3165–241.
 8. Taylor J. The first ESC guidelines on the management of cardiovascular 
diseases during pregnancy. Eur Heart J. 2011;32:3055–6.
 9. Schaefer C. Angiotensin II-receptor-antagonists: further evidence of feto-
toxicity but not teratogenicity. Birth Defects Res Part A Clin Mol Teratol. 
2003;67:591–4.
 10. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital mal-
formations after first-trimester exposure to ACE inhibitors. N Engl J Med. 
2006;354:2443–51.
 11. Shotan A, Widerhorn J, Hurst A, et al. Risks of angiotensin-converting 
enzyme inhibition during pregnancy: experimental and clinical evi-
dence, potential mechanisms, and recommendations for use. Am J Med. 
1994;96:451–6.
 12. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the 
management of patients with atrial fibrillation: a report of the American 
College of Cardiology/American Heart Association Task Force on Practice 
Guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071–104.
 13. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused up-
date of the 2014 AHA/ACC/HRS guideline for the management of pa-
tients with atrial fibrillation: a report of the American College of Cardiol-
ogy/American Heart Association Task Force on Clinical Practice Guidelines 
and the Heart Rhythm Society. Developed in collaboration with the Society 
of Thoracic Surgeons. Circulation. 2019;140:e125–51.
13.1.2. Intervention for Women With Native VHD 
Before and During Pregnancy
13.1.2.1. Pre-Pregnancy Intervention
 1. Leśniak-Sobelga A, Tracz W, KostKiewicz M, et al. Clinical and echocar -
diographic assessment of pregnant women with valvular heart diseases—
maternal and fetal outcome. Int J Cardiol. 2004;94:15–23. 2. Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study 
of pregnancy outcomes in women with heart disease. Circulation. 
2001;104:515–21.
 3. Hameed A, Karaalp IS, Tummala PP , et al. The effect of valvular heart 
disease on maternal and fetal outcome of pregnancy. J Am Coll Cardiol. 
2001;37:893–9.
 4. Barbosa PJ, Lopes AA, Feitosa GS, et al. Prognostic factors of rheumatic 
mitral stenosis during pregnancy and puerperium. Arq Bras Cardiol. 
2000;75:215–24.
 5. Bhatla N, Lal S, Behera G, et al. Cardiac disease in pregnancy. Int J Gynae-
col Obstet. 2003;82:153–9.
 6. Orwat S, Diller G-P , van Hagen IM, et al. Risk of pregnancy in moderate 
and severe aortic stenosis: from the multinational ROPAC registry. J Am 
Coll Cardiol. 2016;68:1727–37.
 7. Tzemos N, Silversides CK, Colman JM, et al. Late cardiac outcomes af-
ter pregnancy in women with congenital aortic stenosis. Am Heart J. 
2009;157:474–80.
 8. Arias F, Pineda J. Aortic stenosis and pregnancy. J Reprod Med. 
1978;20:229–32.
 9. Silversides CK, Colman JM, Sermer M, et al. Early and intermediate-term 
outcomes of pregnancy with congenital aortic stenosis. Am J Cardiol. 
2003;91:1386–9.
 10. Yap S-C, Drenthen W, Pieper PG, et al. Risk of complications dur -
ing pregnancy in women with congenital aortic stenosis. Int J Cardiol. 
2008;126:240–6.
 11. Sugishita Y, Ito I, Kubo T. Pregnancy in cardiac patients: possible influence 
of volume overload by pregnancy on pulmonary circulation. Jpn Circ J. 
1986;50:376–83.
 12. Bryg RJ, Gordon PR, Kudesia VS, et al. Effect of pregnancy on pressure 
gradient in mitral stenosis. Am J Cardiol. 1989;63:384–6.
 13. Palacios IF, Sanchez PL, Harrell LC, et al. Which patients benefit from 
percutaneous mitral balloon valvuloplasty? Prevalvuloplasty and post-
valvuloplasty variables that predict long-term outcome. Circulation. 
2002;105:1465–71.
 14. van Hagen IM, Roos-Hesselink JW, Ruys TPE, et al. Pregnancy in women 
with a mechanical heart valve: data of the European Society of Cardi-
ology Registry of Pregnancy and Cardiac Disease (ROPAC). Circulation. 
2015;132:132–42.
 15. De Santo LS, Romano G, Della Corte A, et al. Mechanical aortic valve 
replacement in young women planning on pregnancy: maternal and fetal 
outcomes under low oral anticoagulation, a pilot observational study on 
a comprehensive pre-operative counseling protocol. J Am Coll Cardiol. 
2012;59:1110–5.
 16. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC 
guidelines for the management of cardiovascular diseases during preg-
nancy. Eur Heart J. 2018;39:3165–241.
13.1.2.2. During-Pregnancy Intervention
 1. Tzemos N, Silversides CK, Colman JM, et al. Late cardiac outcomes af-
ter pregnancy in women with congenital aortic stenosis. Am Heart J. 
2009;157:474–80.
 2. Banning AP , Pearson JF, Hall RJ. Role of balloon dilatation of the aor -
tic valve in pregnant patients with severe aortic stenosis. Br Heart J. 
1993;70:544–5.
 3. Easterling TR, Chadwick HS, Otto CM, et al. Aortic stenosis in pregnancy. 
Obstet Gynecol. 1988;72:113–8.
 4. Lao TT, Adelman AG, Sermer M, et al. Balloon valvuloplasty for congenital 
aortic stenosis in pregnancy. Br J Obstet Gynaecol. 1993;100:1141–2.
 5. McIvor RA. Percutaneous balloon aortic valvuloplasty during pregnancy. 
Int J Cardiol. 1991;32:1–3.
 6. Myerson SG, Mitchell ARJ, Ormerod OJM, et al. What is the role of balloon 
dilatation for severe aortic stenosis during pregnancy? J Heart Valve Dis. 
2005;14:147–50.
 7. Tumelero RT, Duda NT, Tognon AP , et al. Percutaneous balloon aortic 
valvuloplasty in a pregnant adolescent. Arq Bras Cardiol. 2004;82:  
98–101.
 8. McCann GP , Steadman CD, Ray SG, et al. Managing the asymptomatic 
patient with severe aortic stenosis: randomised controlled trials of early 
surgery are overdue. Heart. 2011;97:1119–21.
 9. Ben Farhat M, Gamra H, Betbout F, et al. Percutaneous balloon mitral 
commissurotomy during pregnancy. Heart. 1997;77:564–7.
 10. de Souza JA, Martinez EE Jr, Ambrose JA, et al. Percutaneous balloon mi-
tral valvuloplasty in comparison with open mitral valve commissurotomy 
for mitral stenosis during pregnancy. J Am Coll Cardiol. 2001;37:900–3.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e218
CLINICAL STATEMENTS  
AND GUIDELINES 11. Glantz JC, Pomerantz RM, Cunningham MJ, et al. Percutaneous balloon 
valvuloplasty for severe mitral stenosis during pregnancy: a review of ther -
apeutic options. Obstet Gynecol Surv. 1993;48:503–8.
 12. Iung B, Cormier B, Elias J, et al. Usefulness of percutaneous balloon 
commissurotomy for mitral stenosis during pregnancy. Am J Cardiol. 
1994;73:398–400.
 13. Weiss BM, von Segesser LK, Alon E, et al. Outcome of cardiovascular sur -
gery and pregnancy: a systematic review of the period 1984–1996. Am J 
Obstet Gynecol. 1998;179:1643–53.
 14. Becker RM. Intracardiac surgery in pregnant women. Ann Thorac Surg. 
1983;36:453–8.
 15. Chambers CE, Clark SL. Cardiac surgery during pregnancy. Clin Obstet 
Gynecol. 1994;37:316–23.
 16. Parry AJ, Westaby S. Cardiopulmonary bypass during pregnancy. Ann Tho-
rac Surg. 1996;61:1865–9.
 17. Gulraze A, Kurdi W, Niaz F, et al. Mitral balloon valvuloplasty during preg-
nancy: the long term up to 17 years obstetric outcome and childhood 
development. Pak J Med Sci. 2014;30:86–90.
 18. Vinayakumar D, Vinod GV, Madhavan S, et al. Maternal and fetal out-
comes in pregnant women undergoing balloon mitral valvotomy for rheu-
matic mitral stenosis. Indian Heart J. 2016;68:780–2.
 19. Salome N, Dias CC, Ribeiro J, et al. Balloon mitral valvuloplasty during 
pregnancy—our experience. Rev Port Cardiol. 2002;21:1437–44.
 20. Weiss BM, von Segesser LK, Alon E, et al. Outcome of cardiovascular sur -
gery and pregnancy: a systematic review of the period 1984–1996. Am J 
Obstet Gynecol. 1998;179:1643–53.
13.2. Prosthetic Valves in Pregnant 
Women
13.2.1. Initial Management
 1. Samiei N, Amirsardari M, Rezaei Y, et al. Echocardiographic evaluation of 
hemodynamic changes in left-sided heart valves in pregnant women with 
valvular heart disease. Am J Cardiol. 2016;118:1046–52.
 2. Goland S, Schwartzenberg S, Fan J, et al. Monitoring of anti-Xa in preg-
nant patients with mechanical prosthetic valves receiving low-molecular-
weight heparin: peak or trough levels? J Cardiovasc Pharmacol Ther. 
2014;19:451–6.
 3. Vause S, Clarke B, Tower CL, et al. Pregnancy outcomes in women with 
mechanical prosthetic heart valves: a prospective descriptive population 
based study using the United Kingdom Obstetric Surveillance System 
(UKOSS) data collection system. BJOG. 2017;124:1411–9.
 4. van Hagen IM, Roos-Hesselink JW, Ruys TPE, et al. Pregnancy in women 
with a mechanical heart valve: data of the European Society of Cardi-
ology Registry of Pregnancy and Cardiac Disease (ROPAC). Circulation. 
2015;132:132–42.
 5. D’Souza R, Ostro J, Shah PS, et al. Anticoagulation for pregnant women 
with mechanical heart valves: a systematic review and meta-analysis. Eur 
Heart J. 2017;38:1509–16.
 6. Steinberg ZL, Dominguez-Islas CP , Otto CM, et al. Maternal and fetal 
outcomes of anticoagulation in pregnant women with mechanical heart 
valves. J Am Coll Cardiol. 2017;69:2681–91.
 7. Lancellotti P , Pibarot P , Chambers J, et al. Recommendations for the im-
aging assessment of prosthetic heart valves: a report from the European 
Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 
2016;17:589–90.
 8. Tong AT, Roudaut R, Ozkan M, et al. Transesophageal echocardiogra-
phy improves risk assessment of thrombolysis of prosthetic valve throm-
bosis: results of the international PRO-TEE registry. J Am Coll Cardiol. 
2004;43:77–84.
 9. Özkan M, Çakal B, Karakoyun S, et al. Thrombolytic therapy for the 
treatment of prosthetic heart valve thrombosis in pregnancy with low-
dose, slow infusion of tissue-type plasminogen activator. Circulation. 
2013;128:532–40.
 10. Alshawabkeh L, Economy KE, Valente AM. Anticoagulation during preg-
nancy: evolving strategies with a focus on mechanical valves. J Am Coll 
Cardiol. 2016;68:1804–13.
 11. Tong AT, Roudaut R, Ozkan M, et al. Transesophageal echocardiogra-
phy improves risk assessment of thrombolysis of prosthetic valve throm-
bosis: results of the international PRO-TEE registry. J Am Coll Cardiol. 
2004;43:77–84.
 12. Ozkan M, Cakal B, Karakoyun S, et al. Thrombolytic therapy for the 
treatment of prosthetic heart valve thrombosis in pregnancy with low-dose, slow infusion of tissue-type plasminogen activator. Circulation. 
2013;128:532–40.
13.2.2. Anticoagulation for Pregnant Women 
With Mechanical Prosthetic Heart Valves
 1. Alshawabkeh L, Economy KE, Valente AM. Anticoagulation during preg-
nancy: evolving strategies with a focus on mechanical valves. J Am Coll 
Cardiol. 2016;68:1804–13.
 2. Samiei N, Amirsardari M, Rezaei Y, et al. Echocardiographic evaluation of 
hemodynamic changes in left-sided heart valves in pregnant women with 
valvular heart disease. Am J Cardiol. 2016;118:1046–52.
 3. D’Souza R, Ostro J, Shah PS, et al. Anticoagulation for pregnant women 
with mechanical heart valves: a systematic review and meta-analysis. Eur 
Heart J. 2017;38:1509–16.
 4. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women 
with mechanical heart valves: a systematic review of the literature. Arch 
Intern Med. 2000;160:191–6.
 5. Lawley CM, Lain SJ, Algert CS, et al. Prosthetic heart valves in pregnancy, 
outcomes for women and their babies: a systematic review and meta-
analysis. BJOG. 2015;122:1446–55.
 6. Xu Z, Fan J, Luo X, et al. Anticoagulation regimens during pregnancy in 
patients with mechanical heart valves: a systematic review and meta-anal-
ysis. Can J Cardiol. 2016;32:1248.e1–9.
 7. Batra J, Itagaki S, Egorova NN, et al. Outcomes and long-term effects of 
pregnancy in women with biologic and mechanical valve prostheses. Am 
J Cardiol. 2018;122:1738–44.
 8. Yinon Y, Siu SC, Warshafsky C, et al. Use of low molecular weight hepa-
rin in pregnant women with mechanical heart valves. Am J Cardiol. 
2009;104:1259–63.
 9. Rowan JA, McCowan LM, Raudkivi PJ, et al. Enoxaparin treatment in 
women with mechanical heart valves during pregnancy. Am J Obstet Gy-
necol. 2001;185:633–7.
 10. Abildgaard U, Sandset PM, Hammerstrøm J, et al. Management of preg-
nant women with mechanical heart valve prosthesis: thromboprophylaxis 
with low molecular weight heparin. Thromb Res. 2009;124:262–7.
 11. van Hagen IM, Roos-Hesselink JW, Ruys TPE, et al. Pregnancy in women 
with a mechanical heart valve: data of the European Society of Cardi-
ology Registry of Pregnancy and Cardiac Disease (ROPAC). Circulation. 
2015;132:132–42.
 12. Goland S, Schwartzenberg S, Fan J, et al. Monitoring of anti-Xa in preg-
nant patients with mechanical prosthetic valves receiving low-molecular-
weight heparin: peak or trough levels? J Cardiovasc Pharmacol Ther. 
2014;19:451–6.
 13. Elkayam U. Anticoagulation therapy for pregnant women with mechani-
cal prosthetic heart valves: how to improve safety? J Am Coll Cardiol. 
2017;69:2692–5.
 14. Vause S, Clarke B, Tower CL, et al. Pregnancy outcomes in women with 
mechanical prosthetic heart valves: a prospective descriptive population 
based study using the United Kingdom Obstetric Surveillance System 
(UKOSS) data collection system. BJOG. 2017;124:1411–9.
 15. Oran B, Lee-Parritz A, Ansell J. Low molecular weight heparin for the pro-
phylaxis of thromboembolism in women with prosthetic mechanical heart 
valves during pregnancy. Thromb Haemost. 2004;92:747–51.
 16. Steinberg ZL, Dominguez-Islas CP , Otto CM, et al. Maternal and fetal 
outcomes of anticoagulation in pregnant women with mechanical heart 
valves. J Am Coll Cardiol. 2017;69:2681–91.
 17. D’Souza R, Silversides CK, McLintock C. Optimal anticoagulation for 
pregnant women with mechanical heart valves. Semin Thromb Hemost. 
2016;42:798–804.
 18. Vitale N, De Feo M, De Santo LS, et al. Dose-dependent fetal complica-
tions of warfarin in pregnant women with mechanical heart valves. J Am 
Coll Cardiol. 1999;33:1637–41.
 19. Meschengieser SS, Fondevila CG, Santarelli MT, et al. Anticoagulation 
in pregnant women with mechanical heart valve prostheses. Heart. 
1999;82:23–6.
 20. Sadler L, McCowan L, White H, et al. Pregnancy outcomes and cardiac 
complications in women with mechanical, bioprosthetic and homograft 
valves. BJOG. 2000;107:245–53.
 21. Horlocker TT, Vandermeuelen E, Kopp SL, et al. Regional anesthesia in the 
patient receiving antithrombotic or thrombolytic therapy: American Soci-
ety of Regional Anesthesia and Pain Medicine evidence-based guidelines 
(fourth edition). Reg Anesth Pain Med. 2018;43:263–309.
 22. De Santo LS, Romano G, Della Corte A, et al. Mitral mechanical re-
placement in young rheumatic women: analysis of long-term survival, 
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e219
CLINICAL STATEMENTS  
AND GUIDELINESvalve-related complications, and pregnancy outcomes over a 3707-pa-
tient-year follow-up. J Thorac Cardiovasc Surg. 2005;130:13–9.
 23. Ayad SW, Hassanein MM, Mohamed EA, et al. Maternal and fetal out-
comes in pregnant women with a prosthetic mechanical heart valve. Clin 
Med Insights Cardiol. 2016;10:11–7.
 24. Al-Lawati AAM, Venkitraman M, Al-Delaime T, et al. Pregnancy and me-
chanical heart valves replacement; dilemma of anticoagulation. Eur J Car -
diothorac Surg. 2002;22:223–7.
 25. Hassouna A, Allam H. Limited dose warfarin throughout pregnancy in 
patients with mechanical heart valve prosthesis: a meta-analysis. Interact 
Cardiovasc Thorac Surg. 2014;18:797–806.
 26. Özkan M, Çakal B, Karakoyun S, et al. Thrombolytic therapy for the 
treatment of prosthetic heart valve thrombosis in pregnancy with low-
dose, slow infusion of tissue-type plasminogen activator. Circulation. 
2013;128:532–40.
 27. McLintock C, McCowan LME, North RA. Maternal complications and 
pregnancy outcome in women with mechanical prosthetic heart valves 
treated with enoxaparin. BJOG. 2009;116:1585–92.
 28. Massel DR, Little SH. Antiplatelet and anticoagulation for patients with 
prosthetic heart valves. Cochrane Database Syst Rev. 2013;CD003464.
 29. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran ver -
sus warfarin in patients with mechanical heart valves. N Engl J Med. 
2013;369:1206–14.
 30. Lameijer H, Aalberts JJJ, van Veldhuisen DJ, et al. Efficacy and safety of di-
rect oral anticoagulants during pregnancy; a systematic literature review. 
Thromb Res. 2018;169:123–7.
 31. Beyer-Westendorf J, Michalski F, Tittl L, et al. Pregnancy outcome in pa-
tients exposed to direct oral anticoagulants - and the challenge of event 
reporting. Thromb Haemost. 2016;116:651–8.
 32. Cohen H, Arachchillage DR, Middeldorp S, et al. Management of direct 
oral anticoagulants in women of childbearing potential: guidance from 
the SSC of the ISTH. J Thromb Haemost. 2016;14:1673–6.
 33. Quinn J, Von Klemperer K, Brooks R, et al. Use of high intensity adjusted 
dose low molecular weight heparin in women with mechanical heart 
valves during pregnancy: a single-center experience. Haematologica. 
2009;94:1608–12.
 34. James AH, Brancazio LR, Gehrig TR, et al. Low-molecular-weight heparin 
for thromboprophylaxis in pregnant women with mechanical heart valves. 
J Matern Fetal Neonatal Med. 2006;19:543–9.
 35. Meschengieser SS, Fondevila CG, Santarelli MT, et al. Anticoagulation 
in pregnant women with mechanical heart valve prostheses. Heart. 
1999;82:23–6.
 36. De Santo LS, Romano G, Della Corte A, et al. Mitral mechanical replace-
ment in young rheumatic women: analysis of long-term survival, valve-
related complications, and pregnancy outcomes over a 3707-patient-year 
follow-up. J Thorac Cardiovasc Surg. 2005;130:13–9.
 37. Al-Lawati AA, Venkitraman M, Al-Delaime T, et al. Pregnancy and me-
chanical heart valves replacement; dilemma of anticoagulation. Eur J Car -
diothorac Surg. 2002;22:223–7.
 38. De Santo LS, Romano G, Della Corte A, et al. Mechanical aortic valve replace-
ment in young women planning on pregnancy: maternal and fetal outcomes 
under low oral anticoagulation, a pilot observational study on a comprehen-
sive pre-operative counseling protocol. J Am Coll Cardiol. 2012;59:1110–5.
 39. McLintock C, McCowan LM, North RA. Maternal complications and preg-
nancy outcome in women with mechanical prosthetic heart valves treated 
with enoxaparin. BJOG. 2009;116:1585–92.
 40. Sillesen M, Hjortdal V, Vejlstrup N, et al. Pregnancy with prosthetic heart 
valves—30 years’ nationwide experience in Denmark. Eur J Cardiothorac 
Surg. 2011;40:448–54.
 41. James AH, Brancazio LR, Gehrig TR, et al. Low-molecular-weight heparin 
for thromboprophylaxis in pregnant women with mechanical heart valves. 
J Matern Fetal Neonatal Med. 2006;19:543–9.
 42. Salazar E, Izaguirre R, Verdejo J, et al. Failure of adjusted doses of subcutaneous 
heparin to prevent thromboembolic phenomena in pregnant patients with 
mechanical cardiac valve prostheses. J Am Coll Cardiol. 1996;27:1698–703.
 43. Sbarouni E, Oakley CM. Outcome of pregnancy in women with valve pros-
theses. Br Heart J. 1994;71:196–201.
 44. Ozkan M, Cakal B, Karakoyun S, et al. Thrombolytic therapy for the 
treatment of prosthetic heart valve thrombosis in pregnancy with low-
dose, slow infusion of tissue-type plasminogen activator. Circulation. 
2013;128:532–40.
 45. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran ver -
sus warfarin in patients with mechanical heart valves. N Engl J Med. 
2013;369:1206–14.14. SURGICAL CONSIDERATIONS
14.1. Evaluation and Management of 
CAD in Patients With VHD
14.1.1. Management of CAD in Patients 
Undergoing TAVI
 1. Bajaj A, Pancholy S, Sethi A, et al. Safety and feasibility of PCI in patients 
undergoing TAVR: a systematic review and meta-analysis. Heart Lung. 
2017;46:92–9.
 2. Chakravarty T, Sharma R, Abramowitz Y, et al. Outcomes in patients with 
transcatheter aortic valve replacement and left main stenting: the TAVR-
LM registry. J Am Coll Cardiol. 2016;67:951–60.
 3. Mohr FW, Morice M-C, Kappetein AP , et al. Coronary artery bypass graft 
surgery versus percutaneous coronary intervention in patients with three-
vessel disease and left main coronary disease: 5-year follow-up of the 
randomised, clinical SYNTAX trial. Lancet. 2013;381:629–38.
 4. Thalji NM, Suri RM, Daly RC, et al. The prognostic impact of concomitant 
coronary artery bypass grafting during aortic valve surgery: implications 
for revascularization in the transcatheter era. J Thorac Cardiovasc Surg. 
2015;149:451–60.
 5. Faroux L, Guimaraes L, Wintzer-Wehekind J, et al. Coronary artery disease 
and transcatheter aortic valve replacement: JACC state-of-the-art review. 
J Am Coll Cardiol. 2019;74:362–72.
 6. Goel SS, Ige M, Tuzcu EM, et al. Severe aortic stenosis and coronary artery 
disease—implications for management in the transcatheter aortic valve 
replacement era: a comprehensive review. J Am Coll Cardiol. 2013;62:1–
10.
 7. Sankaramangalam K, Banerjee K, Kandregula K, et al. Impact of coro-
nary artery disease on 30-day and 1-year mortality in patients undergoing 
transcatheter aortic valve replacement: a meta-analysis. J Am Heart Assoc. 
2017;6:e006092.
 8. Millan-Iturbe O, Sawaya FJ, Lønborg J, et al. Coronary artery disease, 
revascularization, and clinical outcomes in transcatheter aortic valve re-
placement: real-world results from the East Denmark Heart Registry. Cath-
eter Cardiovasc Interv. 2018;92:818–26.
 9. Witberg G, Regev E, Chen S, et al. The prognostic effects of coronary 
disease severity and completeness of revascularization on mortality in pa-
tients undergoing transcatheter aortic valve replacement. JACC Cardio-
vasc Interv. 2017;10:1428–35.
 10. Chieffo A, Giustino G, Spagnolo P , et al. Routine screening of coronary 
artery disease with computed tomographic coronary angiography in place 
of invasive coronary angiography in patients undergoing transcatheter 
aortic valve replacement. Circ Cardiovasc Interv. 2015;8:e002025.
 11. Rossi A, De Cecco CN, Kennon SRO, et al. CT angiography to evalu-
ate coronary artery disease and revascularization requirement before 
trans-catheter aortic valve replacement. J Cardiovasc Comput Tomogr. 
2017;11:338–46.
 12. van den Boogert TPW, Vendrik J, Claessen B, et al. CTCA for detection of 
significant coronary artery disease in routine TAVI work-up: A systematic 
review and meta-analysis. Neth Heart J. 2018;26:591–9.
 13. Pesarini G, Scarsini R, Zivelonghi C, et al. Functional assessment of coro-
nary artery disease in patients undergoing transcatheter aortic valve im-
plantation: influence of pressure overload on the evaluation of lesions 
severity. Circ Cardiovasc Interv. 2016;9:e004088.
 14. Ahmad Y, Götberg M, Cook C, et al. Coronary hemodynamics in patients 
with severe aortic stenosis and coronary artery disease undergoing trans-
catheter aortic valve replacement: implications for clinical indices of coro-
nary stenosis severity. JACC Cardiovasc Interv. 2018;11:2019–31.
 15. Yamanaka F, Shishido K, Ochiai T, et al. Instantaneous wave-free ratio for 
the assessment of intermediate coronary artery stenosis in patients with 
severe aortic valve stenosis: comparison with myocardial perfusion scintig-
raphy. JACC Cardiovasc Interv. 2018;11:2032–40.
14.1.2. Management of CAD in Patients 
Undergoing Valve Surgery
 1. Graboys TB, Cohn PF. The prevalence of angina pectoris and abnormal 
coronary arteriograms in severe aortic valvular disease. Am Heart J. 
1977;93:683–6.
 2. Ramsdale DR, Bennett DH, Bray CL, et al. Angina, coronary risk factors 
and coronary artery disease in patients with valvular disease. A prospective 
study. Eur Heart J. 1984;5:716–26.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e220
CLINICAL STATEMENTS  
AND GUIDELINES 3. Dangas G, Khan S, Curry BH, et al. Angina pectoris in severe aortic steno-
sis. Cardiology. 1999;92:1–3.
 4. Basta LL, Raines D, Najjar S, et al. Clinical, haemodynamic, and coronary 
angiographic correlates of angina pectoris in patients with severe aortic 
valve disease. Br Heart J. 1975;37:150–7.
 5. Thalji NM, Suri RM, Daly RC, et al. Assessment of coronary artery disease risk in 
5463 patients undergoing cardiac surgery: when is preoperative coronary an-
giography necessary? J Thorac Cardiovasc Surg. 2013;146:1055–63, 64.e1.
 6. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the 
Framingham Study. Am J Cardiol. 1976;38:46–51.
 7. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical 
diagnosis of coronary-artery disease. N Engl J Med. 1979;300:1350–8.
 8. Heidenreich PA, Kapoor JR. Radiation induced heart disease: systemic dis-
orders in heart disease. Heart. 2009;95:252–8.
 9. Gahl K, Sutton R, Pearson M, et al. Mitral regurgitation in coronary heart 
disease. Br Heart J. 1977;39:13–8.
 10. Enriquez-Sarano M, Klodas E, Garratt KN, et al. Secular trends in coronary 
atherosclerosis—analysis in patients with valvular regurgitation. N Engl J 
Med. 1996;335:316–22.
 11. Breisblatt WM, Cerqueira M, Francis CK, et al. Left ventricular function in 
ischemic mitral regurgitation–a precatheterization assessment. Am Heart 
J. 1988;115:77–82.
 12. Mark DB, Berman DS, Budoff MJ, et al. ACCF/ACR/AHA/NASCI/SAIP/
SCAI/SCCT 2010 expert consensus document on coronary computed to-
mographic angiography: a report of the American College of Cardiology 
Foundation Task Force on Expert Consensus Documents. J Am Coll Car -
diol. 2010;55:2663–99.
 13. Opolski MP , Kim WK, Liebetrau C, et al. Diagnostic accuracy of computed 
tomography angiography for the detection of coronary artery disease in 
patients referred for transcatheter aortic valve implantation. Clin Res Car -
diol. 2015;104:471–80.
 14. Hamdan A, Wellnhofer E, Konen E, et al. Coronary CT angiography for the 
detection of coronary artery stenosis in patients referred for transcatheter 
aortic valve replacement. J Cardiovasc Comput Tomogr. 2015;9:31–41.
 15. Andreini D, Pontone G, Mushtaq S, et al. Diagnostic accuracy of multide-
tector computed tomography coronary angiography in 325 consecutive 
patients referred for transcatheter aortic valve replacement. Am Heart J. 
2014;168:332–9.
 16. Chieffo A, Giustino G, Spagnolo P , et al. Routine screening of coronary 
artery disease with computed tomographic coronary angiography in place 
of invasive coronary angiography in patients undergoing transcatheter 
aortic valve replacement. Circ Cardiovasc Interv. 2015;8:e002025.
 17. Matsumoto S, Yamada Y, Hashimoto M, et al. CT imaging before trans-
catheter aortic valve implantation (TAVI) using variable helical pitch scan-
ning and its diagnostic performance for coronary artery disease. Eur Ra-
diol. 2017;27:1963–70.
 18. Rossi A, De Cecco CN, Kennon SRO, et al. CT angiography to evaluate coro-
nary artery disease and revascularization requirement before trans-catheter 
aortic valve replacement. J Cardiovasc Comput Tomogr. 2017;11:338–46.
 19. Thalji NM, Suri RM, Daly RC, et al. The prognostic impact of concomitant 
coronary artery bypass grafting during aortic valve surgery: implications 
for revascularization in the transcatheter era. J Thorac Cardiovasc Surg. 
2015;149:451–60.
 20. Byrne JG, Leacche M, Vaughan DE, et al. Hybrid cardiovascular proce-
dures. JACC Cardiovasc Interv. 2008;1:459–68.
 21. Pontone G, Andreini D, Bartorelli AL, et al. Feasibility and accuracy of a 
comprehensive multidetector computed tomography acquisition for pa-
tients referred for balloon-expandable transcatheter aortic valve implanta-
tion. Am Heart J. 2011;161:1106–13.
 22. Lund O, Nielsen TT, Pilegaard HK, et al. The influence of coronary artery 
disease and bypass grafting on early and late survival after valve replace-
ment for aortic stenosis. J Thorac Cardiovasc Surg. 1990;100:327–37.
 23. Beach JM, Mihaljevic T, Svensson LG, et al. Coronary artery disease and 
outcomes of aortic valve replacement for severe aortic stenosis. J Am Coll 
Cardiol. 2013;61:837–48.
14.2. Intervention for AF in Patients With 
VHD
 1. Ad N, Henry L, Hunt S, et al. Do we increase the operative risk by add-
ing the Cox Maze III procedure to aortic valve replacement and coronary 
artery bypass surgery? J Thorac Cardiovasc Surg. 2012;143:936–44. 2. Badhwar V, Rankin JS, Damiano RJ Jr, et al. The Society of Thoracic Sur -
geons 2017 clinical practice guidelines for the surgical treatment of atrial 
fibrillation. Ann Thorac Surg. 2017;103:329–41.
 3. Ad N, Holmes SD, Pritchard G, et al. Association of operative risk with the 
outcome of concomitant Cox Maze procedure: a comparison of results 
across risk groups. J Thorac Cardiovasc Surg. 2014;148:3027–33.
 4. Ad N, Holmes SD, Rongione AJ, et al. The long-term safety and efficacy of 
concomitant Cox maze procedures for atrial fibrillation in patients without 
mitral valve disease. J Thorac Cardiovasc Surg. 2019;157:1505–14.
 5. Gillinov AM, Bakaeen F, McCarthy PM, et al. Surgery for paroxysmal atrial 
fibrillation in the setting of mitral valve disease: a role for pulmonary vein 
isolation? Ann Thorac Surg. 2006;81:19–26.
 6. Gillinov AM, Gelijns AC, Parides MK, et al. Surgical ablation of atri-
al fibrillation during mitral-valve surgery. N Engl J Med. 2015;372: 
1399–409.
 7. Abreu Filho CA, Lisboa LA, Dallan LA, et al. Effectiveness of the maze 
procedure using cooled-tip radiofrequency ablation in patients with per -
manent atrial fibrillation and rheumatic mitral valve disease. Circulation. 
2005;112:I20–5.
 8. Akpinar B, Guden M, Sagbas E, et al. Combined radiofrequency modified 
maze and mitral valve procedure through a port access approach: early 
and mid-term results. Eur J Cardiothorac Surg. 2003;24:223–30.
 9. Chua YL, Schaff HV, Orszulak TA, et al. Outcome of mitral valve repair 
in patients with preoperative atrial fibrillation. Should the maze proce-
dure be combined with mitral valvuloplasty? J Thorac Cardiovasc Surg. 
1994;107:408–15.
 10. Deneke T, Khargi K, Grewe PH, et al. Efficacy of an additional MAZE pro-
cedure using cooled-tip radiofrequency ablation in patients with chronic 
atrial fibrillation and mitral valve disease. A randomized, prospective trial. 
Eur Heart J. 2002;23:558–66.
 11. Jessurun ER, van Hemel NM, Defauw JJ, et al. A randomized study of 
combining maze surgery for atrial fibrillation with mitral valve surgery. J 
Cardiovasc Surg (Torino). 2003;44:9–18.
 12. Rankin JS, Grau-Sepulveda MV, Ad N, et al. Associations between surgical 
ablation and operative mortality after mitral valve procedures. Ann Thorac 
Surg. 2018;105:1790–6.
 13. Ad N, Holmes SD, Lamont D, et al. Left-sided surgical ablation for patients 
with atrial fibrillation who are undergoing concomitant cardiac surgical 
procedures. Ann Thorac Surg. 2017;103:58–65.
 14. Huffman MD, Karmali KN, Berendsen MA, et al. Concomitant atrial fibril-
lation surgery for people undergoing cardiac surgery. Cochrane Database 
Syst Rev. 2016;CD011814.
 15. Huffman MD, Malaisrie SC, Karmali KN. Concomitant atrial fibrilla-
tion surgery for people undergoing cardiac surgery. JAMA Cardiol. 
2017;2:334–5.
 16. Friedman DJ, Piccini JP , Wang T, et al. Association between left atrial 
appendage occlusion and readmission for thromboembolism among 
patients with atrial fibrillation undergoing concomitant cardiac surgery. 
JAMA. 2018;319:365–74.
 17. Yao X, Gersh BJ, Holmes DR Jr, et al. Association of surgical left atrial ap-
pendage occlusion with subsequent stroke and mortality among patients 
undergoing cardiac surgery. JAMA. 2018;319:2116–26.
 18. Johnsrud DO, Melduni RM, Lahr B, et al. Evaluation of anticoagulation 
use and subsequent stroke in patients with atrial fibrillation after empiric 
surgical left atrial appendage closure: A retrospective case-control study. 
Clin Cardiol. 2018;41:1578–82.
 19. Abrich VA, Narichania AD, Love WT, et al. Left atrial appendage exclusion 
during mitral valve surgery and stroke in atrial fibrillation. J Interv Card 
Electrophysiol. 2018;53:285–92.
 20. García-Fernández MA, Pérez-David E, Quiles J, et al. Role of left atrial 
appendage obliteration in stroke reduction in patients with mitral valve 
prosthesis: a transesophageal echocardiographic study. J Am Coll Cardiol. 
2003;42:1253–8.
 21. Noseworthy PA, Yao X, Deshmukh AJ, et al. Patterns of anticoagulation 
use and cardioembolic risk after catheter ablation for atrial fibrillation. J 
Am Heart Assoc. 2015;4:e002597.
 22. Eitel C, Koch J, Sommer P , et al. Novel oral anticoagulants in a real-world 
cohort of patients undergoing catheter ablation of atrial fibrillation. Euro-
pace. 2013;15:1587–93.
 23. Melduni RM, Schaff HV, Lee H-C, et al. Impact of left atrial appendage clo-
sure during cardiac surgery on the occurrence of early postoperative atrial 
fibrillation, stroke, and mortality: a propensity score-matched analysis of 
10 633 patients. Circulation. 2017;135:366–78.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021
 e221
CLINICAL STATEMENTS  
AND GUIDELINES15. NONCARDIAC SURGERY IN 
PATIENTS WITH VHD
15.1. Diagnosis of Patients With VHD 
Undergoing Noncardiac Surgery
 1. Liu JB, Liu Y, Cohen ME, et al. Defining the intrinsic cardiac risks of opera-
tions to improve preoperative cardiac risk assessments. Anesthesiology. 
2018;128:283–92.
 2. Wijeysundera DN, Pearse RM, Shulman MA, et al. Assessment of function-
al capacity before major non-cardiac surgery: an international, prospective 
cohort study. Lancet. 2018;391:2631–40.
 3. Dakik HA, Chehab O, Eldirani M, et al. A new index for pre-operative 
cardiovascular evaluation. J Am Coll Cardiol. 2019;73:3067–78.
 4. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for 
the management of patients with valvular heart disease: a report of the 
American College of Cardiology/American Heart Association Task Force 
on Practice Guidelines. Circulation. 2014;129:e521–643.
 5. Douglas PS, Garcia MJ, Haines DE, et al. ACCF/ASE/AHA/ASNC/HFSA/
HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocar -
diography. A report of the American College of Cardiology Foundation 
Appropriate Use Criteria Task Force, American Society of Echocardiog-
raphy, American Heart Association, American Society of Nuclear Cardi-
ology, Heart Failure Society of America, Heart Rhythm Society, Society 
for Cardiovascular Angiography and Interventions, Society of Critical 
Care Medicine, Society of Cardiovascular Computed Tomography, So-
ciety for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 
2011;24:229–67.
15.2. Management of the Symptomatic 
Patient
 1. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guide-
line on perioperative cardiovascular evaluation and management of pa-
tients undergoing noncardiac surgery: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines. 
Circulation. 2014;130:e278–333.
 2. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline 
for the management of patients with valvular heart disease: a report 
of the American College of Cardiology/American Heart Association 
Task Force on Practice Guidelines. Circulation. 2014;129:e521–643. 
 3. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-
valve replacement with a self-expanding prosthesis. N Engl J Med. 
2014;370:1790–8.
 4. Reardon MJ, Adams DH, Kleiman NS, et al. 2-Year outcomes in patients 
undergoing surgical or self-expanding transcatheter aortic valve replace-
ment. J Am Coll Cardiol. 2015;66:113–21.
 5. Thyregod HGH, Steinbrüchel DA, Ihlemann N, et al. Transcatheter versus 
surgical aortic valve replacement in patients with severe aortic valve ste-
nosis: 1-year results from the all-comers NOTION randomized clinical trial. 
J Am Coll Cardiol. 2015;65:2184–94.
 6. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aor -
tic-valve replacement in intermediate-risk patients. N Engl J Med. 
2016;374:1609–20.
 7. Thourani VH, Kodali S, Makkar RR, et al. Transcatheter aortic valve re-
placement versus surgical valve replacement in intermediate-risk patients: 
a propensity score analysis. Lancet. 2016;387:2218–25.
 8. Okuno T, Yahagi K, Horiuchi Y, et al. The role of transcatheter aor -
tic valve replacement in the patients with severe aortic stenosis re-
quiring major non-cardiac surgery. Cardiovasc Interv Ther. 2019;  
34:345–51.
 9. Kogoj P , Devjak R, Bunc M. Balloon aortic valvuloplasty (BAV) as a bridge 
to aortic valve replacement in cancer patients who require urgent non-
cardiac surgery. Radiol Oncol. 2014;48:62–6.
 10. Calicchio F, Guarracino F, Giannini C, et al. Balloon aortic valvuloplasty 
before noncardiac surgery in severe aortic stenosis: a single-center experi-
ence. J Cardiovasc Med (Hagerstown). 2017;18:109–13.
 11. Kennon S, Archbold A. Expert opinion: guidelines for the management of 
patients with aortic stenosis undergoing non-cardiac surgery: out of date 
and overly prescriptive. Interv Cardiol. 2017;12:133–6.15.3. Management of the Asymptomatic 
Patient
 1. Agarwal S, Rajamanickam A, Bajaj NS, et al. Impact of aortic stenosis on 
postoperative outcomes after noncardiac surgeries. Circ Cardiovasc Qual 
Outcomes. 2013;6:193–200.
 2. Zahid M, Sonel AF, Saba S, et al. Perioperative risk of noncardiac surgery 
associated with aortic stenosis. Am J Cardiol. 2005;96:436–8.
 3. Tashiro T, Pislaru SV, Blustin JM, et al. Perioperative risk of major non-
cardiac surgery in patients with severe aortic stenosis: a reappraisal in 
contemporary practice. Eur Heart J. 2014;35:2372–81.
 4. Bajaj NS, Agarwal S, Rajamanickam A, et al. Impact of severe mitral regur -
gitation on postoperative outcomes after noncardiac surgery. Am J Med. 
2013;126:529–35.
 5. Lai H-C, Lai H-C, Lee W-L, et al. Mitral regurgitation complicates postop-
erative outcome of noncardiac surgery. Am Heart J. 2007;153:712–7.
 6. Meyer S, McLaughlin VV, Seyfarth H-J, et al. Outcomes of noncardiac, 
nonobstetric surgery in patients with PAH: an international prospective 
survey. Eur Respir J. 2013;41:1302–7.
 7. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hy-
pertension in adults: update of the CHEST guideline and expert panel 
report. Chest. 2019;155:565–86.
 8. Lai H-C, Lai H-C, Lee W-L, et al. Impact of chronic advanced aortic regur -
gitation on the perioperative outcome of noncardiac surgery. Acta Anaes-
thesiol Scand. 2010;54:580–8.
 9. Goertz AW, Lindner KH, Seefelder C, et al. Effect of phenylephrine bolus 
administration on global left ventricular function in patients with coronary 
artery disease and patients with valvular aortic stenosis. Anesthesiology. 
1993;78:834–41.
 10. Goertz AW, Lindner KH, Schütz W, et al. Influence of phenylephrine bolus 
administration on left ventricular filling dynamics in patients with coronary 
artery disease and patients with valvular aortic stenosis. Anesthesiology. 
1994;81:49–58.
 11. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guide-
line on perioperative cardiovascular evaluation and management of pa-
tients undergoing noncardiac surgery: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines. 
Circulation. 2014;130:e278–333.
 12. Christ M, Sharkova Y, Geldner G, et al. Preoperative and perioperative 
care for patients with suspected or established aortic stenosis facing non-
cardiac surgery. Chest. 2005;128:2944–53.
 13. O’Keefe JHJ, Shub C, Rettke SR. Risk of noncardiac surgical procedures in 
patients with aortic stenosis. Mayo Clin Proc. 1989;64:400–5.
 14. Ho MC, Beathe JC, Sharrock NE. Hypotensive epidural anesthesia in pa-
tients with aortic stenosis undergoing total hip replacement. Reg Anesth 
Pain Med. 2008;33:129–33.
 15. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for 
the management of patients with valvular heart disease: a report of the 
American College of Cardiology/American Heart Association Task Force 
on Practice Guidelines. Circulation. 2014;129:e521–643.
 16. Mittnacht AJ, Fanshawe M, Konstadt S. Anesthetic considerations in the 
patient with valvular heart disease undergoing noncardiac surgery. Semin 
Cardiothorac Vasc Anesth. 2008;12:33–59.
 17. Frogel J, Galusca D. Anesthetic considerations for patients with advanced 
valvular heart disease undergoing noncardiac surgery. Anesthesiol Clin. 
2010;28:67–85.
 18. Smilowitz NR, Armanious A, Bangalore S, et al. Cardiovascular outcomes 
of patients with pulmonary hypertension undergoing noncardiac surgery. 
Am J Cardiol. 2019;123:1532–7.
16. EVIDENCE GAPS AND FUTURE 
DIRECTIONS
16.1. Prevention of Valve Disease: Stage A
 1. Nazarzadeh M, Pinho-Gomes A-C, Smith Byrne K, et al. Systolic blood 
pressure and risk of valvular heart disease: a mendelian randomization 
study. JAMA Cardiol. 2019;4:788–95.
 2. Lindman BR, Clavel M-A, Mathieu P , et al. Calcific aortic stenosis. Nat Rev 
Dis Primers. 2016;2:16006.
 3. Lindman BR. Aortic stenosis: moving from treatment to prevention. J Am 
Coll Cardiol. 2017;69:1533–5.
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923
 e222
CLINICAL STATEMENTS  
AND GUIDELINES 4. Atkins SK, Aikawa E. Valve under the microscope: shining a light on emerging 
technologies elucidating disease mechanisms. Heart. 2019;105:1610–1.
 5. Peeters FECM, Meex SJR, Dweck MR, et al. Calcific aortic valve stenosis: 
hard disease in the heart: a biomolecular approach towards diagnosis and 
treatment. Eur Heart J. 2018;39:2618–24.
 6. Carapetis JR. Rheumatic heart disease in developing countries. N Engl J 
Med. 2007;357:439–41.
 7. Soler-Soler J, Galve E. Worldwide perspective of valve disease. Heart. 
2000;83:721–5.
 8. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: 
a population-based study. Lancet. 2006;368:1005–11.
 9. Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease 
and stroke statistics—2013 update: a report from the American Heart As-
sociation. Circulation. 2013;127:143–52.
 10. Hagler MA, Hadley TM, Zhang H, et al. TGF-β signalling and reactive oxy-
gen species drive fibrosis and matrix remodelling in myxomatous mitral 
valves. Cardiovasc Res. 2013;99:175–84.
 11. Miller JD, Weiss RM, Heistad DD. Calcific aortic valve stenosis: methods, 
models, and mechanisms. Circ Res. 2011;108:1392–412.
 12. Lindman BR, Arnold SV, Bagur R, et al. Priorities for patient-centered re-
search in valvular heart disease: a report from the National Heart, Lung, 
and Blood Institute Working Group. J Am Heart Assoc. 2020;9:e015975.
16.2. Medical Therapy to Treat or Prevent 
Disease Progression: Stage B
 1. Park SJ, Dweck MR. Multimodality imaging for the assessment of severe 
aortic stenosis. J Cardiovasc Imaging. 2019;27:235–46.
 2. Everett RJ, Dweck MR. Renin-angiotensin system inhibition in aortic ste-
nosis: thinking beyond transcatheter aortic valve replacement. J Am Coll 
Cardiol. 2019;74:642–4.
 3. Lindman BR, Otto CM, Douglas PS, et al. Blood pressure and arterial load 
after transcatheter aortic valve replacement for aortic stenosis. Circ Car -
diovasc Imaging. 2017;10:e006308. 4. Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with 
valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503–12.
 5. Lindman BR, Arnold SV, Bagur R, et al. Priorities for patient-cen-
tered research in valvular heart disease: a report from the National 
Heart, Lung, and Blood Institute Working Group. J Am Heart Assoc. 
2020;9:e015975.
16.3. Optimal Timing of Intervention: 
Stage C
 1. Nicolau S, Ionescu T, Cleanoveanu G, et al. [National system for the reg-
istration of congenital malformations and genetic diseases] [Article in Ro-
manian]. Rev Pediatr Obstet Ginecol Pediatr. 1987;36:193–215.
 2. Campo J, Tsoris A, Kruse J, et al. Prognosis of severe asymptomatic aortic 
stenosis with and without surgery. Ann Thorac Surg. 2019;108:74–9.
 3. Kataruka A, Otto CM. Valve durability after transcatheter aortic valve im-
plantation. J Thorac Dis. 2018;10:S3629–S36.
 4. Lindman BR, Arnold SV, Bagur R, et al. Priorities for patient-centered re-
search in valvular heart disease: a report from the National Heart, Lung, 
and Blood Institute Working Group. J Am Heart Assoc. 2020;9:e015975.
16.4. Better Options for Intervention: 
Stage D
 1. Otto CM. Informed shared decisions for patients with aortic stenosis. N 
Engl J Med. 2019;380:1769–70.
 2. Lindman BR, Clavel M-A, Mathieu P , et al. Calcific aortic stenosis. Nat Rev 
Dis Primers. 2016;2:16006.
 3. Lindman BR, Arnold SV, Bagur R, et al. Priorities for patient-centered re-
search in valvular heart disease: a report from the National Heart, Lung, 
and Blood Institute Working Group. J Am Heart Assoc. 2020;9:e015975.
Appendix 1. Author Relationships With Industry and Other Entities (Relevant)—2020 ACC/AHA Guideline for the Management of Patients With 
Valvular Heart Disease
Committee 
Member Employment ConsultantSpeakers 
BureauOwnership/ 
Partnership/ 
PrincipalPersonal 
ResearchInstitutional, 
Organizational, 
or Other 
Financial BenefitExpert 
WitnessVoting 
Recusals by 
Section
Catherine M. 
Otto (Co-Chair)University of Washington— 
J. Ward Kennedy-Hamilton 
Endowed Chair in Cardiology 
and Professor of MedicineNone None None None None None None
Rick A. 
Nishimura
(Co-Chair)Mayo Clinic—Department 
of Cardiovascular Medicine 
and Judd and Mary Morris 
Leighton Professor of 
Cardiovascular Diseases and 
HypertensionNone None None None None None None
Robert O. 
BonowNorthwestern University, 
Feinberg School of Medicine—
Vice Chair for Development 
and Innovation, Department 
of Medicine; Max and Lilly 
Goldberg Distinguished 
Professor of Cardiology; and 
Professor of MedicineNone None None None None None None
Blase A. 
CarabelloEast Carolina Heart Institute 
at East Carolina University—
Professor and Chief, Division 
of CardiologyNone None None •  Edwards 
Lifesciences 
(DSMB)†None None 3, 4, 5, 6, 7, 8, 
9, 10, 12, 13, 
14, 15
John P . Erwin III Clinical Department Chair of 
Internal Medicine, NorthShore 
University Health System Clinical 
Professor, University of Chicago 
Pritzker School of MedicineNone None None None None None None
(Continued )
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e223
CLINICAL STATEMENTS  
AND GUIDELINESFederico 
GentileCentro Cardiologico Gentile, 
Naples, ItalyNone None None None None None None
Hani Jneid Baylor College of Medicine—
Associate Professor of 
Medicine; The Michael 
DeBakey VA Medical Center—
Director of Interventional 
Cardiology ResearchNone None None None None None None
Eric V. Krieger University of Washington, 
School of Medicine—
Associate Professor of 
Medicine; Director, Seattle 
Adult Congenital Heart 
Disease ServiceNone None None None None None None
Michael Mack Baylor Scott & White 
Health—Chair, Cardiovascular 
Service lineNone None None •  Abbott 
Vascular†
•  Edwards 
Lifesciences†
•  Medtronic†None None 3, 4, 5, 6, 7, 8, 
9, 10, 11, 12, 
13, 14, 15
Christopher 
McLeodMayo Clinic—Clinical Director 
for Cardiovascular Medicine 
(Jacksonville, FL)None None None None None None None
Patrick T. 
O’GaraWatkins Family Distinguished 
Chair in Cardiology, Brigham 
and Women’s Hospital: 
Professor of Medicine Harvard 
Medical SchoolNone None None None •  Edwards 
Scientific†
•  MedtronicNone 3, 4, 5, 6, 7, 8, 
9, 10, 12, 13, 
14, 15
Vera H. Rigolin Northwestern University, 
Feinberg School of 
Medicine—Professor of 
Medicine (Cardiology)None None • AstraZeneca 
•  Merck/
Schering-
Plough*
•  Pfizer*None None None 3, 4, 5, 6, 7, 8, 
9, 10, 11, 13, 
14, 15
Thoralf M. 
Sundt IIIMassachusetts General 
Hospital—Chief, Division of 
Cardiac Surgery; Co-Director, 
Corrigan Minehan Heart CenterNone None None •  Thrasos* •  Edwards 
Lifesciences‡
•  Medtronic‡None 3, 4, 5, 6, 7, 8, 
9, 10, 12, 13, 
14, 15
Annemarie 
ThompsonDuke University Medical 
Center—Professor of 
Anesthesiology, Medicine, and 
Population Health Sciences, 
Director, Anesthesiology 
Residency ProgramNone None None None None None None
Christopher 
TolySimulab Corporation—Chief 
Executive Officer, Chief 
Technology OfficerNone None None None None None None
This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These 
relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the Writing Committee during the document development 
process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business 
if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5000 of the fair market value of the business 
entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no 
financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to https://www.acc.
org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy for definitions of disclosure categories or additional information about 
the ACC/AHA Disclosure Policy for Writing Committees.
*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply.
†Significant relationship.
‡This disclosure was entered under the Clinical Trial Enroller category in ACC’s disclosure system. To appear in this category, the author acknowledges that there 
is no direct or institutional relationship with the trial sponsor as defined in the (ACCF or ACC/AHA) Disclosure Policy for Writing Committees.
ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; AHA, American Heart Association; DSMB, Data and Safety 
Monitoring Board; FL, Florida; and VA, Veterans Affairs.Appendix 1. Continued
Committee 
Member Employment ConsultantSpeakers 
BureauOwnership/ 
Partnership/ 
PrincipalPersonal 
ResearchInstitutional, 
Organizational, 
or Other 
Financial BenefitExpert 
WitnessVoting 
Recusals by 
Section
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e224
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive)—2020 ACC/AHA Guideline for the Management of 
Patients With Valvular Heart Disease
Reviewer Representation Employment ConsultantSpeakers 
BureauOwnership/ 
Partnership/
PrincipalPersonal  
ResearchInstitutional, 
Organizational, 
or Other Financial 
BenefitExpert 
Witness
Abigail M. 
KhanOfficial Reviewer—
AHAOregon Health and Science 
UniversityNone None None None None None
Andrew R. 
WaxlerOfficial Reviewer—
Board of Governors 
AlternatePenn State Health None •  Amarin*
•  Sanofi–
Regeron*None None •  DalCor 
Pharmaceutical
•  Medicines 
Company
•  Penn State–St 
Joseph Medical 
Center Foundation 
Board Member†
•  Penn State–St. 
Joseph Medical 
Center Pharmacy 
and Therapeutics 
Committee 
Member†
•  Pfizer Inc
•  Regeneron
•  SanofiNone
Daniel M. 
ShindlerOfficial Reviewer—
ACC Board of 
GovernorsUniversity of Medicine and 
Dentistry, Robert Wood 
Johnson Medical School, 
New Brunswick, New JerseyNone None None None None None
William A. 
Zoghbi Official Reviewer—
ACC Clinical Policy 
Approval CommitteeHouston Methodist-
Chairman, Department of 
CardiologyNone None None None None None
Y. Joseph 
WooContent Reviewer—
Joint Committee 
on Clinical Practice 
Guidelines Stanford University School 
of MedicineNone None None None •  NIH* None
Adrian F. 
HernandezContent Reviewer—
Joint Committee 
on Clinical Practice 
Guidelines Duke University School of 
Medicine•  Amgen Inc.
•  AstraZeneca 
Pharmaceuticals
•  Bayer Corporation 
U.S.
•  Biofourmis
•  Boehringer 
Ingelheim 
Pharmaceuticals, Inc
•  Boston Scientific*
•  Merck and Co., Inc.
•  Novartis*
•  Pfizer
•  Relypsa
•  Sanofi-Aventis*
•  Xogenex None None •  American Regent
•  AstraZeneca*
•  Daiichi Sankyo
•  Genentech, Inc
•  Glaxo Smith 
Kline*
•  Merck and Co., 
Inc.
•  NIH†
•  Novartis*
•  PCORI†
•  Verily*
•  Eidos (DSMB)•  AHA† •  Defendant, 
patent 
dispute, 
2019
Anastasia L. 
ArmbrusterContent Reviewer—
Joint Committee 
on Clinical Practice 
Guidelines St. Louis College of 
Pharmacy None •  AstraZeneca 
PharmaceuticalsNone None None None
Andrew M. 
KatesContent Reviewer—
ACC/AHA Washington University 
School of Medicine-
Professor of Medicine 
Director, Cardiovascular 
Fellowship ProgramNone None None None None None
Andrew 
Wang Official Reviewer—
AHADuke University Medical 
Center-Professor of 
Medicine•  American College of 
Physicians*
•  Cytokinetics
•  RioVant
•  UpToDate None None •  Myokardia* •  Abbott Vascular
•  AHA, Circulation 
Journal*
•  Medtronic
•  MyoKardia, Inc•   Defendant, 
Diagnosis 
of Infective 
Endocarditis,  
2019
Anita Deswal Content Reviewer—
Joint Committee 
on Clinical Practice 
Guidelines The University of Texas 
MD Anderson Cancer 
Center—Department 
Chair, Cardiology, Ting 
Tsung and Wei Fong 
Chao Distinguished Chair, 
Professor of MedicineNone None None •  NIH* •  ACC
•  AHA
•  Heart Failure Society 
of America†None
Ann Bolger Content Reviewer—
ACC/AHA University of California, 
San Francisco-Professor of 
Medicine•  General Electric None None None None None
(Continued )
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e225
CLINICAL STATEMENTS  
AND GUIDELINES(Continued )Brian R. 
Lindman Content Reviewer—
ACC/AHA Vanderbilt University 
Medical Center None None None •  Edwards 
Lifesciences*None None
Bulent 
GorenekContent Reviewer—
Joint Committee 
on Clinical Practice 
Guidelines Eskisehir Osmangazi 
University School of 
Medicine – Professor of 
Cardiology•  AstraZeneca
•  Sandoz None None None None None
Carole A. 
WarnesContent Reviewer—
ACC/AHA Mayo Clinic-Professor of 
MedicineNone None None None None None
Cheryl 
BatzingContent Reviewer—
ACC/AHA Lay 
ReviewerChurch Ministries 
International—Donor 
Relations ManagerNone None None None None None
Christine C. 
RekashContent Reviewer—
ACC/AHA Lay 
ReviewerU.S. Department of 
Justice—Paralegal •  Heart Valve Voice •  Advocate Good 
Samaritan 
Hospital† 
•  AHA 
•  Bluhm 
Cardiovascular 
Institute at 
Northwestern 
Hospital†None None •  Edwards Life 
Sciences
•  Heart Valve Voice
•  PCORINone
Daniel B. 
MarkContent Reviewer—
Joint Committee 
on Clinical Practice 
Guidelines Duke Clinical Research 
Institute—Professor of 
MedicineNone None None •  HeartFlow*
•  Merck and Co., 
Inc.*•  Merck and Co., 
Inc.*None
Dave L. Dixon Content Reviewer—
Joint Committee 
on Clinical Practice 
Guidelines Virginia Commonwealth 
University School of 
PharmacyNone None None •  Centers for 
Disease Control 
and Prevention*
•  Community 
Pharmacy 
Foundation*•  Accreditation 
Council for Clinical 
Lipidology†
•  American 
Pharmacists 
Association
•  American College 
of Pharmacy 
Cardiology Practice 
Research Network†
•  National Lipid 
Association†None
David H. 
Adams Content Reviewer—
ACC/AHA Mt. Sinai Medical Center None None None •  Abbott
•  Medtronic
•  NeoChord •  Edwards 
Lifesciences*
•  Medtronic*None
David E. 
Newby Content Reviewer—
ACC/AHA University of Edinburgh 
Chancellor’s Building—
Professor of Cardiology•  AstraZeneca*
•  Bristol-Myers Squibb 
Company*
•  CellProthera
•  Eli-Lilly
•  Glaxo Smith Kline*
•  Jansen
•  Oncoarendi
•  Pfizer
•  Reckitt Benckiser  
Pharmaceuticals Inc.
•  Roche
•  ToshibaNone None •  AstraZeneca*
•  Boehringer 
Ingelheim*
•  Bristol-Myers 
Squibb 
Company*
•  GlaxoSmithKline*
•  Merck and Co., 
Inc.*
•  Pfizer*
•  UCB Inc. (DSMB)•  AstraZeneca 
Pharmaceuticals
•  Bristol-Myers 
Squibb Company
•  CellProthera
•  Esperion
•  Infraredx None
Jacqueline E. 
Tamis-HollandContent Reviewer—
Joint Committee 
on Clinical Practice 
Guidelines Mount Sinai Saint Luke’s 
HospitalNone None None •  Internal-
Minneapolis Heart 
Institute-North 
American Covid 
STEMI Registry†•  Abbott Vascular†
•  AHA†
•  Bronx Lebanon 
Hospital, Cardiology 
Fellowship Program 
Director†
•  Medscape/Heart.
org
•  Merck and Co., Inc.
•  NIH†
•  The NGS Predict 
Study NoneAppendix 2. Continued
Reviewer Representation Employment ConsultantSpeakers 
BureauOwnership/ 
Partnership/
PrincipalPersonal  
ResearchInstitutional, 
Organizational, 
or Other Financial 
BenefitExpert 
Witness
Downloaded from http://ahajournals.org by on November 12, 2025

February 2, 2021 Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 e226
CLINICAL STATEMENTS  
AND GUIDELINESOtto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Jeanne M. 
DeCara Content Reviewer—
ACC/AHA University of Chicago 
MedicineNone None None None •  Intersocietal 
Accreditation 
Commission†None
José A. Joglar Content Reviewer—
Joint Committee 
on Clinical Practice 
Guidelines UT Southwestern Medical 
Center—Professor, 
Internal Medicine. 
Program Director, Clinical 
Cardiac Electrophysiology 
Fellowship Program
ProfessorNone None None None None None
Joseph 
Edward 
MarineContent Reviewer—
Joint Committee 
on Clinical Practice 
Guidelines Johns Hopkins University 
School of Medicine•  ACC* None None None •  UpToDate None
Kim K. 
BirtcherContent Reviewer—
Joint Committee 
on Clinical Practice 
Guidelines University of Washington—
Director, Adult Congenital 
Heart Disease Program•  Jones & Bartlett 
LearningNone None None None None
Larry M. 
BaddourContent Reviewer—
ACC/AHA Mayo Clinic, Rochester, MN •  Boston Scientific* None None None •  UpToDate, Inc.* None
Latha 
PalaniappanContent Reviewer—
Joint Committee 
on Clinical Practice 
Guidelines Stanford Medicine •  23 and me 
•  National Minority 
Cardiovascular 
AllianceNone None • NIH* None None
Lisa de las 
FuentesContent Reviewer—
Joint Committee 
on Clinical Practice 
Guidelines Washington University, 
School of Medicine, 
Department of Medicine, 
Cardiovascular Division•  Acceleron
•  Altavant
•  Arena
•  Bayer Healthcare 
Pharmaceuticals
•  Express Scripts
•  Johnson & Johnson
•  Mentor Planning 
and Consulting
•  Phase Bio
•  V-wave
•  WebMD, LLC*•  Bayer Healthcare 
Pharmaceuticals*
•  Simply Speaking*None •  Acceleron*
•  Altavant*
•  Bayer Healthcare 
Pharmaceuticals
•  Complexa*
•  Johnson & 
Johnson*
•  Liquidia*
•  Medtronic*
•  NIH*
•  Reata
•  Trio Analytics*
•  United 
Therapeutics*
•  University of 
Kentucky (DSMB)
•  University of 
Toronto†•  ACC†
•  AHA†
•  Circulation Journals, 
Editorial Board
•  Ironwood
•  Pulmonary 
Hypertension 
Association*None
Mariann 
PianoContent Reviewer—
Joint Committee 
on Clinical Practice 
Guidelines Vanderbilt University None None None None None None
Mark 
Reisman Content Reviewer—
ACC/AHA University of Washington 
Medical Center-Section 
Head, Interventional 
Cardiology•  Boston Scientific None None None None None
Milind Y. 
DesaiContent Reviewer—
ACC/AHA Cleveland Clinic None None None None None None
Patrick Collier Content Reviewer—
AHA Cleveland Clinic None None None None None None
Philippe 
PibarotContent Reviewer—
ACC/AHA Professor, Department of 
Medicine, Laval University
Head of Cardiology 
Research, Institut 
Universitaire de Cardiologie 
et de Pneumologie de 
Québec / Québec Heart & 
Lung InstituteNone None None •  Canadian 
Institutes of 
Health Research*
•  Cardiac Phoenix*
•  Edwards 
Lifesciences*
•  Medtronic*
•  V-Wave Ltd.*None None
Rebecca T. 
HahnContent Reviewer—
ACC Professor of Medicine 
at Columbia University 
Medical Center•  Edwards Lifesciences
•  Medtronic
•  Philips Healthcare •  Abbott Vascular
•  Baylis Medical
•  Siemens 
Healthineers •  NaviGate† None •  Director of the Echo 
Core Lab†None
(Continued )Appendix 2. Continued
Reviewer Representation Employment ConsultantSpeakers 
BureauOwnership/ 
Partnership/
PrincipalPersonal  
ResearchInstitutional, 
Organizational, 
or Other Financial 
BenefitExpert 
Witness
Downloaded from http://ahajournals.org by on November 12, 2025

Otto et al 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease
Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923 February 2, 2021 e227
CLINICAL STATEMENTS  
AND GUIDELINESSandra Lauck Content Reviewer—
ACC/AHA University of British 
Columbia, Vancouver, 
CanadaNone •  Abbott
•  Edwards 
Lifesciences*None None None None
Suzanne 
Arnold Content Reviewer—
ACC/AHA St. Luke’s Mid America 
Heart InstituteNone None None None •  Abbott Laboratories None
Terrence D. 
WelchContent Reviewer—
ACC/AHA Dartmouth-Hitchcock 
Medical CenterNone None None None None None
Vinod H. 
ThouraniContent Reviewer—
ACC Piedmont Heart Institute •  Abbott Vascular
•  Boston Scientific
•  Edwards Lifesciences
•  Gore Medical
•  Jenavalve None None None •  Abbott Medical
•  Medtronic†None
Wendy Tsang Content Reviewer—
ACC/AHA Toronto General Hospital •  UpToDate None None •  Heart and Stroke 
Foundation of 
Canada*
•  Peter Munk 
Cardiac Center 
Innovation 
Committee*•  Heart and Stroke 
Foundation of 
Canada*None
William F. 
ArmstrongContent Reviewer—
ACC/AHAUniversity of Michigan 
Professor of Medicine, 
Division of Cardiovascular 
DiseaseNone None None None None •  Defendant, 
medical 
malpractice, 
2019
William 
Schuyler 
JonesContent Reviewer—
Joint Committee 
on Clinical Practice 
Guidelines Duke University Health 
System•  Bayer Healthcare 
Pharmaceuticals*
•  Janssen 
Pharmaceuticals, 
Inc* None None •  Bristol Myers 
Squibb
•  PCORINone None
Zachary D. 
GoldbergerContent Reviewer—
Joint Committee 
on Clinical Practice 
Guidelines University of Wisconsin 
School of Medicine and 
Public Health, Associate 
Professor of MedicineNone None None None None None
Stephan 
WindeckerContent Reviewer—
ACC/AHAInselspital Universitätsspital 
Bern—Direktor und 
Chefarzt, Universitätsklinik 
für KardiologieNone None None None •  Abbott*
•  Amgen*
•  Bayer*
•  Biotronik*
•  Boston Scientific*
•  Bristol-Myers 
Squibb
•  CSL Behring
•  Edwards 
Lifesciences*
•  Medtronic*
•  Polares Medical
•  SINO Medical 
Technologies, IncNone
This table represents all relationships of reviewers with industry and other entities that were reported at the time of peer review, including those not deemed to be relevant to this document, at 
the time this document was under review. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business 
if the interest represents ownership of ≥ 5% of the voting stock or share of the business entity, or ownership of ≥ $5000 of the fair market value of the business entity; or if funds received by the 
person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. 
Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Please refer to https://www.acc.org/guidelines/about-guidelines-
and-clinical-documents/relationships-with-industry-policy for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.
*Significant relationship.
†No financial benefit.
ACC indicates American College of Cardiology; AHA, American Heart Association; DSMB, Data and Safety Monitoring Board; NIH, National Institutes of Health; PCORI, Patient-Centered 
Outcomes Research Institute; and UT, University of Texas.Appendix 2. Continued
Reviewer Representation Employment ConsultantSpeakers 
BureauOwnership/ 
Partnership/
PrincipalPersonal  
ResearchInstitutional, 
Organizational, 
or Other Financial 
BenefitExpert 
Witness
Downloaded from http://ahajournals.org by on November 12, 2025

